"companyid","keydevid","transcriptid","headline","mostimportantdateutc","keydeveventtypename","companyname","speakertypename","componenttextpreview","word_count","componenttext"
94614,314976743,921149,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Operator","Welcome to the Fourth Quarter 2015 Stryker Earnings Call. My name is Adrianne, and I will be your operator for this call. [Operator Instructions] This conference call is being recorded for replay purposes.Before we begin, I would like to remind you that",136,"Welcome to the Fourth Quarter 2015 Stryker Earnings Call. My name is Adrianne, and I will be your operator for this call. [Operator Instructions] This conference call is being recorded for replay purposes.
Before we begin, I would like to remind you that the discussions during this conference call will include forward-looking statements. Factors that could cause actual results to differ materially are discussed in the company's most recent filings with the SEC.
Also, the discussions will include certain non-GAAP financial measures. Reconciliations to the most directly comparable GAAP financial measures can be found in today's press release that is an exhibit to Stryker's current report on Form 8-K filed today with the SEC.
I would now like to turn the call over to Mr. Kevin Lobo, Chairman and Chief Executive Officer. You may proceed, sir."
94614,314976743,921149,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","Good afternoon, everyone, and welcome to Stryker's Fourth Quarter 2015 Earnings Call. Joining me today are Bill Jellison, our CFO; Katherine Owen, Vice President of Strategy and Investor Relations; and Glenn Boehnlein will be taking over for Bill on April",824,"Good afternoon, everyone, and welcome to Stryker's Fourth Quarter 2015 Earnings Call. Joining me today are Bill Jellison, our CFO; Katherine Owen, Vice President of Strategy and Investor Relations; and Glenn Boehnlein will be taking over for Bill on April 1. Following my opening comments, Katherine will provide an update on MAKO, while Bill will offer more details on our quarterly results before turning to questions and answers.
For the 6.4% increase in organic sales in Q4, we continue to deliver on our goal of driving top line growth at the high end of med tech. This marks the 11th consecutive quarter where Stryker delivered 5% or better organic sales growth, demonstrating strong consistency over time. Our diversified sales footprint has, once again, proven to be a key component of our growth strategy as all of our segments, Orthopaedics, MedSurg and Neurotechnology and Spine, posted good results in the quarter. This performance has underscored the strength of our sales and marketing execution and our innovation engine, which is characterized by healthy R&D investments and a focused and disciplined M&A effort.
Approximately 70% of our sales are derived from our U.S. businesses, which, once again, led growth, posting an impressive gain of approximately 8%. I'm also pleased with the growing momentum out of Europe, including strong Q4 results, benefiting from the shift in Transatlantic Operating Model at the beginning of 2015. We are building on the success as we start 2016, with Canada rolling into the model and the other regions now reporting to our Group Presidents, Tim [indiscernible] and David Floyd. 
Our international growth of roughly 4% in constant currency was, once again, impacted by soft performances in China and Brazil. However, as you've seen, we have demonstrated the ability to offset isolated geographic softness through strength in our larger markets. 
Turning to earnings. Our adjusted EPS for Q4 of $1.56 is at the high-end of our revised range of $1.53 to $1.56, primarily driven by the strong top line. The balance of the P&L came in as expected, which Bill will over in his section. 
Looking ahead to 2016, we expect our sales momentum to continue and are targeting organic sales growth for the year of 5% to 6%. This takes into account expected softness in emerging markets for a good portion of the year. 
In addition, the 2-year suspension of the Med Device Tax provides us with the opportunity to bolster investments that will help drive sales growth and innovation, as we plan to invest the majority of for these temporary benefit. 
We are also continuing on our path toward driving greater cost efficiencies, which is a multiyear opportunity. Over the past year, we have been focused on identifying and prioritizing the key target areas for cost reduction within our organization. As we shifted to 2016, we are moving toward project implementation under the leadership of Group President, Lani Carpenter [ph]. We have identified significant areas of savings centered around optimizing our planned network, rationalizing our product lines, professionalizing our indirect procurement in a similar manner as we have done with direct materials to moving to a common ERP system and driving more shared services. Given our history of decentralization, there's considerable authority ahead of us in this program. We believe a methodical and deliberate approach these efforts will allow us to preserve the Stryker's competitive differentiation in the areas of sales, marketing, R&D and business development while helping to ensure we are consistently delivering P&L leverage. This is reflected in our 2016 adjusted EPS range of $5.50 to $5.70 a share. This is an increase of approximately 7.5% to 11.5% versus 2015, and it includes a negative foreign exchange impact of $0.12 to $0.13 a share. 
Finally, I'd like to take a moment to extend my thanks and appreciation to Bill Jellison, who's announced his plans to retire following an impressive 36 career -- 36-year career, the last 3 of which have been with Stryker. Bill was able to quickly move toward implementing a layered hedging program, which has proven to be successful at mitigating our transactional FX exposure. In addition, he helped execute in a number of acquisitions associate of the establishment of a European regional headquarters that's enabled significant savings and has also helped to shape our comprehensive cost reduction program. He's accomplishments have meaningfully contributed to our success and were achieved while enabling our internal talent pool to develop, including Glenn Boehnlein, who's been promoted to CFO effective April 1. Glenn has been with Stryker in various financial results leadership role since 2003, most recently serving as Group CFO for the MedSurg and Neurotechnology group. His group represents roughly half the company and has been a consistent force behind our strong results. I am confident in Glenn's stability in coordination with the broader financial organization to help build on our strong momentum. 
Before turning the call over to Katherine, I've asked Glenn to make a few comments. Glenn?"
94614,314976743,921149,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","Cents Kevin. I appreciate the comments and the support, but I also want to thank Bill for his leadership for the finance organization over the past 2 [ph] years and for his commitment to helping ensure a smooth transition as I take on new responsibilities",97,"Cents Kevin. I appreciate the comments and the support, but I also want to thank Bill for his leadership for the finance organization over the past 2 [ph] years and for his commitment to helping ensure a smooth transition as I take on new responsibilities. It's a very exciting time I Stryker, and I'm thrilled to be part of such a great organization with so many talented and dedicated people. I'm also looking forward to meeting many of our shareholders, analysts at the various events going forward. 
And with that, I'll turn the call over to Katherine."
94614,314976743,921149,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","Thanks, Glenn. The focus of my comments today will be to provide an update on MAKO. 2015 was a year of building momentum for MAKO's robotic-assisted surgery, as we continue to leverage our considerable salesman at the infrastructure to help drive sales. W",194,"Thanks, Glenn. The focus of my comments today will be to provide an update on MAKO. 2015 was a year of building momentum for MAKO's robotic-assisted surgery, as we continue to leverage our considerable salesman at the infrastructure to help drive sales. We are particularly pleased with the increased demand for the hip indication, which has been augmented by combining the robotic technology with our proven portfolio of Stryker Hip systems. The combination enables surgeons to use a best-in-class hip implant surgeon and patient.
[Audio Gap]
For 2016, we are focused on continuing to drive adoption with our current indications, which we believe offers considerable opportunity to drive ongoing robot placements. 
We are also excited about the potential for the total knee indication with our flagship Triathlon system. This year, our efforts will be centered around gaining user experience with key opinion leaders to help ensure an optimal rollout as we look to full commercial release in 2017. We believe the commercial launch, which will be aided by podium presentations from the early users group, will be in place as we head into next year. 
With that, I'll turn the call over to Bill."
94614,314976743,921149,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","Thanks, Katherine. I'd like to sum up by saying I've enjoyed working with Kevin and everyone at Stryker, especially the entire finance organization, who have made significant contributions over the last few years helping the company deliver on its financi",1930,"Thanks, Katherine. I'd like to sum up by saying I've enjoyed working with Kevin and everyone at Stryker, especially the entire finance organization, who have made significant contributions over the last few years helping the company deliver on its financial results. [indiscernible] Stryker with strong cultural fit in personal fit from the first week I joined the company. 
We ended 2015 at the high-end of both our initial sales and earnings guidance that was set at the beginning of the year. As we look at 2016 and set our initial guidance, I am confident that our sales momentum, strong product portfolio and pipeline and the cost containment initiatives that we are driving position us well for the future. I look forward to ensuring a smooth transition with Glenn and entering another stage of my life. I will continue to engage actively and in many of my passions, travel with my family and friends and explore additional Board opportunities. I want to thank you all of you for your support. 
So turning to our financial performance. Sales grew 3.7% in the quarter, including a negative 3.2% impact from foreign currency translation. Constant currency sales growth was 7%, which includes organic growth of 6.4%. 
GAAP EPS for the quarter was $1.38 per share versus $0.68 last year in the fourth quarter, while adjusted earnings per share were $1.56 a share for the quarter versus $1.44 per share in the fourth quarter last year. This quarter's EPS includes negative impacts of roughly $0.04 per share from foreign exchange, which was in line with our guidance. Most currency exchange rates against the U.S. dollar continue to be weaker than last year in the same period. The weaker euro and Swiss franc, along with our layered hedging program, helped to mitigate some of the impact in the quarter, as many of our products are manufactured in Europe, which helped improve our gross margin rates in the period. However, significant weakening in foreign currency rates in emerging markets and the continued weakness of the Japanese yen, Australian dollar and Canadian dollar, where we have minimal manufacturing, negatively impacted our gross margins and operating results in those regions. The most significant non-GAAP adjustments in the quarter were amortization, restructuring charges and a net reduction in the charge associated with the voluntary recall of the Rejuvenate ABG II modular Hips Stem as we resolved some insurance matters in the quarter, which more than offset the additional charge in the period. 
As I have mentioned previously, the charges we have recorded related to the Rejuvenate and ABG II recall represents a minimum of the range of probable loss to resolve this manner, and the charges may increase or decrease over time as additional facts become available and our assumptions more refined. 
In the fourth quarter, our organic growth rate was 6.4%, including 8.1% growth in unit volumes and mix, with price negatively impacting sales by 1.7%. Acquisitions added 0.6%, while FX had a negative 3.2% impact due to significant weakness in both the Japanese yen and the Australian dollar compared to the same period last year. 
Full year 2015 constant currency sales growth were 7%, and organic growth was 6.1%. 
Looking at our segments. Orthopaedics represented 42% of our sales in the quarter, and sales of Orthopaedic products grew 3.3% as reported and 7.1% in constant currency. U.S. Orthopaedic sales grew 9.7% in the quarter. 
Trauma and Extremities had another excellent quarter in the U.S., with sales increasing 13.6%, led by strong growth in Foot & Ankle, which, again, grew approximately 20% for both the fourth quarter and full year. 
U.S. Hips and Knees continued their strong performance of 6.4% and 9.1% organic growth, respectively, in the quarter. These sales were bolstered by increased adoption of recent titanium 3D-printed products. 
Our International Orthopaedic business grew 2.4% in constant currency, as sales growth continued to be negatively impacted by weakness in China and Brazil. However, our International Knee business grew 5.5% in constant currency in the quarter. 
Finally, we sold 31 MAKO units in the quarter and 72 units in the full year. 
Next, our MedSurg segment represented approximately 40% of our total sales, and sales of MedSurg products grew 3% as reported and 5.6% in constant currency. These results were led by growth in our Instruments and Medical business, both of which had strong mid-single-digit percentage growth in constant currency. 
Endoscopy also posted mid-single-digit percentage growth in constant currency in the period on the back of our new camera offering, which was launched in December. All 3 of these large MedSurg businesses continued to manage pricing decisions effectively, with modest price declines of less than 0.5% for the year. 
Our final segment, Neurotechnology and Spine, represented 18% of sales and delivered another good quarter. Sales of Neurotechnology and Spine products grew 6.5% as reported and 9.9% in constant currency. Growth in this segment was led by our Neurotechnology business, which had double-digit growth in the high teens in constant currency in the fourth quarter and grew high teens in the U.S. Spine sales had mid-single-digit percentage growth in constant currency in the period and had high single-digit growth in the U.S. This marks our third consecutive quarter of strong growth in U.S. Spine. Spine also has a new 3D-printed interbody device launching in 2016, which we believe will be a very exciting product for the market, helping us to continue this positive trend. 
In looking at our operational performance, gross margin as a percent of sales on an adjusted basis in the fourth quarter was 67.2% compared to 65.8% in the fourth quarter last year. When compared to the same period last year, the rate was positively impacted by solid operational improvements, product mix and FX rates despite the negative FX impact on earnings per share. 
Price had a negative impact as pricing was lower by 1.7% in the period. Our gross margin as a percentage of sales was 66.5% or 50 basis points higher than last year. 
Research and development expenses increased by 20 basis points to 6% of sales in the fourth quarter compared to 5.8% in the same period last year. 
On an adjusted basis, selling, general and administrative expenses represented 33.7% of sales in the fourth quarter compared to 32.4% in the same period last year. As expected, these expenses were higher for the year as we increased spending to support the cost structure of our European regional headquarters in Amsterdam and our transatlantic operating model. We are confident in our ability to leverage these expenses in 2016 as we continue to drive a number of key cost initiatives even as we reinvest some of the savings from the suspension of the Medical Device Tax. 
Operating margin as a percentage of sales on an adjusted basis were 27.4% in the fourth quarter compared to 27.6% in the same period last year. The full year adjusted operating margin rate was 24.9%, nearly flat compared to last year. During the year, we invested in our European regional headquarters and the establishment of our transatlantic operating model, which reduced the stronger operating margins for the year. 
Other expense in the fourth quarter was $36 million. This increase in expense resulted primarily from higher net interest expense due to increased borrowings and foreign currency exchange transactional losses in the fourth quarter. This is generally consistent with the run rate for this category. 
Our reported tax rate for the fourth quarter was 14.7%, while the adjusted effective tax rate was 16.6% for the fourth quarter compared to 22.6% in the same period last year. The fourth quarter effective tax rate benefited from the renewal of the tax extenders, which was contemplated in our guidance. The full year adjusted effective tax rate was 17.3% compared to 22.3% last year, as we realized the benefits from our global tax structure in European regional headquarters in Amsterdam. 
Looking at the balance sheet, we ended the quarter with $4.1 billion of cash and marketable securities, approximately 50% of it now held in the U.S. We also had $4 billion of debt on the balance sheet at the end of the quarter. 
From an asset management standpoint, accounts receivable days ended the quarter 55, relatively unchanged from last year. Days of inventory finished the quarter at 165, which was an increase of 5 days compared to last year. 
Turning to cash flow. Our cash flow from operations for 2015 were $900 million compared to $1.8 billion last year. But as previously mentioned, we made significant payments earlier this year associated with our Rejuvenate and ABG II recall settlement of $1.2 billion, most of which occurred in the third quarter. Approximately 50% of the funding of the Rejuvenate liability is being sourced from OUS cash. We also repatriated a total of $1.8 billion in 2015, including approximately $1.1 billion in the fourth quarter. Capital expenditures were $270 million in 2015 compared to $233 million last year. 
Finally, regarding share repurchases. In 2015, we repurchased approximately $700 million of our common stock or approximately 7.5 million shares at an average price of approximately $94.67. We have authorization for another $1.9 billion available for repurchase under our current authorization. 
Based on our strong performance in 2015 and assessment of the current economic and market conditions, we are projecting constant currency and organic sales growth in a range of 5% to 6% for 2016 and expect to be at the low end of that range in the first quarter, as we are still anticipating impacts of the market conditions in the emerging markets, especially China and Brazil. 
If foreign currency exchange rates hold near current levels, we anticipate net sales will be negatively impacted by approximately 1% for 2016. We also expect continued unfavorable price reductions of 1.5% to 2%, consistent with the pricing environment experienced in 2015. 
Due to the suspension of the Med Tech Tax, we will also provide some additional visibility to our projected margin rates for 2016. 
Both gross margin and operating income margins are projected to be at least 50 basis points higher in 2016 in total. The benefit from the suspension of the Med Tech Tax will directly benefit our gross profit rate. However, R&D will run slightly higher in 2016, and our SG&A rate will only show modest improvement for the full year, as we expect to reinvest the majority of the benefit we receive into these areas, offsetting much of our cost reductions in '16. As such, our gross margin rate improvements will be the driver of our operating margin rate in 2016. We expect our full year adjusted effective tax rate in 2016 will continue to be approximately 17% to 17.5%. 
Capital expenditures are expected to be $400 million to $450 million in 2016, as we continue to invest in our operations and IT infrastructure to support future growth. Based on the current foreign exchange rates, we expect 2016 to be negatively impacted by approximately $0.12 to $0.13 for the full year and approximately $0.03 for the first quarter. This negative impact is largely driven by the translational component of foreign exchange, which we do not hedge. The transactional impact of foreign exchange on earnings is being offset somewhat by both natural and real hedges, which we continue to layer into our operations. 
Finally, our guidance for adjusted net earnings per diluted share in 2016 is $5.50 to $5.70 for the full year and $1.17 to $1.22 for the first quarter. 
Thanks for your support, and we'd be glad to answer any questions that you may have at this time."
94614,314976743,921149,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Operator","[Operator Instructions] Our first question comes from Bob Hopkins from Bank of America.",13,"[Operator Instructions] Our first question comes from Bob Hopkins from Bank of America."
94614,314976743,921149,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Analysts","So first, Bill, sorry to see you move on, but good luck with the next chapter. So I feel I'd be remiss if I didn't ask a follow-up question on this announcement. And maybe the way to phrase it, the question, Bill, is -- and for Kevin and Katherine, you gu",113,"So first, Bill, sorry to see you move on, but good luck with the next chapter. So I feel I'd be remiss if I didn't ask a follow-up question on this announcement. And maybe the way to phrase it, the question, Bill, is -- and for Kevin and Katherine, you guys have been talking about M&A for some time. And I'm just curious if the CFO transition suggests any change in strategy or maybe suggests that maybe larger deals kind less likely until after this transition is complete. Just kind of curious in how this could affect the strategy and/or the outlook for M&A. And thanks, and again, congrats, Bill, for the decision."
94614,314976743,921149,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","Yes. Thanks, Bob. I would say the company is in very good shape. You can see the way we're performing. This is an internal transition with somebody who is inside our company. So this is not like we're signaling any kind of shift in strategy. I would tell",147,"Yes. Thanks, Bob. I would say the company is in very good shape. You can see the way we're performing. This is an internal transition with somebody who is inside our company. So this is not like we're signaling any kind of shift in strategy. I would tell you, we've been very consistent on capital allocation since I've been with the job and even before, that our approach is to favor M&A for spend dividends and then share buybacks. So there's absolutely 0 change to our operating mode, and I'm expecting a very smooth transition. You can see that we have a whole quarter of overlap, and Bill is still going to be around in this community and available to help us as needed. So I would tell you that you should expect more of the same from Stryker, and this should be a very seamless change."
94614,314976743,921149,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Analysts","All right. And then as a quick follow-up also, Kevin, from a big picture perspective. I was wondering if you could kind of give us your sense for the outlook for hospital capital spending in 2016. What are you seeing from hospitals? Are you expecting any",73,"All right. And then as a quick follow-up also, Kevin, from a big picture perspective. I was wondering if you could kind of give us your sense for the outlook for hospital capital spending in 2016. What are you seeing from hospitals? Are you expecting any changes? Just wanted to get a sense for your view on the 2016 outlook for CapEx, especially since you're launching new products into the market right now."
94614,314976743,921149,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","Thanks, Bob. Look, we see the city market as very stable for capital equipment. You can see, in the fourth quarter, we had very strong performances on MAKO selling capital of that large capital. We also have a lot of small capital arrangements in the very",110,"Thanks, Bob. Look, we see the city market as very stable for capital equipment. You can see, in the fourth quarter, we had very strong performances on MAKO selling capital of that large capital. We also have a lot of small capital arrangements in the very well in the fourth quarter. So we look at the market as being very stable. We're just embarking upon our most of our a new camera, the 15 88 [ph], within Endoscopy. They had a nice start in the month of December and orders White House to go into the year. So we are not seeing really any change, a very stable capital market."
94614,314976743,921149,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Operator","And the next question comes from Michael Weinstein from JPMorgan.",10,"And the next question comes from Michael Weinstein from JPMorgan."
94614,314976743,921149,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Analysts","And Bill, one of my sentiments as well. Thanks for oriel all your help, and enjoy your time with Stryker. Let me ask a couple of questions, guys. So one question is the 5% to 6% constant currency guidance for 2016, obviously, you, by and large, have been",90,"And Bill, one of my sentiments as well. Thanks for oriel all your help, and enjoy your time with Stryker. Let me ask a couple of questions, guys. So one question is the 5% to 6% constant currency guidance for 2016, obviously, you, by and large, have been running above that. Can you just tell us what you have baked in there for the emerging market performance? Because, obviously, you are still assuming a chalice in emerging markets environment for the year. Just want to get some sensitivities around it."
94614,314976743,921149,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","Yes, Mike. In terms of your margin markets, which is in that 7% to 8% of our total sales in China and Brazil are the biggest the point is although we have been seeing nice growth in markets outside of that, we've assumed those smartest rheumatology for th",98,"Yes, Mike. In terms of your margin markets, which is in that 7% to 8% of our total sales in China and Brazil are the biggest the point is although we have been seeing nice growth in markets outside of that, we've assumed those smartest rheumatology for the better part of the year. China as well as Brazil are difficult to predict given the macro issues surrounding them. And we do benefit from easier comparisons as we get to the back half of the year, but we assume market their produce to be a bit of a challenge."
94614,314976743,921149,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","Yes, Mike. I would say the emerging markets for us, we had similar performance in the fourth quarter as we did in the third quarter. So we're slightly negative in terms of growth in our emerging markets, China, of course, being the biggest drag. And for S",144,"Yes, Mike. I would say the emerging markets for us, we had similar performance in the fourth quarter as we did in the third quarter. So we're slightly negative in terms of growth in our emerging markets, China, of course, being the biggest drag. And for Stryker, so we're expecting that to continue to be difficult, and that will be a drag. And it's early in the year, so we're setting our guidance from 5% to 6%. As you saw last year, we moved our guidance up during the year. If these conditions don't or not as severe. You can expect will do the same with the subgenus our ultimate on this as we feel good about our business, but it's really the year and we know those markets are going to be challenged, and we're just baking in some caution around those markets."
94614,314976743,921149,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Analysts","Understood. So let me take 2 quick follow-ups relative to the guidance. So one, you started to talk about the cost transformation initiatives in greater detail in San Francisco. And in the 2016 guidance, you're basically assuming no SG&A leverage, and tha",146,"Understood. So let me take 2 quick follow-ups relative to the guidance. So one, you started to talk about the cost transformation initiatives in greater detail in San Francisco. And in the 2016 guidance, you're basically assuming no SG&A leverage, and that's part of what you're talking about reinvesting back in the business with the benefit of the Med Tech Tax helping the gross margin line. So can you just talk a little bit about the very are going to the government of Investec that will show up in the SG&A or would only show up in R&D? And then second, the separation of the share buyback, and acceleration maybe is not the right term, but you bought back more stocks than you have been buying back in the fourth quarter. Can you just talk a bit about what's in your 2016 guidance for capital deployment?"
94614,314976743,921149,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","Yes, so a couple different questions there, the first one associated with kind of the margin rate and also the SG&A area. We do expect some modest level of improvement still in the broader operating expense category, but the investment is primarily taking",275,"Yes, so a couple different questions there, the first one associated with kind of the margin rate and also the SG&A area. We do expect some modest level of improvement still in the broader operating expense category, but the investment is primarily taking place in both areas, probably about maybe 20 basis points or so of an impact on the R&D-related side and the remainder kind of in the SG&A area. I'd say that with the cost initiatives that we've got in place that you would have seen obviously better leverage there, but with the reinvestment, that will slow that down at least this year. But we should still be showing obviously some very, very solid gross margin rates improvement, and we should be getting good drop was still in the operating income line for that. As it relates to the buybacks, yes, we did jump out to about $700 million in this year. As you can see, our cash has continued to stay very strong. We were able to bring back some additional cash. We have about $2 billion here in the U.S. at this point. And as far as our guidance is concerned, you should expect that we commented before that we've got the authorization out there. We expect to complete that over kind of a 2- to 3-year period of time,barring any sizable acquisitions. And hopefully, as having mesenchyme options are absolutely still our first and foremost kind of attention within that space, and we expect to be very active as we move forward. But those are all based on time situations, right? So -- but that is still our #1 focus."
94614,314976743,921149,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Operator","And our next question comes from Rick Wise from Stifel.",10,"And our next question comes from Rick Wise from Stifel."
94614,314976743,921149,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Analysts","Let me, Kevin, start first question will be on the operating market outlook. I would say, you're '15 at 27.4%. Maybe just comment, if you would, on your aspirational goals here. Is it 30%? Is it 35% over the next 2 to 4, 3 to 5 years? Just talk about the",60,"Let me, Kevin, start first question will be on the operating market outlook. I would say, you're '15 at 27.4%. Maybe just comment, if you would, on your aspirational goals here. Is it 30%? Is it 35% over the next 2 to 4, 3 to 5 years? Just talk about the magnitude and the durability of this seemingly  long-tailed opportunity?"
94614,314976743,921149,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","So Rick, we only give guidance out for 1 year, right? So we provide you guidance this year we show super the manifold levers of the EPS line. Coming off the year, we just delivered leverage if you didn't have the $0.12 to $0.13 a share of negative FX, we'",211,"So Rick, we only give guidance out for 1 year, right? So we provide you guidance this year we show super the manifold levers of the EPS line. Coming off the year, we just delivered leverage if you didn't have the $0.12 to $0.13 a share of negative FX, we'd be giving EPS in the 10% to 14% range. So that's pretty meaningful leverage on the sales of 5% to 6%. So you should expect us to continue to drive meaningful leverage. That's the goal of the constant program. As we've said before, there is significant opportunities in the hundreds of millions of dollars. And as we get to drive those savings, we'll obviously if there's quick opportunists to invest, will invest some of those dollars and some of those dollars will fall to the bottom line. So but I didn't have a magical number and as it also depends on as the years progress, what types of deals we do, how that affects our margin profile. So I think, each year, you will expect us to give the kind of guidance we are giving you this year, nice, robust organic growth and a nice amount of leverage to the bottom line. And I think I'll just leave it at that."
94614,314976743,921149,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Analysts","Okay. And Katherine, maybe for you on MAKO. Can you give us a little more color on your comments? You talked about increased demand for the Hip indication. It seems to me you placed more few more systems than what we expected. Can you talk about the place",64,"Okay. And Katherine, maybe for you on MAKO. Can you give us a little more color on your comments? You talked about increased demand for the Hip indication. It seems to me you placed more few more systems than what we expected. Can you talk about the placements and the utilization and maybe where you are in the rollout for new indications and software?"
94614,314976743,921149,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","Sure. I think it really is reflective is being completed committed year 2 of the acquisition, so working through the integration and really helping the combined sales for us in 2 optimize their education around the features and benefits of our system, on",269,"Sure. I think it really is reflective is being completed committed year 2 of the acquisition, so working through the integration and really helping the combined sales for us in 2 optimize their education around the features and benefits of our system, on the robotic-assisted platform and getting out there and really detailing those benefits. It's a nice mix of both existing Stryker customers, but also new accounts that we're able to get into with the robots. So we're really pleased with the placement as well a having a number of them outside the U.S. I would really just emphasize 2016 is about really working to make sure we are optimally set up for full commercial launch in '17 for the Total Knee. So we are not expecting any with really bad from that this year. We have a lot of work to do to optimize training protocol. We're going to work with key opinion leaders of both from the Erbitux side as well us feel else read the word system to make we're sure that we're measuring those observational studies to really find to be attributable didn't have to turn our own sales force, do the upgrades of the system. So there's a lot of work to begin to make sure, when go to a full commercial launch, we are set to really optimize that and have a presence at the podium personally will continue to attract placements with the existing indications for 2016 while doing the necessary groundwork to really ensure we're in the great position in 2017 will take full advantage of the Total Knee indication."
94614,314976743,921149,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Operator","And our next question comes from David Roman from Goldman Sachs.",11,"And our next question comes from David Roman from Goldman Sachs."
94614,314976743,921149,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Analysts","I wanted to just start with some of the investment spending that you're committing to through the P&L. Over the past several years, you've been very consistent with investing your business, both SG&A and R&D, which obviously produced is very nice for plan",86,"I wanted to just start with some of the investment spending that you're committing to through the P&L. Over the past several years, you've been very consistent with investing your business, both SG&A and R&D, which obviously produced is very nice for plant growth rate. But as you look forward, as you continue to invest in the business, do you see opportunities to enhance the top line growth rate beyond what you're performing today? And where are the most attractive areas of investment for you?"
94614,314976743,921149,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","Well, I can tell you that I get a chance to travel around our divisions over the course rest of the year. And R&D is enough money to spend in new products. So I would say that up all of the divisions of our parties there is clearly some areas we would foc",339,"Well, I can tell you that I get a chance to travel around our divisions over the course rest of the year. And R&D is enough money to spend in new products. So I would say that up all of the divisions of our parties there is clearly some areas we would focus on a little bit more than others. So you've seen our Spine business really start to turn based on our focus investments in R&D. We've had 3 great quarters in a row in the U.S., we still have the dates of those products outside the U.S. But I would say that would be an area where organic development in spending is really paying offer us. So you would expect more in that area. Sports medicine for us is a business that's growing very fast. It's relatively small we didn't Stryker that's also an area of interest, Neurotechnology as well as Extremities. I would say pick those 4 right off the top of my head, but I would tell you we have a long list. And if my other division presidents are listening on the call, I know that you're preparing ideas for me as well. And you will obviously look at all the ideas and to determine, which ones we think and really provide value for us. We're not just going to spend for the sake of spending. And the company us because Stryker is with the decentralized focus. We're seeing that innovation delivers. And I cited one example of 3D printing where, I think, we're seeing it to have an impact on 2 different divisions of the Stryker, our Knee business as well as Spine. And we have a huge lineup of other divisions with ideas and prototypes to get into 3D-printed titanium products. So I would say that those are sort of the top-of-mind areas of focus but that's all the divisions start lining up and we'll be very selective as we march through that. And we will share more as the year unfolds."
94614,314976743,921149,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Analysts","On the capital side, the $400 million to $450 million sort of the high end of the range, it would be almost a doubling from you were, I think, in 2014. Could you maybe just help us go into a little bit detail on with those CapEx dollars or go we? How much",81,"On the capital side, the $400 million to $450 million sort of the high end of the range, it would be almost a doubling from you were, I think, in 2014. Could you maybe just help us go into a little bit detail on with those CapEx dollars or go we? How much of that are sort of the 2016 isolated in nature And What the implications of the additional CapEx are to the rest of the business down the road?"
94614,314976743,921149,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","Sure. I see that there's just supporting the operations in higher growth level that we've got in the company. There's a couple of areas of specific investment. One is on the ERP transformational area, which is strengthening our global ERPs on a worldwide",114,"Sure. I see that there's just supporting the operations in higher growth level that we've got in the company. There's a couple of areas of specific investment. One is on the ERP transformational area, which is strengthening our global ERPs on a worldwide basis and reducing the numbers that we have, so on a more consistent, common system there. The second one is actually we are building a brand-new state-of-the-art 3D printing manufacturing facility this year as well, too. So we're spending some dollars, I think, in some key potential growth areas for us. And we want to take advantage of the series of the from with the conversion what normal CapEx would be."
94614,314976743,921149,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Operator","And our next question comes from David Lewis from Morgan Stanley.",11,"And our next question comes from David Lewis from Morgan Stanley."
94614,314976743,921149,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Analysts","Just a couple of questions. One, Kevin, just to start off with the market. I wonder if you could comment on 2015, if you think about the underlying momentum and the market and your share position, how much relative share you may or may not have taken in '",81,"Just a couple of questions. One, Kevin, just to start off with the market. I wonder if you could comment on 2015, if you think about the underlying momentum and the market and your share position, how much relative share you may or may not have taken in '15? And how those dynamics in your my compare to the outlook into processed in both in terms of how the markets are going to perform and how you see shares shaking out?"
94614,314976743,921149,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","So thanks for the question. Well, obviously, not everybody is finished reporting yet, so we don't have the final results for 2015. We feel very good about the performance across our portfolio. Certainly, hips has been an area of strength for us for the pa",259,"So thanks for the question. Well, obviously, not everybody is finished reporting yet, so we don't have the final results for 2015. We feel very good about the performance across our portfolio. Certainly, hips has been an area of strength for us for the past 4 years. But we're very encouraged be what you are seeing Knees, as Knees have started to pick up in a historical it's really the last 3, 4 years is to be in line with the market or may be slightly below. And I think we're going to start to see a bit of over performance is very behind innovation and launching new products. So we feel good about our position in those 2. Trauma, of course, as you know, has been a standout for us for about 4 years. And we continue to launch new products, and we continue to grow very well. So to us, the market seems very stable. We like our position in each of the categories. If you include Spine within your definition of Orthopaedics, I would say that was an area that have them in more trouble for us but if you went away. And that's not. So across the portfolio, and I just had a chance to spend sometime with the sales meetings for Orthopaedics and Spine, I could tell that they feel very good about our competitive position. And the market it seems very stable. So I think that we'll see more of the same in terms of volume growth, and we'd like our competitive position."
94614,314976743,921149,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Analysts","Okay. And just 2 quick ones. One, just Katherine, just thinking about MAKO for a second. I mean, you're now selling more systems than the target MAKO ever did. And I wonder, are you seeing any pushback on ASPs for the system around $1 million? And in ligh",106,"Okay. And just 2 quick ones. One, just Katherine, just thinking about MAKO for a second. I mean, you're now selling more systems than the target MAKO ever did. And I wonder, are you seeing any pushback on ASPs for the system around $1 million? And in light of when your competitors acquiring other competitors, specifically in robotics, do you expect as pressure in '16 and '17? And and Bill, you spark my interest in the 3D printing facility. Is this a facility that will be capable of doing 3D-printed full Total Knee and Hips? Or is this more of derivative products of the orthopaedic process?"
94614,314976743,921149,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","Yes. On the capital side, obviously, the can be a conversation $7 million capital and easily. But I will tell you, we are selling $1 million [ph] capital. So those robots are sold. They are not placed. I think what we're doing is really leveraging the abi",175,"Yes. On the capital side, obviously, the can be a conversation $7 million capital and easily. But I will tell you, we are selling $1 million [ph] capital. So those robots are sold. They are not placed. I think what we're doing is really leveraging the ability to offer different models, and we talked about our Flex Financial. So giving customers the ability to outright purchase these depending on their needs. And I think, that's helping and it's really I think the difference between were make a stand-alone is we have a very large selling organization that, over the last 2 years, has really come to understand the features and the benefits. And the value proposition has only improved going from a uni been to a Hip with our Hip systems on it and not knowing it although Knee will be coming, I think, helps in that sales process as well. But we are selling those robots, and I don't anticipate that changing in 2016 been related to any competition that might be out there."
94614,314976743,921149,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","Yes. And to the second part of the question's around 3D printing. So launched -- over the past few years, we've started with part of our Knee system to enable cement-less knee, so we'll go baseplate. We have this past year in the middle of the year launch",208,"Yes. And to the second part of the question's around 3D printing. So launched -- over the past few years, we've started with part of our Knee system to enable cement-less knee, so we'll go baseplate. We have this past year in the middle of the year launched for Shinko and switch over to the can be 3D printing we have a patella we launched that's 3D-printed and I we're just about to launch a 3D-printed titanium interbody device for spine. So all of the products we've lost is for this 3D-printed are all innovative, new products in the case of the Spine product and the cementless product. It allows for bony in growth because they are forced materials are getting very good feedback from customers. For the foreseeable future, at least the next 3, 4 years or so, our focus is really on innovative, new products and not replacing our existing products with 3D-printed products. The pipeline of innovative, new geometries that can be made without 3D printing Wisteria focus. So it's not about trying to replace our products and drive down costs. Over time, 10 years from now, that could be the case. But in the near to midterm, it's really focused on innovative, new products."
94614,314976743,921149,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Operator","And our next question comes from Kristen Stewart from Deutsche Bank.",11,"And our next question comes from Kristen Stewart from Deutsche Bank."
94614,314976743,921149,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Analysts","So Bill, I reiterate definitely congratulations on your retirement, and we definitely will miss you. So just a question more strategically. I was just wondering if you feel good about kind of the 3 main buckets that you have now and whether or not, Kevin,",66,"So Bill, I reiterate definitely congratulations on your retirement, and we definitely will miss you. So just a question more strategically. I was just wondering if you feel good about kind of the 3 main buckets that you have now and whether or not, Kevin, you feel like there's any need to kind expand beyond that and get to any other white spaces at this point."
94614,314976743,921149,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","Yes. No, Kristen, let me be consistent saying past couple of years our sanctity the same those 3 segments reelecting the position in these 3 segments. We want to continue, if you look at all of our acquisitions, they've strengthened each of our businesses",140,"Yes. No, Kristen, let me be consistent saying past couple of years our sanctity the same those 3 segments reelecting the position in these 3 segments. We want to continue, if you look at all of our acquisitions, they've strengthened each of our businesses that we're currently in. And every year, we do the white space assessment, and the white space assessment is not as attractive as staying within our segments. There is a significant number of targets within our segments. I know we only completed 2 deals. It was a little bit quieter year in 2015, but I can tell you, the activity level was no different in 2015 with a lot of deals being discussed. And so I would expect us to continue on the our current strategy and don't expect us to suddenly jump into white space."
94614,314976743,921149,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Analysts","Okay. And then with respect within Neurotech area. Are there any notable clinical activities coming up for trial readouts? Or can you speak to any new product pipelines that we should be aware of that could help drive growth? Obviously, it's been going re",48,"Okay. And then with respect within Neurotech area. Are there any notable clinical activities coming up for trial readouts? Or can you speak to any new product pipelines that we should be aware of that could help drive growth? Obviously, it's been going really well, but sustaining it."
94614,314976743,921149,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","Thanks, Kristen. We love this business, and I would say our clothing and extreme stroke were in great shape, and we're growing very well in those 2 categories. The one area for Stryker that is slight gap is the stent segment. We are selling that outside t",126,"Thanks, Kristen. We love this business, and I would say our clothing and extreme stroke were in great shape, and we're growing very well in those 2 categories. The one area for Stryker that is slight gap is the stent segment. We are selling that outside the U.S., but we don't get [indiscernible] U.S. approval. We have completing of our trial and will be submitting for that to do or still have some time before that gets approved. That's the one area we are not in. So we're driving this terrific growth without being in that one segment in the United States. So that's an ongoing process. We'll update you more towards the end of this year in terms of when that will come to market."
94614,314976743,921149,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Operator","Our next question comes from Jason Wittes from Brean Capital.",10,"Our next question comes from Jason Wittes from Brean Capital."
94614,314976743,921149,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Analysts","It sounds like the -- we should a few of the Total Knee coming up next year so the transformational part. If I look into this year, can you kind of maybe highlight sort of the products that we should be focused on that are really drive that growth this ye",51,"It sounds like the -- we should a few of the Total Knee coming up next year so the transformational part. If I look into this year, can you kind of maybe highlight sort of the products that we should be focused on that are really drive that growth this year?"
94614,314976743,921149,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","I would really look at it as across the board very typical Stryker fashion where it's more singles and doubles, whether it's Endo launching our new 1588 camera or MAKO continuing to drive indications like Hip within the new Stryker bands that we talked ab",234,"I would really look at it as across the board very typical Stryker fashion where it's more singles and doubles, whether it's Endo launching our new 1588 camera or MAKO continuing to drive indications like Hip within the new Stryker bands that we talked about or Spine with their new products that are coming out 3D-printed. So it's really a story about those incremental, innovative new products. Usually, no one on its own is a growth driver. It's the totality of that offer and it really allows us to sustain that organic growth at the high end of med tech. Clearly, next year, we're set up for some more impact for products, when you have every MAKO and Total Knee and expect them to be on a clear trajectory is taking meaningful market share as we work our way through '17. Ischemic is one more of those transformational opera despite the fact market development that still needs to take place there around the patient path, referral systems, hospital, intro hospital transfer is we talked about about being a multiyear process, but clearly seeing some very good growth rates but off of a very small base. But I would really think this year as a typical Stryker. We've got a lot of parts, momentum, dedicated sales force with the specially specialty focus is really helping the trend that 5% to 6% growth we're targeting."
94614,314976743,921149,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Analysts","Okay, very helpful. Just a quick follow-up for MAKO. Can you give us a sense of how many of these new placements are to existing accounts and how many of these are de novo. Just got a giving a sense [indiscernible].",41,"Okay, very helpful. Just a quick follow-up for MAKO. Can you give us a sense of how many of these new placements are to existing accounts and how many of these are de novo. Just got a giving a sense [indiscernible]."
94614,314976743,921149,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","So out of the 31, we haven't broken out. I would tell you, though, that it is a combination of both existing Stryker customers as well as new customers where we haven't had any type of meaningful presence. So we haven't given it with more granularity than",54,"So out of the 31, we haven't broken out. I would tell you, though, that it is a combination of both existing Stryker customers as well as new customers where we haven't had any type of meaningful presence. So we haven't given it with more granularity than that, but there is a nice mix."
94614,314976743,921149,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Operator","And the next question comes from Matt Miksic from UBS.",10,"And the next question comes from Matt Miksic from UBS."
94614,314976743,921149,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Analysts","Super job on the numbers like I'll pass on my congratulations and farewell to Bill. We will also miss you. So on MAKO, just a couple of maybe broader questions on how you're positioning the platform. Robotics has been kind of a market development project",121,"Super job on the numbers like I'll pass on my congratulations and farewell to Bill. We will also miss you. So on MAKO, just a couple of maybe broader questions on how you're positioning the platform. Robotics has been kind of a market development project for a while, oftentimes dealing with surgeons and helping them get more comfortable with this new technology, maybe changing the way surgeries are than for the longterm. But at what point does this become, or has it already become an opportunity to try better contracting for you across your implant lines, greater share or is the decision multiline contracting, driven by the merits of the system and the technology? And I have a quick follow-up."
94614,314976743,921149,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","So Matt, I would say, look, we're still in the early stages. But the Stryker Hip brands are now just available recently. And we haven't launched the Total Knee yet. So I think those are at the peak applications. And to say that's impacting contracting, I",145,"So Matt, I would say, look, we're still in the early stages. But the Stryker Hip brands are now just available recently. And we haven't launched the Total Knee yet. So I think those are at the peak applications. And to say that's impacting contracting, I would say, it's too early for that. Once this becomes a more mature business, which will take a couple of years, then, I think, obviously come having system that surgeons are having a great experience and they enjoy it and they want to use the products, it really does provide us with great differentiation, which will -- and differentiation will start in many different ways, including potentially in contracting. But we're always found that the at, we have a lot of work to do in the next couple of years to really gain more broad adoption of the technology."
94614,314976743,921149,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Analysts","Then another on the same topic here. Katherine, someone asked earlier about Hips and what's your change and how you're improving performance there. To put that in perspective, I remember when Hips came out and when you first acquired the system, it wasn't",101,"Then another on the same topic here. Katherine, someone asked earlier about Hips and what's your change and how you're improving performance there. To put that in perspective, I remember when Hips came out and when you first acquired the system, it wasn't generally thought to be really where the bank or the buck was with the robot. But I guess, what's changing? Does the application get a lot easier? are people putting out the benefits of the hip? I mean, what's driving uptick in against what was historical viewed as sort of like that the greatest application for the robot?"
94614,314976743,921149,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","Okay. So I will take this question. So out build you the iterations of the software were a little bit clunky, and it requires quite a bit more registration time to register in the software system. So that's just the next trust that some of the surgeons ar",284,"Okay. So I will take this question. So out build you the iterations of the software were a little bit clunky, and it requires quite a bit more registration time to register in the software system. So that's just the next trust that some of the surgeons are a little bit frustrated with. Over the time, both prior to our acquisition and subsequent to our acquisition, we've made some enhancements of the software to make it a little bit more user-friendly. That's been one factor for sure. I think the most compelling factor is it's showing the surgeons the free and post x-rays that they put the Hip exactly where they want to put it. And I think even the surgeons had some hesitations when they see their pre and post x-rays, they are just -- it's a very compelling visual for them to understand before they weren't doing that. They weren't able to get that same type of consistency. And that's starting to resonate with a lot of surgeons. And now being able to put our implants in addition with easier-to-use software and to get that kind of outcome, it's like all things have changed, right? Change doesn't occur to everybody at the same time. Some people are early the adopters. Some people, frankly, will never adopt. There are just beset in our airways. But what we're seeing is the middle of the bell curve is starting to shift its mindset. And frankly, the more that robotics is talked about, in the community at large, we find that actually a very positive thing because we really believe we have a terrific system, and we're obviously continuing to invest in that system going forward."
94614,314976743,921149,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Operator","Our next question comes from Joanne Wuensch from BMO Capital Markets.",11,"Our next question comes from Joanne Wuensch from BMO Capital Markets."
94614,314976743,921149,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Analysts","I had 2 questions. The first question has to do with 3D printing. It's been quite a we're a couple of years ago, now you're definitely doing a bigger focus on that. What does it take for a 3D-printed, call it, Hip or Knee to become more mainstream? Is it",62,"I had 2 questions. The first question has to do with 3D printing. It's been quite a we're a couple of years ago, now you're definitely doing a bigger focus on that. What does it take for a 3D-printed, call it, Hip or Knee to become more mainstream? Is it manufacturing? Is it clinical data? How should we think about this evolving?"
94614,314976743,921149,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","Well, it's a long answer, Joanne. The reason I paused to get to the technology with 3D-printing will take a long time. The quick summary is the 3D printing metal is very different than sort of the way you think about 3D printing plastic having it on a des",211,"Well, it's a long answer, Joanne. The reason I paused to get to the technology with 3D-printing will take a long time. The quick summary is the 3D printing metal is very different than sort of the way you think about 3D printing plastic having it on a desk and office and cracking up 3D-printed but express a metal is much more competent. It's explosive. It requires a lot of extra programming just don't buy a machine that sort of offer to the races. It's a lot more complicated than that. So we spend a lot of time working on this for many, many years. And so we have a lot of know-how and how to program machines and optimizing machines. And so there's a lot of factors that go into it, to be able to create. And different types of machines work better for smaller products than larger products. So it's difficult for me to just summarize in a short time. I'd just say it's more complicated than plastics or other things that you read about in the mainstream press. And that's why, for us, our focus is much more on innovative new products and not necessarily replacing total systems. That will be many, many, many years ahead of us."
94614,314976743,921149,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Analysts","That's very helpful. As a follow-up, what should we be expect of the upcoming ALS?",16,"That's very helpful. As a follow-up, what should we be expect of the upcoming ALS?"
94614,314976743,921149,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","Is the 1 that will be difficult to clear leaders going to be a big focus around MAKO as we think about uni as well as hip. It's too early in our initial commercialize activities and to have a big focus on user feedback from Total Knees, although I'm sure",120,"Is the 1 that will be difficult to clear leaders going to be a big focus around MAKO as we think about uni as well as hip. It's too early in our initial commercialize activities and to have a big focus on user feedback from Total Knees, although I'm sure there'll be a lot the surgeon presents around that as they're looking to get educated on the features and benefits and we will have a tour of the both of us we have done previously to highlight new products across all the businesses from Trauma, Foot & Ankle, Spine, et cetera. And we'll also have an opportunity to sit down and meet with management and have an open Q&A forum."
94614,314976743,921149,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Operator","And the next question comes from Raj Denhoy from Jefferies.",10,"And the next question comes from Raj Denhoy from Jefferies."
94614,314976743,921149,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Analysts","Wondered if I could ask a question about the CGR or CCGR program that's rolling out. I know that you guys have been pretty clear as of the company's having nothing it's going to have much impact on pricing in the postacute care, which much mirrors what yo",98,"Wondered if I could ask a question about the CGR or CCGR program that's rolling out. I know that you guys have been pretty clear as of the company's having nothing it's going to have much impact on pricing in the postacute care, which much mirrors what you're hearing as well. But my question is really around how stryker interfaces with that model. With your performance solutions business you guys were involved in some of the penis initiatives before. Is there an opportunity for you guys to perhaps benefit from the CGR program as it rolls out?"
94614,314976743,921149,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","Yes. We agree with your comments. We don't think it's going to have a meaningful impact. We have seen a test with some of the prior programs. It really does drive a focus on postacute and patients that are discharged right. So we have given the high cost",194,"Yes. We agree with your comments. We don't think it's going to have a meaningful impact. We have seen a test with some of the prior programs. It really does drive a focus on postacute and patients that are discharged right. So we have given the high cost there. We do have a small business. Our Stryker performance solutions with the help work with hospitals to help make them aware of the data so they can have a sense of what best-in-class is and where some of the cost benefits they can realize,whether it's a rounding detection rates, transfusion, et cetera. So it's not a huge part of our business, but it is one that provides insights and that's up them as they are the but here overall structure. But clearly, we continue to believe based on everything we've seen that it's going to be postacute care. We haven't seen any meaningful change at all in price between those trial areas as it relates to implant pricing and really because that say Bisbee can realize going to focusing on our rehab and really do worth anything else at the point this point in time."
94614,314976743,921149,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Analysts","Right. Maybe as a follow-up. But if you think about that service offering, if that's the way to describe it, was performance solutions are really a sitting over the next several years, do you envision the service component becoming a bigger part of the bu",57,"Right. Maybe as a follow-up. But if you think about that service offering, if that's the way to describe it, was performance solutions are really a sitting over the next several years, do you envision the service component becoming a bigger part of the business offering not just implants to hospitals but perhaps something a bit broader?"
94614,314976743,921149,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","Yes. I mean, that division is continuing to focus on that. It's not a huge part of our company. I think, we see this CGR as a terrific example of an opportunity for us to grow that business. But it's not at a scale at which I really want to start highligh",194,"Yes. I mean, that division is continuing to focus on that. It's not a huge part of our company. I think, we see this CGR as a terrific example of an opportunity for us to grow that business. But it's not at a scale at which I really want to start highlighting it. I would tell you, a year from now, I think we'll have a much better idea of the scope of CCGR can become a broader business for us. So services is not something you to Stryker. Will about our MedSurg business provide services to hospitals we have people in the hospital that our customers pay for, to make sure that all their uptime is working on their equipment. So we're not against services at all, but we don't sort of like to get out in front of ourselves. Let's start see how this unfolds in the business be them something that could be scalable, then we'll talk about it a lot more. But right now it's a small part I agree with you that CCGR does provide an exciting opportunity for that business, but it's a very small part of Stryker."
94614,314976743,921149,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Operator","And our next question comes from Larry Biegelsen from Wells Fargo.",11,"And our next question comes from Larry Biegelsen from Wells Fargo."
94614,314976743,921149,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Analysts","Starting on one start with and M&A. About a year ago, Kevin, you said you expect to put the balance sheet work. And I just wanted to confirm that, that's still the case. And I'm asking because, obviously, you've been relatively quiet on the acquisition fr",76,"Starting on one start with and M&A. About a year ago, Kevin, you said you expect to put the balance sheet work. And I just wanted to confirm that, that's still the case. And I'm asking because, obviously, you've been relatively quiet on the acquisition front over the past 6 to 12 months, which is atypical. So is there any reason you have haven't pulled the trigger on more deals? And I have one follow-up."
94614,314976743,921149,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","Sure. I would tell you, just look deal timing is inherently unpredictable. There's absolutely no change the statement I made before I still intend to put the balance sheet to work. The reason we got the extra share buyback approval level but just in case",129,"Sure. I would tell you, just look deal timing is inherently unpredictable. There's absolutely no change the statement I made before I still intend to put the balance sheet to work. The reason we got the extra share buyback approval level but just in case those that don't get over the line or drag on for extended periods of time, we will start to step of the buybacks. But you should expect us to continue to be very up active acquirer. But you've seen in the past, right, sometimes, some years, there's 1 or 2 deals. Another year, you see many more deals. So our a level of activity hasn't changed. I still see many exciting prospects out there. And so we're staying the course with the existing strategy."
94614,314976743,921149,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Analysts","And then earlier you said that in Q1, you would expect to be at the low end of the 5% to 6%, I think, constant currency growth rate because of what you are seeing in emerging markets and so -- but to expect emerging market to be relatively weak throughout",90,"And then earlier you said that in Q1, you would expect to be at the low end of the 5% to 6%, I think, constant currency growth rate because of what you are seeing in emerging markets and so -- but to expect emerging market to be relatively weak throughout 2016, I believe. So my question is, does getting the growth rate up above that low end of the range, does that depend upon an improvement in emerging markets? And if not, how do you get that growth rate up?"
94614,314976743,921149,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","Yes. I would just comment that if you look at the cadence quarter last year, we had some difficult comparisons in the first quarter that related to emerging markets, more of the pressure, particularly in China unfolded in the year went on. We're going to",90,"Yes. I would just comment that if you look at the cadence quarter last year, we had some difficult comparisons in the first quarter that related to emerging markets, more of the pressure, particularly in China unfolded in the year went on. We're going to have easier comps in the back half the year. We tend to have a seasonally stronger second half the year, particularly as it relates to the fourth quarter. So it's more just reflective of how our quarters play out in some of the year-over-year comparisons."
94614,314976743,921149,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Operator","And our next question comes from Glenn Novarro of RBC Capital.",11,"And our next question comes from Glenn Novarro of RBC Capital."
94614,314976743,921149,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Analysts","Kevin, your U.S. Hip and Knee business had a strong fourth quarter, up 6% and 9%, respectively. Did you see this in the fourth quarter, the U.S. Orthopaedic market accelerate or pick up a bit? Or do you think that was more share capture from Zimmer, given",62,"Kevin, your U.S. Hip and Knee business had a strong fourth quarter, up 6% and 9%, respectively. Did you see this in the fourth quarter, the U.S. Orthopaedic market accelerate or pick up a bit? Or do you think that was more share capture from Zimmer, given the integration between Zimmer and Biomet? And then I have a follow-up question on robotics."
94614,314976743,921149,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","Yes, Solow, do we see everybody report, it's really difficult for me to say how much of it is the market versus competitive share capture. The Knee number, we've been encouraged about that we tend to believe that our Knee brand is driven by the new produc",185,"Yes, Solow, do we see everybody report, it's really difficult for me to say how much of it is the market versus competitive share capture. The Knee number, we've been encouraged about that we tend to believe that our Knee brand is driven by the new products, the revision cones and more uptake of our cementless knee offering. So we believe that's more of the issue that lets call tells first disruptions read other factors does bring up other companies. It's more about our innovation. When I talked to our field the sense of getting a very stable markets. So it wasn't -- a few years ago, we saw this big seasonal fourth quarter lift. We are now seeing the typical fourth quarter. This December was more or less typical. It's more active, but it was more active a year ago, too. So we're not seeing -- we didn't see anything or major in terms of from quarter-to-quarter you do some things slight uptick were don't expect until the report, it's going to difficult for me to comment but if you have a second question."
94614,314976743,921149,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Analysts","Yes, Katherine, in your prepared remarks you talked about the MAKO system, podium presentations in 2016. So can you describe what type of presentations? I'm assuming these are clinical trials. So what type of trials? And when can we see these trials being",44,"Yes, Katherine, in your prepared remarks you talked about the MAKO system, podium presentations in 2016. So can you describe what type of presentations? I'm assuming these are clinical trials. So what type of trials? And when can we see these trials being presented?"
94614,314976743,921149,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","Yes. My comments were that we were going to do observational studies in 2016, so really looking at key opinion leaders who have extensive experience with robotics to understand how we can find some good training protocol and optimize the rollout. We're al",164,"Yes. My comments were that we were going to do observational studies in 2016, so really looking at key opinion leaders who have extensive experience with robotics to understand how we can find some good training protocol and optimize the rollout. We're also going to be doing with observational studies with key opinion leaders level of familiarity with the Triathlon systems of the end much of those 2 data sets and really put us in a position to have a presence at the podiums in 2017, not '16. So we think combining the full commercial launch and being in a position in 2017 for those initial users, those key opinion leaders of the about their experience and how they were able to optimize both the robot as well as our trampling will help drive the adoption. We will recorded with additional clinical data, but that is going to take a number of years. Really focus around observational study to help optimize the training protocol."
94614,314976743,921149,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Operator","And the next question comes from Mike Mount from Needham & Company.",11,"And the next question comes from Mike Mount from Needham & Company."
94614,314976743,921149,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Analysts","I guess, I just wanted to start with the new camera at the Endoscopy business. How does this compare to the prior models? Is it more of an incremental improvement? And just in terms of the impact on the growth rate there. Do you expect that to be more of",70,"I guess, I just wanted to start with the new camera at the Endoscopy business. How does this compare to the prior models? Is it more of an incremental improvement? And just in terms of the impact on the growth rate there. Do you expect that to be more of a step change or more of a ramp in terms of the growth in Endoscopy? Then I have one follow-up."
94614,314976743,921149,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","Yes. So no, the 1588, we try to have a new version, and we call it the [indiscernible] 4888. We went up 1588 and now we're calling it the 1588 is the name of it I would say it's been fully better. So the 1488 had terrific resolution, but we've improved th",271,"Yes. So no, the 1588, we try to have a new version, and we call it the [indiscernible] 4888. We went up 1588 and now we're calling it the 1588 is the name of it I would say it's been fully better. So the 1488 had terrific resolution, but we've improved the backlighting and some of that the image clarity for certain procedures like ENT that -- so our product works well in a wide variety of procedures, but there are certain procedures where the lighting just wasn't quite as optimize your can we make some nice enhancements therapist what was the reach of procedures, surgeons are all going to have a delightful experience, whereas, in the past, it was not necessarily across every specialty. That's the first thing that's anything we have ICG will be tormentors, which we never had before. So it's impossible you can light up the organs, just I'm sure you are familiar with ICG would competitive product out there. But this is not -- it doesn't require an extra piece of capital. To build the writings of the letter is, is it for the surgeons to use, which is wonderful. It also includes and other products for julienne that lights up press the anatomy to so it's really a safe surgery launch that enables safe surgery with enhanced visualization. And we just launched it in December, so we don't have a huge amount of the sales yet, but I would see the early clinical feedback has been very positive. So I do expect Endoscopy to have a better year in 2016 than they did in 2015."
94614,314976743,921149,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Analysts","And then just with regard to this big ERP that you have. What's the execution risk there that something gets some trough in terms of inventory levels and things like that and causing impact on your overall results for the company?",41,"And then just with regard to this big ERP that you have. What's the execution risk there that something gets some trough in terms of inventory levels and things like that and causing impact on your overall results for the company?"
94614,314976743,921149,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","Yes. So with any system implementation, there's always some degree of risk. We're being very thoughtful and careful about how we go about the project. We're staffing -- we're putting our best people on it dedicated workspace. And in fact, my former Head o",255,"Yes. So with any system implementation, there's always some degree of risk. We're being very thoughtful and careful about how we go about the project. We're staffing -- we're putting our best people on it dedicated workspace. And in fact, my former Head of HR, who has also run businesses, is going to be the leading the business component of that and I appointed a new head of IR the tens into refusing about up to the organization, committed to the will be measured launch, so it will take a number of years before it is complete, and we are starting up with our Instruments division. And we're going to continue -- we have a study market plan we have an IT leader we spidery within the business leader who has previous large that the company doing exactly this kind of an implementation over the past 2 years. So we believe it's all about channel, start staffing the right people who know our business, and we're going to do our best, obviously, to mitigate the risk. We had painful experience in Japan of public years ago. I can tell you the a push at the spot project is radically different to the approach we used in that project. And so we feel being in good Hip, and it's not a Big Bang launch. We're going to do division by division, region by region and there'll be a static instance safe something the start to wobble a little bit, it should have very, very little impact."
94614,314976743,921149,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Operator","Our next question comes from Matt Keeler from Barclays bank.",10,"Our next question comes from Matt Keeler from Barclays bank."
94614,314976743,921149,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Analysts","Great. So I was just wondering if you could follow-up on some of those comments on 3D printing and talk about the materiality of the contribution in the quarter and what you're expecting going to be investing in the new plant, home biggest is it and how m",50,"Great. So I was just wondering if you could follow-up on some of those comments on 3D printing and talk about the materiality of the contribution in the quarter and what you're expecting going to be investing in the new plant, home biggest is it and how material is investing?"
94614,314976743,921149,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","Yes. For the moment, it's -- these are innovative products that are adding, I would call, incremental growth. It's not the core growth. The core growth is our big systems, right, our Triathlon, our aquiline. That's where the core amount of our sales comes",281,"Yes. For the moment, it's -- these are innovative products that are adding, I would call, incremental growth. It's not the core growth. The core growth is our big systems, right, our Triathlon, our aquiline. That's where the core amount of our sales comes from. But this gives a little extra boost to put some little bit of jump in our sales force. Step gives us something new to them customers about. So for example, our revision business lagged, the were market share Landover primary business in Knees by about 5 or 6 market share point. So even in a Stryker family account, sometimes they would go to a competitive competitor into their revision procedure. Now that we help we consider best-in-class revision goes. Not only do we keep that, that business, that certain states with Strykercan we gain that sauce but the have something to talk of to a competitive the surgeon about. 
So I would say it's not a huge contributor, but it's an extra shot in the arm. So with robotics and 3D printing, we believe we have the lead on both of those areas. And those are things we can talk about that differentiate us from our competition. So again, not even today robotics is not a huge component of our growth of our actual dollar sales, but we believe they are the ones that are causing that the extra piece of growth and have different view of Stryker for the future. Over time, I expect robotics and 3D printing to take on a more important portion of our overall sales. And they'll Neuro be sustainable in sticky if we have the something that competition doesn't have."
94614,314976743,921149,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Analysts","Okay, great. But just one question on the transatlantic model you're making some progress there can you talk about where you are and how much that's helped to improve some of the OUS results and where you think that could go?",41,"Okay, great. But just one question on the transatlantic model you're making some progress there can you talk about where you are and how much that's helped to improve some of the OUS results and where you think that could go?"
94614,314976743,921149,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","Yes. So look, Europe has exceeded my expectations. We had a really international growth doesn't look fantastic, so you don't see it. But Europe had a mid-single-digit growth year, and it improved progressively from the first quarter to the fourth quarter.",316,"Yes. So look, Europe has exceeded my expectations. We had a really international growth doesn't look fantastic, so you don't see it. But Europe had a mid-single-digit growth year, and it improved progressively from the first quarter to the fourth quarter. So that kind of uptick is, frankly, ahead of where we expected it to be. It's been masked a little bit because of the sluggishness out of China, so that has dampened our international sales. But it's been a really great success. I'm excited about what I'm seeing across our businesses in Europe. Some of the divisions to call Pastor and others but the Extremities and others and Endoscopy now starting to see some nice uptick in Instruments and spread to worse both the end of the year. So more to come in Europe we made a number of investments over the course of the year. Those investments are now taking hold, and I think you'll start to see Europe become a division that delivers better top line and starts to deliver some leverage going forward. We've added Canada, so those are now directly managed. A Division President has direct P&L accountability for Canada, the U.S. and Europe. The other regions, we haven't yet folded into the model, but by eliminating the Group President of international role, we know have them reporting directly to our business Group President. So it just increases speed and connectivity from our regions to come straight to a Group President. Over time, we'll see whether those countries will roll into this model, but we don't want to run too fast to fully integrated complete global business units, especially with my the slide China doors of different our Japan. But we're very pleased with the progress so far taking out that position nothing about cost reduction that was 100% just to increase speed and productivity of those countries to our businesses."
94614,314976743,921149,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Operator","And our next question comes from Matt Keeler from Crdit Suisse.",11,"And our next question comes from Matt Keeler from Crdit Suisse."
94614,314976743,921149,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Analysts","Just 2 quick ones. First, on Hips outside the U.S, you highlighted the drag from emerging markets but your Knee growth as we picked up pretty nicely. But I was wondering if there is much more pronounced impact from that emergent markets a drag on Hips rel",65,"Just 2 quick ones. First, on Hips outside the U.S, you highlighted the drag from emerging markets but your Knee growth as we picked up pretty nicely. But I was wondering if there is much more pronounced impact from that emergent markets a drag on Hips relative to Knees and if there were any other factors that impacted your Knees  business outside of the U.S?"
94614,314976743,921149,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","No, nothing particular. You see this from quarter-to-quarter, and sometimes you see in the Hips jump in case of Hips, 10 [ph] as an example, there was a hip tender that we lost to that about that for some of the growth. There was that 1 can of overall kin",98,"No, nothing particular. You see this from quarter-to-quarter, and sometimes you see in the Hips jump in case of Hips, 10 [ph] as an example, there was a hip tender that we lost to that about that for some of the growth. There was that 1 can of overall kind of story-by-story, country-by-country we see in this quarter-to-quarter sometimes you see our visits that, that because of the U.S. So you do see a little bit more volatility in our numbers, whether it's Hip, Knee, Spine. Once those businesses  get larger, you would expect there'll be less volatility."
94614,314976743,921149,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Analysts","Great. And just lastly. Instruments growth was produced with water, but I think you highlighted that, that possesses the better that product cycle I. Was wondering if you think of that growth we saw in the fourth quarter, if that is sustainable going forw",64,"Great. And just lastly. Instruments growth was produced with water, but I think you highlighted that, that possesses the better that product cycle I. Was wondering if you think of that growth we saw in the fourth quarter, if that is sustainable going forward. What are some of the products to watch where you might be a little later on in the product cycle?"
94614,314976743,921149,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","Yes, of the power tools are the products we refer to as being late in the cycle, the System 7 power tools, which is probably the biggest single product category within Instruments. But Instruments has a lot of other products. So they have Neptune, they ha",151,"Yes, of the power tools are the products we refer to as being late in the cycle, the System 7 power tools, which is probably the biggest single product category within Instruments. But Instruments has a lot of other products. So they have Neptune, they have their launching new switcher line of drills. We actually report that the spread of the BurEau tech but it's Ron Barrett's investigation. But yes, they help the sponge hammer as well, patient safety company we acquired. So these are different kinds of businesses that can trend growth. It's a little less predictable than power tools. So if we're very excited how the finished the year they finished they are very, very strong and within that building will have a good year. But being lower in the cycle sometimes we do see them tailing off a little bit but we expect that to lead the overall."
94614,314976743,921149,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Operator","The next question comes from Richard Newitter from leering partners.",10,"The next question comes from Richard Newitter from leering partners."
94614,314976743,921149,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Analysts","Kevin, I was hoping I'd just get some comments on Spine. You characterize the market as stable, and you're clearly seeing some nice uptick in the growth rates there. You have some new product launches. So my question really is has there been any chance or",77,"Kevin, I was hoping I'd just get some comments on Spine. You characterize the market as stable, and you're clearly seeing some nice uptick in the growth rates there. You have some new product launches. So my question really is has there been any chance or can you give us your updated thoughts on how you view kind of external versus internal investments in these division for you now that things seem to be on better footing?"
94614,314976743,921149,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","Yes, so I am really excited about what we're doing organically. So we've retooled our R&D organization, some of our marketing organization over the past few years and is businesses hitting its stride. And we're launching more and more new products. We're",160,"Yes, so I am really excited about what we're doing organically. So we've retooled our R&D organization, some of our marketing organization over the past few years and is businesses hitting its stride. And we're launching more and more new products. We're getting into MIS, which is an area where softer before if you don't factor 3 or 4 years ago. And so it's great to see the organic growth obviously is much more financially attractive than going out and spending a lot of money on companies. Over time, I do want this to become a bigger division, and I think it's -- you'll likely see a combination of both organic and acquisitions. And it's always been better to have a strong organic business. And so I do not feel at all that I need to do an acquisition because of the strength and what it started to build internally but that is something that will likely happen over time."
94614,314976743,921149,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Analysts","Okay, and just on Extremities. Again, your Foot and Ankle growth, I think you said it was 20%. That's -- the business continues to track along. And the comments on kind of the end markets versus potential share gains that we might have seen in the quarter",60,"Okay, and just on Extremities. Again, your Foot and Ankle growth, I think you said it was 20%. That's -- the business continues to track along. And the comments on kind of the end markets versus potential share gains that we might have seen in the quarter? And specifically, are you seeing any disruption from resend M&A in the field?"
94614,314976743,921149,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","Yes, I would just take this our market sector continued to be very healthy growing double digits. We believe we are the key markets are we've got a dedicated sales force there, some great products and I wouldn't call it any disruption that we're seeing in",66,"Yes, I would just take this our market sector continued to be very healthy growing double digits. We believe we are the key markets are we've got a dedicated sales force there, some great products and I wouldn't call it any disruption that we're seeing in the marketplace. I think it just continues to be really good execution a market that has favorable underlying growth dynamics."
94614,314976743,921149,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Operator","And our next question comes from Jess Jennings of Cowen and Company.",12,"And our next question comes from Jess Jennings of Cowen and Company."
94614,314976743,921149,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Analysts","Kevin, I just wondered if you could touch on pricing do you have commentary about some potential moderation in the pricing headwinds that he was certainly have been experiencing. Any comments in terms of assumptions for pricing headwinds within guidance?",49,"Kevin, I just wondered if you could touch on pricing do you have commentary about some potential moderation in the pricing headwinds that he was certainly have been experiencing. Any comments in terms of assumptions for pricing headwinds within guidance? And then the outlook for pricing, particularly in Orthopaedics?"
94614,314976743,921149,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","Yes. So you saw for the full year, our price did moderate somewhat from the prior year. There was a lot of concern as we exited -- if you remember, as we're exiting '14, there a was a lot of concern the pricing was going to accelerate in '15. In fact, it",126,"Yes. So you saw for the full year, our price did moderate somewhat from the prior year. There was a lot of concern as we exited -- if you remember, as we're exiting '14, there a was a lot of concern the pricing was going to accelerate in '15. In fact, it hasn't. It actually moderated a little bit. But it's much that the moderation is very modest. And in our guidance, we suggest that the price will be between 1.5% to 2%. And so I would say it's a stable market. We continue to have price pressure. It's not going away. But we don't see any accelerators to that price pressure and that's why we for this going to be pretty stable going into 2016."
94614,314976743,921149,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Analysts","Great. And then just one follow-up on MAKO. We haven't heard much over the last year on the Uni knee product. Any commentary there in terms of how it to put into growth in your Knee franchise and just overall growth for that product line?",45,"Great. And then just one follow-up on MAKO. We haven't heard much over the last year on the Uni knee product. Any commentary there in terms of how it to put into growth in your Knee franchise and just overall growth for that product line?"
94614,314976743,921149,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","Thanks, Steve. I would say the uni market, put into the context overall Stryker is very small part of the overall business. And I would say it's a steady computer, but there's nothing remarkable to say about it. It's a good business, but it's a very small",52,"Thanks, Steve. I would say the uni market, put into the context overall Stryker is very small part of the overall business. And I would say it's a steady computer, but there's nothing remarkable to say about it. It's a good business, but it's a very small part of our overall Knee."
94614,314976743,921149,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","When you're talking specifically about for MAKO? so for MAKO it's a first indication, and they're continuing to drive uptick for that as well as with Hips. As we get additional indications acting it helped us does help drive adoption as some customers wer",68,"When you're talking specifically about for MAKO? so for MAKO it's a first indication, and they're continuing to drive uptick for that as well as with Hips. As we get additional indications acting it helped us does help drive adoption as some customers were not interested in just Uni. But as we get more education somebody are starting to adopt for that as well as the others."
94614,314976743,921149,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","Yes, but I'm to strengthen interpret or a that Josh that got up to us to interpret the growth of 9% in the U.S., that's spike in growth. It really wasn't driven by MAKO unis. This driven more by the brother in the business.",44,"Yes, but I'm to strengthen interpret or a that Josh that got up to us to interpret the growth of 9% in the U.S., that's spike in growth. It really wasn't driven by MAKO unis. This driven more by the brother in the business."
94614,314976743,921149,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Analysts","The next question comes from Matthew O'Brien from Piper Jaffray.",11,"The next question comes from Matthew O'Brien from Piper Jaffray."
94614,314976743,921149,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Analysts","Just quickly on MAKO again. The number of systems were pleased international the accelerated during Q4. Was there anything that you call out as for us may be a little bit of a tipping point in terms of interest in the robotics to stem OUS and maybe that c",58,"Just quickly on MAKO again. The number of systems were pleased international the accelerated during Q4. Was there anything that you call out as for us may be a little bit of a tipping point in terms of interest in the robotics to stem OUS and maybe that could be an even more meaningful contributor here in 2016?"
94614,314976743,921149,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","No. Still, the lion share of the focus of the revenues coming from the U.S. and systems outside the U.S. and we'll continue to focus of the support is particularly the places like us a lesson in other markets but the walk of the revenue assume us been mor",61,"No. Still, the lion share of the focus of the revenues coming from the U.S. and systems outside the U.S. and we'll continue to focus of the support is particularly the places like us a lesson in other markets but the walk of the revenue assume us been more of like liquids you at least in their attempt of the U.S."
94614,314976743,921149,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","Yes. In terms of country-by-country thing, so Australia had a terrific year in what sales, I think, in Northern Europe. And as the countries are going to adopt MAKO much more quickly than other countries. So I think each year, you'll sort of see internati",91,"Yes. In terms of country-by-country thing, so Australia had a terrific year in what sales, I think, in Northern Europe. And as the countries are going to adopt MAKO much more quickly than other countries. So I think each year, you'll sort of see international volumes starting to increase but it might be it to lead this year, it might be the U.K. next year over the next few years. But again, to Katherine s point, the market that's the most important by far is going to be the U.S. market."
94614,314976743,921149,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Analysts","Okay, to follow up a little bit on Richards question a little bit more broadly on Trauma desperate Extremities of this was the reason here in Q4 beyond what we've seen over the last several quarters, and I am just curious if that consideration was specifi",74,"Okay, to follow up a little bit on Richards question a little bit more broadly on Trauma desperate Extremities of this was the reason here in Q4 beyond what we've seen over the last several quarters, and I am just curious if that consideration was specific to and the couple of products or geographies around particularly the U.S. and if that level of growth is something that you think is sustainable here in 2016."
94614,314976743,921149,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","Well, I think you've seen our Trauma business in the U.S. It's been 4 years of really terrific growth. So that to me is sustainable and you will at that level. So we're very, very pleased. We rounded our portfolio completely. And so that enables us to do",186,"Well, I think you've seen our Trauma business in the U.S. It's been 4 years of really terrific growth. So that to me is sustainable and you will at that level. So we're very, very pleased. We rounded our portfolio completely. And so that enables us to do complete hospital conversions, something that was impossible at Stryker 5, 6 years ago. Europe really picked up quickly. So as you move to a transatlantic model, I was very encouraged by our Trauma access in your. We have not been nearly as successful in Europe as we have been the United States and with the do know Hepzibah Swisher all approved. So, I think, I expect more commercial success in Europe as well as Japan. Now some of those products to Google the word with approved in Japan. So I think, that once those products of certain direct, will see more uptick in spam as well. But I would say we're in a very good position in that business. We have a very, very strong leadership team. And we expect to continue to have success in Trauma Extremities."
94614,314976743,921149,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Analysts","And our next question comes from Jeff Johnson from Robert Baird.",11,"And our next question comes from Jeff Johnson from Robert Baird."
94614,314976743,921149,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Analysts","Bill, I just want to say best wishes I was putting back this afternoon I think it's been 14 years that you and I have overlapped so that is for all the conversations and all doubt that all the time. And so Kevin, just wanted to ask one question, one follo",108,"Bill, I just want to say best wishes I was putting back this afternoon I think it's been 14 years that you and I have overlapped so that is for all the conversations and all doubt that all the time. And so Kevin, just wanted to ask one question, one follow-up question here just the beginning some of the med-tech tax savings. Is there going to be anytime differential between when the Med Tech Tax savings skinflint that was than maybe when you suck reinvesting those dollars back into SG&A in R&D should those much up evenly in the P&L or a promotion with nobody getting this year?"
94614,314976743,921149,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","I think that, that's fair to say, Jeff, and thanks a lot for your comments. I think that on the cost goods sold category, else with that will start quite of in the beginning of the year. Our investments as we are targeting right now moving again through 2",64,"I think that, that's fair to say, Jeff, and thanks a lot for your comments. I think that on the cost goods sold category, else with that will start quite of in the beginning of the year. Our investments as we are targeting right now moving again through 2016, we would also expect to be doing that reinvestment pretty much consistently throughout the year."
94614,314976743,921149,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","Yes. Sorry, it's going to be clean from the beginning of the year from the beginning of this year to 2017, start immediately. There's a lag effect, which, I think, happened prior with the different  companies. So for us, it's clean. You'll will clean 2 [p",47,"Yes. Sorry, it's going to be clean from the beginning of the year from the beginning of this year to 2017, start immediately. There's a lag effect, which, I think, happened prior with the different  companies. So for us, it's clean. You'll will clean 2 [ph] years."
94614,314976743,921149,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Operator","And our next question comes from Steven Lichtman from Oppenheimer.",10,"And our next question comes from Steven Lichtman from Oppenheimer."
94614,314976743,921149,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Analysts","I just have one follow-up on ERP. You talked about the investment in the capital side. Are there any P&L impacts we should expect over the next couple of years as you start to implement ERP? And when do you anticipate the system being fully in place?",48,"I just have one follow-up on ERP. You talked about the investment in the capital side. Are there any P&L impacts we should expect over the next couple of years as you start to implement ERP? And when do you anticipate the system being fully in place?"
94614,314976743,921149,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","So A couple of different questions. Again, there is a spill on the earpiece out of the equation, from an investment perspective, we won't see the first implementations really for about another 1.5 years or so. And then those will be rolled out over the ne",187,"So A couple of different questions. Again, there is a spill on the earpiece out of the equation, from an investment perspective, we won't see the first implementations really for about another 1.5 years or so. And then those will be rolled out over the next few years after that. As for as the cost side of the equation goes, we would not expect that to be a big leap once we get through that kind of stabilized level that we've got kind of in 2016 year. But moving forward, in fact, if anything, as those systems are implemented, we would expect some of the benefits plus the CT Guinea states we've got kicked tough, those will continue to roll in at different points throughout different years. We do have multi hundreds of millions of dollars targeted for that. Keep mind as well that we have price down to the $150 million to $200 million range that we need to be working to offset. And then as far as the impacts associated with the investment, again, that should be pretty consistent as we're moving forward beyond 2016."
94614,314976743,921149,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","Yes. Just to add to that, I would say, we do have some expense that. Are eating the P&L, but we're absorbing that with the guidance that we have provided to you.",32,"Yes. Just to add to that, I would say, we do have some expense that. Are eating the P&L, but we're absorbing that with the guidance that we have provided to you."
94614,314976743,921149,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Operator","And our next question comes from Kaila Krum Farm William Blair.",11,"And our next question comes from Kaila Krum Farm William Blair."
94614,314976743,921149,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Analysts","Just a couple of quick ones for me. The first, I mean, clearly, you are still emphasizing M&A is the key priority year. And I'm just curious if you can touch on that how or if those conversations have changed tone, some of the evaluation toolbox specifica",53,"Just a couple of quick ones for me. The first, I mean, clearly, you are still emphasizing M&A is the key priority year. And I'm just curious if you can touch on that how or if those conversations have changed tone, some of the evaluation toolbox specifically we had seen in recent weeks?"
94614,314976743,921149,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","Yes, I would say that short of time period doesn't have an impact. And as Kevin articulated, we continue to be focused on a many extra leaders in a be periods work looks more pearlescent of depending on timing and are deleted teams have never been busier,",64,"Yes, I would say that short of time period doesn't have an impact. And as Kevin articulated, we continue to be focused on a many extra leaders in a be periods work looks more pearlescent of depending on timing and are deleted teams have never been busier, and there's no change in the strategy. And we the recent market disruption is what it is."
94614,314976743,921149,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Analysts","Okay. And then, I guess, just a follow-up on an earlier question around worry that there's a potential for long-term growth rate to accelerate. And then just pairing that with your earlier comments about MAKO and the likelihood that 2016 is more of a set",71,"Okay. And then, I guess, just a follow-up on an earlier question around worry that there's a potential for long-term growth rate to accelerate. And then just pairing that with your earlier comments about MAKO and the likelihood that 2016 is more of a set of beer for 2017, is it fair to assume them that overall top line growth would modestly at a federate head into 2017 from 2016 levels?"
94614,314976743,921149,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","That's always our goal to grow sales at the high-end of med tech. And certainly, the we've got some nice opportunities 2 in the ischemic and MAKO. But you're going to be in the early stages next year. So probably premature to start the push towards higher",73,"That's always our goal to grow sales at the high-end of med tech. And certainly, the we've got some nice opportunities 2 in the ischemic and MAKO. But you're going to be in the early stages next year. So probably premature to start the push towards higher growth rates in this year, but we feel really good about what is about this year and hopefully we can build a out in '17."
94614,314976743,921149,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","Yes, Edward and I learned a lot the end of this year we're able to share more than 2 additional platforms, both MAKO and ischemic those are the ones things that can provide change of true that the recent growth for the company. Now when that happens in '1",93,"Yes, Edward and I learned a lot the end of this year we're able to share more than 2 additional platforms, both MAKO and ischemic those are the ones things that can provide change of true that the recent growth for the company. Now when that happens in '17 or '18 or '19, there are new platforms. So it's not easy to predict, but I think we'll learn a lot over the course of this year after only be able to share with you when we provide our guidance in the following weeks."
94614,314976743,921149,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Operator","We have no further question is at this time. I will now turn the conference call back over to Mr. Kevin Lobo for any closing remarks.",26,"We have no further question is at this time. I will now turn the conference call back over to Mr. Kevin Lobo for any closing remarks."
94614,314976743,921149,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","So thank you all for joining our call. Our conference call for the first quarter 2016 results will be held on April 20. Thank you.",25,"So thank you all for joining our call. Our conference call for the first quarter 2016 results will be held on April 20. Thank you."
94614,314976743,921149,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Operator","Thank you, ladies and gentlemen. This concludes today's conference. Thank you for participating, and you may now disconnect.",18,"Thank you, ladies and gentlemen. This concludes today's conference. Thank you for participating, and you may now disconnect."
94614,314976743,921214,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Operator","Welcome to the Fourth Quarter 2015 Stryker Earnings Call. My name is Adrianne, and I will be your operator for today's call. [Operator Instructions] This conference call is being recorded for replay purposes.Before we begin, I would like to remind you t",136,"Welcome to the Fourth Quarter 2015 Stryker Earnings Call. My name is Adrianne, and I will be your operator for today's call. [Operator Instructions] This conference call is being recorded for replay purposes.
Before we begin, I would like to remind you that the discussions during this conference call will include forward-looking statements. Factors that could cause actual results to differ materially are discussed in the company's most recent filings with the SEC. Also, the discussions will include certain non-GAAP financial measures. Reconciliations to the most directly comparative GAAP financial measures can be found in today's press release that is an exhibit to Stryker's current report on Form 8-K filed today with the SEC.
I would now like to turn the call over to Mr. Kevin Lobo, Chairman and Chief Executive Officer. You may proceed, sir."
94614,314976743,921214,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","Good afternoon, everyone, and welcome to Stryker's fourth quarter 2015 earnings call. Joining me today are Bill Jellison, our CFO; Katherine Owen, Vice President of Strategy and Investor Relations; and Glenn Boehnlein, who will be taking over for Bill on",822,"Good afternoon, everyone, and welcome to Stryker's fourth quarter 2015 earnings call. Joining me today are Bill Jellison, our CFO; Katherine Owen, Vice President of Strategy and Investor Relations; and Glenn Boehnlein, who will be taking over for Bill on April 1. Following my opening comments, Katherine will provide an update on MAKO, while Bill will offer more details on our quarterly results before turning to questions and answers.
With a 6.4% increase in organic sales in Q4, we continue to deliver on our goal of driving top line growth at the high-end of med tech. This marks the 11th consecutive quarter where Stryker delivered 5% or better organic sales growth, demonstrating strong consistency over time. Our diversified sales footprint has once again proven to be a key component of our growth strategy as all of our segments, Orthopaedics, MedSurg and Neurotechnology and Spine, posted good results in the quarter. These performances underscore the strength of our sales and marketing execution and our innovation engine, which is characterized by healthy R&D investments and a focused and disciplined M&A effort.
Approximately 70% of our sales are derived from our U.S. businesses, which once again led growth, posting an impressive gain of approximately 8%. I am also pleased with the growing momentum out of Europe, including strong Q4 results benefiting from the shift to the Transatlantic Operating Model at the beginning of 2015. We are building on this success as we start 2016 with Canada rolling into the model and the other regions now reporting to our Group Presidents, Tim Scannell and David Floyd. Our international growth of roughly 4% in constant currency was once again impacted by soft performances in China and Brazil. However, as you've seen, we have demonstrated the ability to offset isolated geographic softness through strength in our larger markets.
Turning to earnings. Our adjusted EPS for Q4 of $1.56 is at the high-end of our revised range of $1.53 to $1.56 primarily driven by the strong top line. The balance of the P&L came in as expected, which Bill will over in his section. Looking ahead to 2016, we expect our sales momentum to continue and are targeting organic sales growth for the year of 5% to 6%. This takes into account expected softness in emerging markets for a good portion of the year.
In addition, the 2-year suspension of the med device tax provides us with the opportunity to bolster investments that will help drive sales growth and innovation as we plan to invest the majority of this temporary benefit. We are also continuing on our path toward driving greater cost efficiencies, which is a multiyear opportunity. Over the past year, we have been focused on identifying and prioritizing the key target areas for cost reduction within our organization.
As we shifted to 2016, we are moving toward project implementation under the leadership of Group President Lonny Carpenter. We have identified significant areas of savings centered around optimizing our plant network, rationalizing our product lines, professionalizing our indirect procurement in a similar manner as we have done with direct materials, moving to a common ERP system and driving more shared services.
given our history of decentralization, there's considerable opportunity ahead of us in this program. We believe a methodical and deliberate approach to these efforts will allow us to preserve Stryker's competitive differentiation in the areas of sales, marketing, R&D and business development while helping to ensure we are consistently delivering P&L leverage. This is reflected in our 2016 adjusted EPS range of $5.50 to $5.70 a share. This is an increase of approximately 7.5% to 11.5% versus 2015, and it includes a negative foreign exchange impact of $0.12 to $0.13 a share.
Finally, I'd like to take a moment to extend my thanks and appreciation to Bill Jellison, who has announced his plans to retire following an impressive 36 career -- 36-year career, the last 3 of which have been with Stryker. Bill was able to quickly move toward implementing a layered hedging program, which has proven to be successful at mitigating our transactional FX exposure. In addition, he helped execute on a number of acquisitions, facilitated the establishment of our European regional headquarters that's enabled significant savings and has also helped to shape our comprehensive cost reduction program.
These accomplishments have meaningfully contributed to our success and were achieved while enabling our internal talent pools to develop, including Glenn Boehnlein, who has been promoted to CFO effective April 1. Glenn has been with Stryker in various financial leadership roles since 2003, most recently serving as Group CFO for the MedSurg and Neurotechnology group. This group represents roughly half the company and has been a consistent force behind our strong results. I am confident in Glenn's ability in coordination with the broader finance organization to help build on our strong momentum.
Before turning the call over to Katherine, I've asked Glenn to make a few comments. Glenn?"
94614,314976743,921214,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","Thanks, Kevin. I appreciate the comments and the support, but I also want to thank Bill for his leadership of the finance organization over the past few years and for his commitment to helping ensure a smooth transition as I take on new responsibilities.",98,"Thanks, Kevin. I appreciate the comments and the support, but I also want to thank Bill for his leadership of the finance organization over the past few years and for his commitment to helping ensure a smooth transition as I take on new responsibilities. It's a very exciting time at Stryker, and I'm thrilled to be part of such a great organization with so many talented and dedicated people. I'm also looking forward to meeting many of our shareholders and analysts at the various events going forward.
And with that, I'll turn the call back over to Katherine."
94614,314976743,921214,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","Thanks, Glenn. The focus of my comments today will be to provide an update on MAKO. 2015 was a year of building momentum for MAKO's robotic-assisted surgery as we continue to leverage our considerable sales and marketing infrastructure to help drive sales",257,"Thanks, Glenn. The focus of my comments today will be to provide an update on MAKO. 2015 was a year of building momentum for MAKO's robotic-assisted surgery as we continue to leverage our considerable sales and marketing infrastructure to help drive sales. We are particularly pleased with the increased demand for the hip indication, which has been augmented by combining the robotic technology with our proven portfolio of Stryker hip systems. The combination enables surgeons to use a best-in-class hip implant with a long-term proven clinical history on a robotic-assisted platform which helps drive consistency, enhance surgeon and patient experience and we believe over time, clinically demonstrated benefits. In total, we sold 31 robots globally in the quarter, 24 of which were in the U.S., which represents a solid ramp from the start of the year and a significant jump year-over-year from 20 in the fourth quarter of 2014. For 2016, we are focused on continuing to drive adoption with our current indications, which we believe offers considerable opportunity to drive ongoing robot placements.
We are also excited about the potential for the Total Knee indication with our flagship Triathlon system. This year, our efforts will be centered around gaining user experience with key opinion leaders to help ensure an optimal rollout as we look to full commercial release in 2017. We believe the commercial launch, which will be aided by podium presentations from the early users group, will be in place as we head into next year.
With that, I'll turn the call over to Bill."
94614,314976743,921214,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","Thanks, Katherine. I'd like to start up by saying I've enjoyed working with Kevin and everyone at Stryker, especially the entire finance organization who have made significant contributions over the last few years helping the company deliver on its financ",1933,"Thanks, Katherine. I'd like to start up by saying I've enjoyed working with Kevin and everyone at Stryker, especially the entire finance organization who have made significant contributions over the last few years helping the company deliver on its financial results. 
[Audio Gap] coming to Stryker with a strong cultural fit and personal fit from the first week that I joined the company.
We ended 2015 at the high-end of both our initial sales and earnings guidance that was set at the beginning of the year. As we look at 2016 and set our initial guidance, I am confident that our sales momentum, strong product portfolio and pipeline and the cost containment initiatives we are driving position us well for the future. I look forward to ensuring a smooth transition with Glenn and entering another stage in my life. I will continue to engage actively in many of my passions, travel with my family and friends and explore additional board opportunities. I want to thank all of you for your support.
So turning to our financial performance. Sales grew 3.7% in the quarter, including a negative 3.2% impact from foreign currency translation. Constant currency sales growth was 7%, which includes organic growth of 6.4%.
GAAP EPS for the quarter was $1.38 per share versus $0.68 last year in the fourth quarter, while adjusted earnings per share were $1.56 a share for the quarter versus $1.44 per share in the fourth quarter last year. This quarter's EPS includes negative impacts of roughly $0.04 per share from foreign exchange, which was in line with our guidance.
Most currency exchange rates against the U.S. dollar continue to be weaker than last year in the same period. The weaker euro and Swiss franc, along with our layered hedging program, helped to mitigate some of the impact in the quarter as many of our products are manufactured in Europe, which helped improve our gross margin rates in the period. However, significant weakening in foreign currency rates in emerging markets and the continued weakness of the Japanese yen, Australian dollar and Canadian dollar, where we have minimal manufacturing, negatively impacted our gross margins and operating results in those regions.
The most significant non-GAAP adjustments in the quarter were amortization, restructuring charges and a net reduction in the charge associated with the voluntary recall of the Rejuvenate, ABG II modular hip stem as we resolved some insurance matters in the quarter, which more than offset the additional charge in the period. As I have mentioned previously, the charges we have recorded related to the Rejuvenate and ABG II recall represents a minimum of the range of probable loss to resolve this manner, and the charges may increase or decrease over time as additional facts become available and our assumptions more refined.
In the fourth quarter, our organic growth rate was 6.4%, including 8.1% growth in unit volumes and mix with price negatively impacting sales by 1.7%. Acquisitions added 0.6%, while FX had a negative 3.2% impact due to significant weakness in both the Japanese yen and the Australian dollar compared to the same period last year. Full year 2015 constant currency sales growth were 7%, and organic growth was 6.1%.
Looking at our segments. Orthopaedics represented 42% of our sales in the quarter, and sales of Orthopaedic products grew 3.3% as reported and 7.1% in constant currency. U.S. Orthopaedic sales grew 9.7% in the quarter. Trauma and Extremities had another excellent quarter in the U.S. with sales increasing 13.6% led by strong growth in Foot & Ankle, which again grew approximately 20% for both the fourth quarter and full year. U.S. Hips and Knees continued their strong performance of 6.4% and 9.1% organic growth, respectively, in the quarter. These sales were bolstered by increased adoption of recent titanium 3D-printed products.
Our International Orthopaedic business grew 2.4% in constant currency as sales growth continued to be negatively impacted by weakness in China and Brazil. However, our International Knee business grew 5.5% in constant currency in the quarter. Finally, we sold 31 MAKO units in the quarter and 72 units in the full year.
Next, our MedSurg segment represented approximately 40% of our total sales, and sales of MedSurg products grew 3% as reported and 5.6% in constant currency. These results were led by growth in our Instruments and Medical business, both of which had strong mid-single-digit percentage growth in constant currency. Endoscopy also posted mid-single-digit percentage growth in constant currency in the period on the back of our new camera offering, which was launched in December. All 3 of these large MedSurg businesses continued to manage pricing decisions effectively with modest price declines of less than 0.5% for the year.
Our final segment, Neurotechnology and Spine, represented 18% of sales and delivered another good quarter. Sales of Neurotechnology and Spine products grew 6.5% as reported and 9.9% in constant currency. Growth in this segment was led by our Neurotechnology business, which had double-digit growth in the high teens in constant currency in the fourth quarter and grew high teens in the U.S. Spine sales had mid-single-digit percentage growth in constant currency in the period and had high single-digit growth in the U.S. This marks our third consecutive quarter of strong growth in U.S. Spine. Spine also has a new 3D-printed interbody device launching in 2016, which we believe will be a very exciting product for the market, helping us to continue this positive trend.
In looking at our operational performance, gross margin as a percent of sales on an adjusted basis in the fourth quarter was 67.2% compared to 65.8% in the fourth quarter last year. When compared to the same period last year, the rate was positively impacted by solid operational improvements, product mix and FX rates despite the negative FX impact on earnings per share.
Price had a negative impact as pricing was lower by 1.7% in the period. Our gross margin as a percentage of sales was 66.5% or 50 basis points higher than last year. Research and development expenses increased by 20 basis points to 6% of sales in the fourth quarter compared to 5.8% in the same period last year.
On an adjusted basis, selling, general and administrative expenses represented 33.7% of sales in the fourth quarter compared to 32.4% in the same period last year. As expected, these expenses were higher for the year as we increased spending to support the cost structure of our European regional headquarters in Amsterdam and our Transatlantic Operating Model. We are confident in our ability to leverage these expenses in 2016 as we continue to drive a number of key cost initiatives even as we reinvest some of the savings from the suspension of the medical device tax.
Operating margin as a percentage of sales on an adjusted basis were 27.4% in the fourth quarter compared to 27.6% in the same period last year. The full year adjusted operating margin rate was 24.9%, nearly flat compared to last year. During the year, we invested in our European regional headquarters and the establishment of our Transatlantic Operating Model, which reduced the stronger operating margins for the year.
Other expense in the fourth quarter was $36 million. This increase in expense resulted primarily from higher net interest expense due to increased borrowings and foreign currency exchange transactional losses in the fourth quarter. This is generally consistent with the run rate for this category.
Our reported tax rate for the fourth quarter was 14.7%, while the adjusted effective tax rate was 16.6% for the fourth quarter compared to 22.6% in the same period last year. The fourth quarter effective tax rate benefited from the renewal of the tax extenders, which was contemplated in our guidance. The full year adjusted effective tax rate was 17.3% compared to 22.3% last year as we realized the benefits from our global tax structure and European regional headquarters in Amsterdam.
Looking at the balance sheet. We ended the quarter with $4.1 billion of cash and marketable securities, approximately 50% of it now held in the U.S. We also had $4 billion of debt on the balance sheet at the end of the quarter. From an asset management standpoint, accounts receivable days ended the quarter at 55, relatively unchanged from last year. Days in inventory finished the quarter at 165, which was an increase of 5 days compared to last year.
Turning to cash flow. Our cash flow from operations for 2015 were $900 million compared to $1.8 billion last year. But as previously mentioned, we made significant payments earlier this year associated with our Rejuvenate and ABG II recall settlement of $1.2 billion, most of which occurred in the third quarter. Approximately 50% of the funding of the Rejuvenate liability is being sourced from OUS cash. We also repatriated a total of $1.8 billion in 2015, including approximately $1.1 billion in the fourth quarter. Capital expenditures were $270 million in 2015 compared to $233 million last year.
Finally, regarding share repurchases. In 2015, we repurchased approximately $700 million of our common stock or approximately 7.5 million shares at an average price of approximately $94.67. We have authorization for another $1.9 billion available for repurchase under our current authorization.
Based on our strong performance in 2015 and assessment of the current economic and market conditions, we are projecting constant currency and organic sales growth in a range of 5% to 6% for 2016 and expect to be at the low end of that range in the first quarter as we are still anticipating impacts of market conditions in the emerging markets, especially China and Brazil. If foreign currency exchange rates hold near current levels, we anticipate net sales will be negatively impacted by approximately 1% for 2016. We also expect continued unfavorable price reductions of 1.5% to 2% consistent with the pricing environment experienced in 2015.
Due to the suspension of the med tech tax, we will also provide some additional visibility to our projected margin rates for 2016. Both gross margin and operating income margins are projected to be at least 50 basis points higher in 2016 in total. The benefit from the suspension of the med tech tax will directly benefit our gross profit rate. However, R&D will run slightly higher in 2016, and our SG&A rate will only show modest improvement for the full year as we expect to reinvest the majority of the benefit we receive into these areas, offsetting much of our cost reductions in '16.
As such, our gross margin rate improvements will be the driver of our operating margin rate in 2016. We expect our full year adjusted effective tax rate in 2016 will continue to be approximately 17% to 17.5%. Capital expenditures are expected to be $400 million to $450 million in 2016 as we continue to invest in our operations and our IT infrastructure to support future growth.
Based on the current foreign exchange rates, we expect 2016 to be negatively impacted by approximately $0.12 to $0.13 for the full year and approximately $0.03 for the first quarter. This negative impact is largely driven by the translational component of foreign exchange, which we do not hedge. The transactional impact of foreign exchange on earnings is being offset somewhat by both natural and real hedges, which we continue to layer into our operations. Finally, our guidance for adjusted net earnings per diluted share in 2016 is $5.50 to $5.70 for the full year and $1.17 to $1.22 for the first quarter.
Thanks for your support, and we'd be glad to answer any questions that you may have at this time."
94614,314976743,921214,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Operator","[Operator Instructions] Our first question comes from Bob Hopkins from Bank of America.",13,"[Operator Instructions] Our first question comes from Bob Hopkins from Bank of America."
94614,314976743,921214,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Analysts","So first, Bill, sorry to see you move on, but good luck with the next chapter. Sort of feel I'd be remiss if I didn't sort of ask a follow-up question on this announcement and maybe the way to phrase the question, Bill, is -- and for Kevin and Katherine,",113,"So first, Bill, sorry to see you move on, but good luck with the next chapter. Sort of feel I'd be remiss if I didn't sort of ask a follow-up question on this announcement and maybe the way to phrase the question, Bill, is -- and for Kevin and Katherine, you guys have been talking about M&A for some time and I'm just curious if the CFO transition suggests any change in strategy or maybe suggests that maybe larger deals kind of less likely until after this transition is complete. Just kind of curious in how this could affect the strategy and/or the outlook for M&A. And again, congrats, Bill, for the decision."
94614,314976743,921214,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","Yes, thanks, Bob. Look, I would say right now the company is in very good shape. You can see the way we're performing. This is an internal transition with somebody who is inside our company, so this is not like we're signaling any kind of shift in strateg",150,"Yes, thanks, Bob. Look, I would say right now the company is in very good shape. You can see the way we're performing. This is an internal transition with somebody who is inside our company, so this is not like we're signaling any kind of shift in strategy. I would tell you, we've been very consistent on capital allocation since I've been in the job and even before, that our approach is to favor M&A first then dividends and then share buybacks. So there's absolutely 0 change to our operating mode, and I'm expecting a very smooth transition. You can see that we have a whole quarter of overlap, and Bill is still going to be around in this community and available to help us as needed. So I would tell you that you should expect more of the same from Stryker, and this should be a very seamless change."
94614,314976743,921214,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Analysts","All right. And then as a quick follow-up also, Kevin, from a big picture perspective. I was wondering if you could kind of give us your sense for the outlook for hospital capital spending in 2016. What are you seeing from hospitals? Are you expecting any",74,"All right. And then as a quick follow-up also, Kevin, from a big picture perspective. I was wondering if you could kind of give us your sense for the outlook for hospital capital spending in 2016. What are you seeing from hospitals? Are you expecting any changes? Just wanted to get a sense for your view on the 2016 outlook for CapEx, especially since you're launching some new products into the market right now."
94614,314976743,921214,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","Thanks, Bob. Look, we see the market as very stable for capital equipment. You can see in the fourth quarter we had very strong performances on MAKO selling capital. That's a large capital. We also have a lot of small capital. Our Instruments division did",107,"Thanks, Bob. Look, we see the market as very stable for capital equipment. You can see in the fourth quarter we had very strong performances on MAKO selling capital. That's a large capital. We also have a lot of small capital. Our Instruments division did very well in the fourth quarter. So we look at the market as being very stable. We're just embarking upon the launch of our new camera, the 1588, within Endoscopy. They had a nice start in the month of December, and the orders look quite healthy going into the year. So we're not seeing really any change. A very stable capital market."
94614,314976743,921214,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Operator","And the next question comes from Mike Weinstein from JPMorgan.",10,"And the next question comes from Mike Weinstein from JPMorgan."
94614,314976743,921214,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Analysts","And Bill, my sentiments as well. Thanks for all your help and enjoy your time away from Stryker. Let me ask a couple questions, guys. So one question is the 5% to 6% constant currency guidance for 2016. Obviously you've, by and large, been running above t",84,"And Bill, my sentiments as well. Thanks for all your help and enjoy your time away from Stryker. Let me ask a couple questions, guys. So one question is the 5% to 6% constant currency guidance for 2016. Obviously you've, by and large, been running above that. Can you just tell us what you have baked in there for the emerging market performance because obviously you're still assuming a challenging emerging market environment for the year? Just want to get some sensitivities around it."
94614,314976743,921214,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","Yes, Mike. In terms of emerging markets, which is in that 7% to 8% of our total sales in China and Brazil are the biggest components although we've been seeing nice growth in markets outside of that, we've assumed those markets remained challenging for th",96,"Yes, Mike. In terms of emerging markets, which is in that 7% to 8% of our total sales in China and Brazil are the biggest components although we've been seeing nice growth in markets outside of that, we've assumed those markets remained challenging for the better part of the year. China as well as Brazil are difficult to predict given the macro issues surrounding them. We do benefit from easier comparisons as we get to the back half of the year, but we assume the overall market there continues to be a bit of a challenge."
94614,314976743,921214,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","Yes, Mike, I would say the emerging markets for us, we had similar performance in the fourth quarter as we did in the third quarter. So we were slightly negative in terms of growth in our emerging markets, China, of course, being the biggest drag. And for",182,"Yes, Mike, I would say the emerging markets for us, we had similar performance in the fourth quarter as we did in the third quarter. So we were slightly negative in terms of growth in our emerging markets, China, of course, being the biggest drag. And for Stryker, we have a capital equipment business, especially the Endoscopy division, that's quite big in China. And so that has a bit more of an impact than the disposables or implants on Stryker. So we're expecting that to continue to be difficult, and that will be a drag. And it's early in the year, so we're setting our guidance from 5% to 6%. As you saw last year, we moved our guidance up during the year. If these conditions don't -- or not as severe, you can expect we would do the same. It doesn't change our outlook on our business. We feel very good about our business, but it's early in the year and we know that those markets are going to be challenged and we're just baking in some caution around those markets."
94614,314976743,921214,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Analysts","Understood. Let me -- just 2 quick follow-ups relative to the guidance. So one, you started to talk about the cost transformation initiatives in greater detail in San Francisco. And in the 2016 guidance, you're basically assuming no SG&A leverage, and tha",144,"Understood. Let me -- just 2 quick follow-ups relative to the guidance. So one, you started to talk about the cost transformation initiatives in greater detail in San Francisco. And in the 2016 guidance, you're basically assuming no SG&A leverage, and that's part of what you're talking about reinvesting back in the business with the benefit of the med tech tax helping the gross margin line. So can you just talk a little bit about where you're going to incrementally invest if that will show up in SG&A or will all show up in R&D? And then second, the acceleration of the share buyback, and acceleration maybe is not the right term, but you bought back more stock than you had been buying back in the fourth quarter. Can you just talk a little bit about what's in your 2016 guidance for capital deployment?"
94614,314976743,921214,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","Yes, so a couple different questions there, the first one associated with kind of the margin rates and also the SG&A area. We do expect some modest level of improvement still in the broader operating expense category, but the reinvestment is primarily tak",278,"Yes, so a couple different questions there, the first one associated with kind of the margin rates and also the SG&A area. We do expect some modest level of improvement still in the broader operating expense category, but the reinvestment is primarily taking place in both areas, probably about maybe 20 basis points or so of an impact on the R&D-related side and the remainder kind of in the SG&A area. I'd say that with the cost initiatives that we've got in place that you would have seen obviously better leverage there. But with the reinvestment, that will slow that down at least this year. But we should still be showing obviously some very, very solid gross margin rate improvement, and we should be getting good drop here still in the operating income line for that. As it relates to the buybacks, yes, we did jump that up to about $700 million in this year. As you can see, our cash has continued to stay very strong. We were able to bring back some additional cash. We have about $2 billion here in the U.S. at this point. And as far as our guidance is concerned, you should expect that -- we commented before that we've got the authorization out there. We expect to complete that over kind of a 2- to 3-year period of time, barring any sizable acquisitions. And hopefully, as Kevin mentioned, acquisitions are absolutely still our first and foremost kind of attention within that space, and we expect to be very active as we move forward, but those are all based on timing situations, right? So -- but that is still our #1 focus."
94614,314976743,921214,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Operator","And our next question comes from Rick Wise from Stifel.",10,"And our next question comes from Rick Wise from Stifel."
94614,314976743,921214,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Analysts","Maybe, Kevin, start -- my first question would be on the operating margin outlook. Obviously you're exiting '15 at 27.4%. Maybe just comment, if you would, on your aspirational goals here. Is it 30%? Is it 35% over the next 2 to 4, 3 to 5 years? Just talk",60,"Maybe, Kevin, start -- my first question would be on the operating margin outlook. Obviously you're exiting '15 at 27.4%. Maybe just comment, if you would, on your aspirational goals here. Is it 30%? Is it 35% over the next 2 to 4, 3 to 5 years? Just talk about the magnitude and the durability of this seemingly long-tailed opportunity?"
94614,314976743,921214,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","So Rick, look, you know we only give guidance out for 1 year, right? So we provided you guidance this year, which shows some pretty meaningful leverage on the EPS line. Coming off the year, we just delivered leverage. And if we didn't have a $0.12 to $0.1",215,"So Rick, look, you know we only give guidance out for 1 year, right? So we provided you guidance this year, which shows some pretty meaningful leverage on the EPS line. Coming off the year, we just delivered leverage. And if we didn't have a $0.12 to $0.13 a share of negative FX, we'd be giving EPS in the 10% to 14% range. So that's pretty meaningful leverage on the sales of 5% to 6%. So you should expect us to continue to drive meaningful leverage. That's the goal of the cost program. There's -- we've said before, there's significant opportunities in the hundreds of millions of dollars. And as we get drive those savings, we'll obviously, if there's great opportunities to invest, we'll invest some of those dollars and some of those dollars will fall to the bottom line. So -- but I don't have a magical number, and I think it also depends on as the years progress, what types of deals that we do, how that affects our margin profile. So I think each year, you'll expect us to give the kind of guidance we're giving you this year: nice, robust organic growth and a nice amount of leverage to the bottom line, and I think I'll just leave it at that."
94614,314976743,921214,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Analysts","Okay. And Katherine, maybe for you on MAKO. Can you give us a little more color on your comments? You talked about increased demand for the hip indication. It seemed to me you placed more -- a few more systems than we expected. Can you talk about the plac",65,"Okay. And Katherine, maybe for you on MAKO. Can you give us a little more color on your comments? You talked about increased demand for the hip indication. It seemed to me you placed more -- a few more systems than we expected. Can you talk about the placements and the utilization and maybe where you are in the rollout for new indications and software?"
94614,314976743,921214,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","Sure. I think it really is reflective of being completed year 2 of the acquisition, so working through the integration and really helping the combined sales forces to optimize their education around the features and benefits of our hip system, on the robo",265,"Sure. I think it really is reflective of being completed year 2 of the acquisition, so working through the integration and really helping the combined sales forces to optimize their education around the features and benefits of our hip system, on the robotic-assisted platform and getting out there and really detailing those benefits. It's a nice mix of both existing Stryker customers but also new accounts that we're able to get into with the robots. So we're really pleased with the placement as well as having a number of them outside the U.S. I would really just emphasize, 2016 is about really working to make sure we are optimally set up for full commercial launch in '17 for the Total Knee. So we are not expecting any real impact from that this year. We have a lot of work to do to optimize the training protocol. We're going to work with key opinion leaders both on the robotics side as well as KOLs with our Triathlon system to make sure we're meshing those observational studies to really fine-tune the training protocol. We didn't have to  train our own sales force, do the upgrades in the system. So there's a lot of work to be done to make sure when we go into full commercial launch, we are set to really optimize that and have a presence at the podium. So we'll continue to drive placements with the existing indications for 2016 while doing the necessary groundwork to really ensure we're in a great position in 2017 to take full advantage of the Total Knee indication."
94614,314976743,921214,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Operator","And our next question comes from David Roman from Goldman Sachs.",11,"And our next question comes from David Roman from Goldman Sachs."
94614,314976743,921214,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Analysts","I wanted just to start with some of the investment spending that you're committing to through the P&L. Over the past several years, you've been very consistent with investing your business both SG&A and R&D, which has obviously produced this very nice top",87,"I wanted just to start with some of the investment spending that you're committing to through the P&L. Over the past several years, you've been very consistent with investing your business both SG&A and R&D, which has obviously produced this very nice top line growth rate. But as you look forward as you continue to invest in the business, do you see opportunities to enhance the top line growth rate beyond what you're performing today? And where are the most attractive areas of investment for you?"
94614,314976743,921214,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","Well, I can tell you that I get a chance to travel around to all of our divisions over the course of the year, and I've yet to meet an R&D leader that has enough money to spend on new products. So I would say that all of the divisions have opportunities.",344,"Well, I can tell you that I get a chance to travel around to all of our divisions over the course of the year, and I've yet to meet an R&D leader that has enough money to spend on new products. So I would say that all of the divisions have opportunities. There's clearly some areas that we would focus on a little bit more than others. So you've seen our Spine business really start to turn based on focused investments in R&D. We've had 3 great quarters in a row in the U.S. We still have to take a lot of those products outside the U.S. But I would say that would be an area where organic development and spending is really paying off for us, so you could expect more in that area. Sports medicine for us is a business that's growing very fast. It's relatively small within Stryker. That's also an area of interest; Neurotechnology as well as Extremities. I would say I picked those 4 right off the top of my head, but I would tell you, we have a long list. And if my other division presidents are listening on the call, I know that they are preparing ideas for me as well. And we'll obviously look at all the ideas and determine which ones we think can really provide value for us. We're not going to just spend for the sake of spending. In a company as big as Stryker is with the decentralized focus, we're seeing that innovation delivers. And I cited one example of 3D printing where I think we're seeing it have an impact on 2 different divisions of Stryker, our Knee business as well as Spine. And we have a huge lineup of other divisions with ideas and prototypes to get into 3D-printed titanium products. So I would say that those are sort of the top-of-mind areas of focus, but all the divisions are lining up and we'll be very selective as we march through that. And we'll share more as the year unfolds."
94614,314976743,921214,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Analysts","Okay. That's very helpful. And then on the capital spending side, the $400 million to $450 million sort of, again, at [ph] the high-end of the range, it would be almost a doubling from where you were, I think, in 2014. Could you maybe just help us go into",90,"Okay. That's very helpful. And then on the capital spending side, the $400 million to $450 million sort of, again, at [ph] the high-end of the range, it would be almost a doubling from where you were, I think, in 2014. Could you maybe just help us go into a little bit detail on where those CapEx dollars are going, how much of that are sort of the 2016 isolated in nature and what the implications of this additional CapEx are to the rest of the business down the road?"
94614,314976743,921214,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","Sure. I'd say that there's a -- beyond just supporting the operations in the higher growth level that we've got in the company, there's a couple areas of specific investment. One is on the ERP transformational area, which is strengthening our global ERPs",123,"Sure. I'd say that there's a -- beyond just supporting the operations in the higher growth level that we've got in the company, there's a couple areas of specific investment. One is on the ERP transformational area, which is strengthening our global ERPs on a worldwide basis and reducing the numbers that we have, so we're on a more consistent, common system there. The second one is actually we're building a brand-new state-of-the-art 3D printing manufacturing facility this year as well, too. So we're spending some dollars, I think, in some key potential growth areas for us, and we want to take advantage of that. This year is a little bit of a blip in comparison to what that normal CapEx would be."
94614,314976743,921214,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Operator","And our next question comes from David Lewis from Morgan Stanley.",11,"And our next question comes from David Lewis from Morgan Stanley."
94614,314976743,921214,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Analysts","Just a couple questions. One, Kevin, just to start off with the ortho market. I wonder if you could just comment on 2015, if you think about the underlying momentum and the market and your share position, how much relative share you may or may not have ta",82,"Just a couple questions. One, Kevin, just to start off with the ortho market. I wonder if you could just comment on 2015, if you think about the underlying momentum and the market and your share position, how much relative share you may or may not have taken in '15, and how those dynamics, in your mind, compare to the outlook you'd see for '16 both in terms of how the market's going to perform and how you see shares shaking out."
94614,314976743,921214,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","So yes, thank you for the question. Well, obviously not everybody has finished reporting yet, so we don't have all the final results for 2015. We feel very good about the performance across our portfolio. Certainly, hips has been an area of strength for u",257,"So yes, thank you for the question. Well, obviously not everybody has finished reporting yet, so we don't have all the final results for 2015. We feel very good about the performance across our portfolio. Certainly, hips has been an area of strength for us for the past 4 years. But we're very encouraged by what we're seeing in knees as knees have started to pick up, and we'd historically -- the last 3, 4 years been in line with the market or maybe slightly below. And I think we're going to start to see a bit of over performance there behind innovation and launching new products. So we feel good about our position in those 2. Trauma, of course, as you know, has been a standout for us for about 4 years, and we continue to launch new products and we continue to grow very well. So to us, the market seems very stable. We like our position in each of the categories. If you include Spine within your definition of Orthopaedics, I would say that was an area that had been more troubled for us, but we feel we're on a very good path now. So across the portfolio, and I just had a chance to spend time at the sales meetings for Orthopaedics and Spine, I could tell you, they feel very good about our competitive position in a market that seems very stable. So I think we'll see more of the same in terms of volume growth, and we like our competitive position."
94614,314976743,921214,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Analysts","Okay. And just 2 quick ones. One, just Katherine, just thinking about MAKO for a second. I mean, you're now selling more systems than the target MAKO ever did. And I wonder, are you seeing any pushback on ASPs for the system around $1 million? And in ligh",112,"Okay. And just 2 quick ones. One, just Katherine, just thinking about MAKO for a second. I mean, you're now selling more systems than the target MAKO ever did. And I wonder, are you seeing any pushback on ASPs for the system around $1 million? And in light of one of your competitors acquiring another competitor, specifically in robotics, do you expect to see some ASP pressure in '16 or '17? And then Bill, just you spark my interest in the 3D printing facility. Is this a facility that will be capable of doing 3D-printed full Total Knee and Hips? Or is this more sort of derivative products to the orthopaedic process?"
94614,314976743,921214,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","Yes, on the capital side, obviously that's always going to be a conversation to sell $1 million capital easily. But I will tell you, we are selling million-dollar capital, so those robots are sold. They are not placed. I think what we're doing is really l",179,"Yes, on the capital side, obviously that's always going to be a conversation to sell $1 million capital easily. But I will tell you, we are selling million-dollar capital, so those robots are sold. They are not placed. I think what we're doing is really leveraging the ability to offer different models. We talked about our Flex Financial, so giving customers the ability to outright purchase or lease depending on their needs. And I think that's helping. And it's really, I think, the difference between when MAKO was stand-alone is we have a very large selling organization that over the last 2 years has really come to understand the features and the benefits. And the value proposition has only improved, going from a uni then to a hip then to a hip with our hip systems on it. And now knowing a Total Knee will be coming, I think, helps in that sales process as well. But we are selling those robots, and I don't anticipate that changing in 2016 related to any competition that might be out there."
94614,314976743,921214,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","Yes, and the second part of your question was around 3D printing. So we launched -- over the past few years, we've started with part of our knee system to enable cementless knee, so tibial baseplate. We have this past year in the middle of the year launch",214,"Yes, and the second part of your question was around 3D printing. So we launched -- over the past few years, we've started with part of our knee system to enable cementless knee, so tibial baseplate. We have this past year in the middle of the year launched revision cones with geometry that can only be made with 3D printing. We have a patella that we've launched that's 3D-printed, and now we're just about to launch a 3D-printed titanium interbody device for spine. So all of the products we've launched thus far that are 3D-printed are all innovative new products, in the case of the spine product and the cementless product. It allows for bony in growth because they're porous materials and getting very good feedback from our customers. For the foreseeable future, at least the next 3, 4 years or so, our focus is really on innovative new products and not replacing our existing products with 3D-printed products. The pipeline of innovative new geometries that can't be made without 3D printing is the area of focus. So it's not about trying to replace our products and drive down costs. Over time, 10 years from now, that could be the case. But in the near to mid-term, it's really focused on innovative new products."
94614,314976743,921214,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Operator","And our next question comes from Kristen Stewart from Deutsche Bank.",11,"And our next question comes from Kristen Stewart from Deutsche Bank."
94614,314976743,921214,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Analysts","So Bill, I'll reiterate. Definitely, congratulations on your retirement, and we definitely will miss you. So just a question more strategically. I was just wondering if you feel good about kind of the 3 main buckets that you have now and whether or not, K",67,"So Bill, I'll reiterate. Definitely, congratulations on your retirement, and we definitely will miss you. So just a question more strategically. I was just wondering if you feel good about kind of the 3 main buckets that you have now and whether or not, Kevin, you feel like there's any need to kind of expand beyond that and get into any other white spaces at this point."
94614,314976743,921214,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","Yes. No, Kristen, let me be consistent. What I've been saying in the past couple of years is and our strategy is to stay within these 3 segments. We like our position in these 3 segments. We want to continue. If you look at all of our acquisitions, they'v",149,"Yes. No, Kristen, let me be consistent. What I've been saying in the past couple of years is and our strategy is to stay within these 3 segments. We like our position in these 3 segments. We want to continue. If you look at all of our acquisitions, they've strengthened each of our businesses that we're currently in. And every year, we do a white space assessment. And the white space assessment is not as attractive as staying within our segments. There are a significant number of targets within our segments. I know we only completed 2 deals. It was a little bit quieter year in 2015. But I can tell you, the activity level was no different in 2015 with a lot of deals being discussed. And so I would expect us to continue along our current strategy and don't expect us to suddenly jump into white space."
94614,314976743,921214,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Analysts","Okay. And then, just with respect within the Neurotech area. Are there any notable clinical activities coming up for trial readouts? Or can you speak to any new product pipelines you think that we should be aware of that could help drive growth? Even thou",57,"Okay. And then, just with respect within the Neurotech area. Are there any notable clinical activities coming up for trial readouts? Or can you speak to any new product pipelines you think that we should be aware of that could help drive growth? Even though, obviously, it's been growing really well but if you can sustain it."
94614,314976743,921214,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","Yes, we're -- we love this business. Thanks, Kristen. We love this business, and I would say our coiling and the ischemic stroke were in great shape. And we're growing very well in those 2 categories. The one area for Stryker that is a slight gap is the f",145,"Yes, we're -- we love this business. Thanks, Kristen. We love this business, and I would say our coiling and the ischemic stroke were in great shape. And we're growing very well in those 2 categories. The one area for Stryker that is a slight gap is the flow diverting stent segment. We are selling that outside the U.S., but we don't yet have U.S. approval. We have -- in the process of just completing up our trial and we'll be submitting for that, but we're still -- we still have some time before that gets approved. That's the one area we were not in. So we're driving this terrific growth without being in that one segment in the United States. So that's an ongoing process. We'll update you more towards the end of this year in terms of when that will come to market."
94614,314976743,921214,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Operator","Our next question comes from Jason Wittes from Brean Capital.",10,"Our next question comes from Jason Wittes from Brean Capital."
94614,314976743,921214,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Analysts","It sounds like the -- we should view the Total Knee coming out next year as sort of a transformational product. If I look into this year, can you kind of maybe highlight sort of the products that we should be focused on that'll really drive that -- the gr",52,"It sounds like the -- we should view the Total Knee coming out next year as sort of a transformational product. If I look into this year, can you kind of maybe highlight sort of the products that we should be focused on that'll really drive that -- the growth this year?"
94614,314976743,921214,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","I would really look at it as across-the-board, very typical Stryker fashion where it's more singles and doubles, whether it's Endo launching the new 1588 camera or MAKO continuing to drive indications like Hip with the new -- the Stryker brands that we ta",245,"I would really look at it as across-the-board, very typical Stryker fashion where it's more singles and doubles, whether it's Endo launching the new 1588 camera or MAKO continuing to drive indications like Hip with the new -- the Stryker brands that we talked about or Spine with their new products that are coming out 3D-printed. So it's really a story about those incremental, innovative new products. Usually, no one on its own is a growth driver. It's the totality of that offer, and that really allows us to sustain that organic growth at the high end of med tech. Clearly, next year, we're set up for some more impactful products that when you think about MAKO and the Total Knee and expect them to be on a clear trajectory as taking meaningful market share as we work our way through '17. Ischemic is one more of those more transformational opportunities. There's a lot of market development that still needs to take place there around the patient path, referral systems, hospital -- into hospital transfers. So we talked about that being a multiyear process, but clearly seeing some very good growth rates but off of a still small base. But I would really think about this year as a typical Stryker story. You've got a lot of products, a lot of momentum, dedicated sales force with a specially -- a specialty focus that's really helping to drive that 5% to 6% growth we're targeting."
94614,314976743,921214,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Analysts","Okay, very helpful. And just a quick follow-up for MAKO. Can you give us a sense of how many of these new placements are to existing accounts and how many of these are de novo. Just kind of give a sense [indiscernible].",42,"Okay, very helpful. And just a quick follow-up for MAKO. Can you give us a sense of how many of these new placements are to existing accounts and how many of these are de novo. Just kind of give a sense [indiscernible]."
94614,314976743,921214,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","Yes, we haven't broken out -- out of the 31, we haven't broken out. I would tell you, though, that it is a combination of both existing Stryker customers as well as new customers where we haven't had any type of meaningful presence. So we haven't given it",61,"Yes, we haven't broken out -- out of the 31, we haven't broken out. I would tell you, though, that it is a combination of both existing Stryker customers as well as new customers where we haven't had any type of meaningful presence. So we haven't given it with more granularity than that, and -- but there is a nice mix."
94614,314976743,921214,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Operator","And the next question comes from Matt Miksic from UBS.",10,"And the next question comes from Matt Miksic from UBS."
94614,314976743,921214,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Analysts","Super job on the numbers it looks like. And I'll pass along my congratulations and farewell to Bill. We will also miss you. So on MAKO, just a couple of maybe broader questions on how you're positioning the platform. Robotics has been kind of a market dev",123,"Super job on the numbers it looks like. And I'll pass along my congratulations and farewell to Bill. We will also miss you. So on MAKO, just a couple of maybe broader questions on how you're positioning the platform. Robotics has been kind of a market development project for a while, oftentimes dealing with surgeons and helping them get more comfortable with this new technology, maybe changing the way surgery is done over the longterm. But at what point does this become, or has it already become, an opportunity to drive better contracting for you across your implant lines, greater share or utilization multiline contracting driven by the merits of the system and the technology? And I have a couple of quick follow-ups."
94614,314976743,921214,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","So Matt, I would say, look, we're still in the early stages. We -- the Stryker Hip brands are now just available recently. And we haven't launched the Total Knee yet. So I think that's -- those are the big applications. And to say that it is impacting con",151,"So Matt, I would say, look, we're still in the early stages. We -- the Stryker Hip brands are now just available recently. And we haven't launched the Total Knee yet. So I think that's -- those are the big applications. And to say that it is impacting contracting yet, I would say, it's too early for that. Once this becomes a more mature business, which will take a couple of years, then I think, obviously, having a system that the surgeons are having a great experience and they enjoy it and they want to use the products, it really does provide us with great differentiation which will -- and differentiation will show up in many different ways, including potentially in contracting. But we're aways from that yet, we have a lot of work to do in the next couple of years to really gain more broad adoption of the technology."
94614,314976743,921214,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Analysts","Then, another on the same topic here. Katherine, someone asked earlier about Hips and what's changing and how you're improving performance there. To put that in perspective, I remember when Hips came out and when you first acquired the system, it wasn't g",105,"Then, another on the same topic here. Katherine, someone asked earlier about Hips and what's changing and how you're improving performance there. To put that in perspective, I remember when Hips came out and when you first acquired the system, it wasn't generally thought to be really where the bang for the buck was with the robot. And I guess, what's changing? Is this application getting a lot easier? Is people getting -- are they proving out the benefits of the Hip? I mean, what's driving uptick and against what was historically viewed as sort of like a not the greatest application for the robot?"
94614,314976743,921214,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","Okay. So I'll take this question. So look, what I'd tell you the first iterations of the Hip software were a little bit clunky, and it requires quite a bit more registration time to register in the software system. So that's just an extra step that some o",286,"Okay. So I'll take this question. So look, what I'd tell you the first iterations of the Hip software were a little bit clunky, and it requires quite a bit more registration time to register in the software system. So that's just an extra step that some of the surgeons are a little bit frustrated with. Over time, both prior to our acquisition and subsequent to our acquisition, we've made some enhancements of the software to make it a little bit more user-friendly. That's been one factor for sure. I think the most compelling factor is showing the surgeons on the pre and post x-rays that they put the Hip exactly where they want to put it. And I think even though surgeons that had some hesitations when they see the pre and post x-rays, they are just -- it's a very compelling visual for them to understand. Before they weren't doing that. They weren't able to get that same type of consistency. And that's starting to resonate with a lot of surgeons. And now being able to put our implants in addition with easier-to-use software and to get that kind of outcome, it's like all things have changed, right? Change doesn't occur to everybody at the same time. Some people are early adopters. Some people, frankly, will never adopt. They'll just be set in their airways. But what we're seeing is the middle of the bell curve is starting to shift its mindset. And frankly, the more that robotics is talked about in the community at large, we find that actually a very positive thing because we really believe we have a terrific system, and we're obviously continuing to invest in that system going forward."
94614,314976743,921214,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Operator","Our next question comes from Joanne Wuensch from BMO Capital Markets.",11,"Our next question comes from Joanne Wuensch from BMO Capital Markets."
94614,314976743,921214,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Analysts","I have 2 questions. The first one has to do with 3D printing. Seemed quite aware of about a couple of years ago, now you're definitely doing a bigger focus on that. What does it take for a 3D-printed, call it, Hip or Knee to become more mainstream? Is it",62,"I have 2 questions. The first one has to do with 3D printing. Seemed quite aware of about a couple of years ago, now you're definitely doing a bigger focus on that. What does it take for a 3D-printed, call it, Hip or Knee to become more mainstream? Is it manufacturing? Is it clinical data? How should we think about this evolving?"
94614,314976743,921214,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","Well, it's a long answer, Joanne. The reason I paused is to get into all the technology on 3D-printing would be -- would take a long time. The quick summary is the 3D printing metal is very different than sort of the way you think about 3D printing plasti",224,"Well, it's a long answer, Joanne. The reason I paused is to get into all the technology on 3D-printing would be -- would take a long time. The quick summary is the 3D printing metal is very different than sort of the way you think about 3D printing plastic having it on a desk in an office and cranking up 3D-printed products. So metal is much more complicated. It's explosive. It requires a lot of extra programming. You just don't buy a machine and sort of just off to the races. It's a lot more complicated than that. And so we spent a lot of time. We've been working on this for many, many years. And so we have a lot of know-how on how to program the machines and optimize the machines. And so there's a lot of factors that go into it to be able to create. And different types of machines work better for smaller products than larger products. So it's difficult for me to just summarize in a short time. I'd just say that it's more complicated than plastics or other things that you read about in the mainstream press. And that's why, for us, our focus is much more on innovative new products and not necessarily replacing total systems. That will be many, many, many years ahead of us."
94614,314976743,921214,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Analysts","That's very helpful. As a follow-up, what should we expect at the upcoming AAOS?",15,"That's very helpful. As a follow-up, what should we expect at the upcoming AAOS?"
94614,314976743,921214,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","Yes, Joanne, I think it will be typical to prior years. Clearly, there's going to be a big focus around MAKO as we think about uni as well as hip. It's too early in our initial commercial launch activities to have a big focus on user feedback from Total K",124,"Yes, Joanne, I think it will be typical to prior years. Clearly, there's going to be a big focus around MAKO as we think about uni as well as hip. It's too early in our initial commercial launch activities to have a big focus on user feedback from Total Knee. Although, I'm sure there'll be a lot of surgeon presence around that as they're looking to get educated on the features and benefits. And we'll have a tour of the booth as we've done previously to highlight new products across all the businesses from Trauma, Foot & Ankle, Spine, et cetera. And we'll also have an opportunity while we're there just to sit down and meet with management and have an open Q&A forum."
94614,314976743,921214,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Operator","And the next question comes from Raj Denhoy from Jefferies.",10,"And the next question comes from Raj Denhoy from Jefferies."
94614,314976743,921214,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Analysts","Wonder if I could ask a question about the CJR or CCJR program that's rolling out. I know that you guys have been pretty clear as all the companies have but you don't think it's going to have much impact on pricing and so it will be focused on the postacu",109,"Wonder if I could ask a question about the CJR or CCJR program that's rolling out. I know that you guys have been pretty clear as all the companies have but you don't think it's going to have much impact on pricing and so it will be focused on the postacute care, which pretty much mirrors what we're hearing as well. But my question is really around how Stryker interfaces with that model. In your performance solutions business, you guys were involved in some of the bundled payments initiatives before. Is there an opportunity for you guys to perhaps benefit from the CJR program as it rolls out?"
94614,314976743,921214,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","Yes. We agree with your comments. We don't think it's going to have a meaningful impact. We have seen a test with some of the prior programs. It really does drive a focus on postacute and patients that are discharged right to rehab given the high cost the",190,"Yes. We agree with your comments. We don't think it's going to have a meaningful impact. We have seen a test with some of the prior programs. It really does drive a focus on postacute and patients that are discharged right to rehab given the high cost there. We do have a small business. Our Stryker performance solutions that we think can help work with hospitals to help them make them aware of the data so they can have a sense of what best-in-class is and where some of the cost benefits they can realize, whether it's around infection rates, transfusions, et cetera. So it's not a huge part of our business, but it is one that provides insights and does help them as they think about their overall cost structure. But clearly, we continue to believe based on everything we've seen that it's going to be postacute care. We haven't seen any meaningful change at all in price between those trial areas as it relates to implant pricing and really the cost savings they can realize focusing on rehab really do dwarf anything else at this point in time."
94614,314976743,921214,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Analysts","Right. Maybe just as a follow-up. But if you think about that service offering, if that's the way to describe it, which performance solutions certainly does some of. As you think about the next several years, do you envision that service component becomin",61,"Right. Maybe just as a follow-up. But if you think about that service offering, if that's the way to describe it, which performance solutions certainly does some of. As you think about the next several years, do you envision that service component becoming a bigger part of the business offering, not just implants to hospitals but perhaps something a bit broader?"
94614,314976743,921214,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","Yes. I mean, that division is continuing to focus on that. It's not a huge part of our company. I think, we see this -- the CCJR is a terrific example, an opportunity for us to grow that business. But it's not at a scale at which I really want to start hi",200,"Yes. I mean, that division is continuing to focus on that. It's not a huge part of our company. I think, we see this -- the CCJR is a terrific example, an opportunity for us to grow that business. But it's not at a scale at which I really want to start highlighting it. I would tell you, a year from now, I think we'll have a much better idea of the scope of CCJR and whether that can become a broader business for us. So services is not something new to Stryker. A lot of our MedSurg business provides services to hospitals. We have people in the hospital that our customers pay for to make sure that all their uptime is working on their equipment. So we're not against services at all, but we don't sort of like to get out in front of ourselves. Let's see how this year unfolds. And if the business becomes something that could be scalable, then we'll talk about it a lot more. But right now, it's a small part -- I agree with you that CCJR does provide an exciting opportunity for that business, but it's a very small part of Stryker."
94614,314976743,921214,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Operator","And our next question comes from Larry Biegelsen from Wells Fargo.",11,"And our next question comes from Larry Biegelsen from Wells Fargo."
94614,314976743,921214,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Analysts","I wan to just star with M&A. About a year ago, Kevin, you said you expect to put the balance sheet to work. And I just wanted to confirm that, that's still the case. And I'm asking because, obviously, you've been relatively quiet on the acquisition front",76,"I wan to just star with M&A. About a year ago, Kevin, you said you expect to put the balance sheet to work. And I just wanted to confirm that, that's still the case. And I'm asking because, obviously, you've been relatively quiet on the acquisition front over the past 6 to 12 months, which is atypical. So is there any reason you haven't pulled the trigger on more deals? And I had one follow-up."
94614,314976743,921214,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","Sure. I would tell you, just look, deal timing is inherently unpredictable. There is absolutely no change in the statement I made before. I still intend to put the balance sheet to work. The reason we got the extra share buyback approval level was just in",130,"Sure. I would tell you, just look, deal timing is inherently unpredictable. There is absolutely no change in the statement I made before. I still intend to put the balance sheet to work. The reason we got the extra share buyback approval level was just in case deals don't get over the line or drag on. For extended periods of time, we would start to step up the buybacks. But you should expect us to continue to be a very active acquirer. But you've seen in the past, right, sometimes, some years, there's 1 or 2 deals. Another year is you see many more deals. So our level of activity hasn't changed. I still see many exciting prospects out there. And so we're staying the course with the existing strategy."
94614,314976743,921214,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Analysts","And then, earlier you said that in Q1, you would expect to be at the low end of the 5% to 6%, I think, constant currency growth rate because of what you're seeing in emerging markets. And so -- but you expect emerging markets to be relatively weak through",91,"And then, earlier you said that in Q1, you would expect to be at the low end of the 5% to 6%, I think, constant currency growth rate because of what you're seeing in emerging markets. And so -- but you expect emerging markets to be relatively weak throughout 2016, I believe. So my question is, does getting the growth rate up above that -- the low end of the range, does that depend upon an improvement in emerging markets? And if not, how do you get that growth rate up?"
94614,314976743,921214,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","Yes. I would just comment that if you look at the cadence of quarters last year, we had some difficult comparisons in the first quarter that related to emerging markets. More of the pressure, particularly in China, unfolded as the year went on. We're goin",94,"Yes. I would just comment that if you look at the cadence of quarters last year, we had some difficult comparisons in the first quarter that related to emerging markets. More of the pressure, particularly in China, unfolded as the year went on. We're going to have easier comps in the back half the year. We tend to have a seasonally stronger second half of the year, particularly as it relates to the fourth quarter. So it's more just reflective of how our quarters tend to play out in some of the year-over-year comparisons."
94614,314976743,921214,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Operator","And the next question comes from Glenn Novarro from RBC Capital.",11,"And the next question comes from Glenn Novarro from RBC Capital."
94614,314976743,921214,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Analysts","Kevin, your U.S. Hip and Knee business had a strong fourth quarter, up 6% and 9%, respectively. Did you see this in the fourth quarter, the U.S. Orthopaedic market accelerate or pick up a bit? Or do you think that was more share capture from Zimmer, given",62,"Kevin, your U.S. Hip and Knee business had a strong fourth quarter, up 6% and 9%, respectively. Did you see this in the fourth quarter, the U.S. Orthopaedic market accelerate or pick up a bit? Or do you think that was more share capture from Zimmer, given the integration between Zimmer and Biomet? And then I had a follow-up question on robotics."
94614,314976743,921214,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","Yes, so look, until we see everybody report, it's really difficult for me to say how much of it is the market versus competitive share capture. The Knee number, we're very encouraged about. We tend to believe our Knee improvement is more driven by the new",194,"Yes, so look, until we see everybody report, it's really difficult for me to say how much of it is the market versus competitive share capture. The Knee number, we're very encouraged about. We tend to believe our Knee improvement is more driven by the new products, the revision cones and more of uptake of our cementless knee offering. So we believe that's more of the issue than, lets call it, sales force disruptions or any other factors that are occurring at other companies. It's more about our innovation. When I talk to our field, they -- the sense I'm getting is a very stable market. So it wasn't -- a few years ago, we saw this big seasonal fourth quarter lift. We now are seeing a typical fourth quarter. This December was more or less typical. It's more active, but it was more active a year ago, too. So we're not seeing -- we didn't see anything or major in terms -- from quarter-to-quarter you do sometimes see slight upticks or downticks. But until they report, it's going to be difficult for me to comment. But I think you had a second question."
94614,314976743,921214,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Analysts","Yes, Katherine, in your prepared remarks you talked about with the MAKO system, podium presentations in 2016. So can you describe what type of presentations? I'm assuming these are clinical trials. So what type of trials? And when can we see these trials",45,"Yes, Katherine, in your prepared remarks you talked about with the MAKO system, podium presentations in 2016. So can you describe what type of presentations? I'm assuming these are clinical trials. So what type of trials? And when can we see these trials being presented?"
94614,314976743,921214,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","Yes. My comments were that we were going to do observational studies in 2016, so really looking at key opinion leaders who have extensive experience with robotics to understand how we can fine tune the training protocol and optimize the rollout. We're als",169,"Yes. My comments were that we were going to do observational studies in 2016, so really looking at key opinion leaders who have extensive experience with robotics to understand how we can fine tune the training protocol and optimize the rollout. We're also going to be doing observational studies with key opinion leaders who have a lot of familiarity with the Triathlon system so we can mesh those 2 data sets and really put us in a position to have a presence at the podiums in 2017, not '16. So we think combining the full commercial launch and being in a position in 2017 for those initial users, those key opinion leaders to talk about their experience and how they were able to optimize both the robot as well as our Triathlon will help drive the adoption. We're going to continue to collect additional clinical data, but that is going to take a number of years. This is really focused around observational studies to help optimize the training protocol."
94614,314976743,921214,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Operator","And the next question comes from Mike Matson from Needham & Company.",11,"And the next question comes from Mike Matson from Needham & Company."
94614,314976743,921214,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Analysts","I guess, I just wanted to start with the new camera at the Endoscopy business. How does this compare to the prior models? Is it more of an incremental improvement? And just in terms of the impact on the growth rate there, do you expect that to be more of",70,"I guess, I just wanted to start with the new camera at the Endoscopy business. How does this compare to the prior models? Is it more of an incremental improvement? And just in terms of the impact on the growth rate there, do you expect that to be more of a step change or more of a ramp in terms of the growth in Endoscopy? Then I have one follow-up."
94614,314976743,921214,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","Yes. So no, this -- the 1588. So each time we have a new version, and we call it -- the last one is 1488, as you know. Now we're calling it 1588. AIM is the name of it. I would say it's meaningfully better. Certainly, 1488 had terrific resolution, but we'",277,"Yes. So no, this -- the 1588. So each time we have a new version, and we call it -- the last one is 1488, as you know. Now we're calling it 1588. AIM is the name of it. I would say it's meaningfully better. Certainly, 1488 had terrific resolution, but we've improved the backlighting and some of the image clarity for certain procedures like ENT that -- so our product works well in a wide variety of procedures. But there are certain procedures where the lighting just wasn't quite as optimized. And we made some nice enhancements there, so across the range of procedures, surgeons are all going to have a delightful experience, whereas, in the past, it was not necessarily across every specialty. So that's the first thing. Second thing is we have ICG built into our light source, which we've never had before. So with a press of a button, you can light up the organs, just -- I'm sure you're familiar with ICG with a competitive product out there. But this is not -- doesn't require extra piece of capital. It's built right into the existing light source, easy for the surgeons to use, which is wonderful. It also includes another product for GYN that lights up parts of the anatomy to -- so it's really a safe surgery launch. It enables safe surgery with enhanced visualization. And we just launched it in December, so we don't have a huge amount of sales yet, but I would say the early clinical feedback has been very positive. So I do expect Endoscopy to have a better year in 2016 than they did in 2015."
94614,314976743,921214,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Analysts","Okay. And then, just with regard to this big ERP project that you have. What's the execution risk there that something gets -- some balls get dropped in terms of the inventory levels and things like that, causing an impact on your overall results for the",47,"Okay. And then, just with regard to this big ERP project that you have. What's the execution risk there that something gets -- some balls get dropped in terms of the inventory levels and things like that, causing an impact on your overall results for the company?"
94614,314976743,921214,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","Yes. So like with any system implementation, there's always some degree of risk. We're being very thoughtful and careful about how we go about the project. We're staffing -- we're putting our best people on it. They're in dedicated -- in a dedicated works",274,"Yes. So like with any system implementation, there's always some degree of risk. We're being very thoughtful and careful about how we go about the project. We're staffing -- we're putting our best people on it. They're in dedicated -- in a dedicated workspace. And in fact, my former Head of HR, who also has run businesses, is going to be leading the business component of that. And I appointed a new Head of HR. That sent a terrific signal to the organization of the kind of commitment we're making. It will be a measured launch, so it will take a number of years before complete, and we're starting off with our Instruments division. And we're going to continue -- we have a study set in March planned. We have an IT leader who's partnering with a business leader who has a -- was previous -- at a previous large med tech company doing exactly this kind of an implementation over the past few years. So we believe it's all about talent, staffing the right people who know our business. And we're going to do our best, obviously, to mitigate the risk. We had a painful experience in Japan a couple of years ago. I can tell you the approach of this project is radically different to the approach we used in that project. And so we feel we'll be in good shape, and it's not a Big Bang launch. We're going to do division by division, region by region, and there'll be a steady cadence. So even if something does start to wobble a little bit, it should have very, very little impact."
94614,314976743,921214,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Operator","Our next question comes from Matt Taylor from Barclays bank.",10,"Our next question comes from Matt Taylor from Barclays bank."
94614,314976743,921214,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Analysts","Great. So I was just wondering if you could follow up on some of those comments on 3D printing and to talk about the materiality of the contributions in the quarter and what you're expecting out that you're going to be investing while in this new plan. Ho",57,"Great. So I was just wondering if you could follow up on some of those comments on 3D printing and to talk about the materiality of the contributions in the quarter and what you're expecting out that you're going to be investing while in this new plan. How big is it and how material could that be?"
94614,314976743,921214,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","Yes, So for the moment, it's -- these are innovative products that are adding, I would call, incremental growth. It's not the core growth. The core growth is our big systems, right, our Triathlon, our Accolade. That's where the core amount of our sales co",290,"Yes, So for the moment, it's -- these are innovative products that are adding, I would call, incremental growth. It's not the core growth. The core growth is our big systems, right, our Triathlon, our Accolade. That's where the core amount of our sales comes from. But this gives a little extra boost to -- and put some little bit of jump in our sales force step, gives them something new to talk to their customer about. So as an example, our revision business lagged, our market share lagged our primary business in Knees by about 5 or 6 market share points. So even in a Stryker friendly account, sometimes they would go to a competitive -- a competitor to do their revision procedure. Now that we have what we consider best-in-class revision cones, not only do we keep that business, that surgeon stays with Stryker, we gain that sales. But they now have something that they can go  talk to a competitive surgeon about.  So I would say it's not a huge contributor, but it's an extra shot in the arm. So with robotics and 3D printing, we believe we have the lead on both of those areas. And those are things we can talk about that differentiate us from our competition. So again, not even today robotics is not a huge component of our growth or our actual dollar sales, but we believe they are the ones that are causing that extra piece of growth and a different view of Stryker for the future. Over time, I expect robotics and 3D printing to take on a more important portion of our overall sales. And they'll be sustainable and sticky if we have something that the competition doesn't have."
94614,314976743,921214,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Analysts","Okay, great. And just one question on the transatlantic model. It seems like you're making some progress there. Can you talk about where you are and how much that's helped to improve some of the OUS results and where you think that could go?",44,"Okay, great. And just one question on the transatlantic model. It seems like you're making some progress there. Can you talk about where you are and how much that's helped to improve some of the OUS results and where you think that could go?"
94614,314976743,921214,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","Yes. So look, Europe has exceeded my expectations. We had a really -- our international growth doesn't look fantastic, so you don't see it. But Europe had a mid-single-digit growth year, and it improved progressively from the first quarter to the fourth q",324,"Yes. So look, Europe has exceeded my expectations. We had a really -- our international growth doesn't look fantastic, so you don't see it. But Europe had a mid-single-digit growth year, and it improved progressively from the first quarter to the fourth quarter. So that kind of uptick is frankly ahead of where I'd expected it to be. It's been masked a little bit because of the sluggishness out of China, so that has dampened our international sales. But it's been a really great success. I'm excited about what I'm seeing across our businesses in Europe. Some of the divisions took off faster than others like Trauma and Extremities and Endoscopy took off really quickly. And now I'm starting to see some nice uptake in Instruments and Spine towards the end of the year. So more to come in Europe. We made a number of investments over the course of the year. Those investments are now taking hold. And I think you'll start to see Europe become a division that delivers better top line and starts to deliver some leverage going forward. We've added Canada, so those are now directly managed. A Division President has direct P&L accountability for Canada, the U.S. and Europe. The other regions, we haven't yet folded into the model, but by eliminating the Group President of international role, they -- we now have them reporting directly to our business Group President. So it just increases speed and connectivity from our regions to come straight to a Group President. Over time, we'll see whether those countries will roll into this model, but we don't want to run too fast to fully integrated complete global business units, especially with markets like China that are so different, or Japan. But we're very pleased with the progress so far. Taking out that position was nothing about cost reduction. That was 100% just to increase speed and connectivity of those countries to our businesses."
94614,314976743,921214,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Operator","And our next question comes from Matt Keeler from Crdit Suisse.",11,"And our next question comes from Matt Keeler from Crdit Suisse."
94614,314976743,921214,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Analysts","Just 2 quick ones. First on Hips outside the U.S, you highlighted the drag from emerging markets but your Knee growth actually picked up pretty nicely. So I'm just wondering if there was a much more pronounced impact from that emerging markets drag on Hip",63,"Just 2 quick ones. First on Hips outside the U.S, you highlighted the drag from emerging markets but your Knee growth actually picked up pretty nicely. So I'm just wondering if there was a much more pronounced impact from that emerging markets drag on Hips relative to Knees and if there were any other factors that impacted your Hip business outside the U.S.?"
94614,314976743,921214,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","No, nothing in particular. You see this from quarter-to-quarter, and sometimes you'll see sort of Hips jump. In the case of Hips Canada as an example, there was a hip tender that we lost so that accounted for some of the Hip growth. There's not 1 sort of",110,"No, nothing in particular. You see this from quarter-to-quarter, and sometimes you'll see sort of Hips jump. In the case of Hips Canada as an example, there was a hip tender that we lost so that accounted for some of the Hip growth. There's not 1 sort of overriding factor. It's just sort of a story-by-story, country-by-country. And we see this from quarter-to-quarter, sometimes you'll see knee -- our business is not as big outside the U.S. So you do see a little bit more volatility in our numbers, whether it's Hip, Knee, Spine. Once those businesses get larger, you would -- you should expect that there'll be less volatility."
94614,314976743,921214,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Analysts","Great. And just lastly, Instruments growth was pretty strong in the quarter. But I think you've highlighted that, that business is later on in its product cycle. So I was just wondering if you think the level of growth we saw in the fourth quarter, if tha",73,"Great. And just lastly, Instruments growth was pretty strong in the quarter. But I think you've highlighted that, that business is later on in its product cycle. So I was just wondering if you think the level of growth we saw in the fourth quarter, if that's sustainable going forward. And what are some of the sort of the products to watch where you're maybe a little later on in that product cycle?"
94614,314976743,921214,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","Yes, so the power tools is the product that we referred to as being late in the cycle, the System 7 power tools, which is probably the biggest single product category within Instruments. But Instruments has a lot of other products. So they have Neptune, t",168,"Yes, so the power tools is the product that we referred to as being late in the cycle, the System 7 power tools, which is probably the biggest single product category within Instruments. But Instruments has a lot of other products. So they have Neptune, they have -- they're launching a new signature line of drills. We actually report that as part of our Neurotech, but it's run by our Instruments division. But yes -- they have the sponge counter as well, patient safety company that we acquired. So these are different kinds of businesses that can drive growth. It's a little less predictable than power tools. So I think we're very excited by how they finished the year. They finished the year very, very strong. And we think they'll have a good year. But being longer in the cycle, sometimes we do see them tailing off a little bit. So but I would expect a year that's similar to the year that they had this year overall."
94614,314976743,921214,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Operator","And our next question comes from Rich Newitter from Leerink Partners.",11,"And our next question comes from Rich Newitter from Leerink Partners."
94614,314976743,921214,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Analysts","Kevin, I was hoping I'd just get some comments on Spine. You characterized the market as stable, and you're clearly seeing some nice uptick in the growth rates there. You have some new product launches. So my question really is has there been any change o",77,"Kevin, I was hoping I'd just get some comments on Spine. You characterized the market as stable, and you're clearly seeing some nice uptick in the growth rates there. You have some new product launches. So my question really is has there been any change or can you give us your updated thoughts on how you view kind of external versus internal investments in this division for you now that things seem to be on better footing?"
94614,314976743,921214,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","Yes. So I am really excited about what we're doing organically. So we've retooled our R&D organization, some of our marketing organization over the past few years. And this business is hitting its stride. And we're launching more and more new products. We",163,"Yes. So I am really excited about what we're doing organically. So we've retooled our R&D organization, some of our marketing organization over the past few years. And this business is hitting its stride. And we're launching more and more new products. We're getting into MIS, which was an area that we were softer in before if you look back 3, 4 years ago. And so it's great to see the organic growth. Organic growth obviously is much more financially attractive than going out and spending a lot of money on companies. Over time, I do want this to become a bigger division, and I think it's -- you'll likely see a combination of both organic and acquisitions. But it's always better to have a strong organic business. And so I do not feel at all that I need to do an acquisition because of the strength and what we've started to build internally. But that's something that will likely happen over time."
94614,314976743,921214,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Analysts","Okay. And then, just on Extremities. Again, your Foot & Ankle growth, I think you said it was 20%. That's -- this business continues to truck along. Any comments on kind of the end markets versus potential share gains that we might have seen in the quarte",60,"Okay. And then, just on Extremities. Again, your Foot & Ankle growth, I think you said it was 20%. That's -- this business continues to truck along. Any comments on kind of the end markets versus potential share gains that we might have seen in the quarter? And specifically, are you seeing any disruption from recent M&A in the field?"
94614,314976743,921214,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","Yes, I would just say these are markets that continue to be very healthy growing double digits. We do believe we're taking market share. We've got a dedicated sales focus there, some great products. I wouldn't call out any disruption that we're seeing in",64,"Yes, I would just say these are markets that continue to be very healthy growing double digits. We do believe we're taking market share. We've got a dedicated sales focus there, some great products. I wouldn't call out any disruption that we're seeing in the marketplace. I think it's just continued to be really good execution, a market that has favorable underlying growth dynamics."
94614,314976743,921214,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Operator","And our next question comes from Josh Jennings from Cowen and Company.",12,"And our next question comes from Josh Jennings from Cowen and Company."
94614,314976743,921214,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Analysts","Kevin, I just was hoping you could touch on pricing. I think recently you had some public commentary about some potential moderation in the pricing headwinds that you've historically been experiencing. Any comments in terms of assumptions for pricing head",51,"Kevin, I just was hoping you could touch on pricing. I think recently you had some public commentary about some potential moderation in the pricing headwinds that you've historically been experiencing. Any comments in terms of assumptions for pricing headwinds within guidance? And then, any outlook for pricing, particularly in Orthopaedics?"
94614,314976743,921214,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","Yes. So you saw for the full year, our price did moderate somewhat from the prior year. And there was a lot of concern as we exited -- if you remember, as we're exiting '14, there a was a lot of concern that pricing was going to accelerate in '15. In fact",127,"Yes. So you saw for the full year, our price did moderate somewhat from the prior year. And there was a lot of concern as we exited -- if you remember, as we're exiting '14, there a was a lot of concern that pricing was going to accelerate in '15. In fact, it hasn't. It actually moderated a little bit. But it's modest, right the moderation is very modest. And in our guidance, we suggest that the price will be between 1.5% to 2%. And so I would say it's a stable market. We continue to have price pressure. It's not going away. But we don't see any accelerators to that price pressure. And that's why we feel it's going to be pretty stable going into 2016."
94614,314976743,921214,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Analysts","Great. And just one follow-up on MAKO. We haven't heard much over the last year on the uni knee product. Any commentary there in terms of how it's contributing to growth in your Knee franchise and just overall growth for that product line?",43,"Great. And just one follow-up on MAKO. We haven't heard much over the last year on the uni knee product. Any commentary there in terms of how it's contributing to growth in your Knee franchise and just overall growth for that product line?"
94614,314976743,921214,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","Thanks. The -- obviously, the uni market, when it's put in the context of overall Stryker, it's a very small part of the overall business. And I would say it's a steady contributor, but there's nothing remarkable to say about it. It's a good business, but",55,"Thanks. The -- obviously, the uni market, when it's put in the context of overall Stryker, it's a very small part of the overall business. And I would say it's a steady contributor, but there's nothing remarkable to say about it. It's a good business, but it's a very small part of our overall Knee."
94614,314976743,921214,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","Were you talking, Josh, specifically about -- for MAKO? So for MAKO, it's a first indication, and they're continuing to drive uptake for that as well as with Hip. And as we get additional indication, it does help drive adoption as some customers were not",67,"Were you talking, Josh, specifically about -- for MAKO? So for MAKO, it's a first indication, and they're continuing to drive uptake for that as well as with Hip. And as we get additional indication, it does help drive adoption as some customers were not interested in just the uni. But as we get more indications, they're starting to adopt for that as well as the others."
94614,314976743,921214,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","Yes, but I'm just trying to interpret, sorry that Josh got cut off, just interpret that the growth to 9% in the U.S., that's spike in growth. It really wasn't driven by MAKO unis. That's driven more by the broader Knee business.",42,"Yes, but I'm just trying to interpret, sorry that Josh got cut off, just interpret that the growth to 9% in the U.S., that's spike in growth. It really wasn't driven by MAKO unis. That's driven more by the broader Knee business."
94614,314976743,921214,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Operator","The next question comes from Matthew O'Brien from Piper Jaffray.",11,"The next question comes from Matthew O'Brien from Piper Jaffray."
94614,314976743,921214,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Analysts","Just quickly on MAKO again. The number of systems you placed internationally accelerated here in Q4. Was there anything that you could call out as far maybe a little bit of a tipping point in terms of interest in the robotics system OUS and maybe that cou",56,"Just quickly on MAKO again. The number of systems you placed internationally accelerated here in Q4. Was there anything that you could call out as far maybe a little bit of a tipping point in terms of interest in the robotics system OUS and maybe that could be an even more meaningful contributor here in 2016?"
94614,314976743,921214,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","No. Still, the lion's share of the focus and the revenue is coming from the U.S.  We did place more systems outside the U.S., and we'll continue to focus on those opportunities, particularly places like Australia and certain other markets. But the bulk of",60,"No. Still, the lion's share of the focus and the revenue is coming from the U.S.  We did place more systems outside the U.S., and we'll continue to focus on those opportunities, particularly places like Australia and certain other markets. But the bulk of the revenue stream has been and will likely continue at least near term to be U.S."
94614,314976743,921214,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","Yes. It tends to be a country-by-country thing, so Australia had a terrific year in robot sales. I think, within Europe, we're going to see certain countries are going to adopt MAKO much more quickly than other countries. So I think each year, you'll sort",94,"Yes. It tends to be a country-by-country thing, so Australia had a terrific year in robot sales. I think, within Europe, we're going to see certain countries are going to adopt MAKO much more quickly than other countries. So I think each year, you'll sort of -- you'll see the international volumes starting to increase, but it might be Italy this year, it might be the U.K. next year over the next few years. But again, to Katherine's point, the market that's the most important by far is going to be the U.S. market."
94614,314976743,921214,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Analysts","Okay, and then just to follow up a little bit on Richard's question, a little more broadly on Trauma and Extremities. I think we saw some acceleration here in Q4 beyond what we've seen over the last several quarters. And I'm just -- I'm curious if that ac",77,"Okay, and then just to follow up a little bit on Richard's question, a little more broadly on Trauma and Extremities. I think we saw some acceleration here in Q4 beyond what we've seen over the last several quarters. And I'm just -- I'm curious if that acceleration was specific to any couple of products or geographies around particularly the U.S. and if that level of growth is something that you think is sustainable here in 2016."
94614,314976743,921214,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","Well, I think you've seen our Trauma business in the U.S. It's been 4 years of really terrific growth. So that to me is sustainable when you're growing at that level. So we're very, very pleased. We've rounded out our portfolio completely. And so that ena",198,"Well, I think you've seen our Trauma business in the U.S. It's been 4 years of really terrific growth. So that to me is sustainable when you're growing at that level. So we're very, very pleased. We've rounded out our portfolio completely. And so that enables us to do complete hospital conversions, something that was impossible at Stryker 5, 6 years ago. Europe really picked up quickly. So as you move to a transatlantic model, I was very encouraged by our Trauma success in Europe. We have not been nearly as successful in Europe as we have been in the United States. And we do now have the same products which are all approved. So I think -- I expect more commercial success in Europe as well as Japan. Now some of those products take a little longer to get approved in Japan. So I think that once those products start to arrive we'll start to see more of an uptake in Japan as well. But I would say we're in a very good position in that business. We have a very, very strong leadership team. And we expect to continue to have success in Trauma and Extremities."
94614,314976743,921214,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Operator","And our next question comes from Jeff Johnson from Robert Baird.",11,"And our next question comes from Jeff Johnson from Robert Baird."
94614,314976743,921214,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Analysts","Bill, I just want to say best wishes. I was looking back this afternoon. I think it's been 14 years that you and I have overlapped. So thanks for all the conversations, all the help over that time. And so Kevin, just wanted to ask one question, one follow",123,"Bill, I just want to say best wishes. I was looking back this afternoon. I think it's been 14 years that you and I have overlapped. So thanks for all the conversations, all the help over that time. And so Kevin, just wanted to ask one question, one follow-up question here, just on the phasing or maybe gating of some of the med tech tax savings. Is there going to be any timing differential between when the med tech tax savings start coming in and influencing the cost of goods line versus when you start reinvesting those dollars back into SG&A and R&D? Should those match up pretty evenly out the P&L or just how to think about the gating throughout this year?"
94614,314976743,921214,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","I think that, that's fair to say, Jeff, and thanks a lot for your comments. I think that on the cost of goods sold category, obviously that will start right off in the beginning of the year. Our investments, as we are targeting right now at moving again t",65,"I think that, that's fair to say, Jeff, and thanks a lot for your comments. I think that on the cost of goods sold category, obviously that will start right off in the beginning of the year. Our investments, as we are targeting right now at moving again through 2016, we would also expect to be doing that reinvestment pretty much consistently throughout the year."
94614,314976743,921214,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","Yes. Sorry, it's going to be clean from the beginning of the year -- from the beginning of this year to 2017. It starts immediately. There's no lag effect, which I think had happened prior with the different companies. So for us, it's clean. You'll see it",52,"Yes. Sorry, it's going to be clean from the beginning of the year -- from the beginning of this year to 2017. It starts immediately. There's no lag effect, which I think had happened prior with the different companies. So for us, it's clean. You'll see it cleanly in the 2 years."
94614,314976743,921214,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Operator","And our next question comes from Steve Lichtman from Oppenheimer.",10,"And our next question comes from Steve Lichtman from Oppenheimer."
94614,314976743,921214,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Analysts","I just have one follow-up on ERP. You talked about the investment on the capital side. Are there any P&L impacts that we should expect over the next couple of years as you start to implement ERP? And when do you anticipate the system being fully in place?",49,"I just have one follow-up on ERP. You talked about the investment on the capital side. Are there any P&L impacts that we should expect over the next couple of years as you start to implement ERP? And when do you anticipate the system being fully in place?"
94614,314976743,921214,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","So a couple of different questions again there. So on the ERP side of the equation, from an investment perspective, we won't see the first implementations really for about another 1.5 years or so. And then those will be rolled out over the next few years",190,"So a couple of different questions again there. So on the ERP side of the equation, from an investment perspective, we won't see the first implementations really for about another 1.5 years or so. And then those will be rolled out over the next few years after that. As far as the cost side of the equation goes, we would not expect that to be a big blip once we get to kind of the stabilized level that we've got kind of this -- in 2016 year. But moving forward, in fact, if anything, as those systems are implemented, we would expect some of the benefits. Plus with the CTG [ph] initiatives that we've got kicked off, those will continue to roll in at different points throughout different years. We do have multi hundreds of millions of dollars targeted for that. Keep in mind as well that we have price downs in the $150 million to $200 million range that we need to be working to offset. And then, as far as the impacts associated with the investment, again, that should be pretty consistent as we're moving forward beyond 2016."
94614,314976743,921214,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","Yes. Just to add to that, I would say, we do have some expense that will be hitting our P&L, but we're absorbing that within the guidance that we have provided to you.",33,"Yes. Just to add to that, I would say, we do have some expense that will be hitting our P&L, but we're absorbing that within the guidance that we have provided to you."
94614,314976743,921214,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Operator","And our next question comes from Kaila Krum from William Blair.",11,"And our next question comes from Kaila Krum from William Blair."
94614,314976743,921214,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Analysts","Just a couple of quick ones for me. The first, I mean, clearly, you all are still emphasizing M&A as the key priority here. And I'm just curious if you can touch on that how or if those conversations have changed tone just with some of the valuation pullb",56,"Just a couple of quick ones for me. The first, I mean, clearly, you all are still emphasizing M&A as the key priority here. And I'm just curious if you can touch on that how or if those conversations have changed tone just with some of the valuation pullbacks specifically that we've seen in recent weeks?"
94614,314976743,921214,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","Yes. I would say that, that short a time period doesn't have an impact. And as Kevin articulated, we continue to be focused on M&A externally. There's going to be periods where it looks more or less active depending on timing. Internally, the teams have n",64,"Yes. I would say that, that short a time period doesn't have an impact. And as Kevin articulated, we continue to be focused on M&A externally. There's going to be periods where it looks more or less active depending on timing. Internally, the teams have never been busier, and there's no change in the strategy. And the recent market disruption is what it is."
94614,314976743,921214,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Analysts","Okay. And then, I guess, just a follow-up on an earlier question just around whether or not there is this potential for longer-term growth rates to accelerate. And then just pairing that with your earlier comments about MAKO and the likelihood that 2016 i",70,"Okay. And then, I guess, just a follow-up on an earlier question just around whether or not there is this potential for longer-term growth rates to accelerate. And then just pairing that with your earlier comments about MAKO and the likelihood that 2016 is more of a set-up year for 2017, is it fair to assume that overall top line growth could modestly accelerate heading into 2017 from 2015 levels?"
94614,314976743,921214,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","It's always our goal to grow sales at the high end of med tech. And certainly, we've got some nice opportunities between ischemic and MAKO, but they're going to be in early stages next year. So probably premature to start the push towards higher growth ra",71,"It's always our goal to grow sales at the high end of med tech. And certainly, we've got some nice opportunities between ischemic and MAKO, but they're going to be in early stages next year. So probably premature to start the push towards higher growth rates in this year, but we feel really good with what we've set up for this year and hopefully can build on that in '17."
94614,314976743,921214,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","Yes. I think we're going to learn a lot. So I think towards the end of this year we'll be able to share more of the 2 additional platforms, both MAKO and ischemic stroke. Those are the ones that I think can provide, let's call them change of trajectories",107,"Yes. I think we're going to learn a lot. So I think towards the end of this year we'll be able to share more of the 2 additional platforms, both MAKO and ischemic stroke. Those are the ones that I think can provide, let's call them change of trajectories in growth for the company. Now whether that happens in '17 or '18 or '19, it's -- they are new platforms so it's not easy to predict. But I think we'll learn a lot over the course of this year and certainly be able to share more with you when we provide our guidance in the following year."
94614,314976743,921214,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Operator","We have no further questions at this time. I'll now turn the conference call over to Mr. Kevin Lobo for any closing remarks.",23,"We have no further questions at this time. I'll now turn the conference call over to Mr. Kevin Lobo for any closing remarks."
94614,314976743,921214,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","So thank you all for joining our call. Our conference call for the first quarter 2016 results will be held on April 20. Thank you.",25,"So thank you all for joining our call. Our conference call for the first quarter 2016 results will be held on April 20. Thank you."
94614,314976743,921214,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Operator","Thank you, ladies and gentlemen. This concludes today's conference. Thank you for participating, and you may now disconnect.",18,"Thank you, ladies and gentlemen. This concludes today's conference. Thank you for participating, and you may now disconnect."
94614,314976743,921224,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Operator","Welcome to the Fourth Quarter 2015 Stryker Earnings Call. My name is Adrianne, and I will be your operator for today's call. [Operator Instructions] This conference call is being recorded for replay purposes.Before we begin, I would like to remind you t",138,"Welcome to the Fourth Quarter 2015 Stryker Earnings Call. My name is Adrianne, and I will be your operator for today's call. [Operator Instructions] This conference call is being recorded for replay purposes.
Before we begin, I would like to remind you that the discussions during this conference call will include forward-looking statements. Factors that could cause actual results to differ materially are discussed in the company's most recent filings with the SEC. Also, the discussions will include certain non-GAAP financial measures. Reconciliations to the most directly comparative GAAP financial measures can be found in today's press release that is an exhibit to Stryker's current report on Form 8-K that was filed today with the SEC.
I would now like to turn the call over to Mr. Kevin Lobo, Chairman and Chief Executive Officer. You may proceed, sir."
94614,314976743,921224,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","Good afternoon, everyone, and welcome to Stryker's fourth quarter 2015 earnings call. Joining me today are Bill Jellison, our CFO; Katherine Owen, Vice President of Strategy and Investor Relations; and Glenn Boehnlein, who will be taking over for Bill on",822,"Good afternoon, everyone, and welcome to Stryker's fourth quarter 2015 earnings call. Joining me today are Bill Jellison, our CFO; Katherine Owen, Vice President of Strategy and Investor Relations; and Glenn Boehnlein, who will be taking over for Bill on April 1. Following my opening comments, Katherine will provide an update on MAKO, while Bill will offer more details on our quarterly results before turning to questions and answers.
With a 6.4% increase in organic sales in Q4, we continue to deliver on our goal of driving top line growth at the high-end of med tech. This marks the 11th consecutive quarter where Stryker delivered 5% or better organic sales growth, demonstrating strong consistency over time. Our diversified sales footprint has once again proven to be a key component of our growth strategy as all of our segments, Orthopaedics, MedSurg and Neurotechnology and Spine, posted good results in the quarter. These performances underscore the strength of our sales and marketing execution and our innovation engine, which is characterized by healthy R&D investments and a focused and disciplined M&A effort.
Approximately 70% of our sales are derived from our U.S. businesses, which once again led growth, posting an impressive gain of approximately 8%. I am also pleased with the growing momentum out of Europe, including strong Q4 results benefiting from the shift to the Transatlantic Operating Model at the beginning of 2015. We are building on this success as we start 2016 with Canada rolling into the model and the other regions now reporting to our Group Presidents, Tim Scannell and David Floyd. Our international growth of roughly 4% in constant currency was once again impacted by soft performances in China and Brazil. However, as you've seen, we have demonstrated the ability to offset isolated geographic softness through strength in our larger markets.
Turning to earnings. Our adjusted EPS for Q4 of $1.56 is at the high-end of our revised range of $1.53 to $1.56 primarily driven by the strong top line. The balance of the P&L came in as expected, which Bill will cover in his section. Looking ahead to 2016, we expect our sales momentum to continue and are targeting organic sales growth for the year of 5% to 6%. This takes into account expected softness in emerging markets for a good portion of the year.
In addition, the 2-year suspension of the med device tax provides us with the opportunity to bolster investments that will help drive sales growth and innovation as we plan to invest the majority of this temporary benefit. We are also continuing on our path toward driving greater cost efficiencies, which is a multiyear opportunity. Over the past year, we have been focused on identifying and prioritizing the key target areas for cost reduction within our organization.
As we shift into 2016, we are moving toward project implementation under the leadership of Group President Lonny Carpenter. We have identified significant areas of savings centered around optimizing our plant network, rationalizing our product lines, professionalizing our indirect procurement in a similar manner as we have done with direct materials, moving to a common ERP system and driving more shared services.
Given our history of decentralization, there's considerable opportunity ahead of us in this program. We believe a methodical and deliberate approach to these efforts will allow us to preserve Stryker's competitive differentiation in the areas of sales, marketing, R&D and business development while helping to ensure we are consistently delivering P&L leverage. This is reflected in our 2016 adjusted EPS range of $5.50 to $5.70 a share. This is an increase of approximately 7.5% to 11.5% versus 2015, and it includes a negative foreign exchange impact of $0.12 to $0.13 a share.
Finally, I'd like to take a moment to extend my thanks and appreciation to Bill Jellison, who has announced his plan to retire following an impressive 36 career -- 36-year career, the last 3 of which have been with Stryker. Bill was able to quickly move toward implementing a layered hedging program, which has proven to be successful at mitigating our transactional FX exposure. In addition, he helped execute on a number of acquisitions, facilitated the establishment of our European regional headquarters that's enabled significant savings and has also helped to shape our comprehensive cost reduction program.
These accomplishments have meaningfully contributed to our success and were achieved while enabling our internal talent pools to develop, including Glenn Boehnlein, who has been promoted to CFO effective April 1. Glenn has been with Stryker in various financial leadership roles since 2003, most recently serving as Group CFO for the MedSurg and Neurotechnology group. This group represents roughly half the company and has been a consistent force behind our strong results. I am confident in Glenn's ability in coordination with the broader finance organization to help build on our strong momentum.
Before turning the call over to Katherine, I've asked Glenn to make a few comments. Glenn?"
94614,314976743,921224,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","Thanks, Kevin. I appreciate the comments and the support, but I also want to thank Bill for his leadership of the finance organization over the past few years and for his commitment to helping ensure a smooth transition as I take on new responsibilities.",98,"Thanks, Kevin. I appreciate the comments and the support, but I also want to thank Bill for his leadership of the finance organization over the past few years and for his commitment to helping ensure a smooth transition as I take on new responsibilities. It's a very exciting time at Stryker, and I'm thrilled to be part of such a great organization with so many talented and dedicated people. I'm also looking forward to meeting many of our shareholders and analysts at the various events going forward.
And with that, I'll turn the call back over to Katherine."
94614,314976743,921224,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","Thanks, Glenn. The focus of my comments today will be to provide an update on MAKO. 2015 was a year of building momentum for MAKO's robotic-assisted surgery as we continue to leverage our considerable sales and marketing infrastructure to help drive sales",257,"Thanks, Glenn. The focus of my comments today will be to provide an update on MAKO. 2015 was a year of building momentum for MAKO's robotic-assisted surgery as we continue to leverage our considerable sales and marketing infrastructure to help drive sales. We are particularly pleased with the increased demand for the hip indication, which has been augmented by combining the robotic technology with our proven portfolio of Stryker hip systems. The combination enables surgeons to use a best-in-class hip implant with a long-term proven clinical history on a robotic-assisted platform which helps drive consistency, enhance surgeon and patient experience and, we believe over time, clinically demonstrated benefits. In total, we sold 31 robots globally in the quarter, 24 of which were in the U.S., which represents a solid ramp from the start of the year and a significant jump year-over-year from 20 in the fourth quarter of 2014. For 2016, we are focused on continuing to drive adoption with our current indications, which we believe offer considerable opportunity to drive ongoing robot placements.
We are also excited about the potential for the Total Knee indication with our flagship Triathlon system. This year, our efforts will be centered around gaining user experience with key opinion leaders to help ensure an optimal rollout as we look to full commercial release in 2017. We believe the commercial launch, which will be aided by podium presentations from the early users group, will be in place as we head into next year.
With that, I'll turn the call over to Bill."
94614,314976743,921224,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","Thanks, Katherine. I'd like to start off by saying I've enjoyed working with Kevin and everyone at Stryker, especially the entire finance organization who have made significant contributions over the last few years helping the company deliver on its finan",1931,"Thanks, Katherine. I'd like to start off by saying I've enjoyed working with Kevin and everyone at Stryker, especially the entire finance organization who have made significant contributions over the last few years helping the company deliver on its financial results. 
Coming to Stryker was a strong cultural fit and personal fit from the first week that I joined the company.
We ended 2015 at the high-end of both our initial sales and earnings guidance that was set at the beginning of the year. As we look at 2016 and set our initial guidance, I am confident that our sales momentum, strong product portfolio and pipeline and the cost containment initiatives we are driving position us well for the future. I look forward to ensuring a smooth transition with Glenn and entering another stage in my life. I will continue to engage actively in many of my passions, travel with my family and friends and explore additional board opportunities. I want to thank all of you for your support.
So turning to our financial performance. Sales grew 3.7% in the quarter, including a negative 3.2% impact from foreign currency translation. Constant currency sales growth was 7%, which includes organic growth of 6.4%.
GAAP EPS for the quarter was $1.38 per share versus $0.68 last year in the fourth quarter, while adjusted earnings per share were $1.56 a share for the quarter versus $1.44 per share in the fourth quarter last year. This quarter's EPS includes negative impacts of roughly $0.04 per share from foreign exchange, which was in line with our guidance.
Most currency exchange rates against the U.S. dollar continued to be weaker than last year in the same period. The weaker euro and Swiss franc, along with our layered hedging program, helped to mitigate some of the impact in the quarter as many of our products are manufactured in Europe, which helped improve our gross margin rates in the period. However, significant weakening in foreign currency rates in emerging markets and the continued weakness of the Japanese yen, Australian dollar and Canadian dollar, where we have minimal manufacturing, negatively impacted our gross margins and operating results in those regions.
The most significant non-GAAP adjustments in the quarter were amortization, restructuring charges and a net reduction in the charge associated with the voluntary recall of the Rejuvenate, ABG II modular hip stem as we resolved some insurance matters in the quarter, which more than offset the additional charge in the period. As I have mentioned previously, the charges we have recorded related to the Rejuvenate and ABG II recall represents the minimum of the range of probable loss to resolve this manner, and the charges may increase or decrease over time as additional facts become available and our assumptions more refined.
In the fourth quarter, our organic growth rate was 6.4%, including 8.1% growth in unit volumes and mix, with price negatively impacting sales by 1.7%. Acquisitions added 0.6%, while FX had a negative 3.2% impact due to significant weakness in both the Japanese yen and the Australian dollar compared to the same period last year. Full year 2015 constant currency sales growth were 7%, and organic growth was 6.1%.
Looking at our segments. Orthopaedics represented 42% of our sales in the quarter, and sales of Orthopaedic products grew 3.3% as reported and 7.1% in constant currency. U.S. Orthopaedic sales grew 9.7% in the quarter. Trauma and Extremities had another excellent quarter in the U.S. with sales increasing 13.6% led by strong growth in Foot & Ankle, which again grew approximately 20% for both the fourth quarter and full year. U.S. Hips and Knees continued their strong performance of 6.4% and 9.1% organic growth, respectively, in the quarter. These sales were bolstered by increased adoption of recent titanium 3D-printed products.
Our International Orthopaedic business grew 2.4% in constant currency as sales growth continued to be negatively impacted by weakness in China and Brazil. However, our International Knee business grew 5.5% in constant currency in the quarter. Finally, we sold 31 MAKO units in the quarter and 72 units in the full year.
Next, our MedSurg segment represented approximately 40% of our total sales, and sales of MedSurg products grew 3% as reported and 5.6% in constant currency. These results were led by growth in our Instruments and Medical business, both of which had strong mid-single-digit percentage growth in constant currency. Endoscopy also posted mid-single-digit percentage growth in constant currency in the period on the back of our new camera offering, which was launched in December. All 3 of these large MedSurg businesses continued to manage pricing decisions effectively with modest price declines of less than 0.5% for the year.
Our final segment, Neurotechnology and Spine, represented 18% of sales and delivered another good quarter. Sales of Neurotechnology and Spine products grew 6.5% as reported and 9.9% in constant currency. Growth in this segment was led by our Neurotechnology business, which had double-digit growth in the high teens in constant currency in the fourth quarter and grew high teens in the U.S. Spine sales had mid-single-digit percentage growth in constant currency in the period and had high single-digit growth in the U.S. This marks our third consecutive quarter of strong growth in U.S. Spine. Spine also has a new 3D-printed interbody device launching in 2016, which we believe will be a very exciting product for the market, helping us to continue this positive trend.
In looking at our operational performance, gross margin as a percent of sales on an adjusted basis in the fourth quarter was 67.2% compared to 65.8% in the fourth quarter last year. When compared to the same period last year, the rate was positively impacted by solid operational improvements, product mix and FX rates despite the negative FX impact on earnings per share.
Price had a negative impact as pricing was lower by 1.7% in the period. Our gross margin as a percentage of sales was 66.5% or 50 basis points higher than last year. Research and development expenses increased by 20 basis points to 6% of sales in the fourth quarter compared to 5.8% in the same period last year.
On an adjusted basis, selling, general and administrative expenses represented 33.7% of sales in the fourth quarter compared to 32.4% in the same period last year. As expected, these expenses were higher for the year as we increased spending to support the cost structure of our European regional headquarters in Amsterdam and our Transatlantic Operating Model. We are confident in our ability to leverage these expenses in 2016 as we continue to drive a number of key cost initiatives even as we reinvest some of the savings from the suspension of the medical device tax.
Operating margin as a percentage of sales on an adjusted basis were 27.4% in the fourth quarter compared to 27.6% in the same period last year. The full year adjusted operating margin rate was 24.9%, nearly flat compared to last year. During the year, we invested in our European regional headquarters and the establishment of our Transatlantic Operating Model, which reduced the stronger operating margins for the year.
Other expense in the fourth quarter was $36 million. This increase in expense resulted primarily from higher net interest expense due to increased borrowings and foreign currency exchange transactional losses in the fourth quarter. This is generally consistent with the run rate for this category.
Our reported tax rate for the fourth quarter was 14.7%, while the adjusted effective tax rate was 16.6% for the fourth quarter compared to 22.6% in the same period last year. The fourth quarter effective tax rate benefited from the renewal of the tax extenders, which was contemplated in our guidance. The full year adjusted effective tax rate was 17.3% compared to 22.3% last year as we realized the benefits from our global tax structure and European regional headquarters in Amsterdam.
Looking at the balance sheet. We ended the quarter with $4.1 billion of cash and marketable securities, approximately 50% of it now held in the U.S. We also had $4 billion of debt on the balance sheet at the end of the quarter. From an asset management standpoint, accounts receivable days ended the quarter at 55, relatively unchanged from last year. Days in inventory finished the quarter at 165, which was an increase of 5 days compared to last year.
Turning to cash flow. Our cash flow from operations for 2015 were $900 million compared to $1.8 billion last year. But as previously mentioned, we made significant payments earlier this year associated with our Rejuvenate and ABG II recall settlement of $1.2 billion, most of which occurred in the third quarter. Approximately 50% of the funding of the Rejuvenate liability is being sourced from OUS cash. We also repatriated a total of $1.8 billion in 2015, including approximately $1.1 billion in the fourth quarter. Capital expenditures were $270 million in 2015 compared to $233 million last year.
Finally, regarding share repurchases. In 2015, we repurchased approximately $700 million of our common stock or approximately 7.5 million shares at an average price of approximately $94.67. We have authorization for another $1.9 billion available for repurchase under our current authorization.
Based on our strong performance in 2015 and assessment of the current economic and market conditions, we are projecting constant currency and organic sales growth in a range of 5% to 6% for 2016 and expect to be at the low end of that range in the first quarter as we are still anticipating impacts of market conditions in the emerging markets, especially China and Brazil. If foreign currency exchange rates hold near current levels, we anticipate net sales will be negatively impacted by approximately 1% for 2016. We also expect continued unfavorable price reductions of 1.5% to 2% consistent with the pricing environment experienced in 2015.
Due to the suspension of the med tech tax, we will also provide some additional visibility to our projected margin rates for 2016. Both gross margin and operating income margins are projected to be at least 50 basis points higher in 2016 in total. The benefit from the suspension of the med tech tax will directly benefit our gross profit rate. However, R&D will run slightly higher in 2016, and our SG&A rate will only show modest improvement for the full year as we expect to reinvest the majority of the benefit we receive into these areas, offsetting much of our cost reductions in '16.
As such, our gross margin rate improvements will be the driver of our operating margin rate in 2016. We expect our full year adjusted effective tax rate in 2016 will continue to be approximately 17% to 17.5%. Capital expenditures are expected to be $400 million to $450 million in 2016 as we continue to invest in our operations and our IT infrastructure to support future growth.
Based on the current foreign exchange rates, we expect 2016 to be negatively impacted by approximately $0.12 to $0.13 for the full year and approximately $0.03 for the first quarter. This negative impact is largely driven by the translational component of foreign exchange, which we do not hedge. The transactional impact of foreign exchange on earnings is being offset somewhat by both natural and real hedges, which we continue to layer into our operations. Finally, our guidance for adjusted net earnings per diluted share in 2016 is $5.50 to $5.70 for the full year and $1.17 to $1.22 for the first quarter.
Thanks for your support, and we'd be glad to answer any questions that you may have at this time."
94614,314976743,921224,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Operator","[Operator Instructions] Our first question comes from Bob Hopkins from Bank of America.",13,"[Operator Instructions] Our first question comes from Bob Hopkins from Bank of America."
94614,314976743,921224,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Analysts","So first, Bill, sorry to see you move on, but good luck with the next chapter. Sort of feel I'd be remiss if I didn't sort of ask a follow-up question on this announcement and maybe the way to phrase the question, Bill, is -- and for Kevin and Katherine,",114,"So first, Bill, sorry to see you move on, but good luck with the next chapter. Sort of feel I'd be remiss if I didn't sort of ask a follow-up question on this announcement and maybe the way to phrase the question, Bill, is -- and for Kevin and Katherine, you guys have been talking about M&A for some time and I'm just curious if this CFO transition suggests any change in strategy or maybe suggests that mid or larger deals kind of less likely until after this transition is complete. Just kind of curious in how this could affect the strategy and/or the outlook for M&A. And again, congrats, Bill, for the decision."
94614,314976743,921224,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","Yes, thanks, Bob. Look, I would tell you right now the company is in very good shape. You can see the way we're performing. This is an internal transition with somebody who is inside our company, so this is not like we're signaling any kind of shift in st",151,"Yes, thanks, Bob. Look, I would tell you right now the company is in very good shape. You can see the way we're performing. This is an internal transition with somebody who is inside our company, so this is not like we're signaling any kind of shift in strategy. I would tell you, we've been very consistent on capital allocation since I've been in the job and even before, that our approach is to favor M&A first then dividends and then share buybacks. So there's absolutely 0 change to our operating mode, and I'm expecting a very smooth transition. You can see that we have a whole quarter of overlap, and Bill is still going to be around in this community and available to help us as needed. So I would tell you that you should expect more of the same from Stryker, and this should be a very seamless change."
94614,314976743,921224,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Analysts","All right. And then as a quick follow-up also, Kevin, from a big picture perspective. I was wondering if you could kind of give us your sense for the outlook for hospital capital spending in 2016. What are you seeing from hospitals? Are you expecting any",74,"All right. And then as a quick follow-up also, Kevin, from a big picture perspective. I was wondering if you could kind of give us your sense for the outlook for hospital capital spending in 2016. What are you seeing from hospitals? Are you expecting any changes? Just wanted to get a sense for your view on the 2016 outlook for CapEx, especially since you're launching some new products into the market right now."
94614,314976743,921224,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","Thanks, Bob. Look, we see the market as very stable for capital equipment. You can see in the fourth quarter we had very strong performances on MAKO selling capital. That's a large capital. We also have a lot of small capital. Our Instruments division did",107,"Thanks, Bob. Look, we see the market as very stable for capital equipment. You can see in the fourth quarter we had very strong performances on MAKO selling capital. That's a large capital. We also have a lot of small capital. Our Instruments division did very well in the fourth quarter. So we look at the market as being very stable. We're just embarking upon the launch of our new camera, the 1588, within Endoscopy. They had a nice start in the month of December, and the orders look quite healthy going into the year. So we're not seeing really any change. A very stable capital market."
94614,314976743,921224,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Operator","And the next question comes from Mike Weinstein from JPMorgan.",10,"And the next question comes from Mike Weinstein from JPMorgan."
94614,314976743,921224,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Analysts","And Bill, my sentiments as well. Thanks for all your help and enjoy your time away from Stryker. Let me ask a couple questions, guys. So one question is the 5% to 6% constant currency guidance for 2016. Obviously you've, by and large, been running above t",84,"And Bill, my sentiments as well. Thanks for all your help and enjoy your time away from Stryker. Let me ask a couple questions, guys. So one question is the 5% to 6% constant currency guidance for 2016. Obviously you've, by and large, been running above that. Can you just tell us what you have baked in there for the emerging market performance because obviously you're still assuming a challenging emerging market environment for the year? Just want to get some sensitivities around it."
94614,314976743,921224,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","Yes, Mike. In terms of emerging markets, which is in that 7% to 8% of our total sales, and China and Brazil are the biggest components. Although we've been seeing nice growth in markets outside of that, we've assumed those markets remain challenging for t",96,"Yes, Mike. In terms of emerging markets, which is in that 7% to 8% of our total sales, and China and Brazil are the biggest components. Although we've been seeing nice growth in markets outside of that, we've assumed those markets remain challenging for the better part of the year. China as well as Brazil are difficult to predict given the macro issues surrounding them. We do benefit from easier comparisons as we get to the back half of the year, but we assume the overall market there continues to be a bit of a challenge."
94614,314976743,921224,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","Yes, Mike, I would say the emerging markets for us, we had similar performance in the fourth quarter as we did in the third quarter. So we were slightly negative in terms of growth in our emerging markets, China, of course, being the biggest drag. And for",182,"Yes, Mike, I would say the emerging markets for us, we had similar performance in the fourth quarter as we did in the third quarter. So we were slightly negative in terms of growth in our emerging markets, China, of course, being the biggest drag. And for Stryker, we have a capital equipment business, especially the Endoscopy division, that's quite big in China. And so that has a bit more of an impact than the disposables or implants on Stryker. So we're expecting that to continue to be difficult, and that will be a drag. And it's early in the year, so we're setting our guidance from 5% to 6%. As you saw last year, we moved our guidance up during the year. If these conditions don't -- or not as severe, you can expect we would do the same. It doesn't change our outlook on our business. We feel very good about our business, but it's early in the year and we know that those markets are going to be challenged and we're just baking in some caution around those markets."
94614,314976743,921224,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Analysts","Understood. Let me -- just 2 quick follow-ups relative to the guidance. So one, you started to talk about the cost transformation initiatives in greater detail in San Francisco. And in the 2016 guidance, you're basically assuming no SG&A leverage, and tha",146,"Understood. Let me -- just 2 quick follow-ups relative to the guidance. So one, you started to talk about the cost transformation initiatives in greater detail in San Francisco. And in the 2016 guidance, you're basically assuming no SG&A leverage, and that's part of it, you're talking about reinvesting back in the business with the benefit of the med tech tax helping the gross margin line. So can you just talk a little bit about where you're going to incrementally invest if that will show up in SG&A or will it all show up in R&D? And then second, the acceleration of the share buyback -- and acceleration maybe is not the right term, but you bought back more stock than you had been buying back in the fourth quarter. Can you just talk a little bit about what's in your 2016 guidance for capital deployment?"
94614,314976743,921224,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","Yes, so a couple different questions there, the first one associated with kind of the margin rates and also the SG&A area. We do expect some modest level of improvement still in the broader operating expense category, but the reinvestment is primarily tak",278,"Yes, so a couple different questions there, the first one associated with kind of the margin rates and also the SG&A area. We do expect some modest level of improvement still in the broader operating expense category, but the reinvestment is primarily taking place in both areas, probably about maybe 20 basis points or so of an impact on the R&D-related side and the remainder kind of in the SG&A area. I'd say that with the cost initiatives that we've got in place that you would have seen obviously better leverage there. But with the reinvestment, that will slow that down at least this year. But we should still be showing obviously some very, very solid gross margin rate improvement, and we should be getting good drops here still in the operating income line for that. As it relates to the buybacks, yes, we did jump that up to about $700 million in this year. As you can see, our cash has continued to stay very strong. We were able to bring back some additional cash. We have about $2 billion here in the U.S. at this point. And as far as our guidance is concerned, you should expect that -- we commented before that we've got the authorization out there. We expect to complete that over kind of a 2- to 3-year period of time, barring any sizable acquisitions. And hopefully, as Kevin mentioned, acquisitions are absolutely still our first and foremost kind of attention within that space, and we expect to be very active as we move forward, but those are all based on timing situations, right? So -- but that is still our #1 focus."
94614,314976743,921224,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Operator","And our next question comes from Rick Wise from Stifel.",10,"And our next question comes from Rick Wise from Stifel."
94614,314976743,921224,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Analysts","Maybe, Kevin, start -- my first question would be on the operating margin outlook. Obviously you're exiting '15 at 27.4%. Maybe just comment, if you would, on your aspirational goals here. Is it 30%? Is it 35% over the next 2 to 4, 3 to 5 years? Just talk",60,"Maybe, Kevin, start -- my first question would be on the operating margin outlook. Obviously you're exiting '15 at 27.4%. Maybe just comment, if you would, on your aspirational goals here. Is it 30%? Is it 35% over the next 2 to 4, 3 to 5 years? Just talk about the magnitude and the durability of this seemingly long-tailed opportunity?"
94614,314976743,921224,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","So Rick, look, you know we only give guidance out for 1 year, right? So we provided you guidance this year, which shows some pretty meaningful leverage on the EPS line. Coming off the year, we just delivered leverage. And if we didn't have a $0.12 to $0.1",216,"So Rick, look, you know we only give guidance out for 1 year, right? So we provided you guidance this year, which shows some pretty meaningful leverage on the EPS line. Coming off the year, we just delivered leverage. And if we didn't have a $0.12 to $0.13 a share of negative FX, we'd be giving EPS in the 10% to 14% range. So that's pretty meaningful leverage on the sales of 5% to 6%. So you should expect us to continue to drive meaningful leverage. That's the goal of the cost program. There's -- we've said before, there's significant opportunities, in the hundreds of millions of dollars. And as we get drive those savings, we'll obviously, if there's great opportunities to invest, we'll invest some of those dollars and some of those dollars will fall to the bottom line. So -- but I don't have a magical number, and I think it also depends on as the years progress, what types of deals that we do, and how that affects our margin profile. So I think each year, you'll expect us to give the kind of guidance we're giving you this year: nice, robust organic growth and a nice amount of leverage to the bottom line, and I think I'll just leave it at that."
94614,314976743,921224,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Analysts","Okay. And Katherine, maybe for you on MAKO. Can you give us a little more color on your comments? You talked about increased demand for the hip indication. It seemed to me you placed more -- a few more systems than we expected. Can you talk about the plac",65,"Okay. And Katherine, maybe for you on MAKO. Can you give us a little more color on your comments? You talked about increased demand for the hip indication. It seemed to me you placed more -- a few more systems than we expected. Can you talk about the placements and the utilization and maybe where you are in the rollout for new indications and software?"
94614,314976743,921224,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","Sure. I think it really is reflective of being completed year 2 of the acquisition, so working through the integration and really helping the combined sales forces to optimize their education around the features and benefits of our hip system, on the robo",266,"Sure. I think it really is reflective of being completed year 2 of the acquisition, so working through the integration and really helping the combined sales forces to optimize their education around the features and benefits of our hip system, on the robotic-assisted platform and getting out there and really detailing those benefits. It's a nice mix of both existing Stryker customers but also new accounts that we're able to get into with the robots. So we're really pleased with the placement as well as having a number of them outside the U.S. I would really just emphasize, 2016 is about really working to make sure we are optimally set up for full commercial launch in '17 for the Total Knee. So we are not expecting any real impact from that this year. We have a lot of work to do to optimize the training protocol. We're going to work with key opinion leaders both on the robotics side as well as KOLs with our Triathlon system to make sure we're meshing those observational studies to really fine-tune the training protocol. We're going to have to  train our own sales force, do the upgrades in the system. So there's a lot of work to be done to make sure when we go into full commercial launch, we are set to really optimize that and have a presence at the podium. So we'll continue to drive placements with the existing indications for 2016 while doing the necessary groundwork to really ensure we're in a great position in 2017 to take full advantage of the Total Knee indication."
94614,314976743,921224,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Operator","And our next question comes from David Roman from Goldman Sachs.",11,"And our next question comes from David Roman from Goldman Sachs."
94614,314976743,921224,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Analysts","I wanted just to start with some of the investment spending that you're committing to through the P&L. Over the past several years, you've been very consistent with investing your business both SG&A and R&D, which has obviously produced this very nice top",87,"I wanted just to start with some of the investment spending that you're committing to through the P&L. Over the past several years, you've been very consistent with investing your business both SG&A and R&D, which has obviously produced this very nice top line growth rate. But as you look forward as you continue to invest in the business, do you see opportunities to enhance the top line growth rate beyond what you're performing today? And where are the most attractive areas of investment for you?"
94614,314976743,921224,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","Well, I can tell you that I get a chance to travel around to all of our divisions over the course of the year, and I've yet to meet an R&D leader that has enough money to spend on new products. So I would say that all of the divisions have opportunities.",345,"Well, I can tell you that I get a chance to travel around to all of our divisions over the course of the year, and I've yet to meet an R&D leader that has enough money to spend on new products. So I would say that all of the divisions have opportunities. There's clearly some areas that we would focus on a little bit more than others. So you've seen our Spine business really start to turn based on focused investments in R&D. We've had 3 great quarters in a row in the U.S. We still have to take a lot of those products outside the U.S. But I would say that would be an area where organic development and spending is really paying off for us, so you can expect more in that area. Sports medicine for us is a business that's growing very fast. It's relatively small within Stryker. That's also an area of interest; Neurotechnology as well as Extremities. I would say -- I picked those 4 right off the top of my head, but I would tell you, we have a long list. And if my other division presidents are listening on the call, I know that they are preparing ideas for me as well. And we'll obviously look at all the ideas and determine which ones we think can really provide value for us. We're not going to just spend for the sake of spending. In a company as big as Stryker is with the decentralized focus, we're seeing that innovation delivers. And I cited one example of 3D printing where I think we're seeing it have an impact on 2 different divisions of Stryker, our Knee business as well as Spine. And we have a huge lineup of other divisions with ideas and prototypes to get into 3D-printed titanium products. So I would say that those are sort of the top-of-mind areas of focus, but all the divisions are lining up and we'll be very selective as we march through that. And we'll share more as the year unfolds."
94614,314976743,921224,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Analysts","Okay. That's very helpful. And then on the capital spending side, the $400 million to $450 million sort of, again, at the high-end of the range, it would be almost a doubling from where you were, I think, in 2014. Could you maybe just help us go into a li",89,"Okay. That's very helpful. And then on the capital spending side, the $400 million to $450 million sort of, again, at the high-end of the range, it would be almost a doubling from where you were, I think, in 2014. Could you maybe just help us go into a little bit detail on where those CapEx dollars are going, how much of that are sort of the 2016 isolated in nature and what the implications of this additional CapEx are to the rest of the business down the road?"
94614,314976743,921224,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","Sure. I'd say that there's a -- beyond just supporting the operations in the higher growth level that we've got in the company, there's a couple areas of specific investment. One is on -- in the ERP transformational area, which is strengthening our global",125,"Sure. I'd say that there's a -- beyond just supporting the operations in the higher growth level that we've got in the company, there's a couple areas of specific investment. One is on -- in the ERP transformational area, which is strengthening our global ERPs on a worldwide basis and reducing the numbers that we have, so we're on a more consistent, common system there. The second one is actually we're building a brand-new state-of-the-art 3D printing manufacturing facility this year as well, too. So we're spending some dollars, I think, in some key potential growth areas for us, and we want to take advantage of that. This year is a little bit of a blip in comparison to what that normal CapEx would be."
94614,314976743,921224,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Operator","And our next question comes from David Lewis from Morgan Stanley.",11,"And our next question comes from David Lewis from Morgan Stanley."
94614,314976743,921224,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Analysts","Just a couple questions. One, Kevin, just to start off with the ortho market. I wonder if you could just comment on 2015, if you think about the underlying momentum and the market and your share position, how much relative share you may or may not have ta",82,"Just a couple questions. One, Kevin, just to start off with the ortho market. I wonder if you could just comment on 2015, if you think about the underlying momentum and the market and your share position, how much relative share you may or may not have taken in '15, and how those dynamics, in your mind, compare to the outlook you'd see for '16 both in terms of how the market's going to perform and how you see shares shaking out."
94614,314976743,921224,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","So yes, thank you for the question. Well, obviously not everybody has finished reporting yet, so we don't have all the final results for 2015. We feel very good about the performance across our portfolio. Certainly, hips has been an area of strength for u",261,"So yes, thank you for the question. Well, obviously not everybody has finished reporting yet, so we don't have all the final results for 2015. We feel very good about the performance across our portfolio. Certainly, hips has been an area of strength for us for the past 4 years. But we're very encouraged by what we're seeing in knees as knees have started to pick up, and we'd historically traded -- the last 3, 4 years has been in line with the market or maybe slightly below. And I think we're going to start to see a bit of over performance there behind innovation and launching new products. So we feel good about our position in those 2. Trauma, of course, as you know, has been a standout for us for about 4 years, and we continue to launch new products and we continue to grow very well. So to us, the market seems very stable. We like our position in each of the categories. If you include Spine within your definition of Orthopaedics, I would say that was an area that had been more troubled for us, but we feel we're on a very good path now. So across the portfolio -- and I just had a chance to spend time at the sales meetings for Orthopaedics and Spine -- I can tell you, they feel very good about our competitive position in a market that seems very stable. So I think we'll see more of the same in terms of volume growth, and we like our competitive position."
94614,314976743,921224,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Analysts","Okay. And just 2 quick ones. One, just Katherine, just thinking about MAKO for a second. I mean, you're now selling more systems than the target MAKO ever did. And I wonder, are you seeing any pushback on ASPs for the system around $1 million? And in ligh",112,"Okay. And just 2 quick ones. One, just Katherine, just thinking about MAKO for a second. I mean, you're now selling more systems than the target MAKO ever did. And I wonder, are you seeing any pushback on ASPs for the system around $1 million? And in light of one of your competitors acquiring another competitor, specifically in robotics, do you expect to see some ASP pressure in '16 or '17? And then Bill, just you sparked my interest in the 3D printing facility. Is this a facility that will be capable of doing 3D-printed full Total Knee and Hips? Or is this more sort of derivative products to the orthopaedic process?"
94614,314976743,921224,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","Yes, on the capital side, obviously that's always going to be a conversation; you don't sell $1 million capital easily. But I will tell you, we are selling million-dollar capital, so those robots are sold. They are not placed. I think what we're doing is",180,"Yes, on the capital side, obviously that's always going to be a conversation; you don't sell $1 million capital easily. But I will tell you, we are selling million-dollar capital, so those robots are sold. They are not placed. I think what we're doing is really leveraging the ability to offer different models. We talked about our Flex Financial, so giving customers the ability to outright purchase or lease depending on their needs. And I think that's helping. And it's really, I think, the difference between when MAKO was stand-alone is we have a very large selling organization that over the last 2 years has really come to understand the features and the benefits. And the value proposition has only improved, going from a uni then to a hip then to a hip with our hip systems on it. And now knowing a Total Knee will be coming, I think, helps in that sales process as well. But we are selling those robots, and I don't anticipate that changing in 2016 related to any competition that might be out there."
94614,314976743,921224,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","Yes, and the second part of your question was around 3D printing. So we launched -- over the past few years, we've started with part of our knee system to enable cementless knee, so tibial baseplate. We have this past year in the middle of the year launch",214,"Yes, and the second part of your question was around 3D printing. So we launched -- over the past few years, we've started with part of our knee system to enable cementless knee, so tibial baseplate. We have this past year in the middle of the year launched revision cones with geometry that can only be made with 3D printing. We have a patella that we've launched that's 3D-printed, and now we're just about to launch a 3D-printed titanium interbody device for spine. So all of the products we've launched thus far that are 3D-printed are all innovative new products. In the case of the spine product and the cementless product, it allows for bony in growth because they're porous materials and getting very good feedback from our customers. For the foreseeable future, at least the next 3, 4 years or so, our focus is really on innovative new products and not replacing our existing products with 3D-printed products. The pipeline of innovative new geometries that can't be made without 3D printing is the area of focus. So it's not about trying to replace our products and drive down costs. Over time, 10 years from now, that could be the case. But in the near to mid-term, it's really focused on innovative new products."
94614,314976743,921224,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Operator","And our next question comes from Kristen Stewart from Deutsche Bank.",11,"And our next question comes from Kristen Stewart from Deutsche Bank."
94614,314976743,921224,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Analysts","So Bill, I'll reiterate. Definitely, congratulations on your retirement, and we definitely will miss you. So just a question more strategically. I was just wondering if you feel good about kind of the 3 main buckets that you have now and whether or not, K",67,"So Bill, I'll reiterate. Definitely, congratulations on your retirement, and we definitely will miss you. So just a question more strategically. I was just wondering if you feel good about kind of the 3 main buckets that you have now and whether or not, Kevin, you feel like there's any need to kind of expand beyond that and get into any other white spaces at this point."
94614,314976743,921224,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","Yes. No, Kristen, I'm going to be consistent with what I've been saying the past couple of years is -- and our strategy is to stay within these 3 segments. We like our position in these 3 segments. We want to continue. If you look at all of our acquisitio",151,"Yes. No, Kristen, I'm going to be consistent with what I've been saying the past couple of years is -- and our strategy is to stay within these 3 segments. We like our position in these 3 segments. We want to continue. If you look at all of our acquisitions, they've strengthened each of our businesses that we're currently in. And every year, we do a white space assessment. And the white space assessment is not as attractive as staying within our segments. There are a significant number of targets within our segments. I know we only completed 2 deals. It was a little bit quieter year in 2015. But I can tell you, the activity level was no different in 2015 with a lot of deals being discussed. And so I would expect us to continue along our current strategy and don't expect us to suddenly jump into white space."
94614,314976743,921224,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Analysts","Okay. And then, just with respect to the Neurotech area. Are there any notable clinical activities coming up for trial readouts? Or can you speak to any new product pipelines you think that we should be aware of that could help drive growth? Even though,",57,"Okay. And then, just with respect to the Neurotech area. Are there any notable clinical activities coming up for trial readouts? Or can you speak to any new product pipelines you think that we should be aware of that could help drive growth? Even though, obviously, it's been growing really well but if you can sustain it."
94614,314976743,921224,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","Yes, we're -- we love this business. Thanks, Kristen. We love this business, and I would say our coiling and the ischemic stroke, we're in great shape. And we're growing very well in those 2 categories. The one area for Stryker that is a slight gap is the",145,"Yes, we're -- we love this business. Thanks, Kristen. We love this business, and I would say our coiling and the ischemic stroke, we're in great shape. And we're growing very well in those 2 categories. The one area for Stryker that is a slight gap is the flow diverting stent segment. We are selling that outside the U.S., but we don't yet have U.S. approval. We have -- in the process of just completing up our trial and we'll be submitting for that, but we're still -- we still have some time before that gets approved. That's the one area we were not in. So we're driving this terrific growth without being in that one segment in the United States. So that's an ongoing process. We'll update you more towards the end of this year in terms of when that will come to market."
94614,314976743,921224,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Operator","Our next question comes from Jason Wittes from Brean Capital.",10,"Our next question comes from Jason Wittes from Brean Capital."
94614,314976743,921224,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Analysts","It sounds like the -- we should view the Total Knee coming out next year as sort of a transformational product. If I look into this year, can you kind of maybe highlight sort of the products that we should be focused on that'll really drive that -- the gr",52,"It sounds like the -- we should view the Total Knee coming out next year as sort of a transformational product. If I look into this year, can you kind of maybe highlight sort of the products that we should be focused on that'll really drive that -- the growth this year?"
94614,314976743,921224,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","I would really look at it as across-the-board, very typical Stryker fashion where it's more singles and doubles, whether it's Endo launching their new 1588 camera or MAKO continuing to drive indications like Hip with the new -- the Stryker brands that we",243,"I would really look at it as across-the-board, very typical Stryker fashion where it's more singles and doubles, whether it's Endo launching their new 1588 camera or MAKO continuing to drive indications like Hip with the new -- the Stryker brands that we talked about or Spine with their new products that are coming out 3D-printed. So it's really a story about those incremental, innovative new products. Usually, no one on its own is a growth driver. It's the totality of that offering that really allows us to sustain that organic growth at the high end of med tech. Clearly, next year, we're set up for some more impactful products that when you think about MAKO and the Total Knee and expect them to be on a clear trajectory as taking meaningful market share as we work our way through '17. Ischemic is one more of those more transformational opportunities. There's a lot of market development that still needs to take place there around the patient path, referral systems, hospital -- inter-hospital transfers. So we talked about that being a multiyear process, but clearly seeing some very good growth rates but off of a still small base. But I would really think about this year as a typical Stryker story. You've got a lot of products, a lot of momentum, dedicated sales force with a specially -- a specialty focus that's really helping to drive that 5% to 6% growth we're targeting."
94614,314976743,921224,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Analysts","Okay, very helpful. And just a quick follow-up for MAKO. Can you give us a sense of how many of these new placements are to existing accounts and how many of these are de novo. Just kind of give us a sense of who's buying.",45,"Okay, very helpful. And just a quick follow-up for MAKO. Can you give us a sense of how many of these new placements are to existing accounts and how many of these are de novo. Just kind of give us a sense of who's buying."
94614,314976743,921224,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","Yes, we haven't broken out -- out of the 31, we haven't broken out. I would tell you, though, that it is a combination of both existing Stryker customers as well as new customers where we haven't had any type of meaningful presence. So we haven't given it",61,"Yes, we haven't broken out -- out of the 31, we haven't broken out. I would tell you, though, that it is a combination of both existing Stryker customers as well as new customers where we haven't had any type of meaningful presence. So we haven't given it with more granularity than that, and -- but there is a nice mix."
94614,314976743,921224,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Operator","And the next question comes from Matt Miksic from UBS.",10,"And the next question comes from Matt Miksic from UBS."
94614,314976743,921224,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Analysts","Super job on the numbers it looks like. And I'll pass along my congratulations and farewell to Bill. We will also miss you. So on MAKO, just a couple of maybe broader questions on how you're positioning the platform. Robotics has been kind of a market dev",124,"Super job on the numbers it looks like. And I'll pass along my congratulations and farewell to Bill. We will also miss you. So on MAKO, just a couple of maybe broader questions on how you're positioning the platform. Robotics has been kind of a market development project for a while, oftentimes dealing with surgeons and helping them get more comfortable with the new technology, maybe changing the way surgery is done over the long term. But at what point does this become, or has it already become, an opportunity to drive better contracting for you across your implant lines, greater share or utilization multiline contracting driven by the merits of the system and the technology? And I have a couple of quick follow-ups."
94614,314976743,921224,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","So Matt, I would say, look, we're still in the early stages. We -- the Stryker Hip brands are now just available recently. And we haven't launched the Total Knee yet. So I think that's -- those are the big applications. And to say that it is impacting con",152,"So Matt, I would say, look, we're still in the early stages. We -- the Stryker Hip brands are now just available recently. And we haven't launched the Total Knee yet. So I think that's -- those are the big applications. And to say that it is impacting contracting yet, I would say, it's too early for that. Once this becomes a more mature business, which will take a couple of years, then I think, obviously, having a system that the surgeons are having a great experience and they enjoy it and they want to use the products, it really does provide us with great differentiation which will -- and differentiation will show up in many different ways, including potentially in contracting. But we're a ways from that yet, we have a lot of work to do in the next couple of years to really gain more broad adoption of the technology."
94614,314976743,921224,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Analysts","Then, another on the same topic here. Katherine, someone asked earlier about Hips and what's changing and how you're improving performance there. To put that in perspective, I remember when Hips came out and when you first acquired the system, it wasn't g",106,"Then, another on the same topic here. Katherine, someone asked earlier about Hips and what's changing and how you're improving performance there. To put that in perspective, I remember when Hips came out and when you first acquired the system, it wasn't generally thought to be really where the bang for the buck was with the robot. And I guess, what's changing? Is this application getting a lot easier? Is people getting -- are they proving out the benefits of the Hip? I mean, what's driving uptick and against what was historically viewed as sort of like a -- not the greatest application for the robot?"
94614,314976743,921224,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","Okay. So I'll take this question. So look, what I'd tell you, the first iterations of the Hip software were a little bit clunky, and it requires quite a bit more registration time to register -- get the register in the software system. So that's just an e",290,"Okay. So I'll take this question. So look, what I'd tell you, the first iterations of the Hip software were a little bit clunky, and it requires quite a bit more registration time to register -- get the register in the software system. So that's just an extra step that some of the surgeons are a little bit frustrated with. Over time, both prior to our acquisition and subsequent to our acquisition, we've made some enhancements of the software to make it a little bit more user-friendly. That's been one factor for sure. I think the most compelling factor is showing the surgeons on the pre and post x-rays that they put the Hip exactly where they want to put it. And I think even those surgeons that had some hesitations, when they see the pre and post x-rays, they are just -- it's a very compelling visual for them to understand. Before they weren't doing that. They weren't able to get that same type of consistency. And that's starting to resonate with a lot of surgeons. And now being able to put our implants in addition with easier-to-use software and to get that kind of outcome, it's like all things have changed, right? Change doesn't occur to everybody at the same time. Some people are early adopters. Some people, frankly, will never adopt. They'll just be set in their ways. But what we're seeing is the middle of the bell curve is starting to shift its mindset. And frankly, the more that robotics is talked about in the community at large, we find that actually a very positive thing because we really believe we have a terrific system, and we're obviously continuing to invest in that system going forward."
94614,314976743,921224,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Operator","Our next question comes from Joanne Wuensch from BMO Capital Markets.",11,"Our next question comes from Joanne Wuensch from BMO Capital Markets."
94614,314976743,921224,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Analysts","I have 2 questions. The first one has to do with 3D printing. It became quite aware about a couple of years ago, now you're definitely doing a bigger focus on that. What does it take for a 3D-printed, call it, Hip or Knee to become more mainstream? Is it",62,"I have 2 questions. The first one has to do with 3D printing. It became quite aware about a couple of years ago, now you're definitely doing a bigger focus on that. What does it take for a 3D-printed, call it, Hip or Knee to become more mainstream? Is it manufacturing? Is it clinical data? How should we think about this evolving?"
94614,314976743,921224,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","Well, it's a long answer, Joanne. The reason I pause is to get into all the technology on 3D-printing would be -- would take a long time. The quick summary is that 3D printing metal is very different than sort of the way you think about 3D printing plasti",225,"Well, it's a long answer, Joanne. The reason I pause is to get into all the technology on 3D-printing would be -- would take a long time. The quick summary is that 3D printing metal is very different than sort of the way you think about 3D printing plastic -- having it on a desk in an office and cranking up 3D-printed products. So metal is much more complicated. It's explosive. It requires a lot of extra programming. You just don't buy a machine and sort of just off to the races. It's a lot more complicated than that. And so we spent a lot of time. We've been working on this for many, many years. And so we have a lot of know-how on how to program the machines and optimize the machines. And so there's a lot of factors that go into it to be able to create. And different types of machines work better for smaller products than larger products. So it's difficult for me to just summarize in a short time. I'd just say that it's more complicated than plastics or other things that you read about in the mainstream press. And that's why, for us, our focus is much more on innovative new products and not necessarily replacing total systems. That will be many, many, many years ahead of us."
94614,314976743,921224,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Analysts","That's very helpful. As a follow-up, what should we expect at the upcoming AAOS?",15,"That's very helpful. As a follow-up, what should we expect at the upcoming AAOS?"
94614,314976743,921224,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","Yes, Joanne, I think it will be typical to prior years. Clearly, there's going to be a big focus around MAKO as we think about uni as well as hip. It's too early in our initial commercial launch activities to have a big focus on user feedback from Total K",124,"Yes, Joanne, I think it will be typical to prior years. Clearly, there's going to be a big focus around MAKO as we think about uni as well as hip. It's too early in our initial commercial launch activities to have a big focus on user feedback from Total Knee. Although, I'm sure there'll be a lot of surgeon presence around that as they're looking to get educated on the features and benefits. And we'll have a tour of the booth as we've done previously to highlight new products across all the businesses from Trauma, Foot & Ankle, Spine, et cetera. And we'll also have an opportunity while we're there just to sit down and meet with management and have an open Q&A forum."
94614,314976743,921224,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Operator","And the next question comes from Raj Denhoy from Jefferies.",10,"And the next question comes from Raj Denhoy from Jefferies."
94614,314976743,921224,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Analysts","Wonder if I could ask you a question about the CJR or CCJR program that's rolling out. I know that you guys have been pretty clear as all the companies have that you don't think it's going to have much impact on pricing and so it will be focused on the po",110,"Wonder if I could ask you a question about the CJR or CCJR program that's rolling out. I know that you guys have been pretty clear as all the companies have that you don't think it's going to have much impact on pricing and so it will be focused on the postacute care, which pretty much mirrors what we're hearing as well. But my question is really around how Stryker interfaces with that model. In your performance solutions business, you guys were involved in some of the bundled payments initiatives before. Is there an opportunity for you guys to perhaps benefit from the CJR program as it rolls out?"
94614,314976743,921224,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","Yes. We agree with your comments. We don't think it's going to have a meaningful impact. We have seen it pass with some of the prior programs. It really does drive a focus on postacute and patients that are discharged right to rehab given the high cost th",191,"Yes. We agree with your comments. We don't think it's going to have a meaningful impact. We have seen it pass with some of the prior programs. It really does drive a focus on postacute and patients that are discharged right to rehab given the high cost there. We do have a small business, our Stryker performance solutions, that we think can help work with hospitals to help them make them aware of the data so they can have a sense of what best-in-class is and where are some of the cost benefits they can realize, whether it's around infection rates, transfusions, et cetera. So it's not a huge part of our business, but it is one that provides insights and does help them as they think about their overall cost structure. But clearly, we continue to believe based on everything we've seen that it's going to be postacute care. We haven't seen any meaningful change at all in price between those trial areas as it relates to implant pricing, and really the cost savings they can realize focusing on rehab really do dwarf anything else at this point in time."
94614,314976743,921224,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Analysts","Right. Maybe just as a follow-up. But if you think about that service offering, if that's the way to describe it, which Performance Solutions certainly does some of -- as you think about the next several years, do you envision that service component becom",62,"Right. Maybe just as a follow-up. But if you think about that service offering, if that's the way to describe it, which Performance Solutions certainly does some of -- as you think about the next several years, do you envision that service component becoming a bigger part of the business, offering not just implants to hospitals but perhaps something a bit broader?"
94614,314976743,921224,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","Yes. I mean, that division is continuing to focus on that. It's not a huge part of our company. I think, we see this -- the CCJR is a terrific example, an opportunity for us to grow that business. But it's not at a scale at which I really want to start hi",200,"Yes. I mean, that division is continuing to focus on that. It's not a huge part of our company. I think, we see this -- the CCJR is a terrific example, an opportunity for us to grow that business. But it's not at a scale at which I really want to start highlighting it. I would tell you, a year from now, I think we'll have a much better idea of the scope of CCJR and whether that can become a broader business for us. So services is not something new to Stryker. A lot of our MedSurg business provides services to hospitals. We have people in the hospital that our customers pay for to make sure that all their uptime is working on their equipment. So we're not against services at all, but we don't sort of like to get out in front of ourselves. Let's see how this year unfolds. And if the business becomes something that could be scalable, then we'll talk about it a lot more. But right now, it's a small part -- I agree with you that CCJR does provide an exciting opportunity for that business, but it's a very small part of Stryker."
94614,314976743,921224,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Operator","And our next question comes from Larry Biegelsen from Wells Fargo.",11,"And our next question comes from Larry Biegelsen from Wells Fargo."
94614,314976743,921224,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Analysts","I want to just star with M&A. About a year ago, Kevin, you said you expected to put the balance sheet to work. And I just wanted to confirm that, that's still the case. And I'm asking because, obviously, you've been relatively quiet on the acquisition fro",76,"I want to just star with M&A. About a year ago, Kevin, you said you expected to put the balance sheet to work. And I just wanted to confirm that, that's still the case. And I'm asking because, obviously, you've been relatively quiet on the acquisition front over the past 6 to 12 months, which is atypical. So is there any reason you haven't pulled the trigger on more deals? And I had one follow-up."
94614,314976743,921224,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","Sure. I would tell you, just look, deal timing is inherently unpredictable. There is absolutely no change in the statement I made before. I still intend to put the balance sheet to work. The reason we got the extra share buyback approval level was just in",130,"Sure. I would tell you, just look, deal timing is inherently unpredictable. There is absolutely no change in the statement I made before. I still intend to put the balance sheet to work. The reason we got the extra share buyback approval level was just in case deals don't get over the line or drag on for extended periods of time, we would start to step up the buybacks. But you should expect us to continue to be a very active acquirer. But you've seen in the past, right, sometimes, some years, there's 1 or 2 deals and other years you see many more deals. So our level of activity hasn't changed. I still see many exciting prospects out there. And so we're staying the course with the existing strategy."
94614,314976743,921224,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Analysts","And then, earlier you said that in Q1, you would expect to be at the low end of the 5% to 6%, I think, constant currency growth rate because of what you're seeing in emerging markets. And so -- but you expect emerging markets to be relatively weak through",91,"And then, earlier you said that in Q1, you would expect to be at the low end of the 5% to 6%, I think, constant currency growth rate because of what you're seeing in emerging markets. And so -- but you expect emerging markets to be relatively weak throughout 2016, I believe. So my question is, does getting the growth rate up above that -- the low end of the range, does that depend upon an improvement in emerging markets? And if not, how do you get that growth rate up?"
94614,314976743,921224,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","Yes. I would just comment that if you look at the cadence of quarters last year, we had some difficult comparisons in the first quarter that related to emerging markets. More of the pressure, particularly in China, unfolded as the year went on. We're goin",95,"Yes. I would just comment that if you look at the cadence of quarters last year, we had some difficult comparisons in the first quarter that related to emerging markets. More of the pressure, particularly in China, unfolded as the year went on. We're going to have easier comps in the back half of the year. We tend to have a seasonally stronger second half of the year, particularly as it relates to the fourth quarter. So it's more just reflective of how our quarters tend to play out in some of the year-over-year comparisons."
94614,314976743,921224,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Operator","And the next question comes from Glenn Novarro from RBC Capital.",11,"And the next question comes from Glenn Novarro from RBC Capital."
94614,314976743,921224,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Analysts","Kevin, your U.S. Hip and Knee business had a strong fourth quarter, up 6% and 9%, respectively. Did you see this in the fourth quarter, the U.S. Orthopaedic market accelerate or pick up a bit? Or do you think that was more share capture from Zimmer, given",62,"Kevin, your U.S. Hip and Knee business had a strong fourth quarter, up 6% and 9%, respectively. Did you see this in the fourth quarter, the U.S. Orthopaedic market accelerate or pick up a bit? Or do you think that was more share capture from Zimmer, given the integration between Zimmer and Biomet? And then I had a follow-up question on robotics."
94614,314976743,921224,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","Yes, so look, until we see everybody report, it's really difficult for me to say how much of it is the market versus competitive share capture. The Knee number, we're very encouraged about. We tend to believe our Knee improvement is more driven by the new",193,"Yes, so look, until we see everybody report, it's really difficult for me to say how much of it is the market versus competitive share capture. The Knee number, we're very encouraged about. We tend to believe our Knee improvement is more driven by the new products, the revision cones and more uptake of our cementless knee offering. So we believe that's more of the issue than, lets call it, sales force disruptions or any other factors that are occurring at other companies. It's more about our innovation. When I talk to our field, they -- the sense I'm getting is a very stable market. So it wasn't -- a few years ago, we saw this big seasonal fourth quarter lift. We now are seeing a typical fourth quarter. This December was more or less typical. It's more active, but it was more active a year ago, too. So we're not seeing -- we didn't see anything or major in terms -- from quarter-to-quarter you do sometimes see slight upticks or downticks. But until they report, it's going to be difficult for me to comment. But I think you had a second question."
94614,314976743,921224,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Analysts","Yes, Katherine, in your prepared remarks you talked about with the MAKO system, podium presentations in 2016. So can you describe what type of presentations? I'm assuming these are clinical trials. So what type of trials? And when can we see these trials",45,"Yes, Katherine, in your prepared remarks you talked about with the MAKO system, podium presentations in 2016. So can you describe what type of presentations? I'm assuming these are clinical trials. So what type of trials? And when can we see these trials being presented?"
94614,314976743,921224,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","Yes. My comments were that we were going to do observational studies in 2016, so really looking at key opinion leaders who have extensive experience with robotics to understand how we can fine tune the training protocol and optimize the rollout. We're als",169,"Yes. My comments were that we were going to do observational studies in 2016, so really looking at key opinion leaders who have extensive experience with robotics to understand how we can fine tune the training protocol and optimize the rollout. We're also going to be doing observational studies with key opinion leaders who have a lot of familiarity with the Triathlon system so we can mesh those 2 data sets and really put us in a position to have a presence at the podiums in 2017, not '16. So we think combining the full commercial launch and being in a position in 2017 for those initial users, those key opinion leaders to talk about their experience and how they were able to optimize both the robot as well as our Triathlon will help drive the adoption. We're going to continue to collect additional clinical data, but that is going to take a number of years. This is really focused around observational studies to help optimize the training protocol."
94614,314976743,921224,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Operator","And the next question comes from Mike Matson from Needham & Company.",11,"And the next question comes from Mike Matson from Needham & Company."
94614,314976743,921224,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Analysts","I guess, I just wanted to start with the new camera at the Endoscopy business. How does this compare to the prior models? Is it more of an incremental improvement? And just in terms of the impact on the growth rate there, do you expect that to be more of",70,"I guess, I just wanted to start with the new camera at the Endoscopy business. How does this compare to the prior models? Is it more of an incremental improvement? And just in terms of the impact on the growth rate there, do you expect that to be more of a step change or more of a ramp in terms of the growth in Endoscopy? Then I have one follow-up."
94614,314976743,921224,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","Yes. So no, this -- the 1588. So each time we have a new version, and we call it -- the last one was 1488, as you know. Now we're calling it 1588. AIM is the name of it. I would say it's meaningfully better. Certainly, 1488 had terrific resolution, but we",277,"Yes. So no, this -- the 1588. So each time we have a new version, and we call it -- the last one was 1488, as you know. Now we're calling it 1588. AIM is the name of it. I would say it's meaningfully better. Certainly, 1488 had terrific resolution, but we've improved the backlighting and some of the image clarity for certain procedures like ENT that -- so our product works well in a wide variety of procedures. But there are certain procedures where the lighting just wasn't quite as optimized. And we made some nice enhancements there, so across the range of procedures, surgeons are all going to have a delightful experience, whereas, in the past, it was not necessarily across every specialty. So that's the first thing. Second thing is we have ICG built into our light source, which we've never had before. So with a press of a button, you can light up the organs, just -- I'm sure you're familiar with ICG with a competitive product out there. But this is not -- doesn't require extra piece of capital. It's built right into the existing light source, easy for the surgeons to use, which is wonderful. It also includes another product for GYN that lights up parts of the anatomy to -- so it's really a safe surgery launch. It enables safe surgery with enhanced visualization. And we just launched it in December, so we don't have a huge amount of sales yet, but I would say the early clinical feedback has been very positive. So I do expect Endoscopy to have a better year in 2016 than they did in 2015."
94614,314976743,921224,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Analysts","Okay. And then, just with regard to this big ERP project that you have. What's the execution risk there that something gets -- some balls get dropped in terms of the inventory levels and things like that, causing an impact on your overall results for the",47,"Okay. And then, just with regard to this big ERP project that you have. What's the execution risk there that something gets -- some balls get dropped in terms of the inventory levels and things like that, causing an impact on your overall results for the company?"
94614,314976743,921224,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","Yes. So like with any system implementation, there's always some degree of risk. We're being very thoughtful and careful about how we go about the project. We're staffing -- we're putting our best people on it. They're in dedicated -- in a dedicated works",272,"Yes. So like with any system implementation, there's always some degree of risk. We're being very thoughtful and careful about how we go about the project. We're staffing -- we're putting our best people on it. They're in dedicated -- in a dedicated workspace. And in fact, my former Head of HR, who also has run businesses, is going to be leading the business component of that. And I appointed a new Head of HR. That sent a terrific signal to the organization of the kind of commitment we're making. It will be a measured launch, so it will take a number of years before complete, and we're starting off with our Instruments division. And we're going to continue -- we have a steady march planned. We have an IT leader who's partnering with a business leader who has a -- was previous -- at a previous large med tech company doing exactly this kind of an implementation over the past few years. So we believe it's all about talent, staffing the right people who know our business. And we're going to do our best, obviously, to mitigate the risk. We had a painful experience in Japan a couple of years ago. I can tell you the approach of this project is radically different to the approach we used in that project. And so we feel we'll be in good shape, and it's not a Big Bang launch. We're going to do division by division, region by region, and there'll be a steady cadence. So even if something does start to wobble a little bit, it should have very, very little impact."
94614,314976743,921224,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Operator","Our next question comes from Matt Taylor from Barclays bank.",10,"Our next question comes from Matt Taylor from Barclays bank."
94614,314976743,921224,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Analysts","Great. So I was just wondering if you could follow up on some of those comments on 3D printing and just talk about the materiality of the contributions in the quarter and what you're expecting now that you're going to be investing more in this new plan. H",57,"Great. So I was just wondering if you could follow up on some of those comments on 3D printing and just talk about the materiality of the contributions in the quarter and what you're expecting now that you're going to be investing more in this new plan. How big is it and how material could that be?"
94614,314976743,921224,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","Yes, So for the moment, it's -- these are innovative products that are adding, I would call, incremental growth. It's not the core growth. The core growth is our big systems, right, our Triathlon, our Accolade. That's where the core amount of our sales co",290,"Yes, So for the moment, it's -- these are innovative products that are adding, I would call, incremental growth. It's not the core growth. The core growth is our big systems, right, our Triathlon, our Accolade. That's where the core amount of our sales comes from. But this gives a little extra boost to -- and puts a little bit of jump in our sales force step, gives them something new to talk to their customer about. So as an example, our revision business lagged, our market share lagged our primary business in Knees by about 5 or 6 market share points. So even in a Stryker-friendly account, sometimes they would go to a competitive -- a competitor to do their revision procedure. Now that we have what we consider best-in-class revision cones, not only do we keep that business, that surgeon stays with Stryker, we gain that sales. But they now have something that they can go talk to a competitive surgeon about.  So I would say it's not a huge contributor, but it's an extra shot in the arm. So with robotics and 3D printing, we believe we have the lead on both of those areas. And those are things we can talk about that differentiate us from our competition. So again, not even today robotics -- is not a huge component of our growth or our actual dollar sales, but we believe they are the ones that are causing that extra piece of growth and a different view of Stryker for the future. Over time, I expect robotics and 3D printing to take on a more important portion of our overall sales. And they'll be sustainable and sticky if we have something that the competition doesn't have."
94614,314976743,921224,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Analysts","Okay, great. And just one question on the transatlantic model. It seems like you're making some progress there. Can you talk about where you are and how much that's helped to improve some of the OUS results and where you think that could go?",44,"Okay, great. And just one question on the transatlantic model. It seems like you're making some progress there. Can you talk about where you are and how much that's helped to improve some of the OUS results and where you think that could go?"
94614,314976743,921224,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","Yes. So look, Europe has exceeded my expectations. We had a really -- our international growth doesn't look fantastic, so you don't see it. But Europe had a mid-single-digit growth year, and it improved progressively from the first quarter to the fourth q",324,"Yes. So look, Europe has exceeded my expectations. We had a really -- our international growth doesn't look fantastic, so you don't see it. But Europe had a mid-single-digit growth year, and it improved progressively from the first quarter to the fourth quarter. So that kind of uptick is frankly ahead of where I'd expected it to be. It's been masked a little bit because of the sluggishness out of China, so that has dampened our international sales. But it's been a really great success. I'm excited about what I'm seeing across our businesses in Europe. Some of the divisions took off faster than others, like Trauma and Extremities and Endoscopy took off really quickly. And now I'm starting to see some nice uptake in Instruments and Spine towards the end of the year. So more to come in Europe. We made a number of investments over the course of the year. Those investments are now taking hold. And I think you'll start to see Europe become a division that delivers better top line and starts to deliver some leverage going forward. We've added Canada, so those are now directly managed. A Division President has direct P&L accountability for Canada, the U.S. and Europe. The other regions we haven't yet folded into the model, but by eliminating the Group President of international role, they -- we now have them reporting directly to our business Group President. So it just increases speed and connectivity from our regions to come straight to a Group President. Over time, we'll see whether those countries will roll into this model, but we don't want to run too fast to fully integrated complete global business units, especially with markets like China that are so different, or Japan. But we're very pleased with the progress so far. Taking out that position was nothing about cost reduction. That was 100% just to increase speed and connectivity of those countries to our businesses."
94614,314976743,921224,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Operator","And our next question comes from Matt Keeler from Crdit Suisse.",11,"And our next question comes from Matt Keeler from Crdit Suisse."
94614,314976743,921224,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Analysts","Just 2 quick ones. First on Hips outside the U.S, you highlighted the drag from emerging markets but your Knee growth actually picked up pretty nicely. So I'm just wondering if there was a much more pronounced impact from that emerging markets drag on Hip",63,"Just 2 quick ones. First on Hips outside the U.S, you highlighted the drag from emerging markets but your Knee growth actually picked up pretty nicely. So I'm just wondering if there was a much more pronounced impact from that emerging markets drag on Hips relative to Knees and if there were any other factors that impacted your Hip business outside the U.S.?"
94614,314976743,921224,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","No, nothing in particular. You see this from quarter-to-quarter, and sometimes you'll see sort of Hips jump. In the case of Hips -- Canada as an example -- there was a hip tender that we lost so that accounted for some of the Hip growth. There's not 1 sor",112,"No, nothing in particular. You see this from quarter-to-quarter, and sometimes you'll see sort of Hips jump. In the case of Hips -- Canada as an example -- there was a hip tender that we lost so that accounted for some of the Hip growth. There's not 1 sort of overriding factor. It's just sort of a story-by-story, country-by-country. And we see this from quarter-to-quarter, sometimes you'll see knee -- our business is not as big outside the U.S. So you do see a little bit more volatility in our numbers, whether it's Hip, Knee, Spine. Once those businesses get larger, you would -- you should expect that there'll be less volatility."
94614,314976743,921224,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Analysts","Great. And just lastly, Instruments growth was pretty strong in the quarter. But I think you've highlighted that, that business is later on in its product cycle. So I was just wondering if you think the level of growth we saw in the fourth quarter, if tha",73,"Great. And just lastly, Instruments growth was pretty strong in the quarter. But I think you've highlighted that, that business is later on in its product cycle. So I was just wondering if you think the level of growth we saw in the fourth quarter, if that's sustainable going forward. And what are some of the sort of the products to watch where you're maybe a little later on in that product cycle?"
94614,314976743,921224,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","Yes, so the power tools is the product that we referred to as being late in the cycle, the System 7 power tools, which is probably the biggest single product category within Instruments. But Instruments has a lot of other products. So they have Neptune, t",168,"Yes, so the power tools is the product that we referred to as being late in the cycle, the System 7 power tools, which is probably the biggest single product category within Instruments. But Instruments has a lot of other products. So they have Neptune, they have -- they're launching a new signature line of drills. We actually report that as part of our Neurotech, but it's run by our Instruments division. But yes -- they have the sponge counter as well, patient safety company that we acquired. So these are different kinds of businesses that can drive growth. It's a little less predictable than power tools. So I think we're very excited by how they finished the year. They finished the year very, very strong. And we think they'll have a good year. But being longer in the cycle, sometimes we do see them tailing off a little bit. So but I would expect a year that's similar to the year that they had this year overall."
94614,314976743,921224,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Operator","And our next question comes from Rich Newitter from Leerink Partners.",11,"And our next question comes from Rich Newitter from Leerink Partners."
94614,314976743,921224,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Analysts","Kevin, I was hoping I'd just get some comments on Spine. You characterized the market as stable, and you're clearly seeing some nice uptick in the growth rates there. You have some new product launches. So my question really is has there been any change o",78,"Kevin, I was hoping I'd just get some comments on Spine. You characterized the market as stable, and you're clearly seeing some nice uptick in the growth rates there. You have some new product launches. So my question really is has there been any change or can you give us your updated thoughts on how you view kind of external versus internal investments in this division for you now that things seem to be on a better footing?"
94614,314976743,921224,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","Yes. So I am really excited about what we're doing organically. So we've retooled our R&D organization, some of our marketing organization over the past few years. And this business is hitting its stride. And we're launching more and more new products. We",163,"Yes. So I am really excited about what we're doing organically. So we've retooled our R&D organization, some of our marketing organization over the past few years. And this business is hitting its stride. And we're launching more and more new products. We're getting into MIS, which was an area that we were softer in before if you look back 3, 4 years ago. And so it's great to see the organic growth. Organic growth obviously is much more financially attractive than going out and spending a lot of money on companies. Over time, I do want this to become a bigger division, and I think it's -- you'll likely see a combination of both organic and acquisitions. But it's always better to have a strong organic business. And so I do not feel at all that I need to do an acquisition because of the strength and what we've started to build internally. But that's something that will likely happen over time."
94614,314976743,921224,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Analysts","Okay. And then, just on Extremities. Again, your Foot & Ankle growth, I think you said it was 20%. That's -- this business continues to truck along. Any comments on kind of the end markets versus potential share gains that we might have seen in the quarte",60,"Okay. And then, just on Extremities. Again, your Foot & Ankle growth, I think you said it was 20%. That's -- this business continues to truck along. Any comments on kind of the end markets versus potential share gains that we might have seen in the quarter? And specifically, are you seeing any disruption from recent M&A in the field?"
94614,314976743,921224,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","Yes, I would just say these are markets that continue to be very healthy, growing double digits. We do believe we're taking market share. We've got a dedicated sales focus there, some great products. I wouldn't call out any disruption that we're seeing in",65,"Yes, I would just say these are markets that continue to be very healthy, growing double digits. We do believe we're taking market share. We've got a dedicated sales focus there, some great products. I wouldn't call out any disruption that we're seeing in the marketplace. I think it just continues to be really good execution in a market that has favorable underlying growth dynamics."
94614,314976743,921224,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Operator","And our next question comes from Josh Jennings from Cowen and Company.",12,"And our next question comes from Josh Jennings from Cowen and Company."
94614,314976743,921224,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Analysts","Kevin, I just was hoping you could touch on pricing. I think recently you had some public commentary about some potential moderation in the pricing headwinds that you've historically been experiencing. Any comments in terms of assumptions for pricing head",51,"Kevin, I just was hoping you could touch on pricing. I think recently you had some public commentary about some potential moderation in the pricing headwinds that you've historically been experiencing. Any comments in terms of assumptions for pricing headwinds within guidance? And then, any outlook for pricing, particularly in Orthopaedics?"
94614,314976743,921224,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","Yes. So you saw for the full year, our price did moderate somewhat from the prior year. And there was a lot of concern as we exited -- if you remember, as we were exiting '14, there a was a lot of concern that pricing was going to accelerate in '15. In fa",128,"Yes. So you saw for the full year, our price did moderate somewhat from the prior year. And there was a lot of concern as we exited -- if you remember, as we were exiting '14, there a was a lot of concern that pricing was going to accelerate in '15. In fact, it hasn't. It actually moderated a little bit. But it's modest, right? The moderation is very modest. And in our guidance, we suggest that the price will be between 1.5% to 2%. And so I would say it's a stable market. We continue to have price pressure. It's not going away. But we don't see any accelerators to that price pressure. And that's why we feel it's going to be pretty stable going into 2016."
94614,314976743,921224,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Analysts","Great. And just one follow-up on MAKO. We haven't heard much over the last year on the uni knee product. Any commentary there in terms of how it's contributing to growth in your Knee franchise and just overall growth for that product line?",43,"Great. And just one follow-up on MAKO. We haven't heard much over the last year on the uni knee product. Any commentary there in terms of how it's contributing to growth in your Knee franchise and just overall growth for that product line?"
94614,314976743,921224,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","Thanks. The -- obviously, the uni market, when it's put in the context of overall Stryker, it's a very small part of the overall business. And I would say it's a steady contributor, but there's nothing remarkable to say about it. It's a good business, but",55,"Thanks. The -- obviously, the uni market, when it's put in the context of overall Stryker, it's a very small part of the overall business. And I would say it's a steady contributor, but there's nothing remarkable to say about it. It's a good business, but it's a very small part of our overall Knee."
94614,314976743,921224,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","Were you talking, Josh, specifically about -- for MAKO?",9,"Were you talking, Josh, specifically about -- for MAKO?"
94614,314976743,921224,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","He got cut off.",4,"He got cut off."
94614,314976743,921224,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","So for MAKO, it's a first indication, and they're continuing to drive uptake for that as well as with Hip. And as we get additional indication, it does help drive adoption as some customers were not interested in just the uni. But as we get more indicatio",58,"So for MAKO, it's a first indication, and they're continuing to drive uptake for that as well as with Hip. And as we get additional indication, it does help drive adoption as some customers were not interested in just the uni. But as we get more indications, they're starting to adopt for that as well as the others."
94614,314976743,921224,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","Yes, but I'm just trying to interpret -- sorry that Josh got cut off -- just interpret that the growth to 9% in the U.S., that spike in growth. It really wasn't driven by MAKO unis. That's driven more by the broader Knee business.",44,"Yes, but I'm just trying to interpret -- sorry that Josh got cut off -- just interpret that the growth to 9% in the U.S., that spike in growth. It really wasn't driven by MAKO unis. That's driven more by the broader Knee business."
94614,314976743,921224,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Operator","The next question comes from Matthew O'Brien from Piper Jaffray.",11,"The next question comes from Matthew O'Brien from Piper Jaffray."
94614,314976743,921224,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Analysts","Just quickly on MAKO again. The number of systems you placed internationally accelerated here in Q4. Was there anything that you could call out as far maybe a little bit of a tipping point in terms of interest in the robotics system OUS, and maybe that co",56,"Just quickly on MAKO again. The number of systems you placed internationally accelerated here in Q4. Was there anything that you could call out as far maybe a little bit of a tipping point in terms of interest in the robotics system OUS, and maybe that could be an even more meaningful contributor here in 2016?"
94614,314976743,921224,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","No. Still, the lion's share of the focus and the revenue is coming from the U.S. We did place more systems outside the U.S., and we'll continue to focus on those opportunities, particularly places like Australia and certain other markets. But the bulk of",60,"No. Still, the lion's share of the focus and the revenue is coming from the U.S. We did place more systems outside the U.S., and we'll continue to focus on those opportunities, particularly places like Australia and certain other markets. But the bulk of the revenue stream has been and will likely continue at least near term to be U.S."
94614,314976743,921224,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","Yes. It tends to be a country-by-country thing, so Australia had a terrific year in robot sales. I think, within Europe, we're going to see certain countries are going to adopt MAKO much more quickly than other countries. So I think each year, you'll sort",94,"Yes. It tends to be a country-by-country thing, so Australia had a terrific year in robot sales. I think, within Europe, we're going to see certain countries are going to adopt MAKO much more quickly than other countries. So I think each year, you'll sort of -- you'll see the international volumes starting to increase, but it might be Italy this year, it might be the U.K. next year over the next few years. But again, to Katherine's point, the market that's the most important by far is going to be the U.S. market."
94614,314976743,921224,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Analysts","Okay, and then just to follow up a little bit on Richard's question, a little more broadly on Trauma and Extremities. I think we saw some acceleration here in Q4 beyond what we've seen over the last several quarters. And I'm just -- I'm curious if that ac",77,"Okay, and then just to follow up a little bit on Richard's question, a little more broadly on Trauma and Extremities. I think we saw some acceleration here in Q4 beyond what we've seen over the last several quarters. And I'm just -- I'm curious if that acceleration was specific to any couple of products or geographies around particularly the U.S. and if that level of growth is something that you think is sustainable here in 2016."
94614,314976743,921224,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","Well, I think you've seen our Trauma business in the U.S. It's been 4 years of really terrific growth. So that to me is sustainable when you're growing at that level. So we're very, very pleased. We've rounded out our portfolio completely. And so that ena",198,"Well, I think you've seen our Trauma business in the U.S. It's been 4 years of really terrific growth. So that to me is sustainable when you're growing at that level. So we're very, very pleased. We've rounded out our portfolio completely. And so that enables us to do complete hospital conversions, something that was impossible at Stryker 5, 6 years ago. Europe really picked up quickly. So as you move to a transatlantic model, I was very encouraged by our Trauma success in Europe. We have not been nearly as successful in Europe as we have been in the United States. And we do now have the same products which are all approved. So I think -- I expect more commercial success in Europe as well as Japan. Now some of those products take a little longer to get approved in Japan. So I think that once those products start to arrive we'll start to see more of an uptake in Japan as well. But I would say we're in a very good position in that business. We have a very, very strong leadership team. And we expect to continue to have success in Trauma and Extremities."
94614,314976743,921224,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Operator","And our next question comes from Jeff Johnson from Robert Baird.",11,"And our next question comes from Jeff Johnson from Robert Baird."
94614,314976743,921224,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Analysts","Bill, I just want to say best wishes. I was looking back this afternoon. I think it's been 14 years that you and I have overlapped. So thanks for all the conversations, all the help over that time. And so Kevin, just wanted to ask one question, one follow",123,"Bill, I just want to say best wishes. I was looking back this afternoon. I think it's been 14 years that you and I have overlapped. So thanks for all the conversations, all the help over that time. And so Kevin, just wanted to ask one question, one follow-up question here, just on the phasing or maybe gating of some of the med tech tax savings. Is there going to be any timing differential between when the med tech tax savings start coming in and influencing the cost of goods line versus when you start reinvesting those dollars back into SG&A and R&D? Should those match up pretty evenly on the P&L or just how to think about the gating throughout this year?"
94614,314976743,921224,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","I think that, that's fair to say, Jeff, and thanks a lot for your comments. I think that on the cost of goods sold category, obviously that will start right off in the beginning of the year. Our investments, as we are targeting right now at moving again t",65,"I think that, that's fair to say, Jeff, and thanks a lot for your comments. I think that on the cost of goods sold category, obviously that will start right off in the beginning of the year. Our investments, as we are targeting right now at moving again through 2016, we would also expect to be doing that reinvestment pretty much consistently throughout the year."
94614,314976743,921224,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","Yes. Sorry, it's going to be clean from the beginning of the year -- from the beginning of this year to 2017. It starts immediately. There's no lag effect, which I think had happened prior with a different company. So for us, it's clean. You'll see it cle",52,"Yes. Sorry, it's going to be clean from the beginning of the year -- from the beginning of this year to 2017. It starts immediately. There's no lag effect, which I think had happened prior with a different company. So for us, it's clean. You'll see it cleanly in the 2 years."
94614,314976743,921224,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Operator","And our next question comes from Steve Lichtman from Oppenheimer.",10,"And our next question comes from Steve Lichtman from Oppenheimer."
94614,314976743,921224,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Analysts","I just have one follow-up on ERP. You talked about the investment on the capital side. Are there any P&L impacts that we should expect over the next couple of years as you start to implement ERP? And when do you anticipate the system being fully in place?",49,"I just have one follow-up on ERP. You talked about the investment on the capital side. Are there any P&L impacts that we should expect over the next couple of years as you start to implement ERP? And when do you anticipate the system being fully in place?"
94614,314976743,921224,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","So a couple of different questions again there. So on the ERP side of the equation, from an investment perspective, we won't see the first implementations really for about another 1.5 years or so. And then those will be rolled out over the next few years",189,"So a couple of different questions again there. So on the ERP side of the equation, from an investment perspective, we won't see the first implementations really for about another 1.5 years or so. And then those will be rolled out over the next few years after that. As far as the cost side of the equation goes, we would not expect that to be a big blip once we get to kind of the stabilized level that we've got kind of this -- in 2016 year. But moving forward, in fact, if anything, as those systems are implemented, we would expect some of the benefits. Plus with the CTG initiative that we've got kicked off, those will continue to roll in at different points throughout different years. We do have multi hundreds of millions of dollars targeted for that. Keep in mind as well that we have price downs in the $150 million to $200 million range that we need to be working to offset. And then, as far as the impacts associated with the investment, again, that should be pretty consistent as we're moving forward beyond 2016."
94614,314976743,921224,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","Yes. Just to add to that, I would say, we do have some expense that will be hitting our P&L, but we're absorbing that within the guidance that we have provided to you.",33,"Yes. Just to add to that, I would say, we do have some expense that will be hitting our P&L, but we're absorbing that within the guidance that we have provided to you."
94614,314976743,921224,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Operator","And our next question comes from Kaila Krum from William Blair.",11,"And our next question comes from Kaila Krum from William Blair."
94614,314976743,921224,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Analysts","Just a couple of quick ones for me. The first, I mean, clearly, you all are still emphasizing M&A as the key priority here. And I'm just curious if you can touch on that how or if those conversations have changed tone just with some of the valuation pullb",56,"Just a couple of quick ones for me. The first, I mean, clearly, you all are still emphasizing M&A as the key priority here. And I'm just curious if you can touch on that how or if those conversations have changed tone just with some of the valuation pullbacks specifically that we've seen in recent weeks?"
94614,314976743,921224,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","Yes. I would say that, that short a time period doesn't have an impact. And as Kevin articulated, we continue to be focused on M&A externally. There's going to be periods where it looks more or less active depending on timing. Internally, the teams have n",64,"Yes. I would say that, that short a time period doesn't have an impact. And as Kevin articulated, we continue to be focused on M&A externally. There's going to be periods where it looks more or less active depending on timing. Internally, the teams have never been busier, and there's no change in the strategy. And the recent market disruption is what it is."
94614,314976743,921224,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Analysts","Okay. And then, I guess, just a follow-up on an earlier question just around whether or not there is this potential for longer-term growth rates to accelerate. And then just pairing that with your earlier comments about MAKO and the likelihood that 2016 i",70,"Okay. And then, I guess, just a follow-up on an earlier question just around whether or not there is this potential for longer-term growth rates to accelerate. And then just pairing that with your earlier comments about MAKO and the likelihood that 2016 is more of a set-up year for 2017, is it fair to assume that overall top line growth could modestly accelerate heading into 2017 from 2016 levels?"
94614,314976743,921224,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","It's always our goal to grow sales at the high end of med tech. And certainly, we've got some nice opportunities between ischemic and MAKO, but they're going to be in early stages next year. So probably premature to start the push towards higher growth ra",71,"It's always our goal to grow sales at the high end of med tech. And certainly, we've got some nice opportunities between ischemic and MAKO, but they're going to be in early stages next year. So probably premature to start the push towards higher growth rates than this year, but we feel really good with what we've set up for this year and hopefully can build on that in '17."
94614,314976743,921224,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","Yes. I think we're going to learn a lot. So I think towards the end of this year we'll be able to share more of the 2 additional platforms, both MAKO and ischemic stroke. Those are the ones that I think can provide, let's call them change of trajectories",107,"Yes. I think we're going to learn a lot. So I think towards the end of this year we'll be able to share more of the 2 additional platforms, both MAKO and ischemic stroke. Those are the ones that I think can provide, let's call them change of trajectories in growth for the company. Now whether that happens in '17 or '18 or '19, it's -- they are new platforms so it's not easy to predict. But I think we'll learn a lot over the course of this year and certainly be able to share more with you when we provide our guidance in the following year."
94614,314976743,921224,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Operator","We have no further questions at this time. I'll now turn the conference call over to Mr. Kevin Lobo for any closing remarks.",23,"We have no further questions at this time. I'll now turn the conference call over to Mr. Kevin Lobo for any closing remarks."
94614,314976743,921224,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","So thank you all for joining our call. Our conference call for the first quarter 2016 results will be held on April 20. Thank you.",25,"So thank you all for joining our call. Our conference call for the first quarter 2016 results will be held on April 20. Thank you."
94614,314976743,921224,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Operator","Thank you, ladies and gentlemen. This concludes today's conference. Thank you for participating, and you may now disconnect.",18,"Thank you, ladies and gentlemen. This concludes today's conference. Thank you for participating, and you may now disconnect."
94614,314976743,923770,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Operator","Welcome to the Fourth Quarter 2015 Stryker Earnings Call. My name is Adrianne, and I will be your operator for today's call. [Operator Instructions] This conference call is being recorded for replay purposes.Before we begin, I would like to remind you t",138,"Welcome to the Fourth Quarter 2015 Stryker Earnings Call. My name is Adrianne, and I will be your operator for today's call. [Operator Instructions] This conference call is being recorded for replay purposes.
Before we begin, I would like to remind you that the discussions during this conference call will include forward-looking statements. Factors that could cause actual results to differ materially are discussed in the company's most recent filings with the SEC. Also, the discussions will include certain non-GAAP financial measures. Reconciliations to the most directly comparative GAAP financial measures can be found in today's press release that is an exhibit to Stryker's current report on Form 8-K that was filed today with the SEC.
I would now like to turn the call over to Mr. Kevin Lobo, Chairman and Chief Executive Officer. You may proceed, sir."
94614,314976743,923770,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","Good afternoon, everyone, and welcome to Stryker's fourth quarter 2015 earnings call. Joining me today are Bill Jellison, our CFO; Katherine Owen, Vice President of Strategy and Investor Relations; and Glenn Boehnlein, who will be taking over for Bill on",822,"Good afternoon, everyone, and welcome to Stryker's fourth quarter 2015 earnings call. Joining me today are Bill Jellison, our CFO; Katherine Owen, Vice President of Strategy and Investor Relations; and Glenn Boehnlein, who will be taking over for Bill on April 1. Following my opening comments, Katherine will provide an update on MAKO, while Bill will offer more details on our quarterly results before turning to questions and answers.
With a 6.4% increase in organic sales in Q4, we continue to deliver on our goal of driving top line growth at the high-end of med tech. This marks the 11th consecutive quarter where Stryker delivered 5% or better organic sales growth, demonstrating strong consistency over time. Our diversified sales footprint has once again proven to be a key component of our growth strategy as all of our segments, Orthopaedics, MedSurg and Neurotechnology and Spine, posted good results in the quarter. These performances underscore the strength of our sales and marketing execution and our innovation engine, which is characterized by healthy R&D investments and a focused and disciplined M&A effort.
Approximately 70% of our sales are derived from our U.S. businesses, which once again led growth, posting an impressive gain of approximately 8%. I am also pleased with the growing momentum out of Europe, including strong Q4 results benefiting from the shift to the Transatlantic Operating Model at the beginning of 2015. We are building on this success as we start 2016 with Canada rolling into the model and the other regions now reporting to our Group Presidents, Tim Scannell and David Floyd. Our international growth of roughly 4% in constant currency was once again impacted by soft performances in China and Brazil. However, as you've seen, we have demonstrated the ability to offset isolated geographic softness through strength in our larger markets.
Turning to earnings. Our adjusted EPS for Q4 of $1.56 is at the high-end of our revised range of $1.53 to $1.56 primarily driven by the strong top line. The balance of the P&L came in as expected, which Bill will cover in his section. Looking ahead to 2016, we expect our sales momentum to continue and are targeting organic sales growth for the year of 5% to 6%. This takes into account expected softness in emerging markets for a good portion of the year.
In addition, the 2-year suspension of the med device tax provides us with the opportunity to bolster investments that will help drive sales growth and innovation as we plan to invest the majority of this temporary benefit. We are also continuing on our path toward driving greater cost efficiencies, which is a multiyear opportunity. Over the past year, we have been focused on identifying and prioritizing the key target areas for cost reduction within our organization.
As we shift into 2016, we are moving toward project implementation under the leadership of Group President Lonny Carpenter. We have identified significant areas of savings centered around optimizing our plant network, rationalizing our product lines, professionalizing our indirect procurement in a similar manner as we have done with direct materials, moving to a common ERP system and driving more shared services.
Given our history of decentralization, there's considerable opportunity ahead of us in this program. We believe a methodical and deliberate approach to these efforts will allow us to preserve Stryker's competitive differentiation in the areas of sales, marketing, R&D and business development while helping to ensure we are consistently delivering P&L leverage. This is reflected in our 2016 adjusted EPS range of $5.50 to $5.70 a share. This is an increase of approximately 7.5% to 11.5% versus 2015, and it includes a negative foreign exchange impact of $0.12 to $0.13 a share.
Finally, I'd like to take a moment to extend my thanks and appreciation to Bill Jellison, who has announced his plan to retire following an impressive 36 career -- 36-year career, the last 3 of which have been with Stryker. Bill was able to quickly move toward implementing a layered hedging program, which has proven to be successful at mitigating our transactional FX exposure. In addition, he helped execute on a number of acquisitions, facilitated the establishment of our European regional headquarters that's enabled significant savings and has also helped to shape our comprehensive cost reduction program.
These accomplishments have meaningfully contributed to our success and were achieved while enabling our internal talent pools to develop, including Glenn Boehnlein, who has been promoted to CFO effective April 1. Glenn has been with Stryker in various financial leadership roles since 2003, most recently serving as Group CFO for the MedSurg and Neurotechnology group. This group represents roughly half the company and has been a consistent force behind our strong results. I am confident in Glenn's ability in coordination with the broader finance organization to help build on our strong momentum.
Before turning the call over to Katherine, I've asked Glenn to make a few comments. Glenn?"
94614,314976743,923770,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","Thanks, Kevin. I appreciate the comments and the support, but I also want to thank Bill for his leadership of the finance organization over the past few years and for his commitment to helping ensure a smooth transition as I take on new responsibilities.",98,"Thanks, Kevin. I appreciate the comments and the support, but I also want to thank Bill for his leadership of the finance organization over the past few years and for his commitment to helping ensure a smooth transition as I take on new responsibilities. It's a very exciting time at Stryker, and I'm thrilled to be part of such a great organization with so many talented and dedicated people. I'm also looking forward to meeting many of our shareholders and analysts at the various events going forward.
And with that, I'll turn the call back over to Katherine."
94614,314976743,923770,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","Thanks, Glenn. The focus of my comments today will be to provide an update on MAKO. 2015 was a year of building momentum for MAKO's robotic-assisted surgery as we continue to leverage our considerable sales and marketing infrastructure to help drive sales",257,"Thanks, Glenn. The focus of my comments today will be to provide an update on MAKO. 2015 was a year of building momentum for MAKO's robotic-assisted surgery as we continue to leverage our considerable sales and marketing infrastructure to help drive sales. We are particularly pleased with the increased demand for the hip indication, which has been augmented by combining the robotic technology with our proven portfolio of Stryker hip systems. The combination enables surgeons to use a best-in-class hip implant with a long-term proven clinical history on a robotic-assisted platform which helps drive consistency, enhance surgeon and patient experience and, we believe over time, clinically demonstrated benefits. In total, we sold 31 robots globally in the quarter, 24 of which were in the U.S., which represents a solid ramp from the start of the year and a significant jump year-over-year from 20 in the fourth quarter of 2014. For 2016, we are focused on continuing to drive adoption with our current indications, which we believe offer considerable opportunity to drive ongoing robot placements.
We are also excited about the potential for the Total Knee indication with our flagship Triathlon system. This year, our efforts will be centered around gaining user experience with key opinion leaders to help ensure an optimal rollout as we look to full commercial release in 2017. We believe the commercial launch, which will be aided by podium presentations from the early users group, will be in place as we head into next year.
With that, I'll turn the call over to Bill."
94614,314976743,923770,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","Thanks, Katherine. I'd like to start off by saying I've enjoyed working with Kevin and everyone at Stryker, especially the entire finance organization who have made significant contributions over the last few years helping the company deliver on its finan",1931,"Thanks, Katherine. I'd like to start off by saying I've enjoyed working with Kevin and everyone at Stryker, especially the entire finance organization who have made significant contributions over the last few years helping the company deliver on its financial results. 
Coming to Stryker was a strong cultural fit and personal fit from the first week that I joined the company.
We ended 2015 at the high-end of both our initial sales and earnings guidance that was set at the beginning of the year. As we look at 2016 and set our initial guidance, I am confident that our sales momentum, strong product portfolio and pipeline and the cost containment initiatives we are driving position us well for the future. I look forward to ensuring a smooth transition with Glenn and entering another stage in my life. I will continue to engage actively in many of my passions, travel with my family and friends and explore additional board opportunities. I want to thank all of you for your support.
So turning to our financial performance. Sales grew 3.7% in the quarter, including a negative 3.2% impact from foreign currency translation. Constant currency sales growth was 7%, which includes organic growth of 6.4%.
GAAP EPS for the quarter was $1.38 per share versus $0.68 last year in the fourth quarter, while adjusted earnings per share were $1.56 a share for the quarter versus $1.44 per share in the fourth quarter last year. This quarter's EPS includes negative impacts of roughly $0.04 per share from foreign exchange, which was in line with our guidance.
Most currency exchange rates against the U.S. dollar continued to be weaker than last year in the same period. The weaker euro and Swiss franc, along with our layered hedging program, helped to mitigate some of the impact in the quarter as many of our products are manufactured in Europe, which helped improve our gross margin rates in the period. However, significant weakening in foreign currency rates in emerging markets and the continued weakness of the Japanese yen, Australian dollar and Canadian dollar, where we have minimal manufacturing, negatively impacted our gross margins and operating results in those regions.
The most significant non-GAAP adjustments in the quarter were amortization, restructuring charges and a net reduction in the charge associated with the voluntary recall of the Rejuvenate, ABG II modular hip stem as we resolved some insurance matters in the quarter, which more than offset the additional charge in the period. As I have mentioned previously, the charges we have recorded related to the Rejuvenate and ABG II recall represents the minimum of the range of probable loss to resolve this manner, and the charges may increase or decrease over time as additional facts become available and our assumptions more refined.
In the fourth quarter, our organic growth rate was 6.4%, including 8.1% growth in unit volumes and mix, with price negatively impacting sales by 1.7%. Acquisitions added 0.6%, while FX had a negative 3.2% impact due to significant weakness in both the Japanese yen and the Australian dollar compared to the same period last year. Full year 2015 constant currency sales growth were 7%, and organic growth was 6.1%.
Looking at our segments. Orthopaedics represented 42% of our sales in the quarter, and sales of Orthopaedic products grew 3.3% as reported and 7.1% in constant currency. U.S. Orthopaedic sales grew 9.7% in the quarter. Trauma and Extremities had another excellent quarter in the U.S. with sales increasing 13.6% led by strong growth in Foot & Ankle, which again grew approximately 20% for both the fourth quarter and full year. U.S. Hips and Knees continued their strong performance of 6.4% and 9.1% organic growth, respectively, in the quarter. These sales were bolstered by increased adoption of recent titanium 3D-printed products.
Our International Orthopaedic business grew 2.4% in constant currency as sales growth continued to be negatively impacted by weakness in China and Brazil. However, our International Knee business grew 5.5% in constant currency in the quarter. Finally, we sold 31 MAKO units in the quarter and 72 units in the full year.
Next, our MedSurg segment represented approximately 40% of our total sales, and sales of MedSurg products grew 3% as reported and 5.6% in constant currency. These results were led by growth in our Instruments and Medical business, both of which had strong mid-single-digit percentage growth in constant currency. Endoscopy also posted mid-single-digit percentage growth in constant currency in the period on the back of our new camera offering, which was launched in December. All 3 of these large MedSurg businesses continued to manage pricing decisions effectively with modest price declines of less than 0.5% for the year.
Our final segment, Neurotechnology and Spine, represented 18% of sales and delivered another good quarter. Sales of Neurotechnology and Spine products grew 6.5% as reported and 9.9% in constant currency. Growth in this segment was led by our Neurotechnology business, which had double-digit growth in the high teens in constant currency in the fourth quarter and grew high teens in the U.S. Spine sales had mid-single-digit percentage growth in constant currency in the period and had high single-digit growth in the U.S. This marks our third consecutive quarter of strong growth in U.S. Spine. Spine also has a new 3D-printed interbody device launching in 2016, which we believe will be a very exciting product for the market, helping us to continue this positive trend.
In looking at our operational performance, gross margin as a percent of sales on an adjusted basis in the fourth quarter was 67.2% compared to 65.8% in the fourth quarter last year. When compared to the same period last year, the rate was positively impacted by solid operational improvements, product mix and FX rates despite the negative FX impact on earnings per share.
Price had a negative impact as pricing was lower by 1.7% in the period. Our gross margin as a percentage of sales was 66.5% or 50 basis points higher than last year. Research and development expenses increased by 20 basis points to 6% of sales in the fourth quarter compared to 5.8% in the same period last year.
On an adjusted basis, selling, general and administrative expenses represented 33.7% of sales in the fourth quarter compared to 32.4% in the same period last year. As expected, these expenses were higher for the year as we increased spending to support the cost structure of our European regional headquarters in Amsterdam and our Transatlantic Operating Model. We are confident in our ability to leverage these expenses in 2016 as we continue to drive a number of key cost initiatives even as we reinvest some of the savings from the suspension of the medical device tax.
Operating margin as a percentage of sales on an adjusted basis were 27.4% in the fourth quarter compared to 27.6% in the same period last year. The full year adjusted operating margin rate was 24.9%, nearly flat compared to last year. During the year, we invested in our European regional headquarters and the establishment of our Transatlantic Operating Model, which reduced the stronger operating margins for the year.
Other expense in the fourth quarter was $36 million. This increase in expense resulted primarily from higher net interest expense due to increased borrowings and foreign currency exchange transactional losses in the fourth quarter. This is generally consistent with the run rate for this category.
Our reported tax rate for the fourth quarter was 14.7%, while the adjusted effective tax rate was 16.6% for the fourth quarter compared to 22.6% in the same period last year. The fourth quarter effective tax rate benefited from the renewal of the tax extenders, which was contemplated in our guidance. The full year adjusted effective tax rate was 17.3% compared to 22.3% last year as we realized the benefits from our global tax structure and European regional headquarters in Amsterdam.
Looking at the balance sheet. We ended the quarter with $4.1 billion of cash and marketable securities, approximately 50% of it now held in the U.S. We also had $4 billion of debt on the balance sheet at the end of the quarter. From an asset management standpoint, accounts receivable days ended the quarter at 55, relatively unchanged from last year. Days in inventory finished the quarter at 165, which was an increase of 5 days compared to last year.
Turning to cash flow. Our cash flow from operations for 2015 were $900 million compared to $1.8 billion last year. But as previously mentioned, we made significant payments earlier this year associated with our Rejuvenate and ABG II recall settlement of $1.2 billion, most of which occurred in the third quarter. Approximately 50% of the funding of the Rejuvenate liability is being sourced from OUS cash. We also repatriated a total of $1.8 billion in 2015, including approximately $1.1 billion in the fourth quarter. Capital expenditures were $270 million in 2015 compared to $233 million last year.
Finally, regarding share repurchases. In 2015, we repurchased approximately $700 million of our common stock or approximately 7.5 million shares at an average price of approximately $94.67. We have authorization for another $1.9 billion available for repurchase under our current authorization.
Based on our strong performance in 2015 and assessment of the current economic and market conditions, we are projecting constant currency and organic sales growth in a range of 5% to 6% for 2016 and expect to be at the low end of that range in the first quarter as we are still anticipating impacts of market conditions in the emerging markets, especially China and Brazil. If foreign currency exchange rates hold near current levels, we anticipate net sales will be negatively impacted by approximately 1% for 2016. We also expect continued unfavorable price reductions of 1.5% to 2% consistent with the pricing environment experienced in 2015.
Due to the suspension of the med tech tax, we will also provide some additional visibility to our projected margin rates for 2016. Both gross margin and operating income margins are projected to be at least 50 basis points higher in 2016 in total. The benefit from the suspension of the med tech tax will directly benefit our gross profit rate. However, R&D will run slightly higher in 2016, and our SG&A rate will only show modest improvement for the full year as we expect to reinvest the majority of the benefit we receive into these areas, offsetting much of our cost reductions in '16.
As such, our gross margin rate improvements will be the driver of our operating margin rate in 2016. We expect our full year adjusted effective tax rate in 2016 will continue to be approximately 17% to 17.5%. Capital expenditures are expected to be $400 million to $450 million in 2016 as we continue to invest in our operations and our IT infrastructure to support future growth.
Based on the current foreign exchange rates, we expect 2016 to be negatively impacted by approximately $0.12 to $0.13 for the full year and approximately $0.03 for the first quarter. This negative impact is largely driven by the translational component of foreign exchange, which we do not hedge. The transactional impact of foreign exchange on earnings is being offset somewhat by both natural and real hedges, which we continue to layer into our operations. Finally, our guidance for adjusted net earnings per diluted share in 2016 is $5.50 to $5.70 for the full year and $1.17 to $1.22 for the first quarter.
Thanks for your support, and we'd be glad to answer any questions that you may have at this time."
94614,314976743,923770,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Operator","[Operator Instructions] Our first question comes from Bob Hopkins from Bank of America.",13,"[Operator Instructions] Our first question comes from Bob Hopkins from Bank of America."
94614,314976743,923770,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Analysts","So first, Bill, sorry to see you move on, but good luck with the next chapter. Sort of feel I'd be remiss if I didn't sort of ask a follow-up question on this announcement and maybe the way to phrase the question, Bill, is -- and for Kevin and Katherine,",114,"So first, Bill, sorry to see you move on, but good luck with the next chapter. Sort of feel I'd be remiss if I didn't sort of ask a follow-up question on this announcement and maybe the way to phrase the question, Bill, is -- and for Kevin and Katherine, you guys have been talking about M&A for some time and I'm just curious if this CFO transition suggests any change in strategy or maybe suggests that mid or larger deals kind of less likely until after this transition is complete. Just kind of curious in how this could affect the strategy and/or the outlook for M&A. And again, congrats, Bill, for the decision."
94614,314976743,923770,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","Yes, thanks, Bob. Look, I would tell you right now the company is in very good shape. You can see the way we're performing. This is an internal transition with somebody who is inside our company, so this is not like we're signaling any kind of shift in st",151,"Yes, thanks, Bob. Look, I would tell you right now the company is in very good shape. You can see the way we're performing. This is an internal transition with somebody who is inside our company, so this is not like we're signaling any kind of shift in strategy. I would tell you, we've been very consistent on capital allocation since I've been in the job and even before, that our approach is to favor M&A first then dividends and then share buybacks. So there's absolutely 0 change to our operating mode, and I'm expecting a very smooth transition. You can see that we have a whole quarter of overlap, and Bill is still going to be around in this community and available to help us as needed. So I would tell you that you should expect more of the same from Stryker, and this should be a very seamless change."
94614,314976743,923770,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Analysts","All right. And then as a quick follow-up also, Kevin, from a big picture perspective. I was wondering if you could kind of give us your sense for the outlook for hospital capital spending in 2016. What are you seeing from hospitals? Are you expecting any",74,"All right. And then as a quick follow-up also, Kevin, from a big picture perspective. I was wondering if you could kind of give us your sense for the outlook for hospital capital spending in 2016. What are you seeing from hospitals? Are you expecting any changes? Just wanted to get a sense for your view on the 2016 outlook for CapEx, especially since you're launching some new products into the market right now."
94614,314976743,923770,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","Thanks, Bob. Look, we see the market as very stable for capital equipment. You can see in the fourth quarter we had very strong performances on MAKO selling capital. That's a large capital. We also have a lot of small capital. Our Instruments division did",107,"Thanks, Bob. Look, we see the market as very stable for capital equipment. You can see in the fourth quarter we had very strong performances on MAKO selling capital. That's a large capital. We also have a lot of small capital. Our Instruments division did very well in the fourth quarter. So we look at the market as being very stable. We're just embarking upon the launch of our new camera, the 1588, within Endoscopy. They had a nice start in the month of December, and the orders look quite healthy going into the year. So we're not seeing really any change. A very stable capital market."
94614,314976743,923770,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Operator","And the next question comes from Mike Weinstein from JPMorgan.",10,"And the next question comes from Mike Weinstein from JPMorgan."
94614,314976743,923770,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Analysts","And Bill, my sentiments as well. Thanks for all your help and enjoy your time away from Stryker. Let me ask a couple questions, guys. So one question is the 5% to 6% constant currency guidance for 2016. Obviously you've, by and large, been running above t",84,"And Bill, my sentiments as well. Thanks for all your help and enjoy your time away from Stryker. Let me ask a couple questions, guys. So one question is the 5% to 6% constant currency guidance for 2016. Obviously you've, by and large, been running above that. Can you just tell us what you have baked in there for the emerging market performance because obviously you're still assuming a challenging emerging market environment for the year? Just want to get some sensitivities around it."
94614,314976743,923770,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","Yes, Mike. In terms of emerging markets, which is in that 7% to 8% of our total sales, and China and Brazil are the biggest components. Although we've been seeing nice growth in markets outside of that, we've assumed those markets remain challenging for t",96,"Yes, Mike. In terms of emerging markets, which is in that 7% to 8% of our total sales, and China and Brazil are the biggest components. Although we've been seeing nice growth in markets outside of that, we've assumed those markets remain challenging for the better part of the year. China as well as Brazil are difficult to predict given the macro issues surrounding them. We do benefit from easier comparisons as we get to the back half of the year, but we assume the overall market there continues to be a bit of a challenge."
94614,314976743,923770,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","Yes, Mike, I would say the emerging markets for us, we had similar performance in the fourth quarter as we did in the third quarter. So we were slightly negative in terms of growth in our emerging markets, China, of course, being the biggest drag. And for",182,"Yes, Mike, I would say the emerging markets for us, we had similar performance in the fourth quarter as we did in the third quarter. So we were slightly negative in terms of growth in our emerging markets, China, of course, being the biggest drag. And for Stryker, we have a capital equipment business, especially the Endoscopy division, that's quite big in China. And so that has a bit more of an impact than the disposables or implants on Stryker. So we're expecting that to continue to be difficult, and that will be a drag. And it's early in the year, so we're setting our guidance from 5% to 6%. As you saw last year, we moved our guidance up during the year. If these conditions don't -- or not as severe, you can expect we would do the same. It doesn't change our outlook on our business. We feel very good about our business, but it's early in the year and we know that those markets are going to be challenged and we're just baking in some caution around those markets."
94614,314976743,923770,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Analysts","Understood. Let me -- just 2 quick follow-ups relative to the guidance. So one, you started to talk about the cost transformation initiatives in greater detail in San Francisco. And in the 2016 guidance, you're basically assuming no SG&A leverage, and tha",146,"Understood. Let me -- just 2 quick follow-ups relative to the guidance. So one, you started to talk about the cost transformation initiatives in greater detail in San Francisco. And in the 2016 guidance, you're basically assuming no SG&A leverage, and that's part of it, you're talking about reinvesting back in the business with the benefit of the med tech tax helping the gross margin line. So can you just talk a little bit about where you're going to incrementally invest if that will show up in SG&A or will it all show up in R&D? And then second, the acceleration of the share buyback -- and acceleration maybe is not the right term, but you bought back more stock than you had been buying back in the fourth quarter. Can you just talk a little bit about what's in your 2016 guidance for capital deployment?"
94614,314976743,923770,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","Yes, so a couple different questions there, the first one associated with kind of the margin rates and also the SG&A area. We do expect some modest level of improvement still in the broader operating expense category, but the reinvestment is primarily tak",278,"Yes, so a couple different questions there, the first one associated with kind of the margin rates and also the SG&A area. We do expect some modest level of improvement still in the broader operating expense category, but the reinvestment is primarily taking place in both areas, probably about maybe 20 basis points or so of an impact on the R&D-related side and the remainder kind of in the SG&A area. I'd say that with the cost initiatives that we've got in place that you would have seen obviously better leverage there. But with the reinvestment, that will slow that down at least this year. But we should still be showing obviously some very, very solid gross margin rate improvement, and we should be getting good drops here still in the operating income line for that. As it relates to the buybacks, yes, we did jump that up to about $700 million in this year. As you can see, our cash has continued to stay very strong. We were able to bring back some additional cash. We have about $2 billion here in the U.S. at this point. And as far as our guidance is concerned, you should expect that -- we commented before that we've got the authorization out there. We expect to complete that over kind of a 2- to 3-year period of time, barring any sizable acquisitions. And hopefully, as Kevin mentioned, acquisitions are absolutely still our first and foremost kind of attention within that space, and we expect to be very active as we move forward, but those are all based on timing situations, right? So -- but that is still our #1 focus."
94614,314976743,923770,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Operator","And our next question comes from Rick Wise from Stifel.",10,"And our next question comes from Rick Wise from Stifel."
94614,314976743,923770,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Analysts","Maybe, Kevin, start -- my first question would be on the operating margin outlook. Obviously you're exiting '15 at 27.4%. Maybe just comment, if you would, on your aspirational goals here. Is it 30%? Is it 35% over the next 2 to 4, 3 to 5 years? Just talk",60,"Maybe, Kevin, start -- my first question would be on the operating margin outlook. Obviously you're exiting '15 at 27.4%. Maybe just comment, if you would, on your aspirational goals here. Is it 30%? Is it 35% over the next 2 to 4, 3 to 5 years? Just talk about the magnitude and the durability of this seemingly long-tailed opportunity?"
94614,314976743,923770,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","So Rick, look, you know we only give guidance out for 1 year, right? So we provided you guidance this year, which shows some pretty meaningful leverage on the EPS line. Coming off the year, we just delivered leverage. And if we didn't have a $0.12 to $0.1",216,"So Rick, look, you know we only give guidance out for 1 year, right? So we provided you guidance this year, which shows some pretty meaningful leverage on the EPS line. Coming off the year, we just delivered leverage. And if we didn't have a $0.12 to $0.13 a share of negative FX, we'd be giving EPS in the 10% to 14% range. So that's pretty meaningful leverage on the sales of 5% to 6%. So you should expect us to continue to drive meaningful leverage. That's the goal of the cost program. There's -- we've said before, there's significant opportunities, in the hundreds of millions of dollars. And as we get drive those savings, we'll obviously, if there's great opportunities to invest, we'll invest some of those dollars and some of those dollars will fall to the bottom line. So -- but I don't have a magical number, and I think it also depends on as the years progress, what types of deals that we do, and how that affects our margin profile. So I think each year, you'll expect us to give the kind of guidance we're giving you this year: nice, robust organic growth and a nice amount of leverage to the bottom line, and I think I'll just leave it at that."
94614,314976743,923770,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Analysts","Okay. And Katherine, maybe for you on MAKO. Can you give us a little more color on your comments? You talked about increased demand for the hip indication. It seemed to me you placed more -- a few more systems than we expected. Can you talk about the plac",65,"Okay. And Katherine, maybe for you on MAKO. Can you give us a little more color on your comments? You talked about increased demand for the hip indication. It seemed to me you placed more -- a few more systems than we expected. Can you talk about the placements and the utilization and maybe where you are in the rollout for new indications and software?"
94614,314976743,923770,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","Sure. I think it really is reflective of being completed year 2 of the acquisition, so working through the integration and really helping the combined sales forces to optimize their education around the features and benefits of our hip system, on the robo",266,"Sure. I think it really is reflective of being completed year 2 of the acquisition, so working through the integration and really helping the combined sales forces to optimize their education around the features and benefits of our hip system, on the robotic-assisted platform and getting out there and really detailing those benefits. It's a nice mix of both existing Stryker customers but also new accounts that we're able to get into with the robots. So we're really pleased with the placement as well as having a number of them outside the U.S. I would really just emphasize, 2016 is about really working to make sure we are optimally set up for full commercial launch in '17 for the Total Knee. So we are not expecting any real impact from that this year. We have a lot of work to do to optimize the training protocol. We're going to work with key opinion leaders both on the robotics side as well as KOLs with our Triathlon system to make sure we're meshing those observational studies to really fine-tune the training protocol. We're going to have to  train our own sales force, do the upgrades in the system. So there's a lot of work to be done to make sure when we go into full commercial launch, we are set to really optimize that and have a presence at the podium. So we'll continue to drive placements with the existing indications for 2016 while doing the necessary groundwork to really ensure we're in a great position in 2017 to take full advantage of the Total Knee indication."
94614,314976743,923770,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Operator","And our next question comes from David Roman from Goldman Sachs.",11,"And our next question comes from David Roman from Goldman Sachs."
94614,314976743,923770,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Analysts","I wanted just to start with some of the investment spending that you're committing to through the P&L. Over the past several years, you've been very consistent with investing your business both SG&A and R&D, which has obviously produced this very nice top",87,"I wanted just to start with some of the investment spending that you're committing to through the P&L. Over the past several years, you've been very consistent with investing your business both SG&A and R&D, which has obviously produced this very nice top line growth rate. But as you look forward as you continue to invest in the business, do you see opportunities to enhance the top line growth rate beyond what you're performing today? And where are the most attractive areas of investment for you?"
94614,314976743,923770,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","Well, I can tell you that I get a chance to travel around to all of our divisions over the course of the year, and I've yet to meet an R&D leader that has enough money to spend on new products. So I would say that all of the divisions have opportunities.",345,"Well, I can tell you that I get a chance to travel around to all of our divisions over the course of the year, and I've yet to meet an R&D leader that has enough money to spend on new products. So I would say that all of the divisions have opportunities. There's clearly some areas that we would focus on a little bit more than others. So you've seen our Spine business really start to turn based on focused investments in R&D. We've had 3 great quarters in a row in the U.S. We still have to take a lot of those products outside the U.S. But I would say that would be an area where organic development and spending is really paying off for us, so you can expect more in that area. Sports medicine for us is a business that's growing very fast. It's relatively small within Stryker. That's also an area of interest; Neurotechnology as well as Extremities. I would say -- I picked those 4 right off the top of my head, but I would tell you, we have a long list. And if my other division presidents are listening on the call, I know that they are preparing ideas for me as well. And we'll obviously look at all the ideas and determine which ones we think can really provide value for us. We're not going to just spend for the sake of spending. In a company as big as Stryker is with the decentralized focus, we're seeing that innovation delivers. And I cited one example of 3D printing where I think we're seeing it have an impact on 2 different divisions of Stryker, our Knee business as well as Spine. And we have a huge lineup of other divisions with ideas and prototypes to get into 3D-printed titanium products. So I would say that those are sort of the top-of-mind areas of focus, but all the divisions are lining up and we'll be very selective as we march through that. And we'll share more as the year unfolds."
94614,314976743,923770,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Analysts","Okay. That's very helpful. And then on the capital spending side, the $400 million to $450 million sort of, again, at the high-end of the range, it would be almost a doubling from where you were, I think, in 2014. Could you maybe just help us go into a li",89,"Okay. That's very helpful. And then on the capital spending side, the $400 million to $450 million sort of, again, at the high-end of the range, it would be almost a doubling from where you were, I think, in 2014. Could you maybe just help us go into a little bit detail on where those CapEx dollars are going, how much of that are sort of the 2016 isolated in nature and what the implications of this additional CapEx are to the rest of the business down the road?"
94614,314976743,923770,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","Sure. I'd say that there's a -- beyond just supporting the operations in the higher growth level that we've got in the company, there's a couple areas of specific investment. One is on -- in the ERP transformational area, which is strengthening our global",125,"Sure. I'd say that there's a -- beyond just supporting the operations in the higher growth level that we've got in the company, there's a couple areas of specific investment. One is on -- in the ERP transformational area, which is strengthening our global ERPs on a worldwide basis and reducing the numbers that we have, so we're on a more consistent, common system there. The second one is actually we're building a brand-new state-of-the-art 3D printing manufacturing facility this year as well, too. So we're spending some dollars, I think, in some key potential growth areas for us, and we want to take advantage of that. This year is a little bit of a blip in comparison to what that normal CapEx would be."
94614,314976743,923770,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Operator","And our next question comes from David Lewis from Morgan Stanley.",11,"And our next question comes from David Lewis from Morgan Stanley."
94614,314976743,923770,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Analysts","Just a couple questions. One, Kevin, just to start off with the ortho market. I wonder if you could just comment on 2015, if you think about the underlying momentum and the market and your share position, how much relative share you may or may not have ta",82,"Just a couple questions. One, Kevin, just to start off with the ortho market. I wonder if you could just comment on 2015, if you think about the underlying momentum and the market and your share position, how much relative share you may or may not have taken in '15, and how those dynamics, in your mind, compare to the outlook you'd see for '16 both in terms of how the market's going to perform and how you see shares shaking out."
94614,314976743,923770,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","So yes, thank you for the question. Well, obviously not everybody has finished reporting yet, so we don't have all the final results for 2015. We feel very good about the performance across our portfolio. Certainly, hips has been an area of strength for u",261,"So yes, thank you for the question. Well, obviously not everybody has finished reporting yet, so we don't have all the final results for 2015. We feel very good about the performance across our portfolio. Certainly, hips has been an area of strength for us for the past 4 years. But we're very encouraged by what we're seeing in knees as knees have started to pick up, and we'd historically traded -- the last 3, 4 years has been in line with the market or maybe slightly below. And I think we're going to start to see a bit of over performance there behind innovation and launching new products. So we feel good about our position in those 2. Trauma, of course, as you know, has been a standout for us for about 4 years, and we continue to launch new products and we continue to grow very well. So to us, the market seems very stable. We like our position in each of the categories. If you include Spine within your definition of Orthopaedics, I would say that was an area that had been more troubled for us, but we feel we're on a very good path now. So across the portfolio -- and I just had a chance to spend time at the sales meetings for Orthopaedics and Spine -- I can tell you, they feel very good about our competitive position in a market that seems very stable. So I think we'll see more of the same in terms of volume growth, and we like our competitive position."
94614,314976743,923770,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Analysts","Okay. And just 2 quick ones. One, just Katherine, just thinking about MAKO for a second. I mean, you're now selling more systems than the target MAKO ever did. And I wonder, are you seeing any pushback on ASPs for the system around $1 million? And in ligh",112,"Okay. And just 2 quick ones. One, just Katherine, just thinking about MAKO for a second. I mean, you're now selling more systems than the target MAKO ever did. And I wonder, are you seeing any pushback on ASPs for the system around $1 million? And in light of one of your competitors acquiring another competitor, specifically in robotics, do you expect to see some ASP pressure in '16 or '17? And then Bill, just you sparked my interest in the 3D printing facility. Is this a facility that will be capable of doing 3D-printed full Total Knee and Hips? Or is this more sort of derivative products to the orthopaedic process?"
94614,314976743,923770,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","Yes, on the capital side, obviously that's always going to be a conversation; you don't sell $1 million capital easily. But I will tell you, we are selling million-dollar capital, so those robots are sold. They are not placed. I think what we're doing is",180,"Yes, on the capital side, obviously that's always going to be a conversation; you don't sell $1 million capital easily. But I will tell you, we are selling million-dollar capital, so those robots are sold. They are not placed. I think what we're doing is really leveraging the ability to offer different models. We talked about our Flex Financial, so giving customers the ability to outright purchase or lease depending on their needs. And I think that's helping. And it's really, I think, the difference between when MAKO was stand-alone is we have a very large selling organization that over the last 2 years has really come to understand the features and the benefits. And the value proposition has only improved, going from a uni then to a hip then to a hip with our hip systems on it. And now knowing a Total Knee will be coming, I think, helps in that sales process as well. But we are selling those robots, and I don't anticipate that changing in 2016 related to any competition that might be out there."
94614,314976743,923770,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","Yes, and the second part of your question was around 3D printing. So we launched -- over the past few years, we've started with part of our knee system to enable cementless knee, so tibial baseplate. We have this past year in the middle of the year launch",214,"Yes, and the second part of your question was around 3D printing. So we launched -- over the past few years, we've started with part of our knee system to enable cementless knee, so tibial baseplate. We have this past year in the middle of the year launched revision cones with geometry that can only be made with 3D printing. We have a patella that we've launched that's 3D-printed, and now we're just about to launch a 3D-printed titanium interbody device for spine. So all of the products we've launched thus far that are 3D-printed are all innovative new products. In the case of the spine product and the cementless product, it allows for bony in growth because they're porous materials and getting very good feedback from our customers. For the foreseeable future, at least the next 3, 4 years or so, our focus is really on innovative new products and not replacing our existing products with 3D-printed products. The pipeline of innovative new geometries that can't be made without 3D printing is the area of focus. So it's not about trying to replace our products and drive down costs. Over time, 10 years from now, that could be the case. But in the near to mid-term, it's really focused on innovative new products."
94614,314976743,923770,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Operator","And our next question comes from Kristen Stewart from Deutsche Bank.",11,"And our next question comes from Kristen Stewart from Deutsche Bank."
94614,314976743,923770,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Analysts","So Bill, I'll reiterate. Definitely, congratulations on your retirement, and we definitely will miss you. So just a question more strategically. I was just wondering if you feel good about kind of the 3 main buckets that you have now and whether or not, K",67,"So Bill, I'll reiterate. Definitely, congratulations on your retirement, and we definitely will miss you. So just a question more strategically. I was just wondering if you feel good about kind of the 3 main buckets that you have now and whether or not, Kevin, you feel like there's any need to kind of expand beyond that and get into any other white spaces at this point."
94614,314976743,923770,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","Yes. No, Kristen, I'm going to be consistent with what I've been saying the past couple of years is -- and our strategy is to stay within these 3 segments. We like our position in these 3 segments. We want to continue. If you look at all of our acquisitio",151,"Yes. No, Kristen, I'm going to be consistent with what I've been saying the past couple of years is -- and our strategy is to stay within these 3 segments. We like our position in these 3 segments. We want to continue. If you look at all of our acquisitions, they've strengthened each of our businesses that we're currently in. And every year, we do a white space assessment. And the white space assessment is not as attractive as staying within our segments. There are a significant number of targets within our segments. I know we only completed 2 deals. It was a little bit quieter year in 2015. But I can tell you, the activity level was no different in 2015 with a lot of deals being discussed. And so I would expect us to continue along our current strategy and don't expect us to suddenly jump into white space."
94614,314976743,923770,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Analysts","Okay. And then, just with respect to the Neurotech area. Are there any notable clinical activities coming up for trial readouts? Or can you speak to any new product pipelines you think that we should be aware of that could help drive growth? Even though,",57,"Okay. And then, just with respect to the Neurotech area. Are there any notable clinical activities coming up for trial readouts? Or can you speak to any new product pipelines you think that we should be aware of that could help drive growth? Even though, obviously, it's been growing really well but if you can sustain it."
94614,314976743,923770,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","Yes, we're -- we love this business. Thanks, Kristen. We love this business, and I would say our coiling and the ischemic stroke, we're in great shape. And we're growing very well in those 2 categories. The one area for Stryker that is a slight gap is the",145,"Yes, we're -- we love this business. Thanks, Kristen. We love this business, and I would say our coiling and the ischemic stroke, we're in great shape. And we're growing very well in those 2 categories. The one area for Stryker that is a slight gap is the flow diverting stent segment. We are selling that outside the U.S., but we don't yet have U.S. approval. We have -- in the process of just completing up our trial and we'll be submitting for that, but we're still -- we still have some time before that gets approved. That's the one area we were not in. So we're driving this terrific growth without being in that one segment in the United States. So that's an ongoing process. We'll update you more towards the end of this year in terms of when that will come to market."
94614,314976743,923770,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Operator","Our next question comes from Jason Wittes from Brean Capital.",10,"Our next question comes from Jason Wittes from Brean Capital."
94614,314976743,923770,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Analysts","It sounds like the -- we should view the Total Knee coming out next year as sort of a transformational product. If I look into this year, can you kind of maybe highlight sort of the products that we should be focused on that'll really drive that -- the gr",52,"It sounds like the -- we should view the Total Knee coming out next year as sort of a transformational product. If I look into this year, can you kind of maybe highlight sort of the products that we should be focused on that'll really drive that -- the growth this year?"
94614,314976743,923770,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","I would really look at it as across-the-board, very typical Stryker fashion where it's more singles and doubles, whether it's Endo launching their new 1588 camera or MAKO continuing to drive indications like Hip with the new -- the Stryker brands that we",243,"I would really look at it as across-the-board, very typical Stryker fashion where it's more singles and doubles, whether it's Endo launching their new 1588 camera or MAKO continuing to drive indications like Hip with the new -- the Stryker brands that we talked about or Spine with their new products that are coming out 3D-printed. So it's really a story about those incremental, innovative new products. Usually, no one on its own is a growth driver. It's the totality of that offering that really allows us to sustain that organic growth at the high end of med tech. Clearly, next year, we're set up for some more impactful products that when you think about MAKO and the Total Knee and expect them to be on a clear trajectory as taking meaningful market share as we work our way through '17. Ischemic is one more of those more transformational opportunities. There's a lot of market development that still needs to take place there around the patient path, referral systems, hospital -- inter-hospital transfers. So we talked about that being a multiyear process, but clearly seeing some very good growth rates but off of a still small base. But I would really think about this year as a typical Stryker story. You've got a lot of products, a lot of momentum, dedicated sales force with a specially -- a specialty focus that's really helping to drive that 5% to 6% growth we're targeting."
94614,314976743,923770,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Analysts","Okay, very helpful. And just a quick follow-up for MAKO. Can you give us a sense of how many of these new placements are to existing accounts and how many of these are de novo. Just kind of give us a sense of who's buying.",45,"Okay, very helpful. And just a quick follow-up for MAKO. Can you give us a sense of how many of these new placements are to existing accounts and how many of these are de novo. Just kind of give us a sense of who's buying."
94614,314976743,923770,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","Yes, we haven't broken out -- out of the 31, we haven't broken out. I would tell you, though, that it is a combination of both existing Stryker customers as well as new customers where we haven't had any type of meaningful presence. So we haven't given it",61,"Yes, we haven't broken out -- out of the 31, we haven't broken out. I would tell you, though, that it is a combination of both existing Stryker customers as well as new customers where we haven't had any type of meaningful presence. So we haven't given it with more granularity than that, and -- but there is a nice mix."
94614,314976743,923770,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Operator","And the next question comes from Matt Miksic from UBS.",10,"And the next question comes from Matt Miksic from UBS."
94614,314976743,923770,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Analysts","Super job on the numbers it looks like. And I'll pass along my congratulations and farewell to Bill. We will also miss you. So on MAKO, just a couple of maybe broader questions on how you're positioning the platform. Robotics has been kind of a market dev",124,"Super job on the numbers it looks like. And I'll pass along my congratulations and farewell to Bill. We will also miss you. So on MAKO, just a couple of maybe broader questions on how you're positioning the platform. Robotics has been kind of a market development project for a while, oftentimes dealing with surgeons and helping them get more comfortable with this new technology, maybe changing the way surgery is done over the long term. But at what point does this become, or has it already become, an opportunity to drive better contracting for you across your implant lines, greater share or utilization multiline contracting driven by the merits of the system and the technology? And I have a couple of quick follow-ups."
94614,314976743,923770,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","So Matt, I would say, look, we're still in the early stages. We -- the Stryker Hip brands are now just available recently. And we haven't launched the Total Knee yet. So I think that's -- those are the big applications. And to say that it is impacting con",152,"So Matt, I would say, look, we're still in the early stages. We -- the Stryker Hip brands are now just available recently. And we haven't launched the Total Knee yet. So I think that's -- those are the big applications. And to say that it is impacting contracting yet, I would say, it's too early for that. Once this becomes a more mature business, which will take a couple of years, then I think, obviously, having a system that the surgeons are having a great experience and they enjoy it and they want to use the products, it really does provide us with great differentiation which will -- and differentiation will show up in many different ways, including potentially in contracting. But we're a ways from that yet, we have a lot of work to do in the next couple of years to really gain more broad adoption of the technology."
94614,314976743,923770,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Analysts","Then, another on the same topic here. Katherine, someone asked earlier about Hips and what's changing and how you're improving performance there. To put that in perspective, I remember when Hips came out and when you first acquired the system, it wasn't g",106,"Then, another on the same topic here. Katherine, someone asked earlier about Hips and what's changing and how you're improving performance there. To put that in perspective, I remember when Hips came out and when you first acquired the system, it wasn't generally thought to be really where the bang for the buck was with the robot. And I guess, what's changing? Is this application getting a lot easier? Is people getting -- are they proving out the benefits of the Hip? I mean, what's driving uptick and against what was historically viewed as sort of like a -- not the greatest application for the robot?"
94614,314976743,923770,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","Okay. So I'll take this question. So look, what I'd tell you, the first iterations of the Hip software were a little bit clunky, and it requires quite a bit more registration time to register -- get the register in the software system. So that's just an e",290,"Okay. So I'll take this question. So look, what I'd tell you, the first iterations of the Hip software were a little bit clunky, and it requires quite a bit more registration time to register -- get the register in the software system. So that's just an extra step that some of the surgeons are a little bit frustrated with. Over time, both prior to our acquisition and subsequent to our acquisition, we've made some enhancements of the software to make it a little bit more user-friendly. That's been one factor for sure. I think the most compelling factor is showing the surgeons on the pre and post x-rays that they put the Hip exactly where they want to put it. And I think even those surgeons that had some hesitations, when they see the pre and post x-rays, they are just -- it's a very compelling visual for them to understand. Before they weren't doing that. They weren't able to get that same type of consistency. And that's starting to resonate with a lot of surgeons. And now being able to put our implants in addition with easier-to-use software and to get that kind of outcome, it's like all things have changed, right? Change doesn't occur to everybody at the same time. Some people are early adopters. Some people, frankly, will never adopt. They'll just be set in their ways. But what we're seeing is the middle of the bell curve is starting to shift its mindset. And frankly, the more that robotics is talked about in the community at large, we find that actually a very positive thing because we really believe we have a terrific system, and we're obviously continuing to invest in that system going forward."
94614,314976743,923770,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Operator","Our next question comes from Joanne Wuensch from BMO Capital Markets.",11,"Our next question comes from Joanne Wuensch from BMO Capital Markets."
94614,314976743,923770,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Analysts","I have 2 questions. The first one has to do with 3D printing. It became quite aware about a couple of years ago, now you're definitely doing a bigger focus on that. What does it take for a 3D-printed, call it, Hip or Knee to become more mainstream? Is it",62,"I have 2 questions. The first one has to do with 3D printing. It became quite aware about a couple of years ago, now you're definitely doing a bigger focus on that. What does it take for a 3D-printed, call it, Hip or Knee to become more mainstream? Is it manufacturing? Is it clinical data? How should we think about this evolving?"
94614,314976743,923770,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","Well, it's a long answer, Joanne. The reason I pause is to get into all the technology on 3D-printing would be -- would take a long time. The quick summary is that 3D printing metal is very different than sort of the way you think about 3D printing plasti",225,"Well, it's a long answer, Joanne. The reason I pause is to get into all the technology on 3D-printing would be -- would take a long time. The quick summary is that 3D printing metal is very different than sort of the way you think about 3D printing plastic -- having it on a desk in an office and cranking up 3D-printed products. So metal is much more complicated. It's explosive. It requires a lot of extra programming. You just don't buy a machine and sort of just off to the races. It's a lot more complicated than that. And so we spent a lot of time. We've been working on this for many, many years. And so we have a lot of know-how on how to program the machines and optimize the machines. And so there's a lot of factors that go into it to be able to create. And different types of machines work better for smaller products than larger products. So it's difficult for me to just summarize in a short time. I'd just say that it's more complicated than plastics or other things that you read about in the mainstream press. And that's why, for us, our focus is much more on innovative new products and not necessarily replacing total systems. That will be many, many, many years ahead of us."
94614,314976743,923770,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Analysts","That's very helpful. As a follow-up, what should we expect at the upcoming AAOS?",15,"That's very helpful. As a follow-up, what should we expect at the upcoming AAOS?"
94614,314976743,923770,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","Yes, Joanne, I think it will be typical to prior years. Clearly, there's going to be a big focus around MAKO as we think about uni as well as hip. It's too early in our initial commercial launch activities to have a big focus on user feedback from Total K",124,"Yes, Joanne, I think it will be typical to prior years. Clearly, there's going to be a big focus around MAKO as we think about uni as well as hip. It's too early in our initial commercial launch activities to have a big focus on user feedback from Total Knee. Although, I'm sure there'll be a lot of surgeon presence around that as they're looking to get educated on the features and benefits. And we'll have a tour of the booth as we've done previously to highlight new products across all the businesses from Trauma, Foot & Ankle, Spine, et cetera. And we'll also have an opportunity while we're there just to sit down and meet with management and have an open Q&A forum."
94614,314976743,923770,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Operator","And the next question comes from Raj Denhoy from Jefferies.",10,"And the next question comes from Raj Denhoy from Jefferies."
94614,314976743,923770,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Analysts","Wonder if I could ask a question about the CJR or CCJR program that's rolling out. I know that you guys have been pretty clear as all the companies have that you don't think it's going to have much impact on pricing and so it will be focused on the postac",109,"Wonder if I could ask a question about the CJR or CCJR program that's rolling out. I know that you guys have been pretty clear as all the companies have that you don't think it's going to have much impact on pricing and so it will be focused on the postacute care, which pretty much mirrors what we're hearing as well. But my question is really around how Stryker interfaces with that model. In your performance solutions business, you guys were involved in some of the bundled payments initiatives before. Is there an opportunity for you guys to perhaps benefit from the CJR program as it rolls out?"
94614,314976743,923770,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","Yes. We agree with your comments. We don't think it's going to have a meaningful impact. We have seen it pass with some of the prior programs. It really does drive a focus on postacute and patients that are discharged right to rehab given the high cost th",191,"Yes. We agree with your comments. We don't think it's going to have a meaningful impact. We have seen it pass with some of the prior programs. It really does drive a focus on postacute and patients that are discharged right to rehab given the high cost there. We do have a small business, our Stryker performance solutions, that we think can help work with hospitals to help them make them aware of the data so they can have a sense of what best-in-class is and where are some of the cost benefits they can realize, whether it's around infection rates, transfusions, et cetera. So it's not a huge part of our business, but it is one that provides insights and does help them as they think about their overall cost structure. But clearly, we continue to believe based on everything we've seen that it's going to be postacute care. We haven't seen any meaningful change at all in price between those trial areas as it relates to implant pricing, and really the cost savings they can realize focusing on rehab really do dwarf anything else at this point in time."
94614,314976743,923770,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Analysts","Right. Maybe just as a follow-up. But if you think about that service offering, if that's the way to describe it, which Performance Solutions certainly does some of -- as you think about the next several years, do you envision that service component becom",62,"Right. Maybe just as a follow-up. But if you think about that service offering, if that's the way to describe it, which Performance Solutions certainly does some of -- as you think about the next several years, do you envision that service component becoming a bigger part of the business, offering not just implants to hospitals but perhaps something a bit broader?"
94614,314976743,923770,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","Yes. I mean, that division is continuing to focus on that. It's not a huge part of our company. I think, we see this -- the CCJR is a terrific example, an opportunity for us to grow that business. But it's not at a scale at which I really want to start hi",200,"Yes. I mean, that division is continuing to focus on that. It's not a huge part of our company. I think, we see this -- the CCJR is a terrific example, an opportunity for us to grow that business. But it's not at a scale at which I really want to start highlighting it. I would tell you, a year from now, I think we'll have a much better idea of the scope of CCJR and whether that can become a broader business for us. So services is not something new to Stryker. A lot of our MedSurg business provides services to hospitals. We have people in the hospital that our customers pay for to make sure that all their uptime is working on their equipment. So we're not against services at all, but we don't sort of like to get out in front of ourselves. Let's see how this year unfolds. And if the business becomes something that could be scalable, then we'll talk about it a lot more. But right now, it's a small part -- I agree with you that CCJR does provide an exciting opportunity for that business, but it's a very small part of Stryker."
94614,314976743,923770,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Operator","And our next question comes from Larry Biegelsen from Wells Fargo.",11,"And our next question comes from Larry Biegelsen from Wells Fargo."
94614,314976743,923770,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Analysts","I want to just star with M&A. About a year ago, Kevin, you said you expected to put the balance sheet to work. And I just wanted to confirm that, that's still the case. And I'm asking because, obviously, you've been relatively quiet on the acquisition fro",76,"I want to just star with M&A. About a year ago, Kevin, you said you expected to put the balance sheet to work. And I just wanted to confirm that, that's still the case. And I'm asking because, obviously, you've been relatively quiet on the acquisition front over the past 6 to 12 months, which is atypical. So is there any reason you haven't pulled the trigger on more deals? And I had one follow-up."
94614,314976743,923770,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","Sure. I would tell you, just look, deal timing is inherently unpredictable. There is absolutely no change in the statement I made before. I still intend to put the balance sheet to work. The reason we got the extra share buyback approval level was just in",130,"Sure. I would tell you, just look, deal timing is inherently unpredictable. There is absolutely no change in the statement I made before. I still intend to put the balance sheet to work. The reason we got the extra share buyback approval level was just in case deals don't get over the line or drag on for extended periods of time, we would start to step up the buybacks. But you should expect us to continue to be a very active acquirer. But you've seen in the past, right, sometimes, some years, there's 1 or 2 deals and other years you see many more deals. So our level of activity hasn't changed. I still see many exciting prospects out there. And so we're staying the course with the existing strategy."
94614,314976743,923770,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Analysts","And then, earlier you said that in Q1, you would expect to be at the low end of the 5% to 6%, I think, constant currency growth rate because of what you're seeing in emerging markets. And so -- but you expect emerging markets to be relatively weak through",91,"And then, earlier you said that in Q1, you would expect to be at the low end of the 5% to 6%, I think, constant currency growth rate because of what you're seeing in emerging markets. And so -- but you expect emerging markets to be relatively weak throughout 2016, I believe. So my question is, does getting the growth rate up above that -- the low end of the range, does that depend upon an improvement in emerging markets? And if not, how do you get that growth rate up?"
94614,314976743,923770,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","Yes. I would just comment that if you look at the cadence of quarters last year, we had some difficult comparisons in the first quarter that related to emerging markets. More of the pressure, particularly in China, unfolded as the year went on. We're goin",95,"Yes. I would just comment that if you look at the cadence of quarters last year, we had some difficult comparisons in the first quarter that related to emerging markets. More of the pressure, particularly in China, unfolded as the year went on. We're going to have easier comps in the back half of the year. We tend to have a seasonally stronger second half of the year, particularly as it relates to the fourth quarter. So it's more just reflective of how our quarters tend to play out in some of the year-over-year comparisons."
94614,314976743,923770,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Operator","And the next question comes from Glenn Novarro from RBC Capital.",11,"And the next question comes from Glenn Novarro from RBC Capital."
94614,314976743,923770,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Analysts","Kevin, your U.S. Hip and Knee business had a strong fourth quarter, up 6% and 9%, respectively. Did you see this in the fourth quarter, the U.S. Orthopaedic market accelerate or pick up a bit? Or do you think that was more share capture from Zimmer, given",62,"Kevin, your U.S. Hip and Knee business had a strong fourth quarter, up 6% and 9%, respectively. Did you see this in the fourth quarter, the U.S. Orthopaedic market accelerate or pick up a bit? Or do you think that was more share capture from Zimmer, given the integration between Zimmer and Biomet? And then I had a follow-up question on robotics."
94614,314976743,923770,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","Yes, so look, until we see everybody report, it's really difficult for me to say how much of it is the market versus competitive share capture. The Knee number, we're very encouraged about. We tend to believe our Knee improvement is more driven by the new",197,"Yes, so look, until we see everybody report, it's really difficult for me to say how much of it is the market versus competitive share capture. The Knee number, we're very encouraged about. We tend to believe our Knee improvement is more driven by the new products, the revision cones and the -- and more of uptake of our cementless knee offering. So we believe that's more of the issue than, lets call it, sales force disruptions or any other factors that are occurring at other companies. It's more about our innovation. When I talk to our field, they -- the sense I'm getting is a very stable market. So it wasn't -- a few years ago, we saw this big seasonal fourth quarter lift. We now are seeing a typical fourth quarter. This December was more or less typical. It's more active, but it was more active a year ago, too. So we're not seeing -- we didn't see anything or major in terms -- from quarter-to-quarter you do sometimes see slight upticks or downticks. But until they report, it's going to be difficult for me to comment. But I think you had a second question."
94614,314976743,923770,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Analysts","Yes, Katherine, in your prepared remarks you talked about with the MAKO system, podium presentations in 2016. So can you describe what type of presentations? I'm assuming these are clinical trials. So what type of trials? And when can we see these trials",45,"Yes, Katherine, in your prepared remarks you talked about with the MAKO system, podium presentations in 2016. So can you describe what type of presentations? I'm assuming these are clinical trials. So what type of trials? And when can we see these trials being presented?"
94614,314976743,923770,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","Yes. My comments were that we were going to do observational studies in 2016, so really looking at key opinion leaders who have extensive experience with robotics to understand how we can fine tune the training protocol and optimize the rollout. We're als",169,"Yes. My comments were that we were going to do observational studies in 2016, so really looking at key opinion leaders who have extensive experience with robotics to understand how we can fine tune the training protocol and optimize the rollout. We're also going to be doing observational studies with key opinion leaders who have a lot of familiarity with the Triathlon system so we can mesh those 2 data sets and really put us in a position to have a presence at the podiums in 2017, not '16. So we think combining the full commercial launch and being in a position in 2017 for those initial users, those key opinion leaders to talk about their experience and how they were able to optimize both the robot as well as our Triathlon will help drive the adoption. We're going to continue to collect additional clinical data, but that is going to take a number of years. This is really focused around observational studies to help optimize the training protocol."
94614,314976743,923770,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Operator","And the next question comes from Mike Matson from Needham & Company.",11,"And the next question comes from Mike Matson from Needham & Company."
94614,314976743,923770,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Analysts","I guess, I just wanted to start with the new camera at the Endoscopy business. How does this compare to the prior models? Is it more of an incremental improvement? And just in terms of the impact on the growth rate there, do you expect that to be more of",70,"I guess, I just wanted to start with the new camera at the Endoscopy business. How does this compare to the prior models? Is it more of an incremental improvement? And just in terms of the impact on the growth rate there, do you expect that to be more of a step change or more of a ramp in terms of the growth in Endoscopy? Then I have one follow-up."
94614,314976743,923770,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","Yes. So no, this -- the 1588. So each time we have a new version, and we call it -- the last one was 1488, as you know. Now we're calling it 1588. AIM is the name of it. I would say it's meaningfully better. Certainly, 1488 had terrific resolution, but we",277,"Yes. So no, this -- the 1588. So each time we have a new version, and we call it -- the last one was 1488, as you know. Now we're calling it 1588. AIM is the name of it. I would say it's meaningfully better. Certainly, 1488 had terrific resolution, but we've improved the backlighting and some of the image clarity for certain procedures like ENT that -- so our product works well in a wide variety of procedures. But there are certain procedures where the lighting just wasn't quite as optimized. And we made some nice enhancements there, so across the range of procedures, surgeons are all going to have a delightful experience, whereas, in the past, it was not necessarily across every specialty. So that's the first thing. Second thing is we have ICG built into our light source, which we've never had before. So with a press of a button, you can light up the organs, just -- I'm sure you're familiar with ICG with a competitive product out there. But this is not -- doesn't require extra piece of capital. It's built right into the existing light source, easy for the surgeons to use, which is wonderful. It also includes another product for GYN that lights up parts of the anatomy to -- so it's really a safe surgery launch. It enables safe surgery with enhanced visualization. And we just launched it in December, so we don't have a huge amount of sales yet, but I would say the early clinical feedback has been very positive. So I do expect Endoscopy to have a better year in 2016 than they did in 2015."
94614,314976743,923770,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Analysts","Okay. And then, just with regard to this big ERP project that you have. What's the execution risk there that something gets -- some balls get dropped in terms of the inventory levels and things like that, causing an impact on your overall results for the",47,"Okay. And then, just with regard to this big ERP project that you have. What's the execution risk there that something gets -- some balls get dropped in terms of the inventory levels and things like that, causing an impact on your overall results for the company?"
94614,314976743,923770,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","Yes. So like with any system implementation, there's always some degree of risk. We're being very thoughtful and careful about how we go about the project. We're staffing -- we're putting our best people on it. They're in dedicated -- in a dedicated works",272,"Yes. So like with any system implementation, there's always some degree of risk. We're being very thoughtful and careful about how we go about the project. We're staffing -- we're putting our best people on it. They're in dedicated -- in a dedicated workspace. And in fact, my former Head of HR, who also has run businesses, is going to be leading the business component of that. And I appointed a new Head of HR. That sent a terrific signal to the organization of the kind of commitment we're making. It will be a measured launch, so it will take a number of years before complete, and we're starting off with our Instruments division. And we're going to continue -- we have a steady march planned. We have an IT leader who's partnering with a business leader who has a -- was previous -- at a previous large med tech company doing exactly this kind of an implementation over the past few years. So we believe it's all about talent, staffing the right people who know our business. And we're going to do our best, obviously, to mitigate the risk. We had a painful experience in Japan a couple of years ago. I can tell you the approach of this project is radically different to the approach we used in that project. And so we feel we'll be in good shape, and it's not a Big Bang launch. We're going to do division by division, region by region, and there'll be a steady cadence. So even if something does start to wobble a little bit, it should have very, very little impact."
94614,314976743,923770,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Operator","Our next question comes from Matt Taylor from Barclays bank.",10,"Our next question comes from Matt Taylor from Barclays bank."
94614,314976743,923770,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Analysts","Great. So I was just wondering if you could follow up on some of those comments on 3D printing and just talk about the materiality of the contributions in the quarter and what you're expecting now that you're going to be investing more in this new plan. H",57,"Great. So I was just wondering if you could follow up on some of those comments on 3D printing and just talk about the materiality of the contributions in the quarter and what you're expecting now that you're going to be investing more in this new plan. How big is it and how material could that be?"
94614,314976743,923770,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","Yes, So for the moment, it's -- these are innovative products that are adding, I would call, incremental growth. It's not the core growth. The core growth is our big systems, right, our Triathlon, our Accolade. That's where the core amount of our sales co",290,"Yes, So for the moment, it's -- these are innovative products that are adding, I would call, incremental growth. It's not the core growth. The core growth is our big systems, right, our Triathlon, our Accolade. That's where the core amount of our sales comes from. But this gives a little extra boost to -- and puts a little bit of jump in our sales force step, gives them something new to talk to their customer about. So as an example, our revision business lagged, our market share lagged our primary business in Knees by about 5 or 6 market share points. So even in a Stryker-friendly account, sometimes they would go to a competitive -- a competitor to do their revision procedure. Now that we have what we consider best-in-class revision cones, not only do we keep that business, that surgeon stays with Stryker, we gain that sales. But they now have something that they can go talk to a competitive surgeon about.  So I would say it's not a huge contributor, but it's an extra shot in the arm. So with robotics and 3D printing, we believe we have the lead on both of those areas. And those are things we can talk about that differentiate us from our competition. So again, not even today robotics -- is not a huge component of our growth or our actual dollar sales, but we believe they are the ones that are causing that extra piece of growth and a different view of Stryker for the future. Over time, I expect robotics and 3D printing to take on a more important portion of our overall sales. And they'll be sustainable and sticky if we have something that the competition doesn't have."
94614,314976743,923770,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Analysts","Okay, great. And just one question on the transatlantic model. It seems like you're making some progress there. Can you talk about where you are and how much that's helped to improve some of the OUS results and where you think that could go?",44,"Okay, great. And just one question on the transatlantic model. It seems like you're making some progress there. Can you talk about where you are and how much that's helped to improve some of the OUS results and where you think that could go?"
94614,314976743,923770,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","Yes. So look, Europe has exceeded my expectations. We had a really -- our international growth doesn't look fantastic, so you don't see it. But Europe had a mid-single-digit growth year, and it improved progressively from the first quarter to the fourth q",324,"Yes. So look, Europe has exceeded my expectations. We had a really -- our international growth doesn't look fantastic, so you don't see it. But Europe had a mid-single-digit growth year, and it improved progressively from the first quarter to the fourth quarter. So that kind of uptick is frankly ahead of where I'd expected it to be. It's been masked a little bit because of the sluggishness out of China, so that has dampened our international sales. But it's been a really great success. I'm excited about what I'm seeing across our businesses in Europe. Some of the divisions took off faster than others, like Trauma and Extremities and Endoscopy took off really quickly. And now I'm starting to see some nice uptake in Instruments and Spine towards the end of the year. So more to come in Europe. We made a number of investments over the course of the year. Those investments are now taking hold. And I think you'll start to see Europe become a division that delivers better top line and starts to deliver some leverage going forward. We've added Canada, so those are now directly managed. A Division President has direct P&L accountability for Canada, the U.S. and Europe. The other regions we haven't yet folded into the model, but by eliminating the Group President of international role, they -- we now have them reporting directly to our business Group President. So it just increases speed and connectivity from our regions to come straight to a Group President. Over time, we'll see whether those countries will roll into this model, but we don't want to run too fast to fully integrated complete global business units, especially with markets like China that are so different, or Japan. But we're very pleased with the progress so far. Taking out that position was nothing about cost reduction. That was 100% just to increase speed and connectivity of those countries to our businesses."
94614,314976743,923770,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Operator","And our next question comes from Matt Keeler from Crdit Suisse.",11,"And our next question comes from Matt Keeler from Crdit Suisse."
94614,314976743,923770,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Analysts","Just 2 quick ones. First on Hips outside the U.S, you highlighted the drag from emerging markets but your Knee growth actually picked up pretty nicely. So I'm just wondering if there was a much more pronounced impact from that emerging markets drag on Hip",63,"Just 2 quick ones. First on Hips outside the U.S, you highlighted the drag from emerging markets but your Knee growth actually picked up pretty nicely. So I'm just wondering if there was a much more pronounced impact from that emerging markets drag on Hips relative to Knees and if there were any other factors that impacted your Hip business outside the U.S.?"
94614,314976743,923770,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","No, nothing in particular. You see this from quarter-to-quarter, and sometimes you'll see sort of Hips jump. In the case of Hips -- Canada as an example -- there was a hip tender that we lost so that accounted for some of the Hip growth. There's not 1 sor",112,"No, nothing in particular. You see this from quarter-to-quarter, and sometimes you'll see sort of Hips jump. In the case of Hips -- Canada as an example -- there was a hip tender that we lost so that accounted for some of the Hip growth. There's not 1 sort of overriding factor. It's just sort of a story-by-story, country-by-country. And we see this from quarter-to-quarter, sometimes you'll see knee -- our business is not as big outside the U.S. So you do see a little bit more volatility in our numbers, whether it's Hip, Knee, Spine. Once those businesses get larger, you would -- you should expect that there'll be less volatility."
94614,314976743,923770,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Analysts","Great. And just lastly, Instruments growth was pretty strong in the quarter. But I think you've highlighted that, that business is later on in its product cycle. So I was just wondering if you think the level of growth we saw in the fourth quarter, if tha",73,"Great. And just lastly, Instruments growth was pretty strong in the quarter. But I think you've highlighted that, that business is later on in its product cycle. So I was just wondering if you think the level of growth we saw in the fourth quarter, if that's sustainable going forward. And what are some of the sort of the products to watch where you're maybe a little later on in that product cycle?"
94614,314976743,923770,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","Yes, so the power tools is the product that we referred to as being late in the cycle, the System 7 power tools, which is probably the biggest single product category within Instruments. But Instruments has a lot of other products. So they have Neptune, t",168,"Yes, so the power tools is the product that we referred to as being late in the cycle, the System 7 power tools, which is probably the biggest single product category within Instruments. But Instruments has a lot of other products. So they have Neptune, they have -- they're launching a new signature line of drills. We actually report that as part of our Neurotech, but it's run by our Instruments division. But yes -- they have the sponge counter as well, patient safety company that we acquired. So these are different kinds of businesses that can drive growth. It's a little less predictable than power tools. So I think we're very excited by how they finished the year. They finished the year very, very strong. And we think they'll have a good year. But being longer in the cycle, sometimes we do see them tailing off a little bit. So but I would expect a year that's similar to the year that they had this year overall."
94614,314976743,923770,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Operator","And our next question comes from Rich Newitter from Leerink Partners.",11,"And our next question comes from Rich Newitter from Leerink Partners."
94614,314976743,923770,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Analysts","Kevin, I was hoping I'd just get some comments on Spine. You characterized the market as stable, and you're clearly seeing some nice uptick in the growth rates there. You have some new product launches. So my question really is has there been any change o",77,"Kevin, I was hoping I'd just get some comments on Spine. You characterized the market as stable, and you're clearly seeing some nice uptick in the growth rates there. You have some new product launches. So my question really is has there been any change or can you give us your updated thoughts on how you view kind of external versus internal investments in this division for you now that things seem to be on better footing?"
94614,314976743,923770,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","Yes. So I am really excited about what we're doing organically. So we've retooled our R&D organization, some of our marketing organization over the past few years. And this business is hitting its stride. And we're launching more and more new products. We",163,"Yes. So I am really excited about what we're doing organically. So we've retooled our R&D organization, some of our marketing organization over the past few years. And this business is hitting its stride. And we're launching more and more new products. We're getting into MIS, which was an area that we were softer in before if you look back 3, 4 years ago. And so it's great to see the organic growth. Organic growth obviously is much more financially attractive than going out and spending a lot of money on companies. Over time, I do want this to become a bigger division, and I think it's -- you'll likely see a combination of both organic and acquisitions. But it's always better to have a strong organic business. And so I do not feel at all that I need to do an acquisition because of the strength and what we've started to build internally. But that's something that will likely happen over time."
94614,314976743,923770,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Analysts","Okay. And then, just on Extremities. Again, your Foot & Ankle growth, I think you said it was 20%. That's -- this business continues to truck along. Any comments on kind of the end markets versus potential share gains that we might have seen in the quarte",60,"Okay. And then, just on Extremities. Again, your Foot & Ankle growth, I think you said it was 20%. That's -- this business continues to truck along. Any comments on kind of the end markets versus potential share gains that we might have seen in the quarter? And specifically, are you seeing any disruption from recent M&A in the field?"
94614,314976743,923770,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","Yes, I would just say these are markets that continue to be very healthy, growing double digits. We do believe we're taking market share. We've got a dedicated sales focus there, some great products. I wouldn't call out any disruption that we're seeing in",65,"Yes, I would just say these are markets that continue to be very healthy, growing double digits. We do believe we're taking market share. We've got a dedicated sales focus there, some great products. I wouldn't call out any disruption that we're seeing in the marketplace. I think it's just continued to be really good execution in a market that has favorable underlying growth dynamics."
94614,314976743,923770,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Operator","And our next question comes from Josh Jennings from Cowen and Company.",12,"And our next question comes from Josh Jennings from Cowen and Company."
94614,314976743,923770,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Analysts","Kevin, I just was hoping you could touch on pricing. I think recently you had some public commentary about some potential moderation in the pricing headwinds that you've historically been experiencing. Any comments in terms of assumptions for pricing head",51,"Kevin, I just was hoping you could touch on pricing. I think recently you had some public commentary about some potential moderation in the pricing headwinds that you've historically been experiencing. Any comments in terms of assumptions for pricing headwinds within guidance? And then, any outlook for pricing, particularly in Orthopaedics?"
94614,314976743,923770,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","Yes. So you saw for the full year, our price did moderate somewhat from the prior year. And there was a lot of concern as we exited -- if you remember, as we were exiting '14, there a was a lot of concern that pricing was going to accelerate in '15. In fa",128,"Yes. So you saw for the full year, our price did moderate somewhat from the prior year. And there was a lot of concern as we exited -- if you remember, as we were exiting '14, there a was a lot of concern that pricing was going to accelerate in '15. In fact, it hasn't. It actually moderated a little bit. But it's modest, right? The moderation is very modest. And in our guidance, we suggest that the price will be between 1.5% to 2%. And so I would say it's a stable market. We continue to have price pressure. It's not going away. But we don't see any accelerators to that price pressure. And that's why we feel it's going to be pretty stable going into 2016."
94614,314976743,923770,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Analysts","Great. And just one follow-up on MAKO. We haven't heard much over the last year on the uni knee product. Any commentary there in terms of how it's contributing to growth in your Knee franchise and just overall growth for that product line?",43,"Great. And just one follow-up on MAKO. We haven't heard much over the last year on the uni knee product. Any commentary there in terms of how it's contributing to growth in your Knee franchise and just overall growth for that product line?"
94614,314976743,923770,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","Thanks. The -- obviously, the uni market, when it's put in the context of overall Stryker, it's a very small part of the overall business. And I would say it's a steady contributor, but there's nothing remarkable to say about it. It's a good business, but",55,"Thanks. The -- obviously, the uni market, when it's put in the context of overall Stryker, it's a very small part of the overall business. And I would say it's a steady contributor, but there's nothing remarkable to say about it. It's a good business, but it's a very small part of our overall Knee."
94614,314976743,923770,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","Were you talking, Josh, specifically about -- for MAKO?",9,"Were you talking, Josh, specifically about -- for MAKO?"
94614,314976743,923770,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","He got cut off.",4,"He got cut off."
94614,314976743,923770,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","So for MAKO, it's a first indication, and they're continuing to drive uptake for that as well as with Hip. And as we get additional indication, it does help drive adoption as some customers were not interested in just the uni. But as we get more indicatio",58,"So for MAKO, it's a first indication, and they're continuing to drive uptake for that as well as with Hip. And as we get additional indication, it does help drive adoption as some customers were not interested in just the uni. But as we get more indications, they're starting to adopt for that as well as the others."
94614,314976743,923770,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","Yes, but I'm just trying to interpret -- sorry that Josh got cut off -- just interpret that the growth to 9% in the U.S., that spike in growth. It really wasn't driven by MAKO unis. That's driven more by the broader Knee business.",44,"Yes, but I'm just trying to interpret -- sorry that Josh got cut off -- just interpret that the growth to 9% in the U.S., that spike in growth. It really wasn't driven by MAKO unis. That's driven more by the broader Knee business."
94614,314976743,923770,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Operator","The next question comes from Matthew O'Brien from Piper Jaffray.",11,"The next question comes from Matthew O'Brien from Piper Jaffray."
94614,314976743,923770,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Analysts","Just quickly on MAKO again. The number of systems you placed internationally accelerated here in Q4. Was there anything that you could call out as far maybe a little bit of a tipping point in terms of interest in the robotics system OUS, and maybe that co",56,"Just quickly on MAKO again. The number of systems you placed internationally accelerated here in Q4. Was there anything that you could call out as far maybe a little bit of a tipping point in terms of interest in the robotics system OUS, and maybe that could be an even more meaningful contributor here in 2016?"
94614,314976743,923770,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","No. Still, the lion's share of the focus and the revenue is coming from the U.S. We did place more systems outside the U.S., and we'll continue to focus on those opportunities, particularly places like Australia and certain other markets. But the bulk of",60,"No. Still, the lion's share of the focus and the revenue is coming from the U.S. We did place more systems outside the U.S., and we'll continue to focus on those opportunities, particularly places like Australia and certain other markets. But the bulk of the revenue stream has been and will likely continue at least near term to be U.S."
94614,314976743,923770,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","Yes. It tends to be a country-by-country thing, so Australia had a terrific year in robot sales. I think, within Europe, we're going to see certain countries are going to adopt MAKO much more quickly than other countries. So I think each year, you'll sort",94,"Yes. It tends to be a country-by-country thing, so Australia had a terrific year in robot sales. I think, within Europe, we're going to see certain countries are going to adopt MAKO much more quickly than other countries. So I think each year, you'll sort of -- you'll see the international volumes starting to increase, but it might be Italy this year, it might be the U.K. next year over the next few years. But again, to Katherine's point, the market that's the most important by far is going to be the U.S. market."
94614,314976743,923770,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Analysts","Okay, and then just to follow up a little bit on Richard's question, a little more broadly on Trauma and Extremities. I think we saw some acceleration here in Q4 beyond what we've seen over the last several quarters. And I'm just -- I'm curious if that ac",77,"Okay, and then just to follow up a little bit on Richard's question, a little more broadly on Trauma and Extremities. I think we saw some acceleration here in Q4 beyond what we've seen over the last several quarters. And I'm just -- I'm curious if that acceleration was specific to any couple of products or geographies around particularly the U.S. and if that level of growth is something that you think is sustainable here in 2016."
94614,314976743,923770,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","Well, I think you've seen our Trauma business in the U.S. It's been 4 years of really terrific growth. So that to me is sustainable when you're growing at that level. So we're very, very pleased. We've rounded out our portfolio completely. And so that ena",198,"Well, I think you've seen our Trauma business in the U.S. It's been 4 years of really terrific growth. So that to me is sustainable when you're growing at that level. So we're very, very pleased. We've rounded out our portfolio completely. And so that enables us to do complete hospital conversions, something that was impossible at Stryker 5, 6 years ago. Europe really picked up quickly. So as you move to a transatlantic model, I was very encouraged by our Trauma success in Europe. We have not been nearly as successful in Europe as we have been in the United States. And we do now have the same products which are all approved. So I think -- I expect more commercial success in Europe as well as Japan. Now some of those products take a little longer to get approved in Japan. So I think that once those products start to arrive we'll start to see more of an uptake in Japan as well. But I would say we're in a very good position in that business. We have a very, very strong leadership team. And we expect to continue to have success in Trauma and Extremities."
94614,314976743,923770,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Operator","And our next question comes from Jeff Johnson from Robert Baird.",11,"And our next question comes from Jeff Johnson from Robert Baird."
94614,314976743,923770,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Analysts","Bill, I just want to say best wishes. I was looking back this afternoon. I think it's been 14 years that you and I have overlapped. So thanks for all the conversations, all the help over that time. And so Kevin, just wanted to ask one question, one follow",123,"Bill, I just want to say best wishes. I was looking back this afternoon. I think it's been 14 years that you and I have overlapped. So thanks for all the conversations, all the help over that time. And so Kevin, just wanted to ask one question, one follow-up question here, just on the phasing or maybe gating of some of the med tech tax savings. Is there going to be any timing differential between when the med tech tax savings start coming in and influencing the cost of goods line versus when you start reinvesting those dollars back into SG&A and R&D? Should those match up pretty evenly out the P&L or just how to think about the gating throughout this year?"
94614,314976743,923770,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","I think that, that's fair to say, Jeff, and thanks a lot for your comments. I think that on the cost of goods sold category, obviously that will start right off in the beginning of the year. Our investments, as we are targeting right now at moving again t",65,"I think that, that's fair to say, Jeff, and thanks a lot for your comments. I think that on the cost of goods sold category, obviously that will start right off in the beginning of the year. Our investments, as we are targeting right now at moving again through 2016, we would also expect to be doing that reinvestment pretty much consistently throughout the year."
94614,314976743,923770,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","Yes. Sorry, it's going to be clean from the beginning of the year -- from the beginning of this year to 2017. It starts immediately. There's no lag effect, which I think had happened prior with a different company. So for us, it's clean. You'll see it cle",52,"Yes. Sorry, it's going to be clean from the beginning of the year -- from the beginning of this year to 2017. It starts immediately. There's no lag effect, which I think had happened prior with a different company. So for us, it's clean. You'll see it cleanly in the 2 years."
94614,314976743,923770,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Operator","And our next question comes from Steve Lichtman from Oppenheimer.",10,"And our next question comes from Steve Lichtman from Oppenheimer."
94614,314976743,923770,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Analysts","I just have one follow-up on ERP. You talked about the investment on the capital side. Are there any P&L impacts that we should expect over the next couple of years as you start to implement ERP? And when do you anticipate the system being fully in place?",49,"I just have one follow-up on ERP. You talked about the investment on the capital side. Are there any P&L impacts that we should expect over the next couple of years as you start to implement ERP? And when do you anticipate the system being fully in place?"
94614,314976743,923770,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","So a couple of different questions again there. So on the ERP side of the equation, from an investment perspective, we won't see the first implementations really for about another 1.5 years or so. And then those will be rolled out over the next few years",190,"So a couple of different questions again there. So on the ERP side of the equation, from an investment perspective, we won't see the first implementations really for about another 1.5 years or so. And then those will be rolled out over the next few years after that. As far as the cost side of the equation goes, we would not expect that to be a big blip once we get to kind of the stabilized level that we've got kind of this -- in 2016 year. But moving forward, in fact, if anything, as those systems are implemented, we would expect some of the benefits. Plus with the CTG [ph] initiatives that we've got kicked off, those will continue to roll in at different points throughout different years. We do have multi hundreds of millions of dollars targeted for that. Keep in mind as well that we have price downs in the $150 million to $200 million range that we need to be working to offset. And then, as far as the impacts associated with the investment, again, that should be pretty consistent as we're moving forward beyond 2016."
94614,314976743,923770,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","Yes. Just to add to that, I would say, we do have some expense that will be hitting our P&L, but we're absorbing that within the guidance that we have provided to you.",33,"Yes. Just to add to that, I would say, we do have some expense that will be hitting our P&L, but we're absorbing that within the guidance that we have provided to you."
94614,314976743,923770,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Operator","And our next question comes from Kaila Krum from William Blair.",11,"And our next question comes from Kaila Krum from William Blair."
94614,314976743,923770,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Analysts","Just a couple of quick ones for me. The first, I mean, clearly, you all are still emphasizing M&A as the key priority here. And I'm just curious if you can touch on that how or if those conversations have changed tone just with some of the valuation pullb",56,"Just a couple of quick ones for me. The first, I mean, clearly, you all are still emphasizing M&A as the key priority here. And I'm just curious if you can touch on that how or if those conversations have changed tone just with some of the valuation pullbacks specifically that we've seen in recent weeks?"
94614,314976743,923770,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","Yes. I would say that, that short a time period doesn't have an impact. And as Kevin articulated, we continue to be focused on M&A externally. There's going to be periods where it looks more or less active depending on timing. Internally, the teams have n",64,"Yes. I would say that, that short a time period doesn't have an impact. And as Kevin articulated, we continue to be focused on M&A externally. There's going to be periods where it looks more or less active depending on timing. Internally, the teams have never been busier, and there's no change in the strategy. And the recent market disruption is what it is."
94614,314976743,923770,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Analysts","Okay. And then, I guess, just a follow-up on an earlier question just around whether or not there is this potential for longer-term growth rates to accelerate. And then just pairing that with your earlier comments about MAKO and the likelihood that 2016 i",70,"Okay. And then, I guess, just a follow-up on an earlier question just around whether or not there is this potential for longer-term growth rates to accelerate. And then just pairing that with your earlier comments about MAKO and the likelihood that 2016 is more of a set-up year for 2017, is it fair to assume that overall top line growth could modestly accelerate heading into 2017 from 2016 levels?"
94614,314976743,923770,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","It's always our goal to grow sales at the high end of med tech. And certainly, we've got some nice opportunities between ischemic and MAKO, but they're going to be in early stages next year. So probably premature to start the push towards higher growth ra",71,"It's always our goal to grow sales at the high end of med tech. And certainly, we've got some nice opportunities between ischemic and MAKO, but they're going to be in early stages next year. So probably premature to start the push towards higher growth rates than this year, but we feel really good with what we've set up for this year and hopefully can build on that in '17."
94614,314976743,923770,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","Yes. I think we're going to learn a lot. So I think towards the end of this year we'll be able to share more of the 2 additional platforms, both MAKO and ischemic stroke. Those are the ones that I think can provide, let's call them change of trajectories",107,"Yes. I think we're going to learn a lot. So I think towards the end of this year we'll be able to share more of the 2 additional platforms, both MAKO and ischemic stroke. Those are the ones that I think can provide, let's call them change of trajectories in growth for the company. Now whether that happens in '17 or '18 or '19, it's -- they are new platforms so it's not easy to predict. But I think we'll learn a lot over the course of this year and certainly be able to share more with you when we provide our guidance in the following year."
94614,314976743,923770,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Operator","We have no further questions at this time. I'll now turn the conference call over to Mr. Kevin Lobo for any closing remarks.",23,"We have no further questions at this time. I'll now turn the conference call over to Mr. Kevin Lobo for any closing remarks."
94614,314976743,923770,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Executives","So thank you all for joining our call. Our conference call for the first quarter 2016 results will be held on April 20. Thank you.",25,"So thank you all for joining our call. Our conference call for the first quarter 2016 results will be held on April 20. Thank you."
94614,314976743,923770,"Stryker Corporation, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Stryker Corporation","Operator","Thank you, ladies and gentlemen. This concludes today's conference. Thank you for participating, and you may now disconnect.",18,"Thank you, ladies and gentlemen. This concludes today's conference. Thank you for participating, and you may now disconnect."
94614,328661858,960171,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Operator","Welcome to the First Quarter 2016 Stryker Earnings Call. My name is Liz, and I will be your operator for today's call. [Operator Instructions]This conference call is being recorded for replay purposes. Before we begin, I would like to remind you that",134,"Welcome to the First Quarter 2016 Stryker Earnings Call. My name is Liz, and I will be your operator for today's call. [Operator Instructions]
This conference call is being recorded for replay purposes. 
Before we begin, I would like to remind you that the discussions during this conference call will include forward-looking statements. Factors that could cause actual results to differ materially are discussed in the company's most recent filings with the SEC. 
Also, the discussions will include certain non-GAAP financial measures. Reconciliations to the most directly comparable GAAP financial measures can be found in today's press release that is an exhibit to Stryker's current report on Form 8-K filed today with the SEC. 
I will now turn the call over to Mr. Kevin Lobo, Chairman and Chief Executive Officer. You may proceed, sir."
94614,328661858,960171,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Executives","Welcome to Stryker's First Quarter Earnings Call. Joining me today are Glenn Boehnlein, who assumed the role of CFO, effective April 1; and Katherine Owen, the VP of Strategy and Investor Relations. For today's call, I will provide opening comments, fol",375,"Welcome to Stryker's First Quarter Earnings Call. Joining me today are Glenn Boehnlein, who assumed the role of CFO, effective April 1; and Katherine Owen, the VP of Strategy and Investor Relations. 
For today's call, I will provide opening comments, followed by an M&A update from Katherine. Glenn will then provide additional details regarding our quarterly results before we open the call to Q&A.
We are pleased with our start to the year, as Q1 organic sales growth of 6.1% came in above our expectations, with strong performances across all 3 segments: Orthopaedics, MedSurg and Neurotechnology and Spine. The performance was led by continued new product introductions and strong sales and marketing execution. 
Geographically, Q1 was powered by ongoing momentum in the U.S., with sales growth of 8.9%. As expected, growth was challenged outside the U.S., given the tough year-over-year comparisons in emerging markets, where growth started to slow in the second quarter of last year. Challenges still exist in emerging markets, although the year-over-year impact should ease in the back half of the year.
We continued to have good performance in Europe, Japan and Australia. Our strategy of business unit specialization with dedicated sales forces, marketing and R&D continued to be a differentiating factor in the sustainability of our above-market growth.
Consistent R&D investment has generated strong internal product pipelines across the company, and we continue to augment them with acquisitions. We are thrilled to welcome Sage, Physio-Control and Synergistics to Stryker and believe that the addition of these companies will further strengthen our businesses. 
Looking at the P&L, we are building on 2015's success and delivered solid adjusted earnings growth of 11.7%, despite modest foreign currency headwinds.
This improvement stemmed from the strong top line and year-over-year gross margin expansion. Importantly, we continued to invest heavily in R&D in both absolute dollars and as a percent of sales. Our cost transformation for growth efforts are in the early stages of and are multi-year in nature, and we are starting to realize benefits. 
Overall, we are confident in our stated goal of achieving sales at the high end of medtech, with ongoing earnings leverage, and believe our Q1 results position us well for 2016.
I will now turn the call over to Katherine."
94614,328661858,960171,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Executives","Thanks, Kevin. My comments today will focus on providing an update on MAKO, along with the 2 larger M&A deals we recently closed on: Sage and Physio-Control. With respect to MAKO, we sold 7 robots during the quarter globally, which is in line with the s",484,"Thanks, Kevin. My comments today will focus on providing an update on MAKO, along with the 2 larger M&A deals we recently closed on: Sage and Physio-Control. 
With respect to MAKO, we sold 7 robots during the quarter globally, which is in line with the same period a year ago. As many of you know, capital sales tend to be the strongest in the fourth quarter and also can fluctuate from quarter-to-quarter. We are highly encouraged by order trends, which reinforces the growing interest in demand for the MAKO robotic system, fueled by the expanded indication and planned launch of the Total Knee system, where we continue to target full commercial rollout in 2017. There is no change to our launch plan for the Total Knee, which will focus throughout 2016 on working with key opinion leaders to optimize the training protocol and gather observational data that will help to frame the anticipated benefits, all of which will ensure a strong podium presence at key orthopaedic meetings and so we move throughout 2017. 
In Q1, we were also encouraged by the robust procedure growth in both partial knees and hips using MAKO.
Turning to the recent M&A activity. In early April, we closed on both Sage and Physio-Control, which will be integrated into our Medical division. Starting with Sage, our focus will be to ensure the continuation of strong double-digit top line growth that the company has had a long history of achieving. With their market-leading product portfolio focused on clinically supported innovation, product ease-of-use and strong sales support, we believe Sage can continue to drive both market expansion and share gains in the prevention of hospital acquired conditions. Given our existing global footprint, which includes strong and broad sales and marketing support, we believe that, over time, Stryker and can drive adoption of the Sage portfolio outside the U.S., where revenue today is limited as the company had historically focused its investments in the U.S. market. 
Regarding Physio-Control, we believe we have significant opportunities over time to drive both sales and earnings synergies, given our combined presence in the prehospital setting. In the near term, both businesses will operate largely independently, with a focus on their respective 2016 targets and planned key new product launches.
Importantly, for both Sage and Physio-Control, we have identified and put in place a highly experienced integration team, which, given our BD history, should help ensure a smooth integration. 
As we move through the first 12 months postclosing of both Sage and Physio-Control, we will provide you with the pro forma quarterly growth rates for each to help provide visibility regarding our execution and of their top line contribution. There is no change to our previously announced expected accretion from both these transactions to adjusted EPS in 2016 and 2017 of $0.07 and $0.15 and $0.18, respectively. 
With that, I will now turn the call over to Glenn."
94614,328661858,960171,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Executives","Thanks, Katherine. My comments on today's will focus on the financial results and key drivers of our first quarter performance. Our detailed financial results have been provided in various schedules included in today's press release. As to our overall p",1150,"Thanks, Katherine. My comments on today's will focus on the financial results and key drivers of our first quarter performance. 
Our detailed financial results have been provided in various schedules included in today's press release. As to our overall performance, our constant currency organic sales growth of 6.1% exceeded the high end of our full year expectations and came in better than our expectations at the start of the quarter. The growth, based on the same number of selling days, reflected strong U.S. volume and mix of 10.2%, marginally offset pricing, which was slightly negative at 1.3%.
Adjusted EPS of $1.24 increased 11.7% from 2015, primarily driven by our strong top line growth and favorable margin performance. Foreign exchange unfavorably impacted EPS by $0.02 per share, roughly in line with our guidance.
Looking at our segment highlights. Orthopaedics constant currency growth was 4.6%, which was led by U.S. Orthopaedics growth of 7.9%, reflecting continued, strong sales in our Trauma and Extremity business, which grew 11%; and a 9% increase in Knees, reflecting continued momentum from our last quarter and the successful of our Triathlon products, driven by our titanium revision [indiscernible], our cementless knee product as well as new customer adoption of our MAKO uni platform.
We are now seeing an acceleration of our revision in planned sales, where previously our market share lagged our overall Total Knee share. Partially offsetting the strong U is orthopaedic performance was the continued challenging markets in China and Brazil, which contributed to the negative 1.4% constant currency decline in international. 
Overall, our first quarter results continue to reflect strong momentum across our Orthopaedics portfolio. 
Our MedSurg segment, with constant currency growth of 4.6%, also demonstrated strong momentum with U.S. growth of 7.6%. Instruments had solid U.S. growth of 10.2%, with good performance in their waste management products. 
Endoscopy's new 1588 camera, which features enhanced visualization that broadens the applicable surge applications, was a primary driver for the division's solid performance and will continue to be a growth engine in 2016. 
Lastly, Medical's growth, which was up against a tough year-over-year comparable, benefited from strong demand for its market-leading structure and ambulance Scott [ph] products, which underscore the strength of its portfolio and the overall health and stability of hospital capital budgets that we're seeing in the market. 
As with Orthopaedics, MedSurg also experienced challenges in emerging markets, primarily China. We expect this to continue as we work through our distributors to drive demand and reduce the buildup of their inventories, recognizing comparisons will also ease as we move through 2016.
All in all, our MedSurg businesses saw healthy order growth in the first quarter and should be well positioned to continue their momentum. 
Turning to Neurotechnology and Spine. The impressive year-end momentum achieved by this group continued in the first quarter with 13.1% constant currency growth. Neurotechnology's 21% growth was highlighted by the developing market for device-based treatment of ischemic stroke. While there's still considerable market develop and require, we are highly encouraged by the potential for this segment and our 3 [indiscernible] retriever technology. As one of 2 majors retrievers on the market, combined with compelling clinical data underscoring the efficacy of these devices, such as the MR CLEAN study, Stryker's well positioned for growth in Neurovascular. 
We also continue to see excellent performance in our Neuro Powered Instruments business, led by strong growth in their signature drill products released last year. 
We also are encouraged by the solid showing of Spine, up 5.8% in the U.S., as new product launches, included and limiting launch of our 3 D-printed interbody device, are clearly having an impact. Neurotechnology and Spine continue to benefit from a new product pipeline resulting from robust R&D investment over the past few years. 
I will now focus on our first quarter operating highlights, starting with gross margin, which, on an adjusted basis, increased 240 basis points to 68%. Of this improvement, roughly 1/4 relates to the 2-year suspension of the Medical Device Tax, while the remainder reflects a favorable mix and favorable foreign exchange, partly offset by negative pricing. 
As for operating expenses, we continue to focus on 
internal innovation with R&D at 6.4% of sales, which is in line with our overall target spend. On an adjusted basis, SG&A increased to 37.4% of sales versus 35.9% in the prior period, which was driven by increased selling activity, anticipated spending related to our new ERP deployment efforts and reinvestment in the Medical Device Tax. 
Looking ahead, we expect SG&A on a full year basis to be comparable to 2015. Overall, our operating margin increased 90 basis points, reflecting solid top line growth and favorable mix and gross margins, offset slightly by higher SG&A for the quarter.
Lastly, some financial highlights on the Other Income and Expense. Other expenses increased due to higher net interest expense related to increased borrowings during the quarter, primarily to fund our recently completed Sage and Physio-Control a acquisitions. Net interest expense will continue to be higher than Q1, as our borrowing occurred at the end of Q1. Our first quarter adjusted effective tax rate of 17.4% reflects the benefits of our global tax structure and the permanent renewal of certain tax extenders, which was included in our guidance.
Moving on to the balance sheet. We continue to maintain a strong balance sheet with $7.5 billion of cash and marketable securities, of which approximately 72% [ph] was held in the U.S. This balance reflects $3.5 billion of proceeds related to our previously mentioned that offerings, which is included in the $7.5 billion of debt on the balance sheet at the end of the quarter. Subsequent to the end of the quarter, $4.1 billion of cash was used to fund the Sage and Physio-Control acquisitions. 
Turning to cash flow. Our cash flow from operations for 2015 was $2 billion compared to $4 billion last year, as we made $0.1 billion of payments associated with our Rejuvenate and ABG II recall. 
Approximately 50% of the funding for the Rejuvenate liability is being sourced from OUS cash. 
Finally, as we have previously announced, we suspended our share repurchases for the remainder of the year. 
With that, I will move on to our guidance. Based on our first quarter performance, we now expect our full year organic sales growth to be in the range of 5.5% to 6.5% for 2016. If foreign currency exchange rates hold near current levels, we anticipate net sales will be negatively impacted by approximately 1% for 2016. 
We also expect continued unfavorable price reductions in the range of 1.5% to 2%, consistent with the pricing environment we experienced in 2015. 
Finally, our guidance for adjusted net earnings per diluted share in 2016 now stands in the range of $5.65 to $5.80 for the full year and $1.33 to $1.38 for the second quarter. 
And now I will open up the call for Q&A."
94614,328661858,960171,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Operator","[Operator Instructions] Your First Call comes from the line of David Lewis with Morgan Stanley.",15,"[Operator Instructions] Your First Call comes from the line of David Lewis with Morgan Stanley."
94614,328661858,960171,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Analysts","So a couple of questions. Kevin, just for a second, just talk about the guidance. Obviously, the quarter was strong and it's a long early in our policy to raise your organic sales estimates of you see some conviction and back half. As a bit above the back",97,"So a couple of questions. Kevin, just for a second, just talk about the guidance. Obviously, the quarter was strong and it's a long early in our policy to raise your organic sales estimates of you see some conviction and back half. As a bit above the back half of the year. Obviously, Medical comparable significant get a easier emerging markets, pressure should also ease. Is there anything else that you see in the business broadly across Stryker that's giving you the confidence in the race organic sales guidance heading in the back half of the year?"
94614,328661858,960171,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Executives","David, thank you. I would say that I feel very good about the strength of our entire business portfolio. So if you look at MedSurg and look at Neurotechnology and even Orthopaedics, I really feel that we have balanced strength across our portfolio. And th",125,"David, thank you. I would say that I feel very good about the strength of our entire business portfolio. So if you look at MedSurg and look at Neurotechnology and even Orthopaedics, I really feel that we have balanced strength across our portfolio. And that balance, strength is what gives us confidence, even after the first quarter, to raise our organic sales guidance. So we had indicated previously that the first quarter was -- would likely be closer to the 5% range, and we exceeded that. And obviously, the emerging market comps will also ease as we get into the back half. So we're feeling very good about the position as we exit the first quarter and obviously confident about raising our organic sales guidance."
94614,328661858,960171,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Analysts","Okay. And I just have 2 quick follow-ups, maybe for Katherine. One, I know, obviously, Neuro number was very strong in the quarter, a lot of focus on some a can you give us a sense, Katherine, where you stand on pipeline opportunities within Neuro specifi",101,"Okay. And I just have 2 quick follow-ups, maybe for Katherine. One, I know, obviously, Neuro number was very strong in the quarter, a lot of focus on some a can you give us a sense, Katherine, where you stand on pipeline opportunities within Neuro specifically, you mentioned Neuro? And secondary, is there any reason to believe MAKO capital sales get harder into the full Knee launch that would be sort of a delayed effect until people see sort of the full evidence and software in the back half of the year? Or based on order patterns, you remain pretty comfortable?"
94614,328661858,960171,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Executives","Yes. So within Neurotech, the bulk of the revenue still from the hemorrhagic side, and we continue to launch next generation of the coil, different sizes, different shapes and continue to launch into additional geographies. And we are the market leader in",240,"Yes. So within Neurotech, the bulk of the revenue still from the hemorrhagic side, and we continue to launch next generation of the coil, different sizes, different shapes and continue to launch into additional geographies. And we are the market leader in that segment of the market. We do have a slow diverter. It's on the market outside the U.S. It's in clinical in the U.S, probably still a year or 2 before a U.S. market launch of that product, but that will clearly be an important product launch, given that these captured a portion of the coil market, where they're applicable. And then, continuing to invest in the ischemic stroke, although Kennedy, what can happen over the next few years in the ischemic segment has more to do with market development, as Glenn mentioned, in his comments. On MAKO, nothing that I would bring out to suggest of placements will get harder. If anything, the economic and value proposition associated with the robot as we move toward full commercial launch of the Total Knee indication only gets greater. So we expect to see continued strong demand. As we've talked about this year, it's really focused on training. So that's going to be to ensure an optimal rollout and to make sure the initial user experience is as positive as it can be. But we would assume continued momentum. And as I mentioned, we're really pleased with incoming order trends."
94614,328661858,960171,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Operator","You're next call comes from the line of Mike Weinstein with JPMorgan.",13,"You're next call comes from the line of Mike Weinstein with JPMorgan."
94614,328661858,960171,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Analysts","A couple quick questions. Stuart, 2 things that probably surprised in the quarter. One would have obviously been a gross margin, which was kind of well above expectations in recent trends. And I was hoping you could spend a minute on why that was. And the",96,"A couple quick questions. Stuart, 2 things that probably surprised in the quarter. One would have obviously been a gross margin, which was kind of well above expectations in recent trends. And I was hoping you could spend a minute on why that was. And then second is just the sustainability of the growth we're seeing in the Neurovascular business, showed no signs of slowing in the U.S. international this quarter. And other than same development trends from 2015 on the back of the data and the guidelines, anything else you could add would be helpful."
94614,328661858,960171,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Executives","Sure, Mike. I'll start off with Neurovascular, and then I'll turn it over to Glenn for the gross margin. So certainly, the ischemic is a new market. And obviously, our many strokes that haven't been treated prior. I kind of think about this a little bit l",189,"Sure, Mike. I'll start off with Neurovascular, and then I'll turn it over to Glenn for the gross margin. So certainly, the ischemic is a new market. And obviously, our many strokes that haven't been treated prior. I kind of think about this a little bit like the Foot & Ankle market, including a new market. And we created a market comps difficult to predict the pace of growth, but there's no doubt that the growth will be very significant. And that was clearly the biggest contributor to the strong performance in  Neurovascular. But equally pleased with the performance of our Neuro Powered Instruments, which are having fantastic growth very strong double-digit growth with our signature drills, which compete with one of the other major players, and we're taking significant market share with those products as well as our [indiscernible] product. So very, very strong performance both the Neurovascular as well as the Neuro Powered Instruments. And even our Craniomaxillofacial business, the third of our Neuro businesses, is enjoying double-digit growth. So across the Neuro portfolio, we're really performing very well. I'll turn it to Glenn for gross margin."
94614,328661858,960171,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Executives","Yes. I think if you look at our gross margin, we really benefited from a positive mix relative to U.S. and international and then even relative to newer products over some of our older products. If you look at the 1588 and the signature drills that were s",86,"Yes. I think if you look at our gross margin, we really benefited from a positive mix relative to U.S. and international and then even relative to newer products over some of our older products. If you look at the 1588 and the signature drills that were sold, sell it largely premiums. And then finally, we also continue to see sort of our solar products, knees, Trauma. Our ischemic stroke and coil products continue to sell fairly robustly, too, which helped lift the overall margin up."
94614,328661858,960171,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Executives","Price was also more moderate than we've seen in the past.",12,"Price was also more moderate than we've seen in the past."
94614,328661858,960171,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Analysts","Right. And Glenn, it also looked like your inventories were up a lot this quarter from the end of the year. Any expectation on those trending down? Anything what I'm asking is any of the uptick in gross margin here onetime? Or do you want to do a sustaina",49,"Right. And Glenn, it also looked like your inventories were up a lot this quarter from the end of the year. Any expectation on those trending down? Anything what I'm asking is any of the uptick in gross margin here onetime? Or do you want to do a sustainable?"
94614,328661858,960171,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Executives","No. I think the inventory's up. It's reflecting what we're planning for the rest of the year and making sure that we're able to satisfy customers. And as far as the gross margin goes, we expect that we'll continue to see this kind of trend throughout the",48,"No. I think the inventory's up. It's reflecting what we're planning for the rest of the year and making sure that we're able to satisfy customers. And as far as the gross margin goes, we expect that we'll continue to see this kind of trend throughout the year."
94614,328661858,960171,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Operator","You're next call comes from the line of Bob Hopkins with Bank of America.",15,"You're next call comes from the line of Bob Hopkins with Bank of America."
94614,328661858,960171,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Analysts","So the first question I want to ask is on the business outside the United States. Specifically, could you comment a little bit on the performance of your Knee business outside the United States, which was the one slightly weak spot within the ortho busine",110,"So the first question I want to ask is on the business outside the United States. Specifically, could you comment a little bit on the performance of your Knee business outside the United States, which was the one slightly weak spot within the ortho business? And then also, Kevin, wondering if you can comment on Europe broadly from a capital equivalent perspective because we've seen some other health care companies that sell capital equipment in the Europe talk about a tough environment. I was wondering if you could just kind of offer a broad comment on Europe from a capital equipment perspective and then also on the OUS Knee business."
94614,328661858,960171,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Executives","Sure, Bob. So on both businesses, I would tell you, we don't have significant businesses, as you probably know. In capital equipment in Europe, from a marketer is quite low. And even for Knees, if you look at last year, we had a pretty good comp. We had p",170,"Sure, Bob. So on both businesses, I would tell you, we don't have significant businesses, as you probably know. In capital equipment in Europe, from a marketer is quite low. And even for Knees, if you look at last year, we had a pretty good comp. We had plus 5% in knee. And quarter-to-quarter, given that we don't have very large businesses, for both capital equipment and and Europe and please, we do tend to see fluctuations. So what call the sort of the normal situation that we get quarter-to-quarter. And we're not really seeing a lot of difficulty with capital equipment. But that market for us in Europe, given that the bulk of our capital is not the large capital, we're not really seeing any new pressures, and we see the Europe market as being fairly healthy, at least for our businesses. Keep in mind though that we do have very low market shares and, we have significant room to grow within both Europe as well as OUS Knees."
94614,328661858,960171,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Analysts","And then on emerging markets, I think the last couple of quarters, the business has been, as you expected, sort of down about mid-single digits. Was that the same sort of growth rate that you saw this particular quarter? And can you just give us a little",69,"And then on emerging markets, I think the last couple of quarters, the business has been, as you expected, sort of down about mid-single digits. Was that the same sort of growth rate that you saw this particular quarter? And can you just give us a little more color on the math and rationale for the expectation that perhaps in the back half things get a little bit better?"
94614,328661858,960171,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Executives","So Bob, the emerging markets actually, the decrease was even more pronounced in the first quarter. So it was negative high signal digits in the first quarter. And that didn't surprise us because we had a very strong first quarter last year. Things really",138,"So Bob, the emerging markets actually, the decrease was even more pronounced in the first quarter. So it was negative high signal digits in the first quarter. And that didn't surprise us because we had a very strong first quarter last year. Things really started to tail off starting in the second quarter last year. So that really contributed to the softness in the international sales was the negative growth in emerging markets. And we do see that starting to taper. And obviously, the comps will ease as well. Inventory bleeds will eventually bleed out. And it's hard to predict exactly when, but as I stated, I think, on our last call, we expect around mid-year would be sort of the bottoming out period, and we should start to see improvement in the second half of the year.,"
94614,328661858,960171,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Operator","You're next call comes from the line of Rick Wise with Stifel.",13,"You're next call comes from the line of Rick Wise with Stifel."
94614,328661858,960171,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Analysts","Kevin, you've been very pointed in focusing us on the potential for more operating leverage in the P&L. We saw it this quarter with 90 basis points of positive leverage. When I look back the last couple of years, you've had a couple of quarters where we'v",96,"Kevin, you've been very pointed in focusing us on the potential for more operating leverage in the P&L. We saw it this quarter with 90 basis points of positive leverage. When I look back the last couple of years, you've had a couple of quarters where we've seen 100 basis points year-over-year improvement, but then it's not sustained. How do we think about this performance in the first quarter? Is it sustainable? Or is there more to come? And is that the right way to think about the 2016, '17 direction in terms of driving leverage?"
94614,328661858,960171,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Executives","Yes. Thanks, Rick. I would tell you if you look at our earnings guidance, it's pretty clear that we're driving leverage. So we've updated both our top line guidance. We've also updated our bottom line guidance. And this is the third time since the beginni",118,"Yes. Thanks, Rick. I would tell you if you look at our earnings guidance, it's pretty clear that we're driving leverage. So we've updated both our top line guidance. We've also updated our bottom line guidance. And this is the third time since the beginning of the year that we've raised our earnings guidance. And we won't be able to deliver that type of earnings guidance unless we drive operating leverage. So I'm not going to promise that it's going to be 90 basis points every single quarter, but we are committed to driving leverage at the operating income level. And you'll see that this year, and you'll see that when we provide guidance for you in 2017."
94614,328661858,960171,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Analysts","Great. And then just following up on the Knee performance, which was really excellent, clearly. I know there are multiple pieces here. Triathlon is doing well, revision. Maybe talk -- remind us of your current mix of revision versus Primary Knee, that mix",87,"Great. And then just following up on the Knee performance, which was really excellent, clearly. I know there are multiple pieces here. Triathlon is doing well, revision. Maybe talk -- remind us of your current mix of revision versus Primary Knee, that mix. How does it differ from sort of industry averages or aspirational norms? And is the story in Knees, at least, in part, that the new products you should us today you're going to drive us toward those norms? How should we think about it?"
94614,328661858,960171,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Executives","Sure. Yes, there are multiple factors that contribute to the Knee performance. We had a great fourth quarter at around 9% growth in the U.S. and another 9% in the first quarter. And certainly, revision's part of it. We've launched this new 3D printed cone",261,"Sure. Yes, there are multiple factors that contribute to the Knee performance. We had a great fourth quarter at around 9% growth in the U.S. and another 9% in the first quarter. And certainly, revision's part of it. We've launched this new 3D printed cones in the middle of last year. And cones are very important part of the procedure. They don't generate huge revenue by themselves, but you get the pull-through of the implant when you use the that our market share was roughly 6 share points below what it was in primary knees and revision. So we did sell in the revision market, but we didn't maintain the same level of market share that we do in our prior knees, roughly 6 points. So we're really excited about the gain, the gain, though 6 points back and then potential even well beyond that because we really believe we now have the best-in-class cones for revision procedures. We also have cementless knees, which is growing demand that's true, our launch of our 3D printed titanium baseplate come up baseplate portion of our Knee system. That's a second factor. Third factor is really great sales force execution, marketing programs and sales force execution. So it's hard for me to describe which of those 3 is the greater. I would say all 3 contributed to a very strong showing in knees, and it's the second quarter in a row. And I really believe we are building momentum and that we'll continue to perform well in Knees through the course of the year."
94614,328661858,960171,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Operator","You're next call comes from the line of David Roman with Goldman Sachs.",14,"You're next call comes from the line of David Roman with Goldman Sachs."
94614,328661858,960171,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Analysts","I was hoping you could talk about the Trauma business in the U.S. And Kevin, that's a franchise that you have mentioned in a couple of different public settings, that you weren't convinced you can is there outgrow the market, to the extent to which you ha",95,"I was hoping you could talk about the Trauma business in the U.S. And Kevin, that's a franchise that you have mentioned in a couple of different public settings, that you weren't convinced you can is there outgrow the market, to the extent to which you have over the past several quarters. But it does look like its continuing here, especially in the U.S. Can you maybe just help us some of the drivers that are supporting the sustainability of growth in the franchise and how we should evaluate that on a go-forward basis?"
94614,328661858,960171,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Executives","Yes, thanks. Look, I'm thrilled with the performance of our from a business, and it's been a multi-year success story. We put [indiscernible] plus 11 against the comp of plus 18 in the prior period. So we really are clicking on all cylinders within our Tr",220,"Yes, thanks. Look, I'm thrilled with the performance of our from a business, and it's been a multi-year success story. We put [indiscernible] plus 11 against the comp of plus 18 in the prior period. So we really are clicking on all cylinders within our Trauma portfolio. It took us years to build out; our portfolio, frankly, on the plating side of the business. We've always been strong in nails. And then of course, the lodging of our Foot & Ankle business was tremendous a few years ago. And that continues to grow above the overall from a growth rate. It was mid-teens growth again this quarter and very strong performance from the STAR Ankle as well. So I would say it's rounding out our portfolio and then terrific sales force execution. And again, it's been a 3-year story. My only caution on Trauma is really being able to maintain 15%, 16% growth quarter-over-quarter for years. It's just challenging, right at the low numbers at some point, you would think will start to catch up with you and just moderate the growth rate. But I have every confidence we will continue to grow above market, and we demonstrated that most likely in the first quarter. Of course, not everybody has reported yet, but we feel that's a very strong showing."
94614,328661858,960171,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Analysts","Okay, that's helpful. Maybe just a follow-up on the cash flow side for Glenn. If you look at kind of the operating cash flow and free cash flow you disclosed for the quarter, it looks like quite a bit of capital deployed toward operating items, and you're",97,"Okay, that's helpful. Maybe just a follow-up on the cash flow side for Glenn. If you look at kind of the operating cash flow and free cash flow you disclosed for the quarter, it looks like quite a bit of capital deployed toward operating items, and you're not converting all that much of your net income to free cash flow. Can we think about -- any onetime factors that may have negatively influenced Q1 that would reverse themselves to the balance of the year, whereby you can start growing cash flow in line with adjusted net income?"
94614,328661858,960171,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Executives","Yes. The biggest thing that we really -- we can't necessarily control the timing of is really sort of the Rejuvenate payments that we made related to the recall. So we made a payment of $0.1 billion in Q1 and don't expect that, based on what we've seen in",60,"Yes. The biggest thing that we really -- we can't necessarily control the timing of is really sort of the Rejuvenate payments that we made related to the recall. So we made a payment of $0.1 billion in Q1 and don't expect that, based on what we've seen in the past, that, that  could necessarily repeat itself throughout the year."
94614,328661858,960171,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Operator","You're next call comes from the line of Richard Newitter with clear and partners.",15,"You're next call comes from the line of Richard Newitter with clear and partners."
94614,328661858,960171,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Analysts","I was hoping to start off with Spine. Kevin, can you give us any color on -- you had 2 quarters now or 3 quarters, I think, of improving growth there above the market. I know you have some new product launches and a nice pipeline. And that's, I'm sure, he",88,"I was hoping to start off with Spine. Kevin, can you give us any color on -- you had 2 quarters now or 3 quarters, I think, of improving growth there above the market. I know you have some new product launches and a nice pipeline. And that's, I'm sure, helping. Can you break out for us at all, is the acceleration carried over into the first quarter volume-related, mix-related? Are you gaining share? Or is it just really you have new products and you're getting premier pricing?"
94614,328661858,960171,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Executives","Great question. I would say it's mostly volume. There is obviously some mix when you launch innovative products. We just had a limited launch of our 3D printed interbody device, and we're getting fantastic feedback on that. And that's obviously sold at a",174,"Great question. I would say it's mostly volume. There is obviously some mix when you launch innovative products. We just had a limited launch of our 3D printed interbody device, and we're getting fantastic feedback on that. And that's obviously sold at a sales price premium. So there is a mix component as well. But I would say it's mostly volume. And it's volume coming from the products of relaunched, most of which we launched last year. We launched a slew of new products, and those are being well adopted in the marketplace. I would say, price continue to be pressured. Spine is the most pressured pricing division within Stryker. And we believe that our price is roughly in line with the market. To the fact that we're growing above market now, I think, is 4 quarters in a row, is really driving by our renewed focus on launching products and having great sales force execution. So I believe we'll have another strong year, just like we did last year in Spine in 2016."
94614,328661858,960171,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Analysts","Okay. And then just one more on bundled payments. It's officially kicked off know, now that we're in April. Just wondering if you had any updates on ways or areas where you're working with or partnering with hospitals or how you're leveraging something th",87,"Okay. And then just one more on bundled payments. It's officially kicked off know, now that we're in April. Just wondering if you had any updates on ways or areas where you're working with or partnering with hospitals or how you're leveraging something that's unique about what Stryker can do in terms of partnering. Is there anything that you're doing more aggressively or hearing from customers that's resonating or allowing you to potentially differentiate and gain share with this new dynamic that's going out of the market?"
94614,328661858,960171,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Executives","Sure. So we have a division within Stryker called Stryker Performance Solution, which has consulted with over 100 hospitals the past 3 years to improve service line performance, including areas directly impacted by bundled payments. So through these engag",235,"Sure. So we have a division within Stryker called Stryker Performance Solution, which has consulted with over 100 hospitals the past 3 years to improve service line performance, including areas directly impacted by bundled payments. So through these engagements, we've developed deep insight into the profitability and opportunities of hospitals that within Orthopaedics. We were also granted conveners status by CMS last year as part of the bundled payments DTCI a program. And we are actively risk --- taking risk with 5 institutions across multiple hospitals on the payment bundling, managing over $55 million in episode spend. With CGR, third-parties like us are not allowed to operate as a convener anymore with that Medicare program. But our Stryker Performance Solution is still providing consulting services to hospitals to help them address the challenges at managing the bundle. So we have a lot of experience. We're continuing to help and consult with our customers. And then what I'd tell you is that the initial focus is really much more on the postacute care, that's where most the majority of the cost of the procedure is and the biggest opportunity in the short term addressing postacute care. But having this division, which is headquartered in Chicago, has been a key asset for us. We have a lot of insights into the economics of the Orthopaedic service line and how to help our customers address this new world."
94614,328661858,960171,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Operator","You're next call comes from the line of Matt Taylor with Barclays.",13,"You're next call comes from the line of Matt Taylor with Barclays."
94614,328661858,960171,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Analysts","I was wondering, the last couple of quarters, you actually had better pricing or less declines. Is there any change in the market where you recall a trend, whether it's consolidation or new products broadly that have helped on price?",40,"I was wondering, the last couple of quarters, you actually had better pricing or less declines. Is there any change in the market where you recall a trend, whether it's consolidation or new products broadly that have helped on price?"
94614,328661858,960171,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Executives","Yes. I would say, obviously, pricing is still negative. It's modestly less negative coming in at 1 3 [ph]. But we're still within very close to the 1 5 [ph] to 2 range. So we wouldn't call out anything significant to that is indicative of a change in the",99,"Yes. I would say, obviously, pricing is still negative. It's modestly less negative coming in at 1 3 [ph]. But we're still within very close to the 1 5 [ph] to 2 range. So we wouldn't call out anything significant to that is indicative of a change in the overall pricing dynamics. Typically, consolidation helps, but again, it's still negative. We've seen it vary quarter-to-quarter. Sometimes it's trended above. Fortunately, more recently it's trending in the lower end. I would say the outlook seems very stable and really no new dynamics that we say putting further pressure on pricing."
94614,328661858,960171,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Analysts","The Other people talk about with CCJR, more procedures moving to out-patient or just getting people out of the hospital quicker or moving to lower activity setting. So I guess, you mentioned your consulting division. But how else are you positioning yours",62,"The Other people talk about with CCJR, more procedures moving to out-patient or just getting people out of the hospital quicker or moving to lower activity setting. So I guess, you mentioned your consulting division. But how else are you positioning yourself that is our product portfolio positioned to kind of capture that trend or beat competitors in that kind of vector?"
94614,328661858,960171,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Executives","No. I really think the way we're positioned to help our customers is going to be through some of the insights that we've had, having this division now for a number of years within Stryker and understanding the economics and to focus on postacute care, giv",98,"No. I really think the way we're positioned to help our customers is going to be through some of the insights that we've had, having this division now for a number of years within Stryker and understanding the economics and to focus on postacute care, given that eats up the bulk of the costs when you're looking at an episode of care. And so we're able to work with them in that regard. But I wouldn't say there is a unique product offering that facilitates or is advantageous in the postacute setting, if I'm understanding the question, correctly."
94614,328661858,960171,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Operator","You're next call comes from the line of Matthew O'Brien with Piper Jaffray.",14,"You're next call comes from the line of Matthew O'Brien with Piper Jaffray."
94614,328661858,960171,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Analysts","Just a follow-up a little bit on Matt's question CJR. I'm curious if there's been any kind of either disruption from that program going to place earlier this month, be it with MAKO or potentially here in Q2, maybe seeing some a little less volume as a res",81,"Just a follow-up a little bit on Matt's question CJR. I'm curious if there's been any kind of either disruption from that program going to place earlier this month, be it with MAKO or potentially here in Q2, maybe seeing some a little less volume as a result. Or maybe some hospitals as they were preparing for started to do more cases in Q1 and there was a benefit specifically in Q1 in anticipation of that program going into play."
94614,328661858,960171,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Executives","No, I wouldn't ascribe any of the change in Q1 to the CJR. Keep in mind that CJR is that impacting I a large portion of the payment -- of the procedures, at least in the short term. It doesn't include Medicare Advantage. It doesn't include Medicaid. it do",146,"No, I wouldn't ascribe any of the change in Q1 to the CJR. Keep in mind that CJR is that impacting I a large portion of the payment -- of the procedures, at least in the short term. It doesn't include Medicare Advantage. It doesn't include Medicaid. it doesn't include commercial payers. It doesn't include the hospitals that were already signed up for the BPCI program. So it's obviously certain NSAs that are required to participate, but it's very small, and there aren't any penalties in the short term. So I really -- I wouldn't get overly concerned about this. It's not a new thing. Bundled payments have been around for a while. They're not brand new. It's now mandatory in certain MSAs, but I don't really see that as a catalyst to changing behavior in any meaningful way, at least not in the short term."
94614,328661858,960171,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Analysts","Okay. And just a follow-up on that, Kevin. Was there any slowdown, especially on the MAKO system side? I think down year-over-year just in anticipation of CJR hospitals are to figure out how that program is going to play? Maybe some of those facilities de",50,"Okay. And just a follow-up on that, Kevin. Was there any slowdown, especially on the MAKO system side? I think down year-over-year just in anticipation of CJR hospitals are to figure out how that program is going to play? Maybe some of those facilities decide just to pause on it."
94614,328661858,960171,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Executives","No, I would say no. I think our orderbook is really strong for robot sales, and our procedure growth was very robust, both in new knees and in hips. [indiscernible]. And the hip procedure growth was very strong in the back half of last year. So no, I woul",74,"No, I would say no. I think our orderbook is really strong for robot sales, and our procedure growth was very robust, both in new knees and in hips. [indiscernible]. And the hip procedure growth was very strong in the back half of last year. So no, I would not say that there were some kind of change in behavior. We're really seeing continued growth, and I'm still very bullish on our MAKO business."
94614,328661858,960171,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Analysts","Okay. And then as my follow-up. Just on the domestic performance again this quarter was extremely strong. I'm just wondering, with Q1 typically being a seasonally soft quarter and the strength that we're seeing here obviously comping on ACA, it just seems",109,"Okay. And then as my follow-up. Just on the domestic performance again this quarter was extremely strong. I'm just wondering, with Q1 typically being a seasonally soft quarter and the strength that we're seeing here obviously comping on ACA, it just seems interesting to me how strong everything has been. Can you just talk about volume, price, mix, share taking? What's driving all that strength domestically? And that should be think about things kind of in the U.S. so now in the back half with OUS kind of picking up and then exiting into 2017, hopefully with both of those segments starting to realize more normalized type of growth?"
94614,328661858,960171,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Executives","I think we're going to continue to see strong performance in the U.S. Obviously, this was a very good quarter, but the real genesis of this is fantastic product pipelines. We have a really -- across our businesses, very, very good condition of our pipelin",233,"I think we're going to continue to see strong performance in the U.S. Obviously, this was a very good quarter, but the real genesis of this is fantastic product pipelines. We have a really -- across our businesses, very, very good condition of our pipeline, with many new launches that are just starting, launches the start of the middle of last year. So having healthy product pipeline is always great, and that leverages our best asset, which is our sales force with Stryker, which really know how to execute. And we have helped across our divisions that. And that wasn't the case a few years ago. We had a few divisions that were a little bit softer. We now have strength in our endoscopy with our new camera. We have strength within our Neuro Powered Instruments. We have the ischemic stroke market taking off. We have a strong pipeline within Spine. You're seeing 3D printed implants taking off. So really across our portfolio, we have very strong pipeline. So that isn't a 1 quarter thing. I think we'll continue to see strong performance through the course of the year. And we continue to spend very robustly in R&D. So we have a cadence of your product so we'll continue. And so I really believe this is sustainable. We'll continue to perform very well in the U.S. It's not a 1 quarter thing."
94614,328661858,960171,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Operator","You're next call comes from the line of Mike Matson with Needham &.",14,"You're next call comes from the line of Mike Matson with Needham &."
94614,328661858,960171,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Analysts","I guess, Katherine, I just want to ask about the Sage and Physio-Control acquisitions. Should we expect the growth rates to continue this year at the historical level, sort of double-digit, let's say, [indiscernible] mid-single digits at Physio-Control? O",56,"I guess, Katherine, I just want to ask about the Sage and Physio-Control acquisitions. Should we expect the growth rates to continue this year at the historical level, sort of double-digit, let's say, [indiscernible] mid-single digits at Physio-Control? Or is there a risk that the growth tapers off a little bit while you're integrating those companies?"
94614,328661858,960171,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Executives","Yes. Recognizing there's always integration that has to happen, so I don't want my comments to be construed as exact targets every quarter. But overall, Sage has a long history of sustaining very strong double-digit growth, and our goal is to make sure we",136,"Yes. Recognizing there's always integration that has to happen, so I don't want my comments to be construed as exact targets every quarter. But overall, Sage has a long history of sustaining very strong double-digit growth, and our goal is to make sure we do everything but it does for them. And over time, a lot more of the opportunity outside the U.S. Physio-Control is embarking this year on a hefty new product launch cycle that will go for the next 2 [ph] years. So I think your estimations are a good place to be thinking about. And again, we'll be very transparent. We're going to give pro forma revenue performance for each business respectively. For the first 12 months, you'll be able to see very clearly how their growing relative to the prior year basis."
94614,328661858,960171,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Analysts","Okay. And then just with regard to the emerging markets, and I guess, China more specifically, can you just talk about the differences and kind of what you're seeing with regard to the implant markets and the procedurally-driven products versus the capita",78,"Okay. And then just with regard to the emerging markets, and I guess, China more specifically, can you just talk about the differences and kind of what you're seeing with regard to the implant markets and the procedurally-driven products versus the capital equipment market? Do you have any sense as to whether or not the actual end markets for procedure volumes have slowed down? Or is that just steady and there's just a stocking going on at distributors?"
94614,328661858,960171,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Executives","So I'd kind of break it into 3 categories. I would say the slowest impact and the greatest negative impact to us has been on the capital equipment. The next would be Spine and Trauma, which is a lot of that is tendered type of business, where you see -- w",130,"So I'd kind of break it into 3 categories. I would say the slowest impact and the greatest negative impact to us has been on the capital equipment. The next would be Spine and Trauma, which is a lot of that is tendered type of business, where you see -- we've seen distributors really have loaded up and are bleeding their inventory. And then the least negatively impacted would be in the Hip and Knee category, which has a lot more cash pay. And so the cash pay market is not as the least impacted. That's kind of that separate in those 3 buckets. And we're seeing obviously, it's all negative, with varying degrees, with capital being the most negative, Spine Trauma second, and then Hips and Knees last."
94614,328661858,960171,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Operator","Your next call comes from the line of Larry Biegelsen with Wells Fargo.",13,"Your next call comes from the line of Larry Biegelsen with Wells Fargo."
94614,328661858,960171,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Analysts","First, I wanted to ask about Trauma and Extremities, and then I had one on M&A. So Kevin, Trauma and Extremities is obviously been a stellar performer for you guys for a long time. But 2 growth areas that you're not participating in are relatively small,",108,"First, I wanted to ask about Trauma and Extremities, and then I had one on M&A. So Kevin, Trauma and Extremities is obviously been a stellar performer for you guys for a long time. But 2 growth areas that you're not participating in are relatively small, shoulder and cervical disc. So could give us an update? I know you launched your shareholders a year or 2 ago. Give us an update there on what you're seeing and in the outlook. And then second, how attractive is the cervical disc market to you? And how important is it to have a cervical disc market? And I got one follow-up."
94614,328661858,960171,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Executives","Sure. So shoulder, you're right. We're a relatively small player, but we're very pleased with the launch of our primary shoulder and our reverse shoulder, which we launched just over a year ago. That has very nice growth, albeit from a strong base. We rea",140,"Sure. So shoulder, you're right. We're a relatively small player, but we're very pleased with the launch of our primary shoulder and our reverse shoulder, which we launched just over a year ago. That has very nice growth, albeit from a strong base. We really believe we have the right products to be able to win in the market. It's going to take time. This isn't like Foot & Ankle, where we're approaching new surgeons. The up to be able to take share. But I was very encouraged by the growth the last 2 quarters in our shoulder business. It really doesn't make a big impact in our overall business just given the size but I feel that we now have a very good portfolio in shoulder will become a growth area for us going forward. What's the second question?"
94614,328661858,960171,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Analysts","On cervical. How important it is to have a cervical disc?",11,"On cervical. How important it is to have a cervical disc?"
94614,328661858,960171,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Executives","We would normally report that if we had a cervical disc, which we don't right now that we report in our Spine business, not in our Trauma and Extremities business. And right now, our Spine business is doing really well. We're launching many, many products",88,"We would normally report that if we had a cervical disc, which we don't right now that we report in our Spine business, not in our Trauma and Extremities business. And right now, our Spine business is doing really well. We're launching many, many products. We don't feel that we have to have a cervical disc at the moment. It will drive growth. It's something we'll look at. But of the current time, we don't see that as an impediment to having strong growth in our Spine business."
94614,328661858,960171,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Analysts","Got it. And [indiscernible] for wrapping that into the Trauma and Extremities. Sorry about that. So Kevin, you spent $4 billion on 2 recent deals. My question is how does that impact your ability or willingness to do more deals right now until you kind of",49,"Got it. And [indiscernible] for wrapping that into the Trauma and Extremities. Sorry about that. So Kevin, you spent $4 billion on 2 recent deals. My question is how does that impact your ability or willingness to do more deals right now until you kind of integrate those 2?"
94614,328661858,960171,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Executives","Sure. We still have significant capacity to do extra deals. So we had a one-notch downgrade from both S&P and Moody's. If you look at S&P, we went from an A+ to A rating. We are committed to maintaining investment grade, but there's obviously a large gap",183,"Sure. We still have significant capacity to do extra deals. So we had a one-notch downgrade from both S&P and Moody's. If you look at S&P, we went from an A+ to A rating. We are committed to maintaining investment grade, but there's obviously a large gap between A rating and investment both the low end of investment grade. Keep in mind, the vast majority of the deals we do are small tuck-in deals. That will continue to be the case for Stryker. That's where we drive the most value when we find the technologies that we can give to our fabulous sales force to drive. So that we continue to see both will be a the majority of the deals, but we still have significant capacity to do more M&A. I was all of our businesses have embedded people. We'll not told them to slow down at all. We're continuing to scour the market to look for opportunities that will add value, and we won't hesitate to pull the trigger on new deals if we believe it will be value-creating for Stryker."
94614,328661858,960171,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Operator","Your next call comes from the line of Matt Keeler with Credit Suisse.",13,"Your next call comes from the line of Matt Keeler with Credit Suisse."
94614,328661858,960171,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Analysts","I guess just start to on Sage. You highlighted the potential to build that in Western Europe, I was wondering if you could help us think about that market opportunity. Is that a market similar in size in western year or the U.S and Sage had a smaller mark",60,"I guess just start to on Sage. You highlighted the potential to build that in Western Europe, I was wondering if you could help us think about that market opportunity. Is that a market similar in size in western year or the U.S and Sage had a smaller market share? Or is that the market you'll be building from scratch?"
94614,328661858,960171,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Executives","This will be much more building the market, much the way Sage did in the U.S. They really were the driving force behind the innovations that allowed solutions to many of these hospital-acquired infections. These very elegant, easy-to-use, solutions for de",156,"This will be much more building the market, much the way Sage did in the U.S. They really were the driving force behind the innovations that allowed solutions to many of these hospital-acquired infections. These very elegant, easy-to-use, solutions for demonstrated clinical data that shows, when they're routinely used. they can significantly limit the occurrence. The same condition hospital-acquired ammonia infections are prevalent around the world. It just was not an area they focused on, given their initial investment in the U.S. market. So this will be market development. It'll be using the sales force as they do to help drive that. But it's very much the same conditions exist, but it'll be more about market expansion, which is why we say over time, this is the volume elected to on the, it's not something that's going to occurs suddenly in 2016. This will be a multi-year process to really start to drive awareness and adoption."
94614,328661858,960171,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Analysts","Okay, great. And my follow-up, last quarter, you shared some margin targets for the year. Just wondering if you'll give us an update on what those look like with Sage and Physio-Control.",32,"Okay, great. And my follow-up, last quarter, you shared some margin targets for the year. Just wondering if you'll give us an update on what those look like with Sage and Physio-Control."
94614,328661858,960171,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Executives","So we provide top line and earnings guidance. We don't provide specific margin guidance, although, as Glenn noted on the call, while the magnitude of the year-over-year increase in gross margin won't continue, we should continue to be at the Q1 levels for",82,"So we provide top line and earnings guidance. We don't provide specific margin guidance, although, as Glenn noted on the call, while the magnitude of the year-over-year increase in gross margin won't continue, we should continue to be at the Q1 levels for 2016. But we haven't given specific guidance. We do expect up margin expansion. That's inclusive of the deal that they closed in early April. But beyond that and the revisions, upward revision to the targets today, there's nothing additional."
94614,328661858,960171,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Operator","Your next call comes from the line of Glenn Navarro with RBC Capital Markets.",14,"Your next call comes from the line of Glenn Navarro with RBC Capital Markets."
94614,328661858,960171,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Analysts","Two questions. One, U.S. knees and Hips for Stryker came in better. Yesterday, J&J also reported a much stronger U.S. in the Hip number. So the markets likely coming in better, but Kevin, I just wanted to see what your view is on the competitive dynamics.",94,"Two questions. One, U.S. knees and Hips for Stryker came in better. Yesterday, J&J also reported a much stronger U.S. in the Hip number. So the markets likely coming in better, but Kevin, I just wanted to see what your view is on the competitive dynamics. Zimmer and Biomet sales forces have combined as of last year. But I'm just wondering, are you still possibly seeing disruption in the marketplace associated with Zimmer and Biomet? And could that be helping your results as well as J&J's results yesterday? And then I had a follow-up."
94614,328661858,960171,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Executives","So we're really pleased with our result, particularly our U.S. performance in both Hips and Knees. At this point, with the largest player having on a reported and along with other competitors in the market, it's very difficult to make any kind of call wit",161,"So we're really pleased with our result, particularly our U.S. performance in both Hips and Knees. At this point, with the largest player having on a reported and along with other competitors in the market, it's very difficult to make any kind of call with conviction around market growth. So clearly, we have a much better sense of additional numbers roll in, where the overall market growth is. But we feel very company was the grew at the high end. It's not above the market, but we'll have to wait and see how the numbers coming together general sense of whether there's been any type of acceleration. Keep in mind, in Recon, you really have to look at rolling 4-quarter trend because growth rates can vary quarter-to-quarter. So I wouldn't want to read too much into at uptick in growth to the degree we see one in the first quarter because it may not be indicative of a trend line."
94614,328661858,960171,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Analysts","Okay. And then one last follow-up on CJR. One of the pushbacks that we get is there's a thought out there that surgeons will start cherry-picking patients. They may not do the more challenging cases. And then they may fall through the system. Our due dili",59,"Okay. And then one last follow-up on CJR. One of the pushbacks that we get is there's a thought out there that surgeons will start cherry-picking patients. They may not do the more challenging cases. And then they may fall through the system. Our due diligence does not suggest that'll happen, but I just wanted to hear your opinion."
94614,328661858,960171,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Executives","Yes. This has obviously gotten a lot of focus of late. I'll tell you, we don't not believe that the masses intended is to reduce utilization. It's really rather do ensure that each patient has access most appropriate care. There's been speculation, but so",188,"Yes. This has obviously gotten a lot of focus of late. I'll tell you, we don't not believe that the masses intended is to reduce utilization. It's really rather do ensure that each patient has access most appropriate care. There's been speculation, but some type of step function reduction in volumes is higher-risk patients are increasingly denied surgeries. We believe this is unlikely. We do think  based on all the work we've done and through NPS and obviously our presence in Recon, that surgeons are going to continues with that optimize treatments for high-risk patients that they do that today. And will include managing their postacute care, which can vary. And so they have and are going to continue to treat all types of patients. The data clearly shows hip and knee surgery has a very high, long-term success rate, and significantly improves quality of life. And after all patients, not just the healthiest ones. So we're not expecting some type of significant change, but rather, we do believe there going to look to find the optimum ways to treat these patients, including the post acute care regimen."
94614,328661858,960171,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Operator","Your next call comes from the line of Kaila Krum.",10,"Your next call comes from the line of Kaila Krum."
94614,328661858,960171,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Analysts","So a follow-up on Richard's earlier question on Spine. Just to dig in a bit further. I mean you mentioned that you're seeing an increase in volume. Can you give us a sense for where you believe that increase in volume is coming from? Is it more market rel",93,"So a follow-up on Richard's earlier question on Spine. Just to dig in a bit further. I mean you mentioned that you're seeing an increase in volume. Can you give us a sense for where you believe that increase in volume is coming from? Is it more market related? Or do you think that you are taking share and in what is the latter, I mean, I'm curious as to whether or not that share takings coming from the bigger players in that segment or from some of the smaller pure plays."
94614,328661858,960171,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Executives","Yes, we think, overall, the market might be modestly improving. But again, it's very difficult to say because we're one of the earlier companies to report results. So we'll have to see how the numbers come in. And it also is going to vary by company, whic",98,"Yes, we think, overall, the market might be modestly improving. But again, it's very difficult to say because we're one of the earlier companies to report results. So we'll have to see how the numbers come in. And it also is going to vary by company, which segment of the market more of your products a weighted towards. So overall, we've been launching a number of new products. We talked about the investments we've made over the last couple of years and R&D pipeline. And we think this is mostly indicative of us gaining more market share back."
94614,328661858,960171,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Executives","Yes. We've seen in the spine market, whether it's small players or larger players, innovation drives growth, and innovation is what takes market share. And our innovation engine is alive and well in our Spine business, and that's what's caused us to grow",46,"Yes. We've seen in the spine market, whether it's small players or larger players, innovation drives growth, and innovation is what takes market share. And our innovation engine is alive and well in our Spine business, and that's what's caused us to grow above the market."
94614,328661858,960171,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Analysts","Okay. And then I'm just curious if you guys had any differences in terms of selling days in the quarter that may have impacted growth in the quarter? And if so, that estimated impact.",34,"Okay. And then I'm just curious if you guys had any differences in terms of selling days in the quarter that may have impacted growth in the quarter? And if so, that estimated impact."
94614,328661858,960171,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Executives","Yes -- no, selling days are equal between quarters, between last year and this year.",15,"Yes -- no, selling days are equal between quarters, between last year and this year."
94614,328661858,960171,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Operator","You're next call comes from the line of Kaila Rosewood can record.",13,"You're next call comes from the line of Kaila Rosewood can record."
94614,328661858,960171,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Analysts","Just to add, one question on MAKO. You talked a lot about refining the processes and the workflow over the course of 2016 compared to the launch in '17. When you think about that, how do you think about the optimal time of the procedure and the trade-off",108,"Just to add, one question on MAKO. You talked a lot about refining the processes and the workflow over the course of 2016 compared to the launch in '17. When you think about that, how do you think about the optimal time of the procedure and the trade-off of your be potentially time-additive? And I guess, the real question is, when you come to market with the MAKO Total Knee, what percentage of that market, from a volume base, do you think the system will be time-neutral to your high volume or to your medium-volume surgery? What's the real market segment that the MAKO is really targeting here?"
94614,328661858,960171,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Executives","Sure. So much of that data you're looking for we're going to be able to track once we going to full commercial launch. And it's going to vary by surgeon. A really high-volume surgeon doing hundreds of the replacements a year. It's going to -- this is goin",183,"Sure. So much of that data you're looking for we're going to be able to track once we going to full commercial launch. And it's going to vary by surgeon. A really high-volume surgeon doing hundreds of the replacements a year. It's going to -- this is going to be time-additive for the work volume surgeon. B2B much closer to time-neutral. But it's also well we wanted to spend our time on the training protocol to really look at ways that we can optimize this with this first-generation product. The other key is this is not just about time. We believe to eventually improve the patient experience. We're going to have a more reproducible surgery because there tends to be tremendous variation, particularly with lower-volume surgeons. We think we can improve muscle disruption and things that add to the fact that close to 30% of knee patients are dissatisfied with the procedure. It's really not just about time. It's really about having experience that's better for the surgeon, better for the patient. And over time, we believe the outcome they will support that."
94614,328661858,960171,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Analysts","Great. And then just another question on the robotic side. We've heard a lot thoughts in rumbling [ph] about robotics in the spine market and, in particular, more of a play on navigated pedicle screw placement. Just your general thoughts on that, given yo",75,"Great. And then just another question on the robotic side. We've heard a lot thoughts in rumbling [ph] about robotics in the spine market and, in particular, more of a play on navigated pedicle screw placement. Just your general thoughts on that, given your overlap in the spine as well as presence from a capital equipment side and navigation. And that's how does, if any, MAKO robot play a factor in those plans moving forward."
94614,328661858,960171,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Executives","So certainly, we have a terrific Navigation unit business. That's within our insurance business. And stir we are very well aware about have a procedure get stuck on whether it's navigation not. That continues to be a growth area for us, both the neuro and",157,"So certainly, we have a terrific Navigation unit business. That's within our insurance business. And stir we are very well aware about have a procedure get stuck on whether it's navigation not. That continues to be a growth area for us, both the neuro and spine market. But we are, in the next few years, really focused on Hip and Knees with MAKO. We a lot of work to do to get the Total Knee. We think that the killer procedure. I think if you look down the road, 5 plus years, certainly, Spine could be an area of interest. Hip arthroscopy could be an area of interest. Shoulder could be an area of interest. There's many areas. I think robotics will be a growth area for many, many years to come. But first things first. We really have to focus on Hips and Knees, and that's where our attention will be for the next few years."
94614,328661858,960171,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Operator","Your next call comes from the line of Amit Hazan with Citigroup.",12,"Your next call comes from the line of Amit Hazan with Citigroup."
94614,328661858,960171,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Analysts","Maybe just start on the Hip and Knee side U.S. volumes. I want to maybe take a big picture and a market view for moment. Kind of when we look at analyze the market model, some of your competitors data, it seems pretty clear that it was in volume have been",124,"Maybe just start on the Hip and Knee side U.S. volumes. I want to maybe take a big picture and a market view for moment. Kind of when we look at analyze the market model, some of your competitors data, it seems pretty clear that it was in volume have been really strong for a couple of years now, maybe up in the 6%, 7%, 8% range for the market as a whole in the U.S. That would be kind of well above the 10-year plus average for volumes. So I'm wondering what you think has been the driver of that over these last couple of years and perhaps, more importantly, the extent to which you think that sustainable on the volume side."
94614,328661858,960171,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Executives","Yes, not -- no, we're seeing a very stable market. I think just look at demographics, right? Everyday [indiscernible] 65, more and more people are talking to friends that have had Hip and Knee replacement. The results are fabulous. People want to be activ",219,"Yes, not -- no, we're seeing a very stable market. I think just look at demographics, right? Everyday [indiscernible] 65, more and more people are talking to friends that have had Hip and Knee replacement. The results are fabulous. People want to be active. So actually we're seeing a lot, certainly we see this with the uni with MAKO. We see a lot of you people going in for surgery. That wasn't happening before. You're seeing unemployment. Unemployment is a great proxy. When we see unemployment come down, we tend to see a lot more replacement, specifically, knees. So that's really hurt when you light out of that. Knees, you can defer. And so we see that as a very good proxy. That's what's more of approximately and anything to do with ACA. So we're really believe we've got a stable market that will continue to be stable for not just the next quarter, but for the next year or 2 years. And demographics is a key part. Patient awareness is a key part. And people wanted to be active. A lot of people want to be active. And so we don't really see from a demand or volume standpoint, we don't see any headwinds right now. And frankly, the lower unemployment is a little bit of a tailwind."
94614,328661858,960171,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Analysts","Great. And then kind of back to MAKO and bundled payment, maybe just asking the question in a different way to throw it out to you guys. What is the sales pitch for MAKO in a bundled payment environment? Potentially, how does MAKO fit into a 90-day care b",70,"Great. And then kind of back to MAKO and bundled payment, maybe just asking the question in a different way to throw it out to you guys. What is the sales pitch for MAKO in a bundled payment environment? Potentially, how does MAKO fit into a 90-day care better, in a better way that is what being done here traditionally, such that it would have added value to the hospital?"
94614,328661858,960171,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Executives","So we really believe MAKO's going to improve outcomes, right? If you have consistent, reproducible product placement, less soft tissue damage, need less we have for your patient, they are more satisfied, that's going to win in the market. So irrespective",165,"So we really believe MAKO's going to improve outcomes, right? If you have consistent, reproducible product placement, less soft tissue damage, need less we have for your patient, they are more satisfied, that's going to win in the market. So irrespective of the type of payment, whether it's a single payer system like in France, a two-tier system like in the U.K. or whether we are now, it's a bundled payments. So the method of payment is less interesting to us, frankly. If we deliver value and prove that value, we will win in the marketplace took. And frankly, when you look at a bundle, again, the implant price, even with a robot, if you factor in the robot and that's still not the majority of the procedure costs. So there's a lot of room to optimize beyond just the implant. And we really believe if we deliver that excellent experience and have better outcomes, that we'll be able to win in the marketplace."
94614,328661858,960171,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Operator","Your next call comes from the line of Jeff Johnson with Robert W. Baird.",14,"Your next call comes from the line of Jeff Johnson with Robert W. Baird."
94614,328661858,960171,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Analysts","Katherine, just now we're in April, on the MHLW price reset, can you just confirm now it's probably going to be what no more than 20, 25 basis point impact to your company-wide pricing?",34,"Katherine, just now we're in April, on the MHLW price reset, can you just confirm now it's probably going to be what no more than 20, 25 basis point impact to your company-wide pricing?"
94614,328661858,960171,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Executives","Yes, that's a good approximation.",5,"Yes, that's a good approximation."
94614,328661858,960171,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Analysts","Okay, good. And then, Kevin, I guess, a question for you. I heard the comments on the ankle performance. In the quarter, it sounds like that was strong. When I PPS proposals come out the Internet, the question I had really thought of it until just there i",151,"Okay, good. And then, Kevin, I guess, a question for you. I heard the comments on the ankle performance. In the quarter, it sounds like that was strong. When I PPS proposals come out the Internet, the question I had really thought of it until just there is some of the rates. The other night, but with us getting out a carveout our total ankle replacement cord, which I don't think anybody really expected that we would again this year, but if you look at the episode of care costs on ankle being higher than Hips and knees but being reimbursed at those same rates, as we go into this bundled payment environment, you think there's any bias or any kind of skew of away from and called hospitals maybe take just as their costs are higher but reimbursement is the same, with being paid under those Hip and Knee codes?"
94614,328661858,960171,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Executives","So first of all, we're just starting with Hip and Knee in bundled payments. And I think Medicare's can going to be looking at higher volume procedures and moving them to the bundle. Total ankle is a very small part of the total market. Still, Fusion is ti",284,"So first of all, we're just starting with Hip and Knee in bundled payments. And I think Medicare's can going to be looking at higher volume procedures and moving them to the bundle. Total ankle is a very small part of the total market. Still, Fusion is till the standard of care. Ankles are growing very fast, from a very small base. So I'm not -- I really don't see this hitting the radar screen, at least, not for a few years back for Medicare. They've got a lot of other procedures they're going to focus on. I do believe bundled care and bundled payments will increase. It's a good thing for the overall health care system. It will address a lot of costs that need to be reduced, frankly, in the case of Hip and Knee procedure. There is an over prescriptive today on the postacute. There's a lot of costs, and we've seen, when we work with hospitals on their service line profitability, that's the area that we tend to focus on the most. So I think we're in a long way, way from bundled payments having a big impact on total ankle. And frankly, it's a better outcome. So Fusion is -- was a standard of care in some of the claim is a long time ago, and that's been replaced by total proceeds. And total ankle will be a better outcome. Of course, like everything in health care, finding payments and getting procedures reimbursed always goes through its ups and downs. But if you have a better outcome, eventually, it'll get paid. So I don't really see I had when for that, at least not in the next few years."
94614,328661858,960171,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Operator","Your next call comes from the line of Josh Jennings with Cowen and Company.",14,"Your next call comes from the line of Josh Jennings with Cowen and Company."
94614,328661858,960171,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Analysts","I just was hoping you could clarify. It looks like there is a step up in CapEx in Q1 from the normal run rate and just the driver behind that. And just link to the question is any major product launches across the major divisions you would call out that a",62,"I just was hoping you could clarify. It looks like there is a step up in CapEx in Q1 from the normal run rate and just the driver behind that. And just link to the question is any major product launches across the major divisions you would call out that are going to help with this 5.5% to 6.5% organic growth trajectory?"
94614,328661858,960171,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Executives","Yes. I think, in Q1, we started some of the spending that's going to be required for our deployment of our new ERP system. And so that's the big thing that kind of stuck out in the cash flow.",39,"Yes. I think, in Q1, we started some of the spending that's going to be required for our deployment of our new ERP system. And so that's the big thing that kind of stuck out in the cash flow."
94614,328661858,960171,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Executives","Yes. As it relates to product launches, so we have a number of product that we talked about at the signature line of your power drills that haven't had a full year impact. But we do have our Neptune 3 launch that's upcoming bridges the main waste manageme",195,"Yes. As it relates to product launches, so we have a number of product that we talked about at the signature line of your power drills that haven't had a full year impact. But we do have our Neptune 3 launch that's upcoming bridges the main waste management product within Instruments, that's coming in the middle of the year. little bit consumer to growth. But I would say it's just a continuation that launch was December. It really was mid-December last year, the 1588. We're getting great customer feedback. So that'll continue going into this year. Sports medicine launching a number of products. Spine, the 3D printed implant, the interbody device, great feedback, but a very small number of surgeons put those into the first quarter. So we'll expand that launch over the course of the year. So I wouldn't point to one single product, just typical of Stryker. We tend to have our growth spread across a wide variety of products. But there are a number of products that will continue to the growth rates. And obviously, raising after 1 quarter, we'll have confidence that we'll be able to sustain this level of growth."
94614,328661858,960171,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Operator","There are no further questions at this time. I will now turn the conference over to Mr. Kevin Lobo for any closing remarks.",23,"There are no further questions at this time. I will now turn the conference over to Mr. Kevin Lobo for any closing remarks."
94614,328661858,960171,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Executives","So thank you all for joining our call. Our conference call for the second quarter 2016 results will be held on July 21. Thank you.",25,"So thank you all for joining our call. Our conference call for the second quarter 2016 results will be held on July 21. Thank you."
94614,328661858,960171,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Operator","Thank you, ladies and gentlemen. This concludes today's conference. Thank you for participating, you may now disconnect.",17,"Thank you, ladies and gentlemen. This concludes today's conference. Thank you for participating, you may now disconnect."
94614,328661858,960268,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Operator","Welcome to the First Quarter 2016 Stryker Earnings Call. My name is Liz, and I will be your operator for today's call. [Operator Instructions]This conference call is being recorded for replay purposes. Before we begin, I would like to remind you that",134,"Welcome to the First Quarter 2016 Stryker Earnings Call. My name is Liz, and I will be your operator for today's call. [Operator Instructions]
This conference call is being recorded for replay purposes. 
Before we begin, I would like to remind you that the discussions during this conference call will include forward-looking statements. Factors that could cause actual results to differ materially are discussed in the company's most recent filings with the SEC. 
Also, the discussions will include certain non-GAAP financial measures. Reconciliations to the most directly comparable GAAP financial measures can be found in today's press release that is an exhibit to Stryker's current report on Form 8-K filed today with the SEC. 
I will now turn the call over to Mr. Kevin Lobo, Chairman and Chief Executive Officer. You may proceed, sir."
94614,328661858,960268,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Executives","Welcome to Stryker's First Quarter Earnings Call. Joining me today are Glenn Boehnlein, who assumed the role of CFO, effective April 1; and Katherine Owen, VP of Strategy and Investor Relations. For today's call, I will provide opening comments, followe",373,"Welcome to Stryker's First Quarter Earnings Call. Joining me today are Glenn Boehnlein, who assumed the role of CFO, effective April 1; and Katherine Owen, VP of Strategy and Investor Relations. 
For today's call, I will provide opening comments, followed by an M&A update from Katherine. Glenn will then provide additional details regarding our quarterly results before we open the call to Q&A.
We are pleased with our start to the year, as Q1 organic sales growth of 6.1% came in above our expectations, with strong performances across all 3 segments: Orthopaedics, MedSurg and Neurotechnology and Spine. The performance was led by continued new product introductions, and strong sales and marketing execution. 
Geographically, Q1 was powered by ongoing momentum in the U.S., with sales growth of 8.9%. As expected, growth was challenged outside the U.S., given the tough year-over-year comparisons in emerging markets, where growth started to slow in the second quarter of last year. Challenges still exist in emerging markets, although the year-over-year impact should ease in the back half of the year.
We continue to have good performance in Europe, Japan and Australia. Our strategy of business unit specialization with dedicated sales forces, marketing and R&D continued to be a differentiating factor in the sustainability of our above-market growth.
Consistent R&D investment has generated strong internal product pipelines across the company, and we continue to augment them with acquisitions. We are thrilled to welcome Sage, Physio-Control and Synergistics to Stryker, and believe that the addition of these companies will further strengthen our businesses. 
Looking at the P&L, we are building on 2015's success, and delivered solid adjusted earnings growth of 11.7%, despite modest foreign currency headwinds.
This improvement stemmed from the strong top line and year-over-year gross margin expansion. Importantly, we continue to invest heavily in R&D in both absolute dollars and as a percent of sales. Our cost transformation for growth efforts are in the early stages and are multi-year in nature, and we are starting to realize benefits. 
Overall, we are confident in our stated goal of achieving sales at the high end of medtech, with ongoing earnings leverage, and believe our Q1 results position us well for 2016.
I will now turn the call over to Katherine."
94614,328661858,960268,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Executives","Thanks, Kevin. My comments today will focus on providing an update on MAKO, along with the 2 larger M&A deals we recently closed on: Sage and Physio-Control. With respect to MAKO, we sold 7 robots during the quarter globally, which is in line with the s",480,"Thanks, Kevin. My comments today will focus on providing an update on MAKO, along with the 2 larger M&A deals we recently closed on: Sage and Physio-Control. 
With respect to MAKO, we sold 7 robots during the quarter globally, which is in line with the same period a year ago. As many of you know, capital sales tend to be the strongest in the fourth quarter, and also can fluctuate from quarter-to-quarter. We are highly encouraged by order trends, which reinforces the growing interest in demand for the MAKO robotic system, fueled by the expanded indication and planned launch of the Total Knee system, where we continue to target full commercial rollout in 2017. There is no change to our launch plan for the Total Knee, which will focus throughout 2016 on working with key opinion leaders to optimize the training protocol and gather observational data that will help to frame the anticipated benefits, all of which will ensure a strong podium presence at key orthopaedic meetings as we move throughout 2017. 
In Q1, we were also encouraged by the robust procedure growth in both partial knees and hips using MAKO.
Turning to the recent M&A activity. In early April, we closed on both Sage and Physio-Control, which will be integrated into our Medical division. Starting with Sage, our focus will be to ensure the continuation of strong double-digit top line growth that the company has had a long history of achieving. With their market-leading product portfolio, focus on clinically supported innovation, product ease-of-use and strong sales support, we believe Sage can continue to drive both market expansion and share gains in the prevention of hospital-acquired conditions. Given our existing global footprint, which includes strong and broad sales and marketing support, we believe that, over time, Stryker can help drive adoption of the Sage portfolio outside the U.S., where revenue today is limited as the company had historically focused its investments in the U.S. market. 
Regarding Physio-Control, we believe we have significant opportunities over time to drive both sales and earnings synergies, given our combined presence in the prehospital setting. In the near term, both businesses will operate largely independently, with a focus on their respective 2016 targets and planned key new product launches.
Importantly, for both Sage and Physio-Control, we have identified and put in place a highly experienced integration team, which given our BD history, should help ensure a smooth integration. 
As we move through the first 12 months postclosing of both Sage and Physio-Control, we will provide you with the pro forma quarterly growth rates for each, to help provide visibility regarding our execution and their top line contribution. There's no change to our previously announced expected accretion from both these transactions to adjusted EPS in 2016 and 2017 of $0.07 and $0.15 to $0.18, respectively. 
With that, I will now turn the call over to Glenn."
94614,328661858,960268,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Executives","Thanks, Katherine. My comments on today's call will focus on the financial results and key drivers of our first quarter performance. Our detailed financial results have been provided in the various schedules included in today's press release. As to our",1149,"Thanks, Katherine. My comments on today's call will focus on the financial results and key drivers of our first quarter performance. 
Our detailed financial results have been provided in the various schedules included in today's press release. As to our overall performance, our constant currency organic sales growth of 6.1% exceeded the high end of our full year expectations, and came in better than our expectations at the start of the quarter. The growth, based on the same number of selling days, reflected strong U.S. volume and mix of 10.2%, marginally offset by pricing, which was slightly negative at 1.3%.
Adjusted EPS of $1.24 increased 11.7% from 2015, primarily driven by our strong top line growth and favorable margin performance. Foreign exchange unfavorably impacted EPS by $0.02 per share, roughly in line with our guidance.
Looking at our segment highlights. Orthopaedics constant currency growth was 4.6%, which was led by U.S. Orthopaedics growth of 7.9%, reflecting continued strong sales in our Trauma and Extremity business, which grew 11%; and a 9% increase in Knees, reflecting continued momentum from our last quarter, and the success of our Triathlon products, driven by our titanium revision cones, our cementless knee products as well as, new customer adoption of our MAKO uni platform.
We are now seeing an acceleration in our revision in planned sales, where previously our market share lagged our overall Total Knee share. Partly offsetting the strong U.S. orthopaedic performance was the continued challenging markets in China and Brazil, which contributed to the negative 1.4% constant currency decline in international. 
Overall, our first quarter results continue to reflect strong momentum across our Orthopaedics portfolio. 
Our MedSurg segment, with constant currency growth of 4.6%, also demonstrated strong momentum, with U.S. growth of 7.6%. Instruments had solid U.S. growth of 10.2%, with good performance in their waste management products. 
Endoscopy's new 1588 camera, which features enhanced visualization, that broadens the applicable surgical applications, was a primary driver for the division's solid performance, and will continue to be a growth engine in 2016. 
Lastly, Medical's growth, which was up against a tough year-over-year comparable, benefited from strong demand for its market-leading structure and ambulance cot products, which underscore the strength of its portfolio and the overall health and stability of hospital capital budgets that we're seeing in the market. 
As with Orthopaedics, MedSurg also experienced challenges in emerging markets, primarily China. We expect this to continue as we work through our distributors to drive demand and reduce the buildup of their inventories. Recognizing comparisons will also ease as we move through 2016.
All in all, our MedSurg businesses saw healthy order growth in the first quarter, and should be well positioned to continue their momentum. 
Turning to Neurotechnology and Spine. The impressive year-end momentum achieved by this group continued in the first quarter with 13.1% constant currency growth. Neurotechnology's 21% growth was highlighted by the developing market for device-based treatment of ischemic stroke. While there's still considerable market development required, we are highly encouraged by the potential for this segment and our Trevo Stentriever technology. As one of the 2 majors Stentrievers on the market, combined with compelling clinical data underscoring the efficacy of these devices, such as the MR CLEAN study, Stryker is well-positioned for growth in Neurovascular. 
We also continue to see excellent performance in our Neuro-Powered Instruments business, led by strong growth in their signature drill products released last year. 
We also are encouraged by the solid showing Upper Spine, up 5.8% in the U.S., as new product launches, included in our limiting launch of our 3D-printed interbody device, are clearly having an impact. Neurotechnology and Spine continue to benefit from a new product pipeline resulting from robust R&D investment over the past few years. 
I will now focus on our first quarter operating highlights, starting with gross margin, which, on an adjusted basis, increased 240 basis points to 68%. Of this improvement, roughly 1/4 relates to the 2-year suspension of the Medical Device Tax, while the remainder reflects a favorable mix and favorable foreign exchange, partly offset by negative pricing. 
As for our operating expenses, we continue to focus on internal innovation, with R&D at 6.4% of sales, which is in line with our overall target spend. On an adjusted basis, SG&A increased to 37.4% of sales versus 35.9% in the prior period, which was driven by increased selling activity, anticipated spending related to our new ERP deployment efforts and reinvestment in the Medical Device Tax. 
Looking ahead, we expect SG&A on a full year basis to be comparable to 2015. Overall, our operating margin increased 90 basis points, reflecting solid top line growth and favorable mix and gross margins, offset slightly by higher SG&A for the quarter.
Lastly, some financial highlights on the Other Income and Expense. Other expenses increased due to higher net interest expense related to increased borrowings during the quarter, primarily to fund our recently completed Sage and Physio-Control acquisitions. Net interest expense will continue to be higher than Q1, as our borrowing occurred at the end of Q1. Our first quarter adjusted effective tax rate of 17.4% reflects the benefits of our global tax structure and the permanent renewal of certain tax extenders, which was included in our guidance.
Moving on to the balance sheet. We continue to maintain a strong balance sheet with $7.5 billion of cash and marketable securities, of which approximately 72% was held in the U.S. This balance reflects $3.5 billion of proceeds related to our previously mentioned debt offering, which is included in the $7.5 billion of debt on the balance sheet at the end of the quarter. Subsequent to the end of the quarter, $4.1 billion of cash was used to fund the Sage and Physio-Control acquisitions. 
Turning to cash flow. Our cash flow from operations for 2015 was $2 billion compared to $4 billion last year, as we made $0.1 billion of payments associated with our Rejuvenate and ABG II recall. 
Approximately 50% of the funding for the Rejuvenate liability is being sourced from OUS cash. 
Finally, as we have previously announced, we have suspended our share repurchases for the remainder of the year. 
With that, I will move on to our guidance. Based on our first quarter performance, we now expect our full year organic sales growth to be in the range of 5.5% to 6.5% for 2016. If foreign currency exchange rates hold near current levels, we anticipate net sales will be negatively impacted by approximately 1% for 2016. 
We also expect continued unfavorable price reductions in the range of 1.5% to 2%, consistent with the pricing environment we experienced in 2015. 
Finally, our guidance for adjusted net earnings per diluted share in 2016 now stands in the range of $5.65 to $5.80 for the full year, and $1.33 to $1.38 for the second quarter. 
And now I will open up the call for Q&A."
94614,328661858,960268,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Operator","[Operator Instructions] Your first call comes from the line of David Lewis with Morgan Stanley.",15,"[Operator Instructions] Your first call comes from the line of David Lewis with Morgan Stanley."
94614,328661858,960268,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Analysts","So a couple of questions. Kevin, just for a second, just talking about the guidance, it's -- obviously, the quarter was strong and it's a little early in the year, obviously, to raising your organic sales estimates. Obviously, you have some conviction in",108,"So a couple of questions. Kevin, just for a second, just talking about the guidance, it's -- obviously, the quarter was strong and it's a little early in the year, obviously, to raising your organic sales estimates. Obviously, you have some conviction in the back half. You know, as I think about the back half of the year, obviously, medical comparables are going to get a little easier; emerging markets, pressure should also ease. Is there anything else, that you see in the business, broadly, across Stryker, that's giving you the confidence in the race to your organic sales guidance heading into the back half of the year?"
94614,328661858,960268,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Executives","David, thank you. I would say that I feel very good about the strength of our entire business portfolio. So if you look at MedSurg, you look at Neurotechnology, and even Orthopaedics, I really feel that we have balanced strength across our portfolio, and",129,"David, thank you. I would say that I feel very good about the strength of our entire business portfolio. So if you look at MedSurg, you look at Neurotechnology, and even Orthopaedics, I really feel that we have balanced strength across our portfolio, and that balanced strength is what gives us the confidence, even after the first quarter, to raise our organic sales guidance. So -- but we had indicated previously that the first quarter was -- would likely be closer to the 5% range, and we exceeded that. And obviously, the emerging market comps will also ease as we get into the back half. So we're feeling very good about our position as we exit the first quarter, and obviously, feel confident about raising our organic sales guidance."
94614,328661858,960268,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Analysts","Okay. And then, maybe, just have 2 quick follow-ups -- maybe for Katherine. One, I know, obviously, Neuro number was very strong in the quarter, there's a lot of focus on Stentriever, but can you just give us a sense, Katherine, where you stand on pipelin",104,"Okay. And then, maybe, just have 2 quick follow-ups -- maybe for Katherine. One, I know, obviously, Neuro number was very strong in the quarter, there's a lot of focus on Stentriever, but can you just give us a sense, Katherine, where you stand on pipeline opportunities within Neuro, specifically, interventional Neuro? And secondarily, is there any reason to believe MAKO capital sales get harder into the full Knee launch, that could be sort of a delayed effect until people see sort of the full evidence and software in the back half of the year? Or based on order patterns, you remain pretty comfortable?"
94614,328661858,960268,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Executives","Yes. So within Neurotech, the bulk of the revenue, it's still from the hemorrhagic side, and we continue to launch next generation of the coil, different sizes, different shapes and continue to launch into additional geographies. And we are the market lea",249,"Yes. So within Neurotech, the bulk of the revenue, it's still from the hemorrhagic side, and we continue to launch next generation of the coil, different sizes, different shapes and continue to launch into additional geographies. And we are the market leader in that segment of the market. We do have a flow diverter. It's on the market outside the U.S. It's in clinicals in the U.S, we're probably still a year or 2 before U.S. market launch of that product, but that will clearly be an important product launch, given that it captured a portion of the coil market, where they're applicable. And then, continuing to invest in ischemic stroke, although candidly, a lot of what's going to have to happen over the next few years in the ischemic segment has more to do with market development, as Glenn mentioned in his comments. On MAKO, nothing that I would bring up to suggest that replacements will get harder. If anything, the economic and value proposition associated with the robot, as we move toward full commercial launch of the Total Knee indication, only gets greater. So -- and we expect to see continued strong demand. As we've talked about this year, it's really focused on training. So that's going to be to ensure an optimal rollout, and to make sure the initial user experience is as positive as it can be. But we would assume continued momentum. And as I mentioned, we're really pleased with our incoming order trends."
94614,328661858,960268,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Operator","You're next call comes from the line of Mike Weinstein with JPMorgan.",13,"You're next call comes from the line of Mike Weinstein with JPMorgan."
94614,328661858,960268,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Analysts","A couple of quick questions. Stuart, 2 things that probably surprised in the quarter, one, would've obviously been the gross margin, which was kind of well above expectations and recent trends. And I was hoping you could spend a minute on why that was. An",101,"A couple of quick questions. Stuart, 2 things that probably surprised in the quarter, one, would've obviously been the gross margin, which was kind of well above expectations and recent trends. And I was hoping you could spend a minute on why that was. And then second is, just the sustainability of the growth we're seeing in the Neurovascular business, you know, it showed no signs of slowing out of the U.S. international this quarter. And other than same development trends from 2015, on the back of the data and the guidelines changes, anything else you could add would be helpful."
94614,328661858,960268,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Executives","Sure. Mike, I'll start off with the Neurovascular, and then I'll turn it over to Glenn for the gross margin. So certainly, the ischemic market, it's a new market. And there -- obviously, are many strokes that haven't been treated prior. I kind of think ab",195,"Sure. Mike, I'll start off with the Neurovascular, and then I'll turn it over to Glenn for the gross margin. So certainly, the ischemic market, it's a new market. And there -- obviously, are many strokes that haven't been treated prior. I kind of think about this a little bit like the Foot & Ankle market, you're creating a new market. When we create a new market, its difficult to predict the pace of growth, but there's no doubt that the growth will be very significant. And that was clearly the biggest contributor to the strong performance in Neurovascular. But equally pleased with the performance of our Neuro Powered Instruments, which are having fantastic growth, very strong double-digit growth with our signature drills, which compete with one of the other major players, and we're taking significant market share with those products as well as our Sonopet product. So very, very strong performance, both in Neurovascular as well as the Neuro Powered Instruments. And even our Craniomaxillofacial business, the third of our Neuro businesses, is enjoying double-digit growth. So across the Neuro portfolio, we're really performing very well. I'll turn it to Glenn for gross margin."
94614,328661858,960268,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Executives","Yes. I think if you look at our gross margin, we really benefited from a positive mix, relative to U.S. and international, and then even relative to newer products over some of our older products. If you look at the 1588 and the signature drills that were",87,"Yes. I think if you look at our gross margin, we really benefited from a positive mix, relative to U.S. and international, and then even relative to newer products over some of our older products. If you look at the 1588 and the signature drills that were sold, those sell at largely premiums. And then finally, we also continue to see sort of our [indiscernible] product, knees, trauma. Our ischemic stroke and coil products continue to sell fairly robustly, too, which helped lift the overall margin up."
94614,328661858,960268,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Executives","And also, price was also more moderate than we've seen in the past.",13,"And also, price was also more moderate than we've seen in the past."
94614,328661858,960268,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Analysts","Right. And Glenn, it also looked like your inventories were up a lot this quarter from the end of the year. Any expectation on those trending down? So is any of that -- I'm asking is, any of the uptick in gross margin here onetime? Or do you want us to vi",55,"Right. And Glenn, it also looked like your inventories were up a lot this quarter from the end of the year. Any expectation on those trending down? So is any of that -- I'm asking is, any of the uptick in gross margin here onetime? Or do you want us to view it as sustainable?"
94614,328661858,960268,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Executives","No. I think the inventory's up. It's reflecting what we're planning for the rest of the year and making sure that we're able to satisfy customers. And as far as the gross margin goes, we expect that we'll continue to see this kind of trend throughout the",48,"No. I think the inventory's up. It's reflecting what we're planning for the rest of the year and making sure that we're able to satisfy customers. And as far as the gross margin goes, we expect that we'll continue to see this kind of trend throughout the year."
94614,328661858,960268,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Operator","You're next call comes from the line of Bob Hopkins with Bank of America.",15,"You're next call comes from the line of Bob Hopkins with Bank of America."
94614,328661858,960268,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Analysts","So the first question I wanted to ask is on the business outside the United States. Specifically, could you comment a little bit on the performance of your Knee business outside the United States? Which was the one slightly weak spot within the ortho busi",112,"So the first question I wanted to ask is on the business outside the United States. Specifically, could you comment a little bit on the performance of your Knee business outside the United States? Which was the one slightly weak spot within the ortho business? And then also, Kevin, I was wondering if you could just comment on Europe, broadly from a capital equivalent perspective, because we've seen some other healthcare companies, that sell capital equipment in the Europe, talk about a tough environment. I was wondering if you could just kind of offer a broad comment on Europe from a capital equipment perspective, and then also on the OUS Knee business."
94614,328661858,960268,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Executives","Sure, Bob. So on both businesses, I would tell you, we don't have significant businesses, as you probably know. In capital equipment in Europe, we -- our market share is quite low. And even for Knees, if you look at last year, we had a pretty good comp. W",173,"Sure, Bob. So on both businesses, I would tell you, we don't have significant businesses, as you probably know. In capital equipment in Europe, we -- our market share is quite low. And even for Knees, if you look at last year, we had a pretty good comp. We had a plus 5% in knee. And quarter-to-quarter, given that we don't have very large businesses, for both capital equipment in Europe and knees, we do tend to see fluctuations. So I would call this, sort of, the normal fluctuations that we get quarter-to-quarter. And we're not really seeing a lot of difficulty with capital equipment. But that market for us in Europe, given that the bulk of our capital is not a large capital, we're not really seeing any new pressures, and we see the Europe market as being fairly healthy, at least for our businesses. Keep in mind though that we do have very low market shares and, we have significant room to grow within both Europe as well as OUS Knees."
94614,328661858,960268,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Analysts","And then on emerging markets, I think the last couple of quarters, the business has been, as you expected, sort of down about mid-single digits. Was that the same sort of growth rate that you saw this particular quarter? And can you just give us a little",69,"And then on emerging markets, I think the last couple of quarters, the business has been, as you expected, sort of down about mid-single digits. Was that the same sort of growth rate that you saw this particular quarter? And can you just give us a little more color on the math and rationale for the expectation, that perhaps in the back half things get a little bit better?"
94614,328661858,960268,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Executives","So Bob, the emerging markets actually, the decrease was even more pronounced in the first quarter. So it was negative high signal digits in the first quarter. And that didn't surprise us, because we had a very strong first quarter last year. Things really",139,"So Bob, the emerging markets actually, the decrease was even more pronounced in the first quarter. So it was negative high signal digits in the first quarter. And that didn't surprise us, because we had a very strong first quarter last year. Things really started to tail off, starting in the second quarter last year. So that really contributed to the softness in our international sales was the negative growth in emerging markets. And we do see that starting to taper. And then obviously, the comps will ease as well. Inventory bleeds will eventually bleed out. And it's hard to predict exactly when, but as I stated, I think, on our last call, we expect around mid-year would be sort of the bottoming out period, and we should start to see improvement in the second half of the year."
94614,328661858,960268,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Operator","You're next call comes from the line of Rick Wise with Stifel.",13,"You're next call comes from the line of Rick Wise with Stifel."
94614,328661858,960268,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Analysts","Kevin, you've been very pointed in focusing us on the potential for more operating leverage in the P&L. We saw it this quarter with 90 basis points of positive leverage. When I look back at the last couple of years, you've had a couple of quarters where w",97,"Kevin, you've been very pointed in focusing us on the potential for more operating leverage in the P&L. We saw it this quarter with 90 basis points of positive leverage. When I look back at the last couple of years, you've had a couple of quarters where we've seen 100 basis points year-over-year improvement, but then it's not sustained. How do we think about this performance in the first quarter? Is it sustainable? Or is there more to come? And is that the right way to think about the 2016, '17 direction, in terms of driving leverage?"
94614,328661858,960268,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Executives","Yes. Thanks, Rick. I would tell you that if you look at our earnings guidance, it's pretty clear that we're driving leverage. So we've updated both our top line guidance, we've also updated our bottom line guidance. And this is the third time, since the b",120,"Yes. Thanks, Rick. I would tell you that if you look at our earnings guidance, it's pretty clear that we're driving leverage. So we've updated both our top line guidance, we've also updated our bottom line guidance. And this is the third time, since the beginning of the year, that we've raised our earnings guidance. And we won't be able to deliver that type of earnings guidance unless we drive operating leverage. So I'm not going to promise that it's going to be 90 basis points every single quarter, but we are committed to driving leverage at the operating income level, and usually you'll see that this year, and you'll see that when we provide guidance for you in 2017."
94614,328661858,960268,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Analysts","Great. And then just following up on the Knee performance, which was really excellent. Clearly, I know there are multiple pieces here. Triathlon is doing well, revision. Maybe talk or remind us of your current mix of revision versus Primary Knee, that mix",86,"Great. And then just following up on the Knee performance, which was really excellent. Clearly, I know there are multiple pieces here. Triathlon is doing well, revision. Maybe talk or remind us of your current mix of revision versus Primary Knee, that mix. How does it differ from industry averages or aspirational norms? And is the story in Knees, at least, in part, that the new products you showed us today are going to drive us toward those norms? Or how should we think about it?"
94614,328661858,960268,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Executives","Sure. Yes, there are multiple factors that contribute to the Knee performance. We had a great fourth quarter with around 9% growth in the U.S., and another 9% in the first quarter. And certainly, revision's part of it. And we've launched these new 3D prin",261,"Sure. Yes, there are multiple factors that contribute to the Knee performance. We had a great fourth quarter with around 9% growth in the U.S., and another 9% in the first quarter. And certainly, revision's part of it. And we've launched these new 3D printed cones in the middle of last year. And cones are very important part of the procedure. They don't generate huge revenue by themselves, but you get the pull-through of the implant when you use the cones. Our market share was roughly 6 share points below what it was in primary knees and revision. So we did sell in the revision market, but we didn't maintain the same level of market share that we do with our primary knees, roughly 6 points. So we're really excited about the gain. We'll gain those 6 points back and then potentially, even well beyond that, because we really believe we now have the best-in-class cones for revision procedures. We also have cementless knees, which is growing, and that's through our launch of our 3D printed titanium baseplate, the baseplate portion of our Knee system. That's a second factor. Third factor is really great sales force execution -- marketing programs and sales force execution. So it's hard for me to describe which of those 3 is the greater. I would say all 3 contributed to a very strong showing in knees, and it's the second quarter in a row. And I really believe we're building momentum and that we'll continue to perform well in Knees through the course of the year."
94614,328661858,960268,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Operator","You're next call comes from the line of David Roman with Goldman Sachs.",14,"You're next call comes from the line of David Roman with Goldman Sachs."
94614,328661858,960268,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Analysts","I was hoping you could talk about the Trauma business in the U.S. And Kevin, that's a franchise, that you have mentioned in a couple of different public settings, that you weren't convinced that you can necessarily outgrow the market, to the extent to whi",97,"I was hoping you could talk about the Trauma business in the U.S. And Kevin, that's a franchise, that you have mentioned in a couple of different public settings, that you weren't convinced that you can necessarily outgrow the market, to the extent to which you have over the past several quarters. But that does look like its continuing here, especially in the U.S. Can you maybe just help us think through some of the drivers that are supporting the sustainability of growth in that franchise, and how we should evaluate that on a go-forward basis?"
94614,328661858,960268,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Executives","Yes, thanks. Look, I'm thrilled with the performance of our Trauma business, and it's been a multi-year success story. We've put -- posted this plus 11 against a comp of plus 18 in the prior period. So we really are clicking on all cylinders within our Tr",224,"Yes, thanks. Look, I'm thrilled with the performance of our Trauma business, and it's been a multi-year success story. We've put -- posted this plus 11 against a comp of plus 18 in the prior period. So we really are clicking on all cylinders within our Trauma portfolio. It took us years to build that, our portfolio, frankly, on the plating side of the business. We've always been strong in nails. And then of course, the launching of our Foot & Ankle business was a tremendous -- a few years ago. And that's, that continues to grow above the overall. From a growth rate it was mid-teens growth again this quarter, and very strong performance from the STAR Ankle as well. So I would say it's rounding out our portfolio, and then terrific sales force execution. And again, it's been a 3-year story. My only caution on Trauma is really being able to maintain 15%, 16% growth quarter-over-quarter for years. It's just challenging, right? The law of numbers at some point, you would think, would start to catch up with you and just moderate the growth rate. But I have every confidence, we will continue to grow above market, and we demonstrated that, most likely, in the first quarter. Of course, not everybody has reported yet, but we feel that's a very strong showing."
94614,328661858,960268,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Analysts","Okay, that's helpful. And then maybe just a follow-up on the cash flow side for Glenn. If I look at kind of the operating cash flow and free cash flow numbers that you've disclosed for the quarter, it looks like quite a bit of capital deployed toward oper",103,"Okay, that's helpful. And then maybe just a follow-up on the cash flow side for Glenn. If I look at kind of the operating cash flow and free cash flow numbers that you've disclosed for the quarter, it looks like quite a bit of capital deployed toward operating items, and you're not converting all that much of your net income to free cash flow. Can we think about, or are there any onetime factors that may have negatively influenced Q1, that would reverse themselves through the balance of the year, whereby you can start growing cash flow in line with adjusted net income?"
94614,328661858,960268,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Executives","Yes. The biggest thing that we really -- we can't necessarily control the timing of, it's really sort of the Rejuvenate payments that we made related to the recall. So we made a payment of $0.1 billion in Q1, and don't expect that, based on what we've see",60,"Yes. The biggest thing that we really -- we can't necessarily control the timing of, it's really sort of the Rejuvenate payments that we made related to the recall. So we made a payment of $0.1 billion in Q1, and don't expect that, based on what we've seen in the past, that, that could necessarily repeat itself throughout the year."
94614,328661858,960268,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Operator","You're next call comes from the line of Richard Newitter with Leerink Partners.",14,"You're next call comes from the line of Richard Newitter with Leerink Partners."
94614,328661858,960268,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Analysts","I was hoping to start off with Spine. Kevin, can you give us any color on -- you had 2 quarters now, or 3 quarters, I think, of improving growth there, above the market. I know you have some new product launches and a nice pipeline. And that's, I'm sure,",89,"I was hoping to start off with Spine. Kevin, can you give us any color on -- you had 2 quarters now, or 3 quarters, I think, of improving growth there, above the market. I know you have some new product launches and a nice pipeline. And that's, I'm sure, helping. Can you break out for us at all, is the acceleration that carried over into the first quarter, volume-related, mix-related? Are you gaining share? Or is it just purely you have new products, and you're getting premium pricing?"
94614,328661858,960268,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Executives","Great question. I would say it's mostly volume. There is obviously some mix when you launch innovative products. We just had a limited launch of our 3D printed interbody device, and we're getting fantastic feedback on that. And that obviously sold at a pr",174,"Great question. I would say it's mostly volume. There is obviously some mix when you launch innovative products. We just had a limited launch of our 3D printed interbody device, and we're getting fantastic feedback on that. And that obviously sold at a price premium. So there is a mix component as well. But I would say it's mostly volume. And it's volume coming from the products that we launched, most of which we launched last year. We launched a slew of new products, and those are being well adopted in the marketplace. I would say, price continues to be pressured. Spine is the most pressured pricing division within Stryker. And we believe that our price is roughly in line with the market. So the fact that we're growing above market now, I think, it's 4 quarters in a row, is really driven by a renewed focus on launching products, and having great sales force execution. So I believe we'll have another strong year, just like we did last year in Spine, in 2016."
94614,328661858,960268,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Analysts","Okay. And then just one more on bundled payments. It's officially kicked off, now that we're in April. Just wondering if you had any updates on ways or areas where you're working with or partnering with hospitals or how you're leveraging something that's",86,"Okay. And then just one more on bundled payments. It's officially kicked off, now that we're in April. Just wondering if you had any updates on ways or areas where you're working with or partnering with hospitals or how you're leveraging something that's unique about what Stryker can do in terms of partnering. Is there anything that you're doing more aggressively or hearing from customers that's resonating or allowing you to potentially differentiate and gain share with this new dynamic that's playing out in the market?"
94614,328661858,960268,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Executives","Sure. So we have a division within Stryker called Stryker Performance Solution, which has consulted with over 100 hospitals the past 3 years to improve service line performance, including areas directly impacted by bundled payments. So through these engag",236,"Sure. So we have a division within Stryker called Stryker Performance Solution, which has consulted with over 100 hospitals the past 3 years to improve service line performance, including areas directly impacted by bundled payments. So through these engagements, we've developed deep insight into the profitability and opportunities that hospitals have within Orthopaedics. We were also granted Convener status by CMS last year as part of the bundled payment, BPCI program. And we are actively at risk --- taking risk with 5 institutions across multiple hospitals on the payment bundling, managing over $55 million in episode spend. With CJR, third-parties like us are not allowed to operate as a convener anymore with the Medicare program. But our Stryker Performance Solution is still providing consulting services to hospitals to help them address the challenges at managing the bundle. So we have a lot of experience. We're continuing to help and consult with our customers. And then what I'd tell you is the initial focus is really much more on the post-acute care, that's where more -- the majority of the costs of the procedure is and the biggest opportunity in the short term in addressing post-acute care. But having this division, which is headquartered in Chicago, has been a key asset for us. We have a lot of insights into the economics of the Orthopaedic service line and how to help our customers address this new world."
94614,328661858,960268,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Operator","Your next call comes from the line of Matt Taylor with Barclays.",12,"Your next call comes from the line of Matt Taylor with Barclays."
94614,328661858,960268,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Analysts","I was wondering, in the last couple of quarters, you've actually had better pricing or less declines Has there been any change in the market where you'd really call a trend, whether it's consolidation or new products broadly that have helped on price?",43,"I was wondering, in the last couple of quarters, you've actually had better pricing or less declines Has there been any change in the market where you'd really call a trend, whether it's consolidation or new products broadly that have helped on price?"
94614,328661858,960268,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Executives","Yes. I would say, obviously, pricing is still negative. It's modestly less negative coming in at 1.3. But we're still within -- very close to the 1.5 to 2 range, so we wouldn't call out anything significant that is indicative of a change in the overall pr",96,"Yes. I would say, obviously, pricing is still negative. It's modestly less negative coming in at 1.3. But we're still within -- very close to the 1.5 to 2 range, so we wouldn't call out anything significant that is indicative of a change in the overall pricing dynamics. Typically, consolidation helps, but again, it's still negative. We've seen it vary quarter-to-quarter. Sometimes, it's trended above. Fortunately, more recently, it's been trending on the lower end. I would say the outlook seems very stable and really no new dynamics that we'd say putting further pressure on pricing."
94614,328661858,960268,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Analysts","The other thing people talk about with CCJR is just more procedures moving to out-patient or just getting people out of the hospital quicker or moving to lower acuity settings. So I guess, you mentioned your consulting division, but how else are you posit",66,"The other thing people talk about with CCJR is just more procedures moving to out-patient or just getting people out of the hospital quicker or moving to lower acuity settings. So I guess, you mentioned your consulting division, but how else are you positioning yourself? Or is your product portfolio positioned to kind of capture that trend or beat competitors in that kind of vector?"
94614,328661858,960268,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Executives","No, I really think the way we're best positioned to help our customers is going to be through some of the insights that we've had, having this division now for a number of years within Stryker and understanding the economics and the focus on post-acute ca",99,"No, I really think the way we're best positioned to help our customers is going to be through some of the insights that we've had, having this division now for a number of years within Stryker and understanding the economics and the focus on post-acute care, given that eats up the bulk of the costs when you're looking at an episode of care. And so we're able to work with them in that regard. But I wouldn't say there is a unique product offering that facilitates or is advantageous in the post-acute setting, if I'm understanding the question correctly."
94614,328661858,960268,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Operator","Your next call comes from the line of Matthew O'Brien with Piper Jaffray.",14,"Your next call comes from the line of Matthew O'Brien with Piper Jaffray."
94614,328661858,960268,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Analysts","Just a follow-up a little bit on Matt's question on the CJR. I'm curious if there's been any kind of either disruption from that program going into place earlier this month, be it with MAKO or potentially here in Q2. Maybe seeing some less -- a little les",87,"Just a follow-up a little bit on Matt's question on the CJR. I'm curious if there's been any kind of either disruption from that program going into place earlier this month, be it with MAKO or potentially here in Q2. Maybe seeing some less -- a little less volume as a result, or if maybe some hospitals, as they were preparing for it, started to do more cases in Q1 and there was a benefit specifically in Q1 in anticipation of that program going into place."
94614,328661858,960268,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Executives","No, I wouldn't describe any of the change in Q1 to the CJR. If you keep in mind that CJR is not impacting a large portion of the payment -- of the procedures, at least in the short term. It doesn't include Medicare Advantage. It doesn't include Medicaid.",147,"No, I wouldn't describe any of the change in Q1 to the CJR. If you keep in mind that CJR is not impacting a large portion of the payment -- of the procedures, at least in the short term. It doesn't include Medicare Advantage. It doesn't include Medicaid. It doesn't include commercial payers. It doesn't include the hospitals that were already signed up for the BPCI program. So it's obviously certain MSAs that are required to participate, but it's very small and there aren't any penalties in the short term. So I really -- I wouldn't get overly concerned about this. It's not a new thing. Bundled payments have been around for a while. They're not brand new. It's now mandatory in certain MSAs, but I don't really see that as a catalyst to changing behavior in any meaningful way, at least not in the short term."
94614,328661858,960268,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Analysts","Okay. And just to kind of follow up on that, Kevin. Was there any slowdown, and potentially on the MAKO system side? That was, I think, down year-over-year just in anticipation of CJR, hospitals trying to figure out how that program is going to play out,",57,"Okay. And just to kind of follow up on that, Kevin. Was there any slowdown, and potentially on the MAKO system side? That was, I think, down year-over-year just in anticipation of CJR, hospitals trying to figure out how that program is going to play out, maybe some of those facilities deciding just to pause on it."
94614,328661858,960268,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Executives","No, I would say no. I think our order book is really strong for robot sales, and our procedure growth was very robust, both in new knees and in hips. [indiscernible]. The hip procedure growth was very strong in the back half of last year. So no, I would n",76,"No, I would say no. I think our order book is really strong for robot sales, and our procedure growth was very robust, both in new knees and in hips. [indiscernible]. The hip procedure growth was very strong in the back half of last year. So no, I would not say that there were some kind of a change in behavior. We were really seeing continued growth, and I'm still very bullish on our MAKO business."
94614,328661858,960268,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Analysts","Okay. And then as my follow-up, just on the domestic performance, again, this quarter was extremely strong. I'm just wondering, with Q1 typically being a seasonally soft quarter and the strength that we're seeing here, obviously, comping on ACA, it just s",109,"Okay. And then as my follow-up, just on the domestic performance, again, this quarter was extremely strong. I'm just wondering, with Q1 typically being a seasonally soft quarter and the strength that we're seeing here, obviously, comping on ACA, it just seems interesting to me how strong everything has been. Can you just talk about volume, price, mix, share taking? What's driving all that strength domestically? And then, should we think about things kind of in the U.S., slowing down in the back half, with OUS kind of picking up and then exiting into 2017, hopefully with both of those segments starting to realize more normalized type of growth?"
94614,328661858,960268,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Executives","I think we're going to continue to see strong performance in the U.S. Obviously, this was a very big quarter, but the real genesis of this is fantastic product pipelines. We have a really, across our businesses, very, very good condition of our pipeline,",230,"I think we're going to continue to see strong performance in the U.S. Obviously, this was a very big quarter, but the real genesis of this is fantastic product pipelines. We have a really, across our businesses, very, very good condition of our pipeline, with many new launches that are just starting, launches that started middle of last year. So having healthy product pipeline is always great, and that leverages our best asset, which is our sales force with Stryker, which we really know how to execute and we have health across our divisions. And then, that wasn't the case a few years ago. We had a few divisions that were a little bit softer. We now have strength in our endoscopy with our new camera. We have strength within our Neuro Powered Instruments. We have the ischemic stroke market taking off. We have a strong pipeline within Spine. You're seeing the 3D-printed implants taking off. So really, across our portfolio, we have very strong pipeline. So that isn't a one-quarter thing. I think we'll continue to see strong performance through the course of the year. And we continue to spend very robustly in R&D. So we have a cadence of new products that will continue. And so I really believe this is sustainable. We'll continue to perform very well in the U.S. This is not a one-quarter thing."
94614,328661858,960268,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Operator","Your next call comes from the line of Mike Matson with Needham & Company.",13,"Your next call comes from the line of Mike Matson with Needham & Company."
94614,328661858,960268,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Analysts","I guess, Weathering, I just wanted to ask about the Sage and Physio-Control acquisitions. Should we expect the growth rates to continue this year at the historical level, sort of double digits at Sage and mid-single digits at Physio-Control? Or is there a",57,"I guess, Weathering, I just wanted to ask about the Sage and Physio-Control acquisitions. Should we expect the growth rates to continue this year at the historical level, sort of double digits at Sage and mid-single digits at Physio-Control? Or is there a risk that the growth tapers off a little bit while you're integrating those companies?"
94614,328661858,960268,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Executives","Yes, recognizing there's always integration that has to happen, so I don't want my comments to be construed as exact targets every quarter. But overall, Sage has a long history of sustaining very strong double-digit growth, and our goal, as I mentioned, i",140,"Yes, recognizing there's always integration that has to happen, so I don't want my comments to be construed as exact targets every quarter. But overall, Sage has a long history of sustaining very strong double-digit growth, and our goal, as I mentioned, is to make sure we do everything to continue to support to them, and over time, unlock more of the opportunity outside the U.S. Physio-Control is embarking this year on a hefty new product launch cycle that will go for the next 2 years. So I think your estimations are a good place to be thinking about. And again, we'll be very transparent. We're going to give pro forma revenue performance for each business, respectively. For the first 12 months, you'll be able to see very clearly how they're growing relative to the year -- prior year base."
94614,328661858,960268,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Analysts","Okay. And then just with regard to the emerging markets, and I guess, China, more specifically, can you just talk about the differences and kind of what you're seeing with regard to the implant markets and the procedurally driven products versus the capit",81,"Okay. And then just with regard to the emerging markets, and I guess, China, more specifically, can you just talk about the differences and kind of what you're seeing with regard to the implant markets and the procedurally driven products versus the capital equipment markets? Do you have any sense as to whether or not the actual end markets for procedure volumes have slowed down? Or is that just steady and there's just so much de-stocking going on at the distributors?"
94614,328661858,960268,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Executives","So I'd kind of break it into 3 categories. I would say that the slowest impact and the greatest negative impact to us has been on the capital equipment. The next would be Spine and Trauma, which is -- and a lot of that is tendered type of business, where",140,"So I'd kind of break it into 3 categories. I would say that the slowest impact and the greatest negative impact to us has been on the capital equipment. The next would be Spine and Trauma, which is -- and a lot of that is tendered type of business, where you'd see -- we've seen the distributors really had loaded up and are bleeding their inventory. And then the least negatively impacted would be in the Hip and Knee category, which has a lot more cash pay. And so the cash pay market is not -- is the least impacted. So that's kind of -- I'd put it in those 3 buckets. And we're seeing -- obviously, it's all negative with varying degrees, with capital being the most negative, Spine and Trauma second, and then Hips and Knees, last."
94614,328661858,960268,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Operator","Your next call comes from the line of Larry Biegelsen with Wells Fargo.",13,"Your next call comes from the line of Larry Biegelsen with Wells Fargo."
94614,328661858,960268,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Analysts","First, I wanted to ask about Trauma and Extremities, and then I had one on M&A. So Kevin, Trauma and Extremities has obviously been a stellar performer for you guys for a long time. But the 2 growth areas that you're not participating in or relatively sma",110,"First, I wanted to ask about Trauma and Extremities, and then I had one on M&A. So Kevin, Trauma and Extremities has obviously been a stellar performer for you guys for a long time. But the 2 growth areas that you're not participating in or relatively small are Shoulder and Cervical Disc. So could give us an update? I know you launched your Shoulders a year or 2 ago. Give us an update there on what you're seeing and in the outlook. And then second, how attractive is the Cervical Disc market to you? And how important is it to have a Cervical Disc market? And ally got one follow-up."
94614,328661858,960268,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Executives","Sure. So Shoulder, you're right, we're a relatively small player, but we're very pleased with the launch of our Primary Shoulder and our Reverse Shoulder, which was launched just over a year ago. That has very nice growth, albeit from a strong base. So we",141,"Sure. So Shoulder, you're right, we're a relatively small player, but we're very pleased with the launch of our Primary Shoulder and our Reverse Shoulder, which was launched just over a year ago. That has very nice growth, albeit from a strong base. So we really believe we have the right products to be able to win in the market. It's going to take time. This isn't like Foot & Ankle, where we're approaching new surgeons. The have to be able to take share. But I was very encouraged by the growth the last 2 quarters in our Shoulder business. It doesn't really make a big impact in our overall business, just given the size, but I feel that we now have a very good portfolio, and Shoulder will become a growth area for us going forward. What's the second question?"
94614,328661858,960268,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Analysts","On Cervical Disc, how important it is to have a Cervical Disc.",12,"On Cervical Disc, how important it is to have a Cervical Disc."
94614,328661858,960268,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Executives","We would normally report that -- if we had a Cervical Disc, which we don't right now, that would be reported in our Spine business, not in our Trauma and Extremities business. And right now, our Spine business is doing really well. We're launching many, m",92,"We would normally report that -- if we had a Cervical Disc, which we don't right now, that would be reported in our Spine business, not in our Trauma and Extremities business. And right now, our Spine business is doing really well. We're launching many, many products. We don't feel that we have to have a Cervical Disc at the moment to be able to drive growth. It's something we'll look at. But at the current time, we don't see that as an impediment to having strong growth in our Spine business."
94614,328661858,960268,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Analysts","Got it. And my apology for wrapping that into Trauma and Extremities. Sorry about that. So Kevin, you spent $4 billion on 2 recent deals. So my question is, how does that impact your ability or willingness to do more deals right -- until you've kind of in",50,"Got it. And my apology for wrapping that into Trauma and Extremities. Sorry about that. So Kevin, you spent $4 billion on 2 recent deals. So my question is, how does that impact your ability or willingness to do more deals right -- until you've kind of integrated those 2?"
94614,328661858,960268,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Executives","Sure. We still have significant capacity to do extra deals. So we had a one-notch downgrade from both S&P and Moody's. And if you look at S&P, we went from an A+ to A rating. We are committed to maintaining investment grade, but there's obviously a large",191,"Sure. We still have significant capacity to do extra deals. So we had a one-notch downgrade from both S&P and Moody's. And if you look at S&P, we went from an A+ to A rating. We are committed to maintaining investment grade, but there's obviously a large gap between A rating and investment, at the low end of investment grade. Keep in mind that the vast majority of the deals we do are small tuck-in deals. So that will continue to be the case for Stryker. That's where we drive the most value when we find great technologies that we can give to our fabulous sales forces to drive. So that -- you'll continue to see those that we've done and the majority of the deals, but we still have significant capacity to do more M&A. I would say, all of our businesses have embedded BD people. We have not told them to slow down at all, so they're continuing to scour the market to look for opportunities that will add value, and we won't hesitate to pull the trigger on new deals if we believe they'll be value-creating for Stryker."
94614,328661858,960268,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Operator","Your next call comes from the line of Matt Keeler with Credit Suisse.",13,"Your next call comes from the line of Matt Keeler with Credit Suisse."
94614,328661858,960268,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Analysts","I guess just to start on, on Sage, you highlighted the potential to build that in Western Europe, and I was wondering if you could help us think about that market opportunity. Is that a market similar in size in Western Europe or the U.S. since Sage has h",64,"I guess just to start on, on Sage, you highlighted the potential to build that in Western Europe, and I was wondering if you could help us think about that market opportunity. Is that a market similar in size in Western Europe or the U.S. since Sage has had a smaller market share? Or is that a market that you'll be building from scratch?"
94614,328661858,960268,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Executives","This will be much more building the market, much the way Sage did in the U.S. They really were the driving force behind the innovations that allowed solutions to many of these hospital-acquired infections. These very elegant, easy-to-use, solutions with d",159,"This will be much more building the market, much the way Sage did in the U.S. They really were the driving force behind the innovations that allowed solutions to many of these hospital-acquired infections. These very elegant, easy-to-use, solutions with demonstrated clinical data that shows when they're routinely used, and they can significantly limit the occurrence. The same conditions, hospital-acquired pneumonia infections are prevalent around the world. It just was not an area they focused on, given their initial investment in the U.S. market. So this will be market development. It'll be using the sales force as they do to help drive that, but it's -- very much the same conditions exist, but it'll be more about market expansion, which is why we'd say, over time, this is the value we look to unlock. It is not something that's going to occur suddenly in 2016. This will be a multi-year process to really start to drive awareness and adoption."
94614,328661858,960268,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Analysts","Okay, great. And my follow-up, last quarter, you shared some margin targets for the year. Just wondering if you'll give us an update on what those will look like with Sage and Physio-Control.",33,"Okay, great. And my follow-up, last quarter, you shared some margin targets for the year. Just wondering if you'll give us an update on what those will look like with Sage and Physio-Control."
94614,328661858,960268,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Executives","So we provide top line and earnings guidance. We don't provide specific margin guidance, although, as Glenn noted on the call, while the magnitude of the year-over-year increase in gross margin won't continue, we should continue to be at the Q1 levels for",83,"So we provide top line and earnings guidance. We don't provide specific margin guidance, although, as Glenn noted on the call, while the magnitude of the year-over-year increase in gross margin won't continue, we should continue to be at the Q1 levels for 2016. But we haven't given specific guidance. We do expect to up margin expansion. That's inclusive of the deal that they closed in early April. But beyond that and the revisions, upward revisions to the targets today, there's nothing additional."
94614,328661858,960268,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Operator","Your next call comes from the line of Glenn Novarro with RBC Capital Markets.",14,"Your next call comes from the line of Glenn Novarro with RBC Capital Markets."
94614,328661858,960268,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Analysts","Two questions. One, U.S. Knees and Hips for Stryker came in better. Yesterday, J&J also reported a much stronger U.S. in the Hip number. So the market is likely coming in better, but Kevin, I just wanted to see what your view is on the competitive dynamic",95,"Two questions. One, U.S. Knees and Hips for Stryker came in better. Yesterday, J&J also reported a much stronger U.S. in the Hip number. So the market is likely coming in better, but Kevin, I just wanted to see what your view is on the competitive dynamics. Zimmer and Biomet sales forces have combined as of last year. But I'm just wondering, are you still possibly seeing disruption in the marketplace associated with Zimmer and Biomet? And could that be helping your results as well as J&J's results yesterday? And then I have a follow-up."
94614,328661858,960268,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Executives","So we're really pleased with our result, particularly our U.S. performance in both Hips and Knees, at this point, with the largest player having not yet reported along with other competitors in the market, it's very difficult to make any kind of call with",167,"So we're really pleased with our result, particularly our U.S. performance in both Hips and Knees, at this point, with the largest player having not yet reported along with other competitors in the market, it's very difficult to make any kind of call with conviction around market growth. So clearly, we'll have a much better sense as additional numbers roll in, where the overall market growth is. But we feel very comfortable in the U.S. that w,e grew at the high end, if not above the market. And -- but we'll have to wait to see how numbers come in to get a general sense of whether there's been any type of acceleration. Keep in mind, in Recon, you really have to look at rolling 4-quarter trends because growth rates can vary quarter-to-quarter. So I wouldn't want to read too much into an uptick in growth, to the degree we see one in the first quarter because it may not be indicative of a trend line."
94614,328661858,960268,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Analysts","Okay. And then one last follow-up on CJR. One of the pushbacks that we get is there's a thought out there that surgeons will start cherry-picking patients. They may not do the more challenging cases, and then they, may fall through the system. Our due dil",59,"Okay. And then one last follow-up on CJR. One of the pushbacks that we get is there's a thought out there that surgeons will start cherry-picking patients. They may not do the more challenging cases, and then they, may fall through the system. Our due diligence does not suggest that'll happen, but I just wanted to hear your opinion."
94614,328661858,960268,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Executives","Yes. This has obviously gotten a lot of focus of late. I would tell you, we do not believe that  CMS's intent is to reduce utilization. It's really rather to ensure that each patient has access to the most appropriate care. There's been a speculation, but",195,"Yes. This has obviously gotten a lot of focus of late. I would tell you, we do not believe that  CMS's intent is to reduce utilization. It's really rather to ensure that each patient has access to the most appropriate care. There's been a speculation, but have some type of step function reduction in volumes as higher-risk patients are increasingly denied surgeries. We believe this is unlikely. We do think, based on all the work we've done and through SPS and obviously, our presence in Recon, that surgeons are going to continue to look to optimize treatments for higher-risk patients. They do that today. And this will include managing their post-acute care, which can vary. And so they have and are going to continue to treat all types of patients. The data clearly shows hip and knee surgery has a very high, long-term success rate and significantly improves quality of life. And that's for all patients, not just the healthiest ones. So we are not expecting some type of significant change, but rather, we do believe they're going to look to find the optimum ways to treat these patients, including the post acute care regimen."
94614,328661858,960268,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Operator","Your next call comes from the line of Kaila Krum with William Blair.",13,"Your next call comes from the line of Kaila Krum with William Blair."
94614,328661858,960268,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Analysts","So a follow-up on Richard's earlier question on Spine. Just to dig in a bit further. I mean, you mentioned that you're seeing an increase in volume. Can you give us a sense for where you believe that increase in volume is coming from? Is it more market re",94,"So a follow-up on Richard's earlier question on Spine. Just to dig in a bit further. I mean, you mentioned that you're seeing an increase in volume. Can you give us a sense for where you believe that increase in volume is coming from? Is it more market related, or do you think that you are taking share? And if it is the latter, I mean, I'm curious as to whether or not that share taking is coming from the bigger players in that segment or from some of the smaller pure plays."
94614,328661858,960268,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Executives","Yes, we think, overall, the market might be modestly improving. But again, it's very difficult to say because we're one of the earlier companies to report results. So we'll have to see how all the numbers come in. And it also is going to vary by company,",100,"Yes, we think, overall, the market might be modestly improving. But again, it's very difficult to say because we're one of the earlier companies to report results. So we'll have to see how all the numbers come in. And it also is going to vary by company, which segment of the market more of your products are weighted towards. So overall, we've been launching a number of new products. We've talked about the investments we've made over the last couple of years in the R&D pipeline. And we think this is mostly indicative of us gaining more market share back."
94614,328661858,960268,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Executives","Yes, we've seen in the Spine market, whether it's small players or larger players, innovation drives growth and innovation is what takes market share. And our innovation engine is alive and well in our Spine business, and that's what's caused us to grow a",46,"Yes, we've seen in the Spine market, whether it's small players or larger players, innovation drives growth and innovation is what takes market share. And our innovation engine is alive and well in our Spine business, and that's what's caused us to grow above the market."
94614,328661858,960268,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Analysts","Okay. And then I'm just curious if you guys had any differences in terms of selling days in the quarter that may have impacted growth in the quarter, and if so, the estimated impact.",34,"Okay. And then I'm just curious if you guys had any differences in terms of selling days in the quarter that may have impacted growth in the quarter, and if so, the estimated impact."
94614,328661858,960268,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Executives","Yes. No, selling days are equal between quarters, between last year and this year.",14,"Yes. No, selling days are equal between quarters, between last year and this year."
94614,328661858,960268,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Operator","Your next call comes from the line of Kyle Rose with Canaccord.",12,"Your next call comes from the line of Kyle Rose with Canaccord."
94614,328661858,960268,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Analysts","Just to add, one question on MAKO. You talked a lot about refining the processes and the workflow over the course of 2016 compared to the launch in '17. When you think about that, how do you think about the optimal time of the procedure and the trade-off",108,"Just to add, one question on MAKO. You talked a lot about refining the processes and the workflow over the course of 2016 compared to the launch in '17. When you think about that, how do you think about the optimal time of the procedure and the trade-off of being potentially time-additive? And I guess, the real question is, when you come to market with the MAKO Total Knee, what percentage of that market, from a volume base, do you think the system will be time-neutral to your high-volume or to your medium-volume surgeon? I mean, what's the real market segment that the MAKO is really targeting here?"
94614,328661858,960268,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Executives","Sure. So much of the data that you're looking for, we're going to be able to track once we go into full commercial launch, and it's going to vary by surgeon, a really high-volume surgeon doing hundreds of knee replacements a year. It's going to -- this is",189,"Sure. So much of the data that you're looking for, we're going to be able to track once we go into full commercial launch, and it's going to vary by surgeon, a really high-volume surgeon doing hundreds of knee replacements a year. It's going to -- this is going to be time-additive for the lower-volume surgeon. They're going to be much closer to time-neutral, but it's also why we wanted to spend our time on the training protocol to really look at ways that we can optimize this with this first-generation product. The other key is this is not just about time. We believe we're going to truly improve the patient experience, we're going to have a more reproducible surgery because there tends to be tremendous variation, particularly with lower-volume surgeons. We think we can improve muscle disruption and things that add to the fact that close to 30% of knee patients are dissatisfied with the procedure. So it's really not just about time, it's truly about having experience that's better for the surgeon, better for the patient. And over time, we believe the outcome's data will support that."
94614,328661858,960268,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Analysts","Great. And then just another question on the robotic side. We've heard a lot thoughts in rumbling -- about robotics in the Spine market, in particular, more of a play on navigated pedicle screw placement. Just your general thoughts on that, given your ove",76,"Great. And then just another question on the robotic side. We've heard a lot thoughts in rumbling -- about robotics in the Spine market, in particular, more of a play on navigated pedicle screw placement. Just your general thoughts on that, given your overlap in the Spine as well as presence from a capital equipment side and navigation. And then, how does, if any, does a MAKO robot play a factor in those plans, moving forward?"
94614,328661858,960268,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Executives","So certainly, we have a terrific navigation unit -- business unit. That's within our Instruments business. And so we're very well aware of how that procedure gets done, whether it's with navigation or not. That continues to be a growth area for us, both t",161,"So certainly, we have a terrific navigation unit -- business unit. That's within our Instruments business. And so we're very well aware of how that procedure gets done, whether it's with navigation or not. That continues to be a growth area for us, both the Neuro and Spine market. But we are, in the next few years, really focused on Hip and Knees with MAKO. We have a lot of work to do to get the Total Knee. We think that's a killer procedure. I think if you look down the road, 5 plus years, certainly, Spine could be an area of interest. Hip Arthroscopy could be an area of interest. Shoulder could be an area of interest. So there's many areas. I think robotics will be a growth area for many, many years to come. But first things first. We really have to focus on Hips and Knees, and that's where our attention will be for the next few years."
94614,328661858,960268,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Operator","Your next call comes from the line of Amit Hazan with Citi.",12,"Your next call comes from the line of Amit Hazan with Citi."
94614,328661858,960268,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Analysts","Maybe just start on the Hip and Knee side, U.S. volumes. I want to maybe take a big picture kind of market view for moment. Kind of, when we look at and analyze a market model, some of your competitors' data, it seems pretty clear that it was -- and volum",125,"Maybe just start on the Hip and Knee side, U.S. volumes. I want to maybe take a big picture kind of market view for moment. Kind of, when we look at and analyze a market model, some of your competitors' data, it seems pretty clear that it was -- and volumes have been really strong for a couple of years now, maybe up in the 6%, 7%, 8% range for the market as a whole in the U.S. That would be kind of well above the 10-year plus average for volumes. So I'm wondering what you think has been the driver of that over these last couple of years and perhaps, more importantly, the extent to which you think that's sustainable on the volume side."
94614,328661858,960268,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Executives","Yes. No, we're seeing a very stable market. I think -- just look at demographics, right? Everyday there are 10,000 people at 65 [ph], more and more people are talking to friends that have had Hip and Knee replacements. The results are fabulous. People wan",228,"Yes. No, we're seeing a very stable market. I think -- just look at demographics, right? Everyday there are 10,000 people at 65 [ph], more and more people are talking to friends that have had Hip and Knee replacements. The results are fabulous. People want to be active. So actually, we're seeing a lot, and certainly, we see this with the uni, with MAKO. We see a lot of young people going in for surgery. That wasn't happening before. You're seeing unemployment. Unemployment is a great proxy. When we see unemployment come down, we tend to see a lot more joint replacements, and specifically, knees. So hips really hurt even when you lie down at night. Knees, you can defer. And so we see that as a very good proxy. That's much more of a proxy than anything to do with ACA. So we really believe we've got a stable market that will continue to be stable for not just the next quarter, but for the next year or 2 years. And demographics is a key part, patient awareness is a key part and people wanted to be active. A lot of people want to be active. And so we don't really see, from a demand or volume standpoint, we don't see any headwinds right now. And frankly, the lower unemployment is a little bit of a tailwind."
94614,328661858,960268,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Analysts","Great. And then just kind of back to the MAKO and bundled payment, maybe just kind of asking that question in a different way to throw it out to you guys. What is the sales pitch for MAKO in a bundled payment environment? Potentially, how does MAKO fit in",76,"Great. And then just kind of back to the MAKO and bundled payment, maybe just kind of asking that question in a different way to throw it out to you guys. What is the sales pitch for MAKO in a bundled payment environment? Potentially, how does MAKO fit into a 90-day expert [ph]at care better -- in a better way than what's being done here traditionally, such that it would have added value to the hospital?"
94614,328661858,960268,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Executives","So we really believe MAKO is going to improve outcomes, right? If you have consistent, reproducible product placement, less soft tissue damage, if you need less, we have for your patient, they're more satisfied, and that's going to win in the market. So i",169,"So we really believe MAKO is going to improve outcomes, right? If you have consistent, reproducible product placement, less soft tissue damage, if you need less, we have for your patient, they're more satisfied, and that's going to win in the market. So irrespective of the type of payment, whether it's a single-payer system like in France, a two-tier system like in the U.K. or whether where we are now, it's a bundled payment system. So the method of payment is less interesting to us, frankly. If we deliver value and prove that value, we will win in the marketplace. And frankly, when you look at a bundle, again, the implant price, and even with a robot, if you factor in the robot and that's still not the majority of the procedure costs. So there's a lot of room to optimize beyond just the implant. And we really believe if we deliver that excellent experience and they have better outcomes, that we'll be able to win in the marketplace."
94614,328661858,960268,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Operator","Your next call comes from the line of Jeff Johnson with Robert W. Baird.",14,"Your next call comes from the line of Jeff Johnson with Robert W. Baird."
94614,328661858,960268,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Analysts","Katherine, just now that we're in April, on the MHLW price reset, can you just confirm now it's probably going to be, what, no more than 20, 25 basis point impact to your company-wide pricing?",35,"Katherine, just now that we're in April, on the MHLW price reset, can you just confirm now it's probably going to be, what, no more than 20, 25 basis point impact to your company-wide pricing?"
94614,328661858,960268,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Executives","Yes, that's a good approximation.",5,"Yes, that's a good approximation."
94614,328661858,960268,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Analysts","Okay, good. And then, Kevin, I guess, a question for you. I heard the comments on the ankle performance. In the quarter, it sounds like that was strong. When IPPS proposals came out the other night, the question, I hadn't really thought of it until just s",154,"Okay, good. And then, Kevin, I guess, a question for you. I heard the comments on the ankle performance. In the quarter, it sounds like that was strong. When IPPS proposals came out the other night, the question, I hadn't really thought of it until just staring at some of the rates the other night. But with us not getting a carveout on a total ankle replacement code, which I don't think anybody really expected that we would, again, this year, but as you look at the episode of care costs on Ankle being higher than Hips and knees, but being reimbursed at those same rates, and as we go into this bundled payment environment, you think there's any bias or any kind of skew away from ankles that hospitals would maybe take just as their costs are higher but reimbursement is the same, with -- being paid under those Hip and Knee codes?"
94614,328661858,960268,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Executives","So first of all, we're just starting with Hip and Knee in bundled payments. And I think -- and Medicare is going to be looking at high-volume procedures and moving them into the bundle. Total ankle is a very small part of the total market. But it's still,",285,"So first of all, we're just starting with Hip and Knee in bundled payments. And I think -- and Medicare is going to be looking at high-volume procedures and moving them into the bundle. Total ankle is a very small part of the total market. But it's still, Fusion is still the standard of care. Ankles are growing very fast but from a very small base. So I'm not -- I really don't see this hitting the radar screen, at least, not for a few years back for Medicare. They've got a lot of other procedures they're going to focus on. I do believe bundled care and bundled payments will increase. It's a good thing for the overall health care system. It will address a lot of costs that need to be reduced, frankly, in the case of Hip and Knee procedure. There is an overprescription today on the post-acute. There's a lot of costs, and we've seen, when we work with hospitals on their service line profitability, that's the area that we tend to focus on the most. So I think we're a long way away from bundled payments having a big impact on Total Ankle, and frankly, it's a better outcome. So Fusion is -- was a standard of care in some of the joint replacements a long time ago, and that's been replaced by Total Prosthesis, and Total Ankle will be a better outcome. Of course, like everything in health care, finding payments and getting procedures reimbursed always goes through its ups and downs. But if you have a better outcome, eventually, it'll get paid. So I don't really see a headwind for that, at least not in the next few years."
94614,328661858,960268,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Operator","Your next call comes from the line of Josh Jennings with Cowen and Company.",14,"Your next call comes from the line of Josh Jennings with Cowen and Company."
94614,328661858,960268,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Analysts","I just was hoping you could clarify. It looks like there's a step-up in CapEx in Q1 from the normal run rate and just the driver behind that. And just link to that question, is any major product launches across the major divisions you would call out that",60,"I just was hoping you could clarify. It looks like there's a step-up in CapEx in Q1 from the normal run rate and just the driver behind that. And just link to that question, is any major product launches across the major divisions you would call out that are going to help with this 5.5% to 6.5% organic growth trajectory?"
94614,328661858,960268,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Executives","Yes. I think, in Q1, we started some of the spending that's going to be required for our deployment of our new ERP system. And so that's the big thing that kind of stuck out in the cash flow.",39,"Yes. I think, in Q1, we started some of the spending that's going to be required for our deployment of our new ERP system. And so that's the big thing that kind of stuck out in the cash flow."
94614,328661858,960268,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Executives","Yes. And as it relates to product launches, so we have a number of products that we've talked about like the signature line of Neuro Powered drills that haven't had a full year impact. But we do have our Neptune 3 launch that's upcoming, which is the main",205,"Yes. And as it relates to product launches, so we have a number of products that we've talked about like the signature line of Neuro Powered drills that haven't had a full year impact. But we do have our Neptune 3 launch that's upcoming, which is the main waste management product within Instruments. That's coming in the middle of the year and that will be bit consumer to growth. But I would say it's just a continuation. That camera launch was December. It really was mid-December last year, the 1588, and we're getting great customer feedback. So that will continue going into this year. Sports medicine is launching a number of products. Spine, the 3D-printed implant, the interbody device, great feedback, but a very small number of surgeons, put those in, in the first quarter, so we'll expand that launch over the course of the year. So I wouldn't point to one single product. It's just typical of Stryker. We tend to have our growth spread across a wide variety of products. But there are a number of products that will contribute to the growth rates, and obviously, racing after one quarter, we'll have confidence that we'll be able to sustain this level of growth."
94614,328661858,960268,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Operator","There are no further questions at this time. I will now turn the conference over to Mr. Kevin Lobo for any closing remarks.",23,"There are no further questions at this time. I will now turn the conference over to Mr. Kevin Lobo for any closing remarks."
94614,328661858,960268,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Executives","So thank you, all, for joining our call. Our conference call for the second quarter 2016 results will be held on July 21. Thank you.",25,"So thank you, all, for joining our call. Our conference call for the second quarter 2016 results will be held on July 21. Thank you."
94614,328661858,960268,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Operator","Thank you, ladies and gentlemen. This concludes today's conference. Thank you for participating, you may now disconnect.",17,"Thank you, ladies and gentlemen. This concludes today's conference. Thank you for participating, you may now disconnect."
94614,328661858,960334,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Operator","Welcome to the First Quarter 2016 Stryker Earnings Call. My name is Liz, and I will be your operator for today's call. [Operator Instructions]This conference call is being recorded for replay purposes. Before we begin, I would like to remind you that",134,"Welcome to the First Quarter 2016 Stryker Earnings Call. My name is Liz, and I will be your operator for today's call. [Operator Instructions]
This conference call is being recorded for replay purposes. 
Before we begin, I would like to remind you that the discussions during this conference call will include forward-looking statements. Factors that could cause actual results to differ materially are discussed in the company's most recent filings with the SEC. 
Also, the discussions will include certain non-GAAP financial measures. Reconciliations to the most directly comparable GAAP financial measures can be found in today's press release that is an exhibit to Stryker's current report on Form 8-K filed today with the SEC. 
I will now turn the call over to Mr. Kevin Lobo, Chairman and Chief Executive Officer. You may proceed, sir."
94614,328661858,960334,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Executives","Welcome to Stryker's First Quarter Earnings Call. Joining me today are Glenn Boehnlein, who assumed the role of CFO, effective April 1; and Katherine Owen, VP of Strategy and Investor Relations. For today's call, I will provide opening comments, followe",375,"Welcome to Stryker's First Quarter Earnings Call. Joining me today are Glenn Boehnlein, who assumed the role of CFO, effective April 1; and Katherine Owen, VP of Strategy and Investor Relations. 
For today's call, I will provide opening comments, followed by an M&A update from Katherine. Glenn will then provide additional details regarding our quarterly results before we open the call to Q&A.
We are pleased with our start to the year, as Q1 organic sales growth of 6.1% came in above our expectations, with strong performances across all 3 segments: Orthopaedics, MedSurg and Neurotechnology and Spine. The performance was led by continued new product introductions, and strong sales and marketing execution. 
Geographically, Q1 was powered by ongoing momentum in the U.S., with sales growth of 8.9%. As expected, growth was challenged outside the U.S., given the tough year-over-year comparisons in emerging markets, where growth started to slow in the second quarter of last year. Challenges still exist in emerging markets, although the year-over-year impact should ease in the back half of the year.
We continue to have good performance in Europe, Japan and Australia. Our strategy of business unit specialization with dedicated sales forces, marketing and R&D continue to be a differentiating factor in the sustainability of our above-market growth.
Consistent R&D investment has generated strong internal product pipelines across the company, and we continue to augment them with acquisitions. We are thrilled to welcome Sage, Physio-Control and Synergestics (sic) [Synergetics] to Stryker, and believe that the addition of these companies will further strengthen our businesses. 
Looking at the P&L, we are building on 2015's success, and delivered solid adjusted earnings growth of 11.7%, despite modest foreign currency headwinds.
This improvement stemmed from the strong top line and year-over-year gross margin expansion. Importantly, we continue to invest heavily in R&D in both absolute dollars and as a percent of sales. Our cost transformation for growth efforts are in the early stages and are multi-year in nature, and we are starting to realize benefits. 
Overall, we are confident in our stated goal of achieving sales at the high end of medtech with ongoing earnings leverage and believe our Q1 results position us well for 2016.
I will now turn the call over to Katherine."
94614,328661858,960334,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Executives","Thanks, Kevin. My comments today will focus on providing an update on MAKO, along with the 2 larger M&A deals we recently closed on: Sage and Physio-Control. With respect to MAKO, we sold 7 robots during the quarter, globally, which is in line with the",480,"Thanks, Kevin. My comments today will focus on providing an update on MAKO, along with the 2 larger M&A deals we recently closed on: Sage and Physio-Control. 
With respect to MAKO, we sold 7 robots during the quarter, globally, which is in line with the same period a year ago. As many of you know, capital sales tend to be the strongest in the fourth quarter, and also can fluctuate from quarter-to-quarter. We are highly encouraged by order trends, which reinforces the growing interest in demand for the MAKO robotic system, fueled by the expanded indications and planned launch of the Total Knee system, where we continue to target full commercial rollout in 2017. There is no change to our launch plan for the Total Knee, which will focus throughout 2016 on working with key opinion leaders to optimize the training protocol and gather observational data that will help to frame the anticipated benefits, all of which will ensure a strong podium presence at key orthopaedic meetings as we move throughout 2017. 
In Q1, we were also encouraged by the robust procedure growth in both partial knees and hips using MAKO.
Turning to the recent M&A activity. In early April, we closed on both Sage and Physio-Control, which will be integrated into our Medical division. Starting with Sage, our focus will be to ensure the continuation of strong double-digit top line growth that the company has had a long history of achieving. With their market-leading product portfolio, focus on clinically supported innovation, product ease-of-use and strong sales support, we believe Sage can continue to drive both market expansion and share gains in the prevention of hospital-acquired conditions. Given our existing global footprint, which includes strong and broad sales and marketing support, we believe that over time Stryker can help drive adoption of the Sage portfolio outside the U.S., where revenue today is limited as the company had historically focused its investments in the U.S. market. 
Regarding Physio-Control, we believe we have significant opportunities over time to drive both sales and earnings synergies, given our combined presence in the prehospital setting. In the near term, both businesses will operate largely independently, with a focus on their respective 2016 targets and planned key new product launches.
Importantly, for both Sage and Physio-Control, we have identified and put in place a highly experienced integration team, which given our BD history, should help ensure a smooth integration. 
As we move through the first 12 months postclosing of both Sage and Physio-Control, we will provide you with the pro forma quarterly growth rates for each, to help provide visibility regarding our execution and their top line contribution. There's no change to our previously announced expected accretion from both these transactions to adjusted EPS in 2016 and 2017 of $0.07 and $0.15 to $0.18, respectively. 
With that, I will now turn the call over to Glenn."
94614,328661858,960334,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Executives","Thanks, Katherine. My comments on today's call will focus on the financial results and key drivers of our first quarter performance. Our detailed financial results have been provided in the various schedules included in today's press release. As to our",1150,"Thanks, Katherine. My comments on today's call will focus on the financial results and key drivers of our first quarter performance. 
Our detailed financial results have been provided in the various schedules included in today's press release. As to our overall performance, our constant currency organic sales growth of 6.1% exceeded the high end of our full year expectations and came in better than our expectations at the start of the quarter. The growth, based on the same number of selling days, reflected strong U.S. volume and mix of 10.2%, marginally offset by pricing, which was slightly negative at 1.3%.
Adjusted EPS of $1.24 increased 11.7% from 2015, primarily driven by our strong top line growth and favorable margin performance. Foreign exchange unfavorably impacted EPS by $0.02 per share, roughly in line with our guidance.
Looking at our segment highlights. Orthopaedics constant currency growth was 4.6%, which was led by U.S. Orthopaedics growth of 7.9%, reflecting continued strong sales in our Trauma and Extremity business, which grew 11%; and a 9% increase in Knees, reflecting continued momentum from our last quarter; and the success of our Triathlon products, driven by our Tritanium revision cones, our cementless knee products as well as new customer adoption of our MAKO uni platform.
We are now seeing an acceleration in our revision implant sales, where previously our market share lagged our overall Total Knee share. Partly offsetting the strong U.S. orthopaedic performance was the continued challenging markets in China and Brazil, which contributed to the negative 1.4% constant currency decline in international. 
Overall, our first quarter results continue to reflect strong momentum across our Orthopaedics portfolio. 
Our MedSurg segment, with constant currency growth of 4.6%, also demonstrated strong momentum, with U.S. growth of 7.6%. Instruments had solid U.S. growth of 10.2%, with good performance in their waste management products. 
Endoscopy's new 1588 camera, which features enhanced visualization that broadens the applicable surgical applications, was a primary driver for the division's solid performance and will continue to be a growth engine in 2016. 
Lastly, Medical's growth, which was up against a tough year-over-year comparable, benefited from strong demand for its market-leading stretcher and ambulance cot products, which underscored the strength of its portfolio and the overall health and stability of hospital capital budgets that we're seeing in the market. 
As with Orthopaedics, MedSurg also experienced challenges in emerging markets, primarily China. We expect this to continue as we work through our distributors to drive demand and reduce the buildup of their inventories, recognizing comparisons will also ease as we move through 2016.
All in all, our MedSurg businesses saw healthy order growth in the first quarter, and should be well positioned to continue their momentum. 
Turning to Neurotechnology and Spine. The impressive year-end momentum achieved by this group continued in the first quarter with 13.1% constant currency growth. Neurotechnology's 21% growth was highlighted by the developing market for device-based treatment of ischemic stroke. While there's still considerable market development required, we are highly encouraged by the potential for this segment and our Trevo Stentriever technology. As 1 of 2 major stentrievers on the market, combined with compelling clinical data underscoring the efficacy of these devices such as the MR CLEAN study, Stryker is well-positioned for growth in Neurovascular. 
We also continue to see excellent performance in our Neuro-Powered Instruments business led by strong growth in their signature drill products released last year. 
We also are encouraged by the solid showing up -- for Spine, up 5.8% in the U.S., as new product launches included in a limiting launch of our 3D-printed interbody device, are clearly having an impact. Neurotechnology and Spine continue to benefit from a new product pipeline resulting from robust R&D investment over the past few years. 
I will now focus on our first quarter operating highlights, starting with gross margin, which, on an adjusted basis, increased 240 basis points to 68%. Of this improvement, roughly 1/4 relates to the 2-year suspension of the Medical Device Tax, while the remainder reflects a favorable mix and favorable foreign exchange, partly offset by negative pricing. 
As for our operating expenses, we continue to focus on internal innovation, with R&D at 6.4% of sales, which is in line with our overall target spend. On an adjusted basis, SG&A increased to 37.4% of sales versus 35.9% in the prior period, which was driven by increased selling activity, anticipated spending related to our new ERP deployment efforts and reinvestment in the Medical Device Tax. 
Looking ahead, we expect SG&A on a full year basis to be comparable to 2015. Overall, our operating margin increased 90 basis points, reflecting solid top line growth and favorable mix and gross margins offset slightly by higher SG&A for the quarter.
Lastly, some financial highlights on the other income and expense. Other expenses increased due to higher net interest expense related to increased borrowings during the quarter, primarily to fund our recently completed Sage and Physio-Control acquisitions. Net interest expense will continue to be higher than Q1, as our borrowing occurred at the end of Q1. Our first quarter adjusted effective tax rate of 17.4% reflects the benefits of our global tax structure and the permanent renewal of certain tax extenders, which was included in our guidance.
Moving on to the balance sheet. We continue to maintain a strong balance sheet with $7.5 billion of cash and marketable securities, of which approximately 72% [ph] was held in the U.S. This balance reflects $3.5 billion of proceeds related to our previously mentioned debt offering, which is included in the $7.5 billion of debt on the balance sheet at the end of the quarter. Subsequent to the end of the quarter, $4.1 billion of cash was used to fund the Sage and Physio-Control acquisitions. 
Turning to cash flow. Our cash flow from operations for 2015 was $2 billion compared to $4 billion last year, as we made $0.1 billion of payments associated with our Rejuvenated and ABG II recall. 
Approximately 50% of the funding for the Rejuvenate liability is being sourced from OUS cash. 
Finally, as we have previously announced, we have suspended our share repurchases for the remainder of the year. 
With that, I will move on to our guidance. Based on our first quarter performance, we now expect our full year organic sales growth to be in the range of 5.5% to 6.5% for 2016. If foreign currency exchange rates hold near current levels, we anticipate net sales will be negatively impacted by approximately 1% for 2016. 
We also expect continued unfavorable price reductions in the range of 1.5% to 2%, consistent with the pricing environment we experienced in 2015. 
Finally, our guidance for adjusted net earnings per diluted share in 2016 now stands in the range of $5.65 to $5.80 for the full year, and $1.33 to $1.38 for the second quarter. 
And now I will open up the call for Q&A."
94614,328661858,960334,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Operator","[Operator Instructions] Your first call comes from the line of David Lewis with Morgan Stanley.",15,"[Operator Instructions] Your first call comes from the line of David Lewis with Morgan Stanley."
94614,328661858,960334,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Analysts","So a couple of questions. Kevin, just first off just talk about the guidance. It's -- obviously, the quarter was strong, and it's a little early in the year, obviously, to be raising your organic sales estimates. So obviously, you have some conviction in",107,"So a couple of questions. Kevin, just first off just talk about the guidance. It's -- obviously, the quarter was strong, and it's a little early in the year, obviously, to be raising your organic sales estimates. So obviously, you have some conviction in the back half. As I think about the back half of the year, obviously, medical comparables are going to get a little easier; emerging market pressure should also ease. Is there anything else that you see in the business, broadly, across Stryker, that's giving you the confidence in the raise to the organic sales guidance heading into the back half of the year?"
94614,328661858,960334,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Executives","David, thank you. I would say that I feel very good about the strength of our entire business portfolio. So if you look at MedSurg, you look at Neurotechnology and even Orthopaedics, I really feel that we have balanced strength across our portfolio. And t",129,"David, thank you. I would say that I feel very good about the strength of our entire business portfolio. So if you look at MedSurg, you look at Neurotechnology and even Orthopaedics, I really feel that we have balanced strength across our portfolio. And that balanced strength is what gives us the confidence, even after the first quarter, to raise our organic sales guidance. So -- but we had indicated previously that the first quarter was -- would likely be closer to the 5% range, and we exceeded that. And obviously, the emerging market comps will also ease as we get into the back half. So we're feeling very good about our position as we exit the first quarter, and obviously, feel confident about raising our organic sales guidance."
94614,328661858,960334,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Analysts","Okay. And then, maybe, just have 2 quick follow-ups -- maybe for Katherine. One, I know, obviously, the Neuro number was very strong in the quarter. There's a lot of focus on Stentriever. But can you just give us a sense, Katherine, where you stand on pip",105,"Okay. And then, maybe, just have 2 quick follow-ups -- maybe for Katherine. One, I know, obviously, the Neuro number was very strong in the quarter. There's a lot of focus on Stentriever. But can you just give us a sense, Katherine, where you stand on pipeline opportunities within Neuro, specifically, interventional Neuro? And secondarily, is there any reason to believe MAKO capital sales get harder into the full Knee launch that could be sort of a delayed effect until people see sort of the full evidence and software in the back half of the year? Or based on order patterns, you remain pretty comfortable?"
94614,328661858,960334,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Executives","Yes. So within Neurotech, the bulk of the revenue is still from the hemorrhagic side, and we continue to launch next generation of the coils, different sizes, different shapes and continue to launch into additional geographies. And we are the market leade",246,"Yes. So within Neurotech, the bulk of the revenue is still from the hemorrhagic side, and we continue to launch next generation of the coils, different sizes, different shapes and continue to launch into additional geographies. And we are the market leader in that segment of the market. We do have a flow diverter. It's on the market outside the U.S. It's in clinicals in the U.S. We're probably still a year or 2 before U.S. market launch of that product, but that will clearly be an important product launch, given that they've captured a portion of the coil market where they're applicable. And then, continuing to invest in ischemic stroke, although candidly, a lot of what's going to have to happen over the next few years in the ischemic segment has more to do with market development, as Glenn mentioned in his comments. On MAKO, nothing that I would bring up to suggest that placements will get harder. If anything, the economic and value proposition associated with the robot, as we move toward full commercial launch of the Total Knee indication, only gets greater. So we expect to see continued strong demand. As we've talked about this year  is really focused on training. So that's going to be to ensure an optimal rollout, and to make sure the initial user experience is as positive as it can be. But we would assume continued momentum. And as I mentioned, we're really pleased with incoming order trends."
94614,328661858,960334,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Operator","You're next call comes from the line of Mike Weinstein with JPMorgan.",13,"You're next call comes from the line of Mike Weinstein with JPMorgan."
94614,328661858,960334,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Analysts","A couple of quick questions. If there were 2 things that probably surprised us in the quarter, one, would've obviously been the gross margin, which was kind of well above expectations and recent trends. And I was hoping you could spend a minute on why tha",101,"A couple of quick questions. If there were 2 things that probably surprised us in the quarter, one, would've obviously been the gross margin, which was kind of well above expectations and recent trends. And I was hoping you could spend a minute on why that was. And then second is just the sustainability of the growth we're seeing in the Neurovascular business. It showed no signs of slowing at the U.S. international this quarter. And other than same development trends from 2015, on the back of the data and the guidelines changes, anything else you could add would be helpful."
94614,328661858,960334,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Executives","Sure. Mike, I'll start off with the Neurovascular, and then I'll turn it over to Glenn for the gross margin. So certainly, the ischemic market, it's a new market. And there, obviously, are many strokes that hadn't been treated prior. I kind of think about",195,"Sure. Mike, I'll start off with the Neurovascular, and then I'll turn it over to Glenn for the gross margin. So certainly, the ischemic market, it's a new market. And there, obviously, are many strokes that hadn't been treated prior. I kind of think about this a little bit like the Foot & Ankle market. You're creating a new market, and when you create a new market it's difficult to predict the pace of growth, but there's no doubt that the growth will be very significant. And that was clearly the biggest contributor to the strong performance in Neurovascular. But equally pleased with the performance of our Neuro Powered Instruments, which are having fantastic growth, very strong double-digit growth with our signature drills, which compete with one of the other major players, and we're taking significant market share with those products as well as our Sonopet product. So very, very strong performance, both in Neurovascular as well as the Neuro Powered Instruments. And even our Craniomaxillofacial business, the third of our Neuro businesses, is enjoying double-digit growth. So across the Neuro portfolio, we're really performing very well. I'll turn it to Glenn for gross margin."
94614,328661858,960334,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Executives","Yes. I think if you look at our gross margin, we really benefited from a positive mix, relative to U.S. and international, and then even relative to newer products over some of our older products. If you look at the 1588 and the signature drills that were",87,"Yes. I think if you look at our gross margin, we really benefited from a positive mix, relative to U.S. and international, and then even relative to newer products over some of our older products. If you look at the 1588 and the signature drills that were sold, those sell at, largely, premiums. And then finally, we also continue to see sort of our stalwart product, knees, trauma. Our ischemic stroke and coil products continue to sell fairly robustly, too, which helped lift the overall margin up."
94614,328661858,960334,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Executives","And also, price was also more moderate than we've seen in the past.",13,"And also, price was also more moderate than we've seen in the past."
94614,328661858,960334,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Analysts","Right. And Glenn, it also looked like your inventories were up a lot this quarter from the end of the year. Any expectation on those trending down? So is any of that -- I'm asking is, any of the uptick in gross margin here onetime? Or do you want us to vi",55,"Right. And Glenn, it also looked like your inventories were up a lot this quarter from the end of the year. Any expectation on those trending down? So is any of that -- I'm asking is, any of the uptick in gross margin here onetime? Or do you want us to view it as sustainable?"
94614,328661858,960334,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Executives","No. I think the inventory's up. It's reflecting what we're planning for the rest of the year in making sure that we're able to satisfy customers. And as far as the gross margin goes, we expect that we'll continue to see this kind of trend throughout the y",48,"No. I think the inventory's up. It's reflecting what we're planning for the rest of the year in making sure that we're able to satisfy customers. And as far as the gross margin goes, we expect that we'll continue to see this kind of trend throughout the year."
94614,328661858,960334,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Operator","You're next call comes from the line of Bob Hopkins with Bank of America.",15,"You're next call comes from the line of Bob Hopkins with Bank of America."
94614,328661858,960334,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Analysts","So the first question I wanted to ask is on the business outside the United States. Specifically, could you comment a little bit on the performance of your knee business outside the United States? Which was the one slightly weak spot within the ortho busi",112,"So the first question I wanted to ask is on the business outside the United States. Specifically, could you comment a little bit on the performance of your knee business outside the United States? Which was the one slightly weak spot within the ortho business. And then also, Kevin, I was wondering if you could just comment on Europe, broadly, from a capital equivalent perspective because we've seen some other health care companies that sell capital equipment into Europe talk about a tough environment. I was wondering if you could just kind of offer a broad comment on Europe from a capital equipment perspective, and then also on the OUS knee business."
94614,328661858,960334,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Executives","Sure, Bob. So on both businesses, I would tell you, we don't have significant businesses, as you probably know. In capital equipment in Europe, we -- our market share is quite low. And even for knees, if you look at last year we had a pretty good comp. We",172,"Sure, Bob. So on both businesses, I would tell you, we don't have significant businesses, as you probably know. In capital equipment in Europe, we -- our market share is quite low. And even for knees, if you look at last year we had a pretty good comp. We had a plus 5% in knee. And quarter-to-quarter, given that we don't have very large businesses for both capital equipment in Europe and knees, we do tend to see fluctuations. So I would call this sort of the normal fluctuations that we get quarter-to-quarter. And we're not really seeing a lot of difficulty with capital equipment. But that market for us in Europe, given that the bulk of our capital is not large capital, we're not really seeing any new pressures, and we see the Europe market as being fairly healthy, at least for our businesses. Keep in mind though that we do have very low market shares, and we have significant room to grow within both Europe as well as OUS knees."
94614,328661858,960334,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Analysts","And then on emerging markets, I think the last couple of quarters the business has been, as you expected, sort of down about mid-single digits. Was that the same sort of growth rate that you saw this particular quarter? And can you just give us a little m",69,"And then on emerging markets, I think the last couple of quarters the business has been, as you expected, sort of down about mid-single digits. Was that the same sort of growth rate that you saw this particular quarter? And can you just give us a little more color on the math and rationale for the expectation that perhaps in the back half things get a little bit better?"
94614,328661858,960334,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Executives","So Bob, the emerging markets, actually, the decrease was even more pronounced in the first quarter. So it was negative high signal digits in the first quarter. And that didn't surprise us, because we had a very strong first quarter last year. Things reall",139,"So Bob, the emerging markets, actually, the decrease was even more pronounced in the first quarter. So it was negative high signal digits in the first quarter. And that didn't surprise us, because we had a very strong first quarter last year. Things really started to tail off starting in the second quarter last year. So that really contributed to the softness in our international sales was the negative growth in emerging markets. And we do see that starting to taper. And then obviously, the comps will ease as well. Inventory bleeds will eventually bleed out. And it's hard to predict exactly when, but as I stated, I think, on our last call, we expect around mid-year would be sort of the bottoming out period, and we should start to see improvement in the second half of the year."
94614,328661858,960334,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Operator","You're next call comes from the line of Rick Wise with Stifel.",13,"You're next call comes from the line of Rick Wise with Stifel."
94614,328661858,960334,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Analysts","Kevin, you've been very pointed in focusing us on the potential for more operating leverage in the P&L. We saw it this quarter with 90 basis points of positive leverage. When I look back at the last couple of years, you've had a couple of quarters where w",96,"Kevin, you've been very pointed in focusing us on the potential for more operating leverage in the P&L. We saw it this quarter with 90 basis points of positive leverage. When I look back at the last couple of years, you've had a couple of quarters where we've seen 100 basis points year-over-year improvement, but then it's not sustained. How do we think about this performance in the first quarter? Is it sustainable? Is there more to come? And is that the right way to think about the 2016, '17 direction in terms of driving leverage?"
94614,328661858,960334,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Executives","Yes. Thanks, Rick. I would tell you that if you look at our earnings guidance, it's pretty clear that we're driving leverage. So we've updated both our top line guidance, we've also updated our bottom line guidance. And this is the third time since the be",122,"Yes. Thanks, Rick. I would tell you that if you look at our earnings guidance, it's pretty clear that we're driving leverage. So we've updated both our top line guidance, we've also updated our bottom line guidance. And this is the third time since the beginning of the year that we've raised our earnings guidance. And we won't be able to deliver that type of earnings guidance unless we drive operating leverage. So I'm not going to promise that it's going to be 90 basis points every single quarter, but we are committed to driving leverage at the operating income level, and you should -- you'll see that this year, and you'll see that when we provide guidance for you in 2017."
94614,328661858,960334,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Analysts","Great. And then just following up on the knee performance, which was really excellent, clearly. I know there are multiple pieces here. Triathlon is doing well, revision. Maybe talk -- remind us of your current mix of revision versus primary knee -- that m",88,"Great. And then just following up on the knee performance, which was really excellent, clearly. I know there are multiple pieces here. Triathlon is doing well, revision. Maybe talk -- remind us of your current mix of revision versus primary knee -- that mix. How does it differ from industry averages or aspirational norms? And is the story in knees, at least in part, that the new products you showed us at AAOS are going to drive us toward those norms? Or how should we think about it?"
94614,328661858,960334,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Executives","Sure. Yes, there are multiple factors that contribute to the knee performance. We had a great fourth quarter with around 9% growth in the U.S., and another 9% in the first quarter. And certainly, revision's part of it. And we've launched these new 3D prin",262,"Sure. Yes, there are multiple factors that contribute to the knee performance. We had a great fourth quarter with around 9% growth in the U.S., and another 9% in the first quarter. And certainly, revision's part of it. And we've launched these new 3D printed cones in the middle of last year. And cones are a very important part of the procedure. They don't generate huge revenue by themselves, but you get the pull-through of the implant when you use the cones. Our market share was, roughly, 6 share points below what it was in primary knees and revision. So we did sell in the revision market, but we didn't maintain the same level of market share that we do with our primary knees: roughly, 6 points. So we're really excited about being able to gain those 6 points back and then, potentially, even grow beyond that. Because we really believe we now have the best-in-class cones for revision procedures. We also have cementless knees, which is growing, and that's through our launch of our 3D printed Tritanium baseplate: the baseplate portion of our knee system. That's a second factor. Third factor is really great sales force execution -- marketing programs and sales force execution. So it's hard for me to describe which of those 3 is the greater. I would say all 3 contributed to a very strong showing in knees, and it's the second quarter in a row. And I really believe we're building momentum and that we'll continue to perform well in knees through the course of the year."
94614,328661858,960334,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Operator","You're next call comes from the line of David Roman with Goldman Sachs.",14,"You're next call comes from the line of David Roman with Goldman Sachs."
94614,328661858,960334,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Analysts","I was hoping you could talk about the Trauma business in the U.S. And Kevin, that's a franchise that you've mentioned in a couple of different public settings, that you weren't convinced that you could necessarily outgrow the market to the extent to which",96,"I was hoping you could talk about the Trauma business in the U.S. And Kevin, that's a franchise that you've mentioned in a couple of different public settings, that you weren't convinced that you could necessarily outgrow the market to the extent to which you have over the past several quarters. But that does look like it's continuing here, especially in the U.S. Can you maybe just help us think through some of the drivers that are supporting the sustainability of growth in that franchise? And how we should evaluate that on a go-forward basis?"
94614,328661858,960334,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Executives","Yes, thanks. Look, I'm thrilled with the performance of our Trauma business, and it's been a multi-year success story. We've put -- posted this plus 11 against a comp of plus 18 in the prior period. So we really are clicking on all cylinders within our Tr",222,"Yes, thanks. Look, I'm thrilled with the performance of our Trauma business, and it's been a multi-year success story. We've put -- posted this plus 11 against a comp of plus 18 in the prior period. So we really are clicking on all cylinders within our Trauma portfolio. It took us years to build out our portfolio, frankly, on the plating side of the business. We've always been strong in nails. And then of course, the launching of our Foot & Ankle business was tremendous a few years ago. And that's -- that continues to grow above the overall Trauma growth rate. It was mid-teens growth again this quarter and very strong performance from the STAR Ankle as well. So I would say it's rounding out our portfolio and then terrific sales force execution. And again, it's been a 3-year story. My only caution on Trauma is, really, being able to maintain 15%, 16% growth quarter-over-quarter for years is just challenging, right? The law of numbers at some point, you would think, would start to catch up with you and just moderate the growth rate. But I have every confidence we will continue to grow above market, and we demonstrated that, most likely, in the first quarter. Of course, not everybody has reported yet, but we feel that's a very strong showing."
94614,328661858,960334,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Analysts","Okay, that's helpful. And then maybe just a follow-up on the cash flow side for Glenn. If I look at kind of the operating cash flow and free cash flow numbers that you've disclosed for the quarter, it looks like quite a bit of capital deployed toward oper",104,"Okay, that's helpful. And then maybe just a follow-up on the cash flow side for Glenn. If I look at kind of the operating cash flow and free cash flow numbers that you've disclosed for the quarter, it looks like quite a bit of capital deployed toward operating items, and you're not converting all that much of your net income to free cash flow. Can we think about -- or are there any onetime factors that may have negatively influenced Q1 that would reverse themselves through the balance of the year, whereby you can start growing cash flow in line with adjusted net income?"
94614,328661858,960334,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Executives","Yes. The biggest thing that we really -- we can't necessarily control the timing of is really sort of the Rejuvenate payments that we made related to the recall. So we made a payment of $0.1 billion in Q1, and don't expect that, based on what we've seen i",60,"Yes. The biggest thing that we really -- we can't necessarily control the timing of is really sort of the Rejuvenate payments that we made related to the recall. So we made a payment of $0.1 billion in Q1, and don't expect that, based on what we've seen in the past that, that could necessarily repeat itself throughout the year."
94614,328661858,960334,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Operator","You're next call comes from the line of Richard Newitter with Leerink Partners.",14,"You're next call comes from the line of Richard Newitter with Leerink Partners."
94614,328661858,960334,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Analysts","I was hoping to start off with Spine. Kevin, can you give us any color on -- you've had 2 quarters now, or 3 quarters, I think, of improving growth there, above the market. I know you have some new product launches and a nice pipeline. And that's, I'm sur",89,"I was hoping to start off with Spine. Kevin, can you give us any color on -- you've had 2 quarters now, or 3 quarters, I think, of improving growth there, above the market. I know you have some new product launches and a nice pipeline. And that's, I'm sure, helping. Can you break out for us at all, is the acceleration that carried over into the first quarter, volume-related, mix-related? Are you gaining share? Or is it just purely you have new products, and you're getting premium pricing?"
94614,328661858,960334,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Executives","Great question. I would say it's mostly volume. There is, obviously, some mix when you launch innovative products. We just had a limited launch of our 3D printed interbody device, and we're getting fantastic feedback on that. And that, obviously, sells at",174,"Great question. I would say it's mostly volume. There is, obviously, some mix when you launch innovative products. We just had a limited launch of our 3D printed interbody device, and we're getting fantastic feedback on that. And that, obviously, sells at a price premium. So there is a mix component as well. But I would say it's mostly volume. And it's volume coming from the products that we launched, most of which we launched last year. We launched a slew of new products, and those are being well adopted in the marketplace. I would say, price continues to be pressured. Spine is the most pressured pricing division within Stryker. And we believe that our price is, roughly, in line with the market. So the fact that we're growing above market now, I think it's 4 quarters in a row, is really driven by a renewed focus on launching products, and having great sales force execution. So I believe we'll have another strong year, just like we did last year in Spine, in 2016."
94614,328661858,960334,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Analysts","Okay. And then just one more on bundled payments. It's officially kicked off now that we're in April. Just wondering if you had any updates on ways or areas where you're working with or partnering with hospitals or how you're leveraging something that's u",86,"Okay. And then just one more on bundled payments. It's officially kicked off now that we're in April. Just wondering if you had any updates on ways or areas where you're working with or partnering with hospitals or how you're leveraging something that's unique about what Stryker can do in terms of partnering. Is there anything that you're doing more aggressively, or hearing from customers that's resonating or allowing you to potentially differentiate and gain share with this new dynamic that's playing out in the market?"
94614,328661858,960334,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Executives","Sure. So we have a division within Stryker called Stryker Performance Solution, which has consulted with over 100 hospitals the past 3 years to improve service line performance, including areas directly impacted by bundled payments. So through these engag",236,"Sure. So we have a division within Stryker called Stryker Performance Solution, which has consulted with over 100 hospitals the past 3 years to improve service line performance, including areas directly impacted by bundled payments. So through these engagements, we've developed deep insight into the profitability and opportunities that hospitals have within Orthopaedics. We were also granted Convener status by CMS last year as part of the bundled payment BPCI program. And we are actively at risk --- taking risk with 5 institutions across multiple hospitals on the payment bundling, managing over $55 million in episode spend. With CJR, third parties like us are not allowed to operate as a convener anymore with the Medicare program. But our Stryker Performance Solution is still providing consulting services to hospitals to help them address the challenges of managing the bundle. So we have a lot of experience. We're continuing to help and consult with our customers. And what I'd tell you is the initial focus is really much more on the post-acute care. That's where more -- the majority of the cost of the procedure is, and the biggest opportunity in the short term is addressing post-acute care. But having this division, which is headquartered in Chicago, has been a key asset for us. We have a lot of insights into the economics of the orthopaedic service line and how to help our customers address this new world."
94614,328661858,960334,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Operator","Your next call comes from the line of Matt Taylor with Barclays.",12,"Your next call comes from the line of Matt Taylor with Barclays."
94614,328661858,960334,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Analysts","I was wondering, in the last couple of quarters, you've actually had better pricing or less declines. Has there been any change in the market where you'd really call a trend, whether it's consolidation or new products, broadly, that have helped on price?",43,"I was wondering, in the last couple of quarters, you've actually had better pricing or less declines. Has there been any change in the market where you'd really call a trend, whether it's consolidation or new products, broadly, that have helped on price?"
94614,328661858,960334,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Executives","Yes. I would say, obviously, pricing is still negative. It's modestly less negative coming in at 1.3. But we're still within -- very close to the 1.5 to 2 range, so we wouldn't call out anything significant that is indicative of a change in the overall pr",96,"Yes. I would say, obviously, pricing is still negative. It's modestly less negative coming in at 1.3. But we're still within -- very close to the 1.5 to 2 range, so we wouldn't call out anything significant that is indicative of a change in the overall pricing dynamic. Typically, consolidation helps, but again, it's still negative. We've seen it vary quarter-to-quarter. Sometimes it's trended above. Fortunately, more recently, it's been trending on the lower end. I would say the outlook seems very stable and really no new dynamics that we see putting further pressure on pricing."
94614,328661858,960334,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Analysts","The other thing people talk about with CCJR is just more procedures moving to outpatient or just getting people out of the hospital quicker or moving to lower acuity settings. So I guess, you mentioned your consulting division, but how else are you positi",65,"The other thing people talk about with CCJR is just more procedures moving to outpatient or just getting people out of the hospital quicker or moving to lower acuity settings. So I guess, you mentioned your consulting division, but how else are you positioning yourself? Or is your product portfolio positioned to kind of capture that trend or beat competitors in that kind of vector?"
94614,328661858,960334,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Executives","No, I really think the way we're best positioned to help our customers is going to be through some of the insights that we've had, having this division now for a number of years within Stryker and understanding the economics and the focus on post-acute ca",99,"No, I really think the way we're best positioned to help our customers is going to be through some of the insights that we've had, having this division now for a number of years within Stryker and understanding the economics and the focus on post-acute care, given that eats up the bulk of the costs when you're looking at an episode of care. And so we're able to work with them in that regard. But I wouldn't say there is a unique product offering that facilitates or is advantageous in the post-acute setting, if I'm understanding the question correctly."
94614,328661858,960334,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Operator","Your next call comes from the line of Matthew O'Brien with Piper Jaffray.",14,"Your next call comes from the line of Matthew O'Brien with Piper Jaffray."
94614,328661858,960334,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Analysts","Just a follow-up a little bit on Matt's question on the CJR. I'm curious if there's been any kind of either disruption from that program going into place earlier this month, be it with MAKO or potentially here in Q2. Maybe seeing some less -- a little les",87,"Just a follow-up a little bit on Matt's question on the CJR. I'm curious if there's been any kind of either disruption from that program going into place earlier this month, be it with MAKO or potentially here in Q2. Maybe seeing some less -- a little less volume as a result, or if maybe some hospitals, as they were preparing for it, started to do more cases in Q1, and there was a benefit specifically in Q1 in anticipation of that program going into place."
94614,328661858,960334,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Executives","No, I wouldn't ascribe any of the change in Q1 to the CJR. Keep in mind that CJR is not impacting a large portion of the pay -- of the procedures, at least in the short term. It doesn't include Medicare Advantage. It doesn't include Medicaid. It doesn't i",145,"No, I wouldn't ascribe any of the change in Q1 to the CJR. Keep in mind that CJR is not impacting a large portion of the pay -- of the procedures, at least in the short term. It doesn't include Medicare Advantage. It doesn't include Medicaid. It doesn't include commercial payers. It doesn't include the hospitals that were already signed up for the BPCI program. So it's, obviously, certain MSAs that are required to participate, but it's very small and there aren't any penalties in the short term. So I really -- I wouldn't get overly concerned about this. It's not a new thing. Bundled payments have been around for a while. They're not brand new. It's now mandatory in certain MSAs, but I don't really see that as a catalyst to changing behavior in any meaningful way, at least not in the short term."
94614,328661858,960334,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Analysts","Okay. And just to kind of follow up on that, Kevin. Was there any slowdown, potentially, on the MAKO system side? That was, I think, down year-over-year just in anticipation of CJR, hospitals trying to figure out how that program is going to play out, may",56,"Okay. And just to kind of follow up on that, Kevin. Was there any slowdown, potentially, on the MAKO system side? That was, I think, down year-over-year just in anticipation of CJR, hospitals trying to figure out how that program is going to play out, maybe some of those facilities deciding just to pause on it."
94614,328661858,960334,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Executives","No, I would say no. I think our order book is really strong for robot sales, and our procedure growth was very robust, both in uni-s and in hips. [indiscernible]. The hip procedure growth was very strong in the back half of last year. So no, I would not s",75,"No, I would say no. I think our order book is really strong for robot sales, and our procedure growth was very robust, both in uni-s and in hips. [indiscernible]. The hip procedure growth was very strong in the back half of last year. So no, I would not say that there was some kind of a change in behavior. We were really seeing continued growth, and I'm still very bullish on our MAKO business."
94614,328661858,960334,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Analysts","Okay. And then as my follow-up, just on the domestic performance, again, this quarter was extremely strong. I'm just wondering, with Q1 typically being a seasonally soft quarter and the strength that we're seeing here, obviously, comping on ACA, it just s",108,"Okay. And then as my follow-up, just on the domestic performance, again, this quarter was extremely strong. I'm just wondering, with Q1 typically being a seasonally soft quarter and the strength that we're seeing here, obviously, comping on ACA, it just seems interesting to me how strong everything has been. Can you just talk about volume, price, mix, share taking? What's driving all that strength, domestically? And then, should we think about things kind of in the U.S. slowing down in the back half with OUS kind of picking up. And then exiting into 2017, hopefully, with both of those segments starting to realize more normalized type growth?"
94614,328661858,960334,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Executives","I think we're going to continue to see strong performance in the U.S. Obviously, this was a very big quarter, but the real genesis of this is fantastic product pipelines. We have a, really, across our businesses, very, very good condition of our pipeline,",229,"I think we're going to continue to see strong performance in the U.S. Obviously, this was a very big quarter, but the real genesis of this is fantastic product pipelines. We have a, really, across our businesses, very, very good condition of our pipeline, with many new launches that are just starting, launches that started middle of last year. So having healthy product pipeline is always great, and that leverages our best asset, which is our sales force with Stryker, which we really know how to execute and we have health across our divisions. And that wasn't the case a few years ago. We had a few divisions that were a little bit softer. We now have strength in our Endoscopy with our new camera. We have strength within our Neuro Powered Instruments. We have the ischemic stroke market taking off. We have a strong pipeline within Spine. You're seeing the 3D-printed implants taking off. So really, across our portfolio, we have very strong pipeline. So that isn't a 1-quarter thing. I think we'll continue to see strong performance through the course of the year. And we continue to spend very robustly in R&D. So we have a cadence of new products that will continue. And so I really believe this is sustainable. We'll continue to perform very well in the U.S. This is not a 1-quarter thing."
94614,328661858,960334,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Operator","Your next call comes from the line of Mike Matson with Needham & Company.",13,"Your next call comes from the line of Mike Matson with Needham & Company."
94614,328661858,960334,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Analysts","I guess, Katherine, I just wanted to ask about the Sage and Physio-Control acquisitions. Should we expect the growth rates to continue this year at the historical levels: sort of double digits at Sage and mid-single digits at Physio-Control? Or is there a",57,"I guess, Katherine, I just wanted to ask about the Sage and Physio-Control acquisitions. Should we expect the growth rates to continue this year at the historical levels: sort of double digits at Sage and mid-single digits at Physio-Control? Or is there a risk that the growth tapers off a little bit while you're integrating those companies?"
94614,328661858,960334,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Executives","Yes, recognizing there's always integration that has to happen, so I don't want my comments to be construed as exact targets for every quarter. But overall, Sage has a long history of sustaining very strong double-digit growth, and our goal, as I mentione",142,"Yes, recognizing there's always integration that has to happen, so I don't want my comments to be construed as exact targets for every quarter. But overall, Sage has a long history of sustaining very strong double-digit growth, and our goal, as I mentioned, is to make sure we do everything to continue to support to them, and over time, unlock more of the opportunity outside the U.S. Physio-Control is embarking this year on a hefty new product launch cycle that will go for the next few years. So I think your estimations are a good place to be thinking about. And again, we'll be very transparent. We're going to give pro forma revenue performance for each business, respectively, for the first 12 months. So you'll be able to see very clearly how they're growing relative to the year -- prior year base."
94614,328661858,960334,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Analysts","Okay. And then just with regard to the emerging markets and I guess China, more specifically. Can you just talk about the differences in kind of what you're seeing with regard to the implant markets and the procedurally-driven products versus the capital",79,"Okay. And then just with regard to the emerging markets and I guess China, more specifically. Can you just talk about the differences in kind of what you're seeing with regard to the implant markets and the procedurally-driven products versus the capital equipment markets? Do you have any sense as to whether or not the actual end markets for procedure volumes have slowed down? Or is that just steady and there's just some de-stocking going on at the distributors?"
94614,328661858,960334,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Executives","So I'd kind of break it into 3 categories. I would say that the slowest impact and the greatest negative impact to us has been on the capital equipment. The next would be Spine and Trauma, which is -- a lot of that is tendered type of business, where you",137,"So I'd kind of break it into 3 categories. I would say that the slowest impact and the greatest negative impact to us has been on the capital equipment. The next would be Spine and Trauma, which is -- a lot of that is tendered type of business, where you -- we've seen the distributors really had loaded up and are bleeding their inventory. And then the least negatively impacted would be in the hip and knee category, which has a lot more cash pay. And so the cash pay market is not -- is the least impacted. So that's kind of -- I'd put it in those 3 buckets. And we're seeing, obviously, it's all negative with varying degrees, with capital being the most negative, Spine and Trauma second, and then hips and knees, last."
94614,328661858,960334,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Operator","Your next call comes from the line of Larry Biegelsen with Wells Fargo.",13,"Your next call comes from the line of Larry Biegelsen with Wells Fargo."
94614,328661858,960334,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Analysts","First, I wanted to ask about Trauma and Extremities, and then I had one on M&A. So Kevin, Trauma and Extremities has obviously been a stellar performer for you guys for a long time. But the 2 growth areas that you're not participating in or relatively sma",111,"First, I wanted to ask about Trauma and Extremities, and then I had one on M&A. So Kevin, Trauma and Extremities has obviously been a stellar performer for you guys for a long time. But the 2 growth areas that you're not participating in or relatively small in are shoulder and cervical disc. So could give us an update? I know you launched your shoulders a year or 2 ago. Give us an update there on what you're seeing and in the outlook. And then second, how attractive is the cervical disc market to you? And how important is it to have a cervical disc market? And I had one follow-up."
94614,328661858,960334,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Executives","Sure. So shoulder, you're right, we're a relatively small player, but we're very pleased with the launch of our primary shoulder and our reverse shoulder, which we launched just over a year ago. That has very nice growth, albeit from a small base. So we r",141,"Sure. So shoulder, you're right, we're a relatively small player, but we're very pleased with the launch of our primary shoulder and our reverse shoulder, which we launched just over a year ago. That has very nice growth, albeit from a small base. So we really believe we have the right products to be able to win in the market. It's going to take time. This isn't like Foot & Ankle, where we're approaching new surgeons. We have to be able to take share. But I was very encouraged by the growth the last 2 quarters in our shoulder business. It doesn't really make a big impact in our overall business, just given the size. But I feel that we now have a very good portfolio, and shoulder will become a growth area for us going forward. What's the second question?"
94614,328661858,960334,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Analysts","On cervical disc, how important it is to have a cervical disc.",12,"On cervical disc, how important it is to have a cervical disc."
94614,328661858,960334,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Executives","We would normally report that -- if we had a cervical disc, which we don't right now, that would be reported in our Spine business, not in our Trauma and Extremities business. And right now, our Spine business is doing really well. We're launching many, m",92,"We would normally report that -- if we had a cervical disc, which we don't right now, that would be reported in our Spine business, not in our Trauma and Extremities business. And right now, our Spine business is doing really well. We're launching many, many products. We don't feel that we have to have a cervical disc at the moment to be able to drive growth. It's something we'll look at. But at the current time, we don't see that as an impediment to having strong growth in our Spine business."
94614,328661858,960334,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Analysts","Got it. And my apology for wrapping that into Trauma and Extremities. Sorry about that. So Kevin, you spent $4 billion on 2 recent deals. So my question is, how does that impact your ability or willingness to do more deals right -- until you kind of integ",50,"Got it. And my apology for wrapping that into Trauma and Extremities. Sorry about that. So Kevin, you spent $4 billion on 2 recent deals. So my question is, how does that impact your ability or willingness to do more deals right -- until you kind of integrate those 2?"
94614,328661858,960334,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Executives","Sure. We still have significant capacity to do extra deals. So we had a one-notch downgrade from both S&P and Moody's. And if you look at S&P, we went from an A+ to A rating. We are committed to maintaining investment grade, but there's obviously a large",189,"Sure. We still have significant capacity to do extra deals. So we had a one-notch downgrade from both S&P and Moody's. And if you look at S&P, we went from an A+ to A rating. We are committed to maintaining investment grade, but there's obviously a large gap between A rating and investment -- the low end of investment grade. Keep in mind that the vast majority of the deals we do are small tuck-in deals. So that will continue to be the case for Stryker. That's where we drive the most value when we find great technologies that we can give to our fabulous sales forces to drive. So that -- you'll continue to see those will be the majority of deals, but we still have significant capacity to do more M&A. And I would say, all of our businesses have embedded BD people. We have not told them to slow down at all, so they're continuing to scour the market to look for opportunities that will add value, and we won't hesitate to pull the trigger on new deals if we believe they'll be value-creating for Stryker."
94614,328661858,960334,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Operator","Your next call comes from the line of Matt Keeler with Crdit Suisse.",13,"Your next call comes from the line of Matt Keeler with Crdit Suisse."
94614,328661858,960334,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Analysts","I guess just to start on, on Sage, you highlighted the potential to build that in Western Europe, and I was wondering if you could help us think about that market opportunity. Is that a market similar in size in Western Europe to the U.S., and Sage just h",64,"I guess just to start on, on Sage, you highlighted the potential to build that in Western Europe, and I was wondering if you could help us think about that market opportunity. Is that a market similar in size in Western Europe to the U.S., and Sage just has a smaller market share? Or is that a market that you'll be building from scratch?"
94614,328661858,960334,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Executives","This will be much more building the market, much the way Sage did in the U.S. They really were the driving force behind the innovations that allowed solutions to many of these hospital-acquired infections. These very elegant, easy-to-use solutions with de",158,"This will be much more building the market, much the way Sage did in the U.S. They really were the driving force behind the innovations that allowed solutions to many of these hospital-acquired infections. These very elegant, easy-to-use solutions with demonstrated clinical data that shows when they're routinely used they can significantly limit the occurrence. The same conditions, hospital-acquired pneumonia infections, are prevalent around the world. It just was not an area they focused on, given their initial investment in the U.S. market. So this will be market development. It'll be using the sales force as they do to help drive that, but it's -- very much the same conditions exist, but it'll be more about market expansion, which is why we'd say, over time, this is the value we look to unlock. It is not something that's going to occur suddenly in 2016. This will be a multi-year process to really start to drive awareness and adoption."
94614,328661858,960334,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Analysts","Okay, great. And my follow-up, last quarter, you shared some margin targets for the year. Just wondering if you'll give us an update on what those will look like with Sage and Physio-Control.",33,"Okay, great. And my follow-up, last quarter, you shared some margin targets for the year. Just wondering if you'll give us an update on what those will look like with Sage and Physio-Control."
94614,328661858,960334,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Executives","So we provide top line and earnings guidance. We don't provide specific margin guidance. Although, as Glenn noted on the call, while the magnitude of the year-over-year increase in gross margin won't continue, we should continue to be at the Q1 levels for",82,"So we provide top line and earnings guidance. We don't provide specific margin guidance. Although, as Glenn noted on the call, while the magnitude of the year-over-year increase in gross margin won't continue, we should continue to be at the Q1 levels for 2016. But we haven't given specific guidance. We do expect margin expansion. That's inclusive of the deals as they closed in early April. But beyond that and the revisions -- upward revisions to the targets today, there's nothing additional."
94614,328661858,960334,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Operator","Your next call comes from the line of Glenn Novarro with RBC Capital Markets.",14,"Your next call comes from the line of Glenn Novarro with RBC Capital Markets."
94614,328661858,960334,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Analysts","Two questions. One, U.S. knees and hips for Stryker came in better. Yesterday, J&J also reported a much stronger U.S. in the hip number. So the market is likely coming in better, but Kevin, I just wanted to see what your view is on the competitive dynamic",95,"Two questions. One, U.S. knees and hips for Stryker came in better. Yesterday, J&J also reported a much stronger U.S. in the hip number. So the market is likely coming in better, but Kevin, I just wanted to see what your view is on the competitive dynamics. Zimmer and Biomet sales forces have combined as of last year. But I'm just wondering, are you still possibly seeing disruption in the marketplace associated with Zimmer and Biomet? And could that be helping your results as well as J&J's results yesterday? And then I have a follow-up."
94614,328661858,960334,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Executives","So we're really pleased with our result, particularly our U.S. performance in both hips and knees. At this point, with the largest player having not yet reported along with other competitors in the market, it's very difficult to make any kind of call with",167,"So we're really pleased with our result, particularly our U.S. performance in both hips and knees. At this point, with the largest player having not yet reported along with other competitors in the market, it's very difficult to make any kind of call with conviction around market growth. So clearly, we'll have a much better sense as additional numbers roll in, where the overall market growth is. But we feel very comfortable in the U.S. that we grew at the high end, if not above the market. And -- but we'll have to wait to see how numbers come in to get a general sense of whether there's been any type of acceleration. Keep in mind, in Recon, you really have to look at rolling 4-quarter trends, because growth rates can vary quarter-to-quarter. So I wouldn't want to read too much into an uptick in growth, to the degree we see one in the first quarter, because it may not be indicative of a trend line."
94614,328661858,960334,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Analysts","Okay. And then one last follow-up on CJR. One of the pushbacks that we get is there's a thought out there that surgeons will start cherry-picking patients. They may not do the more challenging cases, and then they may fall through the system. Our due dili",59,"Okay. And then one last follow-up on CJR. One of the pushbacks that we get is there's a thought out there that surgeons will start cherry-picking patients. They may not do the more challenging cases, and then they may fall through the system. Our due diligence does not suggest that'll happen, but I just wanted to hear your opinion."
94614,328661858,960334,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Executives","Yes. This has obviously gotten a lot of focus of late. I would tell you, we do not believe that  CMS's intent is to reduce utilization. It's really rather to ensure that each patient has access to the most appropriate care. There's been the speculation, b",194,"Yes. This has obviously gotten a lot of focus of late. I would tell you, we do not believe that  CMS's intent is to reduce utilization. It's really rather to ensure that each patient has access to the most appropriate care. There's been the speculation, but -- some type of step function reduction in volumes as higher-risk patients are increasingly denied surgeries. We believe this is unlikely. We do think, based on all the work we've done and through SPS and, obviously, our presence in Recon that surgeons are going to continue to look to optimize treatment for higher-risk patients. They do that today. And this will include managing their post-acute care, which can vary. And so they have and are going to continue to treat all types of patients. The data clearly shows hip and knee surgery has a very high, long-term success rate and significantly improves quality of life. And that's for all patients, not just the healthiest ones. So we are not expecting some type of significant change, but rather, we do believe they're going to look to find the optimum ways to treat these patients, including the post-acute care regimen."
94614,328661858,960334,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Operator","Your next call comes from the line of Kaila Krum with William Blair.",13,"Your next call comes from the line of Kaila Krum with William Blair."
94614,328661858,960334,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Analysts","So a follow-up on Richard's earlier question on Spine. Just to dig in a bit further. I mean, you mentioned that you're seeing an increase in volume. Can you give us a sense for where you believe that increase in volume is coming from? Is it more market re",94,"So a follow-up on Richard's earlier question on Spine. Just to dig in a bit further. I mean, you mentioned that you're seeing an increase in volume. Can you give us a sense for where you believe that increase in volume is coming from? Is it more market related? Or do you think that you are taking share? And if it is the latter, I mean, I'm curious as to whether or not that share taking is coming from the bigger players in that segment or from some of the smaller pure plays."
94614,328661858,960334,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Executives","Yes, we think, overall, the market might be modestly improving. But again, it's very difficult to say because we're one of the earlier companies to report results. So we'll have to see how all the numbers come in. And it also is going to vary by company,",100,"Yes, we think, overall, the market might be modestly improving. But again, it's very difficult to say because we're one of the earlier companies to report results. So we'll have to see how all the numbers come in. And it also is going to vary by company, which segment of the market more of your products are weighted towards. So overall, we've been launching a number of new products. We've talked about the investments we've made over the last couple of years in the R&D pipeline. And we think this is mostly indicative of us gaining more market share back."
94614,328661858,960334,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Executives","Yes, we've seen in the Spine market, whether it's small players or larger players, innovation drives growth, and innovation is what takes market share. And our innovation engine is alive and well in our Spine business, and that's what's caused us to grow",46,"Yes, we've seen in the Spine market, whether it's small players or larger players, innovation drives growth, and innovation is what takes market share. And our innovation engine is alive and well in our Spine business, and that's what's caused us to grow above the market."
94614,328661858,960334,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Analysts","Okay. And then I'm just curious if you guys had any differences in terms of selling days in the quarter that may have impacted growth in the quarter, and if so, the estimated impact.",34,"Okay. And then I'm just curious if you guys had any differences in terms of selling days in the quarter that may have impacted growth in the quarter, and if so, the estimated impact."
94614,328661858,960334,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Executives","Yes. No, selling days are equal between quarters, between last year and this year.",14,"Yes. No, selling days are equal between quarters, between last year and this year."
94614,328661858,960334,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Operator","Your next call comes from the line of Kyle Rose with Canaccord.",12,"Your next call comes from the line of Kyle Rose with Canaccord."
94614,328661858,960334,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Analysts","Just had one question on MAKO. You talked a lot about refining the processes and the workflow over the course of 2016 to prepare for the launch in '17. When you think about that, how do you think about the optimal time of a procedure and the trade-off of",109,"Just had one question on MAKO. You talked a lot about refining the processes and the workflow over the course of 2016 to prepare for the launch in '17. When you think about that, how do you think about the optimal time of a procedure and the trade-off of being potentially time-additive? And I guess, the real question is, is when you come to market with the MAKO Total Knee what percentage of that market, from a volume basis, do you think the system will be time-neutral to your high-volume or to your medium-volume surgeon? I mean, what's the real market segment that the MAKO is really targeting here?"
94614,328661858,960334,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Executives","Sure. So much of the data you're looking for, we're going to be able to track once we go into full commercial launch, and it's going to vary by surgeon. A really high-volume surgeon doing hundreds of knee replacements a year is going to -- this is going t",188,"Sure. So much of the data you're looking for, we're going to be able to track once we go into full commercial launch, and it's going to vary by surgeon. A really high-volume surgeon doing hundreds of knee replacements a year is going to -- this is going to be time-additive. For the lower-volume surgeon, they're going to be much closer to time-neutral, but it's also why we wanted to spend our time on the training protocol to really look at ways that we can optimize this with this first-generation product. The other key is this is not just about time. We believe we're going to truly improve the patient experience, we're going to have a more reproducible surgery because there tends to be tremendous variation, particularly with lower-volume surgeons. We think we can improve muscle disruption and things that add to the fact that close to 30% of knee patients are dissatisfied with the procedure. So it's really not just about time. It's truly about having experience that's better for the surgeon, better for the patient. And over time, we believe the outcomes data will support that."
94614,328661858,960334,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Analysts","Great. And then just another question on the robotic side. We've heard a lot thoughts and rumblings about robotics in the Spine market, in particular, more of a play on navigated pedicle screw placement. Just your general thoughts on that, given your over",75,"Great. And then just another question on the robotic side. We've heard a lot thoughts and rumblings about robotics in the Spine market, in particular, more of a play on navigated pedicle screw placement. Just your general thoughts on that, given your overlap in the Spine as well as presence from a capital equipment side and navigation. And then, how does, if any, does a MAKO robot play a factor in those plans moving forward?"
94614,328661858,960334,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Executives","So certainly, we have a terrific navigation -- business unit. That's within our Instruments business. And so we're very well aware of how that procedure gets done, whether it's with navigation or not. That continues to be a growth area for us, both the Ne",160,"So certainly, we have a terrific navigation -- business unit. That's within our Instruments business. And so we're very well aware of how that procedure gets done, whether it's with navigation or not. That continues to be a growth area for us, both the Neuro and Spine market. But we are, in the next few years, really focused on hip and knees with MAKO. We have a lot of work to do to get the Total Knee. We think that's a killer procedure. I think if you look down the road 5 plus years, certainly, Spine could be an area of interest. Hip arthroscopy could be an area of interest. Shoulder could be an area of interest. So there's many areas. I think robotics will be a growth area for many, many years to come. But first things first. We really have to focus on hips and knees, and that's where our attention will be for the next few years."
94614,328661858,960334,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Operator","Your next call comes from the line of Amit Hazan with Citi.",12,"Your next call comes from the line of Amit Hazan with Citi."
94614,328661858,960334,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Analysts","Maybe just start on the hip and knee side, U.S. volumes. I want to maybe take a big picture kind of market view for a moment. Kind of when we look at and analyze the market models, some of your competitors' data, it seems pretty clear that it was -- volum",125,"Maybe just start on the hip and knee side, U.S. volumes. I want to maybe take a big picture kind of market view for a moment. Kind of when we look at and analyze the market models, some of your competitors' data, it seems pretty clear that it was -- volumes have been really strong for a couple of years now, maybe up in the 6%, 7%, 8% range for the market as a whole in the U.S. That would be kind of well above the 10-year plus average for volumes. So I'm wondering what you think has been the driver of that over these last couple of years and perhaps, more importantly, the extent to which you think that's sustainable on the volume side."
94614,328661858,960334,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Executives","Yes. No, we're seeing a very stable market. I think, just look at demographics, right? Every day, what is it, 10,000 people turn 65? More and more people are talking to friends that have had hip and knee replacements. The results are fabulous. People want",227,"Yes. No, we're seeing a very stable market. I think, just look at demographics, right? Every day, what is it, 10,000 people turn 65? More and more people are talking to friends that have had hip and knee replacements. The results are fabulous. People want to be active. So actually, we're seeing a lot. Certainly, we see this with the uni, with MAKO. We see a lot of young people going in for surgery. That wasn't happening before. You're seeing unemployment. Unemployment is a great proxy. When we see unemployment come down, we tend to see a lot more joint replacement, and specifically, knees. So hips really hurt even when you lie down at night. Knees, you can defer. And so we see that as a very good proxy. That's much more of a proxy than anything to do with ACA. So we really believe we've got a stable market that will continue to be stable for not just the next quarter, but for the next year or 2 years. And demographics is a key part, patient awareness is a key part and people wanting to be active. A lot of people want to be active. And so we don't really see, from a demand or volume standpoint, we don't see any headwinds right now. And frankly, the lower unemployment is a little bit of a tailwind."
94614,328661858,960334,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Analysts","Great. And then kind of back to MAKO and bundled payment. Maybe just kind of asking the question in a different way to throw it out to you guys. What is the sales pitch for MAKO in a bundled payment environment? Essentially, how does MAKO fit into a 90-da",75,"Great. And then kind of back to MAKO and bundled payment. Maybe just kind of asking the question in a different way to throw it out to you guys. What is the sales pitch for MAKO in a bundled payment environment? Essentially, how does MAKO fit into a 90-day expert [ph] of care better -- in a better way than what's being done here traditionally, such that it would have added value to the hospital?"
94614,328661858,960334,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Executives","So we really believe MAKO is going to improve outcomes, right? If you have consistent, reproducible product placement, less soft tissue damage, if you need less rehab for your patient, they're more satisfied. That's going to win in the market. So it's irr",167,"So we really believe MAKO is going to improve outcomes, right? If you have consistent, reproducible product placement, less soft tissue damage, if you need less rehab for your patient, they're more satisfied. That's going to win in the market. So it's irrespective of the type of payment, whether it's a single-payer system like in France, a two-tier system like in the U.K. or whether we're -- now it's a bundled payment system. So the method of payment is less interesting to us, frankly. If we deliver value and prove that value, we will win in the marketplace. And frankly, when you look at a bundle, again, the implant price, and even with a robot, if you factor in the robot and that's still not the majority of the procedure costs. So there's a lot of room to optimize beyond just the implant. And we really believe if we deliver that excellent experience and they have better outcomes, that we'll be able to win in the marketplace."
94614,328661858,960334,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Operator","Your next call comes from the line of Jeff Johnson with Robert W. Baird.",14,"Your next call comes from the line of Jeff Johnson with Robert W. Baird."
94614,328661858,960334,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Analysts","Katherine, just now that we're into April, on the MHLW price reset, can you just confirm now it's probably going to be, what, no more than 20, 25 basis point impact to your company-wide pricing?",35,"Katherine, just now that we're into April, on the MHLW price reset, can you just confirm now it's probably going to be, what, no more than 20, 25 basis point impact to your company-wide pricing?"
94614,328661858,960334,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Executives","Yes, that's a good approximation.",5,"Yes, that's a good approximation."
94614,328661858,960334,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Analysts","Okay, good. And then, Kevin, I guess, a question for you. I heard the comments on the ankle performance. In the quarter, it sounds like that was strong. When IPPS proposals came out the other night, the question -- I hadn't really thought of it until just",155,"Okay, good. And then, Kevin, I guess, a question for you. I heard the comments on the ankle performance. In the quarter, it sounds like that was strong. When IPPS proposals came out the other night, the question -- I hadn't really thought of it until just staring at some of the rates the other night. But with us not getting a carveout on a total ankle replacement code, which I don't think anybody really expected that we would, again, this year. But as you look at the episode of care costs on ankles being higher than hips and knees, but being reimbursed at those same rates, and as we go into this bundled payment environment, you think there's any bias or any kind of skew away from ankles that hospitals would maybe take just as their costs are higher but reimbursement is the same, with -- being paid under those hip and knee codes?"
94614,328661858,960334,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Executives","So first of all, we're just starting with hip and knee in bundled payments. And I think Medicare is going to be looking at high-volume procedures and moving them into the bundle. Total ankle is a very small part of the total market, right? It's still, Fus",282,"So first of all, we're just starting with hip and knee in bundled payments. And I think Medicare is going to be looking at high-volume procedures and moving them into the bundle. Total ankle is a very small part of the total market, right? It's still, Fusion is still the standard of care. Ankles are growing very fast but from a very small base. So I'm not -- I really don't see this hitting the radar screen, at least, not for a few years for Medicare. They've got a lot of other procedures they're going to focus on. I do believe bundled care and bundled payments will increase. It's a good thing for the overall health care system. It will address a lot of costs that need to be reduced. Frankly, in the case of hip and knee procedure there is an overprescription today on the post-acute. There's a lot of costs, and we've seen, when we work with hospitals on their service line profitability that's the area that we tend to focus on the most. So I think we're a long way away from bundled payments having a big impact on total ankle, and frankly, it's a better outcome. So Fusion is -- was a standard of care in some of the joint replacements a long time ago, and that's been replaced by total prosthesis, and total ankle will be a better outcome. Of course, like everything in health care, finding payments and getting procedures reimbursed always goes through its ups and downs. But if you have a better outcome, eventually, it'll get paid. So I don't really see a headwind for that, at least not in the next few years."
94614,328661858,960334,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Operator","Your next call comes from the line of Josh Jennings with Cowen and Company.",14,"Your next call comes from the line of Josh Jennings with Cowen and Company."
94614,328661858,960334,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Analysts","I just was hoping you could clarify. It looks like there's a step-up in CapEx in Q1 from the normal run rate and just the driver behind that. And just linked to that question, is any major product launches across the major divisions that you would call ou",61,"I just was hoping you could clarify. It looks like there's a step-up in CapEx in Q1 from the normal run rate and just the driver behind that. And just linked to that question, is any major product launches across the major divisions that you would call out that are going to help with this 5.5% to 6.5% organic growth trajectory?"
94614,328661858,960334,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Executives","Yes. I think, in Q1, we started some of the spending that's going to be required for our deployment of our new ERP system. And so that's the big thing that kind of stuck out in the cash flow.",39,"Yes. I think, in Q1, we started some of the spending that's going to be required for our deployment of our new ERP system. And so that's the big thing that kind of stuck out in the cash flow."
94614,328661858,960334,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Executives","Yes. And as it relates to product launches, so we have a number of products that we've talked about like the signature line of Neuro Powered drills that haven't had a full year impact. But we do have our Neptune 3 launch that's upcoming, which is the main",204,"Yes. And as it relates to product launches, so we have a number of products that we've talked about like the signature line of Neuro Powered drills that haven't had a full year impact. But we do have our Neptune 3 launch that's upcoming, which is the main waste management product within Instruments. That's coming in the middle of the year. That will be a contributor to growth. But I would say it's just a continuation. That camera launch was December. It really was mid-December of last year, the 1588. We're getting great customer feedback. So that will continue going into this year. Sports medicine is launching a number of products. Spine, the 3D-printed implant, the interbody device, great feedback, but a very small number of surgeons put those in, in the first quarter. So we'll expand that launch over the course of the year. So I wouldn't point to one single product. It's just typical of Stryker. We tend to have our growth spread across a wide variety of products. But there are a number of products that will contribute to the growth rates, and obviously, raising after one quarter, we'll have confidence that we'll be able to sustain this level of growth."
94614,328661858,960334,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Operator","There are no further questions at this time. I will now turn the conference over to Mr. Kevin Lobo for any closing remarks.",23,"There are no further questions at this time. I will now turn the conference over to Mr. Kevin Lobo for any closing remarks."
94614,328661858,960334,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Executives","So thank you, all, for joining our call. Our conference call for the second quarter 2016 results will be held on July 21. Thank you.",25,"So thank you, all, for joining our call. Our conference call for the second quarter 2016 results will be held on July 21. Thank you."
94614,328661858,960334,"Stryker Corporation, Q1 2016 Earnings Call, Apr 20, 2016",2016-04-20,"Earnings Calls","Stryker Corporation","Operator","Thank you, ladies and gentlemen. This concludes today's conference. Thank you for participating, you may now disconnect.",17,"Thank you, ladies and gentlemen. This concludes today's conference. Thank you for participating, you may now disconnect."
94614,331567642,1010081,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Operator","Welcome to the second quarter 2016 Stryker Earnings Call. My name is Andrea, and I will be your operator for today's call. [Operator Instructions] This conference call is being recorded for replay purposes.Before we begin, I would like to remind you tha",134,"Welcome to the second quarter 2016 Stryker Earnings Call. My name is Andrea, and I will be your operator for today's call. [Operator Instructions] This conference call is being recorded for replay purposes.
Before we begin, I would like to remind you that the discussions during this conference call will include forward-looking statements. Factors that could cause actual results to differ materially are discussed in the company's most recent filings with the SEC. Also, the discussions will include certain non-GAAP financial measures. Reconciliations to the most directly comparable GAAP financial measures can be found in today's press release that is an exhibit to Stryker's current report on Form 8-K filed today with the SEC.
I will now turn the call over to Mr. Kevin Lobo, Chairman and Chief Executive Officer. You may proceed, sir."
94614,331567642,1010081,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","Welcome to Stryker's second quarter earnings call. Joining me today are Glenn Boehnlein, Stryker CFO; Tim Scannell, Group President, MedSurg and Neurotechnology; and Katherine Owen, VP of Strategy and Investor Relations. For today's call, I'll provide ope",286,"Welcome to Stryker's second quarter earnings call. Joining me today are Glenn Boehnlein, Stryker CFO; Tim Scannell, Group President, MedSurg and Neurotechnology; and Katherine Owen, VP of Strategy and Investor Relations. For today's call, I'll provide opening comments, followed by Tim with an update on our 2 recent acquisitions, Sage and Video Control. Glenn will then provide additional details regarding our quarterly results before we open the call to Q&A.
With Q2 organic sales growth of 6.6%, we continue to demonstrate the strength of Stryker's diversified revenue base, which is allowing us to consistently deliver sales growth at the high-end of med tech. This quarter, our growth was powered by robust performance in MedSurg and Neurotechnology, while Orthopaedics was in line. Our decentralized business model is enabling us to drive innovation and strong sales and marketing execution.
On a geographic basis, organic growth was led by the U.S., up 9%, while sales outside the U.S. were up 2%, which is continuing to be impacted by ongoing challenges in China.
Beyond the top line achievements, Q2 was highlighted by strong operational expense leverage, that reflects our focus on driving cost transformation across divisions and geographies. As previously mentioned, we have a significant opportunity to deliver greater G&A leverage on a multi-year basis with initiatives such as indirect spending, product lifecycle management and the optimization of our IT systems. As we are starting to see the impact from these initiatives, it underscores our conviction of delivering leverage earnings gains. Based on our first half performance, we now look for full year organic sales growth of 6% to 6.5% and adjusted per-share earnings of $5.78 to $5.80 a share.
I will now turn the call over to Tim."
94614,331567642,1010081,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","Thanks, Kevin. Good afternoon, I'm excited about participating in today's call and providing you with perspectives regarding our recent acquisitions of Sage products and Physio-Control. I will begin with Sage products as we reiterate the strategic rationa",796,"Thanks, Kevin. Good afternoon, I'm excited about participating in today's call and providing you with perspectives regarding our recent acquisitions of Sage products and Physio-Control. I will begin with Sage products as we reiterate the strategic rationale which drove this acquisition. As we are articulating in February, Sage complements Stryker Medical's portfolio of innovative ICU and MedSurg products with disposables targeted and reducing events. It also provides access to an important adjacent market that expands our hospital product offerings and improves our mix of single use versus capital products. Sages' approach to innovation focus is on demonstrating superior clinical outcomes, which underscore the benefits of their products driving customer adoption and loyalty. These innovation efforts have resulted in unique and highly-trusted brands, which are essential part of nurses daily interactions with patients and hospital ICUs and MedSurg units. Sages is #1 in all the segments it serves, and we believe that in North America alone, Sage's products address the segment totaling approximately $1.4 billion.
Turning to the financials for Sage, given that we closed the transaction in April 1, we are able to share a full quarter of sales results. Sage's performance was strong in Q2 with sales growth of roughly 9%. This performance was achieved while contending with an unexpected supply interruption during the quarter that was one-time in nature, and has been resolved. Without the supply interruption, Sage's growth in Q2 would've been approximately 14%.
Sage's success has been fueled by the commitment to innovation, which is resulted in a long history of successful new product introductions, including the-recently launched Airtap products. Using proprietary air resistance technology, Airtap enables caregivers to provide exceptional care by a begin the turning and boosting of patients, while the patients remain in bed. Airtap enhances safety as it requires 80% less force to boost patients versus a typically used draw sheet.
With respect to integration, plans are underway to expand our manufacturing capacity beginning in 2018 to support expected growth. Moreover, our businesses are working to create activity to accelerate revenue in areas such as key account and brands strategies.
Our international focus will begin with Europe, where Sage has experienced some initial success and Canada, where they have done very well. Beyond these markets, we're working to prioritize countries, which value proven clinical solutions that eliminates never events. We are excited by the cultural similarities and positive chemistry between Stryker and Sage, and expect double-digit revenue growth in the second half.
Turning to Physio-Control. I would like to also reinforce the strategic rationale that led us to acquire this company. As we described in mid-February, Physio-Control complement Stryker Medicals portfolio of innovative and differentiated prehospital and hospital products as Physio-Control is a leader in the development, manufacturer and sales of defibrillators and monitors, Beatty's, and CPR-assist devices. We are excited by the synergistic benefits and market strength that resulted from the combination of Physio-Control with our Medical division. Importantly, the vast majority of Physio-Control sales call points overlap with our Medical division call points. Physio-Control holds the #1 or #2 share position at every major segment it serves. We believe that on a global basis, Physio-Control's products address segments sold in approximately $1.7 billion.
With Stryker's market-leading power in [indiscernible] and power low list system, coupled with Physio-Control's suite of defibrillators, monitors and related products, our solution set is extensive. Our existing EMS franchise enjoyed tremendous success in recent years, with growth significantly higher than the market and Stryker as a whole. Physio-Control's business has an attractive mix of 60% capital and 40% recurring business compared to our EMS business, which is nearly 100% capital. In addition, Physio-Control has an impressive in their incompetency in a robust pipeline of products that have recently begun to launched with additional product launches slated for the next several years.
We expect this refreshed product portfolio in the combination of our organizations to result in continued strong sales momentum, integrator profitable deleverage in the future.
As a reminder, we closed the Physio transaction on April 5. The pro forma of Q2 sales grew roughly 9%. On the integration front, our teams are focused on determining the optimal organizational design that best serves our common EMS and hospital customers. In addition, Physio has a significant international structure and our Medical division is assessing opportunities to drive growth by leveraging Physio's international market knowledge, strength and operational infrastructure. We expect high single-digit growth from the Physio-Control business in the second half. With these 2 acquisitions, the Medical division is now bigger, stronger, better diversified geographically and has more base business. Encouragingly, Medical had a strong organic Q2 growth result while integrating these 2 acquisitions.
This concludes my overview commentary on Sage and Physio-Control. Glenn will now discuss our Q2 financials in more detail."
94614,331567642,1010081,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","Thanks, Tim. I will focus my comments today on our financial results and key drivers of our second quarter performance. Our detailed financial results have been provided in today's press release.For the quarter, our organic sales growth of 6.6% exceeded",1062,"Thanks, Tim. I will focus my comments today on our financial results and key drivers of our second quarter performance. Our detailed financial results have been provided in today's press release.
For the quarter, our organic sales growth of 6.6% exceeded the high-end of the range for our full year expectations despite a tough year-over-year comparison, with growth of 6.9% in the year-ago quarter. The quarter included 1 additional selling day compared to prior year and consistent with our previous communications, the additional selling day increased approximately 1% of additional growth. Pricing in the quarter was down 1.3% from the prior year, trending modestly better than we expected.
During the quarter, we continue to see strong U.S. sales with organic growth of 8.6%, while international sales posted organic growth of 2%, reflecting continued destocking challenges in China.
Our adjusted EPS of $1.39 increased 15.8% from the prior year, primarily driven by our strong top line growth, including the impact from the acquisitions completed in the quarter. Interest related to the recent bond offering unfavorably impacted EPS by $0.05 per share and foreign exchange unfavorably impacted EPS by $0.03 during the quarter.
Looking at our segment highlights. Orthopaedics delivered positive currency growth of 4.8% and organic growth of 4.5%. The top line was led by U.S. Orthopaedics gains of 5.9%, highlighted by a 9.5% increase in trauma and extremities, and a 6.8% growth in knees as momentum continued for our 3D-printed titanium provision cones in our cement-less knee products. U.S. hips posted low single-digit growth due to softness in the revision market.
Orthopaedics international delivered constant currency growth of 2.9%, led by a strong performance in our European Me business. Lastly, we placed 17 MAKO units during the quarter. Overall, our second quarter results continue to reflect strong momentum across our Orthopaedics portfolio.
Our MedSurg segment's constant currency growth was 34.2%, including the impact of the recent acquisitions of Sage and Physio. Excluding the impact of acquisitions, our MedSurg business posted organic growth of 8.5%. Our U.S. MedSurg business continued their strong momentum with organic growth of 11.1%. Instruments had solid US growth of 8%, with strong performance in our power tools business, highlighted by double-digit gains in our micropower tools. Endoscopy continued its momentum from Q1, with U.S. growth of 10.8%, driven by continued success of our 15 88 aimed video platform. Excluding the impact of the Sage and Physio acquisitions, Medical had U.S. growth of 16.9%, driven by continued performance of its power cost products as well as solid performance of our med business.
Internationally, MedSurg organic sales were down, 0.5% for the quarter, reflecting ongoing challenges in China, primarily related to the distributor destocking. We expect this to continue throughout 2016 as we work with our distributors to drive and customer demand and reduce the buildup in their inventories.
Neurotechnology and Spine close in constant currency growth of 9% and organic growth of 7.5%, with continued strong momentum in our neuro tech businesses, which increased 14.4%, while Spine was up 1%. As with our other businesses, U.S. neuro tech growth was robust at 15.6%, which reflects the continued strong demand for our Neurovascular products, the 3 [indiscernible] retriever and target coil, our Neuro Powered Instruments and our Craniomaxillofacial vexation products. Our U.S. Spine business grew 4.8%, despite experiencing product supply issues, but continued to see good demand for our newer 3D-printed titanium products. We expect these supply issues to remain into the fourth quarter.
Internationally, neuro tech constant currency growth of 12.3% reflects the broader market momentum for the 3 [indiscernible] retriever and target coils products. Spines international growth was dampened by the aforementioned product supplies issues and continued challenges in China.
Moving on to General operating highlights. Our gross margin on an adjusted basis was roughly flat at 66.2%, down 180 basis points sequentially. We had another quarter of strong impact from our focus on operational efficiencies, including improved productivity and absorption. This was offset by the full impact of our recent acquisitions, including certain accounting reclassification between gross margin and SG&A to align the Stryker policies, sales mix and negative pricing. As for our operating expenses, we continue to focus on internal innovation with R&D spending of 6.4% of sales.
On an adjusted basis, SG&A for the quarter was 34.9%, which was favorable by 120 basis points as compared to the prior year. The improvement reflects the favorable impact of SG&A leverage from our recent acquisitions, the previously mentioned reclassification of certain expenses, our sales mix and continued focus on our operating expense improvements to our CTG program. For the quarter, acquisitions contributed roughly half of our SG&A improvement. Combined, these factors drove a 100 basis points year-over-year increase in our adjusted operating margin to 24.8%.
Lastly, I provide some highlights on our other income expenses. Other expenses increased due to higher net interest expense related to increased borrowings at the end of the first quarter. We anticipate that future quarterly interest expense will be roughly $30 million, which is consistent with this quarter. Our second quarter adjusted effective tax rate of 17.6% reflects the benefits of our global tax structure, partially offset by the impact of higher U.S.-based income from our recent acquisitions.
Moving on to the balance sheet. We continue to maintain a strong balance sheet with $3.5 billion of cash and marketable securities, of which, approximately 38% was held in the U.S. Total debt on the balance sheet at the end of the second quarter was $7.6 billion.
Turning to cash flow. Our year-to-date cash from operations was approximately $671 million. Finally, as we have previously announced at the end of Q1, we suspended our share repurchases for the remainder of the year.
In terms of guidance, based on our second quarter performance, we expect our full year organic sales growth to be in the range of 6% to 6.5% versus 2016. If foreign currency exchange rates hold near current levels, we anticipate net sales will be negatively impacted by approximately 1% for 2016. With negative pricing being in the range of 1.5% to 2%. Lastly, our guidance for adjusted net earnings per diluted share in 2016 now stands in the range of $5.70 to $5.80 for the full year, and we expect the third quarter to be in the range of $1.33 to $1.38.
And now, I will open up the call for Q&A."
94614,331567642,1010081,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Operator","[Operator Instructions] Our first question comes from the line of Mike Weinstein with JPMorgan.",14,"[Operator Instructions] Our first question comes from the line of Mike Weinstein with JPMorgan."
94614,331567642,1010081,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Analysts","Just want to get your thoughts on the couple of items. Number one, understand the guidance updates for the year, one of the questions people are asking is just the third quarter is a little bit below where the Street was modeling. So I don't know, as you",119,"Just want to get your thoughts on the couple of items. Number one, understand the guidance updates for the year, one of the questions people are asking is just the third quarter is a little bit below where the Street was modeling. So I don't know, as you look at street models, if there was anything in particular, you thought The Street was rough on relative to your expectations? And then second, the mix of growth is a little bit different this quarter, if I look at Orthopaedics and MedSurg, within those different businesses. Maybe there's a couple you want to comment on there's a few that stick out to me, but I just want to get your thoughts."
94614,331567642,1010081,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","Okay. I'll take the first one. So as we look at Q3, seasonably, Q3 is usually our softest quarter. I think if you look at our guidance, it's very consistent with our Q3 guidance that we provided in the past, especially when you look at year-over-year grow",47,"Okay. I'll take the first one. So as we look at Q3, seasonably, Q3 is usually our softest quarter. I think if you look at our guidance, it's very consistent with our Q3 guidance that we provided in the past, especially when you look at year-over-year growth."
94614,331567642,1010081,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","As for the second question, Mike. This is Kevin. I would say that from quarter-to-quarter, we -- you see this kind of change at Stryker, and we've seen this for the past few years, where in the first quarter, Orthopaedics had a more robust performance, th",89,"As for the second question, Mike. This is Kevin. I would say that from quarter-to-quarter, we -- you see this kind of change at Stryker, and we've seen this for the past few years, where in the first quarter, Orthopaedics had a more robust performance, this quarter, it was led by MedSurg. From quarter-to-quarter, we see those variations. But what's encouraging to me is if you look at our growth versus the market, we continue to form very well, especially if you look on a rolling 4 quarters basis."
94614,331567642,1010081,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Analysts","And maybe just a couple more, Kevin, just to comment on, sort of the if I look at in different businesses, maybe some of that was a bit surprising was maybe international Spine, which I think you made some comments relative to Orthopaedic business, that w",85,"And maybe just a couple more, Kevin, just to comment on, sort of the if I look at in different businesses, maybe some of that was a bit surprising was maybe international Spine, which I think you made some comments relative to Orthopaedic business, that was some surprises like U.S. hips was less than what we thought, knees was pretty close. But there was some -- relative to what we saw in the first quarter there was some pretty good swings within the business model."
94614,331567642,1010081,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","Yes. So Mike, look, I'll just finish by saying in China, we've had issues and challenges and we highlighted those in the past, that affected Spine, that affected our Endoscopy division, that affected our Trauma division. Spine had some product supply issu",158,"Yes. So Mike, look, I'll just finish by saying in China, we've had issues and challenges and we highlighted those in the past, that affected Spine, that affected our Endoscopy division, that affected our Trauma division. Spine had some product supply issues, which affected both our U.S. Spine business as well as our OUS Spine business. And hips, as you pointed out, it was a little softer this quarter but we lead the market certainly in the U.S. for multiple years and our hip business, and it's just one quarter. So there is for me now concerned there. We see these changes from quarter-to-quarter. And as you've seen, our -- the resiliency of our top line quarter after quarter over the past 3 or 4 years, has been very steady. So yes, there were a bit of swings this quarter, but nothing that causes me any reason for concern. We are very, very strong divisions across the company."
94614,331567642,1010081,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Operator","Our next question comes from the line of Bob Hopkins with Bank of America.",14,"Our next question comes from the line of Bob Hopkins with Bank of America."
94614,331567642,1010081,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Analysts","So just a couple of things to follow-up on. One, just a little more color on maybe on the U.S. hips, recognized it has been strong, it's just 1 quarter but Kevin, you mentioned that you thought it was a software vision market-oriented there was some going",101,"So just a couple of things to follow-up on. One, just a little more color on maybe on the U.S. hips, recognized it has been strong, it's just 1 quarter but Kevin, you mentioned that you thought it was a software vision market-oriented there was some going on with the revision market this quarter. Just wondering if you could give a little bit more color there? And also now that you're kind of 1 quarter in to CJR, maybe any thoughts from the field in terms of what you're seeing, client reaction, your thoughts on how things are developing there."
94614,331567642,1010081,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","Bob, it's Katherine. Just a couple of points. I wouldn't look at the quarter and say something particular, was going on in revisions versus primary. Overall, it was a bit softer than we see. And much like the first quarter, it was a bit stronger than we t",195,"Bob, it's Katherine. Just a couple of points. I wouldn't look at the quarter and say something particular, was going on in revisions versus primary. Overall, it was a bit softer than we see. And much like the first quarter, it was a bit stronger than we typically see. But we're not hearing anything from the fields, from our customers that's just something's changed. It really reinforces why you've heard us say over and over, we really focus on rolling 4 quarter trends because we see this quarter-to-quarter variability that taken as a whole, when you look back, does it mean anything significant in terms of changes and underlying fundamentals. And we're not seeing anything different in this quarter other than it was, obviously, a weaker than normal quarter versus Q1 being the stronger than normal quarter. And in terms of CJR's, it went to effect in April 1. We haven't seen any impact I think it's simply too early. As you know, there's no penalty until after the first full year. So it's just simply too early but nothing has played out yet in terms of a significant change or impact on the market."
94614,331567642,1010081,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Analysts","Okay. And then 2 of the things I want to touch on. One, just made a comment on gross margin. In Q1, you talked about thinking about 68% for the rest of the year, just would like to understand some of them of the parts since you were highlighting in the pa",113,"Okay. And then 2 of the things I want to touch on. One, just made a comment on gross margin. In Q1, you talked about thinking about 68% for the rest of the year, just would like to understand some of them of the parts since you were highlighting in the parent comments. And then lastly, as it relates to the deals. Sounds like things are going well, Tim, previously, you guys adjusted that $0.15 to $0.18 in accretion in 2017 was a good preliminary estimate. Now I was wondering from what you see today, is that still a good pulmonary way of thinking about things? Or is that perhaps, a conservative estimate?"
94614,331567642,1010081,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","Bob, this is Glenn. First of all, if you look at the sequential drop in margin, Q1 to Q2, roughly 180 basis points. I mean, Q2 was really impacted by mix, especially but not just sales mix but by adding in the acquisitions. It's early. Acquisitions are of",243,"Bob, this is Glenn. First of all, if you look at the sequential drop in margin, Q1 to Q2, roughly 180 basis points. I mean, Q2 was really impacted by mix, especially but not just sales mix but by adding in the acquisitions. It's early. Acquisitions are off to a solid start, but that's going to impact gross margin for the rest of the year. And impacted more than just product, we made some reclassifications to harmonize Sage and Physio accounting account and packages with our accounting practices. The centuries shifted some SG&A expenses up to gross margin in order to sort of a line that would howl Stryker does the accounting. It's pretty common that we do that. We don't get a chance to really see it until we really climb into the integration work. So that's one of the things that came out. And then on top of that, I really see to reiterate that there's a lot of other things that make our margin move around, not just price but FX, geographic mix really impacted and all of those are pretty hard to forecast to sort of a single point estimate. As I think about for the rest of the year, and what you should maybe think about for your model, I think we'll be in the range of this 67% range, but understand that if it trend above or below that, based on all those factors that I mentioned."
94614,331567642,1010081,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","And Bob, on the deals. This is Tim speaking. Accretion assumption you cited looks a good. We're on track, and we would expect you could assume those to be good moving forward.",32,"And Bob, on the deals. This is Tim speaking. Accretion assumption you cited looks a good. We're on track, and we would expect you could assume those to be good moving forward."
94614,331567642,1010081,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Operator","Our next question comes from the line of Kristen Stewart with Deutsche Bank.",13,"Our next question comes from the line of Kristen Stewart with Deutsche Bank."
94614,331567642,1010081,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Analysts","Just 2, I guess go back to Bob's question on the accretion from the deal. How should we just think about, I guess, that accretion, thinking about that as flowing through, I realize it's still very early compared to take about next year. But should we thin",93,"Just 2, I guess go back to Bob's question on the accretion from the deal. How should we just think about, I guess, that accretion, thinking about that as flowing through, I realize it's still very early compared to take about next year. But should we think about kind of that baseline growth and if we talked about this in previous calls? Or should we think about that as still a little too soon to kind of dial in accretion above what has been generally a double-digit kind of baseline growth for you?"
94614,331567642,1010081,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","Kirsten, I think it's very consistent with how we message before. This is obviously been one of the variables that gets factored in as we go into our 2017 budgeting process. But clearly, it's incremental accretion above and beyond the normal earnings powe",144,"Kirsten, I think it's very consistent with how we message before. This is obviously been one of the variables that gets factored in as we go into our 2017 budgeting process. But clearly, it's incremental accretion above and beyond the normal earnings power of the businesses as I stand. How much of that flow-through the bottom line, how much of that we reinvest as we think about the opportunities in front of us? All of that will get factored in and will be evident when we get the range. So I wouldn't want to say it's a 1 for 1, just throw it all on top of a normal earnings numbers because we have to look at the opportunities for a investment, recognizing, obviously, it's also incremate accretion and some portion of it is likely to play out at the bottom line as well."
94614,331567642,1010081,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Analysts","Okay. And then just generally on the market trends solution. Just curious, from a competitive standpoint, now that we've had a couple of quarters on which, I guess, zimmers through with its integration of Biomed and we've seen J&J come pick up its momentu",113,"Okay. And then just generally on the market trends solution. Just curious, from a competitive standpoint, now that we've had a couple of quarters on which, I guess, zimmers through with its integration of Biomed and we've seen J&J come pick up its momentum within Hips and Knees. I was wondering if you guys could just comment broadly, if you're seeing, I guess, what other companies are saying in terms of them getting their momentum back. Any particular changes that have been affecting you and perhaps, on the hips side, is there a reflection of some of the other companies getting their steam? Or is it just simply feel just revision market softening?"
94614,331567642,1010081,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","Yes. I would say, again, it's is a quarter that was incrementally weaker versus quarter is where like the first quarter were expelled stronger but we can point to any discernible change or inflection point that suggest that we had a new higher growth mark",135,"Yes. I would say, again, it's is a quarter that was incrementally weaker versus quarter is where like the first quarter were expelled stronger but we can point to any discernible change or inflection point that suggest that we had a new higher growth market. The only ones well recorded roughly J&J, so we have pretty limited visibility into everybody else reports, but we're not seeing or hearing anything that's just what we're seeing some dramatic market share shifted that's generally not how things play out in the recon market. So again, we're not seeing anything that would suggest that there's anything different than the normal quarterly variability that we see play out, obviously, some more fun when its Q1 and it's incrementally stronger. But again, it's why we focus on the rolling 4 quarters."
94614,331567642,1010081,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Operator","Our next question comes from the line of David Lewis with Morgan Stanley.",13,"Our next question comes from the line of David Lewis with Morgan Stanley."
94614,331567642,1010081,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Analysts","Just a few questions, maybe starting off with Kevin. So Kevin, just with the extra selling day here in  the second quarter and thinking about the easier comps at the back half of the year. Biomass, your guidance for the remainder of the year sort of impli",89,"Just a few questions, maybe starting off with Kevin. So Kevin, just with the extra selling day here in  the second quarter and thinking about the easier comps at the back half of the year. Biomass, your guidance for the remainder of the year sort of implies stable comp adjusted growth at the back half of the year. Is that just kind of roughly how you see the business stability on an underlying basis into the back half of the year? Or are there chances for acceleration or deceleration?"
94614,331567642,1010081,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","So David, since the beginning of the year, this is the second time we sort of moved our range upwards. And we've been delivering very strong growth throughout the year. Yes, in China. And even in all the emerging markets, our comps will ease in the second",104,"So David, since the beginning of the year, this is the second time we sort of moved our range upwards. And we've been delivering very strong growth throughout the year. Yes, in China. And even in all the emerging markets, our comps will ease in the second half of the year, but we also have some challenging comps in some of our other businesses that were growing very robustly in the second half of the year. So it's a big business that we're managing. And I think if you're growing north of 6% organically while you're integrating acquisitions, I think you're doing pretty well."
94614,331567642,1010081,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Analysts","I would agree. And then Glenn, I think you gotten questions on margins, but I think this particular quarter, it's sort of the mirror image of the first quarter or gross a little weaker, SG&A controls a little better. I know you had some announcements on t",97,"I would agree. And then Glenn, I think you gotten questions on margins, but I think this particular quarter, it's sort of the mirror image of the first quarter or gross a little weaker, SG&A controls a little better. I know you had some announcements on the ERP integration during the quarter. Can you just give us an update on where you are in terms of the ERP planning? And what's the opportunity for savings for shareholders on the ERP? And then let me get an update on that number, and then I have 1 quick follow-up."
94614,331567642,1010081,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","Yes. David, ERP is one of the things we're focusing on relative to our CTT program, it has several facets. I would say, we're in there pretty early stages of our ERP program, obviously, when you're implementing a new commercial global footprint, it's a mu",101,"Yes. David, ERP is one of the things we're focusing on relative to our CTT program, it has several facets. I would say, we're in there pretty early stages of our ERP program, obviously, when you're implementing a new commercial global footprint, it's a multi-year journey. And we're in the early stages of that. So we'll definitely keep you guys updated as that project moves forward. I think the more immediate term things to think about are indirect procurement and those parts of the project that really, can have more of an impact as we go forward in the next year."
94614,331567642,1010081,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","David, we're signaling on our cost transformation. This is really the engine of being able to sustain leverage earnings year after year. And so in the earlier years, you're going to see more of that savings come through from indirect procurement and in th",127,"David, we're signaling on our cost transformation. This is really the engine of being able to sustain leverage earnings year after year. And so in the earlier years, you're going to see more of that savings come through from indirect procurement and in the later years, you're going to see more of that savings from product was cycle management and coming from the ERP benefits. But I would say, it's been a real rallying force for the company. So everybody, all the different divisions of Stryker working on a common system, which is going very, very well. And it's a shift to SAP from a company that has really no SAP today. But I'm very encouraged with the early progress and I'm very optimistic about the implementation."
94614,331567642,1010081,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Analysts","And then Katherine, just 1 last quick one here. The neurotech number, obviously, very, very strong and, obviously, always see the driver parsley [indiscernible] market. I feel like in the last couple of quarters, you and your competitors some sort of shif",79,"And then Katherine, just 1 last quick one here. The neurotech number, obviously, very, very strong and, obviously, always see the driver parsley [indiscernible] market. I feel like in the last couple of quarters, you and your competitors some sort of shifted away and are much more focused on sort of market development from here. I'm wondering if you could just share with us, and what specifically is Stryker doing on a market development front to drive that market?"
94614,331567642,1010081,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","Yes. David, we have been, for some time, been messaging around the market development, but with Tim here who runs that business, I'm going to pass it over to him.",30,"Yes. David, we have been, for some time, been messaging around the market development, but with Tim here who runs that business, I'm going to pass it over to him."
94614,331567642,1010081,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","Yes. There was a variety of initiatives out there where we're simply partnering with systems, health care systems, hospitals to drive patient flow to the right centers where they're performing these procedures. It will be a multi-year process and hospital",150,"Yes. There was a variety of initiatives out there where we're simply partnering with systems, health care systems, hospitals to drive patient flow to the right centers where they're performing these procedures. It will be a multi-year process and hospitals, all very in their level of maturity. But it's a very real and big challenge to get these patients to the right centers. But our efforts surround largely education, trying to assist, trying to ask the right questions, trying to connect people with the right consultants. Things like that and make sure their stroke centers are properly operating. And they're hitting the patients from the ER to the cap or the interventional lat to treat these patients. So it takes many forms, it takes many years. But I think what we're seeing is steady progress chipping away, but it's going to be years and years and years of efforts here."
94614,331567642,1010081,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Operator","Our next question comes from the line of Rick Wise with Stifel.",12,"Our next question comes from the line of Rick Wise with Stifel."
94614,331567642,1010081,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Analysts","Maybe just starting off with MAKO. In an oblique way, you talked about maybe had solid give us numbers, where are you in the Total Knee rollout for MAKO? Is MAKO -- you didn't callout MAKO as a positive factor driving new volumes in the U.S. Is it a facto",68,"Maybe just starting off with MAKO. In an oblique way, you talked about maybe had solid give us numbers, where are you in the Total Knee rollout for MAKO? Is MAKO -- you didn't callout MAKO as a positive factor driving new volumes in the U.S. Is it a factor? Just remind us where you are in those timelines with commercialization and papers and what's next for MAKO?"
94614,331567642,1010081,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","Yes. Thanks, Rick, this is Kevin. So today, MAKO's not a huge driver because we're really in the knee business, just using it for a unicompartmental knee. We do have a limited launch and the accent is the word, limited. Just a small number of surgeons who",107,"Yes. Thanks, Rick, this is Kevin. So today, MAKO's not a huge driver because we're really in the knee business, just using it for a unicompartmental knee. We do have a limited launch and the accent is the word, limited. Just a small number of surgeons who are doing total knees, early feedback has been very positive so we are encouraged. But a reason for the limited launch is to make sure that we work at all the workflow and defined training protocols that and also being able to have some publications and podium presentations. The full launch of the Total Knee is not until next year."
94614,331567642,1010081,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Analysts","So maybe turning to Tim and Physio. Tim, you talked about high single-digit second half growth for Physio, but you also underscored the pipeline and the products coming. Can you give us any more color on the pipeline? What do you expect? When do we see it",62,"So maybe turning to Tim and Physio. Tim, you talked about high single-digit second half growth for Physio, but you also underscored the pipeline and the products coming. Can you give us any more color on the pipeline? What do you expect? When do we see it? And does that accelerate or sustain that kind of high single-digit growth pace for Physio?"
94614,331567642,1010081,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","Yes. Rick, I would say, with sustained at high single-digit growth rate, I think what I said after the deal was announced was with the accretive to Stryker's sales growth rate. And I would expect over the next several years to see next generation products",135,"Yes. Rick, I would say, with sustained at high single-digit growth rate, I think what I said after the deal was announced was with the accretive to Stryker's sales growth rate. And I would expect over the next several years to see next generation products in each of 3 main categories, defibrillators and monitors, AEDs or automated external defibrillators and circulatory assist devices. This market is now turning into a PMA market in the United States. And so these watches will be global in nature and very timing by markets. So we're going to be overly specific about it. But I would say, we expect to get over the next 4 to 5 years out of consistent stream of new products, which would drive that accretive sales growth out of the Physio division versus Stryker."
94614,331567642,1010081,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Operator","Our next question comes from the line of Chris Pasquale with Guggenheim.",12,"Our next question comes from the line of Chris Pasquale with Guggenheim."
94614,331567642,1010081,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Analysts","I have a couple of questions on Sage. First, can you give us some more color on the supply disruption in the quarter? What happened there?",26,"I have a couple of questions on Sage. First, can you give us some more color on the supply disruption in the quarter? What happened there?"
94614,331567642,1010081,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","On the supply disruption, from time to time, each of our businesses may have some issues. In this case, it was  1 transit in nature. It's over, and that's about as far as we're then going terms of sharing details.",40,"On the supply disruption, from time to time, each of our businesses may have some issues. In this case, it was  1 transit in nature. It's over, and that's about as far as we're then going terms of sharing details."
94614,331567642,1010081,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Analysts","Okay. And then what's the timeline to build out Sage's presence internationally? You talked about a little bit in Europe and Canada initially, with the rest of the business. Can you drop those products in your bag internationally and start to see some syn",151,"Okay. And then what's the timeline to build out Sage's presence internationally? You talked about a little bit in Europe and Canada initially, with the rest of the business. Can you drop those products in your bag internationally and start to see some synergies in the next few quarters? Or is this going to be a protracted process where there are regulatory and tenders that have to go through before we really start to see that? Comps of longer-term progress as we have seen in all our international initiatives, it does take time. And so we do have a foothold in Europe and Canada as we talked about, areas like Australia, maybe for able around but will take a while. Other areas like Japan, we'll take even longer in terms of regulatory pathways. So we'll see -- we see great opportunity but it's going to be a multi-year journey, for sure."
94614,331567642,1010081,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Analysts","Okay. And then just 1 quick one, if I could, on China. Do you guys have any visibility at this point, where inventory levels stand and what's your underlying growth in that market might be excluding these drawdowns, just to give us a sense of how close we",55,"Okay. And then just 1 quick one, if I could, on China. Do you guys have any visibility at this point, where inventory levels stand and what's your underlying growth in that market might be excluding these drawdowns, just to give us a sense of how close we might be to seeing it turn there?"
94614,331567642,1010081,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","Yes. So what we've been saying now for the past few quarters is we did expect this to be a very soft quarter in China. So it was in line with our expectations. We do expect some time in the back half of the year that will start to reach bottom, and that w",106,"Yes. So what we've been saying now for the past few quarters is we did expect this to be a very soft quarter in China. So it was in line with our expectations. We do expect some time in the back half of the year that will start to reach bottom, and that will return to growth. We don't have the precision just based on having multiple tiers of distributors. [indiscernible] precision to be able to identify that exactly, but you should see signs of improvement, certainly, while we exit the year and going into next year. We should bottom out sometime in the second half."
94614,331567642,1010081,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Operator","Our next question comes from the line of Matt Keeler with Credit Suisse.",13,"Our next question comes from the line of Matt Keeler with Credit Suisse."
94614,331567642,1010081,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Analysts","Just first on the ex U.S. ME performance. You mentioned strength in Europe. Can you give us any more color around that? Was that market strength? Are you taking share?",31,"Just first on the ex U.S. ME performance. You mentioned strength in Europe. Can you give us any more color around that? Was that market strength? Are you taking share?"
94614,331567642,1010081,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","I think at this point, it's just [indiscernible] and to everybody reports. We have the numbers similarly and get a better sense of share shipped at that point. But there's nothing specific that we would point to. We obviously, have better execution now un",73,"I think at this point, it's just [indiscernible] and to everybody reports. We have the numbers similarly and get a better sense of share shipped at that point. But there's nothing specific that we would point to. We obviously, have better execution now under our tom model, which is how the number of our businesses. But we'll know in a couple of weeks if there's anything more beyond market growth versus share shift."
94614,331567642,1010081,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","So important just to note that we have a few of our businesses that are really underrepresented in Europe. Our Endoscopy division, our Instruments division and knees, where the market shares that we have are certainly much lower than they are in other par",95,"So important just to note that we have a few of our businesses that are really underrepresented in Europe. Our Endoscopy division, our Instruments division and knees, where the market shares that we have are certainly much lower than they are in other parts of the world. So when we produce a good growth number, it's really just sort of getting back towards to what we would consider our fair share. And it's very encouraging sign and we're pleased with some of the hiring that we've done in Europe, and starting to build the business."
94614,331567642,1010081,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Analysts","Okay. And then just a separate question on Eurotech growth, it's very strong in the quarter but it slowed versus last quarter, sequentially. Can you give us any color on subsegment growth rates in Neurovascular and CMF? What drove that slowdown in growth?",43,"Okay. And then just a separate question on Eurotech growth, it's very strong in the quarter but it slowed versus last quarter, sequentially. Can you give us any color on subsegment growth rates in Neurovascular and CMF? What drove that slowdown in growth?"
94614,331567642,1010081,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","Yes, there's nothing I would point to. I think as Katherine has talked about in some other areas, the growth rates can vary, it could be based on comps or different countries that did better or worse or what have you. I think if we dug down in the numbers",90,"Yes, there's nothing I would point to. I think as Katherine has talked about in some other areas, the growth rates can vary, it could be based on comps or different countries that did better or worse or what have you. I think if we dug down in the numbers, CMS might be up a smidge in Neurovascular, down a little but not think it would point to any dramatic shift. I think in general, we've had very, very strong performance and to me, the good news is that continues."
94614,331567642,1010081,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","Yes. It's important to know, all 3 of those groups, so Neurovascular is, of course, the biggest one, the Neuro powered tools as well as CMF, they're all double-digit growers. And so from quarter-to-quarter, as I mentioned some are a little higher, some ar",74,"Yes. It's important to know, all 3 of those groups, so Neurovascular is, of course, the biggest one, the Neuro powered tools as well as CMF, they're all double-digit growers. And so from quarter-to-quarter, as I mentioned some are a little higher, some are a little lower. We had a 20% comp, almost in the United States from the prior year and we continue to grow strong double digits on top of strong comps."
94614,331567642,1010081,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Operator","Our next question comes from the line of Matthew O'Brien with Piper Jaffray.",14,"Our next question comes from the line of Matthew O'Brien with Piper Jaffray."
94614,331567642,1010081,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Analysts","Just with the team in the room, I'd love to hear a little bit more about the MedSurg strength in the quarter. As you're integrating Sage and Physio, did you get any kind of benefit either from a segment perspective from hospitals about adding those busine",85,"Just with the team in the room, I'd love to hear a little bit more about the MedSurg strength in the quarter. As you're integrating Sage and Physio, did you get any kind of benefit either from a segment perspective from hospitals about adding those businesses? And then if we think about things going forward on an organic basis, now that you can bundle all of these things together, can you still deliver this mid or even upper single-digit growth out of MedSurg going forward?"
94614,331567642,1010081,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","Well, to add a little bit of color. First, I would say we're delighted with the performance of our Medical division in the quarter, that they delivered strong for growth while dealing with the challenges of these 2 large integrations. Their EMS business d",306,"Well, to add a little bit of color. First, I would say we're delighted with the performance of our Medical division in the quarter, that they delivered strong for growth while dealing with the challenges of these 2 large integrations. Their EMS business did particularly well and they performed nicely in the our core been stretcher business. Endoscopy is having an excellent year. For visualization business is performing exceptionally well, with the 15 88 camera. The communications business is doing well and the sports business is doing well there as well. I would point back to a couple of deals we did in 2014. For at total and Pipit, these both are kind of in the mainstream now of being integrated and our teams fully in line with our products. So the life booms and tables have sold well this year. The Pivot products have done very well and our hands as well. And over at Stryker Instruments, this has been a steady, strong performer over time. Their personal protection and fluid waste management businesses were real highlights in the quarter. We do expect a strong second half there as they'll be launching their Neptune 3 fluid waste management system in the coming days. So I think across the board, we were strong. I would also frankly note, the sustainability, business had a strong quarter and they have done very well at recent product launches. And importantly, we process products from Stryker have been embraced to high quality solutions by our hospital customers, despite the fact that that's a challenging and difficult market. I would tell you that now there wasn't really any sentiment in favor of Stryker as a result of these deals. But importantly, we've had strong execution across the board, good new product flow and we're optimistic about the rest of the year."
94614,331567642,1010081,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Analysts","Helpful. And then just shifting over to the common extremity business. Still solid performance there, but on a 2-year stack basis. That growth rate could decelerate here in Q2 versus the last few quarters. Is there anything going on there competitively of",84,"Helpful. And then just shifting over to the common extremity business. Still solid performance there, but on a 2-year stack basis. That growth rate could decelerate here in Q2 versus the last few quarters. Is there anything going on there competitively of note that could prevent you from sustaining this share taking position you've been in for a while? And getting so outperforming the overall market growth rates or should we expect more kind of market growth rates from you and from other extremities?"
94614,331567642,1010081,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","Well we feel really pleased with the performance of both Trauma and Extremeties businesses but obviously, that Extremities base has gotten much bigger now so we're looking at more challenging comparables and still growing very solid double digits. And Tra",93,"Well we feel really pleased with the performance of both Trauma and Extremeties businesses but obviously, that Extremities base has gotten much bigger now so we're looking at more challenging comparables and still growing very solid double digits. And Trauma, we continue to see strong performance for that business as well. There hasn't been any meaningful change, we still feel good about the way those businesses our positioned but obviously, a lot of large numbers that's in and the comps become more difficult. But beyond that, no, there's nothing we'd really point to."
94614,331567642,1010081,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","Keep in mind, we did have an 18% comp in the United States and Trauma. So we had a really huge growth in the prior year. And still strong growth. We still believe this is going to be a growth business for the company. So it's just 1 quarter, decelerate a",59,"Keep in mind, we did have an 18% comp in the United States and Trauma. So we had a really huge growth in the prior year. And still strong growth. We still believe this is going to be a growth business for the company. So it's just 1 quarter, decelerate a little bit but certainly, very impressive number, nonetheless."
94614,331567642,1010081,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Operator","And our next question comes from the line of Joanne Wuensch with BMO Capital Markets.",15,"And our next question comes from the line of Joanne Wuensch with BMO Capital Markets."
94614,331567642,1010081,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Analysts","In looking at your Spine business, that accelerated a little bit last year, it seems through innovation and some better execution but slowed down a little bit this year, year to date. How are you thinking about that in terms of the internal versus externa",46,"In looking at your Spine business, that accelerated a little bit last year, it seems through innovation and some better execution but slowed down a little bit this year, year to date. How are you thinking about that in terms of the internal versus external development?"
94614,331567642,1010081,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","You're right. We have invested a lot in terms of the pipeline and launching new products as we mentioned, we did our system supply disruption and that will continue into the second half here. As you know, we prioritize M&A across all the businesses, but w",109,"You're right. We have invested a lot in terms of the pipeline and launching new products as we mentioned, we did our system supply disruption and that will continue into the second half here. As you know, we prioritize M&A across all the businesses, but we also invest in those businesses in order to be able to deliver results based on internal innovation and R&D. So don't think about that business any differently than any other areas where we look at opportunities. As you know, we have BDP all the division looking at targets but also assessing that around opportunities to invest internally and grow the business organically."
94614,331567642,1010081,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","I would also just like to repeat that was mentioned earlier that we did have some product disruptions in the quarter in our Spine business. The underlying business is a really solid shape. I feel great about the leadership team. The new products, we have",66,"I would also just like to repeat that was mentioned earlier that we did have some product disruptions in the quarter in our Spine business. The underlying business is a really solid shape. I feel great about the leadership team. The new products, we have some supply challenges and that will continue in the third quarter and then it starts to improve in the fourth quarter."
94614,331567642,1010081,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Analysts","And then just to turn back to the gross margin moment. Is there a way to peel this apart a little bit to understand the impact of some of the acquisitions or the categorization may have had on that?",39,"And then just to turn back to the gross margin moment. Is there a way to peel this apart a little bit to understand the impact of some of the acquisitions or the categorization may have had on that?"
94614,331567642,1010081,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","Yes. I think if you think about sort of the sequential change from Q1 to Q2, acquisitions in total were roughly sort of half of that change. And that should continue through the rest of the year, in terms of the total growth, impact on the total gross mar",49,"Yes. I think if you think about sort of the sequential change from Q1 to Q2, acquisitions in total were roughly sort of half of that change. And that should continue through the rest of the year, in terms of the total growth, impact on the total gross margin."
94614,331567642,1010081,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","Keep in mind, when you get that hit of the growth margin, those are also lower SG&A businesses. So part of that big impact, the big SG&A decline as a percent of sales in the leverage is a flip side of that where you're seeing the benefit both from a produ",57,"Keep in mind, when you get that hit of the growth margin, those are also lower SG&A businesses. So part of that big impact, the big SG&A decline as a percent of sales in the leverage is a flip side of that where you're seeing the benefit both from a product mix as well as the reclassification."
94614,331567642,1010081,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Operator","And our next question comes from the line of Glenn Navarro with RBC Capital Markets.",15,"And our next question comes from the line of Glenn Navarro with RBC Capital Markets."
94614,331567642,1010081,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Analysts","Two questions on ortho. First, ortho pricing down 2.2% in 2Q versus down 1.7% in 1Q. Is there anything unusual happening there? Or is that just quarter-to-quarter fluctuations? And then on robotics, you sold 7 in 1Q, up to 17 in 2Q. Maybe talk about the m",72,"Two questions on ortho. First, ortho pricing down 2.2% in 2Q versus down 1.7% in 1Q. Is there anything unusual happening there? Or is that just quarter-to-quarter fluctuations? And then on robotics, you sold 7 in 1Q, up to 17 in 2Q. Maybe talk about the momentum there with these outright sales and what's the pipeline looking for -- looking like in terms of robotic deals in the back-end of the year?"
94614,331567642,1010081,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","Yes. To take your first question. No, I wouldn't read anything into 1.7% versus 2.2%, it's within the normal variability that we have historically seen, much like total pricing, trending, less negative. But still within the range of that 1.5% to 2% that w",92,"Yes. To take your first question. No, I wouldn't read anything into 1.7% versus 2.2%, it's within the normal variability that we have historically seen, much like total pricing, trending, less negative. But still within the range of that 1.5% to 2% that we think about. Yes, very pleased with the robust placements and the fact that we have the early observational studies underway and a limited launch. The orderbook looks strong. We're excited about the outlook there as we prepare, as we talk about going to full commercial launch in '17."
94614,331567642,1010081,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Analysts","And then just a quick follow-up for Glenn or for you, Katherine, you had the extra selling day in 2Q. Is everything normal for 3Q and 4Q?",28,"And then just a quick follow-up for Glenn or for you, Katherine, you had the extra selling day in 2Q. Is everything normal for 3Q and 4Q?"
94614,331567642,1010081,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","Yes. So if you think about it, there was no difference in selling days in the first quarter, whether you look at it U.S., OUS, worldwide. Second quarter, we had 1 extra selling day, which equates to 1% impact overall in our businesses. And then Q3, Q4, th",57,"Yes. So if you think about it, there was no difference in selling days in the first quarter, whether you look at it U.S., OUS, worldwide. Second quarter, we had 1 extra selling day, which equates to 1% impact overall in our businesses. And then Q3, Q4, there's no difference in selling days. U.S., OUS or worldwide."
94614,331567642,1010081,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Operator","And our next question comes from the line of Raj Denhoy with Jefferies.",13,"And our next question comes from the line of Raj Denhoy with Jefferies."
94614,331567642,1010081,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Analysts","Couple of questions if I could. So the Spine product issue you had in the quarter. Perhaps you could provide a little more about that, was that related to the 3D products that you rolled out or was that something different?",41,"Couple of questions if I could. So the Spine product issue you had in the quarter. Perhaps you could provide a little more about that, was that related to the 3D products that you rolled out or was that something different?"
94614,331567642,1010081,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","No. We're not going to get too many details just for competitive reasons. We do have a supply and disruption issue and some supply challenges, we worked through those in the third quarter. We did highlight the titanium products and a lot of momentum aroun",80,"No. We're not going to get too many details just for competitive reasons. We do have a supply and disruption issue and some supply challenges, we worked through those in the third quarter. We did highlight the titanium products and a lot of momentum around and excited about what the product will do for that portfolio. But not going to go into additional details other than to say issue assume the impact lingers into the second half of this year."
94614,331567642,1010081,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Analysts","Okay. And then just for my second question. Medtronic, obviously, made some noise in June about coming into the Orthopaedic market. Curious, have you seen anything? One. And then two, if you have any thoughts just around what Medtronic would mean for this",44,"Okay. And then just for my second question. Medtronic, obviously, made some noise in June about coming into the Orthopaedic market. Curious, have you seen anything? One. And then two, if you have any thoughts just around what Medtronic would mean for this market?"
94614,331567642,1010081,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","No. We haven't seen any impact and they obviously, better positioned to talk about where they are in the launch or signing up customers. So to date, no, we don't see any impact, obviously, we believe in the value of the rep and as well as innovation in th",77,"No. We haven't seen any impact and they obviously, better positioned to talk about where they are in the launch or signing up customers. So to date, no, we don't see any impact, obviously, we believe in the value of the rep and as well as innovation in this market and we're really going to focus on just that. And the MAKO total relaunch that think has the opportunity to be truly disruptive in the Reconstructive market."
94614,331567642,1010081,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Operator","And our next question comes from the line of Mike Matson with Needham & Company.",14,"And our next question comes from the line of Mike Matson with Needham & Company."
94614,331567642,1010081,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Analysts","I guess, I just wanted to start with MAKO in thinking through the Total Knee full launch next year. I guess, to what degree do you think the need to sell very expensive capital equipment of the robots will kind of limit the growth or limit the rate at whi",82,"I guess, I just wanted to start with MAKO in thinking through the Total Knee full launch next year. I guess, to what degree do you think the need to sell very expensive capital equipment of the robots will kind of limit the growth or limit the rate at which she can take market share in the knee market? And is there anything you can do to potentially speed up the placement in order to capture more of that knee implant share?"
94614,331567642,1010081,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","Yes. So we're selling the million-dollar robots right now, we did 17 this quarter, and that's before we've gone into full commercial launch for what we think is the biggest driver of value with the Maiko opportunity. And moreover, we've been selling their",181,"Yes. So we're selling the million-dollar robots right now, we did 17 this quarter, and that's before we've gone into full commercial launch for what we think is the biggest driver of value with the Maiko opportunity. And moreover, we've been selling their very capital on our MedSurg businesses for literally years and years. So we understand how to sell capital. It is fundamentally different than selling implants, they're disposable, which we have a separate dedicated salesforce. We also have for a number of years now, had a Flex Financial Group within the Stryker organization and our MAKO group is using that to leverage their expertise to offer different options to our customers, whether they want to buy outright or lease. And so that expertise that's been developed for a number of years that MedSurg is clearly enabling a different type of discussion or with customers and was possible when MAKE was a standalone. We feel really comfortable in our ability to sell capital and the value proposition that's driven by the different applications that will exist on the MAKO robot."
94614,331567642,1010081,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Analysts","I guess what I was getting at is if you came out with a new type of a knee implant, you could walk into an operating room and the doctor could switch to that new implant on day 1. Whereas if they're going to switch to MAKO, they've got to commit to the ho",79,"I guess what I was getting at is if you came out with a new type of a knee implant, you could walk into an operating room and the doctor could switch to that new implant on day 1. Whereas if they're going to switch to MAKO, they've got to commit to the hospital to buy a really expensive robot first. So that's going to kind of slowdown the ability to take knee any market shares, is it not?"
94614,331567642,1010081,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","Yes. To be able to do a robotic knee, you have to buy the robot. And it will be a closed system and can only use our knee. So that's part of the value proposition. So we go in and we have that discussion and articulate the benefits here. So this is very d",126,"Yes. To be able to do a robotic knee, you have to buy the robot. And it will be a closed system and can only use our knee. So that's part of the value proposition. So we go in and we have that discussion and articulate the benefits here. So this is very different, it's just simply coming out with a new knee and not having to buy capital. Yes, that's correct. But it's also very different in terms of the value that we think will bring forward and will start to get evidence of as we do these observational studies and look at benefits around less tissue disruption and improved alignment, a number of different factors that we think will help support the value proposition."
94614,331567642,1010081,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Analysts","Okay. Just if international growth were to improve, what would that do to your gross margin?",16,"Okay. Just if international growth were to improve, what would that do to your gross margin?"
94614,331567642,1010081,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","Generally, international closed through gross margin at roughly the same rate that we experience on an average year. So it was roughly close to it, about the 67%. It really depends sort of where internationally as well as to because we -- certain emerging",66,"Generally, international closed through gross margin at roughly the same rate that we experience on an average year. So it was roughly close to it, about the 67%. It really depends sort of where internationally as well as to because we -- certain emerging markets are better. European pricing impacts are usually higher. But up and down, from the 67%, that's roughly a good ballpark estimate."
94614,331567642,1010081,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Operator","And our next question comes from the line of Kaila Krum with William Blair.",14,"And our next question comes from the line of Kaila Krum with William Blair."
94614,331567642,1010081,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Analysts","One fine question and then 1 on Medical business. First, I mean what are you seeing sort of in the fine market, probably from a competitive perspective? And really, I'm curious about your thoughts on some of that of multi-year Robotics business but now, s",53,"One fine question and then 1 on Medical business. First, I mean what are you seeing sort of in the fine market, probably from a competitive perspective? And really, I'm curious about your thoughts on some of that of multi-year Robotics business but now, several companies are talking about in that space specifically."
94614,331567642,1010081,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","Yes. We really like that many companies are talking more and more of a Robotics. I think that provides a real good tailwind for MAKO. We believe we have certainly, the best system with have ticks and really terrific intellectual property. And so the more",140,"Yes. We really like that many companies are talking more and more of a Robotics. I think that provides a real good tailwind for MAKO. We believe we have certainly, the best system with have ticks and really terrific intellectual property. And so the more that robots become a positive word in the Medical technology community with our customers, I think that provides a real good tailwind for us on MAKO. We're not seeing anything new in this fine market, it's a tough market with many competitors. We like our ability to win in a market based on the innovations that we've been bringing forward over the last 2, 3 years. We did have our own challenges as we've mention a couple of times in the call related to some supply disruption, but nothing really new from a competitive standpoint."
94614,331567642,1010081,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Analysts","Okay. And then just a follow-up on the recent acquisition in the Medical business. I mean, just looking at the pro forma growth rates you gave us in the quarter, understanding we're obviously early integration process. But with that in mind, how do you ex",78,"Okay. And then just a follow-up on the recent acquisition in the Medical business. I mean, just looking at the pro forma growth rates you gave us in the quarter, understanding we're obviously early integration process. But with that in mind, how do you expect those performance growth rates to trend in the coming quarters? I mean, should we expect modest dislocation before an acceleration or just [indiscernible] interesting growth with a typical seasonality in Q3 and Q4?"
94614,331567642,1010081,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","I'd say, I guess my answer would be consistent growth in Q3 and 4 tied to that, those numbers we cited of high single digits and double digits.",29,"I'd say, I guess my answer would be consistent growth in Q3 and 4 tied to that, those numbers we cited of high single digits and double digits."
94614,331567642,1010081,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Operator","And our next question comes from the line of Larry Biegelsen with Wells Fargo.",14,"And our next question comes from the line of Larry Biegelsen with Wells Fargo."
94614,331567642,1010081,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Analysts","First, international. Kevin, I think you said last quarter, emerging markets were down in the high single digits in the first quarter. Was it similar in Q2? And from Biomet Europe was also a little soft in Q1. How was Europe in Q2 and what's the outlook t",54,"First, international. Kevin, I think you said last quarter, emerging markets were down in the high single digits in the first quarter. Was it similar in Q2? And from Biomet Europe was also a little soft in Q1. How was Europe in Q2 and what's the outlook there? And I think I 1 follow-up."
94614,331567642,1010081,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","Yes. I'd say, in emerging markets, it's a very similar story in Q2 as it was in Q1. It was just as about a quarter. As it relates to Europe, Europe had the mid-single digit growth in the second quarter. So we were actually very pleased with the second qua",70,"Yes. I'd say, in emerging markets, it's a very similar story in Q2 as it was in Q1. It was just as about a quarter. As it relates to Europe, Europe had the mid-single digit growth in the second quarter. So we were actually very pleased with the second quarter performance, otherwise, have been a soft as in the second quarter and got back on track in the second quarter."
94614,331567642,1010081,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Analysts","That's helpful. And then for Tim, on the ischemic stroke market, could you talk a little bit about how that market's been developing in 2016 versus a strong 2015? In terms of patient numbers treated in the U.S, it was probably up 30%, 40%, from about 12,0",70,"That's helpful. And then for Tim, on the ischemic stroke market, could you talk a little bit about how that market's been developing in 2016 versus a strong 2015? In terms of patient numbers treated in the U.S, it was probably up 30%, 40%, from about 12,000 to 16,000, 17,000 last year. Is 2016 looking like a stronger year just from ischemic of treatment endovascular treatment of ischemic stroke?"
94614,331567642,1010081,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","Yes. I think the growth trends have been similar this year and the last year and exact -- certainly, further to this larger numbers and what have you. The growth rates arguable would diminish with time but it continues to be a very robust market, with ver",54,"Yes. I think the growth trends have been similar this year and the last year and exact -- certainly, further to this larger numbers and what have you. The growth rates arguable would diminish with time but it continues to be a very robust market, with very significant growth opportunities lying ahead of us."
94614,331567642,1010081,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Operator","And our next question comes from the line of Richard Newitter with different partners.",14,"And our next question comes from the line of Richard Newitter with different partners."
94614,331567642,1010081,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Analysts","I have 2. The first one, just a follow-up on the robotics question and the competitive landscape. Just specifically, with respect to Spine. Can you talk to us a little bit about what your view is of spine robotics technologies in light of recent investmen",89,"I have 2. The first one, just a follow-up on the robotics question and the competitive landscape. Just specifically, with respect to Spine. Can you talk to us a little bit about what your view is of spine robotics technologies in light of recent investments that others are making there? And then I'm more just thinking if and when you potentially adapt MAKO solution to Spine, how do you -- what area or what capacity the thing that could add value to the procedure? Then I have a follow-up."
94614,331567642,1010081,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","I think it's early right now, there's been a lot of announced but there hasn't been a whole lot launch. And so I think we're just going to have to wait and see do they truly facilitate making the procedure easier or enhancing the outcome. We do believe th",100,"I think it's early right now, there's been a lot of announced but there hasn't been a whole lot launch. And so I think we're just going to have to wait and see do they truly facilitate making the procedure easier or enhancing the outcome. We do believe there's opportunity for Robotics when we look at MAKO and Spine. But it is not the focus right now. We are completely focused on the opportunity in recon and particularly, gearing up for the Total Knee launch. So certainly something that we're going to evaluate but near-term, nit's not the focus."
94614,331567642,1010081,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Analysts","Okay. And then just a second one. Someone asked a question earlier about Medtronic getting in into hips and knees, eventually. I guess, my question to you is Medtronic talked about a risk sharing model. Can you talk a little bit about what if anything, St",65,"Okay. And then just a second one. Someone asked a question earlier about Medtronic getting in into hips and knees, eventually. I guess, my question to you is Medtronic talked about a risk sharing model. Can you talk a little bit about what if anything, Stryker is thinking about doing and potentially going at risk with the hospital and an episode of care payment situation?"
94614,331567642,1010081,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","Yes, we have done that. We had our Stryker performance solution and group within the company now for a number of years. They go at risk. We've got convener status under the prior program. We're able to share with customers. And So this is something that t",140,"Yes, we have done that. We had our Stryker performance solution and group within the company now for a number of years. They go at risk. We've got convener status under the prior program. We're able to share with customers. And So this is something that through that SES, we've got a lot of institutional knowledge, where we say we have a very deep understanding around the Reconstructive procedure, what the value drivers are through the entire episode of care, both in the acute and the postacute setting. So given our long history in ortho, we think we are well-positioned on top of the expertise we developed over recent years through our Stryker performance solution, to really go in and partner with customers. And sometimes go at risk and than others construct models that help them maximize the value chain."
94614,331567642,1010081,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","We just haven't talked about a lot since it's not an enormous part of our business. But you have the capability, we're already doing it. And we certainly having more and more conversations with customers as the CJR rolls into effect.",42,"We just haven't talked about a lot since it's not an enormous part of our business. But you have the capability, we're already doing it. And we certainly having more and more conversations with customers as the CJR rolls into effect."
94614,331567642,1010081,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Operator","Our next question comes from the line of Josh Jennings with Cowen and Company.",14,"Our next question comes from the line of Josh Jennings with Cowen and Company."
94614,331567642,1010081,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Analysts","I just wanted to follow-up on the, Kevin, your comments on Europe and stronger growth in Q2 from Q1. And I think this is the second quarter post the annualization of the trends model initiative. Are you still -- are you beginning to see more benefits in Q",90,"I just wanted to follow-up on the, Kevin, your comments on Europe and stronger growth in Q2 from Q1. And I think this is the second quarter post the annualization of the trends model initiative. Are you still -- are you beginning to see more benefits in Q2? And do you think we should think about the European business continue to potentially accelerate or at least getting to continue to get received benefits from this transit at the model? I just want to see if there's an update there."
94614,331567642,1010081,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","Sure. So first, rather than focus on the first quarter, I think we had a very successful year last year, in the first year of the trans-Atlantic model, but it was not across every business. And we still have a number of businesses that are just really hav",164,"Sure. So first, rather than focus on the first quarter, I think we had a very successful year last year, in the first year of the trans-Atlantic model, but it was not across every business. And we still have a number of businesses that are just really have good growth in front of them. I highlighted knees, I highlighted Instruments, and even part of our Endoscopy division, still has significant growth. So to us, we look at Europe as being a growth market, just given our relatively lower market shares. And we see it as a growth market for the next several years. So regardless of what's going on with Brexit or anything else, our relative low market share creates some big opportunity and this model that we've implemented we feel is contributing to the growth that we're experiencing and will continue to deliver high-growth or higher than we've experienced over the past decades in Europe. So it continues to be a growth market."
94614,331567642,1010081,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Analysts","Great. And just have 1 follow-up on pricing in the press release you called out, the 1.3% headwind in Q2. I was hoping to just get your thoughts on what you're seeing in the market. I know there's a lot of subsegments within our business. But I guess, fro",85,"Great. And just have 1 follow-up on pricing in the press release you called out, the 1.3% headwind in Q2. I was hoping to just get your thoughts on what you're seeing in the market. I know there's a lot of subsegments within our business. But I guess, from a high-level, how should we be thinking about the sustainability, is this a new level? Is there anything to call out in the quarter? And just what you're seeing on the market from the pricing standpoint?"
94614,331567642,1010081,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","If you look at the in the breakout pricing and it tends to be more negative in ortho versus MedSurg, but there's been no real change. Yes, it's trending slightly better or slightly less bad at 1.3% versus the 1.5% to 2% range that we forecast. But we've a",122,"If you look at the in the breakout pricing and it tends to be more negative in ortho versus MedSurg, but there's been no real change. Yes, it's trending slightly better or slightly less bad at 1.3% versus the 1.5% to 2% range that we forecast. But we've also seen quarters not to far back where it trended a little bit worse and came in North of 2%. So it's -- with [indiscernible] basis points of the range, we're targeting and there's so many variables between mix, both products as well as geographic that play in there, but I wouldn't do this to some -- indicative of some new trendline. I think 1.5% to 2% is a good number to focus on."
94614,331567642,1010081,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Operator","And our next question comes from the line of Amit Hazan with Citi.",13,"And our next question comes from the line of Amit Hazan with Citi."
94614,331567642,1010081,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Analysts","0This is Lee on for Amit. I wanted to touch on 2 things from mix. It seems like some of our competitors data for product mix, assumes pretty much seems to be a positive tailwind. It's pretty much flat now. I know you guys get to talk about it in that ki",127,"0
This is Lee on for Amit. I wanted to touch on 2 things from mix. It seems like some of our competitors data for product mix, assumes pretty much seems to be a positive tailwind. It's pretty much flat now. I know you guys get to talk about it in that kind of positive 2% range, and it was offsetting price headwinds at about the same level. And realizing you might not want to throw out a specific number but directionally, are we still in the same ballpark for the product mix that we have been in the past several years or on that positive 2%? And what are your thoughts on sustainability at positive product mix going forward? This is for hips and knees, specifically."
94614,331567642,1010081,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","Okay. When we report price, and I know some companies are at one way, some companies are the other, we report fewer price. And then our -- the other number is volume and mix together. So price is negative, peer price negative in ortho. And it is offset bu",79,"Okay. When we report price, and I know some companies are at one way, some companies are the other, we report fewer price. And then our -- the other number is volume and mix together. So price is negative, peer price negative in ortho. And it is offset but obviously, by volumes. And to a lesser degree, by mix there hasn't been a big change in that in recent years in terms of the overall impact of those items."
94614,331567642,1010081,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Analysts","Okay. And then I have 1 follow-up. If you think about DJR next year, to expect your mix is standard versus premium implant to change it all within your CJR customers for hips and knees?",35,"Okay. And then I have 1 follow-up. If you think about DJR next year, to expect your mix is standard versus premium implant to change it all within your CJR customers for hips and knees?"
94614,331567642,1010081,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","I think it's early. And would will happen next year when they start to go into the penalty phase. Again, we really believe based on all our research that the focus there is going to be much more in the postacute settings, since I think it's 60% of the cos",104,"I think it's early. And would will happen next year when they start to go into the penalty phase. Again, we really believe based on all our research that the focus there is going to be much more in the postacute settings, since I think it's 60% of the cost lie there for the total procedure and there's tremendous opportunity to take cost out when you look at the postacute setting and the number of patients to get discharged through a rehab facility versus Homecare. That's where we think the biggest focus is going to be because that's where the biggest dollars are."
94614,331567642,1010081,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Operator","Our next question comes from the line of Matt Taylor with Barclays.",12,"Our next question comes from the line of Matt Taylor with Barclays."
94614,331567642,1010081,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Analysts","I was wondering if you could just comment, reflecting on the first half, just on utilization, [indiscernible] around here. Are you seeing anything different in the U.S. market [indiscernible] stronger than you'd expect or also see good execution in produc",42,"I was wondering if you could just comment, reflecting on the first half, just on utilization, [indiscernible] around here. Are you seeing anything different in the U.S. market [indiscernible] stronger than you'd expect or also see good execution in product update [indiscernible]?"
94614,331567642,1010081,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","Yes, there's no real change in utilization, obviously, hit utilization was a the bit lower in the U.S. in the second quarter. But no, there has been no overall change in underlying demand across the businesses. It does vary a bit to bit, obviously, that d",62,"Yes, there's no real change in utilization, obviously, hit utilization was a the bit lower in the U.S. in the second quarter. But no, there has been no overall change in underlying demand across the businesses. It does vary a bit to bit, obviously, that demand is going to be greater in something like ischemic. But no, there's been no fundamental change."
94614,331567642,1010081,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Analysts","Once you get through the trial downs in China, what kind of growth do you expect for your businesses in that market? And what visibility do you have on the end market [indiscernible]?",33,"Once you get through the trial downs in China, what kind of growth do you expect for your businesses in that market? And what visibility do you have on the end market [indiscernible]?"
94614,331567642,1010081,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","I think we'll have a better sense once we get through that. We're focus right now and really getting into appropriate inventory level and getting a much better sense end user demand because there is distributor they are there. So it's difficult to predict",104,"I think we'll have a better sense once we get through that. We're focus right now and really getting into appropriate inventory level and getting a much better sense end user demand because there is distributor they are there. So it's difficult to predict right now. The comps get easier in the second half but beyond that, we just don't have the visibility to see what 2 end market demand is going to be. If we start to get better visibility into the channel, we'll be able to share that with you but it'll be premature right now to throw a number out."
94614,331567642,1010081,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","And the area that sort of the most hard to predict is capital equipment. I think on the disposables and implant side of the business, we see that sort of, that still those markets are actually still fairly healthy and we expect that to continue going forw",47,"And the area that sort of the most hard to predict is capital equipment. I think on the disposables and implant side of the business, we see that sort of, that still those markets are actually still fairly healthy and we expect that to continue going forward."
94614,331567642,1010081,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Operator","And our next question comes from the line of Matt Miksic with UBS.",13,"And our next question comes from the line of Matt Miksic with UBS."
94614,331567642,1010081,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Analysts","So 1 follow-up on orthopaedic growth from Q1 to Q2. And I guess, when you do the math on J&J's numbers, hips and knees in the U.S. and it's just for selling days just for price, it wasn't deceleration from Q1 to Q2. And you clearly, you accelerated and be",131,"So 1 follow-up on orthopaedic growth from Q1 to Q2. And I guess, when you do the math on J&J's numbers, hips and knees in the U.S. and it's just for selling days just for price, it wasn't deceleration from Q1 to Q2. And you clearly, you accelerated and be here you also just growing at a higher rate. But I'm curious, is that still in the marketplace? Do you like share gains in terms of accounts or mine share some now? Or do you get the sense at all that there was what the overall market was like, I know this is an end of 2, [ph] but just love to get what your perspective is on their deceleration and your call it modest acceleration, after adjusting for days."
94614,331567642,1010081,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","Yes. So this is really our fourth really good performance in these fourth quarter in a row of really strong performance. And we tend to attribute that much more to the launch of our cementless cones and cementless knee businesses, are really picking up. S",143,"Yes. So this is really our fourth really good performance in these fourth quarter in a row of really strong performance. And we tend to attribute that much more to the launch of our cementless cones and cementless knee businesses, are really picking up. So our 3D-printed products, we really believe that that's a big part of this. And we also get a bit of a MAKO halo impact. So not specifically just the volume that's coming from our units but also wherever we put MAKO is we tend to drive a higher mix of our new business. So rather than commenting on 1 particular competitor. I would just point out that our business is really picked up and it's been multiple quarters now in a row of strong performance, really linked, I believe, to new products and the halo impact of MAKO."
94614,331567642,1010081,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Analysts","Great. And I just want to follow-up, if I could, I have a feeling the answer is going to be, it's early, around bundled payments. But speaking of folks in the field and working at some of these hospitals, either through BPCI or starting to consider how to",131,"Great. And I just want to follow-up, if I could, I have a feeling the answer is going to be, it's early, around bundled payments. But speaking of folks in the field and working at some of these hospitals, either through BPCI or starting to consider how to tackle CJR. There is some thinking that there are centers that are just looking at this and say, we don't do enough of these procedures may be to keep doing hips and knees. And maybe such procedures elsewhere in the network or upstream somehow. Again, I know it's early, but could you give some perspective on how you think that may play out in the market give us so much volume Orthopaedics in the U.S. is done by sort of lower volume centers?"
94614,331567642,1010081,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","Yes. It is early. So it's an accurate comment. Could we see in some hospitals shift? It's possible. But I think it's too early to say that that's going to be a discernible enough trend or how it impacts the volumes of hospitals where it shift to make any",78,"Yes. It is early. So it's an accurate comment. Could we see in some hospitals shift? It's possible. But I think it's too early to say that that's going to be a discernible enough trend or how it impacts the volumes of hospitals where it shift to make any big comments on it. I'm sorry, we just don't have more insights yet given the early stage, combined with the fact that there's no penalty in the first year."
94614,331567642,1010081,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Operator","There are no further questions at this time. I will now turn the conference back over to Kevin Lobo for any closing remarks.",23,"There are no further questions at this time. I will now turn the conference back over to Kevin Lobo for any closing remarks."
94614,331567642,1010081,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","So thank you all for joining our call. Our conference call for the third quarter 2016 results will be held on October 27. Also, our analyst meeting and product fair will be held on November 9, at our Orthopaedics headquarters in Mahwah, New Jersey. Thank",46,"So thank you all for joining our call. Our conference call for the third quarter 2016 results will be held on October 27. Also, our analyst meeting and product fair will be held on November 9, at our Orthopaedics headquarters in Mahwah, New Jersey. Thank you."
94614,331567642,1010081,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Operator","Thank you, ladies and gentlemen. This concludes today's conference. Thank you for participating. You may now disconnect.",17,"Thank you, ladies and gentlemen. This concludes today's conference. Thank you for participating. You may now disconnect."
94614,331567642,1010287,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Operator","Welcome to the Second Quarter 2016 Stryker Earnings Call. My name is Andrea, and I will be your operator for today's call. [Operator Instructions] This conference call is being recorded for replay purposes.Before we begin, I would like to remind you tha",134,"Welcome to the Second Quarter 2016 Stryker Earnings Call. My name is Andrea, and I will be your operator for today's call. [Operator Instructions] This conference call is being recorded for replay purposes.
Before we begin, I would like to remind you that the discussions during this conference call will include forward-looking statements. Factors that could cause actual results to differ materially are discussed in the company's most recent filings with the SEC. Also, the discussions will include certain non-GAAP financial measures. Reconciliations to the most directly comparable GAAP financial measures can be found in today's press release that is an exhibit to Stryker's current report on Form 8-K filed today with the SEC.
I will now turn the call over to Mr. Kevin Lobo, Chairman and Chief Executive Officer. You may proceed, sir."
94614,331567642,1010287,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","Welcome to Stryker's second quarter earnings call. Joining me today are Glenn Boehnlein, Stryker CFO; Tim Scannell, Group President, MedSurg & Neurotechnology; and Katherine Owen, VP of Strategy and Investor Relations. For today's call, I will provide ope",290,"Welcome to Stryker's second quarter earnings call. Joining me today are Glenn Boehnlein, Stryker CFO; Tim Scannell, Group President, MedSurg & Neurotechnology; and Katherine Owen, VP of Strategy and Investor Relations. For today's call, I will provide opening comments, followed by Tim with an update on our 2 recent acquisitions, Sage and Physio-Control. Glenn will then provide additional details regarding our quarterly results before we open the call to Q&A.
With Q2 organic sales growth of 6.6%, we continue to demonstrate the strength of Stryker's diversified revenue base, which is allowing us to consistently deliver sales growth at the high end of med tech. This quarter, our growth was powered by robust performance in MedSurg & Neurotechnology, while Orthopaedics was in line. Our decentralized business model is enabling us to drive innovation and strong sales and marketing execution. On a geographic basis, organic growth was led by the U.S., up 9%, while sales outside the U.S. were up 2%, which is continuing to be impacted by ongoing challenges in China.
Beyond the top line achievement, Q2 was highlighted by strong operational expense leverage that reflects our focus on driving cost transformation across divisions and geographies. As previously mentioned, we have a significant opportunity to deliver greater G&A leverage on a multi-year basis, with initiatives such as indirect spending, product life cycle management and the optimization of our IT systems. As we are starting to see the impact from these initiatives, it underscores our conviction of delivering leveraged earning gains. Based on our first half performance, we now look for full year organic sales growth of 6% to 6.5% and adjusted per share earnings of $ 5.70 to $5.80 a share.
I will now turn the call over to Tim."
94614,331567642,1010287,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","Thanks, Kevin. Good afternoon. I'm excited about participating in today's call and providing you with perspectives regarding our recent acquisitions of Sage Products and Physio-Control. I will begin with Sage Products and reiterate the strategic rationa",793,"Thanks, Kevin. Good afternoon. I'm excited about participating in today's call and providing you with perspectives regarding our recent acquisitions of Sage Products and Physio-Control. 
I will begin with Sage Products and reiterate the strategic rationale which drove this acquisition. As we articulated in February, Sage complements Stryker Medical's portfolio of innovative ICU and MedSurg products, with disposables targeted at reducing never events. It also provides access to an important adjacent market that expands our hospital product offerings and improves our mix of single-use versus capital products. Sage's approach to innovation focuses on demonstrating superior clinical outcomes, which underscore the benefits of their products, driving customer adoption and loyalty. These innovation efforts have resulted in unique and highly trusted brands, which are an essential part of nurses' daily interactions with patients and hospital ICUs and MedSurg units. Sage is #1 in all the segments it serves, and we believe that in North America alone, Sage's products address a segment totaling approximately $1.4 billion.
Turning to the financials for Sage. Given that we closed the transaction on April 1, we are able to share a full quarter of sales results. Sage's performance was strong in Q2, with sales growth of roughly 9%. This performance was achieved while contending with an unexpected supply interruption during the quarter that was onetime in nature and has been resolved. Without the supply interruption, Sage's growth in Q2 would have been approximately 14%.
Sage's success has been fueled by their commitment to innovation, which has resulted in a long history of successful new product introductions, including the recently launched AirTAP product. Using proprietary air-assisted technology, AirTAP enables caregivers to provide exceptional care by aiding in the turning and boosting of patients while the patients remain in bed. AirTAP enhances caregiver safety as it requires 80% less force to boost patients versus the typically used drawsheet.
With respect to integration, plans are underway to expand our manufacturing capacity beginning in 2018 to support expected growth. Moreover, our businesses are working to coordinate activities to accelerate revenue in areas such as key account and brand strategies. Our international focus will begin with Europe, where Sage has experienced some initial success, and Canada, where they have done very well. Beyond these markets, we are working to prioritize countries which value proven clinical solutions that eliminate never events. We are excited by the cultural similarities and positive chemistry between Stryker and Sage and expect double-digit revenue growth in the second half.
Turning to Physio-Control. I would like to also reinforce the strategic rationale that led us to acquire this company. As we described in mid-February, Physio-Control complements Stryker Medical's portfolio of innovative and differentiated prehospital and hospital products as Physio-Control is the leader in the development, manufacture and sale of defibrillators and monitors, AEDs and CPR-assist devices. We are excited by the synergistic benefits and market strength that resulted from the combination of Physio-Control with our Medical division. Importantly, the vast majority of Physio-Control sales call points overlap with our Medical division call points. Physio-Control holds the #1 or #2 share position at every major segment it serves. We believe that on a global basis, Physio-Control's products address segments totaling approximately $1.7 billion.
With Stryker's market-leading power cot and Power-LOAD lift system coupled with Physio-Control's suite of defibrillators, monitors and related products, our solution set is extensive. Our existing EMS franchise has enjoyed tremendous success in recent years, with growth significantly higher than the market and Stryker as a whole. Physio-Control's business has an attractive mix of 60% capital and 40% recurring business compared to our EMS business, which is nearly 100% capital. In addition, Physio-Control has an impressive enduring competency and a robust pipeline of products that have recently begun to launched, with additional product launches slated for the next several years. We expect this refreshed product portfolio and the combination of our organizations to result in continued strong sales momentum and greater profitability leverage in the future.
As a reminder, we closed the Physio transaction on April 5. Pro forma Q2 sales grew roughly 9%. On the integration front, our teams are focused on determining the optimal organizational design that best serves our common EMS and hospital customers. In addition, Physio has a significant international structure and our Medical division is assessing opportunities to drive growth by leveraging Physio's international market knowledge, strength and operational infrastructure. We expect high single-digit growth from the Physio-Control business in the second half. 
With these 2 acquisitions, the Medical division is now bigger, stronger, better diversified geographically and has more base business. Encouragingly, Medical had a strong organic Q2 growth result, well integrating these 2 acquisitions.
This concludes my overview commentary on Sage and Physio-Control. Glenn will now discuss our Q2 financials in more detail."
94614,331567642,1010287,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","Thanks, Tim. I will focus my comments today on our financial results and key drivers of our second quarter performance. Our detailed financial results have been provided in today's press release.For the quarter, our organic sales growth of 6.6% exceeded",1061,"Thanks, Tim. I will focus my comments today on our financial results and key drivers of our second quarter performance. Our detailed financial results have been provided in today's press release.
For the quarter, our organic sales growth of 6.6% exceeded the high end of the range of our full year expectations despite a tough year-over-year comparison, with growth of 6.9% in the year ago quarter. The quarter included one additional selling day compared to prior year, and consistent with our previous communications, the additional selling day equates to approximately 1% of additional growth. Pricing in the quarter was down 1.3% from the prior year, trending modestly better than we expected. During the quarter, we continued to see strong U.S. sales with organic growth of 8.6%, while international sales posted organic growth of 2%, reflecting continued destocking challenges in China. Our adjusted EPS of $1.39 increased 15.8% from the prior year, primarily driven by our strong top line growth, including the impact from the acquisitions completed in the quarter. Interest related to the recent bond offering unfavorably impacted EPS by $0.05 per share, and foreign exchange unfavorably impacted EPS by $0.03 during the quarter.
Looking at our segment highlights. Orthopaedics delivered constant currency growth of 4.8% and organic growth of 4.5%. The top line was led by U.S. Orthopaedics gains of 5.9%, highlighted by a 9.5% increase in Trauma and Extremities and a 6.8% growth in Knees as momentum continued for our 3D-printed titanium revision cone in our cementless knee products. U.S. Hips posted low single-digit growth due to softness in the revision market. Orthopaedics international delivered constant currency growth of 2.9%, led by a strong performance in our European Knee business. Lastly, we placed 17 MAKO units during the quarter. Overall, our second quarter results continue to reflect strong momentum across our Orthopaedics portfolio.
Our MedSurg segment's constant currency growth was 34.2%, including the impact of the recent acquisitions of Sage and Physio. Excluding the impact of acquisitions, our MedSurg business posted organic growth of 8.5%. Our U.S. MedSurg business continued their strong momentum with organic growth of 11.1%. Instruments had solid US growth of 8%, with strong performance in our power tools business, highlighted by double-digit gains in our micro power tools. Endoscopy continued its momentum from Q1, with U.S. growth of 10.8%, driven by continued success of our 1588 AIM video platform. Excluding the impact of the Sage and Physio acquisitions, Medical had U.S. growth of 16.9%, driven by continued performance of its power cot products as well as solid performance of our bed business. Internationally, MedSurg organic sales were down, 0.5% for the quarter, reflecting ongoing challenges in China primarily related to the distributor destocking. We expect this to continue throughout 2016 as we work with our distributors to drive end customer demand and reduce the buildup in their inventories.
Neurotechnology and Spine posted constant currency growth of 9% and organic growth of 7.5%, with continued strong momentum in our neurotech businesses, which increased 14.4%, while Spine was up 1%. As with our other businesses, U.S. neurotech growth was robust at 15.6%, which reflects the continued strong demand for our Neurovascular products, the Trevo stent retriever and Target Coil, our Neuro Powered Instruments and our craniomaxillofacial fixation products. Our U.S. Spine business grew 4.8% despite experiencing product supply issues but continues to see good demand for our new 3D-printed titanium products. We expect these supply issues to remain into the fourth quarter. Internationally, neurotech constant currency growth of 12.3% reflects the broader market momentum for the Trevo stent retriever and Target Coil products. Spine's international growth was dampened by the aforementioned product supplies issues and continued challenges in China.
Moving on to general operating highlights. Our gross margin on an adjusted basis was roughly flat at 66.2%, down 180 basis points sequentially. We had another quarter of strong impact from our focus on operational efficiencies, including improved productivity and absorption. This was offset by the full impact of our recent acquisitions, including certain accounting reclassifications between gross margin and SG&A to align with Stryker policy, sales mix and negative pricing. 
As for our operating expenses, we continue to focus on internal innovation, with R&D spending of 6.4% of sales. On an adjusted basis, SG&A for the quarter was 34.9%, which was favorable by 120 basis points as compared to the prior year. The improvement reflects the favorable impact of SG&A leverage from our recent acquisitions, the previously mentioned reclassification of certain expenses, our sales mix and continued focus on our operating expense improvements through our CPG program. For the quarter, acquisitions contributed roughly half of our SG&A improvement. Combined, these factors drove a 100 basis point year-over-year increase in our adjusted operating margin to 24.8%.
Lastly, I will provide some highlights on our other income expenses. Other expenses increased due to higher net interest expense related to increased borrowings at the end of the first quarter. We anticipate that future quarterly interest expense will be roughly $30 million, which is consistent with this quarter. Our second quarter adjusted effective tax rate of 17.6% reflects the benefits of our global tax structure, partially offset by the impact of higher U.S.-based income from our recent acquisitions.
Moving on to the balance sheet. We continue to maintain a strong balance sheet with $3.5 billion of cash and marketable securities, of which approximately 38% was held in the U.S. Total debt on the balance sheet at the end of the second quarter was $7.6 billion.
Turning to cash flow. Our year-to-date cash from operations was approximately $671 million. Finally, as we had previously announced at the end of Q1, we suspended our share repurchases for the remainder of the year.
In terms of guidance, based on our second quarter performance, we expect our full year organic sales growth to be in the range of 6% to 6.5% versus 2016. If foreign currency exchange rates hold near current levels, we anticipate net sales will be negatively impacted by approximately 1% for 2016, with negative pricing being in the range of 1.5% to 2%. Lastly, our guidance for adjusted net earnings per diluted share in 2016 now stands in the range of $5.70 to $5.80 for the full year, and we expect the third quarter to be in the range of $1.33 to $1.38.
And now we'll open up the call for Q&A."
94614,331567642,1010287,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Operator","[Operator Instructions] Our first question comes from the line of Mike Weinstein with JPMorgan.",14,"[Operator Instructions] Our first question comes from the line of Mike Weinstein with JPMorgan."
94614,331567642,1010287,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Analysts","I just want to get your thoughts on a couple of items. Number one, I understand the guidance update for the year. One of the questions people are asking is just the third quarter is a little bit below where The Street was modeling. So I don't know if -- a",123,"I just want to get your thoughts on a couple of items. Number one, I understand the guidance update for the year. One of the questions people are asking is just the third quarter is a little bit below where The Street was modeling. So I don't know if -- as you look at Street models, if there was anything in particular you thought The Street was off on relative to your expectations. And then second, the mix of growth was a little bit different this quarter if I look at Orthopaedics and MedSurg within those different businesses. Maybe there's a couple you want to comment on. There's a few that stick out to me, but I just want to get your thoughts."
94614,331567642,1010287,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","Okay. I'll take the first one. So as we look at Q3, seasonally, Q3 is usually our softest quarter. I think if you look at our guidance, it's very consistent with our Q3 guidance that we provided in the past, especially when you look at year-over-year grow",47,"Okay. I'll take the first one. So as we look at Q3, seasonally, Q3 is usually our softest quarter. I think if you look at our guidance, it's very consistent with our Q3 guidance that we provided in the past, especially when you look at year-over-year growth."
94614,331567642,1010287,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","And as for the second question -- Mike, this is Kevin. I would say that from quarter to quarter, we -- you see this kind of change at Stryker, and we've seen this for the past few years, where in the first quarter, Orthopaedics had a more robust performan",95,"And as for the second question -- Mike, this is Kevin. I would say that from quarter to quarter, we -- you see this kind of change at Stryker, and we've seen this for the past few years, where in the first quarter, Orthopaedics had a more robust performance. This quarter, it was led by MedSurg. From quarter to quarter, we see those variations. But what's encouraging to me is if you look at our growth versus the market, we continue to perform very well, especially if you look on a rolling 4 quarters basis."
94614,331567642,1010287,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Analysts","And maybe just a couple more, Kevin, just to comment on. So the -- if I look at within different businesses, maybe some of that were a bit surprising with maybe international Spine, which you made some comments relative to the Orthopaedic business. There",84,"And maybe just a couple more, Kevin, just to comment on. So the -- if I look at within different businesses, maybe some of that were a bit surprising with maybe international Spine, which you made some comments relative to the Orthopaedic business. There was some surprises, like U.S. Hips was less than what we thought. Knees was pretty close. But there was some -- relative to what we saw in the first quarter, there was some pretty good swings within the business model."
94614,331567642,1010287,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","Yes. So Mike, look, I'll just finish by saying in China, we've had issues and challenges, and we've highlighted those in the past. That affected Spine. That affected our Endoscopy division. That affected our Trauma division. Spine had some product supply",162,"Yes. So Mike, look, I'll just finish by saying in China, we've had issues and challenges, and we've highlighted those in the past. That affected Spine. That affected our Endoscopy division. That affected our Trauma division. Spine had some product supply issues, which affected both our U.S. Spine business as well as our OUS Spine business. Hips, as you pointed out, is -- was a little softer this quarter, but we've lead the market certainly in the U.S. for multiple years in our Hip business and it's just one quarter. So there is, for me, no concern there. We see these changes from quarter to quarter. And as you've seen, our -- the resiliency of our top line, quarter after quarter over the past 3 or 4 years, has been very steady. So yes, there were a bit of swings this quarter but nothing that causes me any reason for concern. I mean, we have very, very strong divisions across the company."
94614,331567642,1010287,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Operator","Our next question comes from the line of Bob Hopkins with Bank of America.",14,"Our next question comes from the line of Bob Hopkins with Bank of America."
94614,331567642,1010287,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Analysts","So just a couple of things to follow up on. One, just a little more color maybe on the U.S. Hips. I recognize it have been strong. It's just one quarter. But Kevin, you mentioned that you felt it was a soft revision market. So you feel like it was -- ther",109,"So just a couple of things to follow up on. One, just a little more color maybe on the U.S. Hips. I recognize it have been strong. It's just one quarter. But Kevin, you mentioned that you felt it was a soft revision market. So you feel like it was -- there was something going on with the revision market this quarter. So I was wondering if you could give a little bit more color there. And also, now that we're kind of one quarter into CJR, maybe any thoughts from the field in terms of what you're seeing, client reaction, your thoughts on how things are developing there."
94614,331567642,1010287,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","Bob, it's Katherine. Just a couple of points. I wouldn't look at the quarter and say something particular was going on in revisions versus primary. Overall, it was a bit softer than we've seen. And much like the first quarter, it was a bit stronger than w",188,"Bob, it's Katherine. Just a couple of points. I wouldn't look at the quarter and say something particular was going on in revisions versus primary. Overall, it was a bit softer than we've seen. And much like the first quarter, it was a bit stronger than we typically see. But we're not hearing anything from the field, from our customers that suggests something's changed. It really reinforces why you've heard us say over and over, we really focus on rolling 4 quarter trends because we see this quarter-to-quarter variability that, taken as a whole when you look back, doesn't mean anything significant in terms of changes and underlying fundamentals. And we're not seeing anything different in this quarter other than it was obviously a weaker-than-normal quarter versus Q1 being a stronger-than-normal quarter. In terms of CJRs, it went to effect April 1. We haven't seen any impact. I think it's simply too early. As you know, there's no penalty until after the first full year. So it's just simply too early, but nothing has played out yet in terms of a significant change or impact on the market."
94614,331567642,1010287,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Analysts","Okay. And then 2 of the things I want to touch on. One was just maybe a comment on gross margin. In Q1, we talked about thinking about 68% for the rest of the year. I just would like to understand some of the moving parts that you were highlighting in the",116,"Okay. And then 2 of the things I want to touch on. One was just maybe a comment on gross margin. In Q1, we talked about thinking about 68% for the rest of the year. I just would like to understand some of the moving parts that you were highlighting in the prepared comments. And then lastly, as it relates to the deals, it sounds like things are going well. Tim, previously, you guys have suggested that $0.15 to $0.18 of accretion in 2017 was a good preliminary estimate. Now I was wondering, from what you see today, is that still a good preliminary way of thinking about things? Or is that perhaps a conservative estimate?"
94614,331567642,1010287,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","Bob, this is Glenn. First of all, if you look at the sequential drop in margin, Q1 to Q2, roughly 180 basis points, I mean, Q2 was really impacted by mix especially, but not just sales mix but by adding in the acquisitions. It's early. Acquisitions are of",248,"Bob, this is Glenn. First of all, if you look at the sequential drop in margin, Q1 to Q2, roughly 180 basis points, I mean, Q2 was really impacted by mix especially, but not just sales mix but by adding in the acquisitions. It's early. Acquisitions are off to a solid start, but that's going to impact gross margin for the rest of the year. And it impacted more than just product. We made some reclassifications to harmonize Sage and Physio accounting practices with our accounting practices. And this essentially shifted some SG&A expenses up to gross margin in order to sort of align them with how Stryker does the accounting. It's pretty common that we do that, and we don't get a chance to really see it until we really climb into the integration work. So that's one of the things that came out. And then on top of that, I really just need to reiterate that there's a lot of other things that make our margin move around, not just price but FX, geographic mix really impact it. And all of those are pretty hard to forecast to a -- to sort of a single-point estimate. As I think about for the rest of the year and what you should maybe think about for your model, I think we'll be in the range of this 67% range, but understand that it could trend above or below that based on all of those factors that I mentioned."
94614,331567642,1010287,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","And Bob, on the deals -- this is Tim speaking. The accretion assumption you cited look good. We're on track and we would expect you could assume those to be good moving forward.",33,"And Bob, on the deals -- this is Tim speaking. The accretion assumption you cited look good. We're on track and we would expect you could assume those to be good moving forward."
94614,331567642,1010287,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Operator","Our next question comes from the line of Kristen Stewart with Deutsche Bank.",13,"Our next question comes from the line of Kristen Stewart with Deutsche Bank."
94614,331567642,1010287,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Analysts","Just 2, I guess go back to Bob's question on the accretion from the deal. How should we just think about, I guess, that accretion? Thinking [ph] about that as flowing through, I realize it's still very early compared to -- think about next year. But shoul",95,"Just 2, I guess go back to Bob's question on the accretion from the deal. How should we just think about, I guess, that accretion? Thinking [ph] about that as flowing through, I realize it's still very early compared to -- think about next year. But should we think about kind of that baseline growth. I know we've talked about this in previous calls. Or should we think about that as still a little too soon to kind of dial in accretion above what has been generally a double-digit kind of baseline growth for you?"
94614,331567642,1010287,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","Kristen, I think it's very consistent with how we've messaged before. This is obviously going to be one of the variables that gets factored in as we go through our 2017 budgeting process. But clearly, it's incremental accretion above and beyond the normal",148,"Kristen, I think it's very consistent with how we've messaged before. This is obviously going to be one of the variables that gets factored in as we go through our 2017 budgeting process. But clearly, it's incremental accretion above and beyond the normal earnings power of the businesses as they stand. How much of that flow through to the bottom line, how much of that we reinvest as we think about the opportunities in front of us, all of that will get factored in and will be evident when we give the range. So I wouldn't want to say it's a one for one, just throw it all on top of a normal earnings number because we have to look at the opportunities for reinvestment, recognizing, obviously, it's also incremental accretion. And so some portion of it is likely to play out at the bottom line as well."
94614,331567642,1010287,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Analysts","Okay. And then just generally on the market trends. I was just curious, from a competitive standpoint, now that we've had a couple of quarters on which, I guess, Zimmer is through with its integration with Biomet and we've seen J&J come pick up its moment",116,"Okay. And then just generally on the market trends. I was just curious, from a competitive standpoint, now that we've had a couple of quarters on which, I guess, Zimmer is through with its integration with Biomet and we've seen J&J come pick up its momentum within hips and knees. I was wondering if you guys could just comment broadly if you're seeing, I guess, what other companies are saying in terms of them getting their momentum back. Any particular changes that have been affecting you? And perhaps, on the Hips side, is this a reflection of some of the other companies getting their steam? Or is it just simply you feel just revision market softening?"
94614,331567642,1010287,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","Yes. I would say, again, it's just a quarter that was incrementally weaker versus the quarters where -- like the first quarter where it felt stronger but we couldn't point to any discernible change or inflection point that suggested we had a new higher gr",139,"Yes. I would say, again, it's just a quarter that was incrementally weaker versus the quarters where -- like the first quarter where it felt stronger but we couldn't point to any discernible change or inflection point that suggested we had a new higher growth market. The only ones who have reported are roughly J&J. So we have a pretty limited visibility into everybody else's reports, but we're not seeing or hearing anything that suggests that you're seeing some dramatic market share shifts. That's generally not how things play out in the recon market. So again, we're not seeing anything that would suggest that there's anything different than the normal quarterly variability that we see play out. Obviously, it's more fun when it's Q1 and it's incrementally stronger. But again, it's why we focus on the rolling 4 quarters."
94614,331567642,1010287,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Operator","Our next question comes from the line of David Lewis with Morgan Stanley.",13,"Our next question comes from the line of David Lewis with Morgan Stanley."
94614,331567642,1010287,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Analysts","Just a few questions, maybe starting with Kevin. So Kevin, just with the extra selling day here in  the second quarter and thinking about the easier comps in the back half of the year. [indiscernible] your guidance for the remainder of the year sort of im",89,"Just a few questions, maybe starting with Kevin. So Kevin, just with the extra selling day here in  the second quarter and thinking about the easier comps in the back half of the year. [indiscernible] your guidance for the remainder of the year sort of implies stable comp adjusted growth in the back half of the year. Is that just kind of roughly how you see the business stability on an underlying basis into the back half of the year? Or are there other chances for acceleration or deceleration?"
94614,331567642,1010287,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","So David, since the beginning of the year, this is the second time we've sort of moved our range upwards. And we've been delivering a very strong growth throughout the year. Yes, in China and even all the emerging markets, our comps will ease in the secon",104,"So David, since the beginning of the year, this is the second time we've sort of moved our range upwards. And we've been delivering a very strong growth throughout the year. Yes, in China and even all the emerging markets, our comps will ease in the second half of the year, but we also have some challenging comps in some of our other businesses that were growing very robustly in the second half of the year. So it's a big business that we're managing. And I think if you're growing north of 6% organically while you're integrating acquisitions, I think you're doing pretty well."
94614,331567642,1010287,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Analysts","I would agree. And then Glenn, I think you've gotten questions on margins, but I think this particular quarter, it's sort of the mirror image of the first quarter; or gross, a little weaker; SG&A controls, a little better. I know you had some announcement",97,"I would agree. And then Glenn, I think you've gotten questions on margins, but I think this particular quarter, it's sort of the mirror image of the first quarter; or gross, a little weaker; SG&A controls, a little better. I know you had some announcements on the ERP integration during the quarter. Can you just give us an update on where you are in terms of the ERP planning? And what's the opportunity for savings for shareholders on the ERP? And when we may get an update on that number? And then I had one quick follow-up."
94614,331567642,1010287,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","Yes. David, on -- ERP is one of the things we're focusing on relative to our CPG program. It has several facets. I would say we're in the pretty early stages of our ERP program. Obviously, when you're implementing a new commercial global footprint, it's a",102,"Yes. David, on -- ERP is one of the things we're focusing on relative to our CPG program. It has several facets. I would say we're in the pretty early stages of our ERP program. Obviously, when you're implementing a new commercial global footprint, it's a multi-year journey. And we're in the early stages of that. So we'll definitely keep you guys updated as that project moves forward. I think the more immediate-term things to think about are indirect procurement and those parts of the project that really can have more of an impact as we roll forward in the next year."
94614,331567642,1010287,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","Yes. David, what we've been signaling on our cost transformation is this is really the engine of being able to sustain leverage earnings year after year. And so in the earlier years, you're going to see more of that savings coming through from indirect pr",132,"Yes. David, what we've been signaling on our cost transformation is this is really the engine of being able to sustain leverage earnings year after year. And so in the earlier years, you're going to see more of that savings coming through from indirect procurement. And in the later years, you're going to see more of that saving coming from product life cycle management and coming from the ERP benefits. But I would say it's been a real rallying force for the company, so everybody, all the different divisions of Stryker working on a common system, which is going very, very well. And it's a shift to SAP from a company that has really no SAP today. But I'm very encouraged with the early progress, and I'm very optimistic about the implementation."
94614,331567642,1010287,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Analysts","And then Katherine, just one last quick one here. The neurotech number, obviously very, very strong and obviously, the driver partly is the ischemic market. I feel like in the last couple of quarters, you and your competitors have sort of shifted away and",83,"And then Katherine, just one last quick one here. The neurotech number, obviously very, very strong and obviously, the driver partly is the ischemic market. I feel like in the last couple of quarters, you and your competitors have sort of shifted away and they're much more focused on sort of market development from here. I'm wondering if you could share with us what specifically is Stryker doing on the market development front to drive that market. And I'll jump back in queue."
94614,331567642,1010287,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","Yes. David, we have been -- for some time, been messaging around the market development. But with Tim here who runs that business, I'm going to pass it over to him.",31,"Yes. David, we have been -- for some time, been messaging around the market development. But with Tim here who runs that business, I'm going to pass it over to him."
94614,331567642,1010287,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","Yes. There was a variety of initiatives out there where we're simply partnering with systems, health care systems, hospitals to drive patient flow to the right centers where they're performing these procedures. It will be a multi-year process, and hospita",150,"Yes. There was a variety of initiatives out there where we're simply partnering with systems, health care systems, hospitals to drive patient flow to the right centers where they're performing these procedures. It will be a multi-year process, and hospitals all vary in their level of maturity. But it's a very real and big challenge to get these patients to the right centers. But our efforts surround largely education, trying to assist, trying to ask the right questions, trying to connect people with the right consultants, things like that and make sure their stroke centers are properly operating. And they're getting the patients from the ER to the cap or the interventional lab to treat these patients. So it takes many forms. It takes many years. But I think what we're seeing is steady progress chipping away, but it's going to be years and years and years of efforts here."
94614,331567642,1010287,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Operator","Our next question comes from the line of Rick Wise with Stifel.",12,"Our next question comes from the line of Rick Wise with Stifel."
94614,331567642,1010287,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Analysts","Maybe just starting off with MAKO. In an oblique way, you talked about that you had solid U.S. Knee numbers. Where are you in the total knee roll-out for MAKO? Is MAKO -- you didn't call out MAKO as a positive factor driving Knee volumes in the U.S. Is it",71,"Maybe just starting off with MAKO. In an oblique way, you talked about that you had solid U.S. Knee numbers. Where are you in the total knee roll-out for MAKO? Is MAKO -- you didn't call out MAKO as a positive factor driving Knee volumes in the U.S. Is it a factor? Just remind us where you are in those time lines with commercialization and papers and what's next for MAKO."
94614,331567642,1010287,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","Yes, thanks. Rick, this is Kevin. So today, MAKO is not a huge driver because we're really in the Knee business, just using it for unicompartmental knees. We do have a limited launch and the accent is the word, limited, just a small number of surgeons who",105,"Yes, thanks. Rick, this is Kevin. So today, MAKO is not a huge driver because we're really in the Knee business, just using it for unicompartmental knees. We do have a limited launch and the accent is the word, limited, just a small number of surgeons who are doing total knees. Early feedback has been very positive. So we're encouraged. But the reason for the limited launch is to make sure that we work out all the workflow and define training protocols and also be able to have some publications and podium presentations. The full launch in the total knee is not until next year."
94614,331567642,1010287,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Analysts","So maybe turning to Tim and Physio. Tim, you talked about the high single-digit second half growth for Physio, but you also underscored the pipeline and the products coming. Can you give us any more color on the pipeline? What do we expect? When do we see",65,"So maybe turning to Tim and Physio. Tim, you talked about the high single-digit second half growth for Physio, but you also underscored the pipeline and the products coming. Can you give us any more color on the pipeline? What do we expect? When do we see it? And is -- does that accelerate or sustain that kind of high single-digit growth pace for Physio?"
94614,331567642,1010287,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","Yes. Rick, I would say we'd sustain that high single-digit growth rate. I think what I said after the deal was announced was that it would be accretive to Stryker's sales growth rate. And I would expect over the next several years to see next generation p",138,"Yes. Rick, I would say we'd sustain that high single-digit growth rate. I think what I said after the deal was announced was that it would be accretive to Stryker's sales growth rate. And I would expect over the next several years to see next generation products in each of 3 main categories, defibrillators and monitors, AEDs or automated external defibrillators, and circulatory-assist devices. This market is now turning into a PMA market in the United States. And so these launches will be global in nature and vary in timing by markets. So we're not going to be overly specific about it, but I would say we expect, again, over the next 4 to 5 years, to have a consistent stream of new products which would drive that accretive sales growth out of the Physio division versus Stryker."
94614,331567642,1010287,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Operator","Our next question comes from the line of Chris Pasquale with Guggenheim.",12,"Our next question comes from the line of Chris Pasquale with Guggenheim."
94614,331567642,1010287,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Analysts","I had a couple of questions on Sage. First, can you give us some more color on the supply disruption in the quarter? What happened there?",26,"I had a couple of questions on Sage. First, can you give us some more color on the supply disruption in the quarter? What happened there?"
94614,331567642,1010287,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","On the supply disruption, from time to time, each of our businesses may have some issues. In this case, it was one transit in nature. It's over, and that's about as far as we're going to go in terms of sharing details.",42,"On the supply disruption, from time to time, each of our businesses may have some issues. In this case, it was one transit in nature. It's over, and that's about as far as we're going to go in terms of sharing details."
94614,331567642,1010287,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Analysts","Okay. And then what's the time line to build out Sage's presence internationally? You talked about a little bit in Europe and Canada initially with the rest of the business. Can you drop those products in your bag internationally and start to see some syn",77,"Okay. And then what's the time line to build out Sage's presence internationally? You talked about a little bit in Europe and Canada initially with the rest of the business. Can you drop those products in your bag internationally and start to see some synergies in the next few quarters? Or is this going to be a protracted process where there are regulatory and tenders that have to go through before you really start to see that?"
94614,331567642,1010287,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","I think it will be a longer-term process. As we've seen with all our international initiatives, it does take time. And so we do have a foothold in Europe and Canada, as we've talked about. Areas like Australia may be fertile ground but will take a while.",76,"I think it will be a longer-term process. As we've seen with all our international initiatives, it does take time. And so we do have a foothold in Europe and Canada, as we've talked about. Areas like Australia may be fertile ground but will take a while. Other areas like Japan will take even longer in terms of regulatory pathways. So we see great opportunity, but it's going to be a multi-year journey, for sure."
94614,331567642,1010287,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Analysts","Okay. And then just one quick one, if I could, on China. Do you guys have any visibility at this point, where inventory levels stand and what's your underlying growth in that market might be excluding these drawdowns just to give us a sense of how close w",55,"Okay. And then just one quick one, if I could, on China. Do you guys have any visibility at this point, where inventory levels stand and what's your underlying growth in that market might be excluding these drawdowns just to give us a sense of how close we might be to seeing a turn there?"
94614,331567642,1010287,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","Yes. So what we've been saying now for the past few quarters is we did expect this to be a very soft quarter in China. So it was in line with our expectations. We do expect some time in the back half of the year that we'll start to reach bottom and that w",109,"Yes. So what we've been saying now for the past few quarters is we did expect this to be a very soft quarter in China. So it was in line with our expectations. We do expect some time in the back half of the year that we'll start to reach bottom and that we'll return to growth. I -- we don't have the precision just based on having multiple tiers of distributors. We're not positioned to be able to identify that exactly, but you should see signs of improvement certainly while we exit the year and going into next year. We should bottom out sometime in the second half."
94614,331567642,1010287,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Operator","Our next question comes from the line of Matt Keeler with Credit Suisse.",13,"Our next question comes from the line of Matt Keeler with Credit Suisse."
94614,331567642,1010287,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Analysts","Just first on the ex U.S. Knee performance, you mentioned strength in Europe. Can you give us any more color around that? Was that market strength? Are you taking share?",31,"Just first on the ex U.S. Knee performance, you mentioned strength in Europe. Can you give us any more color around that? Was that market strength? Are you taking share?"
94614,331567642,1010287,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","I think at this point, it's just tough to know until everybody reports we have the numbers similarly and get a better sense of share shift at that point. So there's nothing specific that we would point to. We obviously have better execution now under our",74,"I think at this point, it's just tough to know until everybody reports we have the numbers similarly and get a better sense of share shift at that point. So there's nothing specific that we would point to. We obviously have better execution now under our TOM model, which has helped a number of our businesses. But we'll know in a couple of weeks if there's anything more beyond market growth versus share shift."
94614,331567642,1010287,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","Yes. It's important just to note that we have a few of our businesses that are really underrepresented in Europe, our Endoscopy division, our Instruments division and Knees, where the market shares that we have are certainly much lower than they are in ot",97,"Yes. It's important just to note that we have a few of our businesses that are really underrepresented in Europe, our Endoscopy division, our Instruments division and Knees, where the market shares that we have are certainly much lower than they are in other parts of the world. So when we produce a good growth number, it's really just sort of getting back towards to what we would consider our fair share. And it's a very encouraging sign, and we're pleased with some of the hiring that we've done in Europe and starting to build the business."
94614,331567642,1010287,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Analysts","Okay. And then just a separate question on neurotech growth. It's very strong in the quarter, but it slowed versus last quarter sequentially. Can you give us any color on the subsegment growth rates in Neurovascular and CMF? And what drove that slowdown i",45,"Okay. And then just a separate question on neurotech growth. It's very strong in the quarter, but it slowed versus last quarter sequentially. Can you give us any color on the subsegment growth rates in Neurovascular and CMF? And what drove that slowdown in growth?"
94614,331567642,1010287,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","Yes, there would be nothing I would point to. I think as Katherine has talked about in some other areas, the growth rates can vary. It could be based on comps or different countries that did better or worse or what have you. I think if we dug down in the",92,"Yes, there would be nothing I would point to. I think as Katherine has talked about in some other areas, the growth rates can vary. It could be based on comps or different countries that did better or worse or what have you. I think if we dug down in the numbers, CMS might be up a smidge and Neurovascular down a little but nothing that would point to any dramatic shift. I think in general, we've had very, very strong performance. And to me, the good news is that, that continues."
94614,331567642,1010287,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","Yes. It's important to know all 3 of those groups. So Neurovascular is, of course, the biggest one, the neuro powered tools as well as CMF, all -- they're all double-digit growers. And so from quarter to quarter, as Tim mentioned, some are a little higher",78,"Yes. It's important to know all 3 of those groups. So Neurovascular is, of course, the biggest one, the neuro powered tools as well as CMF, all -- they're all double-digit growers. And so from quarter to quarter, as Tim mentioned, some are a little higher, some are a little lower. We had a 20% comp almost in the United States from the prior year, and we continue to grow strong double digits on top of strong comps."
94614,331567642,1010287,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Operator","Our next question comes from the line of Matthew O'Brien with Piper Jaffray.",14,"Our next question comes from the line of Matthew O'Brien with Piper Jaffray."
94614,331567642,1010287,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Analysts","Just with Tim in the room, I'd love to hear a little bit more about the MedSurg strength in the quarter. As you're integrating Sage and Physio, did you get any kind of benefit either from a sentiment [ph] perspective from hospitals about adding those busi",85,"Just with Tim in the room, I'd love to hear a little bit more about the MedSurg strength in the quarter. As you're integrating Sage and Physio, did you get any kind of benefit either from a sentiment [ph] perspective from hospitals about adding those businesses? And then as we think about things going forward on an organic basis now that you can bundle all of these things together, can you still deliver this mid- or even upper single-digit growth out of MedSurg going forward?"
94614,331567642,1010287,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","Well, to add a little bit of color, first, I would say we're delighted with the performance of our Medical division in the quarter that they delivered strong quarter growth while dealing with the challenges of these 2 large integrations. Their EMS busines",303,"Well, to add a little bit of color, first, I would say we're delighted with the performance of our Medical division in the quarter that they delivered strong quarter growth while dealing with the challenges of these 2 large integrations. Their EMS business did particularly well, and they performed nicely in their core bed and stretcher business. Endoscopy is having an excellent year. Their core visualization business is performing exceptionally well with the 1588 camera. The communications business is doing well, and the sports business is doing well there as well. I would point back to a couple of deals we did in 2014, Berchtold and Pivot. These both are kind of in the mainstream now of being integrated, and our team is fully in line with their products. So the Berchtold lights, booms and tables have sold well this year. The Pivot products have done very well in our hands as well. And over at Stryker Instruments, this has been a steady, strong performer over time. Their personal protection and fluid waste management businesses were real highlights in the quarter. We do expect a strong second half there as they'll be launching their Neptune 3 fluid waste management system in the coming days. So I think across the board, we were strong. I would also frankly note that Sustainability business had a strong quarter and they've done well at recent product launches. And importantly, reprocessed products from Stryker have been embraced as a high-quality solution by our hospital customers despite the fact that that's a challenging and difficult market. I would tell you that now, there wasn't really any sentiment in favor of Stryker as a result of these deals. But importantly, we've had strong execution across the board, good new product flow, and we're optimistic about the rest of the year."
94614,331567642,1010287,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Analysts","Helpful. And then just shifting over to the Trauma and Extremities business, still solid performance there, but on a 2-year stack basis, that growth rate did decelerate here at Q2 versus the last few quarters. Is there anything going on there competitivel",86,"Helpful. And then just shifting over to the Trauma and Extremities business, still solid performance there, but on a 2-year stack basis, that growth rate did decelerate here at Q2 versus the last few quarters. Is there anything going on there competitively of note that could prevent you from sustaining this share-taking position you've been in for a while and getting -- so outperforming the overall market growth rates? Or should we expect more kind of market growth rates from you and from Trauma and Extremities?"
94614,331567642,1010287,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","Well, we feel really pleased with the performance of both Trauma and Extremities businesses, but obviously, the Extremities base has gotten much bigger now. So you're looking at more challenging comparables that's still growing very solid double digits. A",91,"Well, we feel really pleased with the performance of both Trauma and Extremities businesses, but obviously, the Extremities base has gotten much bigger now. So you're looking at more challenging comparables that's still growing very solid double digits. And Trauma, we continue to see strong performance for that business as well. There hasn't been any meaningful change. We still feel good about the way those businesses are positioned, but obviously, the large numbers that's in and the comps become more difficult. But beyond that, no, there's nothing we'd really point to."
94614,331567642,1010287,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","Keep in mind, we did have an 18% comp in the United States in Trauma. So we had a really huge growth in the prior year and still strong growth. We still believe this is going to be a growth business for the company. So -- and it's just one quarter. It did",64,"Keep in mind, we did have an 18% comp in the United States in Trauma. So we had a really huge growth in the prior year and still strong growth. We still believe this is going to be a growth business for the company. So -- and it's just one quarter. It did decelerate a little bit but certainly a very impressive number nonetheless."
94614,331567642,1010287,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Operator","And our next question comes from the line of Joanne Wuensch with BMO Capital Markets.",15,"And our next question comes from the line of Joanne Wuensch with BMO Capital Markets."
94614,331567642,1010287,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Analysts","In looking at your Spine business, that accelerated a little bit last year, it seems, through innovation and some better execution but slowed down a little bit this year, year-to-date. How are you thinking about that in terms of internal versus external d",43,"In looking at your Spine business, that accelerated a little bit last year, it seems, through innovation and some better execution but slowed down a little bit this year, year-to-date. How are you thinking about that in terms of internal versus external development?"
94614,331567642,1010287,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","You're right. We have invested a lot in terms of the pipeline and launching new products. As we mentioned, we did have some system supply disruption that will continue into the second half here. As you know, we prioritize M&A across all the businesses, bu",111,"You're right. We have invested a lot in terms of the pipeline and launching new products. As we mentioned, we did have some system supply disruption that will continue into the second half here. As you know, we prioritize M&A across all the businesses, but we also invest in those businesses in order to be able to deliver results based on internal innovation and R&D. So don't think about that business any differently than other areas where we look at opportunities. As you know, we have BD people in all the divisions looking at targets but also assessing that around our opportunities to invest internally and grow the business organically."
94614,331567642,1010287,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","I would also -- just -- I'd just like to repeat that -- what was mentioned earlier that we did have some product disruptions in the quarter in our Spine business. The underlying business is in really solid shape. I feel great about the leadership team, th",73,"I would also -- just -- I'd just like to repeat that -- what was mentioned earlier that we did have some product disruptions in the quarter in our Spine business. The underlying business is in really solid shape. I feel great about the leadership team, the new products. We have some supply challenges, and that will continue in the third quarter and then it will start to improve in the fourth quarter."
94614,331567642,1010287,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Analysts","And then just to turn back to the gross margin moment, is there a way to peel this apart a little bit to understand the impact of some of the acquisitions or the recategorization may have had on that?",39,"And then just to turn back to the gross margin moment, is there a way to peel this apart a little bit to understand the impact of some of the acquisitions or the recategorization may have had on that?"
94614,331567642,1010287,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","Yes. I think if you think about sort of the sequential change from Q1 to Q2, acquisitions in total were roughly sort of half of that change. And that should continue through the rest of the year in terms of the total growth --  the impact on the total gro",51,"Yes. I think if you think about sort of the sequential change from Q1 to Q2, acquisitions in total were roughly sort of half of that change. And that should continue through the rest of the year in terms of the total growth --  the impact on the total gross margin."
94614,331567642,1010287,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","Joanne, just keep in mind when you get that hit at the gross margin, those are also lower SG&A businesses. So part of that big impact, the big SG&A decline as a percent of sales in the leverage, is a flip side of that, where you're seeing the benefit both",59,"Joanne, just keep in mind when you get that hit at the gross margin, those are also lower SG&A businesses. So part of that big impact, the big SG&A decline as a percent of sales in the leverage, is a flip side of that, where you're seeing the benefit both from a product mix as well as the reclassification."
94614,331567642,1010287,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Operator","And our next question comes from the line of Glenn Navarro with RBC Capital Markets.",15,"And our next question comes from the line of Glenn Navarro with RBC Capital Markets."
94614,331567642,1010287,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Analysts","Two questions on ortho. First, ortho pricing down 2.2% in 2Q versus down 1.7% in 1Q, is there anything unusual happening there? Or is that just quarter-to-quarter fluctuations? And then on Robotics, you sold 7 in 1Q, up to 17 in 2Q. Maybe talk about the m",73,"Two questions on ortho. First, ortho pricing down 2.2% in 2Q versus down 1.7% in 1Q, is there anything unusual happening there? Or is that just quarter-to-quarter fluctuations? And then on Robotics, you sold 7 in 1Q, up to 17 in 2Q. Maybe talk about the momentum there. Were these outright sales? And what's the pipeline looking for -- looking like in terms of Robotic deals in the back end of the year?"
94614,331567642,1010287,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","Yes. So to take your -- the first question, no, I wouldn't read anything into 1.7% versus 2.2%. It's within the normal variability that we have historically seen, much like total pricing trending less negative but still within the range of that 1.5% to 2%",98,"Yes. So to take your -- the first question, no, I wouldn't read anything into 1.7% versus 2.2%. It's within the normal variability that we have historically seen, much like total pricing trending less negative but still within the range of that 1.5% to 2% that we think about. Yes, we're very pleased with the robot placements and the fact that we have the early observational studies underway and a limited launch. The order book looks strong. We're excited about the outlook there as we prepare -- as we talk about going to full commercial launch in '17."
94614,331567642,1010287,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Analysts","And then just a quick follow-up for Glenn or for you, Katherine. You had the extra selling day in 2Q. Is everything normal for 3Q and 4Q?",28,"And then just a quick follow-up for Glenn or for you, Katherine. You had the extra selling day in 2Q. Is everything normal for 3Q and 4Q?"
94614,331567642,1010287,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","Yes. So if you think about it, there was no difference in selling days in the first quarter, whether you look at it U.S., OUS, worldwide. Second quarter, we had one extra selling day, which equates to 1% impact overall on our businesses. And then Q3, Q4,",57,"Yes. So if you think about it, there was no difference in selling days in the first quarter, whether you look at it U.S., OUS, worldwide. Second quarter, we had one extra selling day, which equates to 1% impact overall on our businesses. And then Q3, Q4, there's no difference in selling days, U.S., OUS or worldwide."
94614,331567642,1010287,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Operator","And our next question comes from the line of Raj Denhoy with Jefferies.",13,"And our next question comes from the line of Raj Denhoy with Jefferies."
94614,331567642,1010287,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Analysts","A couple of questions, if I could. So the Spine product issue you had in the quarter, perhaps you could provide a little bit more about that. Was that related to the 3D products that you rolled out? Or was that something different?",43,"A couple of questions, if I could. So the Spine product issue you had in the quarter, perhaps you could provide a little bit more about that. Was that related to the 3D products that you rolled out? Or was that something different?"
94614,331567642,1010287,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","No. We're not going to get into too many details just for competitive reasons. We do have a supply disruption issue and some supply challenges. We'll work through those in the third quarter. We did highlight the titanium products, a lot of momentum around",81,"No. We're not going to get into too many details just for competitive reasons. We do have a supply disruption issue and some supply challenges. We'll work through those in the third quarter. We did highlight the titanium products, a lot of momentum around that and excited about what that product will do for that portfolio but not going to go into additional details other than to say you should assume the impact lingers into the second half of this year."
94614,331567642,1010287,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Analysts","Okay. And then just for my second question. Medtronic obviously made some noise in June about coming into the orthopaedic market. Curious if you've seen anything, one; and two, if you have any thoughts just around what Medtronic would mean for this market",43,"Okay. And then just for my second question. Medtronic obviously made some noise in June about coming into the orthopaedic market. Curious if you've seen anything, one; and two, if you have any thoughts just around what Medtronic would mean for this market."
94614,331567642,1010287,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","No. We haven't seen any impact, and they're obviously better positioned to talk about where they are in the launch or signing up customers. So to date, no, we don't have -- we don't see any impact. Obviously, we believe in the value of the rep and -- as w",83,"No. We haven't seen any impact, and they're obviously better positioned to talk about where they are in the launch or signing up customers. So to date, no, we don't have -- we don't see any impact. Obviously, we believe in the value of the rep and -- as well as innovation in this market, and we're really going to focus on just that. And the MAKO total knee launch, we think, has the opportunity to be truly disruptive in the reconstructive market."
94614,331567642,1010287,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Operator","And our next question comes from the line of Mike Matson with Needham & Company.",14,"And our next question comes from the line of Mike Matson with Needham & Company."
94614,331567642,1010287,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Analysts","I guess I just wanted to start with MAKO in thinking through the total knee full launch next year. I guess to what degree do you think the need to sell the very expensive capital equipment or the robots will kind of limit the growth -- or limit the rate a",84,"I guess I just wanted to start with MAKO in thinking through the total knee full launch next year. I guess to what degree do you think the need to sell the very expensive capital equipment or the robots will kind of limit the growth -- or limit the rate at which you can take market share in the knee market? And is there anything you can do to potentially speed up those placements in order to capture more of that knee implant share?"
94614,331567642,1010287,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","Yes. So we're selling the million-dollar robots right now. We did 17 this quarter, and that's before we've gone into full commercial launch for what we think is the biggest driver of value with the MAKO opportunity. And moreover, we've been selling very e",184,"Yes. So we're selling the million-dollar robots right now. We did 17 this quarter, and that's before we've gone into full commercial launch for what we think is the biggest driver of value with the MAKO opportunity. And moreover, we've been selling very expensive capital on our MedSurg businesses for literally years and years. So we understand how to sell capital. It is fundamentally different than selling implants. They're disposable, which is why we have a separate dedicated sales force. We also have, for a number of years now, had a Flex Financial Group within the Stryker organization. And our MAKO group is using that to leverage their expertise to offer different options to our customers, whether they want to buy outright or lease. And so that expertise that's been developed for a number of years through MedSurg is clearly enabling a different type of discussion with customers than was possible when MAKO was a stand-alone. So we feel really comfortable in our ability to sell capital and the value proposition that's driven by the different applications that will exist on the MAKO robot."
94614,331567642,1010287,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Analysts","I guess what I was getting at is if you came out with a new type of a knee implant, you could walk into an operating room and the doctor could switch to that new implant on day 1, whereas if they're going to switch to MAKO, they've got to come in to a hos",80,"I guess what I was getting at is if you came out with a new type of a knee implant, you could walk into an operating room and the doctor could switch to that new implant on day 1, whereas if they're going to switch to MAKO, they've got to come in to a hospital to buy a really expensive robot first. So that's going to kind of slow down the ability to take knee market shares, is it not?"
94614,331567642,1010287,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","Yes. To be able to do a robotic knee, you have to buy the robot. And it will be a closed system and can only use our knee. So that's part of the value proposition. So we go in and we have that discussion and articulate the benefits here. So this is very d",126,"Yes. To be able to do a robotic knee, you have to buy the robot. And it will be a closed system and can only use our knee. So that's part of the value proposition. So we go in and we have that discussion and articulate the benefits here. So this is very different than just simply coming out with a new knee and not having to buy capital. Yes, that's correct. But it's also very different in terms of the value that, we think, we'll bring forward and will start to get evidence of as we do these observational studies and look at benefits around less tissue disruption, improved alignment and a number of different factors that, we think, will help support the value proposition."
94614,331567642,1010287,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Analysts","All right. And then just if international growth were to improve, what would that do to your gross margin?",19,"All right. And then just if international growth were to improve, what would that do to your gross margin?"
94614,331567642,1010287,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","Generally, international flows through gross margin at roughly the same rate that we're experiencing on an average here. So it would roughly flow through about the 67%. It really depends sort of where internationally as well, too, because we -- certain em",64,"Generally, international flows through gross margin at roughly the same rate that we're experiencing on an average here. So it would roughly flow through about the 67%. It really depends sort of where internationally as well, too, because we -- certain emerging markets are better. European pricing impacts are usually higher. But up and down from the 67%, that's roughly a good ballpark estimate."
94614,331567642,1010287,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Operator","And our next question comes from the line of Kaila Krum with William Blair.",14,"And our next question comes from the line of Kaila Krum with William Blair."
94614,331567642,1010287,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Analysts","One Spine question and then one on the Medical business. First, I mean, what are you seeing sort of in the spine market probably from a competitive perspective? And really, I'm curious about your thoughts on -- you hear that multi-year robotics movement t",54,"One Spine question and then one on the Medical business. First, I mean, what are you seeing sort of in the spine market probably from a competitive perspective? And really, I'm curious about your thoughts on -- you hear that multi-year robotics movement that now several companies are talking about in that space specifically."
94614,331567642,1010287,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","Yes. We really like that many companies are talking more and more about robotics. I think that provides a real good tailwind for MAKO. We believe we have certainly the best system with haptics and really a terrific intellectual property. And so the more t",140,"Yes. We really like that many companies are talking more and more about robotics. I think that provides a real good tailwind for MAKO. We believe we have certainly the best system with haptics and really a terrific intellectual property. And so the more that robots become a positive word out in the medical technology community with our customers, I think that provides a real good tailwind for us on MAKO. We're not seeing anything new in the spine market. It's a tough market with many competitors. We like our ability to win in a market based on the innovations that we've been bringing forward over the last 2, 3 years. We did have our own challenges, as we've mentioned a couple of times in the call, related to some supply disruption but nothing really new from a competitive standpoint."
94614,331567642,1010287,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Analysts","Okay. And then just a follow-up on the recent acquisitions in the Medical business. I mean, just looking at the pro forma growth rates you gave us in the quarter, understanding we're obviously early in the integration process, but with that in mind, I mea",82,"Okay. And then just a follow-up on the recent acquisitions in the Medical business. I mean, just looking at the pro forma growth rates you gave us in the quarter, understanding we're obviously early in the integration process, but with that in mind, I mean, how do you expect those pro forma growth rates to trend in the coming quarters? I mean, should we expect modest dislocation before an acceleration or just consistent growth with a typical seasonality in Q3 and Q4?"
94614,331567642,1010287,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","Yes, I'd say -- I guess my answer would be consistent growth in Q3 and 4 tied to that, those numbers we cited of high single digits and double digits.",30,"Yes, I'd say -- I guess my answer would be consistent growth in Q3 and 4 tied to that, those numbers we cited of high single digits and double digits."
94614,331567642,1010287,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Operator","And our next question comes from the line of Larry Biegelsen with Wells Fargo.",14,"And our next question comes from the line of Larry Biegelsen with Wells Fargo."
94614,331567642,1010287,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Analysts","First, international. Kevin, I think you said last quarter, emerging markets were down in the high single digits in the first quarter. Was it similar in Q2? And environment, Europe was also a little soft in Q1. How was Europe in Q2? And what's the outlook",53,"First, international. Kevin, I think you said last quarter, emerging markets were down in the high single digits in the first quarter. Was it similar in Q2? And environment, Europe was also a little soft in Q1. How was Europe in Q2? And what's the outlook there? And I did have one follow-up."
94614,331567642,1010287,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","Yes. I'd say in emerging markets, it was a very similar story in Q2 as it was in Q1. It was just as bad a quarter. As it relates to Europe, Europe had a mid-single digit growth in the second quarter. So we were actually very pleased with the second quarte",74,"Yes. I'd say in emerging markets, it was a very similar story in Q2 as it was in Q1. It was just as bad a quarter. As it relates to Europe, Europe had a mid-single digit growth in the second quarter. So we were actually very pleased with the second quarter performance. Otherwise, there have been a little bit of softness in the first quarter and got back on track in the second quarter."
94614,331567642,1010287,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Analysts","That's helpful. And then for Tim, on the ischemic stroke market, could you talk a little bit about how that market's been developing in 2016 versus a strong 2015? In terms of patient numbers treated in the U.S., it was probably up 30%, 40% from about 12,0",70,"That's helpful. And then for Tim, on the ischemic stroke market, could you talk a little bit about how that market's been developing in 2016 versus a strong 2015? In terms of patient numbers treated in the U.S., it was probably up 30%, 40% from about 12,000 to 16,000, 17,000 last year. Is 2016 looking like a stronger year just from ischemic treatment -- endovascular treatment of ischemic stroke?"
94614,331567642,1010287,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","Yes. I think the growth trends have been similar this year and the last year and exact -- certainly further to this, larger numbers and what have you. The growth rates arguably would diminish with time, but it continues to be a very robust market with ver",54,"Yes. I think the growth trends have been similar this year and the last year and exact -- certainly further to this, larger numbers and what have you. The growth rates arguably would diminish with time, but it continues to be a very robust market with very significant growth opportunities lying ahead of us."
94614,331567642,1010287,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Operator","And our next question comes from the line of Richard Newitter with Leerink Partners.",14,"And our next question comes from the line of Richard Newitter with Leerink Partners."
94614,331567642,1010287,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Analysts","I have 2. The first one, just a follow-up on the Robotics question and the competitive landscape. Just specifically with respect to Spine, can you talk to us a little bit about what your view is of spine robotics technologies in light of recent investment",91,"I have 2. The first one, just a follow-up on the Robotics question and the competitive landscape. Just specifically with respect to Spine, can you talk to us a little bit about what your view is of spine robotics technologies in light of recent investments that others are making there? And then I'm more just thinking if and when you potentially adapt a MAKO solution to Spine, how do -- what area or in what capacity do you think that could add value to the procedure? Then I have a follow-up."
94614,331567642,1010287,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","Yes. I think it is early right now. There's been a lot of announced, but there hasn't been a whole lot launch. And so I think we're just going to have to wait and see. Do they truly facilitate making the procedure easier or enhancing the outcome? We do be",103,"Yes. I think it is early right now. There's been a lot of announced, but there hasn't been a whole lot launch. And so I think we're just going to have to wait and see. Do they truly facilitate making the procedure easier or enhancing the outcome? We do believe there's opportunity for Robotics when we look at MAKO and Spine, but it is not the focus right now. We are completely focused on the opportunity in recon and particularly gearing up for the total knee launch. So it's certainly something that we're going to evaluate, but near term, it's not the focus."
94614,331567642,1010287,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Analysts","Okay. And then just a second one. Someone asked a question earlier about Medtronic getting in into hips and knees eventually. I guess my question to you is -- Medtronic talked about a risk-sharing model. Can you talk a little bit about what, if anything,",65,"Okay. And then just a second one. Someone asked a question earlier about Medtronic getting in into hips and knees eventually. I guess my question to you is -- Medtronic talked about a risk-sharing model. Can you talk a little bit about what, if anything, Stryker is thinking about doing and potentially going at risk with the hospital and an episode of care payment situation?"
94614,331567642,1010287,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","Yes, we have done that. We've had our Stryker Performance Solution group within the company now for a number of years. They go at risk. We've got convener status under the prior program, where we're able to share with customers. And so this is something t",137,"Yes, we have done that. We've had our Stryker Performance Solution group within the company now for a number of years. They go at risk. We've got convener status under the prior program, where we're able to share with customers. And so this is something that, through that SPS, we've got a lot of institutional knowledge. We obviously have a very deep understanding around the reconstructive procedure, what the value drivers are through the entire episode of care both in the acute and the post-acute setting. So given our long history in ortho, we think we're well positioned on top of the expertise we developed over recent years through our Stryker Performance Solution to really go in and partner with customers and sometimes go at risk and others construct models that help them maximize the value chain."
94614,331567642,1010287,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","We just haven't talked about a lot since it's not an enormous part of our business, but we have the capability. We're already doing it, and we certainly are having more and more conversations with customers as the CJR rolls into effect.",43,"We just haven't talked about a lot since it's not an enormous part of our business, but we have the capability. We're already doing it, and we certainly are having more and more conversations with customers as the CJR rolls into effect."
94614,331567642,1010287,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Operator","Our next question comes from the line of Josh Jennings with Cowen and Company.",14,"Our next question comes from the line of Josh Jennings with Cowen and Company."
94614,331567642,1010287,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Analysts","I just wanted to follow up on, Kevin, your comments on Europe and stronger growth in Q2 from Q1. And I think this is the second quarter post the annualization of the Transatlantic model initiative. Are you still -- are you beginning to see more benefits i",90,"I just wanted to follow up on, Kevin, your comments on Europe and stronger growth in Q2 from Q1. And I think this is the second quarter post the annualization of the Transatlantic model initiative. Are you still -- are you beginning to see more benefits in Q2? And do you think we -- should we think about your European business continue to potentially accelerate or at least getting -- continue to get -- receive benefits from this Transatlantic model? I just wanted to see if there's an update there."
94614,331567642,1010287,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","Sure. So first, rather than just focus on the first quarter, I think we had a very successful year last year in the first year of the Transatlantic model, but it wasn't across every business. And we still have a number of businesses that are just really -",167,"Sure. So first, rather than just focus on the first quarter, I think we had a very successful year last year in the first year of the Transatlantic model, but it wasn't across every business. And we still have a number of businesses that are just really -- that have good growth in front of them. I highlighted Knees. I highlighted Instruments. And even part of our Endoscopy division still has significant growth. So to us, we look at Europe as being a growth market just given our relatively lower market shares, and we see it as a growth market for the next several years. So regardless of what's going on with Brexit or anything else, our relative low market share creates a big opportunity. And this model that we've implemented, we feel, is contributing to the growth that we're experiencing and will continue to deliver high growth or higher than we've experienced over the past decades in Europe. So it continues to be a growth market."
94614,331567642,1010287,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Analysts","Great. And just I had one follow-up on pricing. In the press release, you called out a 1.3% headwind in Q2. I was hoping to just get your thoughts on what you're seeing in the market. I know there's a lot of different subsegments within your business. But",89,"Great. And just I had one follow-up on pricing. In the press release, you called out a 1.3% headwind in Q2. I was hoping to just get your thoughts on what you're seeing in the market. I know there's a lot of different subsegments within your business. But I guess from a high level, how should we be thinking about the sustainability? Is this a new level? Is there anything to call out in the quarter? And just what you're seeing out in the market from a pricing standpoint."
94614,331567642,1010287,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","Yes. You -- if you look in the -- we break out the pricing. And it tends to be more negative in ortho versus MedSurg, but there's been no real change. Yes, it's trending slightly better or slightly look bad at 1.3% versus the 1.5% to 2% range that we fore",129,"Yes. You -- if you look in the -- we break out the pricing. And it tends to be more negative in ortho versus MedSurg, but there's been no real change. Yes, it's trending slightly better or slightly look bad at 1.3% versus the 1.5% to 2% range that we forecast. But we've also seen quarters not too far back where it trended a little bit worse then came in north of 2%. So it's within tenths of basis points of the range we're targeting, and there are so many variables between mix, both products as well as geographic, that play in there. But I wouldn't do this to some -- indicative of some new trend line. I think 1.5% to 2% is a good number to focus on."
94614,331567642,1010287,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Operator","And our next question comes from the line of Amit Hazan with Citi.",13,"And our next question comes from the line of Amit Hazan with Citi."
94614,331567642,1010287,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Analysts","This is Lee Preston [ph] on for Amit. I wanted to touch on 2 things for mix. It seems like some of your competitors' data for product mix assume pretty much [indiscernible] a positive tailwind. It's pretty much flat now. I know you guys -- you did talk ab",127,"This is Lee Preston [ph] on for Amit. I wanted to touch on 2 things for mix. It seems like some of your competitors' data for product mix assume pretty much [indiscernible] a positive tailwind. It's pretty much flat now. I know you guys -- you did talk about it in that kind of positive 2% range and it was offsetting price headwinds at about the same level. I realize you might not want to throw out a specific number, but directionally, are we still in the same ballpark for that product mix that we had been in the past several years or on that positive 2%? And what are your thoughts on sustainability at positive product mix going forward? This is for Hips and Knees, specifically."
94614,331567642,1010287,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","Okay. When we report price -- and I know some companies are at one way, some companies go the other, we report pure price. And then our -- the other number is volume and mix together. So price is negative -- pure price negative in ortho. And it is offset",80,"Okay. When we report price -- and I know some companies are at one way, some companies go the other, we report pure price. And then our -- the other number is volume and mix together. So price is negative -- pure price negative in ortho. And it is offset obviously by volumes and to a lesser degree by mix. There hasn't been a big change in that in recent years in terms of the overall impact of those items."
94614,331567642,1010287,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Analysts","Okay. And then I have one follow-up. If you think about CJR next year, do you expect your mix of standard versus premium implant to change at all within your CJR customers for Hips and Knees?",36,"Okay. And then I have one follow-up. If you think about CJR next year, do you expect your mix of standard versus premium implant to change at all within your CJR customers for Hips and Knees?"
94614,331567642,1010287,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","I think it's early. We'll see what happens next year when they start to go into the penalty phase. Again, we really believe, based on all our research, that the focus there is going to be much more in the post-acute setting since 50% to 60% of the cost li",104,"I think it's early. We'll see what happens next year when they start to go into the penalty phase. Again, we really believe, based on all our research, that the focus there is going to be much more in the post-acute setting since 50% to 60% of the cost lie there for the total procedure, and there's tremendous opportunity to take cost out when you look at the post-acute setting and the number of patients who get discharged through a rehab facility versus home care. That's where we think the biggest focus is going to be because that's where the biggest dollars are."
94614,331567642,1010287,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Operator","Our next question comes from the line of Matt Taylor with Barclays.",12,"Our next question comes from the line of Matt Taylor with Barclays."
94614,331567642,1010287,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Analysts","I was wondering if you could just comment, reflecting on the first half, just on utilization [indiscernible], are you seeing anything different in the U.S. market [indiscernible] was stronger than you'd expect? Or are you guys are seeing good execution in",44,"I was wondering if you could just comment, reflecting on the first half, just on utilization [indiscernible], are you seeing anything different in the U.S. market [indiscernible] was stronger than you'd expect? Or are you guys are seeing good execution in product update [indiscernible]?"
94614,331567642,1010287,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","Yes, there's been no real change in utilization. Obviously, Hip utilization was a little bit lower in the U.S. in the second quarter. But no, there has been no overall change in underlying demand across the businesses. It does vary bit to bit. Obviously,",62,"Yes, there's been no real change in utilization. Obviously, Hip utilization was a little bit lower in the U.S. in the second quarter. But no, there has been no overall change in underlying demand across the businesses. It does vary bit to bit. Obviously, the demand is going to be greater in something like ischemic. But no, there's been no fundamental change."
94614,331567642,1010287,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Analysts","And once you get through the drawdowns in China, what kind of growth do you expect for your businesses in that market? Or what visibility do you have on the end markets out there?",34,"And once you get through the drawdowns in China, what kind of growth do you expect for your businesses in that market? Or what visibility do you have on the end markets out there?"
94614,331567642,1010287,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","I think we'll have a better sense once we get through that. We're focused right now on really getting to appropriate inventory level and getting a much better sense of end user demand because there is this distributor layer there. So it's difficult to pre",106,"I think we'll have a better sense once we get through that. We're focused right now on really getting to appropriate inventory level and getting a much better sense of end user demand because there is this distributor layer there. So it's difficult to predict right now. The comps get easier in the second half, but beyond that, we just don't have the visibility to say what 2 [ph] end market demand is going to be. If we'd start to get better visibility into the channel, we'll be able to share that with you, but it'd be premature right now to throw a number out."
94614,331567642,1010287,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","And the area that's sort of the most hard to predict is capital equipment. I think on the disposables and the implant side of the business, we see that sort of -- that still -- those markets are actually still fairly healthy, and we expect that to continu",51,"And the area that's sort of the most hard to predict is capital equipment. I think on the disposables and the implant side of the business, we see that sort of -- that still -- those markets are actually still fairly healthy, and we expect that to continue going forward."
94614,331567642,1010287,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Operator","And our next question comes from the line of Matt Miksic with UBS.",13,"And our next question comes from the line of Matt Miksic with UBS."
94614,331567642,1010287,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Analysts","So one follow-up on Orthopaedic growth from Q1 to Q2. And I guess when we do the math on J&J's numbers, just looking at knees in the U.S. and it's just for selling days, just for price, it was a deceleration from Q1 to Q2. And you -- clearly, a, you've ac",137,"So one follow-up on Orthopaedic growth from Q1 to Q2. And I guess when we do the math on J&J's numbers, just looking at knees in the U.S. and it's just for selling days, just for price, it was a deceleration from Q1 to Q2. And you -- clearly, a, you've accelerated; and b, you're also just growing at a higher rate. But I'm curious, is that -- feeling the marketplace, do you like share gains in terms of accounts or mine [ph] share somehow? Or do you get the sense at all that there was -- what the overall market was like? I know this is an end of 2 [ph], but just love to get what your perspective is on their deceleration and your, sort of, call it, modest acceleration after adjusting for days."
94614,331567642,1010287,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","Yes. So this is really our fourth really good performance in this -- fourth quarter in a row of really strong performance. And we tend to attribute that much more to the launch of our cementless cones, and the cementless knee business are really picking u",143,"Yes. So this is really our fourth really good performance in this -- fourth quarter in a row of really strong performance. And we tend to attribute that much more to the launch of our cementless cones, and the cementless knee business are really picking up, so our 3D-printed products. We really believe that that's a big part of this. And we also get a bit of a MAKO halo impact. So not specifically just the volume that's coming from our unis [ph], but also, wherever we put MAKO, we tend to drive a higher mix of our business. So rather than comment on one particular competitor, I would just point out that our businesses really picked up. And it's been multiple quarters now in a row of strong performance really linked, I believe, to new products and the halo impact of MAKO."
94614,331567642,1010287,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Analysts","Great. And then just one follow-up, if I could. I have a feeling the answer is going to be. It's early around bundled payments. But speaking of folks in the field and working at some of these hospitals either through BPCI or starting to consider how to ta",134,"Great. And then just one follow-up, if I could. I have a feeling the answer is going to be. It's early around bundled payments. But speaking of folks in the field and working at some of these hospitals either through BPCI or starting to consider how to tackle CJR, there is some thinking that there are centers that are just going to look at this and say, ""We don't do enough of these procedures maybe to keep doing hips and knees."" And maybe such 15-or-so [ph] procedures elsewhere in the network or upstream somehow. Again, I know it's early, but could you give some perspective on how you think that may play out in the market given so much of the volume in orthopaedics in the U.S. is done by sort of lower-volume centers?"
94614,331567642,1010287,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","Yes. It is early. So it's an accurate comment. Could we see in some hospital a shift? It's possible and -- but I think it's too early to say that that's going to be a discernible enough trend or how it impacts the volumes of hospitals, where it shifts to,",82,"Yes. It is early. So it's an accurate comment. Could we see in some hospital a shift? It's possible and -- but I think it's too early to say that that's going to be a discernible enough trend or how it impacts the volumes of hospitals, where it shifts to, to make any big comments on it. I'm sorry. We just don't have more insights yet given the early stage combined with the fact that there's no penalty in the first year."
94614,331567642,1010287,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Operator","There are no further questions at this time. I will now turn the conference back over to Mr. Kevin Lobo for any closing remarks.",24,"There are no further questions at this time. I will now turn the conference back over to Mr. Kevin Lobo for any closing remarks."
94614,331567642,1010287,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","So thank you all for joining our call. Our conference call for the third quarter 2016 results will be held on October 27. Also, our analyst meeting and product fair will be held on November 9 at our Orthopaedics headquarters in Mahwah, New Jersey. Thank y",46,"So thank you all for joining our call. Our conference call for the third quarter 2016 results will be held on October 27. Also, our analyst meeting and product fair will be held on November 9 at our Orthopaedics headquarters in Mahwah, New Jersey. Thank you."
94614,331567642,1010287,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Operator","Thank you, ladies and gentlemen. This concludes today's conference. Thank you for participating. You may now disconnect.",17,"Thank you, ladies and gentlemen. This concludes today's conference. Thank you for participating. You may now disconnect."
94614,331567642,1010351,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Operator","Welcome to the Second Quarter 2016 Stryker Earnings Call. My name is Andrea, and I will be your operator for today's call. [Operator Instructions] This conference call is being recorded for replay purposes.Before we begin, I would like to remind you tha",134,"Welcome to the Second Quarter 2016 Stryker Earnings Call. My name is Andrea, and I will be your operator for today's call. [Operator Instructions] This conference call is being recorded for replay purposes.
Before we begin, I would like to remind you that the discussions during this conference call will include forward-looking statements. Factors that could cause actual results to differ materially are discussed in the company's most recent filings with the SEC. Also, the discussions will include certain non-GAAP financial measures. Reconciliations to the most directly comparable GAAP financial measures can be found in today's press release that is an exhibit to Stryker's current report on Form 8-K filed today with the SEC.
I will now turn the call over to Mr. Kevin Lobo, Chairman and Chief Executive Officer. You may proceed, sir."
94614,331567642,1010351,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","Welcome to Stryker's second quarter earnings call. Joining me today are Glenn Boehnlein, Stryker CFO; Tim Scannell, Group President, MedSurg & Neurotechnology; and Katherine Owen, VP of Strategy and Investor Relations. For today's call, I will provide ope",290,"Welcome to Stryker's second quarter earnings call. Joining me today are Glenn Boehnlein, Stryker CFO; Tim Scannell, Group President, MedSurg & Neurotechnology; and Katherine Owen, VP of Strategy and Investor Relations. For today's call, I will provide opening comments, followed by Tim with an update on our 2 recent acquisitions, Sage and Physio-Control. Glenn will then provide additional details regarding our quarterly results before we open the call to Q&A.
With Q2 organic sales growth of 6.6%, we continue to demonstrate the strength of Stryker's diversified revenue base, which is allowing us to consistently deliver sales growth at the high end of med tech. This quarter, our growth was powered by robust performance in MedSurg & Neurotechnology, while Orthopaedics was in line. Our decentralized business model is enabling us to drive innovation and strong sales and marketing execution. On a geographic basis, organic growth was led by the U.S., up 9%, while sales outside the U.S. were up 2%, which is continuing to be impacted by ongoing challenges in China.
Beyond the top line achievement, Q2 was highlighted by strong operational expense leverage that reflects our focus on driving cost transformation across divisions and geographies. As previously mentioned, we have a significant opportunity to deliver greater G&A leverage on a multi-year basis, with initiatives such as indirect spending, product life cycle management and the optimization of our IT systems. As we are starting to see the impact from these initiatives, it underscores our conviction of delivering leveraged earning gains. Based on our first half performance, we now look for full year organic sales growth of 6% to 6.5% and adjusted per share earnings of $ 5.70 to $5.80 a share.
I will now turn the call over to Tim."
94614,331567642,1010351,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","Thanks, Kevin. Good afternoon. I'm excited about participating in today's call and providing you with perspectives regarding our recent acquisitions of Sage Products and Physio-Control. I will begin with Sage Products and reiterate the strategic rationa",793,"Thanks, Kevin. Good afternoon. I'm excited about participating in today's call and providing you with perspectives regarding our recent acquisitions of Sage Products and Physio-Control. 
I will begin with Sage Products and reiterate the strategic rationale which drove this acquisition. As we articulated in February, Sage complements Stryker Medical's portfolio of innovative ICU and MedSurg products, with disposables targeted at reducing never events. It also provides access to an important adjacent market that expands our hospital product offerings and improves our mix of single-use versus capital products. Sage's approach to innovation focuses on demonstrating superior clinical outcomes, which underscore the benefits of their products, driving customer adoption and loyalty. These innovation efforts have resulted in unique and highly trusted brands, which are an essential part of nurses' daily interactions with patients and hospital ICUs and MedSurg units. Sage is #1 in all the segments it serves, and we believe that in North America alone, Sage's products address a segment totaling approximately $1.4 billion.
Turning to the financials for Sage. Given that we closed the transaction on April 1, we are able to share a full quarter of sales results. Sage's performance was strong in Q2, with sales growth of roughly 9%. This performance was achieved while contending with an unexpected supply interruption during the quarter that was onetime in nature and has been resolved. Without the supply interruption, Sage's growth in Q2 would have been approximately 14%.
Sage's success has been fueled by their commitment to innovation, which has resulted in a long history of successful new product introductions, including the recently launched AirTAP product. Using proprietary air-assisted technology, AirTAP enables caregivers to provide exceptional care by aiding in the turning and boosting of patients while the patients remain in bed. AirTAP enhances caregiver safety as it requires 80% less force to boost patients versus the typically used drawsheet.
With respect to integration, plans are underway to expand our manufacturing capacity beginning in 2018 to support expected growth. Moreover, our businesses are working to coordinate activities to accelerate revenue in areas such as key account and brand strategies. Our international focus will begin with Europe, where Sage has experienced some initial success, and Canada, where they have done very well. Beyond these markets, we are working to prioritize countries which value proven clinical solutions that eliminate never events. We are excited by the cultural similarities and positive chemistry between Stryker and Sage and expect double-digit revenue growth in the second half.
Turning to Physio-Control. I would like to also reinforce the strategic rationale that led us to acquire this company. As we described in mid-February, Physio-Control complements Stryker Medical's portfolio of innovative and differentiated prehospital and hospital products as Physio-Control is the leader in the development, manufacture and sale of defibrillators and monitors, AEDs and CPR-assist devices. We are excited by the synergistic benefits and market strength that resulted from the combination of Physio-Control with our Medical division. Importantly, the vast majority of Physio-Control sales call points overlap with our Medical division call points. Physio-Control holds the #1 or #2 share position at every major segment it serves. We believe that on a global basis, Physio-Control's products address segments totaling approximately $1.7 billion.
With Stryker's market-leading power cot and Power-LOAD lift system coupled with Physio-Control's suite of defibrillators, monitors and related products, our solution set is extensive. Our existing EMS franchise has enjoyed tremendous success in recent years, with growth significantly higher than the market and Stryker as a whole. Physio-Control's business has an attractive mix of 60% capital and 40% recurring business compared to our EMS business, which is nearly 100% capital. In addition, Physio-Control has an impressive enduring competency and a robust pipeline of products that have recently begun to launched, with additional product launches slated for the next several years. We expect this refreshed product portfolio and the combination of our organizations to result in continued strong sales momentum and greater profitability leverage in the future.
As a reminder, we closed the Physio transaction on April 5. Pro forma Q2 sales grew roughly 9%. On the integration front, our teams are focused on determining the optimal organizational design that best serves our common EMS and hospital customers. In addition, Physio has a significant international structure and our Medical division is assessing opportunities to drive growth by leveraging Physio's international market knowledge, strength and operational infrastructure. We expect high single-digit growth from the Physio-Control business in the second half. 
With these 2 acquisitions, the Medical division is now bigger, stronger, better diversified geographically and has more base business. Encouragingly, Medical had a strong organic Q2 growth result, well integrating these 2 acquisitions.
This concludes my overview commentary on Sage and Physio-Control. Glenn will now discuss our Q2 financials in more detail."
94614,331567642,1010351,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","Thanks, Tim. I will focus my comments today on our financial results and key drivers of our second quarter performance. Our detailed financial results have been provided in today's press release.For the quarter, our organic sales growth of 6.6% exceeded",1061,"Thanks, Tim. I will focus my comments today on our financial results and key drivers of our second quarter performance. Our detailed financial results have been provided in today's press release.
For the quarter, our organic sales growth of 6.6% exceeded the high end of the range of our full year expectations despite a tough year-over-year comparison, with growth of 6.9% in the year ago quarter. The quarter included one additional selling day compared to prior year, and consistent with our previous communications, the additional selling day equates to approximately 1% of additional growth. Pricing in the quarter was down 1.3% from the prior year, trending modestly better than we expected. During the quarter, we continued to see strong U.S. sales with organic growth of 8.6%, while international sales posted organic growth of 2%, reflecting continued destocking challenges in China. Our adjusted EPS of $1.39 increased 15.8% from the prior year, primarily driven by our strong top line growth, including the impact from the acquisitions completed in the quarter. Interest related to the recent bond offering unfavorably impacted EPS by $0.05 per share, and foreign exchange unfavorably impacted EPS by $0.03 during the quarter.
Looking at our segment highlights. Orthopaedics delivered constant currency growth of 4.8% and organic growth of 4.5%. The top line was led by U.S. Orthopaedics gains of 5.9%, highlighted by a 9.5% increase in Trauma and Extremities and a 6.8% growth in Knees as momentum continued for our 3D-printed titanium revision cones and our cementless knee products. U.S. Hips posted low single-digit growth due to softness in the revision market. Orthopaedics international delivered constant currency growth of 2.9%, led by a strong performance in our European Knee business. Lastly, we placed 17 MAKO units during the quarter. Overall, our second quarter results continue to reflect strong momentum across our Orthopaedics portfolio.
Our MedSurg segment's constant currency growth was 34.2%, including the impact of the recent acquisitions of Sage and Physio. Excluding the impact of acquisitions, our MedSurg business posted organic growth of 8.5%. Our U.S. MedSurg business continued their strong momentum with organic growth of 11.1%. Instruments had solid US growth of 8%, with strong performance in our power tools business, highlighted by double-digit gains in our micro power tools. Endoscopy continued its momentum from Q1, with U.S. growth of 10.8%, driven by continued success of our 1588 AIM video platform. Excluding the impact of the Sage and Physio acquisitions, Medical had U.S. growth of 16.9%, driven by continued performance of its power cot products as well as solid performance of our bed business. Internationally, MedSurg organic sales were down, 0.5% for the quarter, reflecting ongoing challenges in China primarily related to the distributor destocking. We expect this to continue throughout 2016 as we work with our distributors to drive end customer demand and reduce the buildup in their inventories.
Neurotechnology and Spine posted constant currency growth of 9% and organic growth of 7.5%, with continued strong momentum in our neurotech businesses, which increased 14.4%, while Spine was up 1%. As with our other businesses, U.S. neurotech growth was robust at 15.6%, which reflects the continued strong demand for our Neurovascular products, the Trevo stent retriever and Target Coil, our Neuro Powered Instruments and our craniomaxillofacial fixation products. Our U.S. Spine business grew 4.8% despite experiencing product supply issues but continues to see good demand for our new 3D-printed titanium products. We expect these supply issues to remain into the fourth quarter. Internationally, neurotech constant currency growth of 12.3% reflects the broader market momentum for the Trevo stent retriever and Target Coil products. Spine's international growth was dampened by the aforementioned product supplies issues and continued challenges in China.
Moving on to general operating highlights. Our gross margin on an adjusted basis was roughly flat at 66.2%, down 180 basis points sequentially. We had another quarter of strong impact from our focus on operational efficiencies, including improved productivity and absorption. This was offset by the full impact of our recent acquisitions, including certain accounting reclassifications between gross margin and SG&A to align with Stryker policy, sales mix and negative pricing. 
As for our operating expenses, we continue to focus on internal innovation, with R&D spending of 6.4% of sales. On an adjusted basis, SG&A for the quarter was 34.9%, which was favorable by 120 basis points as compared to the prior year. The improvement reflects the favorable impact of SG&A leverage from our recent acquisitions, the previously mentioned reclassification of certain expenses, our sales mix and continued focus on our operating expense improvements through our CPG program. For the quarter, acquisitions contributed roughly half of our SG&A improvement. Combined, these factors drove a 100 basis point year-over-year increase in our adjusted operating margin to 24.8%.
Lastly, I will provide some highlights on our other income expenses. Other expenses increased due to higher net interest expense related to increased borrowings at the end of the first quarter. We anticipate that future quarterly interest expense will be roughly $30 million, which is consistent with this quarter. Our second quarter adjusted effective tax rate of 17.6% reflects the benefits of our global tax structure, partially offset by the impact of higher U.S.-based income from our recent acquisitions.
Moving on to the balance sheet. We continue to maintain a strong balance sheet with $3.5 billion of cash and marketable securities, of which approximately 38% was held in the U.S. Total debt on the balance sheet at the end of the second quarter was $7.6 billion.
Turning to cash flow. Our year-to-date cash from operations was approximately $671 million. Finally, as we had previously announced at the end of Q1, we suspended our share repurchases for the remainder of the year.
In terms of guidance, based on our second quarter performance, we expect our full year organic sales growth to be in the range of 6% to 6.5% versus 2016. If foreign currency exchange rates hold near current levels, we anticipate net sales will be negatively impacted by approximately 1% for 2016, with negative pricing being in the range of 1.5% to 2%. Lastly, our guidance for adjusted net earnings per diluted share in 2016 now stands in the range of $5.70 to $5.80 for the full year, and we expect the third quarter to be in the range of $1.33 to $1.38.
And now we'll open up the call for Q&A."
94614,331567642,1010351,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Operator","[Operator Instructions] Our first question comes from the line of Mike Weinstein with JPMorgan.",14,"[Operator Instructions] Our first question comes from the line of Mike Weinstein with JPMorgan."
94614,331567642,1010351,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Analysts","I just want to get your thoughts on a couple of items. Number one, I understand the guidance update for the year. One of the questions people are asking is just the third quarter is a little bit below where The Street was modeling. So I don't know if -- a",123,"I just want to get your thoughts on a couple of items. Number one, I understand the guidance update for the year. One of the questions people are asking is just the third quarter is a little bit below where The Street was modeling. So I don't know if -- as you look at Street models, if there was anything in particular you thought The Street was off on relative to your expectations. And then second, the mix of growth was a little bit different this quarter if I look at Orthopaedics and MedSurg within those different businesses. Maybe there's a couple you want to comment on. There's a few that stick out to me, but I just want to get your thoughts."
94614,331567642,1010351,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","Okay. I'll take the first one. So as we look at Q3, seasonally, Q3 is usually our softest quarter. I think if you look at our guidance, it's very consistent with our Q3 guidance that we provided in the past, especially when you look at year-over-year grow",47,"Okay. I'll take the first one. So as we look at Q3, seasonally, Q3 is usually our softest quarter. I think if you look at our guidance, it's very consistent with our Q3 guidance that we provided in the past, especially when you look at year-over-year growth."
94614,331567642,1010351,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","And as for the second question -- Mike, this is Kevin. I would say that from quarter to quarter, we -- you see this kind of change at Stryker, and we've seen this for the past few years, where in the first quarter, Orthopaedics had a more robust performan",95,"And as for the second question -- Mike, this is Kevin. I would say that from quarter to quarter, we -- you see this kind of change at Stryker, and we've seen this for the past few years, where in the first quarter, Orthopaedics had a more robust performance. This quarter, it was led by MedSurg. From quarter to quarter, we see those variations. But what's encouraging to me is if you look at our growth versus the market, we continue to perform very well, especially if you look on a rolling 4 quarters basis."
94614,331567642,1010351,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Analysts","And maybe just a couple more, Kevin, just to comment on. So the -- if I look at within different businesses, maybe some of that were a bit surprising with maybe international Spine, which you made some comments relative to the Orthopaedic business. There",84,"And maybe just a couple more, Kevin, just to comment on. So the -- if I look at within different businesses, maybe some of that were a bit surprising with maybe international Spine, which you made some comments relative to the Orthopaedic business. There was some surprises, like U.S. Hips was less than what we thought. Knees was pretty close. But there was some -- relative to what we saw in the first quarter, there was some pretty good swings within the business model."
94614,331567642,1010351,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","Yes. So Mike, look, I'll just finish by saying in China, we've had issues and challenges, and we've highlighted those in the past. That affected Spine. That affected our Endoscopy division. That affected our Trauma division. Spine had some product supply",162,"Yes. So Mike, look, I'll just finish by saying in China, we've had issues and challenges, and we've highlighted those in the past. That affected Spine. That affected our Endoscopy division. That affected our Trauma division. Spine had some product supply issues, which affected both our U.S. Spine business as well as our OUS Spine business. Hips, as you pointed out, is -- was a little softer this quarter, but we've lead the market certainly in the U.S. for multiple years in our Hip business and it's just one quarter. So there is, for me, no concern there. We see these changes from quarter to quarter. And as you've seen, our -- the resiliency of our top line, quarter after quarter over the past 3 or 4 years, has been very steady. So yes, there were a bit of swings this quarter but nothing that causes me any reason for concern. I mean, we have very, very strong divisions across the company."
94614,331567642,1010351,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Operator","Our next question comes from the line of Bob Hopkins with Bank of America.",14,"Our next question comes from the line of Bob Hopkins with Bank of America."
94614,331567642,1010351,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Analysts","So just a couple of things to follow up on. One, just a little more color maybe on the U.S. Hips. I recognize it have been strong. It's just one quarter. But Kevin, you mentioned that you felt it was a soft revision market. So you feel like it was -- ther",109,"So just a couple of things to follow up on. One, just a little more color maybe on the U.S. Hips. I recognize it have been strong. It's just one quarter. But Kevin, you mentioned that you felt it was a soft revision market. So you feel like it was -- there was something going on with the revision market this quarter. So I was wondering if you could give a little bit more color there. And also, now that we're kind of one quarter into CJR, maybe any thoughts from the field in terms of what you're seeing, client reaction, your thoughts on how things are developing there."
94614,331567642,1010351,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","Bob, it's Katherine. Just a couple of points. I wouldn't look at the quarter and say something particular was going on in revisions versus primary. Overall, it was a bit softer than we've seen. And much like the first quarter, it was a bit stronger than w",188,"Bob, it's Katherine. Just a couple of points. I wouldn't look at the quarter and say something particular was going on in revisions versus primary. Overall, it was a bit softer than we've seen. And much like the first quarter, it was a bit stronger than we typically see. But we're not hearing anything from the field, from our customers that suggests something's changed. It really reinforces why you've heard us say over and over, we really focus on rolling 4 quarter trends because we see this quarter-to-quarter variability that, taken as a whole when you look back, doesn't mean anything significant in terms of changes in underlying fundamentals. And we're not seeing anything different in this quarter other than it was obviously a weaker-than-normal quarter versus Q1 being a stronger-than-normal quarter. In terms of CJRs, it went to effect April 1. We haven't seen any impact. I think it's simply too early. As you know, there's no penalty until after the first full year. So it's just simply too early, but nothing has played out yet in terms of a significant change or impact on the market."
94614,331567642,1010351,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Analysts","Okay. And then 2 other things I want to touch on. One was just maybe a comment on gross margin. In Q1, we talked about thinking about 68% for the rest of the year. I just would like to understand some of the moving parts that you were highlighting in the",115,"Okay. And then 2 other things I want to touch on. One was just maybe a comment on gross margin. In Q1, we talked about thinking about 68% for the rest of the year. I just would like to understand some of the moving parts that you were highlighting in the prepared comments. And then lastly, as it relates to the deals, it sounds like things are going well. Tim, previously, you guys have suggested that $0.15 to $0.18 of accretion in 2017 was a good preliminary estimate. Now I was wondering, from what you see today, is that still a good preliminary way of thinking about things? Or is that perhaps a conservative estimate?"
94614,331567642,1010351,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","Bob, this is Glenn. First of all, if you look at the sequential drop in margin, Q1 to Q2, roughly 180 basis points, I mean, Q2 was really impacted by mix especially, but not just sales mix but by adding in the acquisitions. It's early. Acquisitions are of",248,"Bob, this is Glenn. First of all, if you look at the sequential drop in margin, Q1 to Q2, roughly 180 basis points, I mean, Q2 was really impacted by mix especially, but not just sales mix but by adding in the acquisitions. It's early. Acquisitions are off to a solid start, but that's going to impact gross margin for the rest of the year. And it impacted more than just product. We made some reclassifications to harmonize Sage and Physio accounting practices with our accounting practices. And this essentially shifted some SG&A expenses up to gross margin in order to sort of align them with how Stryker does the accounting. It's pretty common that we do that, and we don't get a chance to really see it until we really climb into the integration work. So that's one of the things that came out. And then on top of that, I really just need to reiterate that there's a lot of other things that make our margin move around, not just price but FX, geographic mix really impact it. And all of those are pretty hard to forecast to a -- to sort of a single-point estimate. As I think about for the rest of the year and what you should maybe think about for your model, I think we'll be in the range of this 67% range, but understand that it could trend above or below that based on all of those factors that I mentioned."
94614,331567642,1010351,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","And Bob, on the deals -- this is Tim speaking. The accretion assumption you cited look good. We're on track and we would expect you could assume those to be good moving forward.",33,"And Bob, on the deals -- this is Tim speaking. The accretion assumption you cited look good. We're on track and we would expect you could assume those to be good moving forward."
94614,331567642,1010351,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Operator","Our next question comes from the line of Kristen Stewart with Deutsche Bank.",13,"Our next question comes from the line of Kristen Stewart with Deutsche Bank."
94614,331567642,1010351,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Analysts","Just 2, I guess go back to Bob's question on the accretion from the deal. How should we just think about, I guess, that accretion? Thinking [ph] about that as flowing through, I realize it's still very early compared to -- think about next year. But shoul",95,"Just 2, I guess go back to Bob's question on the accretion from the deal. How should we just think about, I guess, that accretion? Thinking [ph] about that as flowing through, I realize it's still very early compared to -- think about next year. But should we think about kind of that baseline growth. I know we've talked about this in previous calls. Or should we think about that as still a little too soon to kind of dial in accretion above what has been generally a double-digit kind of baseline growth for you?"
94614,331567642,1010351,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","Kristen, I think it's very consistent with how we've messaged before. This is obviously going to be one of the variables that gets factored in as we go through our 2017 budgeting process. But clearly, it's incremental accretion above and beyond the normal",148,"Kristen, I think it's very consistent with how we've messaged before. This is obviously going to be one of the variables that gets factored in as we go through our 2017 budgeting process. But clearly, it's incremental accretion above and beyond the normal earnings power of the businesses as they stand. How much of that flow through to the bottom line, how much of that we reinvest as we think about the opportunities in front of us, all of that will get factored in and will be evident when we give the range. So I wouldn't want to say it's a one for one, just throw it all on top of a normal earnings number because we have to look at the opportunities for reinvestment, recognizing, obviously, it's also incremental accretion. And so some portion of it is likely to play out at the bottom line as well."
94614,331567642,1010351,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Analysts","Okay. And then just generally on the market trends. I was just curious, from a competitive standpoint, now that we've had a couple of quarters on which, I guess, Zimmer is through with its integration with Biomet and we've seen J&J come pick up its moment",116,"Okay. And then just generally on the market trends. I was just curious, from a competitive standpoint, now that we've had a couple of quarters on which, I guess, Zimmer is through with its integration with Biomet and we've seen J&J come pick up its momentum within hips and knees. I was wondering if you guys could just comment broadly if you're seeing, I guess, what other companies are saying in terms of them getting their momentum back. Any particular changes that have been affecting you? And perhaps, on the Hips side, is this a reflection of some of the other companies getting their steam? Or is it just simply you feel just revision market softening?"
94614,331567642,1010351,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","Yes. I would say, again, it's just a quarter that was incrementally weaker versus the quarters where -- like the first quarter where it felt stronger but we couldn't point to any discernible change or inflection point that suggested we had a new higher gr",140,"Yes. I would say, again, it's just a quarter that was incrementally weaker versus the quarters where -- like the first quarter where it felt stronger but we couldn't point to any discernible change or inflection point that suggested we had a new higher growth market. The only ones who have reported are us and J&J. So we have a pretty limited visibility into everybody else's reports, but we're not seeing or hearing anything that suggests that you're seeing some dramatic market share shifts. That's generally not how things play out in the recon market. So again, we're not seeing anything that would suggest that there's anything different than the normal quarterly variability that we see play out. Obviously, it's more fun when it's Q1 and it's incrementally stronger. But again, it's why we focus on the rolling 4 quarters."
94614,331567642,1010351,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Operator","Our next question comes from the line of David Lewis with Morgan Stanley.",13,"Our next question comes from the line of David Lewis with Morgan Stanley."
94614,331567642,1010351,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Analysts","Just a few questions, maybe starting with Kevin. So Kevin, just with the extra selling day here in  the second quarter and thinking about the easier comps in the back half of the year. By our math your guidance for the remainder of the year sort of implie",91,"Just a few questions, maybe starting with Kevin. So Kevin, just with the extra selling day here in  the second quarter and thinking about the easier comps in the back half of the year. By our math your guidance for the remainder of the year sort of implies stable comp adjusted growth in the back half of the year. Is that just kind of roughly how you see the business stability on an underlying basis into the back half of the year? Or are there other chances for acceleration or deceleration?"
94614,331567642,1010351,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","So David, since the beginning of the year, this is the second time we've sort of moved our range upwards. And we've been delivering a very strong growth throughout the year. Yes, in China and even all the emerging markets, our comps will ease in the secon",104,"So David, since the beginning of the year, this is the second time we've sort of moved our range upwards. And we've been delivering a very strong growth throughout the year. Yes, in China and even all the emerging markets, our comps will ease in the second half of the year, but we also have some challenging comps in some of our other businesses that were growing very robustly in the second half of the year. So it's a big business that we're managing. And I think if you're growing north of 6% organically while you're integrating acquisitions, I think you're doing pretty well."
94614,331567642,1010351,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Analysts","I would agree. And then Glenn, I think you've gotten questions on margins, but I think this particular quarter, it's sort of the mirror image of the first quarter; or gross, a little weaker; SG&A controls, a little better. I know you had some announcement",97,"I would agree. And then Glenn, I think you've gotten questions on margins, but I think this particular quarter, it's sort of the mirror image of the first quarter; or gross, a little weaker; SG&A controls, a little better. I know you had some announcements on the ERP integration during the quarter. Can you just give us an update on where you are in terms of the ERP planning? And what's the opportunity for savings for shareholders on the ERP? And when we may get an update on that number? And then I had one quick follow-up."
94614,331567642,1010351,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","Yes. David, on -- ERP is one of the things we're focusing on relative to our CPG program. It has several facets. I would say we're in the pretty early stages of our ERP program. Obviously, when you're implementing a new commercial global footprint, it's a",102,"Yes. David, on -- ERP is one of the things we're focusing on relative to our CPG program. It has several facets. I would say we're in the pretty early stages of our ERP program. Obviously, when you're implementing a new commercial global footprint, it's a multi-year journey. And we're in the early stages of that. So we'll definitely keep you guys updated as that project moves forward. I think the more immediate-term things to think about are indirect procurement and those parts of the project that really can have more of an impact as we roll forward in the next year."
94614,331567642,1010351,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","Yes. David, what we've been signaling on our cost transformation is this is really the engine of being able to sustain leverage earnings year after year. And so in the earlier years, you're going to see more of that savings coming through from indirect pr",132,"Yes. David, what we've been signaling on our cost transformation is this is really the engine of being able to sustain leverage earnings year after year. And so in the earlier years, you're going to see more of that savings coming through from indirect procurement. And in the later years, you're going to see more of that saving coming from product life cycle management and coming from the ERP benefits. But I would say it's been a real rallying force for the company, so everybody, all the different divisions of Stryker working on a common system, which is going very, very well. And it's a shift to SAP from a company that has really no SAP today. But I'm very encouraged with the early progress, and I'm very optimistic about the implementation."
94614,331567642,1010351,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Analysts","And then Katherine, just one last quick one here. The neurotech number, obviously very, very strong and obviously, the driver partly is the ischemic market. I feel like in the last couple of quarters, you and your competitors have sort of shifted away and",83,"And then Katherine, just one last quick one here. The neurotech number, obviously very, very strong and obviously, the driver partly is the ischemic market. I feel like in the last couple of quarters, you and your competitors have sort of shifted away and they're much more focused on sort of market development from here. I'm wondering if you could share with us what specifically is Stryker doing on the market development front to drive that market. And I'll jump back in queue."
94614,331567642,1010351,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","Yes. David, we have been -- for some time, been messaging around the market development. But with Tim here who runs that business, I'm going to pass it over to him.",31,"Yes. David, we have been -- for some time, been messaging around the market development. But with Tim here who runs that business, I'm going to pass it over to him."
94614,331567642,1010351,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","Yes. There was a variety of initiatives out there where we're simply partnering with systems, health care systems, hospitals to drive patient flow to the right centers where they're performing these procedures. It will be a multi-year process, and hospita",150,"Yes. There was a variety of initiatives out there where we're simply partnering with systems, health care systems, hospitals to drive patient flow to the right centers where they're performing these procedures. It will be a multi-year process, and hospitals all vary in their level of maturity. But it's a very real and big challenge to get these patients to the right centers. But our efforts surround largely education, trying to assist, trying to ask the right questions, trying to connect people with the right consultants, things like that and make sure their stroke centers are properly operating. And they're getting the patients from the ER to the cap or the interventional lab to treat these patients. So it takes many forms. It takes many years. But I think what we're seeing is steady progress chipping away, but it's going to be years and years and years of efforts here."
94614,331567642,1010351,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Operator","Our next question comes from the line of Rick Wise with Stifel.",12,"Our next question comes from the line of Rick Wise with Stifel."
94614,331567642,1010351,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Analysts","Maybe just starting off with MAKO. In an oblique way, you talked about that you had solid U.S. Knee numbers. Where are you in the total knee roll-out for MAKO? Is MAKO -- you didn't call out MAKO as a positive factor driving Knee volumes in the U.S. Is it",71,"Maybe just starting off with MAKO. In an oblique way, you talked about that you had solid U.S. Knee numbers. Where are you in the total knee roll-out for MAKO? Is MAKO -- you didn't call out MAKO as a positive factor driving Knee volumes in the U.S. Is it a factor? Just remind us where you are in those time lines with commercialization and papers and what's next for MAKO."
94614,331567642,1010351,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","Yes, thanks. Rick, this is Kevin. So today, MAKO is not a huge driver because we're really in the Knee business, just using it for unicompartmental knees. We do have a limited launch and the accent is the word, limited, just a small number of surgeons who",105,"Yes, thanks. Rick, this is Kevin. So today, MAKO is not a huge driver because we're really in the Knee business, just using it for unicompartmental knees. We do have a limited launch and the accent is the word, limited, just a small number of surgeons who are doing total knees. Early feedback has been very positive. So we're encouraged. But the reason for the limited launch is to make sure that we work out all the workflow and define training protocols and also be able to have some publications and podium presentations. The full launch in the total knee is not until next year."
94614,331567642,1010351,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Analysts","So maybe turning to Tim and Physio. Tim, you talked about the high single-digit second half growth for Physio, but you also underscored the pipeline and the products coming. Can you give us any more color on the pipeline? What do we expect? When do we see",65,"So maybe turning to Tim and Physio. Tim, you talked about the high single-digit second half growth for Physio, but you also underscored the pipeline and the products coming. Can you give us any more color on the pipeline? What do we expect? When do we see it? And is -- does that accelerate or sustain that kind of high single-digit growth pace for Physio?"
94614,331567642,1010351,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","Yes. Rick, I would say we'd sustain that high single-digit growth rate. I think what I said after the deal was announced was that it would be accretive to Stryker's sales growth rate. And I would expect over the next several years to see next generation p",138,"Yes. Rick, I would say we'd sustain that high single-digit growth rate. I think what I said after the deal was announced was that it would be accretive to Stryker's sales growth rate. And I would expect over the next several years to see next generation products in each of 3 main categories, defibrillators and monitors, AEDs or automated external defibrillators, and circulatory-assist devices. This market is now turning into a PMA market in the United States. And so these launches will be global in nature and vary in timing by markets. So we're not going to be overly specific about it, but I would say we expect, again, over the next 4 to 5 years, to have a consistent stream of new products which would drive that accretive sales growth out of the Physio division versus Stryker."
94614,331567642,1010351,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Operator","Our next question comes from the line of Chris Pasquale with Guggenheim.",12,"Our next question comes from the line of Chris Pasquale with Guggenheim."
94614,331567642,1010351,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Analysts","I had a couple of questions on Sage. First, can you give us some more color on the supply disruption in the quarter? What happened there?",26,"I had a couple of questions on Sage. First, can you give us some more color on the supply disruption in the quarter? What happened there?"
94614,331567642,1010351,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","On the supply disruption, from time to time, each of our businesses may have some issues. In this case, it was one transit in nature. It's over, and that's about as far as we're going to go in terms of sharing details.",42,"On the supply disruption, from time to time, each of our businesses may have some issues. In this case, it was one transit in nature. It's over, and that's about as far as we're going to go in terms of sharing details."
94614,331567642,1010351,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Analysts","Okay. And then what's the time line to build out Sage's presence internationally? You talked about a little bit in Europe and Canada initially with the rest of the business. Can you drop those products in your bag internationally and start to see some syn",77,"Okay. And then what's the time line to build out Sage's presence internationally? You talked about a little bit in Europe and Canada initially with the rest of the business. Can you drop those products in your bag internationally and start to see some synergies in the next few quarters? Or is this going to be a protracted process where there are regulatory and tenders that have to go through before you really start to see that?"
94614,331567642,1010351,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","I think it will be a longer-term process. As we've seen with all our international initiatives, it does take time. And so we do have a foothold in Europe and Canada, as we've talked about. Areas like Australia may be fertile ground but will take a while.",76,"I think it will be a longer-term process. As we've seen with all our international initiatives, it does take time. And so we do have a foothold in Europe and Canada, as we've talked about. Areas like Australia may be fertile ground but will take a while. Other areas like Japan will take even longer in terms of regulatory pathways. So we see great opportunity, but it's going to be a multi-year journey, for sure."
94614,331567642,1010351,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Analysts","Okay. And then just one quick one, if I could, on China. Do you guys have any visibility at this point, where inventory levels stand and what's your underlying growth in that market might be excluding these drawdowns just to give us a sense of how close w",55,"Okay. And then just one quick one, if I could, on China. Do you guys have any visibility at this point, where inventory levels stand and what's your underlying growth in that market might be excluding these drawdowns just to give us a sense of how close we might be to seeing a turn there?"
94614,331567642,1010351,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","Yes. So what we've been saying now for the past few quarters is we did expect this to be a very soft quarter in China. So it was in line with our expectations. We do expect some time in the back half of the year that we'll start to reach bottom and that w",109,"Yes. So what we've been saying now for the past few quarters is we did expect this to be a very soft quarter in China. So it was in line with our expectations. We do expect some time in the back half of the year that we'll start to reach bottom and that we'll return to growth. I -- we don't have the precision just based on having multiple tiers of distributors. We're not positioned to be able to identify that exactly, but you should see signs of improvement certainly while we exit the year and going into next year. We should bottom out sometime in the second half."
94614,331567642,1010351,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Operator","Our next question comes from the line of Matt Keeler with Credit Suisse.",13,"Our next question comes from the line of Matt Keeler with Credit Suisse."
94614,331567642,1010351,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Analysts","Just first on the ex U.S. Knee performance, you mentioned strength in Europe. Can you give us any more color around that? Was that market strength? Are you taking share?",31,"Just first on the ex U.S. Knee performance, you mentioned strength in Europe. Can you give us any more color around that? Was that market strength? Are you taking share?"
94614,331567642,1010351,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","I think at this point, it's just tough to know until everybody reports, we have the numbers similarly and get a better sense of share shift at that point. So there's nothing specific that we would point to. We obviously have better execution now under our",74,"I think at this point, it's just tough to know until everybody reports, we have the numbers similarly and get a better sense of share shift at that point. So there's nothing specific that we would point to. We obviously have better execution now under our TOM model, which has helped a number of our businesses. But we'll know in a couple of weeks if there's anything more beyond market growth versus share shift."
94614,331567642,1010351,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","Yes. It's important just to note that we have a few of our businesses that are really underrepresented in Europe, our Endoscopy division, our Instruments division and Knees, where the market shares that we have are certainly much lower than they are in ot",97,"Yes. It's important just to note that we have a few of our businesses that are really underrepresented in Europe, our Endoscopy division, our Instruments division and Knees, where the market shares that we have are certainly much lower than they are in other parts of the world. So when we produce a good growth number, it's really just sort of getting back towards to what we would consider our fair share. And it's a very encouraging sign, and we're pleased with some of the hiring that we've done in Europe and starting to build the business."
94614,331567642,1010351,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Analysts","Okay. And then just a separate question on neurotech growth. It's very strong in the quarter, but it slowed versus last quarter sequentially. Can you give us any color on the subsegment growth rates in Neurovascular and CMF? And what drove that slowdown i",45,"Okay. And then just a separate question on neurotech growth. It's very strong in the quarter, but it slowed versus last quarter sequentially. Can you give us any color on the subsegment growth rates in Neurovascular and CMF? And what drove that slowdown in growth?"
94614,331567642,1010351,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","Yes, there would be nothing I would point to. I think as Katherine has talked about in some other areas, the growth rates can vary. It could be based on comps or different countries that did better or worse or what have you. I think if we dug down in the",92,"Yes, there would be nothing I would point to. I think as Katherine has talked about in some other areas, the growth rates can vary. It could be based on comps or different countries that did better or worse or what have you. I think if we dug down in the numbers, CMF might be up a smidge and Neurovascular down a little but nothing that would point to any dramatic shift. I think in general, we've had very, very strong performance. And to me, the good news is that, that continues."
94614,331567642,1010351,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","Yes. It's important to know all 3 of those groups. So Neurovascular is, of course, the biggest one, the neuro powered tools as well as CMF, all -- they're all double-digit growers. And so from quarter to quarter, as Tim mentioned, some are a little higher",78,"Yes. It's important to know all 3 of those groups. So Neurovascular is, of course, the biggest one, the neuro powered tools as well as CMF, all -- they're all double-digit growers. And so from quarter to quarter, as Tim mentioned, some are a little higher, some are a little lower. We had a 20% comp almost in the United States from the prior year, and we continue to grow strong double digits on top of strong comps."
94614,331567642,1010351,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Operator","Our next question comes from the line of Matthew O'Brien with Piper Jaffray.",14,"Our next question comes from the line of Matthew O'Brien with Piper Jaffray."
94614,331567642,1010351,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Analysts","Just with Tim in the room, I'd love to hear a little bit more about the MedSurg strength in the quarter. As you're integrating Sage and Physio, did you get any kind of benefit either from a sentiment [ph] perspective from hospitals about adding those busi",85,"Just with Tim in the room, I'd love to hear a little bit more about the MedSurg strength in the quarter. As you're integrating Sage and Physio, did you get any kind of benefit either from a sentiment [ph] perspective from hospitals about adding those businesses? And then as we think about things going forward on an organic basis now that you can bundle all of these things together, can you still deliver this mid- or even upper single-digit growth out of MedSurg going forward?"
94614,331567642,1010351,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","Well, to add a little bit of color, first, I would say we're delighted with the performance of our Medical division in the quarter that they delivered strong quarter growth while dealing with the challenges of these 2 large integrations. Their EMS busines",303,"Well, to add a little bit of color, first, I would say we're delighted with the performance of our Medical division in the quarter that they delivered strong quarter growth while dealing with the challenges of these 2 large integrations. Their EMS business did particularly well, and they performed nicely in their core bed and stretcher business. Endoscopy is having an excellent year. Their core visualization business is performing exceptionally well with the 1588 camera. The communications business is doing well, and the sports business is doing well there as well. I would point back to a couple of deals we did in 2014, Berchtold and Pivot. These both are kind of in the mainstream now of being integrated, and our team is fully in line with their products. So the Berchtold lights, booms and tables have sold well this year. The Pivot products have done very well in our hands as well. And over at Stryker Instruments, this has been a steady, strong performer over time. Their personal protection and fluid waste management businesses were real highlights in the quarter. We do expect a strong second half there as they'll be launching their Neptune 3 fluid waste management system in the coming days. So I think across the board, we were strong. I would also frankly note that Sustainability business had a strong quarter and they've done well at recent product launches. And importantly, reprocessed products from Stryker have been embraced as a high-quality solution by our hospital customers despite the fact that that's a challenging and difficult market. I would tell you that now, there wasn't really any sentiment in favor of Stryker as a result of these deals. But importantly, we've had strong execution across the board, good new product flow, and we're optimistic about the rest of the year."
94614,331567642,1010351,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Analysts","Helpful. And then just shifting over to the Trauma and Extremities business, still solid performance there, but on a 2-year stack basis, that growth rate did decelerate here at Q2 versus the last few quarters. Is there anything going on there competitivel",86,"Helpful. And then just shifting over to the Trauma and Extremities business, still solid performance there, but on a 2-year stack basis, that growth rate did decelerate here at Q2 versus the last few quarters. Is there anything going on there competitively of note that could prevent you from sustaining this share-taking position you've been in for a while and getting -- so outperforming the overall market growth rates? Or should we expect more kind of market growth rates from you and from Trauma and Extremities?"
94614,331567642,1010351,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","Well, we feel really pleased with the performance of both Trauma and Extremities businesses, but obviously, the Extremities base has gotten much bigger now. So you're looking at more challenging comparables that's still growing very solid double digits. A",93,"Well, we feel really pleased with the performance of both Trauma and Extremities businesses, but obviously, the Extremities base has gotten much bigger now. So you're looking at more challenging comparables that's still growing very solid double digits. And Trauma, we continue to see strong performance for that business as well. There hasn't been any meaningful change. We still feel good about the way those businesses are positioned, but obviously, the law of large numbers set's in and the comps become more difficult. But beyond that, no, there's nothing we'd really point to."
94614,331567642,1010351,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","Keep in mind, we did have an 18% comp in the United States in Trauma. So we had a really huge growth in the prior year and still strong growth. We still believe this is going to be a growth business for the company. So -- and it's just one quarter. It did",64,"Keep in mind, we did have an 18% comp in the United States in Trauma. So we had a really huge growth in the prior year and still strong growth. We still believe this is going to be a growth business for the company. So -- and it's just one quarter. It did decelerate a little bit but certainly a very impressive number nonetheless."
94614,331567642,1010351,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Operator","And our next question comes from the line of Joanne Wuensch with BMO Capital Markets.",15,"And our next question comes from the line of Joanne Wuensch with BMO Capital Markets."
94614,331567642,1010351,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Analysts","In looking at your Spine business, that accelerated a little bit last year, it seems, through innovation and some better execution but slowed down a little bit this year, year-to-date. How are you thinking about that in terms of internal versus external d",43,"In looking at your Spine business, that accelerated a little bit last year, it seems, through innovation and some better execution but slowed down a little bit this year, year-to-date. How are you thinking about that in terms of internal versus external development?"
94614,331567642,1010351,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","You're right. We have invested a lot in terms of the pipeline and launching new products. As we mentioned, we did have some system supply disruption that will continue into the second half here. As you know, we prioritize M&A across all the businesses, bu",111,"You're right. We have invested a lot in terms of the pipeline and launching new products. As we mentioned, we did have some system supply disruption that will continue into the second half here. As you know, we prioritize M&A across all the businesses, but we also invest in those businesses in order to be able to deliver results based on internal innovation and R&D. So don't think about that business any differently than other areas where we look at opportunities. As you know, we have BD people in all the divisions looking at targets but also assessing that around our opportunities to invest internally and grow the business organically."
94614,331567642,1010351,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","I would also -- just -- I'd just like to repeat that -- what was mentioned earlier that we did have some product disruptions in the quarter in our Spine business. The underlying business is in really solid shape. I feel great about the leadership team, th",73,"I would also -- just -- I'd just like to repeat that -- what was mentioned earlier that we did have some product disruptions in the quarter in our Spine business. The underlying business is in really solid shape. I feel great about the leadership team, the new products. We have some supply challenges, and that will continue in the third quarter and then it will start to improve in the fourth quarter."
94614,331567642,1010351,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Analysts","And then just to turn back to the gross margin moment, is there a way to peel this apart a little bit to understand the impact of some of the acquisitions or the recategorization may have had on that?",39,"And then just to turn back to the gross margin moment, is there a way to peel this apart a little bit to understand the impact of some of the acquisitions or the recategorization may have had on that?"
94614,331567642,1010351,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","Yes. I think if you think about sort of the sequential change from Q1 to Q2, acquisitions in total were roughly sort of half of that change. And that should continue through the rest of the year in terms of the total growth --  the impact on the total gro",51,"Yes. I think if you think about sort of the sequential change from Q1 to Q2, acquisitions in total were roughly sort of half of that change. And that should continue through the rest of the year in terms of the total growth --  the impact on the total gross margin."
94614,331567642,1010351,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","Joanne, just keep in mind when you get that hit at the gross margin, those are also lower SG&A businesses. So part of that big impact, the big SG&A decline as a percent of sales in the leverage, is a flip side of that, where you're seeing the benefit both",59,"Joanne, just keep in mind when you get that hit at the gross margin, those are also lower SG&A businesses. So part of that big impact, the big SG&A decline as a percent of sales in the leverage, is a flip side of that, where you're seeing the benefit both from a product mix as well as the reclassifications."
94614,331567642,1010351,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Operator","And our next question comes from the line of Glenn Navarro with RBC Capital Markets.",15,"And our next question comes from the line of Glenn Navarro with RBC Capital Markets."
94614,331567642,1010351,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Analysts","Two questions on ortho. First, ortho pricing down 2.2% in 2Q versus down 1.7% in 1Q, is there anything unusual happening there? Or is that just quarter-to-quarter fluctuations? And then on Robotics, you sold 7 in 1Q, up to 17 in 2Q. Maybe talk about the m",73,"Two questions on ortho. First, ortho pricing down 2.2% in 2Q versus down 1.7% in 1Q, is there anything unusual happening there? Or is that just quarter-to-quarter fluctuations? And then on Robotics, you sold 7 in 1Q, up to 17 in 2Q. Maybe talk about the momentum there. Were these outright sales? And what's the pipeline looking for -- looking like in terms of Robotic deals in the back end of the year?"
94614,331567642,1010351,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","Yes. So to take your -- the first question, no, I wouldn't read anything into 1.7% versus 2.2%. It's within the normal variability that we have historically seen, much like total pricing trending less negative but still within the range of that 1.5% to 2%",98,"Yes. So to take your -- the first question, no, I wouldn't read anything into 1.7% versus 2.2%. It's within the normal variability that we have historically seen, much like total pricing trending less negative but still within the range of that 1.5% to 2% that we think about. Yes, we're very pleased with the robot placements and the fact that we have the early observational studies underway in a limited launch. The order book looks strong. We're excited about the outlook there as we prepare -- as we talk about going to full commercial launch in '17."
94614,331567642,1010351,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Analysts","And then just a quick follow-up for Glenn or for you, Katherine. You had the extra selling day in 2Q. Is everything normal for 3Q and 4Q?",28,"And then just a quick follow-up for Glenn or for you, Katherine. You had the extra selling day in 2Q. Is everything normal for 3Q and 4Q?"
94614,331567642,1010351,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","Yes. So if you think about it, there was no difference in selling days in the first quarter, whether you look at it U.S., OUS, worldwide. Second quarter, we had one extra selling day, which equates to 1% impact overall on our businesses. And then Q3, Q4,",57,"Yes. So if you think about it, there was no difference in selling days in the first quarter, whether you look at it U.S., OUS, worldwide. Second quarter, we had one extra selling day, which equates to 1% impact overall on our businesses. And then Q3, Q4, there's no difference in selling days, U.S., OUS or worldwide."
94614,331567642,1010351,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Operator","And our next question comes from the line of Raj Denhoy with Jefferies.",13,"And our next question comes from the line of Raj Denhoy with Jefferies."
94614,331567642,1010351,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Analysts","A couple of questions, if I could. So the Spine product issue you had in the quarter, perhaps you could provide a little bit more about that. Was that related to the 3D products that you rolled out? Or was that something different?",43,"A couple of questions, if I could. So the Spine product issue you had in the quarter, perhaps you could provide a little bit more about that. Was that related to the 3D products that you rolled out? Or was that something different?"
94614,331567642,1010351,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","No. We're not going to get into too many details just for competitive reasons. We do have a supply disruption issue and some supply challenges. We'll work through those in the third quarter. We did highlight the titanium products, a lot of momentum around",81,"No. We're not going to get into too many details just for competitive reasons. We do have a supply disruption issue and some supply challenges. We'll work through those in the third quarter. We did highlight the titanium products, a lot of momentum around that and excited about what that product will do for that portfolio but not going to go into additional details other than to say you should assume the impact lingers into the second half of this year."
94614,331567642,1010351,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Analysts","Okay. And then just for my second question. Medtronic obviously made some noise in June about coming into the orthopaedic market. Curious if you've seen anything, one; and two, if you have any thoughts just around what Medtronic would mean for this market",43,"Okay. And then just for my second question. Medtronic obviously made some noise in June about coming into the orthopaedic market. Curious if you've seen anything, one; and two, if you have any thoughts just around what Medtronic would mean for this market."
94614,331567642,1010351,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","No. We haven't seen any impact, and they're obviously better positioned to talk about where they are in the launch or signing up customers. So to date, no, we don't have -- we don't see any impact. Obviously, we believe in the value of the rep and -- as w",83,"No. We haven't seen any impact, and they're obviously better positioned to talk about where they are in the launch or signing up customers. So to date, no, we don't have -- we don't see any impact. Obviously, we believe in the value of the rep and -- as well as innovation in this market, and we're really going to focus on just that. And the MAKO total knee launch, we think, has the opportunity to be truly disruptive in the reconstructive market."
94614,331567642,1010351,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Operator","And our next question comes from the line of Mike Matson with Needham & Company.",14,"And our next question comes from the line of Mike Matson with Needham & Company."
94614,331567642,1010351,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Analysts","I guess I just wanted to start with MAKO in thinking through the total knee full launch next year. I guess to what degree do you think the need to sell the very expensive capital equipment or the robots will kind of limit the growth -- or limit the rate a",84,"I guess I just wanted to start with MAKO in thinking through the total knee full launch next year. I guess to what degree do you think the need to sell the very expensive capital equipment or the robots will kind of limit the growth -- or limit the rate at which you can take market share in the knee market? And is there anything you can do to potentially speed up those placements in order to capture more of that knee implant share?"
94614,331567642,1010351,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","Yes. So we're selling the million-dollar robots right now. We did 17 this quarter, and that's before we've gone into full commercial launch for what we think is the biggest driver of value with the MAKO opportunity. And moreover, we've been selling very e",184,"Yes. So we're selling the million-dollar robots right now. We did 17 this quarter, and that's before we've gone into full commercial launch for what we think is the biggest driver of value with the MAKO opportunity. And moreover, we've been selling very expensive capital on our MedSurg businesses for literally years and years. So we understand how to sell capital. It is fundamentally different than selling implants or disposables, which is why we have a separate dedicated sales force. We also have, for a number of years now, had a Flex Financial Group within the Stryker organization. And our MAKO group is using that to leverage their expertise to offer different options to our customers, whether they want to buy outright or lease. And so that expertise that's been developed for a number of years through MedSurg is clearly enabling a different type of discussion with customers than was possible when MAKO was a stand-alone. So we feel really comfortable in our ability to sell capital and the value proposition that's driven by the different applications that will exist on the MAKO robot."
94614,331567642,1010351,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Analysts","I guess what I was getting at is if you came out with a new type of a knee implant, you could walk into an operating room and the doctor could switch to that new implant on day 1, whereas if they're going to switch to MAKO, they've got to convince the hos",78,"I guess what I was getting at is if you came out with a new type of a knee implant, you could walk into an operating room and the doctor could switch to that new implant on day 1, whereas if they're going to switch to MAKO, they've got to convince the hospital to buy a really expensive robot first. So that's going to kind of slow down the ability to take knee market shares, is it not?"
94614,331567642,1010351,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","Yes. To be able to do a robotic knee, you have to buy the robot. And it will be a closed system and can only use our knee. So that's part of the value proposition. So we go in and we have that discussion and articulate the benefits here. So this is very d",126,"Yes. To be able to do a robotic knee, you have to buy the robot. And it will be a closed system and can only use our knee. So that's part of the value proposition. So we go in and we have that discussion and articulate the benefits here. So this is very different than just simply coming out with a new knee and not having to buy capital. Yes, that's correct. But it's also very different in terms of the value that, we think, we'll bring forward and will start to get evidence of as we do these observational studies and look at benefits around less tissue disruption, improved alignment and a number of different factors that, we think, will help support the value proposition."
94614,331567642,1010351,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Analysts","All right. And then just if international growth were to improve, what would that do to your gross margin?",19,"All right. And then just if international growth were to improve, what would that do to your gross margin?"
94614,331567642,1010351,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","Generally, international flows through gross margin at roughly the same rate that we're experiencing on an average here. So it would roughly flow through about the 67%. It really depends sort of where internationally as well, too, because we -- certain em",64,"Generally, international flows through gross margin at roughly the same rate that we're experiencing on an average here. So it would roughly flow through about the 67%. It really depends sort of where internationally as well, too, because we -- certain emerging markets are better. European pricing impacts are usually higher. But up and down from the 67%, that's roughly a good ballpark estimate."
94614,331567642,1010351,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Operator","And our next question comes from the line of Kaila Krum with William Blair.",14,"And our next question comes from the line of Kaila Krum with William Blair."
94614,331567642,1010351,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Analysts","One Spine question and then one on the Medical business. First, I mean, what are you seeing sort of in the spine market probably from a competitive perspective? And really, I'm curious about your thoughts on -- you hear that multi-year robotics movement t",54,"One Spine question and then one on the Medical business. First, I mean, what are you seeing sort of in the spine market probably from a competitive perspective? And really, I'm curious about your thoughts on -- you hear that multi-year robotics movement that now several companies are talking about in that space specifically."
94614,331567642,1010351,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","Yes. We really like that many companies are talking more and more about robotics. I think that provides a real good tailwind for MAKO. We believe we have certainly the best system with haptics and really a terrific intellectual property. And so the more t",140,"Yes. We really like that many companies are talking more and more about robotics. I think that provides a real good tailwind for MAKO. We believe we have certainly the best system with haptics and really a terrific intellectual property. And so the more that robots become a positive word out in the medical technology community with our customers, I think that provides a real good tailwind for us on MAKO. We're not seeing anything new in the spine market. It's a tough market with many competitors. We like our ability to win in a market based on the innovations that we've been bringing forward over the last 2, 3 years. We did have our own challenges, as we've mentioned a couple of times in the call, related to some supply disruption but nothing really new from a competitive standpoint."
94614,331567642,1010351,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Analysts","Okay. And then just a follow-up on the recent acquisitions in the Medical business. I mean, just looking at the pro forma growth rates you gave us in the quarter, understanding we're obviously early in the integration process, but with that in mind, I mea",82,"Okay. And then just a follow-up on the recent acquisitions in the Medical business. I mean, just looking at the pro forma growth rates you gave us in the quarter, understanding we're obviously early in the integration process, but with that in mind, I mean, how do you expect those pro forma growth rates to trend in the coming quarters? I mean, should we expect modest dislocation before an acceleration or just consistent growth with a typical seasonality in Q3 and Q4?"
94614,331567642,1010351,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","Yes, I'd say -- I guess my answer would be consistent growth in Q3 and 4 tied to that, those numbers we cited of high single digits and double digits.",30,"Yes, I'd say -- I guess my answer would be consistent growth in Q3 and 4 tied to that, those numbers we cited of high single digits and double digits."
94614,331567642,1010351,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Operator","And our next question comes from the line of Larry Biegelsen with Wells Fargo.",14,"And our next question comes from the line of Larry Biegelsen with Wells Fargo."
94614,331567642,1010351,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Analysts","First, international. Kevin, I think you said last quarter, emerging markets were down in the high single digits in the first quarter. Was it similar in Q2? And by our math, Europe was also a little soft in Q1. How was Europe in Q2? And what's the outlook",55,"First, international. Kevin, I think you said last quarter, emerging markets were down in the high single digits in the first quarter. Was it similar in Q2? And by our math, Europe was also a little soft in Q1. How was Europe in Q2? And what's the outlook there? And I did have one follow-up."
94614,331567642,1010351,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","Yes. I'd say in emerging markets, it was a very similar story in Q2 as it was in Q1. It was just as bad a quarter. As it relates to Europe, Europe had a mid-single digit growth in the second quarter. So we were actually very pleased with the second quarte",74,"Yes. I'd say in emerging markets, it was a very similar story in Q2 as it was in Q1. It was just as bad a quarter. As it relates to Europe, Europe had a mid-single digit growth in the second quarter. So we were actually very pleased with the second quarter performance. Otherwise, there have been a little bit of softness in the first quarter and got back on track in the second quarter."
94614,331567642,1010351,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Analysts","That's helpful. And then for Tim, on the ischemic stroke market, could you talk a little bit about how that market's been developing in 2016 versus a strong 2015? In terms of patient numbers treated in the U.S., it was probably up 30%, 40% from about 12,0",71,"That's helpful. And then for Tim, on the ischemic stroke market, could you talk a little bit about how that market's been developing in 2016 versus a strong 2015? In terms of patient numbers treated in the U.S., it was probably up 30%, 40% from about 12,000 to 16,000, 17,000 last year. Is 2016 looking like as strong a year just from ischemic treatment -- endovascular treatment of ischemic stroke?"
94614,331567642,1010351,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","Yes. I think the growth trends have been similar this year and the last year and exact -- certainly further to this law of larger numbers and what have you. The growth rates arguably would diminish with time, but it continues to be a very robust market wi",56,"Yes. I think the growth trends have been similar this year and the last year and exact -- certainly further to this law of larger numbers and what have you. The growth rates arguably would diminish with time, but it continues to be a very robust market with very significant growth opportunities lying ahead of us."
94614,331567642,1010351,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Operator","And our next question comes from the line of Richard Newitter with Leerink Partners.",14,"And our next question comes from the line of Richard Newitter with Leerink Partners."
94614,331567642,1010351,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Analysts","I have 2. The first one, just a follow-up on the Robotics question and the competitive landscape. Just specifically with respect to Spine, can you talk to us a little bit about what your view is of spine robotics technologies in light of recent investment",91,"I have 2. The first one, just a follow-up on the Robotics question and the competitive landscape. Just specifically with respect to Spine, can you talk to us a little bit about what your view is of spine robotics technologies in light of recent investments that others are making there? And then I'm more just thinking if and when you potentially adapt a MAKO solution to Spine, how do -- what area or in what capacity do you think that could add value to the procedure? Then I have a follow-up."
94614,331567642,1010351,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","Yes. I think it is early right now. There's been a lot announced, but there hasn't been a whole lot launch. And so I think we're just going to have to wait and see. Do they truly facilitate making the procedure easier or enhancing the outcome? We do belie",102,"Yes. I think it is early right now. There's been a lot announced, but there hasn't been a whole lot launch. And so I think we're just going to have to wait and see. Do they truly facilitate making the procedure easier or enhancing the outcome? We do believe there's opportunity for Robotics when we look at MAKO and Spine, but it is not the focus right now. We are completely focused on the opportunity in recon and particularly gearing up for the total knee launch. So it's certainly something that we're going to evaluate, but near term, it's not the focus."
94614,331567642,1010351,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Analysts","Okay. And then just a second one. Someone asked a question earlier about Medtronic getting in into hips and knees eventually. I guess my question to you is -- Medtronic talked about a risk-sharing model. Can you talk a little bit about what, if anything,",65,"Okay. And then just a second one. Someone asked a question earlier about Medtronic getting in into hips and knees eventually. I guess my question to you is -- Medtronic talked about a risk-sharing model. Can you talk a little bit about what, if anything, Stryker is thinking about doing and potentially going at risk with the hospital and an episode of care payment situation?"
94614,331567642,1010351,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","Yes, we have done that. We've had our Stryker Performance Solution group within the company now for a number of years. They go at risk. We've got convener status under the prior program, where we're able to share with customers. And so this is something t",137,"Yes, we have done that. We've had our Stryker Performance Solution group within the company now for a number of years. They go at risk. We've got convener status under the prior program, where we're able to share with customers. And so this is something that, through that SPS, we've got a lot of institutional knowledge. We obviously have a very deep understanding around the reconstructive procedure, what the value drivers are through the entire episode of care both in the acute and the post-acute setting. So given our long history in ortho, we think we're well positioned on top of the expertise we developed over recent years through our Stryker Performance Solution to really go in and partner with customers and sometimes go at risk and others construct models that help them maximize the value chain."
94614,331567642,1010351,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","We just haven't talked about a lot since it's not an enormous part of our business, but we have the capability. We're already doing it, and we certainly are having more and more conversations with customers as the CJR rolls into effect.",43,"We just haven't talked about a lot since it's not an enormous part of our business, but we have the capability. We're already doing it, and we certainly are having more and more conversations with customers as the CJR rolls into effect."
94614,331567642,1010351,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Operator","Our next question comes from the line of Josh Jennings with Cowen and Company.",14,"Our next question comes from the line of Josh Jennings with Cowen and Company."
94614,331567642,1010351,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Analysts","I just wanted to follow up on, Kevin, your comments on Europe and stronger growth in Q2 from Q1. And I think this is the second quarter post the annualization of the Transatlantic model initiative. Are you still -- are you beginning to see more benefits i",90,"I just wanted to follow up on, Kevin, your comments on Europe and stronger growth in Q2 from Q1. And I think this is the second quarter post the annualization of the Transatlantic model initiative. Are you still -- are you beginning to see more benefits in Q2? And do you think we -- should we think about your European business continue to potentially accelerate or at least getting -- continue to get -- receive benefits from this Transatlantic model? I just wanted to see if there's an update there."
94614,331567642,1010351,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","Sure. So first, rather than just focus on the first quarter, I think we had a very successful year last year in the first year of the Transatlantic model, but it wasn't across every business. And we still have a number of businesses that are just really -",167,"Sure. So first, rather than just focus on the first quarter, I think we had a very successful year last year in the first year of the Transatlantic model, but it wasn't across every business. And we still have a number of businesses that are just really -- that have good growth in front of them. I highlighted Knees. I highlighted Instruments. And even part of our Endoscopy division still has significant growth. So to us, we look at Europe as being a growth market just given our relatively lower market shares, and we see it as a growth market for the next several years. So regardless of what's going on with Brexit or anything else, our relative low market share creates a big opportunity. And this model that we've implemented, we feel, is contributing to the growth that we're experiencing and will continue to deliver high growth or higher than we've experienced over the past decades in Europe. So it continues to be a growth market."
94614,331567642,1010351,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Analysts","Great. And just I had one follow-up on pricing. In the press release, you called out a 1.3% headwind in Q2. I was hoping to just get your thoughts on what you're seeing in the market. I know there's a lot of different subsegments within your business. But",89,"Great. And just I had one follow-up on pricing. In the press release, you called out a 1.3% headwind in Q2. I was hoping to just get your thoughts on what you're seeing in the market. I know there's a lot of different subsegments within your business. But I guess from a high level, how should we be thinking about the sustainability? Is this a new level? Is there anything to call out in the quarter? And just what you're seeing out in the market from a pricing standpoint."
94614,331567642,1010351,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","Yes. You -- if you look in the -- we break out the pricing. And it tends to be more negative in ortho versus MedSurg, but there's been no real change. Yes, it's trending slightly better or slightly look bad at 1.3% versus the 1.5% to 2% range that we fore",129,"Yes. You -- if you look in the -- we break out the pricing. And it tends to be more negative in ortho versus MedSurg, but there's been no real change. Yes, it's trending slightly better or slightly look bad at 1.3% versus the 1.5% to 2% range that we forecast. But we've also seen quarters not too far back where it trended a little bit worse then came in north of 2%. So it's within tenths of basis points of the range we're targeting, and there are so many variables between mix, both products as well as geographic, that play in there. But I wouldn't do this to some -- indicative of some new trend line. I think 1.5% to 2% is a good number to focus on."
94614,331567642,1010351,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Operator","And our next question comes from the line of Amit Hazan with Citi.",13,"And our next question comes from the line of Amit Hazan with Citi."
94614,331567642,1010351,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Analysts","This is Lee Preston [ph] on for Amit. I wanted to touch on 2 things for mix. It seems like some of your competitors' data for product mix has been -- pretty much ceased to be a positive tailwind. It's pretty much flat now. I know you guys used to talk abo",130,"This is Lee Preston [ph] on for Amit. I wanted to touch on 2 things for mix. It seems like some of your competitors' data for product mix has been -- pretty much ceased to be a positive tailwind. It's pretty much flat now. I know you guys used to talk about it in that kind of positive 2% range and it was offsetting price headwinds at about the same level. I realize you might not want to throw out a specific number, but directionally, are we still in the same ballpark for that product mix that we had been in the past several years or on that positive 2%? And what are your thoughts on sustainability at positive product mix going forward? This is for Hips and Knees, specifically."
94614,331567642,1010351,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","Okay. When we report price -- and I know some companies do it one way, some companies do it the other, we report pure price. And then our -- the other number is volume and mix together. So price is negative -- pure price negative in ortho. And it is offse",81,"Okay. When we report price -- and I know some companies do it one way, some companies do it the other, we report pure price. And then our -- the other number is volume and mix together. So price is negative -- pure price negative in ortho. And it is offset obviously by volumes and to a lesser degree by mix. There hasn't been a big change in that in recent years in terms of the overall impact of those items."
94614,331567642,1010351,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Analysts","Okay. And then I have one follow-up. If you think about CJR next year, do you expect your mix of standard versus premium implant to change at all within your CJR customers for Hips and Knees?",36,"Okay. And then I have one follow-up. If you think about CJR next year, do you expect your mix of standard versus premium implant to change at all within your CJR customers for Hips and Knees?"
94614,331567642,1010351,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","I think it's early. We'll see what happens next year when they start to go into the penalty phase. Again, we really believe, based on all our research, that the focus there is going to be much more in the post-acute setting since 50% to 60% of the cost li",104,"I think it's early. We'll see what happens next year when they start to go into the penalty phase. Again, we really believe, based on all our research, that the focus there is going to be much more in the post-acute setting since 50% to 60% of the cost lie there for the total procedure, and there's tremendous opportunity to take cost out when you look at the post-acute setting and the number of patients who get discharged to a rehab facility versus home care. That's where we think the biggest focus is going to be because that's where the biggest dollars are."
94614,331567642,1010351,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Operator","Our next question comes from the line of Matt Taylor with Barclays.",12,"Our next question comes from the line of Matt Taylor with Barclays."
94614,331567642,1010351,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Analysts","I was wondering if you could just comment, reflecting on the first half, just on utilization more broadly, are you seeing anything different in the U.S. market [indiscernible] was stronger than you'd expect? Or are you guys are seeing good execution in pr",45,"I was wondering if you could just comment, reflecting on the first half, just on utilization more broadly, are you seeing anything different in the U.S. market [indiscernible] was stronger than you'd expect? Or are you guys are seeing good execution in product update [indiscernible]?"
94614,331567642,1010351,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","Yes, there's been no real change in utilization. Obviously, Hip utilization was a little bit lower in the U.S. in the second quarter. But no, there has been no overall change in underlying demand across the businesses. It does vary bit to bit. Obviously,",62,"Yes, there's been no real change in utilization. Obviously, Hip utilization was a little bit lower in the U.S. in the second quarter. But no, there has been no overall change in underlying demand across the businesses. It does vary bit to bit. Obviously, the demand is going to be greater in something like ischemic. But no, there's been no fundamental change."
94614,331567642,1010351,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Analysts","And once you get through the drawdowns in China, what kind of growth do you expect for your businesses in that market? Or what visibility do you have on the end markets out there?",34,"And once you get through the drawdowns in China, what kind of growth do you expect for your businesses in that market? Or what visibility do you have on the end markets out there?"
94614,331567642,1010351,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","I think we'll have a better sense once we get through that. We're focused right now on really getting to appropriate inventory level and getting a much better sense of end user demand because there is this distributor layer there. So it's difficult to pre",106,"I think we'll have a better sense once we get through that. We're focused right now on really getting to appropriate inventory level and getting a much better sense of end user demand because there is this distributor layer there. So it's difficult to predict right now. The comps get easier in the second half, but beyond that, we just don't have the visibility to say what true [ph] end market demand is going to be. If we'd start to get better visibility into the channel, we'll be able to share that with you, but it'd be premature right now to throw a number out."
94614,331567642,1010351,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","And the area that's sort of the most hard to predict is capital equipment. I think on the disposables and the implant side of the business, we see that sort of -- that still -- those markets are actually still fairly healthy, and we expect that to continu",51,"And the area that's sort of the most hard to predict is capital equipment. I think on the disposables and the implant side of the business, we see that sort of -- that still -- those markets are actually still fairly healthy, and we expect that to continue going forward."
94614,331567642,1010351,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Operator","And our next question comes from the line of Matt Miksic with UBS.",13,"And our next question comes from the line of Matt Miksic with UBS."
94614,331567642,1010351,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Analysts","So one follow-up on Orthopaedic growth from Q1 to Q2. And I guess when we do the math on J&J's numbers, just looking at knees in the U.S. and adjust for selling days, adjust for price, it was a deceleration from Q1 to Q2. And you clearly, a, you've accele",135,"So one follow-up on Orthopaedic growth from Q1 to Q2. And I guess when we do the math on J&J's numbers, just looking at knees in the U.S. and adjust for selling days, adjust for price, it was a deceleration from Q1 to Q2. And you clearly, a, you've accelerated; and b, you're also just growing at a higher rate. But I'm curious, is that -- feel in the marketplace, do you like share gains in terms of accounts or mind share somehow? Or do you get the sense at all that there was -- what the overall market was like? I know this is an end of 2 [ph], but just love to get what your perspective is on their deceleration and your, sort of, call it, modest acceleration after adjusting for days."
94614,331567642,1010351,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","Yes. So this is really our fourth really good performance in this -- fourth quarter in a row of really strong performance. And we tend to attribute that much more to the launch of our cementless cones, and the cementless knee business are really picking u",143,"Yes. So this is really our fourth really good performance in this -- fourth quarter in a row of really strong performance. And we tend to attribute that much more to the launch of our cementless cones, and the cementless knee business are really picking up, so our 3D-printed products. We really believe that that's a big part of this. And we also get a bit of a MAKO halo impact. So not specifically just the volume that's coming from our unis [ph], but also, wherever we put MAKO, we tend to drive a higher mix of our business. So rather than comment on one particular competitor, I would just point out that our businesses really picked up. And it's been multiple quarters now in a row of strong performance really linked, I believe, to new products and the halo impact of MAKO."
94614,331567642,1010351,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Analysts","Great. And then just one follow-up, if I could. I have a feeling the answer is going to be, it's early around bundled payments. But speaking of folks in the field and working at some of these hospitals either through BPCI or starting to consider how to ta",134,"Great. And then just one follow-up, if I could. I have a feeling the answer is going to be, it's early around bundled payments. But speaking of folks in the field and working at some of these hospitals either through BPCI or starting to consider how to tackle CJR, there is some thinking that there are centers that are just going to look at this and say, ""We don't do enough of these procedures maybe to keep doing hips and knees."" And maybe start shifting those procedures elsewhere in the network or upstream somehow. Again, I know it's early, but could you give some perspective on how you think that may play out in the market given so much of the volume in orthopaedics in the U.S. is done by sort of lower-volume centers?"
94614,331567642,1010351,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","Yes. It is early. So it's an accurate comment. Could we see in some hospital a shift? It's possible and -- but I think it's too early to say that that's going to be a discernible enough trend or how it impacts the volumes of hospitals, where it shifts to,",82,"Yes. It is early. So it's an accurate comment. Could we see in some hospital a shift? It's possible and -- but I think it's too early to say that that's going to be a discernible enough trend or how it impacts the volumes of hospitals, where it shifts to, to make any big comments on it. I'm sorry. We just don't have more insights yet given the early stage combined with the fact that there's no penalty in the first year."
94614,331567642,1010351,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Operator","There are no further questions at this time. I will now turn the conference back over to Mr. Kevin Lobo for any closing remarks.",24,"There are no further questions at this time. I will now turn the conference back over to Mr. Kevin Lobo for any closing remarks."
94614,331567642,1010351,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","So thank you all for joining our call. Our conference call for the third quarter 2016 results will be held on October 27. Also, our analyst meeting and product fair will be held on November 9 at our Orthopaedics headquarters in Mahwah, New Jersey. Thank y",46,"So thank you all for joining our call. Our conference call for the third quarter 2016 results will be held on October 27. Also, our analyst meeting and product fair will be held on November 9 at our Orthopaedics headquarters in Mahwah, New Jersey. Thank you."
94614,331567642,1010351,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Operator","Thank you, ladies and gentlemen. This concludes today's conference. Thank you for participating. You may now disconnect.",17,"Thank you, ladies and gentlemen. This concludes today's conference. Thank you for participating. You may now disconnect."
94614,331567642,1011093,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Operator","Welcome to the Second Quarter 2016 Stryker Earnings Call. My name is Andrea, and I will be your operator for today's call. [Operator Instructions] This conference call is being recorded for replay purposes.Before we begin, I would like to remind you tha",134,"Welcome to the Second Quarter 2016 Stryker Earnings Call. My name is Andrea, and I will be your operator for today's call. [Operator Instructions] This conference call is being recorded for replay purposes.
Before we begin, I would like to remind you that the discussions during this conference call will include forward-looking statements. Factors that could cause actual results to differ materially are discussed in the company's most recent filings with the SEC. Also, the discussions will include certain non-GAAP financial measures. Reconciliations to the most directly comparable GAAP financial measures can be found in today's press release that is an exhibit to Stryker's current report on Form 8-K filed today with the SEC.
I will now turn the call over to Mr. Kevin Lobo, Chairman and Chief Executive Officer. You may proceed, sir."
94614,331567642,1011093,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","Welcome to Stryker's second quarter earnings call. Joining me today are Glenn Boehnlein, Stryker CFO; Tim Scannell, Group President, MedSurg & Neurotechnology; and Katherine Owen, VP of Strategy and Investor Relations. For today's call, I will provide ope",290,"Welcome to Stryker's second quarter earnings call. Joining me today are Glenn Boehnlein, Stryker CFO; Tim Scannell, Group President, MedSurg & Neurotechnology; and Katherine Owen, VP of Strategy and Investor Relations. For today's call, I will provide opening comments, followed by Tim with an update on our 2 recent acquisitions, Sage and Physio-Control. Glenn will then provide additional details regarding our quarterly results before we open the call to Q&A.
With Q2 organic sales growth of 6.6%, we continue to demonstrate the strength of Stryker's diversified revenue base, which is allowing us to consistently deliver sales growth at the high end of med tech. This quarter, our growth was powered by robust performance in MedSurg & Neurotechnology, while Orthopaedics was in line. Our decentralized business model is enabling us to drive innovation and strong sales and marketing execution. On a geographic basis, organic growth was led by the U.S., up 9%, while sales outside the U.S. were up 2%, which is continuing to be impacted by ongoing challenges in China.
Beyond the top line achievement, Q2 was highlighted by strong operational expense leverage that reflects our focus on driving cost transformation across divisions and geographies. As previously mentioned, we have a significant opportunity to deliver greater G&A leverage on a multi-year basis, with initiatives such as indirect spending, product life cycle management and the optimization of our IT systems. As we are starting to see the impact from these initiatives, it underscores our conviction of delivering leveraged earning gains. Based on our first half performance, we now look for full year organic sales growth of 6% to 6.5% and adjusted per share earnings of $ 5.70 to $5.80 a share.
I will now turn the call over to Tim."
94614,331567642,1011093,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","Thanks, Kevin. Good afternoon. I'm excited about participating in today's call and providing you with perspectives regarding our recent acquisitions of Sage Products and Physio-Control. I will begin with Sage Products and reiterate the strategic rationa",793,"Thanks, Kevin. Good afternoon. I'm excited about participating in today's call and providing you with perspectives regarding our recent acquisitions of Sage Products and Physio-Control. 
I will begin with Sage Products and reiterate the strategic rationale which drove this acquisition. As we articulated in February, Sage complements Stryker Medical's portfolio of innovative ICU and MedSurg products, with disposables targeted at reducing never events. It also provides access to an important adjacent market that expands our hospital product offerings and improves our mix of single-use versus capital products. Sage's approach to innovation focuses on demonstrating superior clinical outcomes, which underscore the benefits of their products, driving customer adoption and loyalty. These innovation efforts have resulted in unique and highly trusted brands, which are an essential part of nurses' daily interactions with patients and hospital ICUs and MedSurg units. Sage is #1 in all the segments it serves, and we believe that in North America alone, Sage's products address a segment totaling approximately $1.4 billion.
Turning to the financials for Sage. Given that we closed the transaction on April 1, we are able to share a full quarter of sales results. Sage's performance was strong in Q2, with sales growth of roughly 9%. This performance was achieved while contending with an unexpected supply interruption during the quarter that was onetime in nature and has been resolved. Without the supply interruption, Sage's growth in Q2 would have been approximately 14%.
Sage's success has been fueled by their commitment to innovation, which has resulted in a long history of successful new product introductions, including the recently launched AirTAP product. Using proprietary air-assisted technology, AirTAP enables caregivers to provide exceptional care by aiding in the turning and boosting of patients while the patients remain in bed. AirTAP enhances caregiver safety as it requires 80% less force to boost patients versus the typically used drawsheet.
With respect to integration, plans are underway to expand our manufacturing capacity beginning in 2018 to support expected growth. Moreover, our businesses are working to coordinate activities to accelerate revenue in areas such as key account and brand strategies. Our international focus will begin with Europe, where Sage has experienced some initial success, and Canada, where they have done very well. Beyond these markets, we are working to prioritize countries which value proven clinical solutions that eliminate never events. We are excited by the cultural similarities and positive chemistry between Stryker and Sage and expect double-digit revenue growth in the second half.
Turning to Physio-Control. I would like to also reinforce the strategic rationale that led us to acquire this company. As we described in mid-February, Physio-Control complements Stryker Medical's portfolio of innovative and differentiated prehospital and hospital products as Physio-Control is the leader in the development, manufacture and sale of defibrillators and monitors, AEDs and CPR-assist devices. We are excited by the synergistic benefits and market strength that resulted from the combination of Physio-Control with our Medical division. Importantly, the vast majority of Physio-Control sales call points overlap with our Medical division call points. Physio-Control holds the #1 or #2 share position at every major segment it serves. We believe that on a global basis, Physio-Control's products address segments totaling approximately $1.7 billion.
With Stryker's market-leading power cot and Power-LOAD lift system coupled with Physio-Control's suite of defibrillators, monitors and related products, our solution set is extensive. Our existing EMS franchise has enjoyed tremendous success in recent years, with growth significantly higher than the market and Stryker as a whole. Physio-Control's business has an attractive mix of 60% capital and 40% recurring business compared to our EMS business, which is nearly 100% capital. In addition, Physio-Control has an impressive enduring competency and a robust pipeline of products that have recently begun to launched, with additional product launches slated for the next several years. We expect this refreshed product portfolio and the combination of our organizations to result in continued strong sales momentum and greater profitability leverage in the future.
As a reminder, we closed the Physio transaction on April 5. Pro forma Q2 sales grew roughly 9%. On the integration front, our teams are focused on determining the optimal organizational design that best serves our common EMS and hospital customers. In addition, Physio has a significant international structure and our Medical division is assessing opportunities to drive growth by leveraging Physio's international market knowledge, strength and operational infrastructure. We expect high single-digit growth from the Physio-Control business in the second half. 
With these 2 acquisitions, the Medical division is now bigger, stronger, better diversified geographically and has more base business. Encouragingly, Medical had a strong organic Q2 growth result, well integrating these 2 acquisitions.
This concludes my overview commentary on Sage and Physio-Control. Glenn will now discuss our Q2 financials in more detail."
94614,331567642,1011093,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","Thanks, Tim. I will focus my comments today on our financial results and key drivers of our second quarter performance. Our detailed financial results have been provided in today's press release.For the quarter, our organic sales growth of 6.6% exceeded",1061,"Thanks, Tim. I will focus my comments today on our financial results and key drivers of our second quarter performance. Our detailed financial results have been provided in today's press release.
For the quarter, our organic sales growth of 6.6% exceeded the high end of the range of our full year expectations despite a tough year-over-year comparison, with growth of 6.9% in the year ago quarter. The quarter included one additional selling day compared to prior year, and consistent with our previous communications, the additional selling day equates to approximately 1% of additional growth. Pricing in the quarter was down 1.3% from the prior year, trending modestly better than we expected. During the quarter, we continued to see strong U.S. sales with organic growth of 8.6%, while international sales posted organic growth of 2%, reflecting continued destocking challenges in China. Our adjusted EPS of $1.39 increased 15.8% from the prior year, primarily driven by our strong top line growth, including the impact from the acquisitions completed in the quarter. Interest related to the recent bond offering unfavorably impacted EPS by $0.05 per share, and foreign exchange unfavorably impacted EPS by $0.03 during the quarter.
Looking at our segment highlights. Orthopaedics delivered constant currency growth of 4.8% and organic growth of 4.5%. The top line was led by U.S. Orthopaedics gains of 5.9%, highlighted by a 9.5% increase in Trauma and Extremities and a 6.8% growth in Knees as momentum continued for our 3D-printed titanium revision cones and our cementless knee products. U.S. Hips posted low single-digit growth due to softness in the revision market. Orthopaedics international delivered constant currency growth of 2.9%, led by a strong performance in our European Knee business. Lastly, we placed 17 MAKO units during the quarter. Overall, our second quarter results continue to reflect strong momentum across our Orthopaedics portfolio.
Our MedSurg segment's constant currency growth was 34.2%, including the impact of the recent acquisitions of Sage and Physio. Excluding the impact of acquisitions, our MedSurg business posted organic growth of 8.5%. Our U.S. MedSurg business continued their strong momentum with organic growth of 11.1%. Instruments had solid US growth of 8%, with strong performance in our power tools business, highlighted by double-digit gains in our micro power tools. Endoscopy continued its momentum from Q1, with U.S. growth of 10.8%, driven by continued success of our 1588 AIM video platform. Excluding the impact of the Sage and Physio acquisitions, Medical had U.S. growth of 16.9%, driven by continued performance of its power cot products as well as solid performance of our bed business. Internationally, MedSurg organic sales were down, 0.5% for the quarter, reflecting ongoing challenges in China primarily related to the distributor destocking. We expect this to continue throughout 2016 as we work with our distributors to drive end customer demand and reduce the buildup in their inventories.
Neurotechnology and Spine posted constant currency growth of 9% and organic growth of 7.5%, with continued strong momentum in our neurotech businesses, which increased 14.4%, while Spine was up 1%. As with our other businesses, U.S. neurotech growth was robust at 15.6%, which reflects the continued strong demand for our Neurovascular products, the Trevo stent retriever and Target Coil, our Neuro Powered Instruments and our craniomaxillofacial fixation products. Our U.S. Spine business grew 4.8% despite experiencing product supply issues but continues to see good demand for our new 3D-printed titanium products. We expect these supply issues to remain into the fourth quarter. Internationally, neurotech constant currency growth of 12.3% reflects the broader market momentum for the Trevo stent retriever and Target Coil products. Spine's international growth was dampened by the aforementioned product supplies issues and continued challenges in China.
Moving on to general operating highlights. Our gross margin on an adjusted basis was roughly flat at 66.2%, down 180 basis points sequentially. We had another quarter of strong impact from our focus on operational efficiencies, including improved productivity and absorption. This was offset by the full impact of our recent acquisitions, including certain accounting reclassifications between gross margin and SG&A to align with Stryker policy, sales mix and negative pricing. 
As for our operating expenses, we continue to focus on internal innovation, with R&D spending of 6.4% of sales. On an adjusted basis, SG&A for the quarter was 34.9%, which was favorable by 120 basis points as compared to the prior year. The improvement reflects the favorable impact of SG&A leverage from our recent acquisitions, the previously mentioned reclassification of certain expenses, our sales mix and continued focus on our operating expense improvements through our CPG program. For the quarter, acquisitions contributed roughly half of our SG&A improvement. Combined, these factors drove a 100 basis point year-over-year increase in our adjusted operating margin to 24.8%.
Lastly, I will provide some highlights on our other income expenses. Other expenses increased due to higher net interest expense related to increased borrowings at the end of the first quarter. We anticipate that future quarterly interest expense will be roughly $30 million, which is consistent with this quarter. Our second quarter adjusted effective tax rate of 17.6% reflects the benefits of our global tax structure, partially offset by the impact of higher U.S.-based income from our recent acquisitions.
Moving on to the balance sheet. We continue to maintain a strong balance sheet with $3.5 billion of cash and marketable securities, of which approximately 38% was held in the U.S. Total debt on the balance sheet at the end of the second quarter was $7.6 billion.
Turning to cash flow. Our year-to-date cash from operations was approximately $671 million. Finally, as we had previously announced at the end of Q1, we suspended our share repurchases for the remainder of the year.
In terms of guidance, based on our second quarter performance, we expect our full year organic sales growth to be in the range of 6% to 6.5% versus 2016. If foreign currency exchange rates hold near current levels, we anticipate net sales will be negatively impacted by approximately 1% for 2016, with negative pricing being in the range of 1.5% to 2%. Lastly, our guidance for adjusted net earnings per diluted share in 2016 now stands in the range of $5.70 to $5.80 for the full year, and we expect the third quarter to be in the range of $1.33 to $1.38.
And now we'll open up the call for Q&A."
94614,331567642,1011093,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Operator","[Operator Instructions] Our first question comes from the line of Mike Weinstein with JPMorgan.",14,"[Operator Instructions] Our first question comes from the line of Mike Weinstein with JPMorgan."
94614,331567642,1011093,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Analysts","I just want to get your thoughts on a couple of items. Number one, I understand the guidance update for the year. One of the questions people are asking is just the third quarter is a little bit below where The Street was modeling. So I don't know if -- a",123,"I just want to get your thoughts on a couple of items. Number one, I understand the guidance update for the year. One of the questions people are asking is just the third quarter is a little bit below where The Street was modeling. So I don't know if -- as you look at Street models, if there was anything in particular you thought The Street was off on relative to your expectations. And then second, the mix of growth was a little bit different this quarter if I look at Orthopaedics and MedSurg within those different businesses. Maybe there's a couple you want to comment on. There's a few that stick out to me, but I just want to get your thoughts."
94614,331567642,1011093,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","Okay. I'll take the first one. So as we look at Q3, seasonally, Q3 is usually our softest quarter. I think if you look at our guidance, it's very consistent with our Q3 guidance that we provided in the past, especially when you look at year-over-year grow",47,"Okay. I'll take the first one. So as we look at Q3, seasonally, Q3 is usually our softest quarter. I think if you look at our guidance, it's very consistent with our Q3 guidance that we provided in the past, especially when you look at year-over-year growth."
94614,331567642,1011093,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","And as for the second question -- Mike, this is Kevin. I would say that from quarter to quarter, we -- you see this kind of change at Stryker, and we've seen this for the past few years, where in the first quarter, Orthopaedics had a more robust performan",95,"And as for the second question -- Mike, this is Kevin. I would say that from quarter to quarter, we -- you see this kind of change at Stryker, and we've seen this for the past few years, where in the first quarter, Orthopaedics had a more robust performance. This quarter, it was led by MedSurg. From quarter to quarter, we see those variations. But what's encouraging to me is if you look at our growth versus the market, we continue to perform very well, especially if you look on a rolling 4 quarters basis."
94614,331567642,1011093,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Analysts","And maybe just a couple more, Kevin, just to comment on. So the -- if I look at within different businesses, maybe some of that were a bit surprising with maybe international Spine, which you made some comments relative to the Orthopaedic business. There",84,"And maybe just a couple more, Kevin, just to comment on. So the -- if I look at within different businesses, maybe some of that were a bit surprising with maybe international Spine, which you made some comments relative to the Orthopaedic business. There was some surprises, like U.S. Hips was less than what we thought. Knees was pretty close. But there was some -- relative to what we saw in the first quarter, there was some pretty good swings within the business model."
94614,331567642,1011093,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","Yes. So Mike, look, I'll just finish by saying in China, we've had issues and challenges, and we've highlighted those in the past. That affected Spine. That affected our Endoscopy division. That affected our Trauma division. Spine had some product supply",162,"Yes. So Mike, look, I'll just finish by saying in China, we've had issues and challenges, and we've highlighted those in the past. That affected Spine. That affected our Endoscopy division. That affected our Trauma division. Spine had some product supply issues, which affected both our U.S. Spine business as well as our OUS Spine business. Hips, as you pointed out, is -- was a little softer this quarter, but we've lead the market certainly in the U.S. for multiple years in our Hip business and it's just one quarter. So there is, for me, no concern there. We see these changes from quarter to quarter. And as you've seen, our -- the resiliency of our top line, quarter after quarter over the past 3 or 4 years, has been very steady. So yes, there were a bit of swings this quarter but nothing that causes me any reason for concern. I mean, we have very, very strong divisions across the company."
94614,331567642,1011093,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Operator","Our next question comes from the line of Bob Hopkins with Bank of America.",14,"Our next question comes from the line of Bob Hopkins with Bank of America."
94614,331567642,1011093,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Analysts","So just a couple of things to follow up on. One, just a little more color maybe on the U.S. Hips. I recognize it have been strong. It's just one quarter. But Kevin, you mentioned that you felt it was a soft revision market. So you feel like it was -- ther",109,"So just a couple of things to follow up on. One, just a little more color maybe on the U.S. Hips. I recognize it have been strong. It's just one quarter. But Kevin, you mentioned that you felt it was a soft revision market. So you feel like it was -- there was something going on with the revision market this quarter. So I was wondering if you could give a little bit more color there. And also, now that we're kind of one quarter into CJR, maybe any thoughts from the field in terms of what you're seeing, client reaction, your thoughts on how things are developing there."
94614,331567642,1011093,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","Bob, it's Katherine. Just a couple of points. I wouldn't look at the quarter and say something particular was going on in revisions versus primary. Overall, it was a bit softer than we've seen. And much like the first quarter, it was a bit stronger than w",188,"Bob, it's Katherine. Just a couple of points. I wouldn't look at the quarter and say something particular was going on in revisions versus primary. Overall, it was a bit softer than we've seen. And much like the first quarter, it was a bit stronger than we typically see. But we're not hearing anything from the field, from our customers that suggests something's changed. It really reinforces why you've heard us say over and over, we really focus on rolling 4 quarter trends because we see this quarter-to-quarter variability that, taken as a whole when you look back, doesn't mean anything significant in terms of changes in underlying fundamentals. And we're not seeing anything different in this quarter other than it was obviously a weaker-than-normal quarter versus Q1 being a stronger-than-normal quarter. In terms of CJRs, it went to effect April 1. We haven't seen any impact. I think it's simply too early. As you know, there's no penalty until after the first full year. So it's just simply too early, but nothing has played out yet in terms of a significant change or impact on the market."
94614,331567642,1011093,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Analysts","Okay. And then 2 other things I want to touch on. One was just maybe a comment on gross margin. In Q1, we talked about thinking about 68% for the rest of the year. I just would like to understand some of the moving parts that you were highlighting in the",115,"Okay. And then 2 other things I want to touch on. One was just maybe a comment on gross margin. In Q1, we talked about thinking about 68% for the rest of the year. I just would like to understand some of the moving parts that you were highlighting in the prepared comments. And then lastly, as it relates to the deals, it sounds like things are going well. Tim, previously, you guys have suggested that $0.15 to $0.18 of accretion in 2017 was a good preliminary estimate. Now I was wondering, from what you see today, is that still a good preliminary way of thinking about things? Or is that perhaps a conservative estimate?"
94614,331567642,1011093,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","Bob, this is Glenn. First of all, if you look at the sequential drop in margin, Q1 to Q2, roughly 180 basis points, I mean, Q2 was really impacted by mix especially, but not just sales mix but by adding in the acquisitions. It's early. Acquisitions are of",248,"Bob, this is Glenn. First of all, if you look at the sequential drop in margin, Q1 to Q2, roughly 180 basis points, I mean, Q2 was really impacted by mix especially, but not just sales mix but by adding in the acquisitions. It's early. Acquisitions are off to a solid start, but that's going to impact gross margin for the rest of the year. And it impacted more than just product. We made some reclassifications to harmonize Sage and Physio accounting practices with our accounting practices. And this essentially shifted some SG&A expenses up to gross margin in order to sort of align them with how Stryker does the accounting. It's pretty common that we do that, and we don't get a chance to really see it until we really climb into the integration work. So that's one of the things that came out. And then on top of that, I really just need to reiterate that there's a lot of other things that make our margin move around, not just price but FX, geographic mix really impact it. And all of those are pretty hard to forecast to a -- to sort of a single-point estimate. As I think about for the rest of the year and what you should maybe think about for your model, I think we'll be in the range of this 67% range, but understand that it could trend above or below that based on all of those factors that I mentioned."
94614,331567642,1011093,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","And Bob, on the deals -- this is Tim speaking. The accretion assumption you cited look good. We're on track and we would expect you could assume those to be good moving forward.",33,"And Bob, on the deals -- this is Tim speaking. The accretion assumption you cited look good. We're on track and we would expect you could assume those to be good moving forward."
94614,331567642,1011093,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Operator","Our next question comes from the line of Kristen Stewart with Deutsche Bank.",13,"Our next question comes from the line of Kristen Stewart with Deutsche Bank."
94614,331567642,1011093,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Analysts","Just 2, I guess go back to Bob's question on the accretion from the deal. How should we just think about, I guess, that accretion? Thinking [ph] about that as flowing through, I realize it's still very early compared to -- think about next year. But shoul",95,"Just 2, I guess go back to Bob's question on the accretion from the deal. How should we just think about, I guess, that accretion? Thinking [ph] about that as flowing through, I realize it's still very early compared to -- think about next year. But should we think about kind of that baseline growth. I know we've talked about this in previous calls. Or should we think about that as still a little too soon to kind of dial in accretion above what has been generally a double-digit kind of baseline growth for you?"
94614,331567642,1011093,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","Kristen, I think it's very consistent with how we've messaged before. This is obviously going to be one of the variables that gets factored in as we go through our 2017 budgeting process. But clearly, it's incremental accretion above and beyond the normal",148,"Kristen, I think it's very consistent with how we've messaged before. This is obviously going to be one of the variables that gets factored in as we go through our 2017 budgeting process. But clearly, it's incremental accretion above and beyond the normal earnings power of the businesses as they stand. How much of that flow through to the bottom line, how much of that we reinvest as we think about the opportunities in front of us, all of that will get factored in and will be evident when we give the range. So I wouldn't want to say it's a one for one, just throw it all on top of a normal earnings number because we have to look at the opportunities for reinvestment, recognizing, obviously, it's also incremental accretion. And so some portion of it is likely to play out at the bottom line as well."
94614,331567642,1011093,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Analysts","Okay. And then just generally on the market trends. I was just curious, from a competitive standpoint, now that we've had a couple of quarters on which, I guess, Zimmer is through with its integration with Biomet and we've seen J&J come pick up its moment",116,"Okay. And then just generally on the market trends. I was just curious, from a competitive standpoint, now that we've had a couple of quarters on which, I guess, Zimmer is through with its integration with Biomet and we've seen J&J come pick up its momentum within hips and knees. I was wondering if you guys could just comment broadly if you're seeing, I guess, what other companies are saying in terms of them getting their momentum back. Any particular changes that have been affecting you? And perhaps, on the Hips side, is this a reflection of some of the other companies getting their steam? Or is it just simply you feel just revision market softening?"
94614,331567642,1011093,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","Yes. I would say, again, it's just a quarter that was incrementally weaker versus the quarters where -- like the first quarter where it felt stronger but we couldn't point to any discernible change or inflection point that suggested we had a new higher gr",140,"Yes. I would say, again, it's just a quarter that was incrementally weaker versus the quarters where -- like the first quarter where it felt stronger but we couldn't point to any discernible change or inflection point that suggested we had a new higher growth market. The only ones who have reported are us and J&J. So we have a pretty limited visibility into everybody else's reports, but we're not seeing or hearing anything that suggests that you're seeing some dramatic market share shifts. That's generally not how things play out in the recon market. So again, we're not seeing anything that would suggest that there's anything different than the normal quarterly variability that we see play out. Obviously, it's more fun when it's Q1 and it's incrementally stronger. But again, it's why we focus on the rolling 4 quarters."
94614,331567642,1011093,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Operator","Our next question comes from the line of David Lewis with Morgan Stanley.",13,"Our next question comes from the line of David Lewis with Morgan Stanley."
94614,331567642,1011093,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Analysts","Just a few questions, maybe starting with Kevin. So Kevin, just with the extra selling day here in the second quarter and thinking about the easier comps in the back half of the year. By our math your guidance for the remainder of the year sort of implies",91,"Just a few questions, maybe starting with Kevin. So Kevin, just with the extra selling day here in the second quarter and thinking about the easier comps in the back half of the year. By our math your guidance for the remainder of the year sort of implies stable comp adjusted growth in the back half of the year. Is that just kind of roughly how you see the business stability on an underlying basis into the back half of the year? Or are there other chances for acceleration or deceleration?"
94614,331567642,1011093,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","So David, since the beginning of the year, this is the second time we've sort of moved our range upwards. And we've been delivering a very strong growth throughout the year. Yes, in China and even all the emerging markets, our comps will ease in the secon",104,"So David, since the beginning of the year, this is the second time we've sort of moved our range upwards. And we've been delivering a very strong growth throughout the year. Yes, in China and even all the emerging markets, our comps will ease in the second half of the year, but we also have some challenging comps in some of our other businesses that were growing very robustly in the second half of the year. So it's a big business that we're managing. And I think if you're growing north of 6% organically while you're integrating acquisitions, I think you're doing pretty well."
94614,331567642,1011093,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Analysts","I would agree. And then Glenn, I think you've gotten questions on margins, but I think this particular quarter, it's sort of the mirror image of the first quarter; or gross, a little weaker; SG&A controls, a little better. I know you had some announcement",97,"I would agree. And then Glenn, I think you've gotten questions on margins, but I think this particular quarter, it's sort of the mirror image of the first quarter; or gross, a little weaker; SG&A controls, a little better. I know you had some announcements on the ERP integration during the quarter. Can you just give us an update on where you are in terms of the ERP planning? And what's the opportunity for savings for shareholders on the ERP? And when we may get an update on that number? And then I had one quick follow-up."
94614,331567642,1011093,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","Yes. David, on -- ERP is one of the things we're focusing on relative to our CPG program. It has several facets. I would say we're in the pretty early stages of our ERP program. Obviously, when you're implementing a new commercial global footprint, it's a",102,"Yes. David, on -- ERP is one of the things we're focusing on relative to our CPG program. It has several facets. I would say we're in the pretty early stages of our ERP program. Obviously, when you're implementing a new commercial global footprint, it's a multi-year journey. And we're in the early stages of that. So we'll definitely keep you guys updated as that project moves forward. I think the more immediate-term things to think about are indirect procurement and those parts of the project that really can have more of an impact as we roll forward in the next year."
94614,331567642,1011093,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","Yes. David, what we've been signaling on our cost transformation is this is really the engine of being able to sustain leverage earnings year after year. And so in the earlier years, you're going to see more of that savings coming through from indirect pr",132,"Yes. David, what we've been signaling on our cost transformation is this is really the engine of being able to sustain leverage earnings year after year. And so in the earlier years, you're going to see more of that savings coming through from indirect procurement. And in the later years, you're going to see more of that saving coming from product life cycle management and coming from the ERP benefits. But I would say it's been a real rallying force for the company, so everybody, all the different divisions of Stryker working on a common system, which is going very, very well. And it's a shift to SAP from a company that has really no SAP today. But I'm very encouraged with the early progress, and I'm very optimistic about the implementation."
94614,331567642,1011093,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Analysts","And then Katherine, just one last quick one here. The neurotech number, obviously very, very strong and obviously, the driver partly is the ischemic market. I feel like in the last couple of quarters, you and your competitors have sort of shifted away and",83,"And then Katherine, just one last quick one here. The neurotech number, obviously very, very strong and obviously, the driver partly is the ischemic market. I feel like in the last couple of quarters, you and your competitors have sort of shifted away and they're much more focused on sort of market development from here. I'm wondering if you could share with us what specifically is Stryker doing on the market development front to drive that market. And I'll jump back in queue."
94614,331567642,1011093,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","Yes. David, we have been -- for some time, been messaging around the market development. But with Tim here who runs that business, I'm going to pass it over to him.",31,"Yes. David, we have been -- for some time, been messaging around the market development. But with Tim here who runs that business, I'm going to pass it over to him."
94614,331567642,1011093,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","Yes. There was a variety of initiatives out there where we're simply partnering with systems, health care systems, hospitals to drive patient flow to the right centers where they're performing these procedures. It will be a multi-year process, and hospita",150,"Yes. There was a variety of initiatives out there where we're simply partnering with systems, health care systems, hospitals to drive patient flow to the right centers where they're performing these procedures. It will be a multi-year process, and hospitals all vary in their level of maturity. But it's a very real and big challenge to get these patients to the right centers. But our efforts surround largely education, trying to assist, trying to ask the right questions, trying to connect people with the right consultants, things like that and make sure their stroke centers are properly operating. And they're getting the patients from the ER to the cap or the interventional lab to treat these patients. So it takes many forms. It takes many years. But I think what we're seeing is steady progress chipping away, but it's going to be years and years and years of efforts here."
94614,331567642,1011093,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Operator","Our next question comes from the line of Rick Wise with Stifel.",12,"Our next question comes from the line of Rick Wise with Stifel."
94614,331567642,1011093,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Analysts","Maybe just starting off with MAKO. In an oblique way, you talked about that you had solid U.S. Knee numbers. Where are you in the total knee roll-out for MAKO? Is MAKO -- you didn't call out MAKO as a positive factor driving Knee volumes in the U.S. Is it",71,"Maybe just starting off with MAKO. In an oblique way, you talked about that you had solid U.S. Knee numbers. Where are you in the total knee roll-out for MAKO? Is MAKO -- you didn't call out MAKO as a positive factor driving Knee volumes in the U.S. Is it a factor? Just remind us where you are in those time lines with commercialization and papers and what's next for MAKO."
94614,331567642,1011093,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","Yes, thanks. Rick, this is Kevin. So today, MAKO is not a huge driver because we're really in the Knee business, just using it for unicompartmental knees. We do have a limited launch and the accent is the word, limited, just a small number of surgeons who",105,"Yes, thanks. Rick, this is Kevin. So today, MAKO is not a huge driver because we're really in the Knee business, just using it for unicompartmental knees. We do have a limited launch and the accent is the word, limited, just a small number of surgeons who are doing total knees. Early feedback has been very positive. So we're encouraged. But the reason for the limited launch is to make sure that we work out all the workflow and define training protocols and also be able to have some publications and podium presentations. The full launch in the total knee is not until next year."
94614,331567642,1011093,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Analysts","So maybe turning to Tim and Physio. Tim, you talked about the high single-digit second half growth for Physio, but you also underscored the pipeline and the products coming. Can you give us any more color on the pipeline? What do we expect? When do we see",65,"So maybe turning to Tim and Physio. Tim, you talked about the high single-digit second half growth for Physio, but you also underscored the pipeline and the products coming. Can you give us any more color on the pipeline? What do we expect? When do we see it? And is -- does that accelerate or sustain that kind of high single-digit growth pace for Physio?"
94614,331567642,1011093,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","Yes. Rick, I would say we'd sustain that high single-digit growth rate. I think what I said after the deal was announced was that it would be accretive to Stryker's sales growth rate. And I would expect over the next several years to see next generation p",138,"Yes. Rick, I would say we'd sustain that high single-digit growth rate. I think what I said after the deal was announced was that it would be accretive to Stryker's sales growth rate. And I would expect over the next several years to see next generation products in each of 3 main categories, defibrillators and monitors, AEDs or automated external defibrillators, and circulatory-assist devices. This market is now turning into a PMA market in the United States. And so these launches will be global in nature and vary in timing by markets. So we're not going to be overly specific about it, but I would say we expect, again, over the next 4 to 5 years, to have a consistent stream of new products which would drive that accretive sales growth out of the Physio division versus Stryker."
94614,331567642,1011093,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Operator","Our next question comes from the line of Chris Pasquale with Guggenheim.",12,"Our next question comes from the line of Chris Pasquale with Guggenheim."
94614,331567642,1011093,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Analysts","I had a couple of questions on Sage. First, can you give us some more color on the supply disruption in the quarter? What happened there?",26,"I had a couple of questions on Sage. First, can you give us some more color on the supply disruption in the quarter? What happened there?"
94614,331567642,1011093,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","On the supply disruption, from time to time, each of our businesses may have some issues. In this case, it was one transit in nature. It's over, and that's about as far as we're going to go in terms of sharing details.",42,"On the supply disruption, from time to time, each of our businesses may have some issues. In this case, it was one transit in nature. It's over, and that's about as far as we're going to go in terms of sharing details."
94614,331567642,1011093,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Analysts","Okay. And then what's the time line to build out Sage's presence internationally? You talked about a little bit in Europe and Canada initially with the rest of the business. Can you drop those products in your bag internationally and start to see some syn",77,"Okay. And then what's the time line to build out Sage's presence internationally? You talked about a little bit in Europe and Canada initially with the rest of the business. Can you drop those products in your bag internationally and start to see some synergies in the next few quarters? Or is this going to be a protracted process where there are regulatory and tenders that have to go through before you really start to see that?"
94614,331567642,1011093,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","I think it will be a longer-term process. As we've seen with all our international initiatives, it does take time. And so we do have a foothold in Europe and Canada, as we've talked about. Areas like Australia may be fertile ground but will take a while.",76,"I think it will be a longer-term process. As we've seen with all our international initiatives, it does take time. And so we do have a foothold in Europe and Canada, as we've talked about. Areas like Australia may be fertile ground but will take a while. Other areas like Japan will take even longer in terms of regulatory pathways. So we see great opportunity, but it's going to be a multi-year journey, for sure."
94614,331567642,1011093,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Analysts","Okay. And then just one quick one, if I could, on China. Do you guys have any visibility at this point, where inventory levels stand and what's your underlying growth in that market might be excluding these drawdowns just to give us a sense of how close w",55,"Okay. And then just one quick one, if I could, on China. Do you guys have any visibility at this point, where inventory levels stand and what's your underlying growth in that market might be excluding these drawdowns just to give us a sense of how close we might be to seeing a turn there?"
94614,331567642,1011093,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","Yes. So what we've been saying now for the past few quarters is we did expect this to be a very soft quarter in China. So it was in line with our expectations. We do expect some time in the back half of the year that we'll start to reach bottom and that w",109,"Yes. So what we've been saying now for the past few quarters is we did expect this to be a very soft quarter in China. So it was in line with our expectations. We do expect some time in the back half of the year that we'll start to reach bottom and that we'll return to growth. I -- we don't have the precision just based on having multiple tiers of distributors. We're not positioned to be able to identify that exactly, but you should see signs of improvement certainly while we exit the year and going into next year. We should bottom out sometime in the second half."
94614,331567642,1011093,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Operator","Our next question comes from the line of Matt Keeler with Credit Suisse.",13,"Our next question comes from the line of Matt Keeler with Credit Suisse."
94614,331567642,1011093,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Analysts","Just first on the ex U.S. Knee performance, you mentioned strength in Europe. Can you give us any more color around that? Was that market strength? Are you taking share?",31,"Just first on the ex U.S. Knee performance, you mentioned strength in Europe. Can you give us any more color around that? Was that market strength? Are you taking share?"
94614,331567642,1011093,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","I think at this point, it's just tough to know until everybody reports, we have the numbers similarly and get a better sense of share shift at that point. So there's nothing specific that we would point to. We obviously have better execution now under our",74,"I think at this point, it's just tough to know until everybody reports, we have the numbers similarly and get a better sense of share shift at that point. So there's nothing specific that we would point to. We obviously have better execution now under our TOM model, which has helped a number of our businesses. But we'll know in a couple of weeks if there's anything more beyond market growth versus share shift."
94614,331567642,1011093,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","Yes. It's important just to note that we have a few of our businesses that are really underrepresented in Europe, our Endoscopy division, our Instruments division and Knees, where the market shares that we have are certainly much lower than they are in ot",97,"Yes. It's important just to note that we have a few of our businesses that are really underrepresented in Europe, our Endoscopy division, our Instruments division and Knees, where the market shares that we have are certainly much lower than they are in other parts of the world. So when we produce a good growth number, it's really just sort of getting back towards to what we would consider our fair share. And it's a very encouraging sign, and we're pleased with some of the hiring that we've done in Europe and starting to build the business."
94614,331567642,1011093,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Analysts","Okay. And then just a separate question on neurotech growth. It's very strong in the quarter, but it slowed versus last quarter sequentially. Can you give us any color on the subsegment growth rates in Neurovascular and CMF? And what drove that slowdown i",45,"Okay. And then just a separate question on neurotech growth. It's very strong in the quarter, but it slowed versus last quarter sequentially. Can you give us any color on the subsegment growth rates in Neurovascular and CMF? And what drove that slowdown in growth?"
94614,331567642,1011093,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","Yes, there would be nothing I would point to. I think as Katherine has talked about in some other areas, the growth rates can vary. It could be based on comps or different countries that did better or worse or what have you. I think if we dug down in the",92,"Yes, there would be nothing I would point to. I think as Katherine has talked about in some other areas, the growth rates can vary. It could be based on comps or different countries that did better or worse or what have you. I think if we dug down in the numbers, CMF might be up a smidge and Neurovascular down a little but nothing that would point to any dramatic shift. I think in general, we've had very, very strong performance. And to me, the good news is that, that continues."
94614,331567642,1011093,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","Yes. It's important to know all 3 of those groups. So Neurovascular is, of course, the biggest one, the neuro powered tools as well as CMF, all -- they're all double-digit growers. And so from quarter to quarter, as Tim mentioned, some are a little higher",78,"Yes. It's important to know all 3 of those groups. So Neurovascular is, of course, the biggest one, the neuro powered tools as well as CMF, all -- they're all double-digit growers. And so from quarter to quarter, as Tim mentioned, some are a little higher, some are a little lower. We had a 20% comp almost in the United States from the prior year, and we continue to grow strong double digits on top of strong comps."
94614,331567642,1011093,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Operator","Our next question comes from the line of Matthew O'Brien with Piper Jaffray.",14,"Our next question comes from the line of Matthew O'Brien with Piper Jaffray."
94614,331567642,1011093,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Analysts","Just with Tim in the room, I'd love to hear a little bit more about the MedSurg strength in the quarter. As you're integrating Sage and Physio, did you get any kind of benefit either from a sentiment [ph] perspective from hospitals about adding those busi",85,"Just with Tim in the room, I'd love to hear a little bit more about the MedSurg strength in the quarter. As you're integrating Sage and Physio, did you get any kind of benefit either from a sentiment [ph] perspective from hospitals about adding those businesses? And then as we think about things going forward on an organic basis now that you can bundle all of these things together, can you still deliver this mid- or even upper single-digit growth out of MedSurg going forward?"
94614,331567642,1011093,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","Well, to add a little bit of color, first, I would say we're delighted with the performance of our Medical division in the quarter that they delivered strong quarter growth while dealing with the challenges of these 2 large integrations. Their EMS busines",303,"Well, to add a little bit of color, first, I would say we're delighted with the performance of our Medical division in the quarter that they delivered strong quarter growth while dealing with the challenges of these 2 large integrations. Their EMS business did particularly well, and they performed nicely in their core bed and stretcher business. Endoscopy is having an excellent year. Their core visualization business is performing exceptionally well with the 1588 camera. The communications business is doing well, and the sports business is doing well there as well. I would point back to a couple of deals we did in 2014, Berchtold and Pivot. These both are kind of in the mainstream now of being integrated, and our team is fully in line with their products. So the Berchtold lights, booms and tables have sold well this year. The Pivot products have done very well in our hands as well. And over at Stryker Instruments, this has been a steady, strong performer over time. Their personal protection and fluid waste management businesses were real highlights in the quarter. We do expect a strong second half there as they'll be launching their Neptune 3 fluid waste management system in the coming days. So I think across the board, we were strong. I would also frankly note that Sustainability business had a strong quarter and they've done well at recent product launches. And importantly, reprocessed products from Stryker have been embraced as a high-quality solution by our hospital customers despite the fact that that's a challenging and difficult market. I would tell you that now, there wasn't really any sentiment in favor of Stryker as a result of these deals. But importantly, we've had strong execution across the board, good new product flow, and we're optimistic about the rest of the year."
94614,331567642,1011093,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Analysts","Helpful. And then just shifting over to the Trauma and Extremities business, still solid performance there, but on a 2-year stack basis, that growth rate did decelerate here at Q2 versus the last few quarters. Is there anything going on there competitivel",86,"Helpful. And then just shifting over to the Trauma and Extremities business, still solid performance there, but on a 2-year stack basis, that growth rate did decelerate here at Q2 versus the last few quarters. Is there anything going on there competitively of note that could prevent you from sustaining this share-taking position you've been in for a while and getting -- so outperforming the overall market growth rates? Or should we expect more kind of market growth rates from you and from Trauma and Extremities?"
94614,331567642,1011093,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","Well, we feel really pleased with the performance of both Trauma and Extremities businesses, but obviously, the Extremities base has gotten much bigger now. So you're looking at more challenging comparables that's still growing very solid double digits. A",93,"Well, we feel really pleased with the performance of both Trauma and Extremities businesses, but obviously, the Extremities base has gotten much bigger now. So you're looking at more challenging comparables that's still growing very solid double digits. And Trauma, we continue to see strong performance for that business as well. There hasn't been any meaningful change. We still feel good about the way those businesses are positioned, but obviously, the law of large numbers set's in and the comps become more difficult. But beyond that, no, there's nothing we'd really point to."
94614,331567642,1011093,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","Keep in mind, we did have an 18% comp in the United States in Trauma. So we had a really huge growth in the prior year and still strong growth. We still believe this is going to be a growth business for the company. So -- and it's just one quarter. It did",64,"Keep in mind, we did have an 18% comp in the United States in Trauma. So we had a really huge growth in the prior year and still strong growth. We still believe this is going to be a growth business for the company. So -- and it's just one quarter. It did decelerate a little bit but certainly a very impressive number nonetheless."
94614,331567642,1011093,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Operator","And our next question comes from the line of Joanne Wuensch with BMO Capital Markets.",15,"And our next question comes from the line of Joanne Wuensch with BMO Capital Markets."
94614,331567642,1011093,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Analysts","In looking at your Spine business, that accelerated a little bit last year, it seems, through innovation and some better execution but slowed down a little bit this year, year-to-date. How are you thinking about that in terms of internal versus external d",43,"In looking at your Spine business, that accelerated a little bit last year, it seems, through innovation and some better execution but slowed down a little bit this year, year-to-date. How are you thinking about that in terms of internal versus external development?"
94614,331567642,1011093,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","You're right. We have invested a lot in terms of the pipeline and launching new products. As we mentioned, we did have some system supply disruption that will continue into the second half here. As you know, we prioritize M&A across all the businesses, bu",111,"You're right. We have invested a lot in terms of the pipeline and launching new products. As we mentioned, we did have some system supply disruption that will continue into the second half here. As you know, we prioritize M&A across all the businesses, but we also invest in those businesses in order to be able to deliver results based on internal innovation and R&D. So don't think about that business any differently than other areas where we look at opportunities. As you know, we have BD people in all the divisions looking at targets but also assessing that around our opportunities to invest internally and grow the business organically."
94614,331567642,1011093,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","I would also -- just -- I'd just like to repeat that -- what was mentioned earlier that we did have some product disruptions in the quarter in our Spine business. The underlying business is in really solid shape. I feel great about the leadership team, th",73,"I would also -- just -- I'd just like to repeat that -- what was mentioned earlier that we did have some product disruptions in the quarter in our Spine business. The underlying business is in really solid shape. I feel great about the leadership team, the new products. We have some supply challenges, and that will continue in the third quarter and then it will start to improve in the fourth quarter."
94614,331567642,1011093,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Analysts","And then just to turn back to the gross margin moment, is there a way to peel this apart a little bit to understand the impact of some of the acquisitions or the recategorization may have had on that?",39,"And then just to turn back to the gross margin moment, is there a way to peel this apart a little bit to understand the impact of some of the acquisitions or the recategorization may have had on that?"
94614,331567642,1011093,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","Yes. I think if you think about sort of the sequential change from Q1 to Q2, acquisitions in total were roughly sort of half of that change. And that should continue through the rest of the year in terms of the total growth -- the impact on the total gros",51,"Yes. I think if you think about sort of the sequential change from Q1 to Q2, acquisitions in total were roughly sort of half of that change. And that should continue through the rest of the year in terms of the total growth -- the impact on the total gross margin."
94614,331567642,1011093,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","Joanne, just keep in mind when you get that hit at the gross margin, those are also lower SG&A businesses. So part of that big impact, the big SG&A decline as a percent of sales in the leverage, is a flip side of that, where you're seeing the benefit both",59,"Joanne, just keep in mind when you get that hit at the gross margin, those are also lower SG&A businesses. So part of that big impact, the big SG&A decline as a percent of sales in the leverage, is a flip side of that, where you're seeing the benefit both from a product mix as well as the reclassifications."
94614,331567642,1011093,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Operator","And our next question comes from the line of Glenn Navarro with RBC Capital Markets.",15,"And our next question comes from the line of Glenn Navarro with RBC Capital Markets."
94614,331567642,1011093,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Analysts","Two questions on ortho. First, ortho pricing down 2.2% in 2Q versus down 1.7% in 1Q, is there anything unusual happening there? Or is that just quarter-to-quarter fluctuations? And then on Robotics, you sold 7 in 1Q, up to 17 in 2Q. Maybe talk about the m",73,"Two questions on ortho. First, ortho pricing down 2.2% in 2Q versus down 1.7% in 1Q, is there anything unusual happening there? Or is that just quarter-to-quarter fluctuations? And then on Robotics, you sold 7 in 1Q, up to 17 in 2Q. Maybe talk about the momentum there. Were these outright sales? And what's the pipeline looking for -- looking like in terms of Robotic deals in the back end of the year?"
94614,331567642,1011093,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","Yes. So to take your -- the first question, no, I wouldn't read anything into 1.7% versus 2.2%. It's within the normal variability that we have historically seen, much like total pricing trending less negative but still within the range of that 1.5% to 2%",98,"Yes. So to take your -- the first question, no, I wouldn't read anything into 1.7% versus 2.2%. It's within the normal variability that we have historically seen, much like total pricing trending less negative but still within the range of that 1.5% to 2% that we think about. Yes, we're very pleased with the robot placements and the fact that we have the early observational studies underway in a limited launch. The order book looks strong. We're excited about the outlook there as we prepare -- as we talk about going to full commercial launch in '17."
94614,331567642,1011093,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Analysts","And then just a quick follow-up for Glenn or for you, Katherine. You had the extra selling day in 2Q. Is everything normal for 3Q and 4Q?",28,"And then just a quick follow-up for Glenn or for you, Katherine. You had the extra selling day in 2Q. Is everything normal for 3Q and 4Q?"
94614,331567642,1011093,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","Yes. So if you think about it, there was no difference in selling days in the first quarter, whether you look at it U.S., OUS, worldwide. Second quarter, we had one extra selling day, which equates to 1% impact overall on our businesses. And then Q3, Q4,",57,"Yes. So if you think about it, there was no difference in selling days in the first quarter, whether you look at it U.S., OUS, worldwide. Second quarter, we had one extra selling day, which equates to 1% impact overall on our businesses. And then Q3, Q4, there's no difference in selling days, U.S., OUS or worldwide."
94614,331567642,1011093,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Operator","And our next question comes from the line of Raj Denhoy with Jefferies.",13,"And our next question comes from the line of Raj Denhoy with Jefferies."
94614,331567642,1011093,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Analysts","A couple of questions, if I could. So the Spine product issue you had in the quarter, perhaps you could provide a little bit more about that. Was that related to the 3D products that you rolled out? Or was that something different?",43,"A couple of questions, if I could. So the Spine product issue you had in the quarter, perhaps you could provide a little bit more about that. Was that related to the 3D products that you rolled out? Or was that something different?"
94614,331567642,1011093,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","No. We're not going to get into too many details just for competitive reasons. We do have a supply disruption issue and some supply challenges. We'll work through those in the third quarter. We did highlight the titanium products, a lot of momentum around",81,"No. We're not going to get into too many details just for competitive reasons. We do have a supply disruption issue and some supply challenges. We'll work through those in the third quarter. We did highlight the titanium products, a lot of momentum around that and excited about what that product will do for that portfolio but not going to go into additional details other than to say you should assume the impact lingers into the second half of this year."
94614,331567642,1011093,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Analysts","Okay. And then just for my second question. Medtronic obviously made some noise in June about coming into the orthopaedic market. Curious if you've seen anything, one; and two, if you have any thoughts just around what Medtronic would mean for this market",43,"Okay. And then just for my second question. Medtronic obviously made some noise in June about coming into the orthopaedic market. Curious if you've seen anything, one; and two, if you have any thoughts just around what Medtronic would mean for this market."
94614,331567642,1011093,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","No. We haven't seen any impact, and they're obviously better positioned to talk about where they are in the launch or signing up customers. So to date, no, we don't have -- we don't see any impact. Obviously, we believe in the value of the rep and -- as w",83,"No. We haven't seen any impact, and they're obviously better positioned to talk about where they are in the launch or signing up customers. So to date, no, we don't have -- we don't see any impact. Obviously, we believe in the value of the rep and -- as well as innovation in this market, and we're really going to focus on just that. And the MAKO total knee launch, we think, has the opportunity to be truly disruptive in the reconstructive market."
94614,331567642,1011093,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Operator","And our next question comes from the line of Mike Matson with Needham & Company.",14,"And our next question comes from the line of Mike Matson with Needham & Company."
94614,331567642,1011093,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Analysts","I guess I just wanted to start with MAKO in thinking through the total knee full launch next year. I guess to what degree do you think the need to sell the very expensive capital equipment or the robots will kind of limit the growth -- or limit the rate a",84,"I guess I just wanted to start with MAKO in thinking through the total knee full launch next year. I guess to what degree do you think the need to sell the very expensive capital equipment or the robots will kind of limit the growth -- or limit the rate at which you can take market share in the knee market? And is there anything you can do to potentially speed up those placements in order to capture more of that knee implant share?"
94614,331567642,1011093,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","Yes. So we're selling the million-dollar robots right now. We did 17 this quarter, and that's before we've gone into full commercial launch for what we think is the biggest driver of value with the MAKO opportunity. And moreover, we've been selling very e",184,"Yes. So we're selling the million-dollar robots right now. We did 17 this quarter, and that's before we've gone into full commercial launch for what we think is the biggest driver of value with the MAKO opportunity. And moreover, we've been selling very expensive capital on our MedSurg businesses for literally years and years. So we understand how to sell capital. It is fundamentally different than selling implants or disposables, which is why we have a separate dedicated sales force. We also have, for a number of years now, had a Flex Financial Group within the Stryker organization. And our MAKO group is using that to leverage their expertise to offer different options to our customers, whether they want to buy outright or lease. And so that expertise that's been developed for a number of years through MedSurg is clearly enabling a different type of discussion with customers than was possible when MAKO was a stand-alone. So we feel really comfortable in our ability to sell capital and the value proposition that's driven by the different applications that will exist on the MAKO robot."
94614,331567642,1011093,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Analysts","I guess what I was getting at is if you came out with a new type of a knee implant, you could walk into an operating room and the doctor could switch to that new implant on day 1, whereas if they're going to switch to MAKO, they've got to convince the hos",78,"I guess what I was getting at is if you came out with a new type of a knee implant, you could walk into an operating room and the doctor could switch to that new implant on day 1, whereas if they're going to switch to MAKO, they've got to convince the hospital to buy a really expensive robot first. So that's going to kind of slow down the ability to take knee market shares, is it not?"
94614,331567642,1011093,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","Yes. To be able to do a robotic knee, you have to buy the robot. And it will be a closed system and can only use our knee. So that's part of the value proposition. So we go in and we have that discussion and articulate the benefits here. So this is very d",126,"Yes. To be able to do a robotic knee, you have to buy the robot. And it will be a closed system and can only use our knee. So that's part of the value proposition. So we go in and we have that discussion and articulate the benefits here. So this is very different than just simply coming out with a new knee and not having to buy capital. Yes, that's correct. But it's also very different in terms of the value that, we think, we'll bring forward and will start to get evidence of as we do these observational studies and look at benefits around less tissue disruption, improved alignment and a number of different factors that, we think, will help support the value proposition."
94614,331567642,1011093,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Analysts","All right. And then just if international growth were to improve, what would that do to your gross margin?",19,"All right. And then just if international growth were to improve, what would that do to your gross margin?"
94614,331567642,1011093,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","Generally, international flows through gross margin at roughly the same rate that we're experiencing on an average here. So it would roughly flow through about the 67%. It really depends sort of where internationally as well, too, because we -- certain em",64,"Generally, international flows through gross margin at roughly the same rate that we're experiencing on an average here. So it would roughly flow through about the 67%. It really depends sort of where internationally as well, too, because we -- certain emerging markets are better. European pricing impacts are usually higher. But up and down from the 67%, that's roughly a good ballpark estimate."
94614,331567642,1011093,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Operator","And our next question comes from the line of Kaila Krum with William Blair.",14,"And our next question comes from the line of Kaila Krum with William Blair."
94614,331567642,1011093,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Analysts","One Spine question and then one on the Medical business. First, I mean, what are you seeing sort of in the spine market probably from a competitive perspective? And really, I'm curious about your thoughts on -- you hear that multi-year robotics movement t",54,"One Spine question and then one on the Medical business. First, I mean, what are you seeing sort of in the spine market probably from a competitive perspective? And really, I'm curious about your thoughts on -- you hear that multi-year robotics movement that now several companies are talking about in that space specifically."
94614,331567642,1011093,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","Yes. We really like that many companies are talking more and more about robotics. I think that provides a real good tailwind for MAKO. We believe we have certainly the best system with haptics and really a terrific intellectual property. And so the more t",140,"Yes. We really like that many companies are talking more and more about robotics. I think that provides a real good tailwind for MAKO. We believe we have certainly the best system with haptics and really a terrific intellectual property. And so the more that robots become a positive word out in the medical technology community with our customers, I think that provides a real good tailwind for us on MAKO. We're not seeing anything new in the spine market. It's a tough market with many competitors. We like our ability to win in a market based on the innovations that we've been bringing forward over the last 2, 3 years. We did have our own challenges, as we've mentioned a couple of times in the call, related to some supply disruption but nothing really new from a competitive standpoint."
94614,331567642,1011093,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Analysts","Okay. And then just a follow-up on the recent acquisitions in the Medical business. I mean, just looking at the pro forma growth rates you gave us in the quarter, understanding we're obviously early in the integration process, but with that in mind, I mea",82,"Okay. And then just a follow-up on the recent acquisitions in the Medical business. I mean, just looking at the pro forma growth rates you gave us in the quarter, understanding we're obviously early in the integration process, but with that in mind, I mean, how do you expect those pro forma growth rates to trend in the coming quarters? I mean, should we expect modest dislocation before an acceleration or just consistent growth with a typical seasonality in Q3 and Q4?"
94614,331567642,1011093,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","Yes, I'd say -- I guess my answer would be consistent growth in Q3 and 4 tied to that, those numbers we cited of high single digits and double digits.",30,"Yes, I'd say -- I guess my answer would be consistent growth in Q3 and 4 tied to that, those numbers we cited of high single digits and double digits."
94614,331567642,1011093,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Operator","And our next question comes from the line of Larry Biegelsen with Wells Fargo.",14,"And our next question comes from the line of Larry Biegelsen with Wells Fargo."
94614,331567642,1011093,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Analysts","First, international. Kevin, I think you said last quarter, emerging markets were down in the high single digits in the first quarter. Was it similar in Q2? And by our math, Europe was also a little soft in Q1. How was Europe in Q2? And what's the outlook",55,"First, international. Kevin, I think you said last quarter, emerging markets were down in the high single digits in the first quarter. Was it similar in Q2? And by our math, Europe was also a little soft in Q1. How was Europe in Q2? And what's the outlook there? And I did have one follow-up."
94614,331567642,1011093,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","Yes. I'd say in emerging markets, it was a very similar story in Q2 as it was in Q1. It was just as bad a quarter. As it relates to Europe, Europe had a mid-single digit growth in the second quarter. So we were actually very pleased with the second quarte",74,"Yes. I'd say in emerging markets, it was a very similar story in Q2 as it was in Q1. It was just as bad a quarter. As it relates to Europe, Europe had a mid-single digit growth in the second quarter. So we were actually very pleased with the second quarter performance. Otherwise, there have been a little bit of softness in the first quarter and got back on track in the second quarter."
94614,331567642,1011093,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Analysts","That's helpful. And then for Tim, on the ischemic stroke market, could you talk a little bit about how that market's been developing in 2016 versus a strong 2015? In terms of patient numbers treated in the U.S., it was probably up 30%, 40% from about 12,0",71,"That's helpful. And then for Tim, on the ischemic stroke market, could you talk a little bit about how that market's been developing in 2016 versus a strong 2015? In terms of patient numbers treated in the U.S., it was probably up 30%, 40% from about 12,000 to 16,000, 17,000 last year. Is 2016 looking like as strong a year just from ischemic treatment -- endovascular treatment of ischemic stroke?"
94614,331567642,1011093,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","Yes. I think the growth trends have been similar this year and the last year and exact -- certainly further to this law of larger numbers and what have you. The growth rates arguably would diminish with time, but it continues to be a very robust market wi",56,"Yes. I think the growth trends have been similar this year and the last year and exact -- certainly further to this law of larger numbers and what have you. The growth rates arguably would diminish with time, but it continues to be a very robust market with very significant growth opportunities lying ahead of us."
94614,331567642,1011093,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Operator","And our next question comes from the line of Richard Newitter with Leerink Partners.",14,"And our next question comes from the line of Richard Newitter with Leerink Partners."
94614,331567642,1011093,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Analysts","I have 2. The first one, just a follow-up on the Robotics question and the competitive landscape. Just specifically with respect to Spine, can you talk to us a little bit about what your view is of spine robotics technologies in light of recent investment",91,"I have 2. The first one, just a follow-up on the Robotics question and the competitive landscape. Just specifically with respect to Spine, can you talk to us a little bit about what your view is of spine robotics technologies in light of recent investments that others are making there? And then I'm more just thinking if and when you potentially adapt a MAKO solution to Spine, how do -- what area or in what capacity do you think that could add value to the procedure? Then I have a follow-up."
94614,331567642,1011093,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","Yes. I think it is early right now. There's been a lot announced, but there hasn't been a whole lot launch. And so I think we're just going to have to wait and see. Do they truly facilitate making the procedure easier or enhancing the outcome? We do belie",102,"Yes. I think it is early right now. There's been a lot announced, but there hasn't been a whole lot launch. And so I think we're just going to have to wait and see. Do they truly facilitate making the procedure easier or enhancing the outcome? We do believe there's opportunity for Robotics when we look at MAKO and Spine, but it is not the focus right now. We are completely focused on the opportunity in recon and particularly gearing up for the total knee launch. So it's certainly something that we're going to evaluate, but near term, it's not the focus."
94614,331567642,1011093,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Analysts","Okay. And then just a second one. Someone asked a question earlier about Medtronic getting in into hips and knees eventually. I guess my question to you is -- Medtronic talked about a risk-sharing model. Can you talk a little bit about what, if anything,",65,"Okay. And then just a second one. Someone asked a question earlier about Medtronic getting in into hips and knees eventually. I guess my question to you is -- Medtronic talked about a risk-sharing model. Can you talk a little bit about what, if anything, Stryker is thinking about doing and potentially going at risk with the hospital and an episode of care payment situation?"
94614,331567642,1011093,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","Yes, we have done that. We've had our Stryker Performance Solution group within the company now for a number of years. They go at risk. We've got convener status under the prior program, where we're able to share with customers. And so this is something t",137,"Yes, we have done that. We've had our Stryker Performance Solution group within the company now for a number of years. They go at risk. We've got convener status under the prior program, where we're able to share with customers. And so this is something that, through that SPS, we've got a lot of institutional knowledge. We obviously have a very deep understanding around the reconstructive procedure, what the value drivers are through the entire episode of care both in the acute and the post-acute setting. So given our long history in ortho, we think we're well positioned on top of the expertise we developed over recent years through our Stryker Performance Solution to really go in and partner with customers and sometimes go at risk and others construct models that help them maximize the value chain."
94614,331567642,1011093,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","We just haven't talked about a lot since it's not an enormous part of our business, but we have the capability. We're already doing it, and we certainly are having more and more conversations with customers as the CJR rolls into effect.",43,"We just haven't talked about a lot since it's not an enormous part of our business, but we have the capability. We're already doing it, and we certainly are having more and more conversations with customers as the CJR rolls into effect."
94614,331567642,1011093,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Operator","Our next question comes from the line of Josh Jennings with Cowen and Company.",14,"Our next question comes from the line of Josh Jennings with Cowen and Company."
94614,331567642,1011093,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Analysts","I just wanted to follow up on, Kevin, your comments on Europe and stronger growth in Q2 from Q1. And I think this is the second quarter post the annualization of the Transatlantic model initiative. Are you still -- are you beginning to see more benefits i",90,"I just wanted to follow up on, Kevin, your comments on Europe and stronger growth in Q2 from Q1. And I think this is the second quarter post the annualization of the Transatlantic model initiative. Are you still -- are you beginning to see more benefits in Q2? And do you think we -- should we think about your European business continue to potentially accelerate or at least getting -- continue to get -- receive benefits from this Transatlantic model? I just wanted to see if there's an update there."
94614,331567642,1011093,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","Sure. So first, rather than just focus on the first quarter, I think we had a very successful year last year in the first year of the Transatlantic model, but it wasn't across every business. And we still have a number of businesses that are just really -",167,"Sure. So first, rather than just focus on the first quarter, I think we had a very successful year last year in the first year of the Transatlantic model, but it wasn't across every business. And we still have a number of businesses that are just really -- that have good growth in front of them. I highlighted Knees. I highlighted Instruments. And even part of our Endoscopy division still has significant growth. So to us, we look at Europe as being a growth market just given our relatively lower market shares, and we see it as a growth market for the next several years. So regardless of what's going on with Brexit or anything else, our relative low market share creates a big opportunity. And this model that we've implemented, we feel, is contributing to the growth that we're experiencing and will continue to deliver high growth or higher than we've experienced over the past decades in Europe. So it continues to be a growth market."
94614,331567642,1011093,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Analysts","Great. And just I had one follow-up on pricing. In the press release, you called out a 1.3% headwind in Q2. I was hoping to just get your thoughts on what you're seeing in the market. I know there's a lot of different subsegments within your business. But",89,"Great. And just I had one follow-up on pricing. In the press release, you called out a 1.3% headwind in Q2. I was hoping to just get your thoughts on what you're seeing in the market. I know there's a lot of different subsegments within your business. But I guess from a high level, how should we be thinking about the sustainability? Is this a new level? Is there anything to call out in the quarter? And just what you're seeing out in the market from a pricing standpoint."
94614,331567642,1011093,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","Yes. You -- if you look in the -- we break out the pricing. And it tends to be more negative in ortho versus MedSurg, but there's been no real change. Yes, it's trending slightly better or slightly look bad at 1.3% versus the 1.5% to 2% range that we fore",129,"Yes. You -- if you look in the -- we break out the pricing. And it tends to be more negative in ortho versus MedSurg, but there's been no real change. Yes, it's trending slightly better or slightly look bad at 1.3% versus the 1.5% to 2% range that we forecast. But we've also seen quarters not too far back where it trended a little bit worse then came in north of 2%. So it's within tenths of basis points of the range we're targeting, and there are so many variables between mix, both products as well as geographic, that play in there. But I wouldn't do this to some -- indicative of some new trend line. I think 1.5% to 2% is a good number to focus on."
94614,331567642,1011093,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Operator","And our next question comes from the line of Amit Hazan with Citi.",13,"And our next question comes from the line of Amit Hazan with Citi."
94614,331567642,1011093,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Analysts","This is Lee Preston [ph] on for Amit. I wanted to touch on 2 things for mix. It seems like some of your competitors' data for product mix has been -- pretty much ceased to be a positive tailwind. It's pretty much flat now. I know you guys used to talk abo",130,"This is Lee Preston [ph] on for Amit. I wanted to touch on 2 things for mix. It seems like some of your competitors' data for product mix has been -- pretty much ceased to be a positive tailwind. It's pretty much flat now. I know you guys used to talk about it in that kind of positive 2% range and it was offsetting price headwinds at about the same level. I realize you might not want to throw out a specific number, but directionally, are we still in the same ballpark for that product mix that we had been in the past several years or on that positive 2%? And what are your thoughts on sustainability at positive product mix going forward? This is for Hips and Knees, specifically."
94614,331567642,1011093,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","Okay. When we report price -- and I know some companies do it one way, some companies do it the other, we report pure price. And then our -- the other number is volume and mix together. So price is negative -- pure price negative in ortho. And it is offse",81,"Okay. When we report price -- and I know some companies do it one way, some companies do it the other, we report pure price. And then our -- the other number is volume and mix together. So price is negative -- pure price negative in ortho. And it is offset obviously by volumes and to a lesser degree by mix. There hasn't been a big change in that in recent years in terms of the overall impact of those items."
94614,331567642,1011093,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Analysts","Okay. And then I have one follow-up. If you think about CJR next year, do you expect your mix of standard versus premium implant to change at all within your CJR customers for Hips and Knees?",36,"Okay. And then I have one follow-up. If you think about CJR next year, do you expect your mix of standard versus premium implant to change at all within your CJR customers for Hips and Knees?"
94614,331567642,1011093,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","I think it's early. We'll see what happens next year when they start to go into the penalty phase. Again, we really believe, based on all our research, that the focus there is going to be much more in the post-acute setting since 50% to 60% of the cost li",104,"I think it's early. We'll see what happens next year when they start to go into the penalty phase. Again, we really believe, based on all our research, that the focus there is going to be much more in the post-acute setting since 50% to 60% of the cost lie there for the total procedure, and there's tremendous opportunity to take cost out when you look at the post-acute setting and the number of patients who get discharged to a rehab facility versus home care. That's where we think the biggest focus is going to be because that's where the biggest dollars are."
94614,331567642,1011093,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Operator","Our next question comes from the line of Matt Taylor with Barclays.",12,"Our next question comes from the line of Matt Taylor with Barclays."
94614,331567642,1011093,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Analysts","I was wondering if you could just comment, reflecting on the first half, just on utilization more broadly, are you seeing anything different in the U.S. market [indiscernible] was stronger than you'd expect? Or are you guys are seeing good execution in pr",45,"I was wondering if you could just comment, reflecting on the first half, just on utilization more broadly, are you seeing anything different in the U.S. market [indiscernible] was stronger than you'd expect? Or are you guys are seeing good execution in product update [indiscernible]?"
94614,331567642,1011093,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","Yes, there's been no real change in utilization. Obviously, Hip utilization was a little bit lower in the U.S. in the second quarter. But no, there has been no overall change in underlying demand across the businesses. It does vary bit to bit. Obviously,",62,"Yes, there's been no real change in utilization. Obviously, Hip utilization was a little bit lower in the U.S. in the second quarter. But no, there has been no overall change in underlying demand across the businesses. It does vary bit to bit. Obviously, the demand is going to be greater in something like ischemic. But no, there's been no fundamental change."
94614,331567642,1011093,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Analysts","And once you get through the drawdowns in China, what kind of growth do you expect for your businesses in that market? Or what visibility do you have on the end markets out there?",34,"And once you get through the drawdowns in China, what kind of growth do you expect for your businesses in that market? Or what visibility do you have on the end markets out there?"
94614,331567642,1011093,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","I think we'll have a better sense once we get through that. We're focused right now on really getting to appropriate inventory level and getting a much better sense of end user demand because there is this distributor layer there. So it's difficult to pre",106,"I think we'll have a better sense once we get through that. We're focused right now on really getting to appropriate inventory level and getting a much better sense of end user demand because there is this distributor layer there. So it's difficult to predict right now. The comps get easier in the second half, but beyond that, we just don't have the visibility to say what true [ph] end market demand is going to be. If we'd start to get better visibility into the channel, we'll be able to share that with you, but it'd be premature right now to throw a number out."
94614,331567642,1011093,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","And the area that's sort of the most hard to predict is capital equipment. I think on the disposables and the implant side of the business, we see that sort of -- that still -- those markets are actually still fairly healthy, and we expect that to continu",51,"And the area that's sort of the most hard to predict is capital equipment. I think on the disposables and the implant side of the business, we see that sort of -- that still -- those markets are actually still fairly healthy, and we expect that to continue going forward."
94614,331567642,1011093,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Operator","And our next question comes from the line of Matt Miksic with UBS.",13,"And our next question comes from the line of Matt Miksic with UBS."
94614,331567642,1011093,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Analysts","So one follow-up on Orthopaedic growth from Q1 to Q2. And I guess when we do the math on J&J's numbers, just looking at knees in the U.S. and adjust for selling days, adjust for price, it was a deceleration from Q1 to Q2. And you clearly, a, you've accele",135,"So one follow-up on Orthopaedic growth from Q1 to Q2. And I guess when we do the math on J&J's numbers, just looking at knees in the U.S. and adjust for selling days, adjust for price, it was a deceleration from Q1 to Q2. And you clearly, a, you've accelerated; and b, you're also just growing at a higher rate. But I'm curious, is that -- feel in the marketplace, do you like share gains in terms of accounts or mind share somehow? Or do you get the sense at all that there was -- what the overall market was like? I know this is an end of 2 [ph], but just love to get what your perspective is on their deceleration and your, sort of, call it, modest acceleration after adjusting for days."
94614,331567642,1011093,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","Yes. So this is really our fourth really good performance in this -- fourth quarter in a row of really strong performance. And we tend to attribute that much more to the launch of our cementless cones, and the cementless knee business are really picking u",143,"Yes. So this is really our fourth really good performance in this -- fourth quarter in a row of really strong performance. And we tend to attribute that much more to the launch of our cementless cones, and the cementless knee business are really picking up, so our 3D-printed products. We really believe that that's a big part of this. And we also get a bit of a MAKO halo impact. So not specifically just the volume that's coming from our unis [ph], but also, wherever we put MAKO, we tend to drive a higher mix of our business. So rather than comment on one particular competitor, I would just point out that our businesses really picked up. And it's been multiple quarters now in a row of strong performance really linked, I believe, to new products and the halo impact of MAKO."
94614,331567642,1011093,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Analysts","Great. And then just one follow-up, if I could. I have a feeling the answer is going to be, it's early around bundled payments. But speaking of folks in the field and working at some of these hospitals either through BPCI or starting to consider how to ta",134,"Great. And then just one follow-up, if I could. I have a feeling the answer is going to be, it's early around bundled payments. But speaking of folks in the field and working at some of these hospitals either through BPCI or starting to consider how to tackle CJR, there is some thinking that there are centers that are just going to look at this and say, ""We don't do enough of these procedures maybe to keep doing hips and knees."" And maybe start shifting those procedures elsewhere in the network or upstream somehow. Again, I know it's early, but could you give some perspective on how you think that may play out in the market given so much of the volume in orthopaedics in the U.S. is done by sort of lower-volume centers?"
94614,331567642,1011093,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","Yes. It is early. So it's an accurate comment. Could we see in some hospital a shift? It's possible and -- but I think it's too early to say that that's going to be a discernible enough trend or how it impacts the volumes of hospitals, where it shifts to,",82,"Yes. It is early. So it's an accurate comment. Could we see in some hospital a shift? It's possible and -- but I think it's too early to say that that's going to be a discernible enough trend or how it impacts the volumes of hospitals, where it shifts to, to make any big comments on it. I'm sorry. We just don't have more insights yet given the early stage combined with the fact that there's no penalty in the first year."
94614,331567642,1011093,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Operator","There are no further questions at this time. I will now turn the conference back over to Mr. Kevin Lobo for any closing remarks.",24,"There are no further questions at this time. I will now turn the conference back over to Mr. Kevin Lobo for any closing remarks."
94614,331567642,1011093,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Executives","So thank you all for joining our call. Our conference call for the third quarter 2016 results will be held on October 27. Also, our analyst meeting and product fair will be held on November 9 at our Orthopaedics headquarters in Mahwah, New Jersey. Thank y",46,"So thank you all for joining our call. Our conference call for the third quarter 2016 results will be held on October 27. Also, our analyst meeting and product fair will be held on November 9 at our Orthopaedics headquarters in Mahwah, New Jersey. Thank you."
94614,331567642,1011093,"Stryker Corporation, Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Stryker Corporation","Operator","Thank you, ladies and gentlemen. This concludes today's conference. Thank you for participating. You may now disconnect.",17,"Thank you, ladies and gentlemen. This concludes today's conference. Thank you for participating. You may now disconnect."
94614,377148003,1063970,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Operator","Welcome to the Third Quarter 2016 Stryker Earnings Call. My name is Crystal, and I will be your operator for today's call. [Operator Instructions] This conference call is being recorded for replay purposes. Before we begin, I would like to remind you",134,"Welcome to the Third Quarter 2016 Stryker Earnings Call. My name is Crystal, and I will be your operator for today's call. [Operator Instructions] 
This conference call is being recorded for replay purposes. 
Before we begin, I would like to remind you that the discussions during this conference call will include forward-looking statements. Factors that could cause actual results to differ materially are discussed in the company's most recent filings with the SEC. Also, the discussions will include certain non-GAAP financial measures. Reconciliations to the most directly comparable GAAP financial measures can be found in today's press release that is an exhibit to Stryker's current report on Form 8-K filed today with the SEC. 
I will now turn the call over to Mr. Kevin Lobo, Chairman and Chief Executive Officer. You may proceed, sir."
94614,377148003,1063970,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Executives","Welcome to Stryker's Third Quarter Earnings Call. Joining me today are Glenn Boehnlein, Stryker's CFO; and Katherine Owen, VP of Strategy and Investor Relations.For today's call, I will provide opening comments, followed by Katherine with an update on M",315,"Welcome to Stryker's Third Quarter Earnings Call. Joining me today are Glenn Boehnlein, Stryker's CFO; and Katherine Owen, VP of Strategy and Investor Relations.
For today's call, I will provide opening comments, followed by Katherine with an update on MAKO and our November analyst meeting. Glenn will then provide additional details regarding our quarterly results before we open the call for Q&A. 
We achieved another quarter of solid organic sales growth coming in at 6.2% and fueled by a strong showing for both MedSurg and Neurotechnology, with both delivering roughly 7% increases.
Orthopaedics growth was consistent at approximately 5% organically. On a geographic basis, Q3 sales were balanced with a 6% increase in the U.S. and a 6.7% gain in international, driven by strong momentum in Europe and a return to growth in emerging markets.
We are pleased with the performance of our acquisitions, including both Sage and Physio-Control, which are well positioned to help us drive stronger organic sales growth for Stryker in the coming years.
A strong top line performance, coupled with our ongoing focus on G&A leverage, resulted in an EPS of $1.39, up 11.2% and $0.01 above the high end of our target range. Based on our performance for the first 9 months of 2016, we are confident in our ability to deliver on our commitments, with organic sales growth for the full year expected at 6% to 6.5%. We are narrowing our adjusted EPS range to the upper end, which now stands at $5.75 to $5.80 per share. Overall, we believe the strength of our people, diversified revenue model and new product flow positions us well to continue to deliver sales at the high end of med tech, with leveraged earnings gains. 
We look forward to providing our 2017 financial guidance on our Q4 earnings call in January.
With that, I will now turn the call over to Katherine."
94614,377148003,1063970,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Executives","Thanks, Kevin. My comments on today's call will include an update on MAKO as well as a preview of our upcoming analyst meeting. Starting with MAKO. Results in the quarter were strong with a total of 30 robots installed globally, representing a roughly 7",437,"Thanks, Kevin. My comments on today's call will include an update on MAKO as well as a preview of our upcoming analyst meeting. 
Starting with MAKO. Results in the quarter were strong with a total of 30 robots installed globally, representing a roughly 75% year-over-year increase with 23 in the U.S. Consistent with prior quarters, approximately 40% of the installations were in competitive accounts where Stryker has no or relatively low market share. Demand for the MAKO robot is being fueled by the expanded indications, including the Total Knee, which began a limited launch in June. Since that time, we have had KOL surgeons trained on the robots for the Total Knee, including those with prior robot experience but with less exposure to our triathlon knee as well as surgeons who had not previously used a robot for joint reconstruction. As we discussed previously, by observing both these groups, we are optimizing the training protocol. 
Of note, since the start of the limited market really for the Total Knee, over 200 cases have been performed, and we've been pleased with the results to date. We are targeting the 2017 AAOS meeting to move into the full commercial launch. 
I will now shift to the analyst meeting, which will be held on November 9 at our Orthopaedics headquarters in New Jersey. In order to optimize utility of this meeting, we will be focusing the formal part of the meeting on several key areas. This will include a MAKO physician panel with 2 surgeons who have been part of the limited market release. We will also have a Stryker Performance Solutions panel, which will include an XPS customer and focus on how we've been able to deploy our expertise in the joint reconstruction episode of care to help reduce our procedural costs. 
Turning to cost transformation for growth. Lonny Carpenter, Group President of Global Quality and Operations, will provide an update on the various initiatives within CTG, including the expected financial contribution over the next 2 [ph] years. Glenn will provide a financial update, including our longer-term targets. We will conclude the formal part of the meeting with a Q&A session with the leadership team. We will then move to the product fair, which will include product highlights for MedSurg & Neurotechnology and opportunity to interact in formerly with the broader Stryker leadership team.
We hope you will be able to join us for the meeting. The event details at the pin agenda, including the various guest speakers and their backgrounds, are available on the event registration site. 
With that, I will now turn the calll over to Glenn."
94614,377148003,1063970,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Executives","Thanks, Katherine. Today I will focus my comments on our third quarter financial results and performance drivers. Our detailed financial results have been provided in today's press release. Our organic sales grew 6.2% in the quarter, which was within ou",1056,"Thanks, Katherine. Today I will focus my comments on our third quarter financial results and performance drivers. Our detailed financial results have been provided in today's press release. 
Our organic sales grew 6.2% in the quarter, which was within our range of full year expectations of 6% to 6.5%, with no difference in selling days. Pricing in the quarter was down 1.3% from the prior year, while foreign currency exchange had a nominal impact on sales. 
U.S. sales continued to demonstrate strong momentum, with organic growth of 6%, reflecting solid performances across our portfolio, especially in MedSurg and Neurotech. International sales grew 6.7 organically, highlighted by solid gains in Europe, Canada and Australia, somewhat offset by the continued impact of our previously discussed destocking issues in China. We expect that the fourth quarter will show some improvement in our China business, as prior year comparables continue to ease. 
Our adjusted EPS of $1.39 increased 11.2% [ph] from the prior year, reflecting strong sales growth, accretive acquisitions and good operating expense control. Our third quarter EPS was negatively impacted by $0.03 related to transactional foreign currency exchange. 
Focusing on our segment highlights. Orthopaedics delivered constant currency growth of 5.3% and organic growth of 4.8%, led by the U.S. organic growth of 4.7%. These gains reflect solid performances in Trauma and Extremities at 6.9% and Knees and 5.1%. This growth reflects strong demand for our 3D-printed products, our Foot & Ankle portfolio and our MAKO platform, which had 30 units installed, including 7 outside the U.S. Orthopaedics international delivered constant currency growth of 6.3% and organic growth of 5.1%, led by our European business. 
MedSurg posted strong gains across all businesses in the quarter, with constant currency growth of 33% and organic gains of 7.3%, which included a 7.7% increase in the U.S. 
Instruments, which was up 5.2% in the U.S., maintained good momentum with its waste management business and the newly launched Neptune 3 and continued strong performance related to its Navigation business.
Endoscopy delivered U.S. growth of 10.4%, driven by strong double-digit performances of its camera and light source products and strong gains in its communications, sports medicine and ProCare service businesses. 
Our Medical division had U.S. organic growth of 6.8%, driven by double-digit growth of its core bed and power cut products. On a comparable basis, Medical's Physio business was up 6.3%. Its Sage business grew 12.5%, including the impact of the recent recall. Excluding this, Sage grew 15%. We are pleased with these results and the ongoing integration efforts at Medical. 
Internationally, MedSurg organic sales growth was 6%, which reflects strong European and Australian sales and some easing of the MedSurg comparable in China. 
Neurotechnology and Spine continues to drive of above-market performance with constant currency growth of 8.7% and organic growth of 6.9%. This growth reflects continued strong demand for our Neurotech products. 
U.S. Neurotech posted growth of 9.1% in the quarter, highlighted by our AAS product and our Neuro Powered Instruments. 
Our Spine business in the U.S. continued to see some supply issues, offset somewhat by strong demand for our 3D-printed interbody Tritanium products. As I have said last quarter, we expect the supply issues to remain into the fourth quarter.
Internationally, Neurotech had constant currency growth of 16.7%. This performance was driven by continued strong demand for our Trevo Stentriever and Target Coil products in Europe and Asia. 
Spine's international growth was 1.6% and was impacted by the aforementioned supply issues and challenges in China. 
Now I will focus on the operating highlights within the quarter. Our gross margin which, on an adjusted basis, was 66.3%, was down 60 basis points from the prior year quarter. Gross margin was favorably impacted by absorption and productivity gains, which was offset by mix, including the impact of acquisitions and foreign currency exchange. 
SG&A for the third quarter was 34.9% of sales on an adjusted basis, which was favorable by 70 basis points as compared to the prior year quarter. This improvement reflects favorable leverage from continued focus on operating expense improvement through our CTG program, cost-containment efforts and business mix, including leverage from our recent acquisitions. 
We continue to invest in internal innovation with R&D, which is up 10 basis points year-over-year to 6.5% of sales. 
In total, adjusted operating expenses at 41.4% of sales was favorable 60 basis points to the prior year quarter, and these results continue to reflect our focus on leverage growth.
In summary, our operating margin was 24.9% of sales in Q3, flat year-over-year but up 64 basis points on a year-to-date basis. This performance reflects the positive results from our various CTG programs, continued cost control and favorable accretion from acquisitions, offset by business mix, pricing and foreign exchange.
Lastly, I will provide some highlights on other income and expense. Other expenses increased due to the higher net interest expense related to increased borrowings at the end of the first quarter. During the third quarter, we also paid down $750 million of debt, and accounting for the impact of this, we anticipate our future quarterly run rate of interest expense to be approximately $65 million.
Our third quarter adjusted effective tax rate of 17.5% reflects the benefits of our global tax structure, partially offset by the impact of higher U.S.-based income from our recent acquisitions.
Moving on to the balance sheet. We continue to maintain a strong balance sheet with $3 billion of cash and marketable securities, of which approximately 80% was held outside the U.S. Total debt on the balance sheet at the end of the second quarter was $6.8 billion. 
Turning to cash flow. Our year-to-date cash from operations was approximately $1.2 billion. Finally, as we have previously announced at the end of Q1, we have suspended our share repurchases for the remainder of 2016.
In terms of guidance, we reconfirm our previous full year organic sales growth range of 6% to 6.5% for 2016.
If foreign currency exchange rates hold near current levels, we expect a neutral impact in the fourth quarter and a negative foreign currency impact of less than 0.5% for the full year.
Lastly, our guidance for adjusted net earnings per diluted share in 2016 is now expected to be in the range of $5.75 to $5.80 for the full year. 
And now I will open up the call for Q&A."
94614,377148003,1063970,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Operator","[Operator Instructions] And our first question comes from Bob Hopkins from Bank of America.",14,"[Operator Instructions] 
And our first question comes from Bob Hopkins from Bank of America."
94614,377148003,1063970,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Analysts","So I have 2 questions. One, I'll start with you, Kevin. I was encouraged to hear your comments about emerging markets and turning back to the positive there. So maybe you could just kind of lay out specifically what improved and what you think the prospec",88,"So I have 2 questions. One, I'll start with you, Kevin. I was encouraged to hear your comments about emerging markets and turning back to the positive there. So maybe you could just kind of lay out specifically what improved and what you think the prospects are for your emerging market growth. Now that you have kind of turned the corner, can we get back to mid- to high single digits in a reasonable timeframe for emerging markets? Just want to here a little more color on EM."
94614,377148003,1063970,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Executives","Yes, sure. So outside of China, I would say, I'm really encouraged by the progress in India, which is really a continuation of what we've been experiencing the past few quarters. Brail returned to growth, and as you know, Brazil has been a very challengin",196,"Yes, sure. So outside of China, I would say, I'm really encouraged by the progress in India, which is really a continuation of what we've been experiencing the past few quarters. Brail returned to growth, and as you know, Brazil has been a very challenging market for us over the past year or 2. And we also had good results in Russia, Turkey. So  it was really across the board. Our other emerging market countries performed very well. So China's still a bit of a lagger, but as Glenn mentioned in his prepared remarks, we expect China to return to growth in the fourth quarter. So we're starting to see an improvement. Part of this is really the comparables that we're sort of lapping the years of sort of corporate performance. So we would expect a bit of a turnaround. But I -- it's really early. It's only 1 quarter, but I'm starting to see a trend that we will see growth. Now whether we'll get back to double-digit as we experienced in prior years, it's a little early for me to say, but certainly, look more positive than it has been over the past year."
94614,377148003,1063970,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Analysts","Okay. And then for Katherine, as a follow-up, just on your comments on the Analyst Day and MAKO. On the Analyst Day, can you just -- I know you're not giving guidance till the fourth quarter, but what will you be quantifying at the Analyst Day in some of",85,"Okay. And then for Katherine, as a follow-up, just on your comments on the Analyst Day and MAKO. On the Analyst Day, can you just -- I know you're not giving guidance till the fourth quarter, but what will you be quantifying at the Analyst Day in some of these prepared commentary? Will there be any quantification of cost savings or long-term margin opportunities? Just want to make sure I have a good understanding of exactly what we're going to get at the Analyst Day."
94614,377148003,1063970,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Executives","Yes. In addition to the panels, I focused on MAKO and SPS, Lonny will be giving a CTG update, which will include a greater quantification and visibly around the long-term potential from the cost savings that we're targeting. And then Glenn will be giving",87,"Yes. In addition to the panels, I focused on MAKO and SPS, Lonny will be giving a CTG update, which will include a greater quantification and visibly around the long-term potential from the cost savings that we're targeting. And then Glenn will be giving an update with some of our longer-term financial targets. We'll go into the full detail of that after Analyst Day. But also to be clear, we won't be giving 2017 guidance ranges, the formalization of our target until the January fourth quarter call."
94614,377148003,1063970,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Operator","Our next question comes from Rick Wise from Stifel.",9,"Our next question comes from Rick Wise from Stifel."
94614,377148003,1063970,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Analysts","Maybe I'll also start with MAKO. You always had an exceptionally strong quarter. Maybe, Kevin or Katherine, you could give us a little more color there. Maybe just sort of multipart question on this. What kind of pull-through are you seeing for Stryker pr",91,"Maybe I'll also start with MAKO. You always had an exceptionally strong quarter. Maybe, Kevin or Katherine, you could give us a little more color there. Maybe just sort of multipart question on this. What kind of pull-through are you seeing for Stryker products, particularly in competitive accounts? And maybe talk a little more, if you could, about some of the data surrounding -- clinical data surrounding MAKO we might see. I know that's been a prio for this year. What might be seen? And when will we see it?"
94614,377148003,1063970,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Executives","Yes, I think, obviously, the 30 robots placed, we're very pleased with that, that number of installations. We're also pleased that they are going into roughly 40% into competitive accounts. It's also what is helping drive our Knee growth, which, I believe",227,"Yes, I think, obviously, the 30 robots placed, we're very pleased with that, that number of installations. We're also pleased that they are going into roughly 40% into competitive accounts. It's also what is helping drive our Knee growth, which, I believe, is above market and, I mean, clearly is a big focus for our sales force right now, given their excitement around that. We do believe qualitatively, we're going to get continued to receive feedback around benefit, including alignment, tissue disruption and, ultimately, patient satisfaction. Longer term, clinical data on that is going to take us time to collect. We will be garnering that, but that's going to be 1-, 2-, 3-year data and obviously will take that long. I think it'll be a great opportunity at the panel at the Analyst Day where we're going to have a surgeon who had no experience with a robot prior to becoming part of the limited market release of the knee, as well as a longer-term robot user to ask those questions and hear what their experiences has been. But with the 200 cases to date, we've been really pleased with what we see so far and the ability both get into competitive accounts and optimize the training protocol. I had a full commercial launch which as we said will take place in March at The Academy meeting."
94614,377148003,1063970,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Analysts","Great. Just a follow-up on Sage and Physio briefly. Maybe just highlight -- I know we'll hear more soon, but where are we in terms of the integration and cost in sales? Kevin, you feel like you're on plan. Sage grew faster than the second quarter; physio,",63,"Great. Just a follow-up on Sage and Physio briefly. Maybe just highlight -- I know we'll hear more soon, but where are we in terms of the integration and cost in sales? Kevin, you feel like you're on plan. Sage grew faster than the second quarter; physio, a tad lower. I assume that's seasonal. But again, any more color there will be welcome."
94614,377148003,1063970,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Executives","Yes. Thanks, Rick. So first of all, over the full 6-month period, we're really pleased with both companies' performance. They're really line with our expectations. The integrations are going very well. As you know, Sage's we call it more a letter integrat",129,"Yes. Thanks, Rick. So first of all, over the full 6-month period, we're really pleased with both companies' performance. They're really line with our expectations. The integrations are going very well. As you know, Sage's we call it more a letter integration, given that there's less of an overlap with the call point. But certainly, we're sharing leads with the Sage organization. And Physio, we have a little bit more of overlap. It's really more of a planning phase this year. Sales forces are running independently this year. And over the course of the next year or 2, we'll start to integrate those sales forces. But I would stay, so far so good on an integration, and we're pleased with the performance and, really, the outlook for the future."
94614,377148003,1063970,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Operator","Our next question comes from Mike Weinstein from JPMorgan.",9,"Our next question comes from Mike Weinstein from JPMorgan."
94614,377148003,1063970,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Analysts","Katherine, the September health care conferences proved a bit trickier this year. And there was a bunch of questions, as you know, come out of them where people are asking about comments that you guys have made so maybe I thought speak the opportunity to",169,"Katherine, the September health care conferences proved a bit trickier this year. And there was a bunch of questions, as you know, come out of them where people are asking about comments that you guys have made so maybe I thought speak the opportunity to clarify a couple of them. And Katherine, Kevin chime in here. 2 sets of comments were Kevin just about your outlook for the Trauma business and the Hip business and some potential deceleration in growth there. And then naturally, people try to get you to comment on 2017 preliminary and have to think about operating and financial leverage, excluding the impact of the acquisitions. There seems to be some confusion around that. So maybe just want to spend a minute on both the outlook for the Trauma and then the Hip business in light of all the focus on the Knee side and then just comment, if you would, about how we should think about operating leverage heading into '17 without, obviously, giving guidance."
94614,377148003,1063970,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Executives","Sure, Mike. I'll take the Trauma and the Hip question, and then I'll pass it over to Katherine to talk about, I think, some perceptions about 2017. So what I've been saying for some time on the Trauma business is that sustaining 15% growth year-over-year",308,"Sure, Mike. I'll take the Trauma and the Hip question, and then I'll pass it over to Katherine to talk about, I think, some perceptions about 2017. So what I've been saying for some time on the Trauma business is that sustaining 15% growth year-over-year is pretty unlikely. We've done that for over 3 years coming to this year. If you look at last year's third quarter, we grew 15.1% in the U.S. And so to put up a 7% growth against that comp is still a pretty solid performance. But not a big numbers as we've been submitting that Trauma will start to slow down a little bit in terms of its growth rate but certainly performing above market and I think still a strong solid performance this quarter. But the only signal there is that sustaining that level of outperformance 3x the market is not likely to do indefinitely. So no concerns. We have a very strong Trauma leadership team, strong business, strong pipeline, so very bullish about that division. As it relates to Hips, we are longer in our product cycle, with Accolate II being one of the newer product that we launched a few years ago. And a lot of excitement in knees. And as you know, same sales force that sells both Hips and knees, we have a big launch upcoming with MAKO Total Knee. We have a lot of cementless products in the Knee portfolio. So I would say that there's been a bit of attention focused on these, and we've seen this in our industry for decades that it's very difficult to be able to focus on both products equally. So the fact that our Hip growth, which have been above-market for about 3 or 4 years, is now moving, let's say, more in line with market is not also surprising."
94614,377148003,1063970,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Executives","Yes, just going back to some of the misperceptions around some of the conferences and health the conference is in September. I will tell you, candidly, we were surprised as anybody that there was misperception. We try to be very consistent in terms of our",172,"Yes, just going back to some of the misperceptions around some of the conferences and health the conference is in September. I will tell you, candidly, we were surprised as anybody that there was misperception. We try to be very consistent in terms of our goal of growing sales at the high end of med tech. We think the med tech markets are largely stable, at least for segments where our product portfolio competes. But as Kevin said, in his prepared comments, start of this call, we feel really good about our ability to continue to deliver that. The specific range around that in which may have been somewhere of the misperceptions came, we will talk about in January, as we do every year. So to the degree unwillingness to give guidance ahead of when we normally do it caused some concern, I think that was incorrect. We feel great about the momentum and the product portfolio, and we'll look to specific -- specify that in terms of financial ranges in January."
94614,377148003,1063970,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Analysts","Katherine, just one follow-up, if I can. The growth in MAKO this quarter and the units sold their place, was that to -- just to characterize, was that to the beta sites that have been doing the, call it, early launch feedback for you guys? Or is that the",53,"Katherine, just one follow-up, if I can. The growth in MAKO this quarter and the units sold their place, was that to -- just to characterize, was that to the beta sites that have been doing the, call it, early launch feedback for you guys? Or is that the centers anticipating the launch?"
94614,377148003,1063970,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Executives","It's both. Some of those are to those that are part of the limited market release, but that's a small group. Some of those are just, for lack of a better word, putting it in the Q because they want to be part of the upgrades and ready for the total launch",71,"It's both. Some of those are to those that are part of the limited market release, but that's a small group. Some of those are just, for lack of a better word, putting it in the Q because they want to be part of the upgrades and ready for the total launch. So it's a mix, but it is, I would say, that limited market release customers are the minority."
94614,377148003,1063970,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Operator","Our next question comes from David Lewis from Morgan Stanley.",10,"Our next question comes from David Lewis from Morgan Stanley."
94614,377148003,1063970,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Analysts","Just 2 quick questions, one for Kevin, one for Katherine. Kevin, just you've got a wide range of businesses now is you're back above [ph] 6% organic this quarter, and I agree with Mike, that was nice to see. I wondered if you could just comment, just give",161,"Just 2 quick questions, one for Kevin, one for Katherine. Kevin, just you've got a wide range of businesses now is you're back above [ph] 6% organic this quarter, and I agree with Mike, that was nice to see. I wondered if you could just comment, just given the broader environment particular quarter, couple of things. One, just your capital business very strong. There's some emerging concern that the election cycle is going to result in some capital freeze and result in that months in September and October heading the election cycle to just part of capital environment heading into election, are you seeing any change in sort of relative backlogs? And then utilization, sort of a similar question, a lot of talk about polarization from July, August versus September. I mean, do you see a change how is a position trend in some of the Orthopaedic business is across the quarter? And then I had a quick one for Katherine."
94614,377148003,1063970,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Executives","Yes, so thanks, David. What I would call tell you is we haven't seen really any change in the capital. It's been extremely stable. The election to us is really a nonevent in terms of the businesses that we participate in. As you know, there's a lot of att",128,"Yes, so thanks, David. What I would call tell you is we haven't seen really any change in the capital. It's been extremely stable. The election to us is really a nonevent in terms of the businesses that we participate in. As you know, there's a lot of attention being drawn into pharma, a lot of commentary about pharma. The med tech is very small percent of the overall health care spend, and we're not seeing really an impact whatsoever. And as it relates to procedural volume, again, we didn't see anything unusual within the month of the quarter, very, very stable market. And that's not new. The market has been stable for the past 2 years, 3 years, and we continue to perform well in this market."
94614,377148003,1063970,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Analysts","Okay. Kevin, I want to ask you who you're voting for. Kevin -- sorry, Katherine, in terms of back half '17, you said MAKO is unlikely we see share movement till back half '17. In the early I just think about it the biggest year-on-year system add you've h",91,"Okay. Kevin, I want to ask you who you're voting for. Kevin -- sorry, Katherine, in terms of back half '17, you said MAKO is unlikely we see share movement till back half '17. In the early I just think about it the biggest year-on-year system add you've had, I think, since you bought the company. You've got 40% competitive accounts, and obviously, you got a very large U.S. Is the back half of '17 still the earliest that we can start to see share of movement in the Knee channel?"
94614,377148003,1063970,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Executives","I think that's the way to think about it right now. Remember, these robots how to get installed and that takes time and energy and people. We have to train. And so there's a cadence. This is not like an easy product that you launch overnight, and then it",112,"I think that's the way to think about it right now. Remember, these robots how to get installed and that takes time and energy and people. We have to train. And so there's a cadence. This is not like an easy product that you launch overnight, and then it runs. So we need to be thoughtful in that regard we can target Academy for the full commercial launch, and we'll be well prepared to go out and training from there. But I still think that cup of the year is the best time to be focused on in terms of starting to see indications that we're gaining meaningful knee market share."
94614,377148003,1063970,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Operator","Our next question comes from Kristen Stewart from Deutsche Bank.",10,"Our next question comes from Kristen Stewart from Deutsche Bank."
94614,377148003,1063970,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Analysts","Just to go back, I guess, to some of the comments on the acquisitions. I know you said that integration's going so far. Would you be willing to say in terms of the 2017 accretion numbers that those still look to be intact based upon how the businesses are",58,"Just to go back, I guess, to some of the comments on the acquisitions. I know you said that integration's going so far. Would you be willing to say in terms of the 2017 accretion numbers that those still look to be intact based upon how the businesses are performing, better or worse than you had originally stated?"
94614,377148003,1063970,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Executives","Kristen, it's Glenn. Yes, we actually were on track in 2016 to the accretion numbers that we put out there. And then also for 2017, based on our preliminary planning, we think we'll be on track to hit the numbers that we put out for accretion as well.",48,"Kristen, it's Glenn. Yes, we actually were on track in 2016 to the accretion numbers that we put out there. And then also for 2017, based on our preliminary planning, we think we'll be on track to hit the numbers that we put out for accretion as well."
94614,377148003,1063970,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Analysts","Okay, great. And then has FX changed at all in terms of the bottom line impact? And with the change in stock option, can you give us a sense in terms of how that may also impact or maybe what the impact might be in 2016 or '15 or anything to that extent y",57,"Okay, great. And then has FX changed at all in terms of the bottom line impact? And with the change in stock option, can you give us a sense in terms of how that may also impact or maybe what the impact might be in 2016 or '15 or anything to that extent you can help frame?"
94614,377148003,1063970,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Executives","Yes, yes. It feels like 2 questions. I'll take a stab at them both. So first off, on FX. As you can see, translational is easing, especially in Q3, and we expect it to be nominal in Q4. Transactional will still continue to impact us as it did this quarter",132,"Yes, yes. It feels like 2 questions. I'll take a stab at them both. So first off, on FX. As you can see, translational is easing, especially in Q3, and we expect it to be nominal in Q4. Transactional will still continue to impact us as it did this quarter, and it will next quarter. And part of that is related to our hedging program and the way we lock in hedges 18 months ahead of time and how that relates to the current exchange rates that are out there. And then secondly, as it relates to the change in stock option, I think if you take a look, we've disclosed what we think that'll be, which is roughly maybe $30 million. And we don't plan on adopting it until next year."
94614,377148003,1063970,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Operator","Our next question comes from Chris Pasquale from Guggenheim.",9,"Our next question comes from Chris Pasquale from Guggenheim."
94614,377148003,1063970,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Analysts","Kevin, it's been a while since you guys hosted an analyst meeting, and I know you talked about not wanting to comment too much on forward guidance yet. But you had a chance to talk about some of the progress you've made with some of the investments to get",118,"Kevin, it's been a while since you guys hosted an analyst meeting, and I know you talked about not wanting to comment too much on forward guidance yet. But you had a chance to talk about some of the progress you've made with some of the investments to get the cost in the middle of the income statement, in particular. I see Lonny's on the agenda. Can you talk a little bit about some of those programs? You've highlighted the ERP transition, some of the other things you're doing. And will this be an opportunity sort of lay out the next steps on how we get some leverage, particularly in the middle of the income statement going forward?"
94614,377148003,1063970,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Executives","I think what you'll hear Lonny's talk about is progress on multiple fronts as we've gotten in the CPG program underway. ERP is one of them, product life cycle management, planned optimization, indirect spend and, as we try to articulate, giving greater qu",72,"I think what you'll hear Lonny's talk about is progress on multiple fronts as we've gotten in the CPG program underway. ERP is one of them, product life cycle management, planned optimization, indirect spend and, as we try to articulate, giving greater quantification around the longer-term targets and expected contributions from that. That will be the focus of his comments while Glenn will focus on our longer-term financial targets beyond '17."
94614,377148003,1063970,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Analysts","Okay. That's helpful. And then sorry if I missed this earlier. Been jumping around. But can you talk a little bit about the Trauma and Extremities business? Good quarter there, a little bit of a pickup from where we saw last quarter. Anything in particula",47,"Okay. That's helpful. And then sorry if I missed this earlier. Been jumping around. But can you talk a little bit about the Trauma and Extremities business? Good quarter there, a little bit of a pickup from where we saw last quarter. Anything in particular driving that?"
94614,377148003,1063970,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Executives","No, I would say it's just continued strong performance, and we've been performing well in our Trauma business over the last 3 years. And it was this more of the same this quarter.",33,"No, I would say it's just continued strong performance, and we've been performing well in our Trauma business over the last 3 years. And it was this more of the same this quarter."
94614,377148003,1063970,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Operator","Our next question comes from Kaila Krum with William Blair.",10,"Our next question comes from Kaila Krum with William Blair."
94614,377148003,1063970,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Analysts","Just a couple for me. So in terms of acquisition strategy and, I guess, specific to Orthopaedics and Spine, are you guys more focused on scale or growth at this point in time? And granted they do come hand-in-hand, but one tends to lead to the together, s",56,"Just a couple for me. So in terms of acquisition strategy and, I guess, specific to Orthopaedics and Spine, are you guys more focused on scale or growth at this point in time? And granted they do come hand-in-hand, but one tends to lead to the together, so trying to better understand your M&A strategy there."
94614,377148003,1063970,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Executives","There's no change in M&A strategy, whether it's the company overall or performance versus MedSurg or Neurotech. It's focused on our core and key adjacent markets. If you look historically, the bulk of our deals have been in core markets with a few [indisc",65,"There's no change in M&A strategy, whether it's the company overall or performance versus MedSurg or Neurotech. It's focused on our core and key adjacent markets. If you look historically, the bulk of our deals have been in core markets with a few [indiscernible] acquisitions. And that will continue to be the strategy going forward across all the divisions. So no change from that."
94614,377148003,1063970,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Analysts","Okay. And then just a follow-up on the Extremities business. I mean, just looking specifically at Foot & Ankle. Can you guys talk about higher Foot & Ankle performance has been recently? Are they still sort of trending in historical levels? And just any c",52,"Okay. And then just a follow-up on the Extremities business. I mean, just looking specifically at Foot & Ankle. Can you guys talk about higher Foot & Ankle performance has been recently? Are they still sort of trending in historical levels? And just any commentary on market trends there would be helpful."
94614,377148003,1063970,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Executives","Yes, so we're really pleased with our Foot & Ankle performance. In the U.S., this quarter, we grew 15%, very much in line with the performance we've had over the past year and continues to be a very good market.",40,"Yes, so we're really pleased with our Foot & Ankle performance. In the U.S., this quarter, we grew 15%, very much in line with the performance we've had over the past year and continues to be a very good market."
94614,377148003,1063970,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Operator","Our next question comes from Glenn Navarro from RBC Capital.",10,"Our next question comes from Glenn Navarro from RBC Capital."
94614,377148003,1063970,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Analysts","Two questions. First, pricing in Orthopaedics down 2.2%. That was similar to the second quarter. So I'm wondering if the new trend line of Orthopaedic pricing is now going to be in that 2% to 2.5% range. Then I had a follow-up on pricing.",44,"Two questions. First, pricing in Orthopaedics down 2.2%. That was similar to the second quarter. So I'm wondering if the new trend line of Orthopaedic pricing is now going to be in that 2% to 2.5% range. Then I had a follow-up on pricing."
94614,377148003,1063970,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Executives","I think we feel comfortable, from a total company perspective, that pricing is going to be down in that 1.5%, 2% vicinity. It's been trending slightly less negative. Ortho, it seems relatively stable, but candidly, try to predict that level of accuracy, 5",98,"I think we feel comfortable, from a total company perspective, that pricing is going to be down in that 1.5%, 2% vicinity. It's been trending slightly less negative. Ortho, it seems relatively stable, but candidly, try to predict that level of accuracy, 50, 100 [ph] basis points moves in price, it's really difficult. We have greater confidence and visibility when you look at the totality of the company because we have areas with less price, is pricing pressure. And so we really try to focus on the total versus specific line item where it can move around quarter-to-quarter."
94614,377148003,1063970,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Analysts","Okay. And then just as a follow-up to that. Pricing again I look at it sequentially, pretty stable. And now we're in the 6 months of CJR, so it seems like there's been no impact to pricing. So I'm curious as to what your thoughts are on the implementation",58,"Okay. And then just as a follow-up to that. Pricing again I look at it sequentially, pretty stable. And now we're in the 6 months of CJR, so it seems like there's been no impact to pricing. So I'm curious as to what your thoughts are on the implementation of CJR. And are you seeing any pricing pressures?"
94614,377148003,1063970,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Executives","We would agree, we really haven't seen an impact. But in fairness, too, it has only been 6 months. And in the first year, there is no financial penalty. So we really believe you're going to see a greater focus on hospital when there's more of our financia",132,"We would agree, we really haven't seen an impact. But in fairness, too, it has only been 6 months. And in the first year, there is no financial penalty. So we really believe you're going to see a greater focus on hospital when there's more of our financial incentive. Now as you go into 2017, I think you'll be able to get a lot better visibility or hopefully will at the Analyst Day because we will have a hospital customer who's had experience under the bundled payment but we continue to believe there focus is going to be in the post-acute setting on rehab costs and there was tremendous value to be realized by shifting more patients to the home and not some of the skilled nursing facilities and other rehab facilities."
94614,377148003,1063970,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Operator","Our next question comes from Matthew Miksic from UBS.",9,"Our next question comes from Matthew Miksic from UBS."
94614,377148003,1063970,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Analysts","So one kind of topical question coming out NASH and your demonstration of Tritanium and your products, and then I have one follow just on the ortho side, if I could. So one of the things you talked about in your presentation in the Q&A afterwards, there w",153,"So one kind of topical question coming out NASH and your demonstration of Tritanium and your products, and then I have one follow just on the ortho side, if I could. So one of the things you talked about in your presentation in the Q&A afterwards, there was just a buildout you've put in place around 3D-printed products in general. Of course, that drives the Spine portfolio of really one key product at the moment, but also your [indiscernible] knee, cementless knee platform you've talked a lot about. So I'm wondering, as you build that out, I mean, just given the proportion of your business, given the performance of your business, how are you prioritizing I guess? Are you getting leverage across those 2 platforms, they way manufacture and how you're sort of think about which one of these sort of high-demand products gets the volume over time? And I have more follow-up."
94614,377148003,1063970,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Executives","Sure, Matt. The short answer is they all do, but we have been capacity-constrained. We are adding 3D printing capacity on a monthly basis. We broke around a dedicated 3D printing facility in Ireland last year. As you know, this is extremely highly technic",89,"Sure, Matt. The short answer is they all do, but we have been capacity-constrained. We are adding 3D printing capacity on a monthly basis. We broke around a dedicated 3D printing facility in Ireland last year. As you know, this is extremely highly technical with a great deal of know-how around 3D printing these types of metals. And we will be launching additional 3D-printed products. And -- but you should assume you'll see the benefit of that Spine as well as on our vision and press fit knee portfolio."
94614,377148003,1063970,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Analysts","Okay. And then the follow-up, just on the trends in Orthopaedics. I mean, the knee number, U.S. in particular, I thought was quite strong going up against a pretty significantly tougher comp. Hips, kind of the same. So just in terms of trends there, I thi",112,"Okay. And then the follow-up, just on the trends in Orthopaedics. I mean, the knee number, U.S. in particular, I thought was quite strong going up against a pretty significantly tougher comp. Hips, kind of the same. So just in terms of trends there, I think we talked about, back in September, what should we expect in terms of recovery in Hips or annualizing some of the launches that you got in Hips? And then on Knees, if you could -- is it the press fit that's really making of the difference in driving are we getting a mix benefit, penetration benefit on the Knees side that's driving that? I appreciate it."
94614,377148003,1063970,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Executives","Yes, so keep in mind, it's the sales force with the same customer base on Hips and Knees. Accolade, which has been a terrific product lines for us, several years into that now, whereas MAKO is getting an enormous among the focus and there's a huge product",199,"Yes, so keep in mind, it's the sales force with the same customer base on Hips and Knees. Accolade, which has been a terrific product lines for us, several years into that now, whereas MAKO is getting an enormous among the focus and there's a huge product launch. And as a result, sales force has focused on that. So there is a Halo effect that's helping our Knee business. We also have additional new products on the Knee side, our 3D-printed revision cones and fleets and, as we just mentioned, our 3D-printed cementless knee, which is really driving us to know low double-digit penetration for cementless knees, which is well above the interest rates so I think right now you just been a period where there's a lot of happening on the knee side and a lot continue to happen as we go to the full commercial launch. We will be introducing more hip products, but sales force likes to focus on what's new and hot clearly a lot of that momentum right now is on the knee side. And so we think that's probably more like overall market growth these was the continued to be above the market."
94614,377148003,1063970,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Executives","But certainly, when you look at the overall, we're very pleased with our performance. Our sales teams are doing an excellent job, and we're exited about the future years.",29,"But certainly, when you look at the overall, we're very pleased with our performance. Our sales teams are doing an excellent job, and we're exited about the future years."
94614,377148003,1063970,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Operator","Our next question comes from Mike Matson from Needham & Company.",10,"Our next question comes from Mike Matson from Needham & Company."
94614,377148003,1063970,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Analysts","We've seen a real pickup in the amount of M&A and the Spine space. And Kevin, last I heard, I think you were saying that you were happy with the performance of the Spine business and the turnaround there. You  didn't really feel the need to do something f",71,"We've seen a real pickup in the amount of M&A and the Spine space. And Kevin, last I heard, I think you were saying that you were happy with the performance of the Spine business and the turnaround there. You  didn't really feel the need to do something from an acquisition standpoint in Spine. But I just wanted to check in and see if that was still how you felt."
94614,377148003,1063970,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Executives","Yes, so as you look at our Spine business, you see that we've had some issues around for the performances, supply chain disruptions. But we have a great leadership team, and we had a number of quarters a very strong growth. And I believe in this leadershi",120,"Yes, so as you look at our Spine business, you see that we've had some issues around for the performances, supply chain disruptions. But we have a great leadership team, and we had a number of quarters a very strong growth. And I believe in this leadership team, and Tritanium is a great example of the 3D-printed interbody device, which is performing very well. I'm confident our team can continue to perform well and grow the business. Related to M&A, I would give you the same comment I give for all our divisions. We're always looking to strengthen our businesses, but we're not going to comment on whether we're going to acquisitions, big or small, on any of our divisions."
94614,377148003,1063970,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Analysts","Okay, understand. And then you do have a significant portion of cash -- of your cash outside the U.S. So I know there's some talk of a potential tax deal after the election. So if that were to occur, obviously, it would depend of the terms of that. But wo",73,"Okay, understand. And then you do have a significant portion of cash -- of your cash outside the U.S. So I know there's some talk of a potential tax deal after the election. So if that were to occur, obviously, it would depend of the terms of that. But would you repatriate any of that cash? And if you did, what would you -- how would you prioritize the use of that cash?"
94614,377148003,1063970,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Executives","As we look at our cash, I'm sure we are in the same position as several other U.S. companies. And if something like that became available, as it did a few years back, we would definitely take advantage of it and repatriate our cash to the extent possible.",106,"As we look at our cash, I'm sure we are in the same position as several other U.S. companies. And if something like that became available, as it did a few years back, we would definitely take advantage of it and repatriate our cash to the extent possible. In terms of how we might prioritize that cash, it's hard to say at this point. We've said before about what our priorities are around capital allocation, and that would mean M&A. That would mean dividends, and it may mean share buybacks. But commenting beyond that, I don't think I can do that at this point in time."
94614,377148003,1063970,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Operator","Our next question comes from Bruce Nudell from SunTrust.",9,"Our next question comes from Bruce Nudell from SunTrust."
94614,377148003,1063970,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Analysts","Kevin, I have a couple for you. Firstly, I'm fascinated by this 40% placement of MAKO and competitive accounts. One of the big issues with Orthopaedics is that there's tremendous brand synergization of product on the part of surgeons as well as institutio",86,"Kevin, I have a couple for you. Firstly, I'm fascinated by this 40% placement of MAKO and competitive accounts. One of the big issues with Orthopaedics is that there's tremendous brand synergization of product on the part of surgeons as well as institutions for hips or knees. So how do you accomplish that where you put a robot in and get people to go beyond new knees and kind of standardize on knees with the Stryker brand that may not use most of the time today?"
94614,377148003,1063970,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Executives","The way we look at our MAKO adoption is really around behavioral segmentation, which surgeons like new technology and believe that they can become better after delivering value to their patients with technology. And so it's not about whether they like Str",88,"The way we look at our MAKO adoption is really around behavioral segmentation, which surgeons like new technology and believe that they can become better after delivering value to their patients with technology. And so it's not about whether they like Stryker or whether they like Zimmer or whether they like J&J. It's about do they like robotics and do they believe in robotics. And that's why, not surprising that many of the placements are in competitive. We're getting a lot of feedback. Can you hear me, Bruce?"
94614,377148003,1063970,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Analysts","Yes, I can.",3,"Yes, I can."
94614,377148003,1063970,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Executives","I'm sorry, we're getting a little feedback in the room. But -- so what I'd tell you on this front is it's really all about the surgeon who wants to become better and who believes in technology, the less so about our specific relationship or whether the ho",183,"I'm sorry, we're getting a little feedback in the room. But -- so what I'd tell you on this front is it's really all about the surgeon who wants to become better and who believes in technology, the less so about our specific relationship or whether the hospital is with Stryker or a different account. It's a different knees that we're serving. If you look at MAKO prior to our acquisition, they were able to obtain about 18% of the knee market over a 4-year period. There were not a proven entity. They weren't even in orthopaedic company. So we really believe this about technology adoption certainly in the first couple of years. It's really around the, which surgeons believe in technology. And we're going to go to the surgeon said believe in it. There are many skeptics, as you know, with all disruptive technology. And some of those skeptics are Stryker loyal surgeons. And they won't be the first to adopt, and that doesn't concern is because there are many surgeons who are interested and, who will be willing to adopt."
94614,377148003,1063970,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Analysts","And my second question is as we were launching on Stryker, what really struck me was that despite the acquisitive nature of the company, ROIC has been maintained. And could you just -- and it seems to be like a core strength of the company. Can you talk a",72,"And my second question is as we were launching on Stryker, what really struck me was that despite the acquisitive nature of the company, ROIC has been maintained. And could you just -- and it seems to be like a core strength of the company. Can you talk about how that influences the profile of what you buy, how it fits in? And is that a formula you can maintain going forward?"
94614,377148003,1063970,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Executives","It's long been in our history to be very disciplined in our deployment of capital. So we look at deals we want to strengthen every division that we have in the company. But we won't just pay whatever the companies. We're very disciplined. We walk away wit",171,"It's long been in our history to be very disciplined in our deployment of capital. So we look at deals we want to strengthen every division that we have in the company. But we won't just pay whatever the companies. We're very disciplined. We walk away with the prices are above our ability to deliver value. And sometimes, there's some that we like and the price point's just too high and we have discipline to walk away from deals. And I think that's why you see the ROIC still consistent year over year over year in spite of the acquisition nature. And also, the ability to have acquisition that fit in our exiting business, that plug into our sales force, which is the bulk of the deals we do, we have a proven model to deliver value with those types of acquisitions. So I think it's a combination of playing to our strengths in terms of our commercial execution and being financially disciplined with the deal that we do make."
94614,377148003,1063970,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Operator","Our next question comes from Richard Newitter from Leerink Partners.",10,"Our next question comes from Richard Newitter from Leerink Partners."
94614,377148003,1063970,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Analysts","I want to maybe, for you Kevin, to start off. We're at [indiscernible], obviously, it's topical. We're seeing a lot of robotics take a bigger presence on the floor. Being that you were the first major company to kind of really validate the robotics catego",76,"I want to maybe, for you Kevin, to start off. We're at [indiscernible], obviously, it's topical. We're seeing a lot of robotics take a bigger presence on the floor. Being that you were the first major company to kind of really validate the robotics category, we'd love to hear what your view is of the robotics kind of push in spine we're trying to see and then how MAKO potentially could send over the longer term."
94614,377148003,1063970,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Executives","Well, we love the fact that robotics is taking a lot of the discussion because, as you know, with MAKO, we believe in robotics. Right now, at Stryker, our focus is on hips and knees and specifically the Total Knee launch. But we see, over time, that certa",83,"Well, we love the fact that robotics is taking a lot of the discussion because, as you know, with MAKO, we believe in robotics. Right now, at Stryker, our focus is on hips and knees and specifically the Total Knee launch. But we see, over time, that certainly robotics will extend into other procedural areas, including spine. We do have a smaller effort underway, but it's too early for us to speculate on when we would come to the market in that specialty."
94614,377148003,1063970,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Analysts","Okay. And then maybe just one more follow-up. Out-patient surgery and it's out-patient in a military surgery care, it's clearly where hospitals are trying to go. I'd love to just hear how you deal the Stryker's position, either through technology or other",62,"Okay. And then maybe just one more follow-up. Out-patient surgery and it's out-patient in a military surgery care, it's clearly where hospitals are trying to go. I'd love to just hear how you deal the Stryker's position, either through technology or other means to capitalize on that trend. And specifically, talk whether or not MAKO is lending a hand in that effort."
94614,377148003,1063970,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Executives","We have a lot of experience with the ambulatory service entering with our sports medicine business and, as you know, Spine number of procedures the more simpler producer starting to move to the regulatory service center. At this stage, MAKO hasn't had a b",121,"We have a lot of experience with the ambulatory service entering with our sports medicine business and, as you know, Spine number of procedures the more simpler producer starting to move to the regulatory service center. At this stage, MAKO hasn't had a big impact but we do see our robotics going to have a play in all of the different aspects of the care continuum. I think this trend will continue towards shift side of the tort surgery centers will continue, but it's not something that we're not prepared for. We have plans across our divisions. And as you saw with the [indiscernible] you saw the Spine divisions actually created a program that's a very specific for the surgery center."
94614,377148003,1063970,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Operator","Our next question comes from Larry Biegelsen from Wells Fargo.",10,"Our next question comes from Larry Biegelsen from Wells Fargo."
94614,377148003,1063970,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Analysts","So I wanted to just touch on and focus on the [indiscernible].",12,"So I wanted to just touch on and focus on the [indiscernible]."
94614,377148003,1063970,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Executives","Larry, I apologize. We can't hear you.",7,"Larry, I apologize. We can't hear you."
94614,377148003,1063970,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Executives","You're on speaker. Could you pick up, please?",9,"You're on speaker. Could you pick up, please?"
94614,377148003,1063970,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Analysts","Neurotech, that was a little slower than the U.S. this quarter. What drove the deceleration? Could you talk a little bit about how your [indiscernible] with this performance? I know you talked about that as a key growth driver for you guys.",42,"Neurotech, that was a little slower than the U.S. this quarter. What drove the deceleration? Could you talk a little bit about how your [indiscernible] with this performance? I know you talked about that as a key growth driver for you guys."
94614,377148003,1063970,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Executives","Yes, so we continue to see good momentum in the AES market. As we talked about before, predicting the slope and the speed of that market adoption is tricky to move around quarter-to-quarter and AIS wasn't slower sequentially, although still healthy growth",66,"Yes, so we continue to see good momentum in the AES market. As we talked about before, predicting the slope and the speed of that market adoption is tricky to move around quarter-to-quarter and AIS wasn't slower sequentially, although still healthy growth in that segment. We did have a recall in the quarter, which impacted our hemorrhagic business. That's fully resolved and shouldn't impact going forward."
94614,377148003,1063970,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Operator","Our next question comes from Matthew O'Brien from Piper Jaffray.",11,"Our next question comes from Matthew O'Brien from Piper Jaffray."
94614,377148003,1063970,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Analysts","Just want to start with MAKO and continue to focus on this a little bit more. But first of all, did you fully spell 13 additional systems this quarter versus Q3 of last year? And the reason I asked that question is if you backed that out, assuming you sol",114,"Just want to start with MAKO and continue to focus on this a little bit more. But first of all, did you fully spell 13 additional systems this quarter versus Q3 of last year? And the reason I asked that question is if you backed that out, assuming you sold it all, it would seem like your core Knee business was a little bit than one of your competitors recorded this quarter and then on a 2-year stack basis, it's little bit soft as well. So is there [indiscernible] sales forces focus on MAKO the could see some of the traditional Knee business soften a little bit, along with the Hip business as well?"
94614,377148003,1063970,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Executives","Well, we continue to sell all of our robots, just to be clear. And we report our robots sales in the other Orthopaedic category. We continue to see it's up quite a bit. And other items that are shown in that other category includes bone cement, and bone c",117,"Well, we continue to sell all of our robots, just to be clear. And we report our robots sales in the other Orthopaedic category. We continue to see it's up quite a bit. And other items that are shown in that other category includes bone cement, and bone cement was down in the quarter, both in the U.S. and internationally. We used to have a lot more stocking orders for bone cement, and now our hospital customers are sort of buying it as they need it. And so bone cement does tend to be volatile from quarter-to-quarter. But when you look at our knee number, those are implants that you're seeing in the number to robots sales."
94614,377148003,1063970,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Analysts","[indiscernible] which is, obviously, the first question I just had, but it looks like, I think, physio grew about 9% pro forma last quarter, and it grew about 6% this quarter. Obviously, we don't have the comparables to look at, but is there anything that",68,"[indiscernible] which is, obviously, the first question I just had, but it looks like, I think, physio grew about 9% pro forma last quarter, and it grew about 6% this quarter. Obviously, we don't have the comparables to look at, but is there anything that's going on that's maybe going a little bit as you integrate that asset? Or it's just more tougher comp this time last year?"
94614,377148003,1063970,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Executives","I wouldn't read anything into that. Remember, it's a capital business. It tends to move around quarter-to-quarter. And so there wasn't anything unique relative to Q2 to Q3. We're very pleased with that integration and so far, recognizing as early as Kevin",76,"I wouldn't read anything into that. Remember, it's a capital business. It tends to move around quarter-to-quarter. And so there wasn't anything unique relative to Q2 to Q3. We're very pleased with that integration and so far, recognizing as early as Kevin commented on. But you will see capital move around. We tend to try and focus on multi-quarter rolling trends to really get a good sense with that business, but nothing to call out."
94614,377148003,1063970,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Operator","Our next question comes from Matt Taylor from Barclays.",9,"Our next question comes from Matt Taylor from Barclays."
94614,377148003,1063970,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Analysts","This is actually Ian in for Matt. So there's been a lot of discussion on Spine during this call, but I wanted to sort of explore a little more and just as about what you're seeing in terms of competition. I mean, we've heard a lot about redoubled efforts",74,"This is actually Ian in for Matt. So there's been a lot of discussion on Spine during this call, but I wanted to sort of explore a little more and just as about what you're seeing in terms of competition. I mean, we've heard a lot about redoubled efforts to focus on that area from some of your competitors. So just wanted to see if you're seeing anything different there. Any commentary to highlight?"
94614,377148003,1063970,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Executives","There's nothing we would uniquely call out. It remains a highly competitive market with a lot of players across the board with the larger, more established companies and, obviously, the smaller ones. But there's nothing that we are seeing different with r",55,"There's nothing we would uniquely call out. It remains a highly competitive market with a lot of players across the board with the larger, more established companies and, obviously, the smaller ones. But there's nothing that we are seeing different with respect to any of the key competitors in the market at this time."
94614,377148003,1063970,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Operator","And our next question comes from Jeff Johnson from Baird.",10,"And our next question comes from Jeff Johnson from Baird."
94614,377148003,1063970,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Analysts","Most of my questions have been answered, but Glenn, can you talk about any of the drivers in gross margin between maybe price, currency or product or geographic mix, just kind of big buckets, kind of what drove the change in gross margin this year this qu",108,"Most of my questions have been answered, but Glenn, can you talk about any of the drivers in gross margin between maybe price, currency or product or geographic mix, just kind of big buckets, kind of what drove the change in gross margin this year this quarter? And then as I think about some of the movements we've seen on the and some emerging market currency here recently and given the 18 months hedging program, just any very high level comments you can make about how we can think about the currency hedge portion settling out the cost of goods how that impacts over the next several quarters?"
94614,377148003,1063970,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Executives","Sure. I think if you look quarter-to-quarter, Q3 to Q4, our margin is fairly consistent. And I talked about this before. Like you mentioned, there's lots of variables that impact our margin, not only price, but FX, acquisition. And certainly, one of the b",212,"Sure. I think if you look quarter-to-quarter, Q3 to Q4, our margin is fairly consistent. And I talked about this before. Like you mentioned, there's lots of variables that impact our margin, not only price, but FX, acquisition. And certainly, one of the biggest factors is mix, and the mix plays out in 2 ways. It plays out in sort of geographic mix but also sort of business and product mix. And so as I look year-over-year for the third quarter, really probably the biggest impact that we had was related to business mix in terms of how much MedSurg versus Orthopaedics versus international we had last year versus this year. And then on the FX front, we entered the hedging program back when foreign currency was a lot more volatile, and the whole idea was to lock in the predictability of foreign currency for us. So like you had mentioned, currencies move up and down. Our hedging program provides stability and predictability to us. And so for the third quarter, I think, as I said, there'll be sort of a nominal impact on sales related to translational, but that will have, potentially, a minor impact similar to this quarter related to transactional FX. And that's where, I think, we'll come out."
94614,377148003,1063970,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Analysts","And over the next 4 -- 3, 4 quarters, just will the currency side alone and we can make our own is options and everything else, with currency, should we be thinking of that as a small drag still for the next several quarters on gross margins? Is that a fa",52,"And over the next 4 -- 3, 4 quarters, just will the currency side alone and we can make our own is options and everything else, with currency, should we be thinking of that as a small drag still for the next several quarters on gross margins? Is that a fair comment?"
94614,377148003,1063970,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Executives","Yes, I don't know I wish I had the currency crystal ball to figure out how things were going to flow. But it's hard to say because it's not only impacted by, say, what we've done in hedging but with the underlying transactions are. So I do think I can rea",58,"Yes, I don't know I wish I had the currency crystal ball to figure out how things were going to flow. But it's hard to say because it's not only impacted by, say, what we've done in hedging but with the underlying transactions are. So I do think I can really comment that far out at this point."
94614,377148003,1063970,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Operator","And there are no further questions at this time. I will now turn the conference over to Mr. Kevin Lobo for any closing remarks.",24,"And there are no further questions at this time. I will now turn the conference over to Mr. Kevin Lobo for any closing remarks."
94614,377148003,1063970,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Executives","Thank you all for joining our call. With our conference call for the fourth quarter 2016 results will be held on January 24, 2017. Thank you.",26,"Thank you all for joining our call. With our conference call for the fourth quarter 2016 results will be held on January 24, 2017. Thank you."
94614,377148003,1063970,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Operator","Thank you, ladies and gentlemen. This concludes today's conference. Thank you for participating. You may now disconnect.",17,"Thank you, ladies and gentlemen. This concludes today's conference. Thank you for participating. You may now disconnect."
94614,377148003,1064403,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Operator","Welcome to the Third Quarter 2016 Stryker Earnings Call. My name is Crystal, and I will be your operator for today's call. [Operator Instructions] This conference call is being recorded for replay purposes.Before we begin, I would like to remind you tha",134,"Welcome to the Third Quarter 2016 Stryker Earnings Call. My name is Crystal, and I will be your operator for today's call. [Operator Instructions] This conference call is being recorded for replay purposes.
Before we begin, I would like to remind you that the discussions during this conference call will include forward-looking statements. Factors that could cause actual results to differ materially are discussed in the company's most recent filings with the SEC. Also, the discussions will include certain non-GAAP financial measures. Reconciliations to the most directly comparable GAAP financial measures can be found in today's press release that is an exhibit to Stryker's current report on Form 8-K filed today with the SEC.
I will now turn the call over to Mr. Kevin Lobo, Chairman and Chief Executive Officer. You may proceed, sir."
94614,377148003,1064403,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Executives","Welcome to Stryker's Third Quarter Earnings Call. Joining me today are Glenn Boehnlein, Stryker's CFO; and Katherine Owen, VP of Strategy and Investor Relations.For today's call, I will provide opening comments, followed by Katherine with an update on M",314,"Welcome to Stryker's Third Quarter Earnings Call. Joining me today are Glenn Boehnlein, Stryker's CFO; and Katherine Owen, VP of Strategy and Investor Relations.
For today's call, I will provide opening comments, followed by Katherine with an update on MAKO and our November analyst meeting. Glenn will then provide additional details regarding our quarterly results before we open the call to Q&A.
We achieved another quarter of solid organic sales growth, coming in at 6.2% and fueled by a strong showing for both MedSurg & Neurotechnology, with both delivering roughly 7% increases. Orthopaedics growth was consistent at approximately 5% organically. On a geographic basis, Q3 sales were balanced with a 6% increase in the U.S. and a 6.7% gain in international, driven by strong momentum in Europe and a return to growth in emerging markets.
We are pleased with the performance of our acquisitions, including both Sage and Physio-Control, which are well positioned to help us drive stronger organic sales growth for Stryker in the coming years.
A strong top line performance, coupled with our ongoing focus on G&A leverage, resulted in an EPS of $1.39, up 11.2% and $0.01 above the high end of our target range. Based on our performance for the first 9 months of 2016, we are confident in our ability to deliver our commitments, with organic sales growth for the full year expected at 6% to 6.5%.
We are narrowing our adjusted EPS range to the upper end, which now stands at $5.75 to $5.80 per share. Overall, we believe the strength of our people, diversified revenue model and new product flow positions us well to continue to deliver sales at the high end of med tech with leveraged earnings gains. 
We look forward to providing our 2017 financial guidance on our Q4 earnings call in January.
With that, I will now turn the call over to Katherine."
94614,377148003,1064403,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Executives","Thanks, Kevin. My comments on today's call will include an update on MAKO as well as a preview of our upcoming analyst meeting.Starting with MAKO. Results in the quarter were strong with a total of 30 robots installed globally, representing a roughly 75",440,"Thanks, Kevin. My comments on today's call will include an update on MAKO as well as a preview of our upcoming analyst meeting.
Starting with MAKO. Results in the quarter were strong with a total of 30 robots installed globally, representing a roughly 75% year-over-year increase with 23 in the U.S. Consistent with prior quarters, approximately 40% of the installations were in competitive accounts where Stryker has no or relatively low market share.
Demand for the MAKO robot is being fueled by the expanded indications, including the total knee, which began a limited launch in June. Since that time, we have had KOL surgeons trained on the robots for the total knee, including those with prior robot experience but with less exposure to our Triathlon knee as well as surgeons who had not previously used a robot for joint reconstruction. As we discussed previously, by observing both these groups, we are optimizing the training protocol.
Of note, since the start of the limited market release for the total knee, over 200 cases have been performed, and we've been pleased with the results to date. We are targeting the 2017 AAOS meeting to move into the full commercial launch.
I will now shift to the analyst meeting, which will be held on November 9 at our Orthopaedics headquarters in New Jersey. In order to optimize the utility of this meeting, we will be focusing the formal part of the meeting on several key areas. This will include a MAKO physician panel with 2 surgeons who have been part of the limited market release. We will also have a Stryker Performance Solutions panel, which will include an SPS customer and focus on how we've been able to deploy our expertise in the joint reconstruction episode of care to help reduce our procedural costs.
Turning to cost transformation for growth. Lonny Carpenter, Group President of Global Quality and Operations, will provide an update on the various initiatives within CTG, including the expected financial contribution over the next 2 years. Glenn Boehnlein will provide a financial update, including our longer-term targets. We will conclude the formal part of the meeting with a Q&A session with the leadership team. We will then move to the product fair, which will include product highlights for MedSurg & Neurotechnology and will afford [ph] the opportunity to interact informally with the broader Stryker leadership team.
We hope you will be able to join us for the meeting. The event details and complete agenda, including the various guest speakers and their backgrounds, are available on the event registration site.
With that, I will now turn the call over to Glenn."
94614,377148003,1064403,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Executives","Thanks, Katherine. Today, I will focus my comments on our third quarter financial results and performance drivers. Our detailed financial results have been provided in today's press release.Our organic sales grew 6.2% in the quarter, which was within ou",1060,"Thanks, Katherine. Today, I will focus my comments on our third quarter financial results and performance drivers. Our detailed financial results have been provided in today's press release.
Our organic sales grew 6.2% in the quarter, which was within our range of full year expectations of 6% to 6.5%, with no difference in selling days. Pricing in the quarter was down 1.3% from the prior year, while foreign currency exchange had a nominal impact on sales.
U.S. sales continue to demonstrate strong momentum with organic growth of 6%, reflecting solid performances across our portfolio, especially in MedSurg & Neurotech. International sales grew 6.7% organically, highlighted by solid gains in Europe, Canada and Australia, somewhat offset by the continued impact of our previously discussed destocking issues in China. We expect that the fourth quarter will show some improvement on our  China business as prior year comparables continued to ease.
Our adjusted EPS of $1.39 increased 11.2% from the prior year, reflecting strong sales growth, accretive acquisitions and good operating expense control. Our third quarter EPS was negatively impacted by $0.03 related to transactional foreign currency exchange.
Focusing on our segment highlights. Orthopaedics delivered constant currency growth of 5.3% and organic growth of 4.8%, led by the U.S. organic growth of 4.7%. These gains reflect solid performances in Trauma and Extremities at 6.9% and knees at 5.1%. This growth reflects strong demand for our 3D-printed products, our Foot & Ankle portfolio and our MAKO platform, which had 30 units installed, including 7 outside the U.S. Orthopaedics international delivered constant currency growth of 6.3% and organic growth of 5.1%, led by our European business.
MedSurg posted strong gains across all businesses in the quarter with constant currency growth of 33% and organic gains of 7.3%, which included a 7.7% increase in the U.S. Instruments, which was up 5.2% in the U.S., maintained good momentum with its waste management business and the newly launched Neptune 3 and continued strong performance related to its Navigation business.
Endoscopy delivered U.S. growth of 10.4%, driven by strong double-digit performances of its camera and light source products and strong gains in its communications, sports medicine and ProCare service businesses. 
Our Medical division had U.S. organic growth of 6.8%, driven by double-digit growth of its core bed and tower cot products. On a comparable basis, Medical's Physio business was up 6.3%. Its Sage business grew 12.5%, including the impact of the recent recall. Excluding this, Sage grew 15%. We are pleased with these results and the ongoing integration efforts at Medical.
Internationally, MedSurg organic sales growth was 6%, which reflects strong European and Australian sales and some easing of the MedSurg comparable in China. Neurotechnology and Spine continues to drive of above-market performance with constant currency growth of 8.7% and organic growth of 6.9%. This growth reflects continued strong demand for our Neurotech products. U.S. Neurotech posted growth of 9.1% in the quarter, highlighted by our AIS products and our Neuro Powered Instruments.
Our Spine business in the U.S. continued to see some supply issues, offset somewhat by strong demand for our 3D-printed interbody Tritanium products. As I have said last quarter, we expect the supply issues to remain into the fourth quarter.
Internationally, Neurotech had constant currency growth of 16.7%. This performance was driven by continued strong demand for our Trevo stent retriever and Target Coil products in Europe and Asia. Spine's international growth was 1.6% and was impacted by the aforementioned supply issues and challenges in China.
Now I will focus on the operating highlights within the quarter. Our gross margin, which, on an adjusted basis, was 66.3%, was down 60 basis points from the prior year quarter. Gross margin was favorably impacted by absorption and productivity gains, which was offset by mix, including the impact of acquisitions and foreign currency exchange.
SG&A for the third quarter was 34.9% of sales on an adjusted basis, which was favorable by 70 basis points as compared to the prior year quarter. This improvement reflects favorable leverage from continued focus on operating expense improvements through our CTG program, cost-containment efforts and business mix, including leverage from our recent acquisitions.
We continue to invest in internal innovation with R&D, which is up 10 basis points year-over-year to 6.5% of sales. In total, adjusted operating expenses at 41.4% of sales was favorable 60 basis points to the prior year quarter, and these results continue to reflect our focus on leverage growth.
In summary, our operating margin was 24.9% of sales in Q3, flat year-over-year but up 64 basis points on a year-to-date basis. This performance reflects the positive results from our various CTG programs, continued cost control and favorable accretion from acquisitions, offset by business mix, pricing and foreign exchange.
Lastly, I will provide some highlights on other income and expense. Other expenses increased due to the higher net interest expense related to increased borrowings at the end of the first quarter. During the third quarter, we also paid down $750 million of debt. And accounting for the impact of this, we anticipate our future quarterly run rate of interest expense to be approximately $65 million.
Our third quarter adjusted effective tax adjusted effect of tax rate of 17.5% reflects the benefits of our global tax structure, partially offset by the impact of higher U.S.-based income from our recent acquisitions.
Moving on to the balance sheet. We continue to maintain a strong balance sheet with $3 billion of cash and marketable securities, of which approximately 80% was held outside the U.S. Total debt on the balance sheet at the end of the second quarter was $6.8 billion.
Turning to cash flow. Our year-to-date cash from operations was approximately $1.2 billion. Finally, as we have previously announced at the end of Q1, we have suspended our share repurchases for the remainder of 2016.
In terms of guidance, we reconfirm our previous full year organic sales growth range of 6% to 6.5% for 2016. If foreign currency exchange rates hold near current levels, we expect a neutral impact in the fourth quarter and a negative foreign currency impact of less than 0.5% for the full year.
Lastly, our guidance for adjusted net earnings per diluted share in 2016 is now expected to be in the range of $5.75 to $5.80 for the full year.
And now I will open up the call for Q&A."
94614,377148003,1064403,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Operator","[Operator Instructions] And our first question comes from Bob Hopkins from Bank of America.",14,"[Operator Instructions] And our first question comes from Bob Hopkins from Bank of America."
94614,377148003,1064403,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Analysts",";So I have 2 questions. One, I'll start with you, Kevin. I was encouraged to hear your comments about emerging markets and turning back to the positive there. So maybe you could just kind of lay out specifically what improved and what you think the pros",88,";
So I have 2 questions. One, I'll start with you, Kevin. I was encouraged to hear your comments about emerging markets and turning back to the positive there. So maybe you could just kind of lay out specifically what improved and what you think the prospects are for your emerging market growth. Now that you've kind of turned the corner, can we get back to mid to high single digits in a reasonable time frame for emerging markets? Just want to hear a little more color on EM."
94614,377148003,1064403,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Executives","Yes, sure. So outside of China, I would say, I'm really encouraged by the progress in India, which is really a continuation of what we've been experiencing the past few quarters. Brazil returned to growth. And as you know, Brazil has been a very challengi",198,"Yes, sure. So outside of China, I would say, I'm really encouraged by the progress in India, which is really a continuation of what we've been experiencing the past few quarters. Brazil returned to growth. And as you know, Brazil has been a very challenging market for us over the past year to 2. And we also like the results in Russia, Turkey. So it's really across the board. Our other emerging market countries performed very well. China's still a bit of a laggard, but as Glenn's mentioned in his prepared remarks, we expect China to return to growth in the fourth quarter. So we're starting to see an improvement. Part of this is really the comparables that we're sort of lapping the years of sort of core performance. So we would expect a bit of a turnaround. But I -- it's really early. It's only one quarter, but I'm starting to see a trend that we will see growth. Now whether we'll get back to double digit as we experienced in prior years, it's a little early for me to say. But certainly, they'll look as much more positive than it has been over the past year."
94614,377148003,1064403,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Analysts","Okay. And then for Katherine, as a follow-up, just on your comments on the Analyst Day and MAKO. On the Analyst Day, can you just -- I know you're not giving guidance until the fourth quarter, but what will you be quantifying at the Analyst Day in some of",85,"Okay. And then for Katherine, as a follow-up, just on your comments on the Analyst Day and MAKO. On the Analyst Day, can you just -- I know you're not giving guidance until the fourth quarter, but what will you be quantifying at the Analyst Day in some of these prepared commentary? Will there be any quantification of cost savings or long-term margin opportunity? Just want to make sure I have a good understanding of exactly what we're going to get at the Analyst Day."
94614,377148003,1064403,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Executives","Yes. In addition to the panels, I focused on MAKO and SPS. Lonny will be giving a CTG update, which will include a greater quantification and visibility around the long-term potential from the cost savings that we're targeting. And then Glenn will be givi",89,"Yes. In addition to the panels, I focused on MAKO and SPS. Lonny will be giving a CTG update, which will include a greater quantification and visibility around the long-term potential from the cost savings that we're targeting. And then Glenn will be giving an update with some of our longer-term financial targets. Now we'll go into the full detail of that at the Analyst Day. But also to be clear, we won't be giving 2017 guidance ranges, the formalization of our targets, until the January fourth quarter call."
94614,377148003,1064403,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Operator","Our next question comes from Rick Wise from Stifel.",9,"Our next question comes from Rick Wise from Stifel."
94614,377148003,1064403,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Analysts","Maybe I'll also start with MAKO. You always had an exceptionally strong quarter. Maybe, Kevin or Katherine, you could give us a little more color there. Maybe just sort of multipart question on this. What kind of pull-through are you seeing for Stryker pr",91,"Maybe I'll also start with MAKO. You always had an exceptionally strong quarter. Maybe, Kevin or Katherine, you could give us a little more color there. Maybe just sort of multipart question on this. What kind of pull-through are you seeing for Stryker products, particularly in competitive accounts? And maybe talk a little more, if you could, about some of the data surrounding -- clinical data surrounding MAKO we might see. I know that's been a priority for this year. What might be seen and when will we see it?"
94614,377148003,1064403,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Executives","Yes, I think, obviously, the 30 robots placed, we're very pleased with that, that number of installations. We're also pleased that they are going into -- roughly 40% into competitive accounts. It's also what is helping drive our knee growth, which, I beli",233,"Yes, I think, obviously, the 30 robots placed, we're very pleased with that, that number of installations. We're also pleased that they are going into -- roughly 40% into competitive accounts. It's also what is helping drive our knee growth, which, I believe, is above market and I mean, clearly is a big focus for our sales force right now, given their excitement around that. We do believe qualitatively, we're going to get -- continue to receive feedback around benefits, including alignment, less tissue disruption and ultimately, patient satisfaction. Longer term, clinical data on that is going to take us some time to collect. We will be gathering that, but that's going to be 1-, 2-, 3-year data and obviously, it will take that long. I think it will be a great opportunity at the panel at the Analyst Day where we're going to have a surgeon who had no experience with a robot prior to becoming part of the limited market release of the knee as well as a longer-term robot user to ask those questions and hear what their experience has been. But with the 200 cases to date, we've been really pleased with what we've seen so far and the ability to both get into competitive accounts and optimize the training protocol ahead of full commercial launch, which, as we said, will take place in March at the academy meeting."
94614,377148003,1064403,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Analysts","Great. Just a follow-up on Sage and Physio briefly. Maybe just highlight -- I know we'll hear more soon, but where are we in terms of the integration and cost and sales? Kevin, you feel like you're on plan. Sage grew a little faster than the second quarte",65,"Great. Just a follow-up on Sage and Physio briefly. Maybe just highlight -- I know we'll hear more soon, but where are we in terms of the integration and cost and sales? Kevin, you feel like you're on plan. Sage grew a little faster than the second quarter. Physio, a tad slower. I assume that's seasonal. But again, any more color there would be welcome."
94614,377148003,1064403,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Executives","Yes. Thanks, Rick. So first of all, over the full 6-month period, we're really pleased with both companies' performance. They're really line with our expectations. The integrations are going very well. As you know, Sage is, I'll call it, more of a lighter",134,"Yes. Thanks, Rick. So first of all, over the full 6-month period, we're really pleased with both companies' performance. They're really line with our expectations. The integrations are going very well. As you know, Sage is, I'll call it, more of a lighter integration, given that there's less of an overlap with the call point. But certainly, we're sharing leads with the Sage organization. At Physio, we have a little bit more of call point overlap. It's really more of a planning phase this year. Our sales forces are running independently this year. And then over the course of the next year or 2, we'll start to integrate those sales forces. But I would stay, so far so good on integration, and we're pleased with the performance and really, the outlook for the future."
94614,377148003,1064403,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Operator","Our next question comes from Mike Weinstein from JPMorgan.",9,"Our next question comes from Mike Weinstein from JPMorgan."
94614,377148003,1064403,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Analysts","Congratulations on getting back to above that 6% bar. That's nice to see. Katherine, the September health care conferences proved a bit trickier this year. And there was a bunch of questions, as you know, that come out of them where people were asking abo",187,"Congratulations on getting back to above that 6% bar. That's nice to see. Katherine, the September health care conferences proved a bit trickier this year. And there was a bunch of questions, as you know, that come out of them where people were asking about comments that you guys have made. So maybe I thought it was a good opportunity to clarify a couple of them. And Katherine, Kevin, chime in here, 2 sets of comments were -- Kevin, just about your outlook for the Trauma business and the Hip business and some potential deceleration in growth. And then naturally, people try to get you to comment on 2017 preliminarily and how to think about operating a financial leverage, excluding the impact of the acquisitions. There seems to be some confusion around that. So maybe just want to spend a minute on both the outlook for the Trauma and then the Hip business in light of the -- all the focus on the knee side and then just comment, if you would, about how we should think about operating leverage heading into '17 without obviously giving guidance."
94614,377148003,1064403,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Executives","Sure, Mike. I'll take the Trauma and Hip question, and then I'll pass it over to Katherine to talk about, I think, some misperceptions around 2017. So what I've been saying for some time on the Trauma business is that sustaining 15% growth quarter after q",312,"Sure, Mike. I'll take the Trauma and Hip question, and then I'll pass it over to Katherine to talk about, I think, some misperceptions around 2017. So what I've been saying for some time on the Trauma business is that sustaining 15% growth quarter after quarter is pretty unlikely. We've done that for over 3 years coming into this year. If you look at last year's third quarter, we grew 15.1% in the U.S. And so to put up a 7% growth against that comp is still a pretty solid performance. But while big numbers is -- we've been signaling that Trauma will start to slow down a little bit in terms of its growth rate, but certainly performing above market and I think it still had a strong solid performance this quarter. But the only signal there is that sustaining that level of outperformance 3x the market is not likely to do indefinitely. So no concerns. We have a very strong Trauma leadership team, strong business, strong pipeline. I'm still very bullish about that division. As it relates to Hips, we're longer in our product cycle, with Accolade II being one of the newer products that we launched a few years ago. And a lot of excitement in knees. And as you know, same sales force that sells both Hips and Knees. We have a big launch upcoming with MAKO total knee. We have a lot of cementless products in the knee portfolio. So I would say that there's been a bit of attention focused on these. And we've seen this in our industry for decades that it's very difficult to be able to focus on both products equally. So the fact that our Hip growth, which have been above market for about 3 or 4 years, is now moving, let's say, more in line with market is not also surprising."
94614,377148003,1064403,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Executives","Yes. And just going back to some of the misperceptions around some of the conferences, the health care conferences in September, I will tell you, candidly, we were surprised if anybody -- that there was any misperception. We try to be very consistent in t",176,"Yes. And just going back to some of the misperceptions around some of the conferences, the health care conferences in September, I will tell you, candidly, we were surprised if anybody -- that there was any misperception. We try to be very consistent in terms of our goal of growing sales at the high end of med tech. We think the med tech markets are largely stable, at least the segments where our product portfolio competes. But as Kevin said in his prepared comments at the start of this call, we feel really good about our ability to continue to deliver that. The specific range around that, in which may have been, where some of the misperceptions came, we will talk about in January as we do every year. So to the degree of unwillingness to give guidance ahead of when we normally do it caused some concern, I think that was incorrect. We feel great about the momentum and the product portfolio, and we'll look to specify that in terms of financial ranges in January."
94614,377148003,1064403,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Analysts","So there's -- Katherine, just one follow-up, if I can. The growth in MAKO this quarter and the units that sold their place, was that to -- just characterize it, was that to the beta sites that have been doing the, call it, early launch feedback for you gu",58,"So there's -- Katherine, just one follow-up, if I can. The growth in MAKO this quarter and the units that sold their place, was that to -- just characterize it, was that to the beta sites that have been doing the, call it, early launch feedback for you guys? Or is that the centers anticipating the launch?"
94614,377148003,1064403,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Executives","It's both. Some of those are to those that are part of the limited market release, but that's a small group. Some of those were just, for lack of a better word, putting and getting in the queue because they want to be part of the upgrades and ready for th",73,"It's both. Some of those are to those that are part of the limited market release, but that's a small group. Some of those were just, for lack of a better word, putting and getting in the queue because they want to be part of the upgrades and ready for the total launch. So it's a mix, but it is -- I would say that limited market release customers are the minority."
94614,377148003,1064403,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Operator","Our next question comes from David Lewis from Morgan Stanley.",10,"Our next question comes from David Lewis from Morgan Stanley."
94614,377148003,1064403,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Analysts","Just 2 quick questions, one for Kevin, one for Katherine. Kevin, just -- you've got a wide range of businesses now that you're back above 6% organic this quarter, and I agree with Mike, that was nice to see. I wonder if you could just comment, just given",167,"Just 2 quick questions, one for Kevin, one for Katherine. Kevin, just -- you've got a wide range of businesses now that you're back above 6% organic this quarter, and I agree with Mike, that was nice to see. I wonder if you could just comment, just given the broader environment this particular quarter, a couple of things. One, just your capital business is very strong. There's some emerging concern that the election cycle is going to result in some capital freeze and result in that months in September and October heading to the election cycle. So just due to the broader capital environment heading into election, are you seeing any change in sort of relative backlogs? And then utilization, sort of a similar question, a lot of talk about polarization in sort of July, August versus September. I mean, do you see a change in how utilization trended in some of your Orthopaedic businesses across the quarter? And then I had a quick one for Katherine."
94614,377148003,1064403,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Executives","Yes. So thanks, David. What I would tell you is we haven't seen really any change in the capital. Business has been extremely stable. The election to us is really a nonevent in terms of the businesses that we participate in. As you know, there's a lot of",129,"Yes. So thanks, David. What I would tell you is we haven't seen really any change in the capital. Business has been extremely stable. The election to us is really a nonevent in terms of the businesses that we participate in. As you know, there's a lot of attention being drawn to pharma, a lot of commentary made about pharma. But med tech is very small percent of the overall health care spend, and we're not seeing really any impact whatsoever. And as it relates to procedural volume, again, we didn't see anything unusual within the month of the quarter, very, very stable market. And that's not new. The market has been stable for the past 2 years, 3 years, and we continue to perform well in this market."
94614,377148003,1064403,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Analysts","Kevin -- sorry, Katherine, in terms of back half '17, you'd said MAKO, it's unlikely we see share movement until back half '17 the earliest. I just think about -- it's the biggest year-on-year system add you've had, I think, since you bought the company.",82,"Kevin -- sorry, Katherine, in terms of back half '17, you'd said MAKO, it's unlikely we see share movement until back half '17 the earliest. I just think about -- it's the biggest year-on-year system add you've had, I think, since you bought the company. You've got 40% competitive accounts, and obviously, you're going to have a bigger launch at AAOS. Is the back half of '17 still the earliest that we could start to see share movement in the knee channel?"
94614,377148003,1064403,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Executives","I think that's the way to be thinking about it right now. Remember, these robots have to get installed. That takes time and energy and people we have to train. And so there's a cadence. This is not like an easy product that you launch overnight and it run",114,"I think that's the way to be thinking about it right now. Remember, these robots have to get installed. That takes time and energy and people we have to train. And so there's a cadence. This is not like an easy product that you launch overnight and it runs. So we need to be thoughtful in that regard clearly that we can target academy for the full commercial launch, and we'll be well prepared to go out and train from there. But I still think the back half of the year is the best time to be focused on in terms of starting to see indications that we're gaining meaningful knee market share."
94614,377148003,1064403,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Operator","Our next question comes from Kristen Stewart from Deutsche Bank.",10,"Our next question comes from Kristen Stewart from Deutsche Bank."
94614,377148003,1064403,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Analysts","Just to go back, I guess, to some of the comments on the acquisitions. I know you said that integration's going so far. Would you be willing to say in terms of the 2017 accretion numbers that those still look to be intact based upon how the businesses are",58,"Just to go back, I guess, to some of the comments on the acquisitions. I know you said that integration's going so far. Would you be willing to say in terms of the 2017 accretion numbers that those still look to be intact based upon how the businesses are performing, better or worse than you had originally stated?"
94614,377148003,1064403,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Executives","Kristen, it's Glenn. Yes, we actually were on track in 2016 to -- with the accretion numbers that we put out there. And then also, for 2017, based on our preliminary planning, we think we'll be on track to hit the numbers that we put out for accretion as",50,"Kristen, it's Glenn. Yes, we actually were on track in 2016 to -- with the accretion numbers that we put out there. And then also, for 2017, based on our preliminary planning, we think we'll be on track to hit the numbers that we put out for accretion as well."
94614,377148003,1064403,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Analysts","Okay, great. And then has FX changed at all in terms of the bottom line impact? And with the change in stock option accounting, can you give us a sense in terms of how that may also impact or maybe what the impact might be in 2016 or '15 or anything to th",58,"Okay, great. And then has FX changed at all in terms of the bottom line impact? And with the change in stock option accounting, can you give us a sense in terms of how that may also impact or maybe what the impact might be in 2016 or '15 or anything to that extent you could help frame?"
94614,377148003,1064403,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Executives","Yes, yes. It feels like 2 questions, and I'll take a stab at them both. So first off, on FX, as you can see, translational is easing, especially in Q3, and we expect it to be nominal in Q4. Transactional will still continue to impact us as it did this qua",133,"Yes, yes. It feels like 2 questions, and I'll take a stab at them both. So first off, on FX, as you can see, translational is easing, especially in Q3, and we expect it to be nominal in Q4. Transactional will still continue to impact us as it did this quarter and it will next quarter. And part of that is related to our hedging program and the way we lock in hedges 18 months ahead of time and how that relates to the current exchange rates that are out there. And then secondly, as it relates to the change in stock option, I think if you take a look, we've disclosed what we think that'll be, which is roughly maybe $30 million. And we don't plan on adopting it until next year."
94614,377148003,1064403,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Operator","Our next question comes from Chris Pasquale from Guggenheim.",9,"Our next question comes from Chris Pasquale from Guggenheim."
94614,377148003,1064403,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Analysts","Kevin, it's been a while since you guys hosted an analyst meeting, and I know you talked about not wanting to comment too much on forward guidance yet. But you're going to have the chance to talk about some of the progress you've made with some of the inv",120,"Kevin, it's been a while since you guys hosted an analyst meeting, and I know you talked about not wanting to comment too much on forward guidance yet. But you're going to have the chance to talk about some of the progress you've made with some of the investments to get a cost in the middle of the income statement, in particular. I see Lonny's on the agenda. Can you talk a little bit about some of those programs? You've highlighted the ERP transition, some of the other things you're doing. And will this be an opportunity to sort of layout the next steps to how we get some leverage, particularly in the middle of the income statement going forward?"
94614,377148003,1064403,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Executives","I think what you'll hear Lonny talk about is progress on multiple fronts as we've gotten the CTG program underway. ERP is one of them, product life cycle management, planned optimization, indirect spend and as we try to articulate, giving greater quantifi",71,"I think what you'll hear Lonny talk about is progress on multiple fronts as we've gotten the CTG program underway. ERP is one of them, product life cycle management, planned optimization, indirect spend and as we try to articulate, giving greater quantification around the longer-term targets and expected contribution from that. That will be the focus of his comments while Glenn will focus on our longer-term financial targets beyond '17."
94614,377148003,1064403,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Analysts","Okay. That's helpful. And then sorry if I missed this earlier, I've been jumping around. But can you talk a little bit about the Trauma and Extremities business? Good quarter there, a little bit of a pickup from what we saw last quarter. Anything in parti",48,"Okay. That's helpful. And then sorry if I missed this earlier, I've been jumping around. But can you talk a little bit about the Trauma and Extremities business? Good quarter there, a little bit of a pickup from what we saw last quarter. Anything in particular driving that?"
94614,377148003,1064403,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Executives","No, I would say it's just continued strong performance, and we've been performing well in our Trauma business over the last 3 years, and it was just more of the same this quarter.",33,"No, I would say it's just continued strong performance, and we've been performing well in our Trauma business over the last 3 years, and it was just more of the same this quarter."
94614,377148003,1064403,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Operator","Our next question comes from Kaila Krum from William Blair.",10,"Our next question comes from Kaila Krum from William Blair."
94614,377148003,1064403,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Analysts","Just a couple for me. So in terms of acquisition strategy and I guess, specific to Orthopaedics and Spine, are you guys more focused on scale or growth at this point in time? And granted they do come hand-in-hand, but one tends to lead to the together, so",57,"Just a couple for me. So in terms of acquisition strategy and I guess, specific to Orthopaedics and Spine, are you guys more focused on scale or growth at this point in time? And granted they do come hand-in-hand, but one tends to lead to the together, so just trying to better understand your M&A strategy there."
94614,377148003,1064403,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Executives","There's no change in M&A strategy. Whether it's the company overall or Ortho versus MedSurg & Neurotech, it's focused on our core and key adjacent markets. If you look historically, the bulk of our deals have been in core markets with a few key adjacent a",66,"There's no change in M&A strategy. Whether it's the company overall or Ortho versus MedSurg & Neurotech, it's focused on our core and key adjacent markets. If you look historically, the bulk of our deals have been in core markets with a few key adjacent acquisitions. And that will continue to be the strategy going forward across all the divisions. So no change from that."
94614,377148003,1064403,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Analysts","Okay. And then just a follow-up on the Extremities business. I mean, just looking specifically at Foot & Ankle, can you guys talk about how your Foot & Ankle performance has been recently? Are they still sort of trending in historical levels? And just any",53,"Okay. And then just a follow-up on the Extremities business. I mean, just looking specifically at Foot & Ankle, can you guys talk about how your Foot & Ankle performance has been recently? Are they still sort of trending in historical levels? And just any commentary on market trends there would be helpful."
94614,377148003,1064403,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Executives","Yes. So we're really pleased with our Foot & Ankle performance. In the U.S., this quarter, we grew 15%, very much in line with the performance we've had over the past year. It continues to be a very good market.",40,"Yes. So we're really pleased with our Foot & Ankle performance. In the U.S., this quarter, we grew 15%, very much in line with the performance we've had over the past year. It continues to be a very good market."
94614,377148003,1064403,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Operator","Our next question comes from Glenn Novarro from RBC Capital.",10,"Our next question comes from Glenn Novarro from RBC Capital."
94614,377148003,1064403,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Analysts","Two questions. First, pricing in Orthopaedics, down 2.2%. That was similar to the second quarter. So I'm wondering if the new trend line of Orthopaedic pricing is now going to be in that 2% to 2.5% range. Then I had a follow-up on pricing.",44,"Two questions. First, pricing in Orthopaedics, down 2.2%. That was similar to the second quarter. So I'm wondering if the new trend line of Orthopaedic pricing is now going to be in that 2% to 2.5% range. Then I had a follow-up on pricing."
94614,377148003,1064403,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Executives","I think we feel comfortable, from a total company perspective, that pricing is going to be down in that 1.5%, 2% vicinity. It's been trending slightly less negative. Ortho, it seems relatively stable, but candidly trying to predict that level of accuracy.",97,"I think we feel comfortable, from a total company perspective, that pricing is going to be down in that 1.5%, 2% vicinity. It's been trending slightly less negative. Ortho, it seems relatively stable, but candidly trying to predict that level of accuracy. 50, 100 basis points moves in price. It's really difficult. We have greater confidence and visibility when you look at the totality of the company because we have areas with less price, less pricing pressure. And so we really try to focus on the total versus specific line item where it can move around quarter-to-quarter."
94614,377148003,1064403,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Analysts","Okay. And then just as a follow-up to that. Pricing, again, I look at it sequentially, pretty stable. And now we're in the 6 months of CJR, so it seems like there's been no impact to pricing. So I'm curious as to what your thoughts are on the implementati",58,"Okay. And then just as a follow-up to that. Pricing, again, I look at it sequentially, pretty stable. And now we're in the 6 months of CJR, so it seems like there's been no impact to pricing. So I'm curious as to what your thoughts are on the implementation of CJR. And are you seeing any pricing pressures?"
94614,377148003,1064403,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Executives","We would agree, we really haven't seen an impact. But in fairness, too, it has only been 6 months. And in the first year, there is no financial penalty. So we really believe you're going to see a greater focus by hospitals when there's more of a financial",133,"We would agree, we really haven't seen an impact. But in fairness, too, it has only been 6 months. And in the first year, there is no financial penalty. So we really believe you're going to see a greater focus by hospitals when there's more of a financial incentive. Now as you go into 2017, I think you'll be able to get a lot better visibility or hopefully will at the Analyst Day because we will have a hospital customer who's had experience under the bundled payment. But we continue to believe their focus is going to be in the post-acute setting on rehab costs as there is tremendous value to be realized by shifting more patients to the home and not at some of the skilled nursing facilities and other rehab facilities."
94614,377148003,1064403,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Operator","Our next question comes from Matt Miksic from UBS.",9,"Our next question comes from Matt Miksic from UBS."
94614,377148003,1064403,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Analysts","So I had one kind of topical question coming out NASS and your demonstration of Tritanium and your 3D-printed products. And then I had one follow-up just on the Ortho side, if I could. So one of the things you've talked about in your presentation and the",159,"So I had one kind of topical question coming out NASS and your demonstration of Tritanium and your 3D-printed products. And then I had one follow-up just on the Ortho side, if I could. So one of the things you've talked about in your presentation and the Q&A afterwards, there was just a buildout you've put in place around 3D-printed products in general. Of course, that drives the Spine portfolio of really one key product at the moment. But also, your press-fit knee, cementless knee platform you've talked a lot about. So I'm wondering, as you build that out, I mean, just given the proportion of your business, given the performance of your business, how are you prioritizing, I guess? Are you getting leverage across those 2 platforms and the way you manufacture and how you're sort of thinking about which one of these sort of high-demand products gets the volume over time? And I have more follow-up."
94614,377148003,1064403,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Executives","Sure, Matt. The short answer is they all do, but we have been capacity-constrained. We are adding 3D printing capacity on a monthly basis. We broke ground on a dedicated 3D printing facility in Ireland last year. As you know, this is extremely highly tech",89,"Sure, Matt. The short answer is they all do, but we have been capacity-constrained. We are adding 3D printing capacity on a monthly basis. We broke ground on a dedicated 3D printing facility in Ireland last year. As you know, this is extremely highly technical with a great deal of know-how around 3D printing these types of metals. We will be launching additional 3D-printed products. And -- but you should assume you'll see the benefit of that in Spine as well as on our revision and press-fit knee portfolio."
94614,377148003,1064403,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Analysts","Okay. And then the follow-up, just on the trends in Orthopaedics. I mean, the knee number, U.S. in particular, I thought was quite strong going up against a pretty significantly tougher comp. Hips, kind of the same. So just in terms of trends there, I thi",114,"Okay. And then the follow-up, just on the trends in Orthopaedics. I mean, the knee number, U.S. in particular, I thought was quite strong going up against a pretty significantly tougher comp. Hips, kind of the same. So just in terms of trends there, I think we talked about, back in September, what should we expect in terms of our recovery in Hips or annualizing some of the launches that you got in Hips. And then on knees, if you could -- is it the press-fit that's really making out the difference in driving -- are we getting a mix benefit, penetration benefit on the knee side that's driving that strength? I appreciate it."
94614,377148003,1064403,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Executives","Yes. So keep in mind, it's the same sales force and the same customer base on Hips and Knees. Accolade, which has been a terrific product launch for us, is several years into that now, whereas MAKO is getting an enormous amount of focus and has a huge pro",205,"Yes. So keep in mind, it's the same sales force and the same customer base on Hips and Knees. Accolade, which has been a terrific product launch for us, is several years into that now, whereas MAKO is getting an enormous amount of focus and has a huge product launch. And as a result, the sales force has focused on that. So there is a halo effect that's helping our knee business. We also have additional new products on the knee side, our 3D-printed revision cones and sleeves and as we just mentioned, our 3D-printed cementless knee, which is really driving us to now low double-digit penetration for cementless knees, which is well above the industry. So I think right now, you're just in a period where there's a lot of happening on the knee side and a lot will continue to happen as we go to full commercial launch. We will be introducing more hip products, but sales force likes to focus on what's new and hot. And clearly, a lot of that momentum right now is on the knee side. And so we think hips, probably more like overall market growth. Knees, we believe, we're going to continue to grow above the market."
94614,377148003,1064403,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Executives","But certainly, when you look at the overall, we're very pleased with our performance. Our sales teams are doing an excellent job, and we're excited about the future years.",29,"But certainly, when you look at the overall, we're very pleased with our performance. Our sales teams are doing an excellent job, and we're excited about the future years."
94614,377148003,1064403,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Operator","Our next question comes from Mike Matson from Needham & Company.",10,"Our next question comes from Mike Matson from Needham & Company."
94614,377148003,1064403,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Analysts","We've seen a real pickup in the amount of M&A and the spine space. And Kevin, last I heard, I think you were saying that you're happy with the performance of the Spine business and the turnaround there and you didn't really feel the need to do something f",70,"We've seen a real pickup in the amount of M&A and the spine space. And Kevin, last I heard, I think you were saying that you're happy with the performance of the Spine business and the turnaround there and you didn't really feel the need to do something from an acquisition standpoint in Spine. But I just wanted to check and see if that was still how you felt."
94614,377148003,1064403,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Executives","Yes, so as you look at our Spine business, you see that we've had some issues around product performances, supply chain disruptions. But we have a great leadership team, and we had a number of quarters of very strong growth. And I believe in this leadersh",120,"Yes, so as you look at our Spine business, you see that we've had some issues around product performances, supply chain disruptions. But we have a great leadership team, and we had a number of quarters of very strong growth. And I believe in this leadership team, and Tritanium is a great example of the 3D-printed interbody device, which is performing very well. I'm confident our team can continue to perform well and grow the business. Related to M&A, I would give you the same comment I give for all our divisions. We're always looking to strengthen our businesses, but we're not going to comment on whether we're going to do acquisitions, big or small, on any of our divisions."
94614,377148003,1064403,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Analysts","Okay, I understand. And then you do have a significant portion of cash -- of your cash outside the U.S. So I know there's some talk of a potential tax deal after the election. So if that were to occur, obviously, it would depend of the terms of that. But",74,"Okay, I understand. And then you do have a significant portion of cash -- of your cash outside the U.S. So I know there's some talk of a potential tax deal after the election. So if that were to occur, obviously, it would depend of the terms of that. But would you repatriate any of that cash? And if you did, what would you -- how would you prioritize the use of that cash?"
94614,377148003,1064403,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Executives","As we look at our cash, I'm sure we're in the same position as several other U.S. companies. And if something like that became available, as it did a few years back, we would definitely take advantage of it and repatriate our cash to the extent possible.",105,"As we look at our cash, I'm sure we're in the same position as several other U.S. companies. And if something like that became available, as it did a few years back, we would definitely take advantage of it and repatriate our cash to the extent possible. In terms of how we might prioritize that cash, it's hard to say at this point. We've said before about what our priorities are around capital allocation, and that would mean M&A, that would mean dividends and it may mean share buybacks. But commenting beyond that, I don't think I can do that at this point in time."
94614,377148003,1064403,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Operator","Our next question comes from Bruce Nudell from SunTrust.",9,"Our next question comes from Bruce Nudell from SunTrust."
94614,377148003,1064403,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Analysts","Kevin, I have a couple for you. Firstly, I'm fascinated by this 40% placement of MAKO at competitive accounts. One of the big issues with Orthopaedics is that there's tremendous brand synergization of product on the part of surgeons as well as institution",87,"Kevin, I have a couple for you. Firstly, I'm fascinated by this 40% placement of MAKO at competitive accounts. One of the big issues with Orthopaedics is that there's tremendous brand synergization of product on the part of surgeons as well as institutions for hips or knees. So how do you accomplish that where you put a robot in and get people to go beyond new knees and kind of standardize on knees with the Stryker brand that they may not use most of the time today?"
94614,377148003,1064403,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Executives","The way we look at our MAKO adoption is really around behavioral segmentation, which surgeons like new technology and believe that they can become better at delivering value to their patients with technology. And so it's not about whether they like Stryke",90,"The way we look at our MAKO adoption is really around behavioral segmentation, which surgeons like new technology and believe that they can become better at delivering value to their patients with technology. And so it's not about whether they like Stryker or whether they like Zimmer or whether they like J&J. It's about do they like robotics and do they believe in robotics. And that's why, not surprising that many of the placements are in competitive products. [ph] We're getting a lot of feedback. Can you hear me, Bruce?"
94614,377148003,1064403,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Analysts","Yes. Yes, I can.",4,"Yes. Yes, I can."
94614,377148003,1064403,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Executives","I'm sorry, we're getting a little feedback in the room. But -- so what I'd tell you on this front is it's really all about the surgeon who wants to become better and who believes in technology, less so about our specific relationships or whether the hospi",182,"I'm sorry, we're getting a little feedback in the room. But -- so what I'd tell you on this front is it's really all about the surgeon who wants to become better and who believes in technology, less so about our specific relationships or whether the hospital is with Stryker or a different account, if it's different knees that we're serving. If you look at MAKO prior to our acquisition, they were able to obtain about 18% of the knee market over a 4-year period. There were not a proven entity. They weren't even an orthopedic company. So we really believe this about technology adoption certainly in the first couple of years. It's really around behavior, which surgeons believe in technology, and we're going to go to the surgeons that believe in it. There are many skeptics, as you know, with all disruptive technology. And some of those skeptics are Stryker loyal surgeons. And they won't be the first to adopt. And that doesn't concern us because there are many surgeons who are interested and who will be willing to adopt."
94614,377148003,1064403,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Analysts","And my second question is as we're relaunching on Stryker, what really struck me was that despite the acquisitive nature of the company, ROIC has been maintained. And could you just -- and it seems to be like a core strength of the company. Could you talk",72,"And my second question is as we're relaunching on Stryker, what really struck me was that despite the acquisitive nature of the company, ROIC has been maintained. And could you just -- and it seems to be like a core strength of the company. Could you talk about how that influences the profile of what you buy, how it fits in? And is that a formula you can maintain going forward?"
94614,377148003,1064403,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Executives","It's long been our history to be very disciplined in our deployment of capital. So when we look at deals, we want to strengthen every division that we have in the company. But we won't just pay whatever to companies. We're very disciplined. We walk away w",172,"It's long been our history to be very disciplined in our deployment of capital. So when we look at deals, we want to strengthen every division that we have in the company. But we won't just pay whatever to companies. We're very disciplined. We walk away when the prices are above our ability to deliver value. And sometimes, there's assets that we like and the price point's just too high and we have discipline to walk away from deals. And I think that's why you see the ROIC still consistent year over year over year in spite of the acquisition nature. The -- also, the ability to have acquisition that fit in our existing business, that plug into our sales force, which is the bulk of the deals we do. We have a proven model to deliver value with those types of acquisitions. So I think it's a combination of playing to our strengths in terms of our commercial execution and being financially disciplined with the deals that we do make."
94614,377148003,1064403,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Operator","Our next question comes from Richard Newitter from Leerink Partners.",10,"Our next question comes from Richard Newitter from Leerink Partners."
94614,377148003,1064403,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Analysts","I want to, maybe for you, Kevin, to start off. We're at NASS. Obviously, it's topical. We're seeing a lot of robotics take a bigger presence on the floor. Being that you were the first major company to kind of really validate the robotics category, we'd l",76,"I want to, maybe for you, Kevin, to start off. We're at NASS. Obviously, it's topical. We're seeing a lot of robotics take a bigger presence on the floor. Being that you were the first major company to kind of really validate the robotics category, we'd love to hear what your view is of the robotics kind of push in spine we're starting to see and then how MAKO potentially fits in over the long run."
94614,377148003,1064403,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Executives","Well, we love the fact that robotics is taking up a lot of the discussion because as you know, with MAKO, we believe in robotics. Right now, at Stryker, our focus is on hips and knees and specifically, the total knee launch. But we see, over time, that ce",86,"Well, we love the fact that robotics is taking up a lot of the discussion because as you know, with MAKO, we believe in robotics. Right now, at Stryker, our focus is on hips and knees and specifically, the total knee launch. But we see, over time, that certainly, robotics will extend into other procedural areas, including spine. We do have a smaller NDF underway right now, but it's too early for us to speculate on when we would come to the market in that specialty."
94614,377148003,1064403,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Analysts","Okay. And then maybe just one more follow-up. Outpatient surgery and the trend to outpatient ambulatory surgery care, it's clearly where hospitals are trying to go. I'd love to just hear how you deal Stryker's position, either through technology or other",64,"Okay. And then maybe just one more follow-up. Outpatient surgery and the trend to outpatient ambulatory surgery care, it's clearly where hospitals are trying to go. I'd love to just hear how you deal Stryker's position, either through technology or other means to capitalize on that trend. And specifically, if you could talk whether or not MAKO is lending a hand in that effort."
94614,377148003,1064403,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Executives","We have a lot of experience with the ambulatory surgery center with our sports medicine business. And as you know spine, the number of procedures -- the more simpler procedures are starting to move into the ambulatory surgery center. At this stage, MAKO h",129,"We have a lot of experience with the ambulatory surgery center with our sports medicine business. And as you know spine, the number of procedures -- the more simpler procedures are starting to move into the ambulatory surgery center. At this stage, MAKO hasn't had a big impact but we do see our robotics is going to have a play in all of the different aspects of the care continuum. I think this trend will continue towards -- shift the side of care towards surgery centers will continue, but it's not something that we're -- nothing prepared for. We have plans across our divisions. And as you saw with -- you're at NASS, you saw the Spine division's actually created a program that's very specific for the surgery center."
94614,377148003,1064403,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Operator","Our next question comes from Larry Biegelsen from Wells Fargo.",10,"Our next question comes from Larry Biegelsen from Wells Fargo."
94614,377148003,1064403,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Analysts","So I wanted to just touch on and focus on the [indiscernible]",12,"So I wanted to just touch on and focus on the [indiscernible]"
94614,377148003,1064403,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Executives","Larry, I apologize. We can't hear you.",7,"Larry, I apologize. We can't hear you."
94614,377148003,1064403,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Executives","Are you on speaker? Could you pick up, please?",9,"Are you on speaker? Could you pick up, please?"
94614,377148003,1064403,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Analysts","Look, sorry about that. Neurotech, that was a little slower in the U.S. this quarter. What drove the deceleration? Is it -- could you talk a little bit about how your [indiscernible] business is performing? I know you talked about that as a key growth dri",49,"Look, sorry about that. Neurotech, that was a little slower in the U.S. this quarter. What drove the deceleration? Is it -- could you talk a little bit about how your [indiscernible] business is performing? I know you talked about that as a key growth driver for you guys."
94614,377148003,1064403,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Executives","Yes, so we continue to see good momentum in the AIS market. As we talked about before, predicting the slope and the speed of that market adoption is tricky. So we'll move around quarter-to-quarter and AIS was a bit slower sequentially, although still heal",70,"Yes, so we continue to see good momentum in the AIS market. As we talked about before, predicting the slope and the speed of that market adoption is tricky. So we'll move around quarter-to-quarter and AIS was a bit slower sequentially, although still healthy growth in that segment. We did have a coil recall in the quarter, which impacted our hemorrhagic business. That's fully resolved and shouldn't impact going forward."
94614,377148003,1064403,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Operator","Our next question comes from Matthew O'Brien from Piper Jaffray.",11,"Our next question comes from Matthew O'Brien from Piper Jaffray."
94614,377148003,1064403,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Analysts","Just wanted to start with MAKO and continue to focus on this a little bit more. But first of all, did you fully spell all 13 additional systems this quarter versus Q3 of last year? And the reason I asked that question is if you backed that out, assuming y",119,"Just wanted to start with MAKO and continue to focus on this a little bit more. But first of all, did you fully spell all 13 additional systems this quarter versus Q3 of last year? And the reason I asked that question is if you backed that out, assuming you sold it all, it would seem like your core knee business was a little bit softer than one of your competitors recorded this quarter. And then on a 2-year stack basis, it's little bit soft as well. So is there a risk as sales force focuses on MAKO that we could see kind of the traditional knee business soften a little bit, along with the hip business as well?"
94614,377148003,1064403,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Executives","Well, we continue to sell all of our robots, just to be clear. And we report our robot sales in the other Orthopaedic category. We can see it's up quite a bit. The other items that are shown in that other category includes bone cement, and bone cement was",116,"Well, we continue to sell all of our robots, just to be clear. And we report our robot sales in the other Orthopaedic category. We can see it's up quite a bit. The other items that are shown in that other category includes bone cement, and bone cement was down in the quarter, both in the U.S. and internationally. We used to have a lot more stocking orders for bone cement, and now our hospital customers are sort of buying it as they need it. And so bone cement does tend to be volatile from quarter-to-quarter. But when you look at our knee number, those are implants that you're seeing in knee number, no robot sales."
94614,377148003,1064403,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Analysts","And I'm also going off my memory [ph] on this one too, which is, obviously, [indiscernible] given the first question I just had. But it looks like, I think, Physio grew about 9% pro forma last quarter, and it grew about 6% this quarter. Obviously, we don'",87,"And I'm also going off my memory [ph] on this one too, which is, obviously, [indiscernible] given the first question I just had. But it looks like, I think, Physio grew about 9% pro forma last quarter, and it grew about 6% this quarter. Obviously, we don't have the comparables to look at, but is there anything that's going on that's maybe slowing a little bit as you integrate that asset? Or is it just more, ""Hey, we had a tougher comp this time last year""?"
94614,377148003,1064403,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Executives","I wouldn't read anything into that. Remember, it's a capital business. It tends to move around quarter-to-quarter. And so the -- there wasn't anything unique relative Q2 to Q3. We're very pleased with that integration so far, recognizing it early, as Kevi",76,"I wouldn't read anything into that. Remember, it's a capital business. It tends to move around quarter-to-quarter. And so the -- there wasn't anything unique relative Q2 to Q3. We're very pleased with that integration so far, recognizing it early, as Kevin commented on. But you will see capital move around. We tend to try and focus on multi-quarter rolling trends to really get a good sense with that business, but nothing to call out."
94614,377148003,1064403,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Operator","Our next question comes from Matt Taylor from Barclays.",9,"Our next question comes from Matt Taylor from Barclays."
94614,377148003,1064403,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Analysts","This is actually Ian Mahmud in for Matt. So there's been a lot of discussion on Spine during this call. But I wanted to sort of explore a little more and just ask about what you're seeing in terms of competition. I mean, we've heard a lot about redoubled",75,"This is actually Ian Mahmud in for Matt. So there's been a lot of discussion on Spine during this call. But I wanted to sort of explore a little more and just ask about what you're seeing in terms of competition. I mean, we've heard a lot about redoubled efforts to focus on that area from some of your competitors. So just wanted to see if you're seeing anything different there, any commentary to highlight."
94614,377148003,1064403,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Executives","There's nothing we would uniquely call out. It remains a highly competitive market with a lot of players across the board with the larger, more established companies and obviously, the smaller ones. But there's nothing that we're seeing different with res",54,"There's nothing we would uniquely call out. It remains a highly competitive market with a lot of players across the board with the larger, more established companies and obviously, the smaller ones. But there's nothing that we're seeing different with respect to any of the key competitors in the market at this time."
94614,377148003,1064403,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Operator","And our next question comes from Jeff Johnson from Baird.",10,"And our next question comes from Jeff Johnson from Baird."
94614,377148003,1064403,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Analysts","Most of my questions have been answered. But Glenn, maybe I missed it. But could you talk about any of the drivers in gross margin between maybe price, currency or product or geographic mix, just kind of big buckets, kind of what drove the change in gross",114,"Most of my questions have been answered. But Glenn, maybe I missed it. But could you talk about any of the drivers in gross margin between maybe price, currency or product or geographic mix, just kind of big buckets, kind of what drove the change in gross margin this year or this quarter? And then as I think about some of the movements we've seen on the yen and some emerging market currencies here recently and given the 18-month hedging program, just any very high level comments you can make about how we think of just the currency hedge portion, settling out the cost of goods, how that impacts over the next several quarters?"
94614,377148003,1064403,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Executives","Sure. I think if you look quarter-to-quarter, Q3 to Q4, our margin is fairly consistent. And I talked about this before. There's -- like you mentioned, there's lots of variables that impact our margin, not only price, but the FX, acquisitions. And certain",215,"Sure. I think if you look quarter-to-quarter, Q3 to Q4, our margin is fairly consistent. And I talked about this before. There's -- like you mentioned, there's lots of variables that impact our margin, not only price, but the FX, acquisitions. And certainly, one of the biggest factors is mix, and the mix plays out in 2 ways. It plays out in sort of geographic mix but also sort of business and product mix. And so as I look year-over-year for third quarter, really, probably the biggest impact that we had was related to business mix in terms of how much MedSurg versus Orthopaedics versus international we had last year versus this year. And then on the FX front, we entered the hedging program back when foreign currency was a lot more volatile, and the whole idea was to lock in the predictability of foreign currency for us. So like you had mentioned, currencies move up and down. Our hedging program provides stability and predictability to us. And so for the third quarter, I think, as I said, there will be sort of a nominal impact on sales related to translational, but that will have, potentially, a minor impact similar to this quarter related to transactional FX. And that's where, I think, we'll come out."
94614,377148003,1064403,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Analysts","And over the next 4 -- 3, 4 quarters, just -- will the currency side alone, and we can make our own assumptions on everything else, but with currency, should we be thinking of that as a small drag still for the next several quarters on gross margins? Is t",53,"And over the next 4 -- 3, 4 quarters, just -- will the currency side alone, and we can make our own assumptions on everything else, but with currency, should we be thinking of that as a small drag still for the next several quarters on gross margins? Is that a fair comment?"
94614,377148003,1064403,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Executives","Yes, I don't know. I wish I had the currency crystal ball to figure out what -- how things were going to flow. But it's hard to say because it's not only impacted by, say, what we've done in hedging but what the underlying transactions are. So I don't thi",60,"Yes, I don't know. I wish I had the currency crystal ball to figure out what -- how things were going to flow. But it's hard to say because it's not only impacted by, say, what we've done in hedging but what the underlying transactions are. So I don't think I can really comment that far out at this point."
94614,377148003,1064403,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Operator","And there are no further questions at this time. I will now turn the conference over to Mr. Kevin Lobo for any closing remarks.",24,"And there are no further questions at this time. I will now turn the conference over to Mr. Kevin Lobo for any closing remarks."
94614,377148003,1064403,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Executives","Thank you all for joining our call. Our conference call for the fourth quarter 2016 results will be held on January 24, 2017. Thank you.",25,"Thank you all for joining our call. Our conference call for the fourth quarter 2016 results will be held on January 24, 2017. Thank you."
94614,377148003,1064403,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Operator","Thank you, ladies and gentlemen. This concludes today's conference. Thank you for participating. You may now disconnect.",17,"Thank you, ladies and gentlemen. This concludes today's conference. Thank you for participating. You may now disconnect."
94614,377148003,1064540,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Operator","Welcome to the Third Quarter 2016 Stryker Earnings Call. My name is Crystal, and I will be your operator for today's call. [Operator Instructions] This conference call is being recorded for replay purposes.Before we begin, I would like to remind you tha",134,"Welcome to the Third Quarter 2016 Stryker Earnings Call. My name is Crystal, and I will be your operator for today's call. [Operator Instructions] This conference call is being recorded for replay purposes.
Before we begin, I would like to remind you that the discussions during this conference call will include forward-looking statements. Factors that could cause actual results to differ materially are discussed in the company's most recent filings with the SEC. Also, the discussions will include certain non-GAAP financial measures. Reconciliations to the most directly comparable GAAP financial measures can be found in today's press release that is an exhibit to Stryker's current report on Form 8-K filed today with the SEC.
I will now turn the call over to Mr. Kevin Lobo, Chairman and Chief Executive Officer. You may proceed, sir."
94614,377148003,1064540,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Executives","Welcome to Stryker's Third Quarter Earnings Call. Joining me today are Glenn Boehnlein, Stryker's CFO; and Katherine Owen, VP of Strategy and Investor Relations.For today's call, I will provide opening comments, followed by Katherine with an update on M",314,"Welcome to Stryker's Third Quarter Earnings Call. Joining me today are Glenn Boehnlein, Stryker's CFO; and Katherine Owen, VP of Strategy and Investor Relations.
For today's call, I will provide opening comments, followed by Katherine with an update on MAKO and our November analyst meeting. Glenn will then provide additional details regarding our quarterly results before we open the call to Q&A.
We achieved another quarter of solid organic sales growth, coming in at 6.2% and fueled by a strong showing for both MedSurg & Neurotechnology, with both delivering roughly 7% increases. Orthopaedics growth was consistent at approximately 5% organically. On a geographic basis, Q3 sales were balanced with a 6% increase in the U.S. and a 6.7% gain in international, driven by strong momentum in Europe and a return to growth in emerging markets.
We are pleased with the performance of our acquisitions, including both Sage and Physio-Control, which are well positioned to help us drive stronger organic sales growth for Stryker in the coming years.
A strong top line performance, coupled with our ongoing focus on G&A leverage, resulted in an EPS of $1.39, up 11.2% and $0.01 above the high end of our target range. Based on our performance for the first 9 months of 2016, we are confident in our ability to deliver our commitments, with organic sales growth for the full year expected at 6% to 6.5%.
We are narrowing our adjusted EPS range to the upper end, which now stands at $5.75 to $5.80 per share. Overall, we believe the strength of our people, diversified revenue model and new product flow positions us well to continue to deliver sales at the high end of med tech with leveraged earnings gains. 
We look forward to providing our 2017 financial guidance on our Q4 earnings call in January.
With that, I will now turn the call over to Katherine."
94614,377148003,1064540,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Executives","Thanks, Kevin. My comments on today's call will include an update on MAKO as well as a preview of our upcoming analyst meeting.Starting with MAKO. Results in the quarter were strong with a total of 30 robots installed globally, representing a roughly 75",439,"Thanks, Kevin. My comments on today's call will include an update on MAKO as well as a preview of our upcoming analyst meeting.
Starting with MAKO. Results in the quarter were strong with a total of 30 robots installed globally, representing a roughly 75% year-over-year increase with 23 in the U.S. Consistent with prior quarters, approximately 40% of the installations were in competitive accounts where Stryker has no or relatively low market share.
Demand for the MAKO robot is being fueled by the expanded indications, including the total knee, which began a limited launch in June. Since that time, we have had KOL surgeons trained on the robots for the total knee, including those with prior robot experience but with less exposure to our Triathlon knee as well as surgeons who had not previously used a robot for joint reconstruction. As we discussed previously, by observing both these groups, we are optimizing the training protocol.
Of note, since the start of the limited market release for the total knee, over 200 cases have been performed, and we've been pleased with the results to date. We are targeting the 2017 AAOS meeting to move into the full commercial launch.
I will now shift to the analyst meeting, which will be held on November 9 at our Orthopaedics headquarters in New Jersey. In order to optimize the utility of this meeting, we will be focusing the formal part of the meeting on several key areas. This will include a MAKO physician panel with 2 surgeons who have been part of the limited market release. We will also have a Stryker Performance Solutions panel, which will include an SPS customer and focus on how we've been able to deploy our expertise in the joint reconstruction episode of care to help reduce our procedural costs.
Turning to cost transformation for growth. Lonny Carpenter, Group President of Global Quality and Operations, will provide an update on the various initiatives within CTG, including the expected financial contribution over the next 2 years. Glenn Boehnlein will provide a financial update, including our longer-term targets. We will conclude the formal part of the meeting with a Q&A session with the leadership team. We will then move to the product fair, which will include product highlights for MedSurg & Neurotechnology and will afford the opportunity to interact informally with the broader Stryker leadership team.
We hope you will be able to join us for the meeting. The event details and complete agenda, including the various guest speakers and their backgrounds, are available on the event registration site.
With that, I will now turn the call over to Glenn."
94614,377148003,1064540,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Executives","Thanks, Katherine. Today, I will focus my comments on our third quarter financial results and performance drivers. Our detailed financial results have been provided in today's press release.Our organic sales grew 6.2% in the quarter, which was within ou",1059,"Thanks, Katherine. Today, I will focus my comments on our third quarter financial results and performance drivers. Our detailed financial results have been provided in today's press release.
Our organic sales grew 6.2% in the quarter, which was within our range of full year expectations of 6% to 6.5%, with no difference in selling days. Pricing in the quarter was down 1.3% from the prior year, while foreign currency exchange had a nominal impact on sales.
U.S. sales continue to demonstrate strong momentum with organic growth of 6%, reflecting solid performances across our portfolio, especially in MedSurg & Neurotech. International sales grew 6.7% organically, highlighted by solid gains in Europe, Canada and Australia, somewhat offset by the continued impact of our previously discussed destocking issues in China. We expect that the fourth quarter will show some improvement in our  China business as prior year comparables continued to ease.
Our adjusted EPS of $1.39 increased 11.2% from the prior year, reflecting strong sales growth, accretive acquisitions and good operating expense control. Our third quarter EPS was negatively impacted by $0.03 related to transactional foreign currency exchange.
Focusing on our segment highlights. Orthopaedics delivered constant currency growth of 5.3% and organic growth of 4.8%, led by the U.S. organic growth of 4.7%. These gains reflect solid performances in Trauma and Extremities at 6.9% and knees at 5.1%. This growth reflects strong demand for our 3D-printed products, our Foot & Ankle portfolio and our MAKO platform, which had 30 units installed, including 7 outside the U.S. Orthopaedics international delivered constant currency growth of 6.3% and organic growth of 5.1%, led by our European business.
MedSurg posted strong gains across all businesses in the quarter with constant currency growth of 33% and organic gains of 7.3%, which included a 7.7% increase in the U.S. Instruments, which was up 5.2% in the U.S., maintained good momentum with its waste management business and the newly launched Neptune 3 and continued strong performance related to its Navigation business.
Endoscopy delivered U.S. growth of 10.4%, driven by strong double-digit performances of its camera and light source products and strong gains in its communications, sports medicine and ProCare service businesses. 
Our Medical division had U.S. organic growth of 6.8%, driven by double-digit growth of its core bed and power cot products. On a comparable basis, Medical's Physio business was up 6.3%. Its Sage business grew 12.5%, including the impact of the recent recall. Excluding this, Sage grew 15%. We are pleased with these results and the ongoing integration efforts at Medical.
Internationally, MedSurg organic sales growth was 6%, which reflects strong European and Australian sales and some easing of the MedSurg comparable in China. Neurotechnology and Spine continues to drive above-market performance with constant currency growth of 8.7% and organic growth of 6.9%. This growth reflects continued strong demand for our Neurotech products. U.S. Neurotech posted growth of 9.1% in the quarter, highlighted by our AIS products and our Neuro Powered Instruments.
Our Spine business in the U.S. continued to see some supply issues, offset somewhat by strong demand for our 3D-printed interbody Tritanium products. As I have said last quarter, we expect the supply issues to remain into the fourth quarter.
Internationally, Neurotech had constant currency growth of 16.7%. This performance was driven by continued strong demand for our Trevo stent retriever and Target Coil products in Europe and Asia. Spine's international growth was 1.6% and was impacted by the aforementioned supply issues and challenges in China.
Now I will focus on the operating highlights within the quarter. Our gross margin, which, on an adjusted basis, was 66.3%, was down 60 basis points from the prior year quarter. Gross margin was favorably impacted by absorption and productivity gains, which was offset by mix, including the impact of acquisitions and foreign currency exchange.
SG&A for the third quarter was 34.9% of sales on an adjusted basis, which was favorable by 70 basis points as compared to the prior year quarter. This improvement reflects favorable leverage from continued focus on operating expense improvements through our CTG program, cost-containment efforts and business mix, including leverage from our recent acquisitions.
We continue to invest in internal innovation with R&D, which is up 10 basis points year-over-year to 6.5% of sales. In total, adjusted operating expenses at 41.4% of sales was favorable 60 basis points to the prior year quarter, and these results continue to reflect our focus on leverage growth.
In summary, our operating margin was 24.9% of sales in Q3, flat year-over-year but up 64 basis points on a year-to-date basis. This performance reflects the positive results from our various CTG programs, continued cost control and favorable accretion from acquisitions, offset by business mix, pricing and foreign exchange.
Lastly, I will provide some highlights on other income and expense. Other expenses increased due to the higher net interest expense related to increased borrowings at the end of the first quarter. During the third quarter, we also paid down $750 million of debt. And accounting for the impact of this, we anticipate our future quarterly run rate of interest expense to be approximately $65 million.
Our third quarter adjusted effective tax adjusted effect of tax rate of 17.5% reflects the benefits of our global tax structure, partially offset by the impact of higher U.S.-based income from our recent acquisitions.
Moving on to the balance sheet. We continue to maintain a strong balance sheet with $3 billion of cash and marketable securities, of which approximately 80% was held outside the U.S. Total debt on the balance sheet at the end of the second quarter was $6.8 billion.
Turning to cash flow. Our year-to-date cash from operations was approximately $1.2 billion. Finally, as we have previously announced at the end of Q1, we have suspended our share repurchases for the remainder of 2016.
In terms of guidance, we reconfirm our previous full year organic sales growth range of 6% to 6.5% for 2016. If foreign currency exchange rates hold near current levels, we expect a neutral impact in the fourth quarter and a negative foreign currency impact of less than 0.5% for the full year.
Lastly, our guidance for adjusted net earnings per diluted share in 2016 is now expected to be in the range of $5.75 to $5.80 for the full year.
And now I will open up the call for Q&A."
94614,377148003,1064540,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Operator","[Operator Instructions] And our first question comes from Bob Hopkins from Bank of America.",14,"[Operator Instructions] And our first question comes from Bob Hopkins from Bank of America."
94614,377148003,1064540,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Analysts",";So I have 2 questions. One, I'll start with you, Kevin. I was encouraged to hear your comments about emerging markets and turning back to the positive there. So maybe you could just kind of lay out specifically what improved and what you think the pros",88,";
So I have 2 questions. One, I'll start with you, Kevin. I was encouraged to hear your comments about emerging markets and turning back to the positive there. So maybe you could just kind of lay out specifically what improved and what you think the prospects are for your emerging market growth. Now that you've kind of turned the corner, can we get back to mid to high single digits in a reasonable time frame for emerging markets? Just want to hear a little more color on EM."
94614,377148003,1064540,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Executives","Yes, sure. So outside of China, I would say, I'm really encouraged by the progress in India, which is really a continuation of what we've been experiencing the past few quarters. Brazil returned to growth. And as you know, Brazil has been a very challengi",198,"Yes, sure. So outside of China, I would say, I'm really encouraged by the progress in India, which is really a continuation of what we've been experiencing the past few quarters. Brazil returned to growth. And as you know, Brazil has been a very challenging market for us over the past year to 2. And we also like the results in Russia, Turkey. So it's really across the board. Our other emerging market countries performed very well. China's still a bit of a laggard, but as Glenn's mentioned in his prepared remarks, we expect China to return to growth in the fourth quarter. So we're starting to see an improvement. Part of this is really the comparables that we're sort of lapping the years of sort of core performance. So we would expect a bit of a turnaround. But I -- it's really early. It's only one quarter, but I'm starting to see a trend that we will see growth. Now whether we'll get back to double digit as we experienced in prior years, it's a little early for me to say. But certainly, the outlook is much more positive than it has been over the past year."
94614,377148003,1064540,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Analysts","Okay. And then for Katherine, as a follow-up, just on your comments on the Analyst Day and MAKO. On the Analyst Day, can you just -- I know you're not giving guidance until the fourth quarter, but what will you be quantifying at the Analyst Day in some of",85,"Okay. And then for Katherine, as a follow-up, just on your comments on the Analyst Day and MAKO. On the Analyst Day, can you just -- I know you're not giving guidance until the fourth quarter, but what will you be quantifying at the Analyst Day in some of these prepared commentary? Will there be any quantification of cost savings or long-term margin opportunity? Just want to make sure I have a good understanding of exactly what we're going to get at the Analyst Day."
94614,377148003,1064540,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Executives","Yes. In addition to the panels, I focused on MAKO and SPS. Lonny will be giving a CTG update, which will include a greater quantification and visibility around the long-term potential from the cost savings that we're targeting. And then Glenn will be givi",89,"Yes. In addition to the panels, I focused on MAKO and SPS. Lonny will be giving a CTG update, which will include a greater quantification and visibility around the long-term potential from the cost savings that we're targeting. And then Glenn will be giving an update with some of our longer-term financial targets. Now we'll go into the full detail of that at the Analyst Day. But also to be clear, we won't be giving 2017 guidance ranges, the formalization of our targets, until the January fourth quarter call."
94614,377148003,1064540,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Operator","Our next question comes from Rick Wise from Stifel.",9,"Our next question comes from Rick Wise from Stifel."
94614,377148003,1064540,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Analysts","Maybe I'll also start with MAKO. You obviously had an exceptionally strong quarter. Maybe, Kevin or Katherine, you could give us a little more color there. Maybe just sort of multipart question on this. What kind of pull-through are you seeing for Stryker",91,"Maybe I'll also start with MAKO. You obviously had an exceptionally strong quarter. Maybe, Kevin or Katherine, you could give us a little more color there. Maybe just sort of multipart question on this. What kind of pull-through are you seeing for Stryker products, particularly in competitive accounts? And maybe talk a little more, if you could, about some of the data surrounding -- clinical data surrounding MAKO we might see. I know that's been a priority for this year. What might be seen and when will we see it?"
94614,377148003,1064540,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Executives","Yes, I think, obviously, the 30 robots placed, we're very pleased with that, that number of installations. We're also pleased that they are going into -- roughly 40% into competitive accounts. It's also what is helping drive our knee growth, which, I beli",233,"Yes, I think, obviously, the 30 robots placed, we're very pleased with that, that number of installations. We're also pleased that they are going into -- roughly 40% into competitive accounts. It's also what is helping drive our knee growth, which, I believe, is above market and I mean, clearly is a big focus for our sales force right now, given their excitement around that. We do believe qualitatively, we're going to get -- continue to receive feedback around benefits, including alignment, less tissue disruption and ultimately, patient satisfaction. Longer term, clinical data on that is going to take us some time to collect. We will be gathering that, but that's going to be 1-, 2-, 3-year data and obviously, it will take that long. I think it will be a great opportunity at the panel at the Analyst Day where we're going to have a surgeon who had no experience with a robot prior to becoming part of the limited market release of the knee as well as a longer-term robot user to ask those questions and hear what their experience has been. But with the 200 cases to date, we've been really pleased with what we've seen so far and the ability to both get into competitive accounts and optimize the training protocol ahead of full commercial launch, which, as we said, will take place in March at the academy meeting."
94614,377148003,1064540,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Analysts","Great. Just a follow-up on Sage and Physio briefly. Maybe just highlight -- I know we'll hear more soon, but where are we in terms of the integration and cost and sales? Kevin, you feel like you're on plan. Sage grew a little faster than the second quarte",65,"Great. Just a follow-up on Sage and Physio briefly. Maybe just highlight -- I know we'll hear more soon, but where are we in terms of the integration and cost and sales? Kevin, you feel like you're on plan. Sage grew a little faster than the second quarter. Physio, a tad slower. I assume that's seasonal. But again, any more color there would be welcome."
94614,377148003,1064540,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Executives","Yes. Thanks, Rick. So first of all, over the full 6-month period, we're really pleased with both companies' performance. They're really line with our expectations. The integrations are going very well. As you know, Sage is, I'll call it, more of a lighter",134,"Yes. Thanks, Rick. So first of all, over the full 6-month period, we're really pleased with both companies' performance. They're really line with our expectations. The integrations are going very well. As you know, Sage is, I'll call it, more of a lighter integration, given that there's less of an overlap with the call point. But certainly, we're sharing leads with the Sage organization. At Physio, we have a little bit more of call point overlap. It's really more of a planning phase this year. Our sales forces are running independently this year. And then over the course of the next year or 2, we'll start to integrate those sales forces. But I would stay, so far so good on integration, and we're pleased with the performance and really, the outlook for the future."
94614,377148003,1064540,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Operator","Our next question comes from Mike Weinstein from JPMorgan.",9,"Our next question comes from Mike Weinstein from JPMorgan."
94614,377148003,1064540,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Analysts","Congratulations on getting back to above that 6% bar. That's nice to see. Katherine, the September health care conferences proved a bit trickier this year. And there was a bunch of questions, as you know, that come out of them where people were asking abo",187,"Congratulations on getting back to above that 6% bar. That's nice to see. Katherine, the September health care conferences proved a bit trickier this year. And there was a bunch of questions, as you know, that come out of them where people were asking about comments that you guys have made. So maybe I thought it was a good opportunity to clarify a couple of them. And Katherine, Kevin, chime in here, 2 sets of comments were -- Kevin, just about your outlook for the Trauma business and the Hip business and some potential deceleration in growth. And then naturally, people try to get you to comment on 2017 preliminarily and how to think about operating a financial leverage, excluding the impact of the acquisitions. There seems to be some confusion around that. So maybe just want to spend a minute on both the outlook for the Trauma and then the Hip business in light of the -- all the focus on the knee side and then just comment, if you would, about how we should think about operating leverage heading into '17 without obviously giving guidance."
94614,377148003,1064540,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Executives","Sure, Mike. I'll take the Trauma and Hip question, and then I'll pass it over to Katherine to talk about, I think, some misperceptions around 2017. So what I've been saying for some time on the Trauma business is that sustaining 15% growth quarter after q",312,"Sure, Mike. I'll take the Trauma and Hip question, and then I'll pass it over to Katherine to talk about, I think, some misperceptions around 2017. So what I've been saying for some time on the Trauma business is that sustaining 15% growth quarter after quarter is pretty unlikely. We've done that for over 3 years coming into this year. If you look at last year's third quarter, we grew 15.1% in the U.S. And so to put up a 7% growth against that comp is still a pretty solid performance. But while big numbers is -- we've been signaling that Trauma will start to slow down a little bit in terms of its growth rate, but certainly performing above market and I think it still had a strong solid performance this quarter. But the only signal there is that sustaining that level of outperformance 3x the market is not likely to do indefinitely. So no concerns. We have a very strong Trauma leadership team, strong business, strong pipeline. I'm still very bullish about that division. As it relates to Hips, we're longer in our product cycle, with Accolade II being one of the newer products that we launched a few years ago. And a lot of excitement in knees. And as you know, same sales force that sells both Hips and Knees. We have a big launch upcoming with MAKO total knee. We have a lot of cementless products in the knee portfolio. So I would say that there's been a bit of attention focused on knees. And we've seen this in our industry for decades that it's very difficult to be able to focus on both products equally. So the fact that our Hip growth, which have been above market for about 3 or 4 years, is now moving, let's say, more in line with market is not also surprising."
94614,377148003,1064540,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Executives","Yes. And just going back to some of the misperceptions around some of the conferences, the health care conferences in September, I will tell you, candidly, we were surprised if anybody -- that there was any misperception. We try to be very consistent in t",176,"Yes. And just going back to some of the misperceptions around some of the conferences, the health care conferences in September, I will tell you, candidly, we were surprised if anybody -- that there was any misperception. We try to be very consistent in terms of our goal of growing sales at the high end of med tech. We think the med tech markets are largely stable, at least the segments where our product portfolio competes. And as Kevin said in his prepared comments at the start of this call, we feel really good about our ability to continue to deliver that. The specific range around that, in which may have been, where some of the misperceptions came, we will talk about in January as we do every year. So to the degree of unwillingness to give guidance ahead of when we normally do it caused some concern, I think that was incorrect. We feel great about the momentum and the product portfolio, and we'll look to specify that in terms of financial ranges in January."
94614,377148003,1064540,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Analysts","So there's -- Katherine, just one follow-up, if I can. The growth in MAKO this quarter and the units that sold their place, was that to -- just characterize it, was that to the beta sites that have been doing the, call it, early launch feedback for you gu",58,"So there's -- Katherine, just one follow-up, if I can. The growth in MAKO this quarter and the units that sold their place, was that to -- just characterize it, was that to the beta sites that have been doing the, call it, early launch feedback for you guys? Or is that the centers anticipating the launch?"
94614,377148003,1064540,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Executives","It's both. Some of those are to those that are part of the limited market release, but that's a small group. Some of those were just, for lack of a better word, putting and getting in the queue because they want to be part of the upgrades and ready for th",73,"It's both. Some of those are to those that are part of the limited market release, but that's a small group. Some of those were just, for lack of a better word, putting and getting in the queue because they want to be part of the upgrades and ready for the total launch. So it's a mix, but it is -- I would say that limited market release customers are the minority."
94614,377148003,1064540,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Operator","Our next question comes from David Lewis from Morgan Stanley.",10,"Our next question comes from David Lewis from Morgan Stanley."
94614,377148003,1064540,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Analysts","Just 2 quick questions, one for Kevin, one for Katherine. Kevin, just -- you've got a wide range of businesses now that you're back above 6% organic this quarter, and I agree with Mike, that was nice to see. I wonder if you could just comment, just given",166,"Just 2 quick questions, one for Kevin, one for Katherine. Kevin, just -- you've got a wide range of businesses now that you're back above 6% organic this quarter, and I agree with Mike, that was nice to see. I wonder if you could just comment, just given the broader environment this particular quarter, a couple of things. One, just your capital business is very strong. There's some emerging concern that the election cycle is going to result in some capital freeze and result in that months in September and October heading to the election cycle. So just == the broader capital environment heading into election, are you seeing any change in sort of relative backlogs? And then utilization, sort of a similar question, a lot of talk about polarization in sort of July, August versus September. I mean, do you see a change in how utilization trended in some of your Orthopaedic businesses across the quarter? And then I had a quick one for Katherine."
94614,377148003,1064540,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Executives","Yes. So thanks, David. What I would tell you is we haven't seen really any change in the capital. Business has been extremely stable. The election to us is really a nonevent in terms of the businesses that we participate in. As you know, there's a lot of",129,"Yes. So thanks, David. What I would tell you is we haven't seen really any change in the capital. Business has been extremely stable. The election to us is really a nonevent in terms of the businesses that we participate in. As you know, there's a lot of attention being drawn to pharma, a lot of commentary made about pharma. But med tech is very small percent of the overall health care spend, and we're not seeing really any impact whatsoever. And as it relates to procedural volume, again, we didn't see anything unusual within the month of the quarter, very, very stable market. And that's not new. The market has been stable for the past 2 years, 3 years, and we continue to perform well in this market."
94614,377148003,1064540,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Analysts","Kevin -- sorry, Katherine, in terms of back half '17, you'd said MAKO, it's unlikely we see share movement until back half '17 the earliest. I just think about -- it's the biggest year-on-year system add you've had, I think, since you bought the company.",82,"Kevin -- sorry, Katherine, in terms of back half '17, you'd said MAKO, it's unlikely we see share movement until back half '17 the earliest. I just think about -- it's the biggest year-on-year system add you've had, I think, since you bought the company. You've got 40% competitive accounts, and obviously, you're going to have a bigger launch at AAOS. Is the back half of '17 still the earliest that we could start to see share movement in the knee channel?"
94614,377148003,1064540,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Executives","I think that's the way to be thinking about it right now. Remember, these robots have to get installed. That takes time and energy and people we have to train. And so there's a cadence. This is not like an easy product that you launch overnight and it run",114,"I think that's the way to be thinking about it right now. Remember, these robots have to get installed. That takes time and energy and people we have to train. And so there's a cadence. This is not like an easy product that you launch overnight and it runs. So we need to be thoughtful in that regard clearly that we can target academy for the full commercial launch, and we'll be well prepared to go out and train from there. But I still think the back half of the year is the best time to be focused on in terms of starting to see indications that we're gaining meaningful knee market share."
94614,377148003,1064540,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Operator","Our next question comes from Kristen Stewart from Deutsche Bank.",10,"Our next question comes from Kristen Stewart from Deutsche Bank."
94614,377148003,1064540,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Analysts","Just to go back, I guess, to some of the comments on the acquisitions. I know you said that integration's going so far. Would you be willing to say in terms of the 2017 accretion numbers that those still look to be intact based upon how the businesses are",58,"Just to go back, I guess, to some of the comments on the acquisitions. I know you said that integration's going so far. Would you be willing to say in terms of the 2017 accretion numbers that those still look to be intact based upon how the businesses are performing, better or worse than you had originally stated?"
94614,377148003,1064540,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Executives","Kristen, it's Glenn. Yes, we actually were on track in 2016 to hit the accretion numbers that we put out there. And then also, for 2017, based on our preliminary planning, we think we'll be on track to hit the numbers that we put out for accretion as well",49,"Kristen, it's Glenn. Yes, we actually were on track in 2016 to hit the accretion numbers that we put out there. And then also, for 2017, based on our preliminary planning, we think we'll be on track to hit the numbers that we put out for accretion as well."
94614,377148003,1064540,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Analysts","Okay, great. And then has FX changed at all in terms of the bottom line impact? And with the change in stock option accounting, can you give us a sense in terms of how that may also impact or maybe what the impact might be in 2016 or '15 or anything to th",58,"Okay, great. And then has FX changed at all in terms of the bottom line impact? And with the change in stock option accounting, can you give us a sense in terms of how that may also impact or maybe what the impact might be in 2016 or '15 or anything to that extent you could help frame?"
94614,377148003,1064540,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Executives","Yes, yes. It feels like 2 questions, and I'll take a stab at them both. So first off, on FX, as you can see, translational is easing, especially in Q3, and we expect it to be nominal in Q4. Transactional will still continue to impact us as it did this qua",133,"Yes, yes. It feels like 2 questions, and I'll take a stab at them both. So first off, on FX, as you can see, translational is easing, especially in Q3, and we expect it to be nominal in Q4. Transactional will still continue to impact us as it did this quarter and it will next quarter. And part of that is related to our hedging program and the way we lock in hedges 18 months ahead of time and how that relates to the current exchange rates that are out there. And then secondly, as it relates to the change in stock option, I think if you take a look, we've disclosed what we think that'll be, which is roughly maybe $30 million. And we don't plan on adopting it until next year."
94614,377148003,1064540,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Operator","Our next question comes from Chris Pasquale from Guggenheim.",9,"Our next question comes from Chris Pasquale from Guggenheim."
94614,377148003,1064540,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Analysts","Kevin, it's been a while since you guys hosted an analyst meeting, and I know you talked about not wanting to comment too much on forward guidance yet. But you're going to have the chance to talk about some of the progress you've made with some of the inv",120,"Kevin, it's been a while since you guys hosted an analyst meeting, and I know you talked about not wanting to comment too much on forward guidance yet. But you're going to have the chance to talk about some of the progress you've made with some of the investments to get a cost in the middle of the income statement, in particular. I see Lonny's on the agenda. Can you talk a little bit about some of those programs? You've highlighted the ERP transition, some of the other things you're doing. And will this be an opportunity to sort of layout the next steps to how we get some leverage, particularly in the middle of the income statement going forward?"
94614,377148003,1064540,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Executives","I think what you'll hear Lonny talk about is progress on multiple fronts as we've gotten the CTG program underway. ERP is one of them, product life cycle management, plant optimization, indirect spend and as we try to articulate, giving greater quantifica",71,"I think what you'll hear Lonny talk about is progress on multiple fronts as we've gotten the CTG program underway. ERP is one of them, product life cycle management, plant optimization, indirect spend and as we try to articulate, giving greater quantification around the longer-term targets and expected contribution from that. That will be the focus of his comments while Glenn will focus on our longer-term financial targets beyond '17."
94614,377148003,1064540,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Analysts","Okay. That's helpful. And then sorry if I missed this earlier, I've been jumping around. But can you talk a little bit about the Trauma and Extremities business? Good quarter there, a little bit of a pickup from what we saw last quarter. Anything in parti",48,"Okay. That's helpful. And then sorry if I missed this earlier, I've been jumping around. But can you talk a little bit about the Trauma and Extremities business? Good quarter there, a little bit of a pickup from what we saw last quarter. Anything in particular driving that?"
94614,377148003,1064540,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Executives","No, I would say it's just continued strong performance, and we've been performing well in our Trauma business over the last 3 years, and it was just more of the same this quarter.",33,"No, I would say it's just continued strong performance, and we've been performing well in our Trauma business over the last 3 years, and it was just more of the same this quarter."
94614,377148003,1064540,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Operator","Our next question comes from Kaila Krum from William Blair.",10,"Our next question comes from Kaila Krum from William Blair."
94614,377148003,1064540,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Analysts","Just a couple for me. So in terms of acquisition strategy and I guess, specific to Orthopaedics and Spine, are you guys more focused on scale or growth at this point in time? And granted they do come hand-in-hand, but one tends to lead to the other, so ju",57,"Just a couple for me. So in terms of acquisition strategy and I guess, specific to Orthopaedics and Spine, are you guys more focused on scale or growth at this point in time? And granted they do come hand-in-hand, but one tends to lead to the other, so just trying to better understand your M&A strategy there."
94614,377148003,1064540,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Executives","There's no change in M&A strategy. Whether it's the company overall or Ortho versus MedSurg & Neurotech, it's focused on our core and key adjacent markets. If you look historically, the bulk of our deals have been in core markets with a few key adjacent a",66,"There's no change in M&A strategy. Whether it's the company overall or Ortho versus MedSurg & Neurotech, it's focused on our core and key adjacent markets. If you look historically, the bulk of our deals have been in core markets with a few key adjacent acquisitions. And that will continue to be the strategy going forward across all the divisions. So no change from that."
94614,377148003,1064540,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Analysts","Okay. And then just a follow-up on the Extremities business. I mean, just looking specifically at Foot & Ankle, can you guys talk about how your Foot & Ankle performance has been recently? Are they still sort of trending in historical levels? And just any",53,"Okay. And then just a follow-up on the Extremities business. I mean, just looking specifically at Foot & Ankle, can you guys talk about how your Foot & Ankle performance has been recently? Are they still sort of trending in historical levels? And just any commentary on market trends there would be helpful."
94614,377148003,1064540,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Executives","Yes. So we're really pleased with our Foot & Ankle performance. In the U.S., this quarter, we grew 15%, very much in line with the performance we've had over the past year. It continues to be a very good market.",40,"Yes. So we're really pleased with our Foot & Ankle performance. In the U.S., this quarter, we grew 15%, very much in line with the performance we've had over the past year. It continues to be a very good market."
94614,377148003,1064540,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Operator","Our next question comes from Glenn Novarro from RBC Capital.",10,"Our next question comes from Glenn Novarro from RBC Capital."
94614,377148003,1064540,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Analysts","Two questions. First, pricing in Orthopaedics, down 2.2%. That was similar to the second quarter. So I'm wondering if the new trend line of Orthopaedic pricing is now going to be in that 2% to 2.5% range. Then I had a follow-up on pricing.",44,"Two questions. First, pricing in Orthopaedics, down 2.2%. That was similar to the second quarter. So I'm wondering if the new trend line of Orthopaedic pricing is now going to be in that 2% to 2.5% range. Then I had a follow-up on pricing."
94614,377148003,1064540,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Executives","I think we feel comfortable, from a total company perspective, that pricing is going to be down in that 1.5%, 2% vicinity. It's been trending slightly less negative. Ortho, it seems relatively stable, but candidly trying to predict that level of accuracy.",97,"I think we feel comfortable, from a total company perspective, that pricing is going to be down in that 1.5%, 2% vicinity. It's been trending slightly less negative. Ortho, it seems relatively stable, but candidly trying to predict that level of accuracy. 50, 100 basis points moves in price. It's really difficult. We have greater confidence and visibility when you look at the totality of the company because we have areas with less price, less pricing pressure. And so we really try to focus on the total versus specific line item where it can move around quarter-to-quarter."
94614,377148003,1064540,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Analysts","Okay. And then just as a follow-up to that. Pricing, again, I look at it sequentially, pretty stable. And now we're in the 6 months of CJR, so it seems like there's been no impact to pricing. So I'm curious as to what your thoughts are on the implementati",58,"Okay. And then just as a follow-up to that. Pricing, again, I look at it sequentially, pretty stable. And now we're in the 6 months of CJR, so it seems like there's been no impact to pricing. So I'm curious as to what your thoughts are on the implementation of CJR. And are you seeing any pricing pressures?"
94614,377148003,1064540,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Executives","We would agree, we really haven't seen an impact. But in fairness, too, it has only been 6 months. And in the first year, there is no financial penalty. So we really believe you're going to see a greater focus by hospitals when there's more of a financial",133,"We would agree, we really haven't seen an impact. But in fairness, too, it has only been 6 months. And in the first year, there is no financial penalty. So we really believe you're going to see a greater focus by hospitals when there's more of a financial incentive. Now as you go into 2017, I think you'll be able to get a lot better visibility or hopefully will at the Analyst Day because we will have a hospital customer who's had experience under the bundled payment. But we continue to believe their focus is going to be in the post-acute setting on rehab costs as there is tremendous value to be realized by shifting more patients to the home and not at some of the skilled nursing facilities and other rehab facilities."
94614,377148003,1064540,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Operator","Our next question comes from Matt Miksic from UBS.",9,"Our next question comes from Matt Miksic from UBS."
94614,377148003,1064540,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Analysts","So I had one kind of topical question coming out NASS and your demonstration of Tritanium and your 3D-printed products. And then I had one follow-up just on the Ortho side, if I could. So one of the things you've talked about in your presentation and the",159,"So I had one kind of topical question coming out NASS and your demonstration of Tritanium and your 3D-printed products. And then I had one follow-up just on the Ortho side, if I could. So one of the things you've talked about in your presentation and the Q&A afterwards, there was just a buildout you've put in place around 3D-printed products in general. Of course, that drives the Spine portfolio of really one key product at the moment. But also, your press-fit knee, cementless knee platform you've talked a lot about. So I'm wondering, as you build that out, I mean, just given the proportion of your business, given the performance of your business, how are you prioritizing, I guess? Are you getting leverage across those 2 platforms and the way you manufacture and how you're sort of thinking about which one of these sort of high-demand products gets the volume over time? And I have more follow-up."
94614,377148003,1064540,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Executives","Sure, Matt. The short answer is they all do, but we have been capacity-constrained. We are adding 3D printing capacity on a monthly basis. We broke ground on a dedicated 3D printing facility in Ireland last year. As you know, this is extremely highly tech",89,"Sure, Matt. The short answer is they all do, but we have been capacity-constrained. We are adding 3D printing capacity on a monthly basis. We broke ground on a dedicated 3D printing facility in Ireland last year. As you know, this is extremely highly technical with a great deal of know-how around 3D printing these type of metals. We will be launching additional 3D-printed products. And -- but you should assume you'll see the benefit of that in Spine as well as on our revision and press-fit knee portfolio."
94614,377148003,1064540,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Analysts","Okay. And then the follow-up, just on the trends in Orthopaedics. I mean, the knee number, U.S. in particular, I thought was quite strong going up against a pretty significantly tougher comp. Hips, kind of the same. So just in terms of trends there, I thi",114,"Okay. And then the follow-up, just on the trends in Orthopaedics. I mean, the knee number, U.S. in particular, I thought was quite strong going up against a pretty significantly tougher comp. Hips, kind of the same. So just in terms of trends there, I think we talked about, back in September, what should we expect in terms of our recovery in Hips or annualizing some of the launches that you've had in Hips. And then on knees, if you could -- is it the press-fit that's really making out the difference in driving -- are we getting a mix benefit, penetration benefit on the knee side that's driving that strength? I appreciate it."
94614,377148003,1064540,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Executives","Yes. So keep in mind, it's the same sales force and the same customer base on Hips and Knees. Accolade, which has been a terrific product launch for us, is several years into that now, whereas MAKO is getting an enormous amount of focus and has a huge pro",205,"Yes. So keep in mind, it's the same sales force and the same customer base on Hips and Knees. Accolade, which has been a terrific product launch for us, is several years into that now, whereas MAKO is getting an enormous amount of focus and has a huge product launch. And as a result, the sales force has focused on that. So there is a halo effect that's helping our knee business. We also have additional new products on the knee side, our 3D-printed revision cones and sleeves and as we just mentioned, our 3D-printed cementless knee, which is really driving us to now low double-digit penetration for cementless knees, which is well above the industry. So I think right now, you're just in a period where there's a lot of happening on the knee side and a lot will continue to happen as we go to full commercial launch. We will be introducing more hip products, but sales force likes to focus on what's new and hot. And clearly, a lot of that momentum right now is on the knee side. And so we think hips, probably more like overall market growth. Knees, we believe, we're going to continue to grow above the market."
94614,377148003,1064540,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Executives","But certainly, when you look at the overall, we're very pleased with our performance. Our sales teams are doing an excellent job, and we're excited about the future years.",29,"But certainly, when you look at the overall, we're very pleased with our performance. Our sales teams are doing an excellent job, and we're excited about the future years."
94614,377148003,1064540,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Operator","Our next question comes from Mike Matson from Needham & Company.",10,"Our next question comes from Mike Matson from Needham & Company."
94614,377148003,1064540,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Analysts","We've seen a real pickup in the amount of M&A and the spine space. And Kevin, last I heard, I think you were saying that you're happy with the performance of the Spine business and the turnaround there and you didn't really feel the need to do something f",70,"We've seen a real pickup in the amount of M&A and the spine space. And Kevin, last I heard, I think you were saying that you're happy with the performance of the Spine business and the turnaround there and you didn't really feel the need to do something from an acquisition standpoint in Spine. But I just wanted to check and see if that was still how you felt."
94614,377148003,1064540,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Executives","Yes, so as you look at our Spine business, you see that we've had some issues around product performances, supply chain disruptions. But we have a great leadership team, and we had a number of quarters of very strong growth. And I believe in this leadersh",120,"Yes, so as you look at our Spine business, you see that we've had some issues around product performances, supply chain disruptions. But we have a great leadership team, and we had a number of quarters of very strong growth. And I believe in this leadership team, and Tritanium is a great example of the 3D-printed interbody device, which is performing very well. I'm confident our team can continue to perform well and grow the business. Related to M&A, I would give you the same comment I give for all our divisions. We're always looking to strengthen our businesses, but we're not going to comment on whether we're going to do acquisitions, big or small, on any of our divisions."
94614,377148003,1064540,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Analysts","Okay, I understand. And then you do have a significant portion of cash -- of your cash outside the U.S. So I know there's some talk of a potential tax deal after the election. So if that were to occur, obviously, it would depend of the terms of that. But",74,"Okay, I understand. And then you do have a significant portion of cash -- of your cash outside the U.S. So I know there's some talk of a potential tax deal after the election. So if that were to occur, obviously, it would depend of the terms of that. But would you repatriate any of that cash? And if you did, what would you -- how would you prioritize the use of that cash?"
94614,377148003,1064540,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Executives","As we look at our cash, I'm sure we're in the same position as several other U.S. companies. And if something like that became available, as it did a few years back, we would definitely take advantage of it and repatriate our cash to the extent possible.",105,"As we look at our cash, I'm sure we're in the same position as several other U.S. companies. And if something like that became available, as it did a few years back, we would definitely take advantage of it and repatriate our cash to the extent possible. In terms of how we might prioritize that cash, it's hard to say at this point. We've said before about what our priorities are around capital allocation, and that would mean M&A, that would mean dividends and it may mean share buybacks. But commenting beyond that, I don't think I can do that at this point in time."
94614,377148003,1064540,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Operator","Our next question comes from Bruce Nudell from SunTrust.",9,"Our next question comes from Bruce Nudell from SunTrust."
94614,377148003,1064540,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Analysts","Kevin, I have a couple for you. Firstly, I'm fascinated by this 40% placement of MAKO at competitive accounts. One of the big issues with Orthopaedics is that there's tremendous brand synergization of product on the part of surgeons as well as institution",87,"Kevin, I have a couple for you. Firstly, I'm fascinated by this 40% placement of MAKO at competitive accounts. One of the big issues with Orthopaedics is that there's tremendous brand synergization of product on the part of surgeons as well as institutions for hips or knees. So how do you accomplish that where you put a robot in and get people to go beyond new knees and kind of standardize on knees with the Stryker brand that they may not use most of the time today?"
94614,377148003,1064540,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Executives","The way we look at our MAKO adoption is really around behavioral segmentation, which surgeons like new technology and believe that they can become better at delivering value to their patients with technology. And so it's not about whether they like Stryke",90,"The way we look at our MAKO adoption is really around behavioral segmentation, which surgeons like new technology and believe that they can become better at delivering value to their patients with technology. And so it's not about whether they like Stryker or whether they like Zimmer or whether they like J&J. It's about do they like robotics and do they believe in robotics. And that's why, not surprising that many of the placements are in competitive products. [ph] We're getting a lot of feedback. Can you hear me, Bruce?"
94614,377148003,1064540,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Analysts","Yes. Yes, I can.",4,"Yes. Yes, I can."
94614,377148003,1064540,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Executives","I'm sorry, we're getting a little feedback in the room. But -- so what I'd tell you on this front is it's really all about the surgeon who wants to become better and who believes in technology, less so about our specific relationships or whether the hospi",182,"I'm sorry, we're getting a little feedback in the room. But -- so what I'd tell you on this front is it's really all about the surgeon who wants to become better and who believes in technology, less so about our specific relationships or whether the hospital is with Stryker or a different account, if it's different niche that we're serving. If you look at MAKO prior to our acquisition, they were able to obtain about 18% of the knee market over a 4-year period. There were not a proven entity. They weren't even an orthopedic company. So we really believe this about technology adoption certainly in the first couple of years. It's really around behavior, which surgeons believe in technology, and we're going to go to the surgeons that believe in it. There are many skeptics, as you know, with all disruptive technology. And some of those skeptics are Stryker loyal surgeons. And they won't be the first to adopt. And that doesn't concern us because there are many surgeons who are interested and who will be willing to adopt."
94614,377148003,1064540,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Analysts","And my second question is as we're relaunching on Stryker, what really struck me was that despite the acquisitive nature of the company, ROIC has been maintained. And could you just -- and it seems to be like a core strength of the company. Could you talk",72,"And my second question is as we're relaunching on Stryker, what really struck me was that despite the acquisitive nature of the company, ROIC has been maintained. And could you just -- and it seems to be like a core strength of the company. Could you talk about how that influences the profile of what you buy, how it fits in? And is that a formula you can maintain going forward?"
94614,377148003,1064540,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Executives","It's long been our history to be very disciplined in our deployment of capital. So when we look at deals, we want to strengthen every division that we have in the company. But we won't just pay whatever to companies. We're very disciplined. We walk away w",172,"It's long been our history to be very disciplined in our deployment of capital. So when we look at deals, we want to strengthen every division that we have in the company. But we won't just pay whatever to companies. We're very disciplined. We walk away when the prices are above our ability to deliver value. And sometimes, there's assets that we like and the price point's just too high and we have discipline to walk away from deals. And I think that's why you see the ROIC still consistent year over year over year in spite of the acquisition nature. The -- also, the ability to have acquisition that fit in our existing business, that plug into our sales force, which is the bulk of the deals we do. We have a proven model to deliver value with those types of acquisitions. So I think it's a combination of playing to our strengths in terms of our commercial execution and being financially disciplined with the deals that we do make."
94614,377148003,1064540,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Operator","Our next question comes from Richard Newitter from Leerink Partners.",10,"Our next question comes from Richard Newitter from Leerink Partners."
94614,377148003,1064540,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Analysts","I want to, maybe for you, Kevin, to start off. We're at NASS. Obviously, it's topical. We're seeing a lot of robotics take a bigger presence on the floor. Being that you were the first major company to kind of really validate the robotics category, we'd l",76,"I want to, maybe for you, Kevin, to start off. We're at NASS. Obviously, it's topical. We're seeing a lot of robotics take a bigger presence on the floor. Being that you were the first major company to kind of really validate the robotics category, we'd love to hear what your view is of the robotics kind of push in spine we're starting to see and then how MAKO potentially fits in over the long run."
94614,377148003,1064540,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Executives","Well, we love the fact that robotics is taking up a lot of the discussion because as you know, with MAKO, we believe in robotics. Right now, at Stryker, our focus is on hips and knees and specifically, the total knee launch. But we see, over time, that ce",86,"Well, we love the fact that robotics is taking up a lot of the discussion because as you know, with MAKO, we believe in robotics. Right now, at Stryker, our focus is on hips and knees and specifically, the total knee launch. But we see, over time, that certainly, robotics will extend into other procedural areas, including spine. We do have a smaller NDF underway right now, but it's too early for us to speculate on when we would come to the market in that specialty."
94614,377148003,1064540,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Analysts","Okay. And then maybe just one more follow-up. Outpatient surgery and the trend to outpatient ambulatory surgery care, it's clearly where hospitals are trying to go. I'd love to just hear how you feel Stryker's position, either through technology or other",64,"Okay. And then maybe just one more follow-up. Outpatient surgery and the trend to outpatient ambulatory surgery care, it's clearly where hospitals are trying to go. I'd love to just hear how you feel Stryker's position, either through technology or other means to capitalize on that trend. And specifically, if you could talk whether or not MAKO is lending a hand in that effort."
94614,377148003,1064540,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Executives","We have a lot of experience with the ambulatory surgery center with our sports medicine business. And as you know spine, the number of procedures -- the more simpler procedures are starting to move into the ambulatory surgery center. At this stage, MAKO h",130,"We have a lot of experience with the ambulatory surgery center with our sports medicine business. And as you know spine, the number of procedures -- the more simpler procedures are starting to move into the ambulatory surgery center. At this stage, MAKO hasn't had a big impact but we do see our robotics is going to have a play in all of the different aspects of the care continuum. I think this trend will continue towards -- shift the side of care towards surgery centers will continue, but it's not something that we're -- not been prepared for. We have plans across our divisions. And as you saw with -- you're at NASS, you saw the Spine division's actually created a program that's very specific for the surgery center."
94614,377148003,1064540,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Operator","Our next question comes from Larry Biegelsen from Wells Fargo.",10,"Our next question comes from Larry Biegelsen from Wells Fargo."
94614,377148003,1064540,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Analysts","So I wanted to just touch on and focus on the [indiscernible]",12,"So I wanted to just touch on and focus on the [indiscernible]"
94614,377148003,1064540,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Executives","Larry, I apologize. We can't hear you.",7,"Larry, I apologize. We can't hear you."
94614,377148003,1064540,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Executives","Are you on speaker? Could you pick up, please?",9,"Are you on speaker? Could you pick up, please?"
94614,377148003,1064540,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Analysts","Look, sorry about that. Neurotech, that was a little slower in the U.S. this quarter. What drove the deceleration? Is it -- could you talk a little bit about how your [indiscernible] business is performing? I know you talked about that as a key growth dri",49,"Look, sorry about that. Neurotech, that was a little slower in the U.S. this quarter. What drove the deceleration? Is it -- could you talk a little bit about how your [indiscernible] business is performing? I know you talked about that as a key growth driver for you guys."
94614,377148003,1064540,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Executives","Yes, so we continue to see good momentum in the AIS market. As we talked about before, predicting the slope and the speed of that market adoption is tricky. So we'll move around quarter-to-quarter and AIS was a bit slower sequentially, although still heal",70,"Yes, so we continue to see good momentum in the AIS market. As we talked about before, predicting the slope and the speed of that market adoption is tricky. So we'll move around quarter-to-quarter and AIS was a bit slower sequentially, although still healthy growth in that segment. We did have a coil recall in the quarter, which impacted our hemorrhagic business. That's fully resolved and shouldn't impact going forward."
94614,377148003,1064540,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Operator","Our next question comes from Matthew O'Brien from Piper Jaffray.",11,"Our next question comes from Matthew O'Brien from Piper Jaffray."
94614,377148003,1064540,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Analysts","Just wanted to start with MAKO and continue to focus on this a little bit more. But first of all, did you fully spell all 13 additional systems this quarter versus Q3 of last year? And the reason I asked that question is if you backed that out, assuming y",119,"Just wanted to start with MAKO and continue to focus on this a little bit more. But first of all, did you fully spell all 13 additional systems this quarter versus Q3 of last year? And the reason I asked that question is if you backed that out, assuming you sold it all, it would seem like your core knee business was a little bit softer than one of your competitors recorded this quarter. And then on a 2-year stack basis, it's little bit soft as well. So is there a risk as sales force focuses on MAKO that we could see kind of the traditional knee business soften a little bit, along with the hip business as well?"
94614,377148003,1064540,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Executives","Well, we continue to sell all of our robots, just to be clear. And we report our robot sales in the other Orthopaedic category. We can see it's up quite a bit. The other items that are shown in that other category includes bone cement, and bone cement was",116,"Well, we continue to sell all of our robots, just to be clear. And we report our robot sales in the other Orthopaedic category. We can see it's up quite a bit. The other items that are shown in that other category includes bone cement, and bone cement was down in the quarter, both in the U.S. and internationally. We used to have a lot more stocking orders for bone cement, and now our hospital customers are sort of buying it as they need it. And so bone cement does tend to be volatile from quarter-to-quarter. But when you look at our knee number, those are implants that you're seeing in knee number, no robot sales."
94614,377148003,1064540,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Analysts","And I'm also going off of memory on this one too, which is, obviously scary given the first question I just had. But it looks like, I think, Physio grew about 9% pro forma last quarter, and it grew about 6% this quarter. Obviously, we don't have the compa",86,"And I'm also going off of memory on this one too, which is, obviously scary given the first question I just had. But it looks like, I think, Physio grew about 9% pro forma last quarter, and it grew about 6% this quarter. Obviously, we don't have the comparables to look at, but is there anything that's going on that's maybe slowing a little bit as you integrate that asset? Or is it just more, ""Hey, we had a tougher comp this time last year""?"
94614,377148003,1064540,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Executives","I wouldn't read anything into that. Remember, it's a capital business. It tends to move around quarter-to-quarter. And so the -- there wasn't anything unique relative Q2 to Q3. We're very pleased with that integration so far, recognizing it early, as Kevi",76,"I wouldn't read anything into that. Remember, it's a capital business. It tends to move around quarter-to-quarter. And so the -- there wasn't anything unique relative Q2 to Q3. We're very pleased with that integration so far, recognizing it early, as Kevin commented on. But you will see capital move around. We tend to try and focus on multi-quarter rolling trends to really get a good sense with that business, but nothing to call out."
94614,377148003,1064540,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Operator","Our next question comes from Matt Taylor from Barclays.",9,"Our next question comes from Matt Taylor from Barclays."
94614,377148003,1064540,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Analysts","This is actually Ian Mahmud in for Matt. So there's been a lot of discussion on Spine during this call. But I wanted to sort of explore a little more and just ask about what you're seeing in terms of competition. I mean, we've heard a lot about redoubled",75,"This is actually Ian Mahmud in for Matt. So there's been a lot of discussion on Spine during this call. But I wanted to sort of explore a little more and just ask about what you're seeing in terms of competition. I mean, we've heard a lot about redoubled efforts to focus on that area from some of your competitors. So just wanted to see if you're seeing anything different there, any commentary to highlight."
94614,377148003,1064540,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Executives","There's nothing we would uniquely call out. It remains a highly competitive market with a lot of players across the board with the larger, more established companies and obviously, the smaller ones. But there's nothing that we're seeing different with res",54,"There's nothing we would uniquely call out. It remains a highly competitive market with a lot of players across the board with the larger, more established companies and obviously, the smaller ones. But there's nothing that we're seeing different with respect to any of the key competitors in the market at this time."
94614,377148003,1064540,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Operator","And our next question comes from Jeff Johnson from Baird.",10,"And our next question comes from Jeff Johnson from Baird."
94614,377148003,1064540,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Analysts","Most of my questions have been answered. But Glenn, maybe I missed it. But could you talk about any of the drivers in gross margin between maybe price, currency or product or geographic mix, just kind of big buckets, kind of what drove the change in gross",114,"Most of my questions have been answered. But Glenn, maybe I missed it. But could you talk about any of the drivers in gross margin between maybe price, currency or product or geographic mix, just kind of big buckets, kind of what drove the change in gross margin this year or this quarter? And then as I think about some of the movements we've seen on the yen and some emerging market currencies here recently and given the 18-month hedging program, just any very high level comments you can make about how we think of just the currency hedge portion, settling out the cost of goods, how that impacts over the next several quarters?"
94614,377148003,1064540,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Executives","Sure. I think if you look quarter-to-quarter, Q3 to Q4, our margin is fairly consistent. And I talked about this before. There's -- like you mentioned, there's lots of variables that impact our margin, not only price, but the FX, acquisitions. And certain",215,"Sure. I think if you look quarter-to-quarter, Q3 to Q4, our margin is fairly consistent. And I talked about this before. There's -- like you mentioned, there's lots of variables that impact our margin, not only price, but the FX, acquisitions. And certainly, one of the biggest factors is mix, and the mix plays out in 2 ways. It plays out in sort of geographic mix but also sort of business and product mix. And so as I look year-over-year for third quarter, really, probably the biggest impact that we had was related to business mix in terms of how much MedSurg versus Orthopaedics versus international we had last year versus this year. And then on the FX front, we entered the hedging program back when foreign currency was a lot more volatile, and the whole idea was to lock in the predictability of foreign currency for us. So like you had mentioned, currencies move up and down. Our hedging program provides stability and predictability to us. And so for the third quarter, I think, as I said, there will be sort of a nominal impact on sales related to translational, but that will have, potentially, a minor impact similar to this quarter related to transactional FX. And that's where, I think, we'll come out."
94614,377148003,1064540,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Analysts","And over the next 4 -- 3, 4 quarters, just -- will the currency side alone, and we can make our own assumptions on everything else, but with currency, should we be thinking of that as a small drag still for the next several quarters on gross margins? Is t",53,"And over the next 4 -- 3, 4 quarters, just -- will the currency side alone, and we can make our own assumptions on everything else, but with currency, should we be thinking of that as a small drag still for the next several quarters on gross margins? Is that a fair comment?"
94614,377148003,1064540,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Executives","Yes, I don't know. I wish I had the currency crystal ball to figure out what -- how things were going to flow. But it's hard to say because it's not only impacted by, say, what we've done in hedging but what the underlying transactions are. So I don't thi",60,"Yes, I don't know. I wish I had the currency crystal ball to figure out what -- how things were going to flow. But it's hard to say because it's not only impacted by, say, what we've done in hedging but what the underlying transactions are. So I don't think I can really comment that far out at this point."
94614,377148003,1064540,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Operator","And there are no further questions at this time. I will now turn the conference over to Mr. Kevin Lobo for any closing remarks.",24,"And there are no further questions at this time. I will now turn the conference over to Mr. Kevin Lobo for any closing remarks."
94614,377148003,1064540,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Executives","Thank you all for joining our call. Our conference call for the fourth quarter 2016 results will be held on January 24, 2017. Thank you.",25,"Thank you all for joining our call. Our conference call for the fourth quarter 2016 results will be held on January 24, 2017. Thank you."
94614,377148003,1064540,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Operator","Thank you, ladies and gentlemen. This concludes today's conference. Thank you for participating. You may now disconnect.",17,"Thank you, ladies and gentlemen. This concludes today's conference. Thank you for participating. You may now disconnect."
94614,377148003,1065623,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Operator","Welcome to the Third Quarter 2016 Stryker Earnings Call. My name is Crystal, and I will be your operator for today's call. [Operator Instructions] This conference call is being recorded for replay purposes.Before we begin, I would like to remind you tha",134,"Welcome to the Third Quarter 2016 Stryker Earnings Call. My name is Crystal, and I will be your operator for today's call. [Operator Instructions] This conference call is being recorded for replay purposes.
Before we begin, I would like to remind you that the discussions during this conference call will include forward-looking statements. Factors that could cause actual results to differ materially are discussed in the company's most recent filings with the SEC. Also, the discussions will include certain non-GAAP financial measures. Reconciliations to the most directly comparable GAAP financial measures can be found in today's press release that is an exhibit to Stryker's current report on Form 8-K filed today with the SEC.
I will now turn the call over to Mr. Kevin Lobo, Chairman and Chief Executive Officer. You may proceed, sir."
94614,377148003,1065623,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Executives","Welcome to Stryker's Third Quarter Earnings Call. Joining me today are Glenn Boehnlein, Stryker's CFO; and Katherine Owen, VP of Strategy and Investor Relations.For today's call, I will provide opening comments, followed by Katherine with an update on M",314,"Welcome to Stryker's Third Quarter Earnings Call. Joining me today are Glenn Boehnlein, Stryker's CFO; and Katherine Owen, VP of Strategy and Investor Relations.
For today's call, I will provide opening comments, followed by Katherine with an update on MAKO and our November analyst meeting. Glenn will then provide additional details regarding our quarterly results before we open the call to Q&A.
We achieved another quarter of solid organic sales growth, coming in at 6.2% and fueled by a strong showing for both MedSurg & Neurotechnology, with both delivering roughly 7% increases. Orthopaedics growth was consistent at approximately 5% organically. On a geographic basis, Q3 sales were balanced with a 6% increase in the U.S. and a 6.7% gain in international, driven by strong momentum in Europe and a return to growth in emerging markets.
We are pleased with the performance of our acquisitions, including both Sage and Physio-Control, which are well positioned to help us drive stronger organic sales growth for Stryker in the coming years.
A strong top line performance, coupled with our ongoing focus on G&A leverage, resulted in an EPS of $1.39, up 11.2% and $0.01 above the high end of our target range. Based on our performance for the first 9 months of 2016, we are confident in our ability to deliver our commitments, with organic sales growth for the full year expected at 6% to 6.5%.
We are narrowing our adjusted EPS range to the upper end, which now stands at $5.75 to $5.80 per share. Overall, we believe the strength of our people, diversified revenue model and new product flow positions us well to continue to deliver sales at the high end of med tech with leveraged earnings gains. 
We look forward to providing our 2017 financial guidance on our Q4 earnings call in January.
With that, I will now turn the call over to Katherine."
94614,377148003,1065623,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Executives","Thanks, Kevin. My comments on today's call will include an update on MAKO as well as a preview of our upcoming analyst meeting.Starting with MAKO. Results in the quarter were strong with a total of 30 robots installed globally, representing a roughly 75",439,"Thanks, Kevin. My comments on today's call will include an update on MAKO as well as a preview of our upcoming analyst meeting.
Starting with MAKO. Results in the quarter were strong with a total of 30 robots installed globally, representing a roughly 75% year-over-year increase with 23 in the U.S. Consistent with prior quarters, approximately 40% of the installations were in competitive accounts where Stryker has no or relatively low market share.
Demand for the MAKO robot is being fueled by the expanded indications, including the total knee, which began a limited launch in June. Since that time, we have had KOL surgeons trained on the robots for the total knee, including those with prior robot experience but with less exposure to our Triathlon knee as well as surgeons who had not previously used a robot for joint reconstruction. As we discussed previously, by observing both these groups, we are optimizing the training protocol.
Of note, since the start of the limited market release for the total knee, over 200 cases have been performed, and we've been pleased with the results to date. We are targeting the 2017 AAOS meeting to move into the full commercial launch.
I will now shift to the analyst meeting, which will be held on November 9 at our Orthopaedics headquarters in New Jersey. In order to optimize the utility of this meeting, we will be focusing the formal part of the meeting on several key areas. This will include a MAKO physician panel with 2 surgeons who have been part of the limited market release. We will also have a Stryker Performance Solutions panel, which will include an SPS customer and focus on how we've been able to deploy our expertise in the joint reconstruction episode of care to help reduce our procedural costs.
Turning to cost transformation for growth. Lonny Carpenter, Group President of Global Quality and Operations, will provide an update on the various initiatives within CTG, including the expected financial contribution over the next 2 years. Glenn Boehnlein will provide a financial update, including our longer-term targets. We will conclude the formal part of the meeting with a Q&A session with the leadership team. We will then move to the product fair, which will include product highlights for MedSurg & Neurotechnology and will afford the opportunity to interact informally with the broader Stryker leadership team.
We hope you will be able to join us for the meeting. The event details and complete agenda, including the various guest speakers and their backgrounds, are available on the event registration site.
With that, I will now turn the call over to Glenn."
94614,377148003,1065623,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Executives","Thanks, Katherine. Today, I will focus my comments on our third quarter financial results and performance drivers. Our detailed financial results have been provided in today's press release.Our organic sales grew 6.2% in the quarter, which was within ou",1059,"Thanks, Katherine. Today, I will focus my comments on our third quarter financial results and performance drivers. Our detailed financial results have been provided in today's press release.
Our organic sales grew 6.2% in the quarter, which was within our range of full year expectations of 6% to 6.5%, with no difference in selling days. Pricing in the quarter was down 1.3% from the prior year, while foreign currency exchange had a nominal impact on sales.
U.S. sales continue to demonstrate strong momentum with organic growth of 6%, reflecting solid performances across our portfolio, especially in MedSurg & Neurotech. International sales grew 6.7% organically, highlighted by solid gains in Europe, Canada and Australia, somewhat offset by the continued impact of our previously discussed destocking issues in China. We expect that the fourth quarter will show some improvement in our  China business as prior year comparables continued to ease.
Our adjusted EPS of $1.39 increased 11.2% from the prior year, reflecting strong sales growth, accretive acquisitions and good operating expense control. Our third quarter EPS was negatively impacted by $0.03 related to transactional foreign currency exchange.
Focusing on our segment highlights. Orthopaedics delivered constant currency growth of 5.3% and organic growth of 4.8%, led by the U.S. organic growth of 4.7%. These gains reflect solid performances in Trauma and Extremities at 6.9% and knees at 5.1%. This growth reflects strong demand for our 3D-printed products, our Foot & Ankle portfolio and our MAKO platform, which had 30 units installed, including 7 outside the U.S. Orthopaedics international delivered constant currency growth of 6.3% and organic growth of 5.1%, led by our European business.
MedSurg posted strong gains across all businesses in the quarter with constant currency growth of 33% and organic gains of 7.3%, which included a 7.7% increase in the U.S. Instruments, which was up 5.2% in the U.S., maintained good momentum with its waste management business and the newly launched Neptune 3 and continued strong performance related to its Navigation business.
Endoscopy delivered U.S. growth of 10.4%, driven by strong double-digit performances of its camera and light source products and strong gains in its communications, sports medicine and ProCare service businesses. 
Our Medical division had U.S. organic growth of 6.8%, driven by double-digit growth of its core bed and power cot products. On a comparable basis, Medical's Physio business was up 6.3%. Its Sage business grew 12.5%, including the impact of the recent recall. Excluding this, Sage grew 15%. We are pleased with these results and the ongoing integration efforts at Medical.
Internationally, MedSurg organic sales growth was 6%, which reflects strong European and Australian sales and some easing of the MedSurg comparable in China. Neurotechnology and Spine continues to drive above-market performance with constant currency growth of 8.7% and organic growth of 6.9%. This growth reflects continued strong demand for our Neurotech products. U.S. Neurotech posted growth of 9.1% in the quarter, highlighted by our AIS products and our Neuro Powered Instruments.
Our Spine business in the U.S. continued to see some supply issues, offset somewhat by strong demand for our 3D-printed interbody Tritanium products. As I have said last quarter, we expect the supply issues to remain into the fourth quarter.
Internationally, Neurotech had constant currency growth of 16.7%. This performance was driven by continued strong demand for our Trevo stent retriever and Target Coil products in Europe and Asia. Spine's international growth was 1.6% and was impacted by the aforementioned supply issues and challenges in China.
Now I will focus on the operating highlights within the quarter. Our gross margin, which, on an adjusted basis, was 66.3%, was down 60 basis points from the prior year quarter. Gross margin was favorably impacted by absorption and productivity gains, which was offset by mix, including the impact of acquisitions and foreign currency exchange.
SG&A for the third quarter was 34.9% of sales on an adjusted basis, which was favorable by 70 basis points as compared to the prior year quarter. This improvement reflects favorable leverage from continued focus on operating expense improvements through our CTG program, cost-containment efforts and business mix, including leverage from our recent acquisitions.
We continue to invest in internal innovation with R&D, which is up 10 basis points year-over-year to 6.5% of sales. In total, adjusted operating expenses at 41.4% of sales was favorable 60 basis points to the prior year quarter, and these results continue to reflect our focus on leverage growth.
In summary, our operating margin was 24.9% of sales in Q3, flat year-over-year but up 64 basis points on a year-to-date basis. This performance reflects the positive results from our various CTG programs, continued cost control and favorable accretion from acquisitions, offset by business mix, pricing and foreign exchange.
Lastly, I will provide some highlights on other income and expense. Other expenses increased due to the higher net interest expense related to increased borrowings at the end of the first quarter. During the third quarter, we also paid down $750 million of debt. And accounting for the impact of this, we anticipate our future quarterly run rate of interest expense to be approximately $65 million.
Our third quarter adjusted effective tax adjusted effect of tax rate of 17.5% reflects the benefits of our global tax structure, partially offset by the impact of higher U.S.-based income from our recent acquisitions.
Moving on to the balance sheet. We continue to maintain a strong balance sheet with $3 billion of cash and marketable securities, of which approximately 80% was held outside the U.S. Total debt on the balance sheet at the end of the second quarter was $6.8 billion.
Turning to cash flow. Our year-to-date cash from operations was approximately $1.2 billion. Finally, as we have previously announced at the end of Q1, we have suspended our share repurchases for the remainder of 2016.
In terms of guidance, we reconfirm our previous full year organic sales growth range of 6% to 6.5% for 2016. If foreign currency exchange rates hold near current levels, we expect a neutral impact in the fourth quarter and a negative foreign currency impact of less than 0.5% for the full year.
Lastly, our guidance for adjusted net earnings per diluted share in 2016 is now expected to be in the range of $5.75 to $5.80 for the full year.
And now I will open up the call for Q&A."
94614,377148003,1065623,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Operator","[Operator Instructions] And our first question comes from Bob Hopkins from Bank of America.",14,"[Operator Instructions] And our first question comes from Bob Hopkins from Bank of America."
94614,377148003,1065623,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Analysts",";So I have 2 questions. One, I'll start with you, Kevin. I was encouraged to hear your comments about emerging markets and turning back to the positive there. So maybe you could just kind of lay out specifically what improved and what you think the pros",88,";
So I have 2 questions. One, I'll start with you, Kevin. I was encouraged to hear your comments about emerging markets and turning back to the positive there. So maybe you could just kind of lay out specifically what improved and what you think the prospects are for your emerging market growth. Now that you've kind of turned the corner, can we get back to mid to high single digits in a reasonable time frame for emerging markets? Just want to hear a little more color on EM."
94614,377148003,1065623,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Executives","Yes, sure. So outside of China, I would say, I'm really encouraged by the progress in India, which is really a continuation of what we've been experiencing the past few quarters. Brazil returned to growth. And as you know, Brazil has been a very challengi",198,"Yes, sure. So outside of China, I would say, I'm really encouraged by the progress in India, which is really a continuation of what we've been experiencing the past few quarters. Brazil returned to growth. And as you know, Brazil has been a very challenging market for us over the past year to 2. And we also like the results in Russia, Turkey. So it's really across the board. Our other emerging market countries performed very well. China's still a bit of a laggard, but as Glenn's mentioned in his prepared remarks, we expect China to return to growth in the fourth quarter. So we're starting to see an improvement. Part of this is really the comparables that we're sort of lapping the years of sort of core performance. So we would expect a bit of a turnaround. But I -- it's really early. It's only one quarter, but I'm starting to see a trend that we will see growth. Now whether we'll get back to double digit as we experienced in prior years, it's a little early for me to say. But certainly, the outlook is much more positive than it has been over the past year."
94614,377148003,1065623,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Analysts","Okay. And then for Katherine, as a follow-up, just on your comments on the Analyst Day and MAKO. On the Analyst Day, can you just -- I know you're not giving guidance until the fourth quarter, but what will you be quantifying at the Analyst Day in some of",85,"Okay. And then for Katherine, as a follow-up, just on your comments on the Analyst Day and MAKO. On the Analyst Day, can you just -- I know you're not giving guidance until the fourth quarter, but what will you be quantifying at the Analyst Day in some of these prepared commentary? Will there be any quantification of cost savings or long-term margin opportunity? Just want to make sure I have a good understanding of exactly what we're going to get at the Analyst Day."
94614,377148003,1065623,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Executives","Yes. In addition to the panels, I focused on MAKO and SPS. Lonny will be giving a CTG update, which will include a greater quantification and visibility around the long-term potential from the cost savings that we're targeting. And then Glenn will be givi",89,"Yes. In addition to the panels, I focused on MAKO and SPS. Lonny will be giving a CTG update, which will include a greater quantification and visibility around the long-term potential from the cost savings that we're targeting. And then Glenn will be giving an update with some of our longer-term financial targets. Now we'll go into the full detail of that at the Analyst Day. But also to be clear, we won't be giving 2017 guidance ranges, the formalization of our targets, until the January fourth quarter call."
94614,377148003,1065623,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Operator","Our next question comes from Rick Wise from Stifel.",9,"Our next question comes from Rick Wise from Stifel."
94614,377148003,1065623,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Analysts","Maybe I'll also start with MAKO. You obviously had an exceptionally strong quarter. Maybe, Kevin or Katherine, you could give us a little more color there. Maybe just sort of multipart question on this. What kind of pull-through are you seeing for Stryker",91,"Maybe I'll also start with MAKO. You obviously had an exceptionally strong quarter. Maybe, Kevin or Katherine, you could give us a little more color there. Maybe just sort of multipart question on this. What kind of pull-through are you seeing for Stryker products, particularly in competitive accounts? And maybe talk a little more, if you could, about some of the data surrounding -- clinical data surrounding MAKO we might see. I know that's been a priority for this year. What might be seen and when will we see it?"
94614,377148003,1065623,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Executives","Yes, I think, obviously, the 30 robots placed, we're very pleased with that, that number of installations. We're also pleased that they are going into -- roughly 40% into competitive accounts. It's also what is helping drive our knee growth, which, I beli",233,"Yes, I think, obviously, the 30 robots placed, we're very pleased with that, that number of installations. We're also pleased that they are going into -- roughly 40% into competitive accounts. It's also what is helping drive our knee growth, which, I believe, is above market and I mean, clearly is a big focus for our sales force right now, given their excitement around that. We do believe qualitatively, we're going to get -- continue to receive feedback around benefits, including alignment, less tissue disruption and ultimately, patient satisfaction. Longer term, clinical data on that is going to take us some time to collect. We will be gathering that, but that's going to be 1-, 2-, 3-year data and obviously, it will take that long. I think it will be a great opportunity at the panel at the Analyst Day where we're going to have a surgeon who had no experience with a robot prior to becoming part of the limited market release of the knee as well as a longer-term robot user to ask those questions and hear what their experience has been. But with the 200 cases to date, we've been really pleased with what we've seen so far and the ability to both get into competitive accounts and optimize the training protocol ahead of full commercial launch, which, as we said, will take place in March at the academy meeting."
94614,377148003,1065623,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Analysts","Great. Just a follow-up on Sage and Physio briefly. Maybe just highlight -- I know we'll hear more soon, but where are we in terms of the integration and cost and sales? Kevin, you feel like you're on plan. Sage grew a little faster than the second quarte",65,"Great. Just a follow-up on Sage and Physio briefly. Maybe just highlight -- I know we'll hear more soon, but where are we in terms of the integration and cost and sales? Kevin, you feel like you're on plan. Sage grew a little faster than the second quarter. Physio, a tad slower. I assume that's seasonal. But again, any more color there would be welcome."
94614,377148003,1065623,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Executives","Yes. Thanks, Rick. So first of all, over the full 6-month period, we're really pleased with both companies' performance. They're really line with our expectations. The integrations are going very well. As you know, Sage is, I'll call it, more of a lighter",134,"Yes. Thanks, Rick. So first of all, over the full 6-month period, we're really pleased with both companies' performance. They're really line with our expectations. The integrations are going very well. As you know, Sage is, I'll call it, more of a lighter integration, given that there's less of an overlap with the call point. But certainly, we're sharing leads with the Sage organization. At Physio, we have a little bit more of call point overlap. It's really more of a planning phase this year. Our sales forces are running independently this year. And then over the course of the next year or 2, we'll start to integrate those sales forces. But I would stay, so far so good on integration, and we're pleased with the performance and really, the outlook for the future."
94614,377148003,1065623,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Operator","Our next question comes from Mike Weinstein from JPMorgan.",9,"Our next question comes from Mike Weinstein from JPMorgan."
94614,377148003,1065623,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Analysts","Congratulations on getting back to above that 6% bar. That's nice to see. Katherine, the September health care conferences proved a bit trickier this year. And there was a bunch of questions, as you know, that come out of them where people were asking abo",187,"Congratulations on getting back to above that 6% bar. That's nice to see. Katherine, the September health care conferences proved a bit trickier this year. And there was a bunch of questions, as you know, that come out of them where people were asking about comments that you guys have made. So maybe I thought it was a good opportunity to clarify a couple of them. And Katherine, Kevin, chime in here, 2 sets of comments were -- Kevin, just about your outlook for the Trauma business and the Hip business and some potential deceleration in growth. And then naturally, people try to get you to comment on 2017 preliminarily and how to think about operating a financial leverage, excluding the impact of the acquisitions. There seems to be some confusion around that. So maybe just want to spend a minute on both the outlook for the Trauma and then the Hip business in light of the -- all the focus on the knee side and then just comment, if you would, about how we should think about operating leverage heading into '17 without obviously giving guidance."
94614,377148003,1065623,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Executives","Sure, Mike. I'll take the Trauma and Hip question, and then I'll pass it over to Katherine to talk about, I think, some misperceptions around 2017. So what I've been saying for some time on the Trauma business is that sustaining 15% growth quarter after q",312,"Sure, Mike. I'll take the Trauma and Hip question, and then I'll pass it over to Katherine to talk about, I think, some misperceptions around 2017. So what I've been saying for some time on the Trauma business is that sustaining 15% growth quarter after quarter is pretty unlikely. We've done that for over 3 years coming into this year. If you look at last year's third quarter, we grew 15.1% in the U.S. And so to put up a 7% growth against that comp is still a pretty solid performance. But while big numbers is -- we've been signaling that Trauma will start to slow down a little bit in terms of its growth rate, but certainly performing above market and I think it still had a strong solid performance this quarter. But the only signal there is that sustaining that level of outperformance 3x the market is not likely to do indefinitely. So no concerns. We have a very strong Trauma leadership team, strong business, strong pipeline. I'm still very bullish about that division. As it relates to Hips, we're longer in our product cycle, with Accolade II being one of the newer products that we launched a few years ago. And a lot of excitement in knees. And as you know, same sales force that sells both Hips and Knees. We have a big launch upcoming with MAKO total knee. We have a lot of cementless products in the knee portfolio. So I would say that there's been a bit of attention focused on knees. And we've seen this in our industry for decades that it's very difficult to be able to focus on both products equally. So the fact that our Hip growth, which have been above market for about 3 or 4 years, is now moving, let's say, more in line with market is not also surprising."
94614,377148003,1065623,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Executives","Yes. And just going back to some of the misperceptions around some of the conferences, the health care conferences in September, I will tell you, candidly, we were surprised if anybody -- that there was any misperception. We try to be very consistent in t",176,"Yes. And just going back to some of the misperceptions around some of the conferences, the health care conferences in September, I will tell you, candidly, we were surprised if anybody -- that there was any misperception. We try to be very consistent in terms of our goal of growing sales at the high end of med tech. We think the med tech markets are largely stable, at least the segments where our product portfolio competes. And as Kevin said in his prepared comments at the start of this call, we feel really good about our ability to continue to deliver that. The specific range around that, in which may have been, where some of the misperceptions came, we will talk about in January as we do every year. So to the degree of unwillingness to give guidance ahead of when we normally do it caused some concern, I think that was incorrect. We feel great about the momentum and the product portfolio, and we'll look to specify that in terms of financial ranges in January."
94614,377148003,1065623,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Analysts","So there's -- Katherine, just one follow-up, if I can. The growth in MAKO this quarter and the units that sold their place, was that to -- just characterize it, was that to the beta sites that have been doing the, call it, early launch feedback for you gu",58,"So there's -- Katherine, just one follow-up, if I can. The growth in MAKO this quarter and the units that sold their place, was that to -- just characterize it, was that to the beta sites that have been doing the, call it, early launch feedback for you guys? Or is that the centers anticipating the launch?"
94614,377148003,1065623,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Executives","It's both. Some of those are to those that are part of the limited market release, but that's a small group. Some of those were just, for lack of a better word, putting and getting in the queue because they want to be part of the upgrades and ready for th",73,"It's both. Some of those are to those that are part of the limited market release, but that's a small group. Some of those were just, for lack of a better word, putting and getting in the queue because they want to be part of the upgrades and ready for the total launch. So it's a mix, but it is -- I would say that limited market release customers are the minority."
94614,377148003,1065623,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Operator","Our next question comes from David Lewis from Morgan Stanley.",10,"Our next question comes from David Lewis from Morgan Stanley."
94614,377148003,1065623,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Analysts","Just 2 quick questions, one for Kevin, one for Katherine. Kevin, just -- you've got a wide range of businesses now that you're back above 6% organic this quarter, and I agree with Mike, that was nice to see. I wonder if you could just comment, just given",166,"Just 2 quick questions, one for Kevin, one for Katherine. Kevin, just -- you've got a wide range of businesses now that you're back above 6% organic this quarter, and I agree with Mike, that was nice to see. I wonder if you could just comment, just given the broader environment this particular quarter, a couple of things. One, just your capital business is very strong. There's some emerging concern that the election cycle is going to result in some capital freeze and result in that months in September and October heading to the election cycle. So just == the broader capital environment heading into election, are you seeing any change in sort of relative backlogs? And then utilization, sort of a similar question, a lot of talk about polarization in sort of July, August versus September. I mean, do you see a change in how utilization trended in some of your Orthopaedic businesses across the quarter? And then I had a quick one for Katherine."
94614,377148003,1065623,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Executives","Yes. So thanks, David. What I would tell you is we haven't seen really any change in the capital. Business has been extremely stable. The election to us is really a nonevent in terms of the businesses that we participate in. As you know, there's a lot of",129,"Yes. So thanks, David. What I would tell you is we haven't seen really any change in the capital. Business has been extremely stable. The election to us is really a nonevent in terms of the businesses that we participate in. As you know, there's a lot of attention being drawn to pharma, a lot of commentary made about pharma. But med tech is very small percent of the overall health care spend, and we're not seeing really any impact whatsoever. And as it relates to procedural volume, again, we didn't see anything unusual within the month of the quarter, very, very stable market. And that's not new. The market has been stable for the past 2 years, 3 years, and we continue to perform well in this market."
94614,377148003,1065623,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Analysts","Kevin -- sorry, Katherine, in terms of back half '17, you'd said MAKO, it's unlikely we see share movement until back half '17 the earliest. I just think about -- it's the biggest year-on-year system add you've had, I think, since you bought the company.",82,"Kevin -- sorry, Katherine, in terms of back half '17, you'd said MAKO, it's unlikely we see share movement until back half '17 the earliest. I just think about -- it's the biggest year-on-year system add you've had, I think, since you bought the company. You've got 40% competitive accounts, and obviously, you're going to have a bigger launch at AAOS. Is the back half of '17 still the earliest that we could start to see share movement in the knee channel?"
94614,377148003,1065623,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Executives","I think that's the way to be thinking about it right now. Remember, these robots have to get installed. That takes time and energy and people we have to train. And so there's a cadence. This is not like an easy product that you launch overnight and it run",114,"I think that's the way to be thinking about it right now. Remember, these robots have to get installed. That takes time and energy and people we have to train. And so there's a cadence. This is not like an easy product that you launch overnight and it runs. So we need to be thoughtful in that regard clearly that we can target academy for the full commercial launch, and we'll be well prepared to go out and train from there. But I still think the back half of the year is the best time to be focused on in terms of starting to see indications that we're gaining meaningful knee market share."
94614,377148003,1065623,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Operator","Our next question comes from Kristen Stewart from Deutsche Bank.",10,"Our next question comes from Kristen Stewart from Deutsche Bank."
94614,377148003,1065623,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Analysts","Just to go back, I guess, to some of the comments on the acquisitions. I know you said that integration's going so far. Would you be willing to say in terms of the 2017 accretion numbers that those still look to be intact based upon how the businesses are",58,"Just to go back, I guess, to some of the comments on the acquisitions. I know you said that integration's going so far. Would you be willing to say in terms of the 2017 accretion numbers that those still look to be intact based upon how the businesses are performing, better or worse than you had originally stated?"
94614,377148003,1065623,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Executives","Kristen, it's Glenn. Yes, we actually were on track in 2016 to hit the accretion numbers that we put out there. And then also, for 2017, based on our preliminary planning, we think we'll be on track to hit the numbers that we put out for accretion as well",49,"Kristen, it's Glenn. Yes, we actually were on track in 2016 to hit the accretion numbers that we put out there. And then also, for 2017, based on our preliminary planning, we think we'll be on track to hit the numbers that we put out for accretion as well."
94614,377148003,1065623,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Analysts","Okay, great. And then has FX changed at all in terms of the bottom line impact? And with the change in stock option accounting, can you give us a sense in terms of how that may also impact or maybe what the impact might be in 2016 or '15 or anything to th",58,"Okay, great. And then has FX changed at all in terms of the bottom line impact? And with the change in stock option accounting, can you give us a sense in terms of how that may also impact or maybe what the impact might be in 2016 or '15 or anything to that extent you could help frame?"
94614,377148003,1065623,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Executives","Yes, yes. It feels like 2 questions, and I'll take a stab at them both. So first off, on FX, as you can see, translational is easing, especially in Q3, and we expect it to be nominal in Q4. Transactional will still continue to impact us as it did this qua",133,"Yes, yes. It feels like 2 questions, and I'll take a stab at them both. So first off, on FX, as you can see, translational is easing, especially in Q3, and we expect it to be nominal in Q4. Transactional will still continue to impact us as it did this quarter and it will next quarter. And part of that is related to our hedging program and the way we lock in hedges 18 months ahead of time and how that relates to the current exchange rates that are out there. And then secondly, as it relates to the change in stock option, I think if you take a look, we've disclosed what we think that'll be, which is roughly maybe $30 million. And we don't plan on adopting it until next year."
94614,377148003,1065623,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Operator","Our next question comes from Chris Pasquale from Guggenheim.",9,"Our next question comes from Chris Pasquale from Guggenheim."
94614,377148003,1065623,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Analysts","Kevin, it's been a while since you guys hosted an analyst meeting, and I know you talked about not wanting to comment too much on forward guidance yet. But you're going to have the chance to talk about some of the progress you've made with some of the inv",120,"Kevin, it's been a while since you guys hosted an analyst meeting, and I know you talked about not wanting to comment too much on forward guidance yet. But you're going to have the chance to talk about some of the progress you've made with some of the investments to get a cost in the middle of the income statement, in particular. I see Lonny's on the agenda. Can you talk a little bit about some of those programs? You've highlighted the ERP transition, some of the other things you're doing. And will this be an opportunity to sort of layout the next steps to how we get some leverage, particularly in the middle of the income statement going forward?"
94614,377148003,1065623,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Executives","I think what you'll hear Lonny talk about is progress on multiple fronts as we've gotten the CTG program underway. ERP is one of them, product life cycle management, plant optimization, indirect spend and as we try to articulate, giving greater quantifica",71,"I think what you'll hear Lonny talk about is progress on multiple fronts as we've gotten the CTG program underway. ERP is one of them, product life cycle management, plant optimization, indirect spend and as we try to articulate, giving greater quantification around the longer-term targets and expected contribution from that. That will be the focus of his comments while Glenn will focus on our longer-term financial targets beyond '17."
94614,377148003,1065623,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Analysts","Okay. That's helpful. And then sorry if I missed this earlier, I've been jumping around. But can you talk a little bit about the Trauma and Extremities business? Good quarter there, a little bit of a pickup from what we saw last quarter. Anything in parti",48,"Okay. That's helpful. And then sorry if I missed this earlier, I've been jumping around. But can you talk a little bit about the Trauma and Extremities business? Good quarter there, a little bit of a pickup from what we saw last quarter. Anything in particular driving that?"
94614,377148003,1065623,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Executives","No, I would say it's just continued strong performance, and we've been performing well in our Trauma business over the last 3 years, and it was just more of the same this quarter.",33,"No, I would say it's just continued strong performance, and we've been performing well in our Trauma business over the last 3 years, and it was just more of the same this quarter."
94614,377148003,1065623,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Operator","Our next question comes from Kaila Krum from William Blair.",10,"Our next question comes from Kaila Krum from William Blair."
94614,377148003,1065623,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Analysts","Just a couple for me. So in terms of acquisition strategy and I guess, specific to Orthopaedics and Spine, are you guys more focused on scale or growth at this point in time? And granted they do come hand-in-hand, but one tends to lead to the other, so ju",57,"Just a couple for me. So in terms of acquisition strategy and I guess, specific to Orthopaedics and Spine, are you guys more focused on scale or growth at this point in time? And granted they do come hand-in-hand, but one tends to lead to the other, so just trying to better understand your M&A strategy there."
94614,377148003,1065623,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Executives","There's no change in M&A strategy. Whether it's the company overall or Ortho versus MedSurg & Neurotech, it's focused on our core and key adjacent markets. If you look historically, the bulk of our deals have been in core markets with a few key adjacent a",66,"There's no change in M&A strategy. Whether it's the company overall or Ortho versus MedSurg & Neurotech, it's focused on our core and key adjacent markets. If you look historically, the bulk of our deals have been in core markets with a few key adjacent acquisitions. And that will continue to be the strategy going forward across all the divisions. So no change from that."
94614,377148003,1065623,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Analysts","Okay. And then just a follow-up on the Extremities business. I mean, just looking specifically at Foot & Ankle, can you guys talk about how your Foot & Ankle performance has been recently? Are they still sort of trending in historical levels? And just any",53,"Okay. And then just a follow-up on the Extremities business. I mean, just looking specifically at Foot & Ankle, can you guys talk about how your Foot & Ankle performance has been recently? Are they still sort of trending in historical levels? And just any commentary on market trends there would be helpful."
94614,377148003,1065623,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Executives","Yes. So we're really pleased with our Foot & Ankle performance. In the U.S., this quarter, we grew 15%, very much in line with the performance we've had over the past year. It continues to be a very good market.",40,"Yes. So we're really pleased with our Foot & Ankle performance. In the U.S., this quarter, we grew 15%, very much in line with the performance we've had over the past year. It continues to be a very good market."
94614,377148003,1065623,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Operator","Our next question comes from Glenn Novarro from RBC Capital.",10,"Our next question comes from Glenn Novarro from RBC Capital."
94614,377148003,1065623,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Analysts","Two questions. First, pricing in Orthopaedics, down 2.2%. That was similar to the second quarter. So I'm wondering if the new trend line of Orthopaedic pricing is now going to be in that 2% to 2.5% range. Then I had a follow-up on pricing.",44,"Two questions. First, pricing in Orthopaedics, down 2.2%. That was similar to the second quarter. So I'm wondering if the new trend line of Orthopaedic pricing is now going to be in that 2% to 2.5% range. Then I had a follow-up on pricing."
94614,377148003,1065623,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Executives","I think we feel comfortable, from a total company perspective, that pricing is going to be down in that 1.5%, 2% vicinity. It's been trending slightly less negative. Ortho, it seems relatively stable, but candidly trying to predict that level of accuracy.",97,"I think we feel comfortable, from a total company perspective, that pricing is going to be down in that 1.5%, 2% vicinity. It's been trending slightly less negative. Ortho, it seems relatively stable, but candidly trying to predict that level of accuracy. 50, 100 basis points moves in price. It's really difficult. We have greater confidence and visibility when you look at the totality of the company because we have areas with less price, less pricing pressure. And so we really try to focus on the total versus specific line item where it can move around quarter-to-quarter."
94614,377148003,1065623,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Analysts","Okay. And then just as a follow-up to that. Pricing, again, I look at it sequentially, pretty stable. And now we're in the 6 months of CJR, so it seems like there's been no impact to pricing. So I'm curious as to what your thoughts are on the implementati",58,"Okay. And then just as a follow-up to that. Pricing, again, I look at it sequentially, pretty stable. And now we're in the 6 months of CJR, so it seems like there's been no impact to pricing. So I'm curious as to what your thoughts are on the implementation of CJR. And are you seeing any pricing pressures?"
94614,377148003,1065623,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Executives","We would agree, we really haven't seen an impact. But in fairness, too, it has only been 6 months. And in the first year, there is no financial penalty. So we really believe you're going to see a greater focus by hospitals when there's more of a financial",133,"We would agree, we really haven't seen an impact. But in fairness, too, it has only been 6 months. And in the first year, there is no financial penalty. So we really believe you're going to see a greater focus by hospitals when there's more of a financial incentive. Now as you go into 2017, I think you'll be able to get a lot better visibility or hopefully will at the Analyst Day because we will have a hospital customer who's had experience under the bundled payment. But we continue to believe their focus is going to be in the post-acute setting on rehab costs as there is tremendous value to be realized by shifting more patients to the home and not at some of the skilled nursing facilities and other rehab facilities."
94614,377148003,1065623,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Operator","Our next question comes from Matt Miksic from UBS.",9,"Our next question comes from Matt Miksic from UBS."
94614,377148003,1065623,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Analysts","So I had one kind of topical question coming out NASS and your demonstration of Tritanium and your 3D-printed products. And then I had one follow-up just on the Ortho side, if I could. So one of the things you've talked about in your presentation and the",159,"So I had one kind of topical question coming out NASS and your demonstration of Tritanium and your 3D-printed products. And then I had one follow-up just on the Ortho side, if I could. So one of the things you've talked about in your presentation and the Q&A afterwards, there was just a buildout you've put in place around 3D-printed products in general. Of course, that drives the Spine portfolio of really one key product at the moment. But also, your press-fit knee, cementless knee platform you've talked a lot about. So I'm wondering, as you build that out, I mean, just given the proportion of your business, given the performance of your business, how are you prioritizing, I guess? Are you getting leverage across those 2 platforms and the way you manufacture and how you're sort of thinking about which one of these sort of high-demand products gets the volume over time? And I have more follow-up."
94614,377148003,1065623,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Executives","Sure, Matt. The short answer is they all do, but we have been capacity-constrained. We are adding 3D printing capacity on a monthly basis. We broke ground on a dedicated 3D printing facility in Ireland last year. As you know, this is extremely highly tech",89,"Sure, Matt. The short answer is they all do, but we have been capacity-constrained. We are adding 3D printing capacity on a monthly basis. We broke ground on a dedicated 3D printing facility in Ireland last year. As you know, this is extremely highly technical with a great deal of know-how around 3D printing these type of metals. We will be launching additional 3D-printed products. And -- but you should assume you'll see the benefit of that in Spine as well as on our revision and press-fit knee portfolio."
94614,377148003,1065623,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Analysts","Okay. And then the follow-up, just on the trends in Orthopaedics. I mean, the knee number, U.S. in particular, I thought was quite strong going up against a pretty significantly tougher comp. Hips, kind of the same. So just in terms of trends there, I thi",114,"Okay. And then the follow-up, just on the trends in Orthopaedics. I mean, the knee number, U.S. in particular, I thought was quite strong going up against a pretty significantly tougher comp. Hips, kind of the same. So just in terms of trends there, I think we talked about, back in September, what should we expect in terms of our recovery in Hips or annualizing some of the launches that you've had in Hips. And then on knees, if you could -- is it the press-fit that's really making out the difference in driving -- are we getting a mix benefit, penetration benefit on the knee side that's driving that strength? I appreciate it."
94614,377148003,1065623,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Executives","Yes. So keep in mind, it's the same sales force and the same customer base on Hips and Knees. Accolade, which has been a terrific product launch for us, is several years into that now, whereas MAKO is getting an enormous amount of focus and has a huge pro",205,"Yes. So keep in mind, it's the same sales force and the same customer base on Hips and Knees. Accolade, which has been a terrific product launch for us, is several years into that now, whereas MAKO is getting an enormous amount of focus and has a huge product launch. And as a result, the sales force has focused on that. So there is a halo effect that's helping our knee business. We also have additional new products on the knee side, our 3D-printed revision cones and sleeves and as we just mentioned, our 3D-printed cementless knee, which is really driving us to now low double-digit penetration for cementless knees, which is well above the industry. So I think right now, you're just in a period where there's a lot of happening on the knee side and a lot will continue to happen as we go to full commercial launch. We will be introducing more hip products, but sales force likes to focus on what's new and hot. And clearly, a lot of that momentum right now is on the knee side. And so we think hips, probably more like overall market growth. Knees, we believe, we're going to continue to grow above the market."
94614,377148003,1065623,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Executives","But certainly, when you look at the overall, we're very pleased with our performance. Our sales teams are doing an excellent job, and we're excited about the future years.",29,"But certainly, when you look at the overall, we're very pleased with our performance. Our sales teams are doing an excellent job, and we're excited about the future years."
94614,377148003,1065623,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Operator","Our next question comes from Mike Matson from Needham & Company.",10,"Our next question comes from Mike Matson from Needham & Company."
94614,377148003,1065623,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Analysts","We've seen a real pickup in the amount of M&A and the spine space. And Kevin, last I heard, I think you were saying that you're happy with the performance of the Spine business and the turnaround there and you didn't really feel the need to do something f",70,"We've seen a real pickup in the amount of M&A and the spine space. And Kevin, last I heard, I think you were saying that you're happy with the performance of the Spine business and the turnaround there and you didn't really feel the need to do something from an acquisition standpoint in Spine. But I just wanted to check and see if that was still how you felt."
94614,377148003,1065623,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Executives","Yes, so as you look at our Spine business, you see that we've had some issues around product performances, supply chain disruptions. But we have a great leadership team, and we had a number of quarters of very strong growth. And I believe in this leadersh",120,"Yes, so as you look at our Spine business, you see that we've had some issues around product performances, supply chain disruptions. But we have a great leadership team, and we had a number of quarters of very strong growth. And I believe in this leadership team, and Tritanium is a great example of the 3D-printed interbody device, which is performing very well. I'm confident our team can continue to perform well and grow the business. Related to M&A, I would give you the same comment I give for all our divisions. We're always looking to strengthen our businesses, but we're not going to comment on whether we're going to do acquisitions, big or small, on any of our divisions."
94614,377148003,1065623,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Analysts","Okay, I understand. And then you do have a significant portion of cash -- of your cash outside the U.S. So I know there's some talk of a potential tax deal after the election. So if that were to occur, obviously, it would depend of the terms of that. But",74,"Okay, I understand. And then you do have a significant portion of cash -- of your cash outside the U.S. So I know there's some talk of a potential tax deal after the election. So if that were to occur, obviously, it would depend of the terms of that. But would you repatriate any of that cash? And if you did, what would you -- how would you prioritize the use of that cash?"
94614,377148003,1065623,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Executives","As we look at our cash, I'm sure we're in the same position as several other U.S. companies. And if something like that became available, as it did a few years back, we would definitely take advantage of it and repatriate our cash to the extent possible.",105,"As we look at our cash, I'm sure we're in the same position as several other U.S. companies. And if something like that became available, as it did a few years back, we would definitely take advantage of it and repatriate our cash to the extent possible. In terms of how we might prioritize that cash, it's hard to say at this point. We've said before about what our priorities are around capital allocation, and that would mean M&A, that would mean dividends and it may mean share buybacks. But commenting beyond that, I don't think I can do that at this point in time."
94614,377148003,1065623,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Operator","Our next question comes from Bruce Nudell from SunTrust.",9,"Our next question comes from Bruce Nudell from SunTrust."
94614,377148003,1065623,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Analysts","Kevin, I have a couple for you. Firstly, I'm fascinated by this 40% placement of MAKO at competitive accounts. One of the big issues with Orthopaedics is that there's tremendous brand synergization of product on the part of surgeons as well as institution",87,"Kevin, I have a couple for you. Firstly, I'm fascinated by this 40% placement of MAKO at competitive accounts. One of the big issues with Orthopaedics is that there's tremendous brand synergization of product on the part of surgeons as well as institutions for hips or knees. So how do you accomplish that where you put a robot in and get people to go beyond new knees and kind of standardize on knees with the Stryker brand that they may not use most of the time today?"
94614,377148003,1065623,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Executives","The way we look at our MAKO adoption is really around behavioral segmentation, which surgeons like new technology and believe that they can become better at delivering value to their patients with technology. And so it's not about whether they like Stryke",90,"The way we look at our MAKO adoption is really around behavioral segmentation, which surgeons like new technology and believe that they can become better at delivering value to their patients with technology. And so it's not about whether they like Stryker or whether they like Zimmer or whether they like J&J. It's about do they like robotics and do they believe in robotics. And that's why, not surprising that many of the placements are in competitive products. [ph] We're getting a lot of feedback. Can you hear me, Bruce?"
94614,377148003,1065623,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Analysts","Yes. Yes, I can.",4,"Yes. Yes, I can."
94614,377148003,1065623,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Executives","I'm sorry, we're getting a little feedback in the room. But -- so what I'd tell you on this front is it's really all about the surgeon who wants to become better and who believes in technology, less so about our specific relationships or whether the hospi",182,"I'm sorry, we're getting a little feedback in the room. But -- so what I'd tell you on this front is it's really all about the surgeon who wants to become better and who believes in technology, less so about our specific relationships or whether the hospital is with Stryker or a different account, if it's different niche that we're serving. If you look at MAKO prior to our acquisition, they were able to obtain about 18% of the knee market over a 4-year period. There were not a proven entity. They weren't even an orthopedic company. So we really believe this about technology adoption certainly in the first couple of years. It's really around behavior, which surgeons believe in technology, and we're going to go to the surgeons that believe in it. There are many skeptics, as you know, with all disruptive technology. And some of those skeptics are Stryker loyal surgeons. And they won't be the first to adopt. And that doesn't concern us because there are many surgeons who are interested and who will be willing to adopt."
94614,377148003,1065623,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Analysts","And my second question is as we're relaunching on Stryker, what really struck me was that despite the acquisitive nature of the company, ROIC has been maintained. And could you just -- and it seems to be like a core strength of the company. Could you talk",72,"And my second question is as we're relaunching on Stryker, what really struck me was that despite the acquisitive nature of the company, ROIC has been maintained. And could you just -- and it seems to be like a core strength of the company. Could you talk about how that influences the profile of what you buy, how it fits in? And is that a formula you can maintain going forward?"
94614,377148003,1065623,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Executives","It's long been our history to be very disciplined in our deployment of capital. So when we look at deals, we want to strengthen every division that we have in the company. But we won't just pay whatever to companies. We're very disciplined. We walk away w",172,"It's long been our history to be very disciplined in our deployment of capital. So when we look at deals, we want to strengthen every division that we have in the company. But we won't just pay whatever to companies. We're very disciplined. We walk away when the prices are above our ability to deliver value. And sometimes, there's assets that we like and the price point's just too high and we have discipline to walk away from deals. And I think that's why you see the ROIC still consistent year over year over year in spite of the acquisition nature. The -- also, the ability to have acquisition that fit in our existing business, that plug into our sales force, which is the bulk of the deals we do. We have a proven model to deliver value with those types of acquisitions. So I think it's a combination of playing to our strengths in terms of our commercial execution and being financially disciplined with the deals that we do make."
94614,377148003,1065623,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Operator","Our next question comes from Richard Newitter from Leerink Partners.",10,"Our next question comes from Richard Newitter from Leerink Partners."
94614,377148003,1065623,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Analysts","I want to, maybe for you, Kevin, to start off. We're at NASS. Obviously, it's topical. We're seeing a lot of robotics take a bigger presence on the floor. Being that you were the first major company to kind of really validate the robotics category, we'd l",76,"I want to, maybe for you, Kevin, to start off. We're at NASS. Obviously, it's topical. We're seeing a lot of robotics take a bigger presence on the floor. Being that you were the first major company to kind of really validate the robotics category, we'd love to hear what your view is of the robotics kind of push in spine we're starting to see and then how MAKO potentially fits in over the long run."
94614,377148003,1065623,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Executives","Well, we love the fact that robotics is taking up a lot of the discussion because as you know, with MAKO, we believe in robotics. Right now, at Stryker, our focus is on hips and knees and specifically, the total knee launch. But we see, over time, that ce",86,"Well, we love the fact that robotics is taking up a lot of the discussion because as you know, with MAKO, we believe in robotics. Right now, at Stryker, our focus is on hips and knees and specifically, the total knee launch. But we see, over time, that certainly, robotics will extend into other procedural areas, including spine. We do have a smaller NDF underway right now, but it's too early for us to speculate on when we would come to the market in that specialty."
94614,377148003,1065623,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Analysts","Okay. And then maybe just one more follow-up. Outpatient surgery and the trend to outpatient ambulatory surgery care, it's clearly where hospitals are trying to go. I'd love to just hear how you feel Stryker's position, either through technology or other",64,"Okay. And then maybe just one more follow-up. Outpatient surgery and the trend to outpatient ambulatory surgery care, it's clearly where hospitals are trying to go. I'd love to just hear how you feel Stryker's position, either through technology or other means to capitalize on that trend. And specifically, if you could talk whether or not MAKO is lending a hand in that effort."
94614,377148003,1065623,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Executives","We have a lot of experience with the ambulatory surgery center with our sports medicine business. And as you know spine, the number of procedures -- the more simpler procedures are starting to move into the ambulatory surgery center. At this stage, MAKO h",130,"We have a lot of experience with the ambulatory surgery center with our sports medicine business. And as you know spine, the number of procedures -- the more simpler procedures are starting to move into the ambulatory surgery center. At this stage, MAKO hasn't had a big impact but we do see our robotics is going to have a play in all of the different aspects of the care continuum. I think this trend will continue towards -- shift the side of care towards surgery centers will continue, but it's not something that we're -- not been prepared for. We have plans across our divisions. And as you saw with -- you're at NASS, you saw the Spine division's actually created a program that's very specific for the surgery center."
94614,377148003,1065623,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Operator","Our next question comes from Larry Biegelsen from Wells Fargo.",10,"Our next question comes from Larry Biegelsen from Wells Fargo."
94614,377148003,1065623,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Analysts","So I wanted to just touch on and focus on the [indiscernible]",12,"So I wanted to just touch on and focus on the [indiscernible]"
94614,377148003,1065623,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Executives","Larry, I apologize. We can't hear you.",7,"Larry, I apologize. We can't hear you."
94614,377148003,1065623,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Executives","Are you on speaker? Could you pick up, please?",9,"Are you on speaker? Could you pick up, please?"
94614,377148003,1065623,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Analysts","Look, sorry about that. Neurotech, that was a little slower in the U.S. this quarter. What drove the deceleration? Is it -- could you talk a little bit about how your [indiscernible] business is performing? I know you talked about that as a key growth dri",49,"Look, sorry about that. Neurotech, that was a little slower in the U.S. this quarter. What drove the deceleration? Is it -- could you talk a little bit about how your [indiscernible] business is performing? I know you talked about that as a key growth driver for you guys."
94614,377148003,1065623,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Executives","Yes, so we continue to see good momentum in the AIS market. As we talked about before, predicting the slope and the speed of that market adoption is tricky. So we'll move around quarter-to-quarter and AIS was a bit slower sequentially, although still heal",70,"Yes, so we continue to see good momentum in the AIS market. As we talked about before, predicting the slope and the speed of that market adoption is tricky. So we'll move around quarter-to-quarter and AIS was a bit slower sequentially, although still healthy growth in that segment. We did have a coil recall in the quarter, which impacted our hemorrhagic business. That's fully resolved and shouldn't impact going forward."
94614,377148003,1065623,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Operator","Our next question comes from Matthew O'Brien from Piper Jaffray.",11,"Our next question comes from Matthew O'Brien from Piper Jaffray."
94614,377148003,1065623,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Analysts","Just wanted to start with MAKO and continue to focus on this a little bit more. But first of all, did you fully spell all 13 additional systems this quarter versus Q3 of last year? And the reason I asked that question is if you backed that out, assuming y",119,"Just wanted to start with MAKO and continue to focus on this a little bit more. But first of all, did you fully spell all 13 additional systems this quarter versus Q3 of last year? And the reason I asked that question is if you backed that out, assuming you sold it all, it would seem like your core knee business was a little bit softer than one of your competitors recorded this quarter. And then on a 2-year stack basis, it's little bit soft as well. So is there a risk as sales force focuses on MAKO that we could see kind of the traditional knee business soften a little bit, along with the hip business as well?"
94614,377148003,1065623,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Executives","Well, we continue to sell all of our robots, just to be clear. And we report our robot sales in the other Orthopaedic category. We can see it's up quite a bit. The other items that are shown in that other category includes bone cement, and bone cement was",116,"Well, we continue to sell all of our robots, just to be clear. And we report our robot sales in the other Orthopaedic category. We can see it's up quite a bit. The other items that are shown in that other category includes bone cement, and bone cement was down in the quarter, both in the U.S. and internationally. We used to have a lot more stocking orders for bone cement, and now our hospital customers are sort of buying it as they need it. And so bone cement does tend to be volatile from quarter-to-quarter. But when you look at our knee number, those are implants that you're seeing in knee number, no robot sales."
94614,377148003,1065623,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Analysts","And I'm also going off of memory on this one too, which is, obviously scary given the first question I just had. But it looks like, I think, Physio grew about 9% pro forma last quarter, and it grew about 6% this quarter. Obviously, we don't have the compa",86,"And I'm also going off of memory on this one too, which is, obviously scary given the first question I just had. But it looks like, I think, Physio grew about 9% pro forma last quarter, and it grew about 6% this quarter. Obviously, we don't have the comparables to look at, but is there anything that's going on that's maybe slowing a little bit as you integrate that asset? Or is it just more, ""Hey, we had a tougher comp this time last year""?"
94614,377148003,1065623,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Executives","I wouldn't read anything into that. Remember, it's a capital business. It tends to move around quarter-to-quarter. And so the -- there wasn't anything unique relative Q2 to Q3. We're very pleased with that integration so far, recognizing it early, as Kevi",76,"I wouldn't read anything into that. Remember, it's a capital business. It tends to move around quarter-to-quarter. And so the -- there wasn't anything unique relative Q2 to Q3. We're very pleased with that integration so far, recognizing it early, as Kevin commented on. But you will see capital move around. We tend to try and focus on multi-quarter rolling trends to really get a good sense with that business, but nothing to call out."
94614,377148003,1065623,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Operator","Our next question comes from Matt Taylor from Barclays.",9,"Our next question comes from Matt Taylor from Barclays."
94614,377148003,1065623,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Analysts","This is actually Ian Mahmud in for Matt. So there's been a lot of discussion on Spine during this call. But I wanted to sort of explore a little more and just ask about what you're seeing in terms of competition. I mean, we've heard a lot about redoubled",75,"This is actually Ian Mahmud in for Matt. So there's been a lot of discussion on Spine during this call. But I wanted to sort of explore a little more and just ask about what you're seeing in terms of competition. I mean, we've heard a lot about redoubled efforts to focus on that area from some of your competitors. So just wanted to see if you're seeing anything different there, any commentary to highlight."
94614,377148003,1065623,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Executives","There's nothing we would uniquely call out. It remains a highly competitive market with a lot of players across the board with the larger, more established companies and obviously, the smaller ones. But there's nothing that we're seeing different with res",54,"There's nothing we would uniquely call out. It remains a highly competitive market with a lot of players across the board with the larger, more established companies and obviously, the smaller ones. But there's nothing that we're seeing different with respect to any of the key competitors in the market at this time."
94614,377148003,1065623,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Operator","And our next question comes from Jeff Johnson from Baird.",10,"And our next question comes from Jeff Johnson from Baird."
94614,377148003,1065623,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Analysts","Most of my questions have been answered. But Glenn, maybe I missed it. But could you talk about any of the drivers in gross margin between maybe price, currency or product or geographic mix, just kind of big buckets, kind of what drove the change in gross",114,"Most of my questions have been answered. But Glenn, maybe I missed it. But could you talk about any of the drivers in gross margin between maybe price, currency or product or geographic mix, just kind of big buckets, kind of what drove the change in gross margin this year or this quarter? And then as I think about some of the movements we've seen on the yen and some emerging market currencies here recently and given the 18-month hedging program, just any very high level comments you can make about how we think of just the currency hedge portion, settling out the cost of goods, how that impacts over the next several quarters?"
94614,377148003,1065623,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Executives","Sure. I think if you look quarter-to-quarter, Q3 to Q4, our margin is fairly consistent. And I talked about this before. There's -- like you mentioned, there's lots of variables that impact our margin, not only price, but the FX, acquisitions. And certain",215,"Sure. I think if you look quarter-to-quarter, Q3 to Q4, our margin is fairly consistent. And I talked about this before. There's -- like you mentioned, there's lots of variables that impact our margin, not only price, but the FX, acquisitions. And certainly, one of the biggest factors is mix, and the mix plays out in 2 ways. It plays out in sort of geographic mix but also sort of business and product mix. And so as I look year-over-year for third quarter, really, probably the biggest impact that we had was related to business mix in terms of how much MedSurg versus Orthopaedics versus international we had last year versus this year. And then on the FX front, we entered the hedging program back when foreign currency was a lot more volatile, and the whole idea was to lock in the predictability of foreign currency for us. So like you had mentioned, currencies move up and down. Our hedging program provides stability and predictability to us. And so for the third quarter, I think, as I said, there will be sort of a nominal impact on sales related to translational, but that will have, potentially, a minor impact similar to this quarter related to transactional FX. And that's where, I think, we'll come out."
94614,377148003,1065623,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Analysts","And over the next 4 -- 3, 4 quarters, just -- will the currency side alone, and we can make our own assumptions on everything else, but with currency, should we be thinking of that as a small drag still for the next several quarters on gross margins? Is t",53,"And over the next 4 -- 3, 4 quarters, just -- will the currency side alone, and we can make our own assumptions on everything else, but with currency, should we be thinking of that as a small drag still for the next several quarters on gross margins? Is that a fair comment?"
94614,377148003,1065623,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Executives","Yes, I don't know. I wish I had the currency crystal ball to figure out what -- how things were going to flow. But it's hard to say because it's not only impacted by, say, what we've done in hedging but what the underlying transactions are. So I don't thi",60,"Yes, I don't know. I wish I had the currency crystal ball to figure out what -- how things were going to flow. But it's hard to say because it's not only impacted by, say, what we've done in hedging but what the underlying transactions are. So I don't think I can really comment that far out at this point."
94614,377148003,1065623,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Operator","And there are no further questions at this time. I will now turn the conference over to Mr. Kevin Lobo for any closing remarks.",24,"And there are no further questions at this time. I will now turn the conference over to Mr. Kevin Lobo for any closing remarks."
94614,377148003,1065623,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Executives","Thank you all for joining our call. Our conference call for the fourth quarter 2016 results will be held on January 24, 2017. Thank you.",25,"Thank you all for joining our call. Our conference call for the fourth quarter 2016 results will be held on January 24, 2017. Thank you."
94614,377148003,1065623,"Stryker Corporation, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Stryker Corporation","Operator","Thank you, ladies and gentlemen. This concludes today's conference. Thank you for participating. You may now disconnect.",17,"Thank you, ladies and gentlemen. This concludes today's conference. Thank you for participating. You may now disconnect."
